

Robert L. Kane

Joseph G. Ouslander

Itamar B. Abrass

Barbara Resnick

Essentials of
**Clinical
Geriatrics**

seventh edition

ESSENTIALS OF CLINICAL GERIATRICS

NOTICE

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

ESSENTIALS OF CLINICAL GERIATRICS

SEVENTH EDITION

Robert L. Kane, MD

Professor and Minnesota Endowed Chair in Long-Term Care and Aging
School of Public Health
University of Minnesota
Minneapolis, Minnesota

Joseph G. Ouslander, MD

Professor and Senior Associate Dean for Geriatric Programs
Charles E. Schmidt College of Medicine
Professor (Courtesy), Christine E. Lynn College of Nursing
Florida Atlantic University
Boca Raton, Florida

Itamar B. Abrass, MD

Professor Emeritus
Department of Medicine
Division of Gerontology and Geriatric Medicine
University of Washington
Harborview Medical Center
Seattle, Washington

Barbara Resnick, PhD, CRNP, FAAN, FAANP

Professor
University of Maryland School of Nursing
Sonya Gershowitz Chair in Gerontology
Baltimore, Maryland



Medical

New York Chicago San Francisco Lisbon London Madrid Mexico City
Milan New Delhi San Juan Seoul Singapore Sydney Toronto

Copyright © 2013, 2009, 2004 by McGraw-Hill Education LLC. All rights reserved. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher.

ISBN: 978-0-07-179219-6

MHID: 0-07-179219-8

e-book conversion by Cenveo® Publisher Services

Version 1.0

The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-179218-9, MHID: 0-07-179218-X.

All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designations appear in this book, they have been printed with initial caps.

McGraw-Hill Education eBooks are available at special quantity discounts to use as premiums and sales promotions or for use in corporate training programs. To contact a representative, please visit the Contact Us page at www.mhprofessional.com.

TERMS OF USE

This is a copyrighted work and McGraw-Hill Education LLC and its licensors reserve all rights in and to the work. Use of this work is subject to these terms. Except as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any part of it without McGraw-Hill Education's prior consent. You may use the work for your own noncommercial and personal use; any other use of the work is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms.

THE WORK IS PROVIDED "AS IS." McGRAW-HILL EDUCATION LLC AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill Education LLC and its licensors do not warrant or guarantee that the functions contained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill Education LLC nor its licensors shall be liable to you or anyone else for any inaccuracy, error or omission, regardless of cause, in the work or for any damages resulting therefrom. McGraw-Hill Education LLC has no responsibility for the content of any information accessed through the work. Under no circumstances shall McGraw-Hill Education LLC and/or its licensors be liable for any indirect, incidental, special, punitive, consequential or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise.

CONTENTS

List of Tables and Figures	vii
Preface	xvii

PART I

THE AGING PATIENT AND GERIATRIC ASSESSMENT

1. Clinical Implications of the Aging Process	3
2. The Geriatric Patient: Demography, Epidemiology, and Health Services Utilization	23
3. Evaluating the Geriatric Patient	41
4. Chronic Disease Management	71

PART II

DIFFERENTIAL DIAGNOSIS AND MANAGEMENT

5. Prevention	93
6. Delirium and Dementia	133
7. Diagnosis and Management of Depression	159
8. Incontinence	187
9. Falls	229
10. Immobility	247

PART III

GENERAL MANAGEMENT STRATEGIES

11. Cardiovascular Disorders	277
12. Decreased Vitality	303
13. Sensory Impairment	341
14. Drug Therapy	361
15. Health Services	381

vi Contents

16. Nursing Home Care 419

17. Ethical Issues in the Care of Older Persons 447

18. Palliative Care 467

APPENDIX Selected Internet Resources on Geriatrics 481

Index 485

TABLES AND FIGURES

CHAPTER ONE

Table 1-1.	Pertinent Changes That Commonly Occur with Aging.	6
Table 1-2.	Major Theories on Aging.	9
Table 1-3.	Web-Based Resources for Health Promotion.	16

CHAPTER TWO

Table 2-1.	The Elderly Population of The United States: Trends 1900-2050.	26
Table 2-2.	Average Per Capita Health Spending for Medicare Beneficiaries Age 65 and Over (Age-Adjusted) in 2003, Dollars by Functional Status, 1992-2003.	27
Table 2-3.	Changes in Commonest Causes of Death, 1900-2002, All Ages and Those 65 Years and Older	27
Table 2-4.	Percentage of Older Adults Having Any Difficulty Performing Selected Activities.	29
Table 2-5.	Hospital Discharge Diagnoses and Procedures for Persons Age 65 Years and Older, 2008	33
Table 2-6.	Postacute Care Used Within 30 Days, 2006 and 2008, for the Top Five Diagnostic Related Groups	34
Table 2-7.	Percentage of Office Visits by Selected Medical Conditions, 2008	34
Table 2-8.	Factors Affecting the Need for Nursing Home Admission.	37
Figure 2-1.	Deaths Per 100,000 Men, Age 65 and Over (Age-Adjusted), Selected Causes, 1981-2004.	24
Figure 2-2.	Life Expectancy at Age 65 by Sex and Race/Ethnicity, 1950-2003.	24
Figure 2-3.	Living Arrangements by Age and Sex, 2006.	30
Figure 2-4.	Percent of Persons Age 65 and Over (Age-Adjusted) Reporting Selected Chronic Conditions by Sex, 2004-2005.	31
Figure 2-5.	Nursing Home Residents per 1000 Population by Age, Sex, and Race/ Ethnicity, 2004.	36

CHAPTER THREE

Table 3-1.	Examples of Randomized Controlled Trials of Geriatric Assessment	43
Table 3-2.	Potential Difficulties in Taking Geriatric Histories.	45
Table 3-3.	Important Aspects of the Geriatric History	46
Table 3-4.	Common Physical Findings and Their Potential Significance in Geriatrics.	50
Table 3-5.	Laboratory Assessment of Geriatric Patients.	53

viii Tables and Figures

Table 3-6. Important Concepts for Geriatric Functional Assessment. 55

Table 3-7. Purposes and Objectives of Functional Status Measures. 55

Table 3-8. Examples of Measures of Physical Functioning. 56

Table 3-9. Important Aspects of the History in Assessment of Pain 59

Table 3-10. Important Aspects of the Physical Examination in
Assessment of Pain. 59

Table 3-11. Assessment of Body Composition. 60

Table 3-12. Critical Questions in Assessing a Patient for Malnutrition 61

Table 3-13. Factors That Place Older Adults at Risk for Malnutrition 61

Table 3-14. Mini Nutrition Assessment 62

Table 3-15. Example of a Screening Tool to Identify Potentially
Remediable Geriatric Problems. 64

Table 3-16. Questions on the Probability of Repeated Admissions Instrument
for Identifying Geriatric Patients at Risk for Health Service Use 65

Table 3-17. Suggested Format for Summarizing the Results of a
Comprehensive Geriatric Consultation. 65

Table 3-18. Key Factors in the Preoperative Evaluation of the Geriatric Patient 66

Figure 3-1. Components of Assessment of Older Patients. 42

Figure 3-2. Samples of Two Pain Intensity Scales That Have Been Studied
in Older Persons.. . . . 60

CHAPTER FOUR

Table 4-1. Chronic Care Tenets. 72

Table 4-2. Rationale for Using Outcomes. 81

Table 4-3. Outcomes Measurement Issues 82

Table 4-4. ACOVE Recommendations 87

Figure 4-1. Paths to Chronic Disease Catastrophe. 72

Figure 4-2. Narrowing of the Therapeutic Window. 72

Figure 4-3. A Conceptual Model of the Difference Between Expected and
Actual Care.. . . . 73

Figure 4-4. Clinical Glidepath Models.. 77

CHAPTER FIVE

Table 5-1. Considerations in Assessing Prevention in Older Patients 94

Table 5-2. Preventive Strategies for Older Persons 95

Table 5-3. Healthy People Report Card Items for Seniors 95

Table 5-4. U.S. Preventive Services Task Force (USPSTF) Recommendations for
Screening Older Adults and Medicare Coverage 96

Table 5-5.	Additional Preventive Services From U.S. Preventive Services Task Force (USPSTF) (May Be Suitable for Older Adults) and Medicare Coverage	101
Table 5-6.	Types of Exercise.	117
Table 5-7.	Relative Effectiveness of Various Osteoporosis Treatments.	122
Table 5-8.	Common Iatrogenic Problems of Older Persons	122
Table 5-9.	Frequency of Patient Risk Factors for Iatrogenic Hospital Events.	124
Table 5-10.	The Hazards of Hospitalization	125
Table 5-11.	Patient Risk Factors for Iatrogenic Hospital Events	125
Table 5-12.	Risk Factors for Functional Decline in Elderly Hospitalized Patients.	126
Table 5-13.	Potential Complications of Bed Rest in Older Persons.	126
Figure 5-1.	Changes in Health Habits Among Persons 65 Years and Older.	115
Figure 5-2.	Narrowing of the Therapeutic Window.	123

CHAPTER SIX

Table 6-1.	Key Aspects of Mental Status Examination	134
Table 6-2.	Diagnostic Criteria for Delirium	136
Table 6-3.	Comparison of Presentation of Delirium and Dementia	138
Table 6-4.	Common Causes of Delirium in Geriatric Patients.	139
Table 6-5.	Drugs That Can Cause or Contribute to Delirium and Dementia	140
Table 6-6.	Causes of Potentially Reversible Dementias	141
Table 6-7.	Causes of Nonreversible Dementias	142
Table 6-8.	Diagnostic Criteria for Alzheimer Dementia	143
Table 6-9.	Alzheimer Disease Versus Multi-Infarct Dementia: Comparison of Clinical Characteristics	144
Table 6-10.	Symptoms That May Indicate Dementia	146
Table 6-11.	Evaluating Dementia: The History	147
Table 6-12.	Evaluating Dementia: Recommended Diagnostic Studies	148
Table 6-13.	Key Principles in the Management of Dementia	150
Figure 6-1.	Primary Degenerative Dementia Versus Multi-Infarct Dementia: Comparison of Time Courses.	145

CHAPTER SEVEN

Table 7-1.	Factors Associated with Suicide in the Geriatric Population	161
Table 7-2.	Factors Predisposing Older People to Depression	162
Table 7-3.	Examples of Physical Symptoms That Can Represent Depression.	164
Table 7-4.	Key Factors in Evaluating the Complaint of Insomnia	165
Table 7-5.	Medical Illnesses Associated with Depression	167

x Tables and Figures

Table 7-6.	Drugs That Can Cause Symptoms of Depression.	169
Table 7-7.	Some Differences in the Presentation of Depression in the Older Population, as Compared with the Younger Population.	170
Table 7-8.	Summary Criteria for Major Depressive Episode	171
Table 7-9.	Major Depression Versus Other Forms of Depression	172
Table 7-10.	Examples of Screening Tools for Depression.	173
Table 7-11.	Diagnostic Studies Helpful in Evaluating Depressed Geriatric Patients with Somatic Symptoms	174
Table 7-12.	Evidence-Based Treatment Modalities for Depression.	175
Table 7-13.	Antidepressants for Geriatric Patients	179
Table 7-14.	Characteristics of Selected Antidepressants for Geriatric Patients.	182

CHAPTER EIGHT

Table 8-1.	Potential Adverse Effects of Urinary Incontinence.	188
Table 8-2.	Requirements for Continence	189
Table 8-3.	Reversible Conditions That Cause or Contribute to Geriatric Urinary Incontinence.	194
Table 8-4.	Medications That Can Cause or Contribute to Urinary Incontinence	195
Table 8-5.	Mnemonic for Potentially Reversible Conditions.	195
Table 8-6.	Basic Types and Causes of Persistent Urinary Incontinence	198
Table 8-7.	Components of the Diagnostic Evaluation of Persistent Urinary Incontinence	200
Table 8-8.	Key Aspects of an Incontinent Patient's History	201
Table 8-9.	Key Aspects of an Incontinent Patient's Physical Examination	204
Table 8-10.	Criteria for Considering Referral of Incontinent Patients for Urological, Gynecological, or Urodynamic Evaluation	207
Table 8-11.	Treatment Options for Geriatric Urinary Incontinence	210
Table 8-12.	Primary Treatments for Different Types of Geriatric Urinary Incontinence.	211
Table 8-13.	Examples of Behavioral Interventions for Urinary Incontinence	212
Table 8-14.	Example of a Bladder Retraining Protocol.	214
Table 8-15.	Example of a Prompted Voiding Protocol for a Nursing Home	215
Table 8-16.	Drug Treatment for Urinary Incontinence and Overactive Bladder	217
Table 8-17.	Indications for Chronic Indwelling Catheter Use	223
Table 8-18.	Key Principles of Chronic Indwelling Catheter Care.	223
Table 8-19.	Causes of Fecal Incontinence	224
Table 8-20.	Causes of Constipation	224
Table 8-21.	Drugs Used to Treat Constipation	225
Figure 8-1.	Prevalence of Urinary Incontinence.	188

Figure 8-2.	Structural Components of Normal Micturition.	190
Figure 8-3.	Peripheral Nerves Involved in Micturition.	191
Figure 8-4.	Simplified Schematic of the Dynamic Function of the Lower Urinary Tract During Bladder Filling (<i>left</i>) and Emptying (<i>right</i>). . . .	192
Figure 8-5.	Basic Underlying Causes of Geriatric Urinary Incontinence.. . . .	193
Figure 8-6.	Simplified Schematic Depicting Age-Associated Changes in Pelvic Floor Muscle, Bladder, and Urethra-Vesicle Position, Predisposing to Stress Incontinence.. . . .	193
Figure 8-7.	Basic Types of Persistent Geriatric Urinary Incontinence.	197
Figure 8-8.	Example of a Bladder Record for Ambulatory Care Settings.. . . .	202
Figure 8-9.	Example of a Record to Monitor Bladder and Bowel Functions in Institutional Settings.	203
Figure 8-10.	Example of a Simplified Grading System for Cystoceles.. . . .	205
Figure 8-11.	Algorithm Protocol for Evaluating Incontinence.	209

CHAPTER NINE

Table 9-1.	Complications of Falls in Elderly Patients	230
Table 9-2.	Age-Related Factors Contributing to Instability and Falls.	231
Table 9-3.	Causes of Falls	233
Table 9-4.	Common Environmental Hazards	234
Table 9-5.	Factors Associated with Falls Among Older Nursing Home Residents. . . .	234
Table 9-6.	Evaluating the Elderly Patient Who Falls: Key Points in the History. . . .	238
Table 9-7.	Evaluating the Elderly Patient Who Falls: Key Aspects of the Physical Examination	239
Table 9-8.	Example of a Performance-Based Assessment of Gait and Balance (Get Up and Go)	240
Table 9-9.	Principles of Management for Elderly Patients with Complaints of Instability and/or Falls	243
Table 9-10.	Examples of Treatment for Underlying Causes of Falls	244
Figure 9-1.	Multifactorial Causes and Potential Contributors to Falls in Older Persons.. . . .	230

CHAPTER TEN

Table 10-1.	Common Causes of Immobility in Older Adults.	248
Table 10-2.	Complications of Immobility	250
Table 10-3.	Assessment of Immobile Older Patients	251
Table 10-4.	Example of How to Grade Muscle Strength in Immobile Older Patients	252

xii Tables and Figures

Table 10-5.	Clinical Features of Osteoarthritis Versus Inflammatory Arthritis	254
Table 10-6.	Drugs Used to Treat Parkinson Disease	258
Table 10-7.	Clinical Characteristics of Pressure Sores	262
Table 10-8.	Principles of Skin Care in Immobile Older Patients	263
Table 10-9.	Types of Pain, Examples, and Treatment	266
Table 10-10.	Basic Principles of Rehabilitation in Older Patients	268
Table 10-11.	Physical Therapy in the Management of Immobile Older Patients	269
Table 10-12.	Occupational Therapy in the Management of Immobile Older Patients	270
Figure 10-1.	Characteristics of Different Types of Hip Fractures	256

CHAPTER ELEVEN

Table 11-1.	Resting Cardiac Function in Persons Age 30 to 80 Years Old Compared with That in Persons Age 30 Years Old	278
Table 11-2.	Performance at Maximum Exercise in Sample Screened for Coronary Artery Disease, Age 30 to 80 Years	278
Table 11-3.	Initial Evaluation of Hypertension in Older Adults	279
Table 11-4.	Secondary Hypertension in Older Persons	280
Table 11-5.	Thiazide Diuretics for Antihypertensive Therapy	281
Table 11-6.	Antihypertensive Medications	283
Table 11-7.	Stroke	285
Table 11-8.	Outcome for Survivors of Stroke	285
Table 11-9.	Modifiable Risk Factors for Ischemic Stroke	286
Table 11-10.	Transient Ischemic Attack: Presenting Symptoms	287
Table 11-11.	Factors in Prognosis for Rehabilitation	288
Table 11-12.	Stroke Rehabilitation	289
Table 11-13.	Presenting Symptoms of Myocardial Infarction	290
Table 11-14.	Differentiation of Systolic Murmurs	292
Table 11-15.	Manifestations of Sick Sinus Syndrome	295
Table 11-16.	Calculation of the Ankle-Brachial Index	297

CHAPTER TWELVE

Table 12-1.	Step-Care Approach to the Treatment of Type 2 Diabetes	306
Table 12-2.	Hyperosmolar Nonketotic (HNC) Coma and Diabetic Ketoacidosis (DKA)	311
Table 12-3.	Thyroid Function in the Normal Elderly	311
Table 12-4.	Laboratory Evaluation of Thyroid Disease in the Elderly	312

Table 12-5.	Thyroid Function Tests in Nonthyroidal Illness.	312
Table 12-6.	Myxedema Coma	314
Table 12-7.	Laboratory Findings in Metabolic Bone Disease	317
Table 12-8.	Signs and Symptoms of Anemia.	318
Table 12-9.	Differential Tests in Hypochromic Anemia	320
Table 12-10.	Nutritional Requirements in Older Persons.	322
Table 12-11.	Factors Predisposing to Infection in Older Adults	326
Table 12-12.	Pathogens of Common Infections in Older Adults.	328
Table 12-13.	Clinical Presentation of Hypothermia	331
Table 12-14.	Clinical Presentation of Hyperthermia.	332
Table 12-15.	Complications of Heat Stroke	333
Figure 12-1.	Flow Diagram for Treatment of Hospitalized (Nonintensive Care Unit) Patients with Type 2 Diabetes Mellitus.	309
Figure 12-2.	An Algorithm for the Management of Subclinical Hypothyroidism.	314

CHAPTER THIRTEEN

Table 13-1.	Physiological and Functional Changes of the Eye	342
Table 13-2.	Ophthalmological Screening	343
Table 13-3.	Restoring Vision After Cataract Surgery.	344
Table 13-4.	Signs and Symptoms Associated with Common Visual Problems in Older Adults	348
Table 13-5.	Aids to Maximize Visual Function	349
Table 13-6.	Potential Adverse Effects of Ophthalmic Solutions	349
Table 13-7.	Peripheral and Central Auditory Nervous System	350
Table 13-8.	Functional Components of the Auditory System.	351
Table 13-9.	Assessment of Hearing Function.	351
Table 13-10.	Effects of Aging on the Hearing Mechanism.	352
Table 13-11.	Hearing Performance in Older Adults	352
Table 13-12.	Disorders of Hearing in Older Adults.	354
Table 13-13.	Factors in Evaluation for a Hearing Aid	355
Figure 13-1.	Prevalence of Vision Problems in Older Persons, 1984.	343
Figure 13-2.	Prevalence of Hearing Problems in Older Persons, 1984.	350
Figure 13-3.	Diagnostic Approach to Polyneuropathy.	357

CHAPTER FOURTEEN

Table 14-1.	Strategies to Improve Compliance in the Geriatric Population	364
Table 14-2.	Examples of Common and Potentially Serious Adverse Drug Reactions in the Geriatric Population	366

xiv Tables and Figures

Table 14-3. Examples of Potentially Clinically Important
Drug-Drug Interactions 368

Table 14-4. Examples of Potentially Clinically Important
Drug-Patient Interactions 369

Table 14-5. Age-Related Changes Relevant to Drug Pharmacology. 370

Table 14-6. Renal Function in Relation to Age. 372

Table 14-7. General Recommendations for Geriatric Prescribing 374

Table 14-8. Examples of Antipsychotic Drugs 375

Table 14-9. Examples of Hypnotics Approved for Insomnia by the U.S.
Food and Drug Administration 375

Figure 14-1. Factors That Can Interfere with Successful Drug Therapy. 362

Figure 14-2. Example of a Basic Medication Record. 363

CHAPTER FIFTEEN

Table 15-1. Summary of Major Federal Programs for Elderly Patients. 393

Table 15-2. Remaining Lifetime Use of Long-Term Supportive Services (LTSS)
by People Turning 65 in 2005. 404

Table 15-3. Comparison of Nursing Home Residents and the
Noninstitutionalized Population Age 65, 1995 405

Table 15-4. RUG-IV Classification System. 408

Table 15-5. Home Care Provided Under Various Federal Programs 411

Table 15-6. Examples Of Community Long-Term Care Programs 414

Table 15-7. Variations in Case Management 416

Figure 15-1. Theoretical Model of Observed Versus Expected Clinical Course. 382

Figure 15-2. Distribution of Personal Health-Care Expenditure, by Type of
Service: Selected Calendar Years 1980, 1990, 2000, and 2010. 383

Figure 15-3. Percent Distribution of Medicare Program Payments,
by Type of Service: Calendar Years 1967 and 2010. 385

Figure 15-4. Distribution of Medicaid Vendor Payments, by Type of Service:
Fiscal Years 1975 and 2008. 386

Figure 15-5. Distribution of Place of Residence Among Older Persons with
Disabilities, 1999 and 2004. 396

Figure 15-6. Age-Adjusted Disability Rates Among the 65+ Population,
1984-2004. 397

Figure 15-7. Disability Prevalence and the Need for Assistance by Age: 2005. 398

Figure 15-8. Projected Growth in Numbers of Older Persons
with Disabilities, 1996-2050. 398

Figure 15-9. Long-Term Care Spending, by Payer CY 2007. 399

Figure 15-10. Change in the Rate of Nursing Home Use by Age Group, 1973-2004. 402

Figure 15-11. Use of Different Types of Institutional Long-Term Care by Age Group, 1985 and 2004.	403
Figure 15-12. Rate of Institutional Use Among Persons Age 65+ by Level of Disability, 1984 and 2004.. . . .	403
Figure 15-13. Relative Likelihood of Using a Nursing Home as Function of Potentially Changeable Lifestyle Disease.. . . .	405

CHAPTER SIXTEEN

Table 16-1. Goals of Nursing Home Care.	420
Table 16-2. Factors That Distinguish Assessment and Treatment in the Nursing Home Different From Assessment and Treatment in Other Settings.	422
Table 16-3. Common Clinical Disorders in the Nursing Home Population	423
Table 16-4. Important Aspects of Various Types of Assessment in the Nursing Home.	426
Table 16-5. SOAP Format for Medical Progress Notes on Nursing Home Residents	434
Table 16-6. Screening, Health Maintenance, and Preventive Practices in the Nursing Home	435
Table 16-7. Common Ethical Issues in the Nursing Home	443
Figure 16-1. Basic Types of Nursing Home Patients.. . . .	420
Figure 16-2. Example of a Face Sheet for a Nursing Home Record.	432
Figure 16-3. Example of an INTERACT VERSION 3.0 Care Path for Managing Acute Change in Condition in a Nursing Home.. . . .	440

CHAPTER SEVENTEEN

Table 17-1. Major Ethical Principles.	448
Table 17-2. Components of a Durable Power of Attorney for Health Care.	451
Table 17-3. Goals of Care and Symptoms Requiring Management at the End of Life.	457

CHAPTER EIGHTEEN

Table 18-1. Hospice Services	468
Table 18-2. A Five-Step Framework for Discussing Care Choices at the End of Life.	469
Table 18-3. Signs and Symptoms of Frailty	471
Table 18-4. Management of Symptoms Noted at End of Life	474
Table 18-5. Adjuvant Treatments for Pain Management	476

This page intentionally left blank

PREFACE

Since we wrote the original text almost 30 years ago, geriatrics has gone through a number of transitions. The world has become increasingly aware of the centrality of chronic disease and people have begun to recognize that the principles of geriatrics are eminently suited to addressing this challenge. Sadly and ironically, just as the need for more and better primary care and comprehensive care has grown, interest in primary care and geriatrics has waned. The concepts and practices embodied in this book have never been more salient. If society fails to embrace these ideas and to find ways to implement them, we will face a medical catastrophe.

There is growing appreciation that our medical care system is not structured to effectively address complex chronic disease and multimorbidity, which are both common in the geriatric population. Proposals for changes are endemic. At their heart is coordination and broader accountability, principles embraced by geriatrics.

Stated simply, geriatrics stands at the intersection of three forces:

1. Gerontology (both basic and applied)
2. Chronic disease management, especially multimorbidities
3. End-of-life care

Principles of gerontology can help to explain insights of geriatric care. For example, the atypical presentation of disease in older persons occurs because a hallmark of aging is a decreased ability to respond to stress, and the body's stress response is what typically generates the symptoms of an illness. Older people fail to respond as actively. Hence, they may not spike fevers or show elevated white counts in the face of an infection. Heart disease may be silent.

Chronic disease management is difficult on its own. It is much more difficult when an older patient suffers from multiple simultaneous diseases. Basic care guidelines may not work. Indeed, they make pose a threat. Guidelines are disease specific, and application of guidelines may result in recommendations for a plethora of nonpharmacological and pharmacological interventions that are unrealistic, unacceptable, expensive, and hazardous. Much of the emphasis in geriatric care planning is directed at containing disease and maintaining function. Moreover, geriatrics recognizes that medical issues can interact with other social and environmental issues, mandating comprehensive approaches to care.

Death is a part of old age. Geriatrics must deal with that reality and help patients and families deal with end of life, helping them to make informed decisions that reflect their goals and priorities. But geriatrics cannot focus exclusively on end-of-life-care. One compromise has been the evolution of palliative care (discussed in Chapter 18 of this edition).

To this list, one might also add appropriate attention to prevention. Healthy aging remains a goal.

This seventh edition of *Essentials of Clinical Geriatrics* represents a timely tome that combines practical information to help clinicians and other practitioners from a variety of disciplines to more effectively address the challenges posed by the grey tsunami. But a thoughtful reading will also reveal many tips for better chronic care practice in general.

It is organized to provide linear exposition on salient topics but also as a rapid reference guide with many tables and figures that summarize and simplify complex areas. The goal of the book remains to help people do a better job of caring for older patients.

As ever, we welcome ideas and suggestions about how we can make the book more useful.

This page intentionally left blank

PART I

**THE AGING PATIENT AND
GERIATRIC ASSESSMENT**

This page intentionally left blank

CHAPTER 1

Clinical Implications of the Aging Process

Geriatrics stands at the intersection of three forces:

1. Gerontology (both basic and applied)
2. Chronic disease management, especially multimorbidities
3. End-of-life care

Principles of gerontology can help to explain insights of geriatric care. For example, the presentation of disease is often different in older persons because the response to stress is different. A hallmark of aging is a decreased ability to respond to stress. The body's stress response is what typically generates the symptoms of an illness. Older people fail to respond as actively. Hence, they may not have spiking fevers or elevated white blood cell counts in the face of an infection. Heart disease may be silent.

Chronic disease management is difficult on its own. It is much more difficult when an older patient suffers from multiple simultaneous diseases. Basic care guidelines may not work. Indeed, they may pose a threat (Boyd et al., 2005).

Much of the emphasis in care planning is directed at containing disease and maintaining function and improving quality of life. Death is a part of old age. Geriatrics must deal with that reality and help patients and families deal with end of life, helping them to make informed decisions that reflect their goals and priorities. But geriatrics cannot focus exclusively on end-of-life care. One compromise has been the evolution of palliative care (discussed in Chapter 18). To this triad, some might also add a role for advocating reasonable preventive actions (see Chapter 5).

The care of older patients differs from that of younger patients for a number of reasons. While there continues to be a debate about the cause of these differences, it is likely that they are a combination of biological changes that occur during the course of aging, associated diseases, and attitudes and beliefs of older adults and their caregivers. Aging is defined as the time-sequential deterioration that occurs in most living beings, including weakness, increased susceptibility to disease and adverse environmental conditions, loss of mobility and agility, and age-related physiological changes (Goldsmith, 2006). At least in vitro, it is clear that the "aging clock" can be reset (reviewed in Rando and Chang, 2012). Somatic cell nuclear transfer of the nucleus of a mature somatic cell into an enucleated oocyte can give rise to mature, fertile animals.

It is important to distinguish life expectancy from life span. The former refers to what proportion of the possible maximum age a person may live. The latter suggests a biological limit to how many years a species can expect to survive. In general, geriatrics has the most to contribute to improving life expectancy, but new genetic

breakthroughs may ultimately affect life span as well. Another helpful distinction is between chronological aging and gerontological aging. The latter is calculated on the basis of the risk of dying, the so-called force of mortality. Thus, two people of the same chronological age may have biologically very different ages depending on their health state. Some of that propensity for death is malleable; some is simply predictable.

Perhaps one of the most intriguing challenges in medicine is to unravel the process of aging. From a medical perspective, the question continues to haunt us as to whether aging is a feature of an organism's design that has evolved over time and is beneficial to the survival of species, or aging is a disease or defect that confers no survival benefit. Even more important to medical management of aging is the question of whether there are medically treatable factors that are common to the various manifestations of aging we see. Could aging treatments delay the signs and symptoms of aging such as sensory changes, musculoskeletal problems, or skin-related changes?

Nonetheless, the distinction between so-called normal aging and pathologic changes is critical to the care of older people. We wish to avoid both dismissing treatable pathology as simply a concomitant of old age and treating natural aging processes as though they were diseases. The latter is particularly dangerous because older adults are so vulnerable to iatrogenic effects.

There is growing appreciation that everyone does not age in the same way or at the same rate. The changing composition of today's older adults compared with that of a generation ago may actually reflect a bimodal shift wherein there are both more disabled people and more healthy older people. We continue to learn more and more about healthy or successful aging through hearing the stories of the growing number of centenarians. Generally the consensus is that moderation in all areas (eg, food intake, alcohol intake), regular physical activity, and an engaging social life are critical to successful aging. A recent large actuarial study (Gavrilova and Gavrilov, 2005) further suggested that environmental factors may also be relevant. Social factors can also play a strong role (Banks et al., 2006). The challenge is to recognize and appreciate aging changes while using resources to prevent or halt further changes and overcome aging challenges.

CHANGES ASSOCIATED WITH "NORMAL" AGING

Clinicians often face a major challenge in attributing a finding to either the expected course of aging or the result of pathologic changes. This distinction perplexes the researcher as well. We currently lack precise knowledge of what constitutes normal aging. Much of our information comes from cross-sectional studies, which compare findings from a group of younger persons with those from a group of older individuals. Such data may reflect differences other than simply the effects of age, such as those associated with lifestyle behaviors (physical activity, alcohol intake, smoking, and diet), as well as prophylactic medication management. For example, older adults in the coming century may present with less evidence of osteoporosis because of prophylactic lifelong intake of high calcium and vitamin D diets, regular physical activity, and early interventions with biphosphanates and potentially future treatments for osteoporosis. Statins can drastically affect the course of cardiovascular disease.

Many of the changes associated with aging result from a gradual loss of homeostatic mechanisms. (Jack Rowe termed this “homeostenosis.”) These losses may often begin in early adulthood, but—thanks to the redundancy of most organ systems—the decrement does not become functionally significant until the loss is fairly extensive.

The concept of aging, or at least what constitutes old age, has changed as life expectancy has increased, although the biology has not. Based on cross-sectional comparisons of groups at different ages, most organ systems seem to lose function at about 1% a year beginning around age 30 years. Other data suggest that the changes in people followed longitudinally are much less dramatic and certainly begin well after age 70 years. In some organ systems, such as the kidney, a subgroup of persons appears to experience gradually declining function over time, whereas others’ function remains constant. These findings suggest that the earlier theory of gradual loss must be reassessed as reflecting disease rather than aging. Given a pattern of gradual deterioration—whether from aging or disease or both—we are best advised to think in terms of thresholds.

The loss of function does not become significant until it crosses a given level. Thus, the functional performance of an organ in an older person depends on two principal factors: (1) the rate of deterioration and (2) the level of performance needed. It is not surprising then to learn that most older persons will have normal laboratory values. The critical difference—in fact, the hallmark of aging—lies not in the resting level of performance but in how the organ (or organism) adapts to external stress. For example, an older person may have a normal fasting blood sugar but be unable to handle a glucose load within the normal parameters for younger subjects.

This failure to respond to stress explains the atypical presentation of many diseases in older patients. Many of the signs and symptoms of disease are actually the body’s response to those assaults. A depressed response will mean not having a high white blood cell count with an infection or even pain with a heart attack. For example, although currently not recommended for screening of asymptomatic patients, cardiac magnetic resonance imaging reveals unrecognized myocardial infarctions in asymptomatic older adults that are associated with increased mortality (Schelbert et al., 2012).

The same pattern of decreased response to stress can be seen in the performance of other endocrine systems or the cardiovascular system. An older individual may have a normal resting pulse and cardiac output but be unable to achieve an adequate increase in either with exercise.

Sometimes the changes of aging work together to produce apparently normal resting values in other ways. For example, although both glomerular filtration and renal blood flow decrease with age, many elderly persons have normal serum creatinine levels because of the concomitant decreases in lean muscle mass and creatinine production. Thus serum creatinine is not as good an indicator of renal function in older adults as in younger persons. Knowledge of kidney function is critical in drug therapy. Therefore, it is important to get an accurate measure of kidney function. A useful formula for estimating creatinine clearance on the basis of serum creatinine values in the elderly was developed (Cockcroft and Gault, 1976). (The actual formula is provided in Chapter 14.) [Table 1-1](#) (Schmidt, 1999) summarizes some

TABLE 1-1. Pertinent Changes That Commonly Occur with Aging

System	Common age changes	Implications of changes
Cardiovascular	Atrophy of muscle fibers that line the endocardium Atherosclerosis of vessels Increased systolic blood pressure Decreased compliance of the left ventricle Decreased number of pacemaker cells Decreased sensitivity of baroreceptors	Increased blood pressure Increased emphasis on atrial contraction with an S ₄ heard Increased arrhythmias Increased risk of hypotension with position change Valsalva maneuver may cause a drop in blood pressure Decreased exercise tolerance
Neurological	Decreased number of neurons and increase in size and number of neuroglial cells Decline in nerves and nerve fibers Atrophy of the brain and increase in cranial dead space Thickened leptomeninges in spinal cord	Increased risk for neurological problems: cerebrovascular accident Parkinsonism Slower conduction of fibers across the synapses Modest decline in short-term memory Alterations in gait pattern: wide based, shorter stepped, and flexed forward Increased risk of hemorrhage before symptoms are apparent
Respiratory	Decreased lung tissue elasticity Thoracic wall calcification Cilia atrophy Decreased respiratory muscle strength Decreased partial pressure of arterial oxygen (Pao ₂)	Decreased efficiency of ventilatory exchange Increased susceptibility to infection and atelectasis Increased risk of aspiration Decreased ventilatory response to hypoxia and hypercapnia Increased sensitivity to narcotics
Integumentary	Loss of dermal and epidermal thickness Flattening of papillae Atrophy of sweat glands Decreased vascularity Collagen cross-linking Elastin regression Loss of subcutaneous fat Decreased melanocytes Decline in fibroblast proliferation	Thinning of skin and increased susceptibility to tearing Dryness and pruritus Decreased sweating and ability to regulate body heat Increased wrinkling and laxity of the skin Loss of fatty pads protecting bone and resulting in pain Increased need for protection from the sun Increased time for healing of wounds

(continued)

TABLE 1-1. Pertinent Changes That Commonly Occur with Aging (continued)

System	Common age changes	Implications of changes
Gastrointestinal	Decreased liver size Less efficient cholesterol stabilization and absorption Fibrosis and atrophy of salivary glands Decreased muscle tone in bowel Atrophy of and decrease in number of taste buds Slowing in esophageal emptying Decreased hydrochloric acid secretion Decreased gastric acid secretion Atrophy of the mucosal lining Decreased absorption of calcium	Change in intake caused by decreased appetite Discomfort after eating related to slowed passage of food Decreased absorption of calcium and iron Alteration of drug effectiveness Increased risk of constipation, esophageal spasm, and diverticular disease
Urinary	Reduced renal mass Loss of glomeruli Decline in number of functioning nephrons Changes in small vessel walls Decreased bladder muscle tone	Decreased GFR Decreased sodium-conserving ability Decreased creatinine clearance Increased BUN Decreased renal blood flow Altered drug clearance Decreased ability to dilute urine Decreased bladder capacity and increased residual urine Increased urgency
Reproductive	Atrophy and fibrosis of cervical and uterine walls Decreased vaginal elasticity and lubrication Decreased hormones and reduced oocytes Decreased seminiferous tubules Proliferation of stromal and glandular tissue Involution of mammary gland tissue	Vaginal dryness and burning and pain with intercourse Decreased seminal fluid volume and force of ejaculation Reduced elevation of the testes Prostatic hypertrophy Connective breast tissue is replaced by adipose tissue, making breast examinations easier
Musculoskeletal	Decreased muscle mass Decreased myosin adenosine triphosphatase activity Deterioration and drying of joint cartilage Decreased bone mass and osteoblastic activity	Decreased muscle strength Decreased bone density Loss of height Joint pain and stiffness Increased risk of fracture Alterations in gait and posture

(continued)

TABLE 1-1. Pertinent Changes That Commonly Occur with Aging (*continued*)

System	Common age changes	Implications of changes
Sensory: Vision	Decreased rod and cone function Pigment accumulation Decreased speed of eye movements Increased intraocular pressure Ciliary muscle atrophy Increased lens size and yellowing of the lens Decreased tear secretion	Decreased visual acuity, visual fields, and light/dark adaptation Increased sensitivity to glare Increased incidence of glaucoma Distorted depth perception with increased falls Less able to differentiate blues, greens, and violets Increased eye dryness and irritation
Sensory: Hearing	Loss of auditory neurons Loss of hearing from high to low frequency Increased cerumen Angiosclerosis of ear	Decreased hearing acuity and isolation (specifically, decreased ability to hear consonants) Difficulty hearing, especially when there is background noise, or when speech is rapid Cerumen impaction may cause hearing loss
Sensory: Smell, taste, and touch	Decreased number of olfactory nerve fibers Altered ability to taste sweet and salty foods; bitter and sour tastes remain Decreased sensation	Inability to smell noxious odors Decreased food intake Safety risk with regard to recognizing dangers in the environment: hot water, fire alarms, or small objects that result in tripping
Endocrine	Decreased testosterone, GH, insulin, adrenal androgens, aldosterone, and thyroid hormone Decreased thermoregulation Decreased febrile response Increased nodularity and fibrosis of thyroid Decreased basal metabolic rate	Decreased ability to tolerate stressors such as surgery Decreased sweating and shivering and temperature regulation Lower baseline temperature; infection may not cause an elevation in temperature Decreased insulin response, glucose tolerance Decreased sensitivity of renal tubules to antidiuretic hormone Weight gain Increased incidence of thyroid disease

BUN, blood urea nitrogen; GFR, glomerular filtration rate; GH, growth hormone.

of the pertinent changes that occur with aging. For many items, the changes begin in adulthood and proceed gradually; others may not manifest themselves until well into seniority.

THEORIES OF AGING

It is helpful to be familiar with the many theories of aging, as these theories help direct the philosophy of care that is provided. If we believe that there is no way to intervene in the aging process, we will likely help our older patients accept and adjust to these changes and focus on disease management. Conversely, if we believe in the potential of antiaging medicine and treatments and protocols that slow or eliminate many manifestations of aging (eg, statins and aspirin), we will likely approach these individuals differently.

It is now a commonly accepted notion that aging is a multifactorial process. Extended longevity is frequently associated with enhanced metabolic capacity and response to stress. The importance of genetics in the regulation of biological aging is demonstrated by the characteristic longevity of each animal species. However, heritability of life span accounts for $\leq 35\%$ of its variance, whereas environmental factors account for $>65\%$ of the variance (Finch and Tanzi, 1997), and genes specifically selected to promote aging are unlikely to exist.

Several theories of aging have been promulgated (Vijg and Wei, 1995; Kirkwood and Austad, 2000; Kaeblerlein, 2007). These theories fall into one of three general categories: (1) accumulation of damage to informational molecules, (2) the regulation of specific genes, or (3) depletion of stem cells (Table 1-2).

Biological theories of aging focus on the belief that aging, or life span, is part of the organism's design. Researchers such as Hayflick (2007) promote the idea that genes do not drive the aging process but the general loss of molecular fidelity does. Specifically, he postulates that every molecule becomes the substrate that experiences the thermodynamic instability characteristic of the aging process.

TABLE 1-2. Major Theories on Aging

Theory	Mechanisms	Manifestations
Accumulation of damage to informational molecules	Spontaneous mutagenesis	Copying errors
	Failure in DNA repair systems	
	Errors in DNA, RNA, and protein synthesis	Error catastrophe
Regulation of specific genes	Superoxide radicals and loss of scavenging enzymes	Oxidative cellular damage
	Appearance of specific protein(s)	Genetically programmed senescence
Depletion of stem cells	Convergence of above mechanisms	Proliferative potential decreases

Aging is thus different from disease because it occurs in every multicellular animal that reaches a fixed size at reproductive maturity, occurs in all species after reproductive maturity, and has the same universal molecular etiology, that is, thermodynamic instability.

Evolution theory has been a traditional theory of aging as described by Darwin. This theory suggests that the designs of current organisms resulted from an incrementally accumulative evolutionary process. This is essentially the “survival of the fittest” premise as organisms that survived longer had more opportunity to breed and therefore propagate their particular design in the population. According to traditional Darwinian evolution theory, it is impossible for an organism to evolve in a way that reduces its life span, unless the evolution simultaneously improves the organism’s ability to produce adult descendents. Human aging, however, does not improve our ability to procreate unless one emphasizes the group effect of having the old die to make room for the young. Many theories were subsequently developed to adjust the Darwinian evolution theory to correct for the changes in reproduction that occur. These include group selection theories, selfish gene theory, and evolvability theory. Evolvability theory, for example, holds that organisms can generally evolve characteristics that act to improve their ability to evolve and adapt to external circumstances by changing the genetic design of subsequent generations. If aging is a design feature, there might be increased benefit if a species could regulate life span. For example, the life spans of individual animals having the same genetic design could be adjusted to compensate for external conditions.

Damage theories are another group of theories of aging that have been propagated. These theories suggest that aging is a result of wearing out caused by damage to fundamental life processes that occur in accumulative microscopic increments such as damage to chromosomes, accumulation of poisonous by-products, nuclear radiation, or the forces of entropy. Damage theories are clearly pessimistic regarding medical intervention. The reader who seeks additional information on theories of aging should review the online resources included at the end of this chapter and the work of Goldsmith (2006) and Hayflick (2007).

DNA undergoes continuous change in response to both exogenous agents and intrinsic processes. Stability is maintained by the double-strandedness of DNA and by specific repair enzymes. It has been proposed that somatic mutagenesis, either owing to greater susceptibility to mutagenesis or deficits in repair mechanisms, is a factor in biological aging. In fact, there is a positive correlation of species longevity with DNA repair enzymes. In humans, the spontaneous mutagenesis rate is not adequate to account for the number of changes that would be necessary, and there is no evidence that a general failure in repair systems causes aging. However, limited maintenance and repair may lead to accumulation of somatic damage.

A related theory, the error catastrophe theory, proposes that errors occur in DNA, RNA, and protein synthesis, each augmenting the other and finally culminating in an error catastrophe. Translation was considered the most likely source for age-dependent errors because it was the final common pathway. However, increased translational errors have not been found in either *in vivo* or *in vitro* aging.

Amino acid substitutions do not increase with age, although some enzyme activities may be altered by changes in posttranslational modification, such as glycosylation.

The major by-products of oxidative metabolism include superoxide radicals that can react with DNA, RNA, proteins, and lipids, leading to cellular damage and aging. There are several scavenging enzymes and some small molecules such as vitamins C and E that protect the cell from oxidative damage. There is no significant loss of scavenging enzymes in aging, and vitamins C and E do not increase longevity in experimental animals. However, interest in this hypothesis persists because overexpression of antioxidative enzymes retards the age-related accrual of oxidative damage and extends the maximum life span of transgenic fruit flies; moreover, caloric restriction lowers levels of oxidative stress and damage and extends the maximum life span of rodents (Finkel and Holbrook, 2000; Masoro and Austad, 2010).

One hypothesis of aging is that it is regulated by specific genes. Support for such a hypothesis has been gained mainly from yeast, nematodes, fruit flies, and models of *in vitro* aging. Several genes in yeast, nematodes, and fruit flies have been found to extend the species life span. They appear to reinforce the importance of metabolic capacity and stress responses in aging. By DNA microarrays, relatively few genes changed in human fibroblasts with aging, and downregulation of genes involved in control of mitosis was proposed as a possible general cause of aging (Ly et al., 2000). However, others have not shown the same gene pattern changes in other aging tissues, suggesting that different changes underlie aging in different tissues.

In adulthood, cells can be placed into one of three categories based on their replicative capacity: continuously replicating, replicating in response to a challenge, and nonreplicating. Epidermal, gastrointestinal, and hematopoietic cells are continuously renewed; the liver can regenerate in response to injury, whereas neurons and cardiac and skeletal muscle do not regenerate.

In vitro replication is closely related to *in vivo* proliferation. Neurons and cardiac myocytes from adults can be maintained in culture but do not divide, whereas hepatocytes, marrow cells, endothelial cells, and fibroblasts replicate *in vitro*. Because they are easily obtained from skin, fibroblasts have been the most extensively studied. Although some cells continuously replicate *in vivo*, they have a finite replicative life. For fibroblasts *in vitro*, this is about 50 doublings (Hayflick, 2007). Replicative life *in vitro* correlates with the age of the donor, such that the older the donor, the fewer the doublings *in vitro*. With time in culture, doubling time decreases and ultimately stops. Several lines of evidence suggest that replicative senescence evolved to protect higher organisms from developing cancer (Campisi, 2000).

With each cell division, a portion of the terminal end of chromosomes (the telomere) is not replicated and therefore shortens. It is proposed that telomere shortening is the clock that results in the shift to a senescent pattern of gene expression and ultimately cell senescence (Fossel, 1998). Telomerase is an enzyme that acts by adding DNA bases to telomeres. Transfection of the catalytic component of this enzyme into senescent cells extends their telomeres as well as the replicative life span of the cells and induces a pattern of gene expression typical of young cells. The extent to which telomere shortening is relevant to cellular senescence and aging *in vivo*,

however, remains unknown. In contrast, telomerase inhibitors may be potent anti-cancer therapies. The role of replicative senescence in aging and associated chronic disease processes is now being explored. Studies of the oldest old have not demonstrated any relationship between telomere length and mortality. However, telomere length may be associated with function and health rather than exceptional longevity, as healthy centenarians had significantly longer telomeres than did unhealthy centenarians (Terry et al., 2008). The findings were similar in a population-based cohort study of individuals aged 70 to 79 years (Njajou et al., 2009).

These experiments help define the finite life span of cells *in vitro* but do not themselves explain *in vivo* aging. However, factors associated with finite cell replication may more directly influence *in vivo* aging. Fibroblasts aged *in vitro* or obtained from older adult donors are less sensitive to a host of growth factors. Such changes occur at both the receptor and postreceptor levels. A decrease in such growth factors, a change in sensitivity to growth factors, and/or a slowing of the cell cycle may slow wound healing and thus place the older individual at greater risk for infection.

For tissues with nonreplicating cells, cell loss may lead to a permanent deficit. With aging, dopaminergic neurons are lost, thus influencing gait and balance and the susceptibility to drug side effects. With further decrements such as ischemia or viral infection, Parkinson disease may develop. Similar cell loss and/or functional deficits may occur in other neurotransmitter systems and lead to autonomic dysfunction as well as alteration in mental function and neuroendocrine control.

The immune system demonstrates similar phenomena. Lymphocytes from older adults have a diminished proliferative response to a host of mitogens. This appears to be a result of both a decrease in lymphokines and a decrease in response to extracellular signals. As the thymus involutes after puberty, levels of thymic hormones (thymosins) decrease.

Basal and stimulated interleukin-2 (IL-2) production and responsiveness also diminish with age. The latter appears to be due, at least in part, to a decreased expression of IL-2 receptors. Some immune functions can be restored by the addition of these hormones to lymphocytes *in vitro*, or *in vivo*, by their administration to aged animals. The proliferative defect can also be reversed *in vitro* by calcium ionophores and activators of protein kinase C, suggesting that the T-cell defect may be in transduction of extracellular signals to intracellular function. *In vivo* molecular mechanisms, such as those described earlier, contribute to physiological deficits and altered homeostatic mechanisms that predispose older individuals to dysfunction in the face of stress and disease.

The gene for Werner syndrome, a progeric syndrome associated with the early onset of age-related changes—such as gray hair, balding, atherosclerosis, insulin resistance, and cataracts, but not Alzheimer disease—has been cloned. The gene codes for a helicase involved in DNA replication. There is great interest in understanding how a defect in just this one gene leads to the multiple abnormalities of this syndrome.

Molecular geneticists have also cloned several genes related to early-onset familial Alzheimer disease and identified susceptibility genes for the late-onset form of the disease (Tanzi et al., 1996).

A small number of families have mutations in the amyloid precursor protein located on chromosome 21. The largest number of families with early-onset familial Alzheimer disease have a mutation in a gene on chromosome 14. This gene has been named presenilin 1. A similar gene has been identified on chromosome 1 and labeled presenilin 2. The role of the presenilins in Alzheimer disease pathology is not yet known, but the identification of the three loci mentioned earlier has led to much excitement for the potential understanding of pathophysiological mechanisms in this devastating disease. Similarly, the identification of apolipoprotein (apo E) alleles as risk factors for late-onset Alzheimer disease has raised interest in both the diagnosis and pathology of this disease.

Interventions that slow aging are likely to delay the onset of many important diseases including cancer, diabetes, cardiovascular diseases, and neurodegenerative diseases. Dietary restriction (DR) remains the major intervention in enhancing longevity (reviewed in Masoro and Austad, 2010). DR is known to increase life span in yeast, worms, flies, and rodents. Although one group has reported health and mortality benefits from caloric restriction in primates (Colman et al., 2009), a more recent study did not find similar benefits (Maxmen, 2012). DR is not likely to be a successful intervention in humans. Therefore, much attention is being given to understanding the pathways that mediate DR and to the development of DR mimetics that target these pathways to enhance health and longevity without requiring reduced food consumption.

Growth hormone (GH) has received notoriety as a potential antiaging treatment, but so far has not been proven to be effective (reviewed in Perls, 2004). In rodents, reduced GH signaling, rather than increased activity, is correlated with increased longevity. In addition to reduced GH levels, reduced insulin and insulin-like growth factor-1 levels increase the life span of worms and flies. Human longevity, too, may be associated with more efficient glucose handling. Research in genetics, and the interface between genetics and hormone signaling, is ongoing.

Tissue-specific stem cells offer hope to greatly extend the numbers and range of patients who could benefit from cell replacement therapy to treat debilitating diseases such as diabetes, Parkinson, Huntington, and Alzheimer. There is a long way to go in basic research before new therapies will be established, but clinical trials in some diseases are under way. However, embryonic stem cells and pluripotent stem cells are not the reversal of aging. One of the major limitations of these cells therapeutically is that upon transplantation they have the propensity to form tumors. The ideal would be to reset the aging clock, but leave the differentiated state untouched (Rando and Chang, 2012).

Although there continue to be many theories of aging, there is some evidence to support the feasibility of antiaging medicine as we move toward the aging of the baby boomers and a new cohort of older adults. Caloric restriction, or nutritionally balanced semistarvation, when applied to mammals has been noted to increase life span as much as 50% (Antebi, 2007; Lenaerts, van Eygen, and van Fleteren, 2007; Colman et al., 2009). Such an approach is not practical for people interested in maximizing the healthy years of their life. Research is focused on identifying an agent

that would signal caloric restriction when it actually was not occurring and thus alter the aging system.

There is no direct evidence that DNA mutations are the proximal cause of cellular aging, and no experiment has demonstrated that a reduction in DNA mutations leads to an extension of life span. Thus, there is currently much interest in the role of epigenetic processes as mediators of the aging process. Epigenetic reprogramming refers to changes in the stable profile of a cell without changes in DNA sequences. The observations that life span can be modified by environmental influences suggest strongly that the manifestations, and possibly the causes, of aging may be largely epigenetic (Rando and Chang, 2012). The connections between aging and epigenetics are exemplified by the life span–extending effects of DR, which exerts multiple effects on chromatin through sirtuins, target of rapamycin (TOR), and other factors. These mediators, then, have become targets for life span extension without caloric restriction. However, reprogramming of the epigenome has certain risks and uncertainties. There may be an increased risk of developing malignancies among cells that have acquired genomic mutations during normal aging but then acquire increased proliferative potential. The challenge is to reset aging back to the appropriate adult stage.

Among the key regulators associated with food, energy, and growth factor restriction is the mammalian TOR (mTOR), which senses cellular nutrient levels and in turn regulates rates of protein synthesis and energy utilization. Rapamycin, an mTOR inhibitor, was effective in extending life span of genetically heterogeneous mice when treatment was begun in late life (Sharp and Strong, 2010). Tissue-specific stem cells maintained their differentiated states, but functioned as though there was partial rewinding of the aging clock. It is important to determine if rapamycin has similar effects in other animals such as nonhuman primates. It is possible that rapamycin's efficacy may be restricted to laboratory animals. For human application, an obvious potential problem is possible immunosuppressive effects of rapamycin.

Much excitement was generated when it was found that activation of a sirtuin, another regulator of the effects of caloric restriction, extended life span in yeast (Guarente, 2011). However, the sirtuin story is unraveling as those experiments have not been replicated by others (Couzin-Frankel, 2011). In mice, modulation of sirtuins does not extend life span but expands health span with less diabetes mellitus, healthier metabolic profiles, and healthier livers. Similarly, initial excitement occurred with resveratrol, a molecule from red wine that acted through a sirtuin, when it was found to extend life span in worms and flies. Again, these findings have not been confirmed in other laboratories. However, resveratrol, too, may extend health span.

A defining feature of humans is their plasticity, or flexibility, in the range and spectrum of function and in their ability to adapt to endogenous changes in themselves and exogenous changes in the environment. Findings from cognitive training studies in life span psychology, use of mind plasticity interventions in individuals with early dementia, and physical training using a plasticity philosophy for those recovering from neurological disorders such as stroke have shown some useful outcomes. Increasingly we are finding that older adults still possess substantial reserved

plasticity and even have demonstrated neurogenesis and physical and cognitive benefits to these interventions. While not a specific theory of aging, a philosophy of care of older adults that considers plasticity as an option is an important consideration and one in which future research will focus.

CLINICAL IMPLICATIONS

As we try to understand aging, we appreciate the limitations of available information. Several large studies in the United States, Israel, and Italy have followed cohorts of people longitudinally as they age. The findings thus far consistently suggest much variability to aging, despite anticipated declines in areas such as cardiovascular function; strength; and brain, bone, and muscle mass. Further, there are indications that environment, behavior, and health are interrelated and can alter physical changes. For example, in Israeli older adults, normal renal function, good vision, avoiding afternoon naps, volunteer or compensated work, physical activity, and instrumental activities of daily living (IADL) independence all correlated with improved survival. Moreover, good vision, volunteer work or work for pay, and physical activity were independently associated with continued functional independence over a 7-year period. Similar findings associated with remaining engaged in regular physical activity have been noted in the Baltimore Longitudinal Studies of Aging (<http://www.grc.nia.nih.gov/branches/blsa/blsa.htm>) and the Italian InChianti Study (<http://www.inchiantistudy.net/>).

The health-care provider must use the notion of variability in aging to help individuals make lifestyle and treatment choices to optimize their own aging. This is particularly true given that there are many age-related changes that occur that are lessened by medical and behavioral interventions. It has been noted that there are longitudinal changes in the rate of decline in peak VO_2 in healthy adults. These changes are not constant across the age span in healthy persons, but accelerate markedly with each successive age decade, regardless of physical activity habits. Bone changes also occur with age, and in addition to the common development of osteoporosis, persons with radiographic osteoarthritis, a common finding with age, lose bone at different rates than those with normal radiographs. This relationship varies between the site of the osteoarthritis and the site of measurement of bone mass density (BMD). Reports have shown that there tends to be significant longitudinal tissue loss for both gray and white matter even in the brains of very healthy older adults. Metabolic syndrome was noted to be a very common finding in aged Italians and was associated with stroke and diabetes in both sexes.

Conversely, much evidence supports the benefit of lifestyle interventions, specifically diet and physical activity, that will help to overcome some of the physical changes that can occur with age and may improve overall health and quality of life. With regard to diet, repeatedly it has been noted that there are protective effects to diets low in saturated fats and high in fruits and vegetables. Likewise, engaging in regular physical activity, at least 30 minutes daily, has been noted to have both physical and mental health benefits. Numerous resources help clinicians prescribe

and motivate older adults to change prior behaviors and/or continue to engage in health-promoting activities (Table 1-3).

It is impossible to address aging without considering the psychosocial aspects that occur in addition to the more visible biological and physical changes (Rowe and Kahn, 1987). Transitions associated with aging are commonly noted around retirement, loss of a spouse or significant other, pet, home, car and ability to drive, as well

TABLE 1-3. Web-Based Resources for Health Promotion	
National Guideline Clearinghouse	www.guideline.gov
Centers for Disease Control and Prevention: Healthy Living	www.cdc.gov/HealthyLiving/
Canadian Task Force on Preventive Health Care	www.phac-aspc.gc.ca/cd-mc/ctfphc-geccsp-eng.php
National Cholesterol Education Program	www.nhlbi.nih.gov/about/ncep/
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7)	www.nhlbi.nih.gov/guidelines/hypertension/
Agency for Healthcare Research and Quality Guidelines from the U.S. Preventative Services Task Force	www.ahrq.gov/clinic/uspstfix.htm
American Academy of Family Physicians: Summary of Policy Recommendations for Periodic Health Examinations	www.aafp.org/exam.xml
Web-based resources related to exercise facilitation in older adults	
AgePage: Exercise: Feeling Fit for Life	www.iamfitforlife.com/
The Exercise Assessment and Screening for You Tool	www.easyforyou.info
International Counsel on Active Aging	www.icaa.cc/
National Blueprint: Increasing Physical Activity Among Adults Age 50 and Older	www.agingblueprint.org/tips.cfm
National Institute of Aging: Exercise: A Guide from the National Institute of Aging	www.nia.nih.gov/HealthInformation/Publications/ExerciseGuide/
President’s Council on Physical Fitness and Sports	www.fitness.gov/
YMCA Programs Such as Active Older Adults (AOA)	www.ymca-austin.org/aoa.htm
American Heart Association	www.heart.org
Fitness Past 50 Materials	www.fitnesspastfifty.com/articles.html
International Council on Active Aging (ICAA)	www.icaa.cc/checklist.htm

as the loss of sensory function (hearing and vision), or ambulatory ability or capacity. Many fear the loss of independence with age and cognitive decline, and worry about having an acute catastrophic problem such as a hip fracture or stroke. Conversely, many older adults are quite resilient in the face of these losses and have much to teach the younger generation on how to respond to loss, optimize remaining function and ability, and adjust.

It is critical when working with older adults to be well aware of one's own beliefs with regard to theories of aging, attitudes about the aging process, and philosophies about how to age successfully. Recognizing these beliefs, clinicians must be open to evaluating their patient's beliefs and attitudes about aging and match interventions and recommendations with those beliefs. From a diagnostic perspective, this is particularly important as the older adults, who assume that with age it is normal to be short of breath, forgetful, and fatigued, may not report these symptoms as significant and thereby won't provide the health-care provider with the necessary information to facilitate a diagnosis. This requires the provider working with older adults to develop keen assessment skills and to use objective measures appropriately developed for older individuals.

Common examples of missed diagnoses occur related to cognitive impairment and depression. Older individuals, particularly those who have strong social skills and were well educated and engaged in social and professional activities throughout their life, may appear to be cognitively intact in the course of a social interaction and even a brief medical visit. However, on closer evaluation and with the use of standardized screening measures of memory, it may become evident that the individual has significantly impaired short-term memory. Functional assessment tests are particularly useful for a variety of assessments in older adults (Gallo et al., 2006) as are online resources (consultgerirn.org).

A hallmark of aging is the reduced response to stress, including the stress of disease. Many symptoms of disease are not the direct effect of the disease, but rather the organism's response. Thus, the symptom intensity may be dampened by the aged body's decreased responsiveness. The presentation of illness in the geriatric patient can be thought of as a combination of dampened primary sound in the presence of background noise.

In treating an older adult, it is useful to keep in mind that an individual's ability to function depends on a combination of his or her characteristics (eg, innate capacity, motivation, pain tolerance, or fear) and the setting in which that person is expected to function. The same individual may be functional in one setting and dependent in another. Think of how well you would do if you were suddenly transported to a country where you could not speak the language or understand the customs. It is critical to allow the older adult to independently perform all activities during clinical encounters to facilitate a true assessment of capability and function. For example, observing the patient's ability to get up and down from an examination chair or table, walk into the examination room, and don and doff a shirt are critical components of the examination. Physicians and other primary health-care providers should serve as role models to encourage optimal function among older individuals. Unfortunately, caregivers, both

formal and informal, may tend to provide unnecessary care for the older individual in an effort to decrease their risk of trauma or fatigue. This propagates a dependent status and can cause functional impairment and disability.

The clinician's first responsibility is to diagnose any acute clinical problems and alleviate all treatable symptoms. Once the patient's physical and psychological health has been optimized, the health-care provider has the opportunity to engage all members of the health-care team (nursing, physical and occupational therapy, social work, etc) to help the patient achieve his or her highest level of function and quality of life. For example, a social worker may help to identify community resources that can provide friendly visits to an older adult who is feeling isolated in the home setting.

Special consideration should be given to the older adult's physical and social environment. While multiple environmental assessments can be used (Gallo et al., 2006), it is also important to consider the fit between the individual and their environment. The Housing Enabler (www.enabler.nu/) is a tool that helps the clinician conduct such a comprehensive evaluation considering not only the environment and the environment risks, but the match of the person's functional abilities with that environment. Again, once evaluated, the team can be used to identify interventions to decrease risks of falls and optimize function.

GERIATRIC SYNDROME

Because diagnoses often do not tell the whole story in geriatrics, it is more helpful to think in terms of presenting problems. One aid to recalling some of the common problems of geriatrics uses a series of I's:

- Immobility
- Instability
- Incontinence
- Intellectual impairment
- Infection
- Impairment of vision and hearing
- Irritable colon
- Isolation (depression)
- Inanition (malnutrition)
- Impecunity
- Iatrogenesis
- Insomnia
- Immune deficiency
- Impotence

The list is important for several reasons. Especially with older patients, the expression of the problem may not be a good clue to the etiology. Conversely, a problem may occur for a variety of reasons.

For example, immobility may be caused by a variety of underlying physical and emotional problems. The older individual may have sustained a fractured hip or

congestive heart failure, a recent fall and fear of falling, or significant pain caused by degenerative joint disease, any or all of which may cause immobility. It is important to explore with the individual the underlying cause(s) so that appropriate interventions can be implemented. It may be necessary, for example, to alleviate patients' pain and address their fear of falling before initiating therapy or engaging the individual in a regular exercise program.

Among the list of I's is iatrogenesis, which is an all too common problem for older individuals. The risk of iatrogenesis increases with exposure to the care system. This includes tests, surgical interventions, and medications and treatments. In all patient interactions, the risk–benefit of any given treatment should be considered and, of course, explained to the individual and his or her health-care proxy. Medication management in particular needs considerable and careful deliberation as older adults are well known to have marked changes in absorption, metabolism, and excretion (see Chapter 4). Even more dangerous is the careless, hasty application of clinical “labels.” The patient who becomes confused and disoriented in the hospital may not be suffering from dementia. The individual who has an occasional urinary accident is not necessarily incontinent. Labeling patients as demented or incontinent is too often the first step toward their placement in a nursing home, a setting that can make such labels self-fulfilling prophecies. We must exercise great caution in applying these potent labels. They should be reserved for patients who have been carefully evaluated, lest we unnecessarily condemn countless persons to a lifetime of institutionalization.

ATYPICAL PRESENTATION OF COMMON CLINICAL PROBLEMS

One of the greatest challenges in the care of older adults is the atypical presentation of many diseases. It is not unusual for the first sign of an acute problem such as an infection (urine, respiration, or wound being the most common) to present with an atypical finding such as confusion, functional change, or a fall, rather than more typical symptoms such as urinary burning, cough, or fever. When the older individual has an underlying cognitive impairment, these changes may be very subtle, and caregivers may report that “he just isn't himself today” without providing more specific clinical signs. It is not unusual for independent and cognitively intact older individuals to come into the office with complaints that they just didn't feel right or didn't feel like making their bed and, on examination, are in acute atrial fibrillation. Any report of this type of new or sudden change in the individual's behavior or function should be treated as an acute medical problem, and a comprehensive evaluation should be done.

The first and principal task of the physician is to identify a correctable problem and correct it. No amount of rehabilitation, compassionate care, or environmental manipulation will compensate for missing a remediable diagnosis. However, diagnoses alone are usually insufficient. The elderly are the repositories of chronic disease more often cared for than cured. The process of geriatrics is thus threefold: (1) careful clinical assessment and management to identify acute and remediable problems, (2) ongoing management of underlying chronic illnesses, and (3) careful evaluation for evidence of geriatric syndromes (as per the I's discussed previously). It is only

through optimal medical management of these clinical problems that the individual will be able to optimize the use of resources (eg, environmental interventions, social interactions) and achieve his or her highest level of health and function.

REFERENCES

- Antebi A. Ageing: when less is more. *Nature*. 2007;447:536-537.
- Banks J, Marmot M, Oldfield Z, et al. Disease and disadvantage in the United States and in England. *JAMA*. 2006;295:2037-2045.
- Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. *JAMA*. 2005;294:716-724.
- Campisi J. Aging, chromatin, and food restriction—connecting the dots. *Science*. 2000;289:2062-2063.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16:31-41.
- Colman RJ, Anderson RM, Johnson SC, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. *Science*. 2009;325:201-204.
- Couzin-Frankel J. Aging genes: the sirtuin story unravels. *Science*. 2011;334:1194-1198.
- Finch CE, Tanzi RE. Genetics of aging. *Science*. 1997;278:407-411.
- Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. *Nature*. 2000;408:239-247.
- Fossel M. Telomerase and the aging cell: implications for human health. *JAMA*. 1998;279:1732-1735.
- Gallo JJ, Bogner HR, Fulmer T, et al. *Handbook of Geriatric Assessment*. 4th ed. Rockville, MD: Aspen; 2006.
- Gavrilova NS, Gavrilov LA. Search for predictors of exceptional human longevity. In: *Living to 100 and Beyond Monograph*. Schaumburg, IL: The Society of Actuaries; 2005:1-49.
- Goldsmith TC. Aging theories and their implications for medicine. 2006. Available at: http://www.azinet.com/aging/anti-aging_medicine.pdf. Accessed November 22, 2012.
- Guarente L. Sirtuins, aging, and medicine. *N Engl J Med*. 2011;364:2235-2244.
- Hayflick L. Biological aging is no longer an unsolved problem. *Ann NY Acad Sci*. 2007;1100:1-13.
- Kaeberlein M. Molecular basis of ageing. *EMBO Rep*. 2007;8:907-911.
- Kirkwood TB, Austad SN. Why do we age? *Nature*. 2000;408:233-238.
- Lenaerts I, van Eygen S, van Fleteren J. Adult-limited dietary restriction slows gompertzian aging in *Caenorhabditis elegans*. *Ann NY Acad Sci*. 2007;1100:442-448.
- Ly DH, Lockhart DJ, Lerner RA, Schultz PG. Mitotic misregulation and human aging. *Science*. 2000;287:2486-2492.
- Masoro EJ, Austad SN, eds. *Handbook of the Biology of Aging*. 7th ed. San Diego, CA: Academic Press; 2010.
- Maxmen A. Calorie restriction falters in the long run. *Nature*. 2012;488:569.
- Njajou OT, Hsueh W-C, Blackburn EH, et al. Association between telomere length, specific causes of death, and years of healthy life in health, aging, and body composition, a population-based study. *J Gerontol A Biol Sci Med Sci*. 2009;64:860-864.
- Perls TT. Anti-aging quackery: human growth hormone and tricks of the trade: more dangerous than ever. *J Gerontol A Biol Sci Med Sci*. 2004;59:682-691.
- Rando TA, Chang HY. Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock. *Cell*. 2012;418:46-57.

- Rowe JW, Kahn RL. Human aging: usual and successful. *Science*. 1987;237:143-149.
- Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. *JAMA*. 2012;308:890-897.
- Schmidt K. Physiology and pathophysiology of senescence. *Int J Vitam Nutr Res*. 1999;69:150-153.
- Sharp ZD, Strong R. The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity. *J Gerontol Biol Sci Med Sci*. 2010;65:580-589.
- Tanzi RE, Kovacs DM, Kim T-W, et al. The gene defects responsible for familial Alzheimer's disease. *Neurobiol Dis*. 1996;3:159-168.
- Terry DF, Nolan VG, Andersen SL, et al. Association of longer telomeres with better health in centenarians. *J Gerontol Biol Sci Med Sci*. 2008;63:809-812.
- Vijg J, Wei JY. Understanding the biology of aging: the key to prevention and therapy. *J Am Geriatr Soc*. 1995;43:426-434.

SUGGESTED READINGS

- Caldo RT, Young NS. Telomere diseases. *N Engl J Med*. 2009;361:2353-2365.
- Campisi J, Vijg J. Does damage to DNA and other macromolecules play a role in aging? If so, how? *J Gerontol A Biol Sci Med Sci*. 2009;64A:175-178.
- Goldsmith TC. *The Evolution of Aging*. 2nd ed. Annapolis, MD: Azinet Press; 2006.
- Hoeijmakers JHJ. DNA damage, aging, and cancer. *N Engl J Med*. 2009;361:1475-1485.

This page intentionally left blank

CHAPTER 2

The Geriatric Patient: Demography, Epidemiology, and Health Services Utilization

From the physician's perspective, the demographic curve strongly argues that medical practice in the future will include a growing number of older adults. Today persons age 65 years and older currently represent a little more than one-third of the patients seen by a primary care physician; in 40 years, we can safely predict that at least every other adult patient will age 65 or older. The "old-old" (older than 85), however, are the most rapidly growing group of older individuals, with a growth rate twice that of those age 65 years and older and four times that of the total population. This group now represents approximately 10% of the older population and is anticipated to grow from 5.7 million in 2010 to over 19 million by 2050 (Day, 1993). Among this old-old group those age 90 and above will show the steepest population rise (Federal Interagency Forum on Aging-Related Statistics, 2010). People in this old-old group tend to have poorer physical activity, be more dependent in activities of daily living, and have more cognitive impairment (Zhao et al., 2010).

The concern so often heard about the epidemic of aging stems primarily from two factors: numbers and dollars. We hear a great deal of talk about the incipient demise of Social Security, the bankrupt status of Medicare, the death of the family as a social institution, and dire predictions of demographic cataclysms. There is, indeed, cause for concern but not necessarily for alarm. The message of the numbers is straightforward: we cannot go on as we have; new approaches are needed. The shape of those approaches to meeting the needs of growing numbers of elderly persons in this society will reflect societal values. The costs associated with an aging society have already stimulated major changes in the way we provide care.

There is actually some basis for optimism. Data from the National Long-Term Care Survey show a decline in the rate of disability among older people. Overall, the rate of disability among older persons has decreased by 1% or more annually for the last several decades. However, the growth in the aging population more than offsets this gain. The number of disabled persons age 65 years and older in 1982 was 6.4 million. It increased to 7 million in 1994, and in 1999, the projected level of disability applied to population projections called for was about 9.3 million. It remains to be seen whether this trend toward lower disability rates can be sustained, but if so, it will greatly offset the effects of an aging population. Death rates from major killers have been falling in some areas. As seen in [Figure 2-1](#), death in older men from heart disease has dropped precipitously, while death from cerebrovascular disease has declined somewhat, but death from cancer overall has




FIGURE 2-1 Deaths per 100,000 men, age 65 and over (age-adjusted), selected causes, 1981-2004. (Data source: *The National Vital Statistics System*.)

not changed much. The pattern for women is very similar. Life expectancy at age 65 continues to increase for both men and women, and the gender gap is narrowing (**Fig. 2-2**). However, the obesity epidemic we now face may alter longevity among current adults. In a recent study, for example, obesity reduced U.S. life expectancy at age 50 years by 1.5 years for women and by 1.9 years for men (Preston and Stokes, 2011). Similarly, the number of patients with type 2 diabetes is increasing rapidly, which is known to be associated with premature death




FIGURE 2-2 Life expectancy at age 65 by sex and race/ethnicity, 1950-2003. (Data source: *The National Vital Statistics System*.)

(van Dieren et al., 2010). Consequently, life expectancy in the United States is anticipated to drop lower than that experienced in other countries. Global excess mortality attributable to diabetes in adults was estimated to be 3.8 million deaths.

However, aging is not the only contributor to the rapidly escalating costs of care. Although older people use a disproportionately large amount of medical care, most of the growth in costs is traceable to tremendous expansion in medical technology, both diagnostic and therapeutic. We have potent, but often expensive tools at our disposal. In some ways, we can be said to be reaping the fruits of our success. While a substantial number of older people live to enjoy many active years, some persons who might not have survived in earlier times are now living into old age and bringing with them the chronic disease burden that would have been avoided by death.

The Patient Protection and Affordable Care Act (PPACA) and the Reconciliation Act contain provisions designed to reduce Medicare program costs by approximately \$390 billion over the next 10 years through adjustments in payments to certain types of providers, by equalizing payment rates between Medicare Advantage and fee-for-service Medicare, and by increasing efficiencies in the way that health services are paid for and delivered. Medical practices and other organizations are changing in response to the PPACA and developing into patient-centered medical homes or accountable care organizations.

It is not clear exactly what changes in health care will be implemented. It is, however, an exciting time for geriatricians and other members of the health-care profession as we rethink how care is provided to best meet the needs of an aging America. Increasingly, there will be an emphasis on quality versus quantity of life. Older adults and their caregivers will be looking to geriatricians to help them with decisions about screening practices, such as when to stop going for mammography, as well as treatment decisions, such as whether or not to undergo cancer treatment or invasive surgical interventions.

GROWTH IN NUMBERS

A look at a few trends will help to focus the problem. The numbers of older people in this country (and in the world) have been growing in both absolute and relative terms. The growth in numbers can be traced to two phenomena: (1) the advances in medical science that have improved survival rates from specific diseases and (2) the birth rate. The relative numbers of older persons is primarily the result of two birth rates: (1) the one that occurred 65 or more years ago and (2) the current one. The first one provides the people, most of whom will survive, to become old. The second means that the proportion of those who are old depends on how many were born subsequently. This ratio is critical in estimating the size of the workforce available to support an elderly population. The looming demographic crisis is based on the forecast of a large number of older persons increasing through the first half of the next century as a result of the post–World War II baby boom. That group of people, born in the late 1940s and early 1950s, will begin to reach seniority by 2010. The relative rate of growth increases with each decade over age 75 years. Indeed, many

TABLE 2-1. The Elderly Population of The United States: Trends 1900-2050

Percentage of the total population							
Age (years)	1900	1940	1960	1990	2010	2030	2050
65-74	2.9	4.8	6.1	7.3	7.4	12.0	10.5
75-84	1.0	1.7	2.6	4.0	4.3	7.1	7.2
85+	0.2	0.3	0.5	1.3	2.2	2.7	5.1
65+	4.0	6.8	9.2	12.6	13.9	21.8	22.9

Source: U.S. Senate Subcommittee on Aging; American Association of Retired Persons; Federal Council on Aging; and U.S. Administration on Aging. *Aging America: Trends and Projections*. Washington, DC: US Department of Health and Human Services; 1991. DHHS Publ No. (FCoA) 91-28001.

older persons are now surviving longer. It is no longer rare to encounter a centenarian. In fact, the United States currently has the greatest number of centenarians of any nation, estimated at 70,490 on September 1, 2010 (Census Data, 2010). This corresponds to a national incidence of one centenarian per 4400 people.

The impact of this projection can be better appreciated by looking at [Table 2-1](#), which expresses the growth as a percentage of the total population. Although these forecasts can vary with the future birth and death rates, they are likely to be reasonably accurate. Thus, since the turn of the twentieth century, we have gone from a situation in which 4% of the population was age 65 or older to a time when more than 12% has reached 65 years. By the year 2030, that older population will have almost doubled. Put another way, in 2030, there will be as many people older than 75 years as there are today who are older than 65 years. When that observation is combined with the reduction in births in the cohort behind the baby boomers, the social implications become more obvious. There will be fewer workers to support the larger older population. This demographic observation has led to several urgent recommendations: (1) redefine retirement age to recognize the increase in life expectancy and thereby reduce the ratio of retirees to workers; (2) encourage younger persons to personally save more for their retirement to avoid excessive dependency on public funds; (3) encourage volunteerism among older adults to augment services in libraries, health-care facilities, and schools as well as provide professional services (von Bonsdorff and Rantanen, 2011); and (4) change public programs to address the needs of an aging society.

Because older people use more health-care services than do younger people, there will be an even greater demand on the health-care system and a concomitant rise in total health-care costs. Because Medicare beneficiaries use more institutional services (ie, hospital and nursing home care), their health-care costs are higher than those for younger groups. Only 12% of the population, those age 65 years and older, accounts for over one-third of health expenditures.

As seen in [Table 2-2](#), health expenditures increase substantially with disability. However, the rate of increase has been greater among those with less disability.

TABLE 2-2. Average Per Capita Health Spending for Medicare Beneficiaries Age 65 and Over (Age-Adjusted) in 2003, Dollars by Functional Status, 1992-2003

Limitations	1992	2003	% Change 1992-2003
None	\$4,257	\$6,683	57%
Physical limitation only	\$4,954	\$7,639	54%
IADL	\$8,243	\$11,669	42%
1-2 ADLs	\$10,533	\$14,573	38%
3-6 ADLs	\$24,368	\$29,433	21%

Source: Medicare Current Beneficiary Survey.
ADLs, activities of daily living; IADLs, instrumental activities of daily living.

The growth in the number of aged persons reflects improvements in both social living conditions and medical care. Over the course of this century, we have moved from a preponderance of acute diseases (especially infections) to an era of chronic illnesses. Today at least two-thirds of all the money spent on health care goes toward chronic disease. (For older people that proportion is closer to 95%.) Changes in the health-care system proposed within the PPACA are facilitating an increased focus on chronic care and management of not only single but multiple chronic illnesses (Boult and Wieland, 2010). [Table 2-3](#) reflects the changes in the common causes

TABLE 2-3. Changes in Commonest Causes of Death, 1900-2002, All Ages and Those 65 Years and Older

	Rate per 100,000					
	All ages				Age 65+	
	1900	Rank	2002	Rank	2000	Rank
Diseases of heart	13.8	4	847	1	1677	1
Malignant neoplasms	6.4	8	193		1311	
Cerebrovascular diseases	10.7	5	56	2	431	2
Chronic lower respiratory diseases	4.5	9	43		386	3
Influenza and pneumonia	22.9	1	23		154	5
Diabetes mellitus	1.1		25	5	183	
Alzheimer disease			20	6	158	4
Nephritis, nephritic syndrome, and nephrosis	8.9	6	14	7	109	7
Accidents	7.2	7	37		101	8
Septicemia			12	8	86	9
Other			181	9	955	10

Source: Anderson and Smith, 2005.

of death from 1900 to 2002 (Anderson and Smith, 2005). Many of those common at the turn of the twentieth century are no longer even listed. Today, the pattern of death in old age is generally similar to that of the population as a whole. The leading causes are basically the same, but there are some differences in the rankings. The leading causes of death are heart disease, cancer, stroke, chronic obstructive pulmonary disease, and influenza/pneumonia. Alzheimer disease features prominently.

Although the most dramatic reduction of mortality has occurred in infants and mothers, there has been a perceptible increase in survival even after age 65. Our stereotypes of what to expect from older people may therefore need reexamination. The average 65-year-old woman can expect to live another 19.2 years and a 65-year-old man another 16.3 years. Even at age 85, there is an expectation of more than 5 years.

However, this gain in survival includes both active and dependent years. Indeed, one of the great controversies of modern gerontological epidemiology is whether the gain in life expectancy brings with it equivalent gains in years free of dependency. The answer lies somewhere between. Although increased survival may be associated with more disability, the overall effect has been a pattern of decreasing disability (Cutler, 2001). Moreover, not all disability is permanent. Some older people experience transient episodes.

Some analysts have used disability as the basis for defining quality of life. They have then seized on the concept of active life expectancy to create a concept of quality-adjusted life-years (QALYs). Under this formulation, which is especially popular with economists who are seeking a common denominator against which to weigh all interventions, the goal of health care is to maximize individuals' periods of disability-free time. However, such a formulation immediately raises concerns about the care of all those who are already frail; they would derive no benefit from any actions on their behalf unless they could convert them to a disability-free state.

DISABILITY

The World Health Organization distinguishes among impairments, disabilities, and handicaps. A disease may create impairment in organ function. That failure can eventually lead to a reduced ability to perform certain tasks. This inability to perform may become a handicap when those tasks are necessary to carry out social activities.

Hence, a handicap is the result of external demands and may be mitigated by environmental alterations. The distinction can provide a useful framework within which to consider the care of older persons.

There is a general pattern of increased impairment in the senses and in orthopedic problems with age. Because they tend to accumulate over time, the prevalence of chronic conditions increases with age. However, the nature of survivorship produces the occasional twist. The association between prevalence and age is not absolute. Those afflicted with diabetes and those with chronic lung disease, for example, do not survive as readily to age 85 and above. The majority of older adults have one or more chronic conditions including common problems such as hypertension (53%), degenerative

joint disease (50%), heart disease (31%), cancer (21%), and diabetes (18%). Despite having more chronic conditions and impairments, older people tend to report their health as generally good, although three out of 10 Medicare beneficiaries rate their health as fair or poor. In the 75- to 84-year age group, 24% of individuals rate their health as fair or poor, with the remainder rating their health as good, very good, or excellent. This increases such that among those age 85 years and older, 30% rate their health as fair or poor, and the remainder indicate that they have good, very good, or excellent health. This contrast highlights the coping abilities of elderly persons discussed in Chapter 1.

Because physicians tend to see the sick, they may form a distorted picture of senior citizens. Most older persons are indeed self-sufficient and able to function on their own or with minimal assistance.

Those who need the most help are likely to be the very old. Functioning can be measured in a variety of ways. Commonly, we use the ability to perform specific tasks as a reflection of independence. These are grouped into two classes of measures. The term instrumental activities of daily living (IADLs) refers to tasks required to maintain an independent household. IADLs include such tasks as using the telephone, managing money, shopping, preparing meals, doing light housework, and getting around the community. They generally demand a combination of both physical and cognitive performance. The ability to carry out basic self-care activities is reflected in the so-called activities of daily living (ADLs). Dependencies in terms of ADLs—which include such tasks as eating, using the toilet, dressing, transferring, walking, and bathing—are less common than IADL losses. As shown in [Table 2-4](#), even among the oldest groups, the prevalence of ADL dependency is generally low. As with the decline in health ratings, there is a decline in ability to perform ADLs and

TABLE 2-4. Percentage of Older Adults Having Any Difficulty Performing Selected Activities			
	Percent		
	60-69 years	70-79 years	80+ years
Managing money	6	10	24
Walking one-fourth mile	21	30	49
Lifting/carrying 10 lb	22	28	46
Preparing own meals	8	12	27
Standing from armless chair	17	26	45
Getting in/out of bed	14	15	28
Dressing oneself	10	13	24
Going out for shopping, movies, etc	15	21	39

Source: Ervin RB. Prevalence of functional limitations among adults 60 years of age and over: United States, 1999-2002 advance data from Vital and Health Statistics No. 375. Washington, DC: National Center for Health Statistics, Centers for Disease Control and Prevention; August 2006.

IADLs among those in the 85+ age group. Approximately 23% of those age 65 to 84 years and 48% of those age 85 years and older indicate that they need help with ADLs. Similarly, with regard to IADLs, 23% of those age 65 to 84 years and 43% of those age 85 years and older need help with IADLs. Overall, men tend to be less likely to independently perform ADLs and IADLs across all age groups (Cubanksi et al., 2010).

SOCIAL SUPPORT

An important feature in determining an older person’s ability to live in the community is the extent of support available. The family is the heart of long-term care (LTC). Family and friends provide the bulk of services in each category with, or more often without, the help of formal caregivers. Informal care is largely provided by women.

Because women are both the major givers and receivers of LTC, a natural coalition has formed between those advocating for improved LTC and women’s organizations. Even as women are entering the workforce in large numbers, they continue to bear the majority of the caregiving load. Largely because they outlive men, over twice as many older women, as compared with men, live alone (Fig. 2-3), but the gap narrows by age 85. Wives and daughters are the most important source of family support for older persons. Those who are unmarried are more likely to live in LTC facilities, as are those who are female and older than age 85.




FIGURE 2-3 Living arrangements by age and sex, 2006. (Data source: Current Population Survey.)

Survey data suggest that more than 70% of persons age 65 and older have surviving children. (Remember that the children of persons age 85 and older may themselves be age 65 or older.) These “children” provide more than a third of the informal care.

The difference between needing and not needing a nursing home can depend on the availability of such support. Extrapolating from available data, we estimate that for every person older than age 65 in a nursing home, from one to three people are equally disabled living in the community. The importance of social support must be kept continuously in mind. Formal community supports will continue to rely heavily on family and friends to see that adequate amounts of care are provided to maintain an elderly individual in the community. Efforts to reduce the burden of caregiving include encouraging respite care and providing direct assistance to the caregivers, both formal care to share the burden and pragmatic instruction about how to cope with the behavioral problems of demented patients. Geriatricians and other members of the health-care team must work together to help caregivers provide the type and level of care needed to maintain older individuals in their least restrictive living situation and to avoid high-cost LTC.

USE OF SERVICES

In general, the use of health-care services increases with age. The exception to the pattern of age-related increase is seen with dental care; it is not clear whether this reflects the lack of coverage under Medicare or a loss of teeth, but probably is at least greatly influenced by the former. Older people are more likely to see physicians because of chronic problems (Fig. 2-4).

Hospitalizations account for nearly one-third of the \$2 trillion spent on health care in the United States annually. Nearly 20% of these hospitalizations are rehospitalizations occurring within 30 days of discharge. In 2008, there were 57,852




FIGURE 2-4 Percent of persons age 65 and over (age-adjusted) reporting selected chronic conditions by sex, 2004-2005. (Data source: National Health Interview Survey.)

readmissions in Pennsylvania, amounting to approximately \$2.5 billion in charges. Thirty-eight percent of these readmissions were related to complications or infections. From June 2004 through August 2009, 1791 events of readmission to the emergency department within 48 hours were reported to the Pennsylvania Patient Safety Authority, 8% of which were serious events (indicating harm to the patient). In June 2008, the Medicare Payment Advisory Commission calculated the annual cost of readmissions to the Medicare program at \$15 billion. Reducing Medicare readmissions has become an important strategy for funding health-care reform. The Centers for Medicare and Medicaid Services (CMS) posts hospital readmission rates for three conditions on its website. National readmission rates show a wide variance across states as well as variance between facilities within the same state. This high variance rate suggests that significant financial savings could be realized if best practices for preventing unnecessary readmissions were adopted.

According to the Medicare Payment Advisory Commission (MedPAC), in 2005, 6.2% of acute care hospitalizations of Medicare beneficiaries resulted in readmission within 7 days and 17.6% of hospitalizations resulted in readmission within 30 days. The 17.6% of hospital readmissions accounted for \$15 billion in Medicare spending. MedPAC identified seven conditions that make up almost 30% of spending on readmissions:

- Heart failure
- Chronic obstructive pulmonary disease
- Pneumonia
- Acute myocardial infarction (heart attack)
- Coronary artery bypass graft
- Percutaneous transluminal coronary angioplasty
- Other vascular diseases

In October 1, 2012, a major focus on decreasing hospital readmissions after discharge was implemented. Thus, there is increased focus on retooling health-care providers across a variety of settings to be able to best manage these clinical problems in acute care settings and to optimize recovery for older adults.

The introduction of a prospective payment system (PPS) for hospitals under Medicare in 1984 was associated with shorter lengths of stay and decreased admission rates. [Table 2-5](#) shows the most common discharge diagnoses and surgical procedures in 2008. Heart disease, cancer, stroke, and pneumonia continue to dominate the scene. The growth of technology can be seen in the frequent use of procedures, especially catheterization and endoscopy.

The introduction of PPS greatly spurred the use of postacute care. Patients discharged earlier from hospitals often needed someplace to recuperate. As a result, Medicare began paying twice for hospital care. It paid a fixed amount for shorter stays and then often again for the posthospital care. Indeed, postacute care has been the fastest growing segment of Medicare. In reaction, the 1997 Balanced Budget Act imposed separate prospective payment methods on each of the predominate

TABLE 2-5. Hospital Discharge Diagnoses and Procedures for Persons Age 65 Years and Older, 2008

Diagnoses	Rate per 10,000 population
Congestive heart failure	803
Malignant neoplasms	636
Cerebrovascular disease	606
Fracture, neck of femur	566
Cardiac dysrhythmias	522
Pneumonia	496
Coronary atherosclerosis	496
Osteoarthritis	452
Acute myocardial infarction	394
Volume depletion	240
Psychoses	191
Diabetes mellitus	188
Chronic bronchitis	88
Procedures	
Reduction of fracture	273
Endoscopy of small intestine	570
Cardiac catheterization	529
Insertion, replacement, removal of cardiac pacemaker	361
Total knee replacement	328
Balloon angioplasty of coronary artery	327
Arteriography and angiography using contrast material	327
Coronary artery bypass graft	237
Insertion of coronary stent	324
Endoscopy of large intestine	297
Cholecystectomy	129
Total hip replacement	126
Prostatectomy	103
Treatments/Tests	
Respiratory therapy	476
Diagnostic ultrasound	432
Computerized axial tomography	312
Hemodialysis	295
Insertion of endotracheal tube	221

DeFrances C, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital Discharge Survey. National Health Statistic Reports. 2008. Available at: <http://www.cdc.gov/nchs/data/nhsr/nhsr005.pdf>. Accessed November 28, 2012.

TABLE 2-6. Postacute Care Used Within 30 Days, 2006 and 2008, for the Top Five Diagnostic Related Groups

	Any PAC		SNF		LTCH		HHA		Therapy	
	2006	2008	2006	2008	2006	2008	2006	2008	2006	2008
Joint replacement	94	94	36	37	0.2	2.0	34	37	12	10
Stroke	74	75	39	37	2.0	0.1	16	17	8	8
Hip procedure	95	95	67	68	1.0	0.4	7	8	2	2
Pneumonia	36	36	52	51	1.2	0.9	38	38	7	9
Kidney, urinary tract infection	43	44	61	58	0.5	0.4	27	29	10	11

HHA, home health care; LTCH, long-term care hospital; PAC, postacute care; SNF, skilled nursing facility; Therapy, rehabilitation.

modes of postacute care (home health care, skilled nursing facilities, and inpatient rehabilitation). As shown in [Table 2-6](#), the use of postacute care was relatively stable between 2006 and 2008.

Ambulatory care visits for those 65 years of age and older are higher than for all other age groups with the exception of infants (Centers for Disease Control and Prevention, 2008). [Table 2-7](#) describes the patterns for ambulatory visits at various ages. Despite the general principle that bad things are more common with increasing age after age 75, not all diagnoses increase with age. Close to half (41%) of all visits for older adults are due to chronic versus acute medical problems.

TABLE 2-7. Percentage of Office Visits by Selected Medical Conditions, 2008

	Age 45-64 years	Age 65-74 years	Age 75+ years
Arthritis	17	24	24
Ischemic heart disease	4	10	12
Congestive heart failure	1	3	7
Chronic obstructive pulmonary disease	4	8	8
Depression	13	7	6
Diabetes	15	21	19
Hypertension	34	50	54
Obesity	9	7	5

Source: Centers for Disease Control and Prevention, 2008.

NURSING HOME USE

The nursing home has traditionally been used as the touchstone for LTC, but its role has changed with the changes in hospital payment under Medicare. The fixed-payment approach and the consequent shortening of hospital stays have spawned a new industry of posthospital care, sometimes called subacute care or postacute care. This includes services such as dialysis, rehabilitation, management of patients on ventilators, and wound care. In effect, care that was formerly rendered in a hospital is now provided in other settings, including the nursing home and the home of the patient.

Some nursing homes have sought to increase their capacity to support such care by changing the compilation of their nursing staff and establishing separate units for short-stay postacute care versus LTC residents, whereas others provide these services to residents without making such changes. Thus, the distinction between long-stay and short-stay nursing home residents can be confusing for staff, residents, and families. Some residents are in nursing homes for chronic care, whereas others are there just for rehabilitation and to recover from an acute event such as a hip fracture.

The majority of nursing home care is paid for by Medicaid (65%) and Medicare (14%). Those who do pay privately often spend down their resources and turn to public assistance. While nursing homes have increased their Medicare business dramatically, their long-stay business has been threatened by a growing disinclination to use such facilities. New forms of care, like assisted living, personal care homes, residential care homes, or sheltered housing, have provided other options, especially for those who can pay for such care. Regardless of the name, these facilities vary greatly depending on the state in which they are in and state regulations and regarding services offered, philosophy of care, and cost. Assisted living services are not covered by Medicare, although some states (approximately 38 at this time) have some coverage through Medicaid, and this may begin to increase given that it is cheaper than the cost of a long-term stay in a nursing home.

We are prone to cite an estimated 5% for the proportion of those age 65 years and older who are in nursing homes at any moment. But such a figure is a potentially misleading generalization in two respects. As [Figure 2-5](#) suggests, age is a very important factor. Among those age 65 to 74 years old, the rate is less than 2%. It rises to approximately 7% for those age 75 to 84 and then jumps to 20% for those age 85 and older. Moreover, what were formerly considered permanent stays have increasingly become short, transient visits. Thus, it is important to distinguish between these prevalence rates and the lifetime probability of entering a nursing home. Longitudinal studies suggest that persons age 65 have a 46% chance of spending some time in a nursing home before they die. Discharge rates of residents from nursing homes to other settings (eg, assisted living, home), particularly for those who have been in the facility for <30 days, have increased. For those who remain in facilities for >90 days, however, the likelihood of being discharged continues to be low. Those who are determined to return home and have lower care needs are more likely to be discharged (Arling et al., 2010). Nursing homes are needed not only because of the presence of diseases and functional disabilities, but also as a result of a lack of social support. Often the family




FIGURE 2-5 Nursing home residents per 1000 population by age, sex, and race/ethnicity, 2004. (Data source: *The National Nursing Home Survey*.)

becomes exhausted after caring for an elderly patient for a long period. Family fatigue is especially a problem when the patient has dementia and associated behavioral symptoms that are very disruptive.

The predictors for nursing home placement include older age, functional impairment prior to nursing home admission, lower perceived health, cognitive impairment, and lack of social supports. Predictors for those diagnosed with cognitive impairment include older age, inability to independently toilet, impaired balance, and lack of social support (ie, living alone). [Table 2-8](#) summarizes the factors associated with increased likelihood of nursing home placement for all nursing home residents as well as specifically for those with cognitive impairment (Dramé et al., 2012; Luppá et al., 2010).

The majority of admissions to nursing homes come from acute care facilities (62%-75%). To qualify for Medicare skilled nursing home services, the older individual must require daily skilled nursing (eg, wound care) or rehabilitative therapy services, generally within 30 days of a hospital stay of at least 3 days in length, and must be admitted to the nursing home due to a condition related to that hospitalization. Medicare offers full coverage on the first 20 days and partial coverage for days 21 to 100. Changes in the hospital environment are resulting in some situations in which older individuals are not eligible for skilled services. Increasingly, hospitals are using “observation” stays in which patients are not officially admitted to the hospital and yet remain in an “observation” bed receiving acute care services for up to 48 hours. If they do get admitted, these 2 days cannot be used toward Medicare eligibility.

Hospitalization often represents the last step in a series of steps involving the deterioration of the patient and the inability of the patient's social supports to provide the level of care needed. For others, hospitalization results from an acute event, for example, a broken hip or a stroke, that then necessitates at least a short stay for rehabilitation. Following transfers from acute care settings to nursing facilities, admissions to nursing facilities occur from home settings at a rate of 23%. A smaller, although growing, percentage of individuals in assisted living settings are transferred to nursing homes (9%), and this is particularly true if those facilities are associated with a nursing home or have one geographically close.

TABLE 2-8. Factors Affecting the Need for Nursing Home Admission	
For all nursing home residents	For nursing home residents with known cognitive impairment
Age	
Social supports	Ability to use the toilet
	Balance
	Living alone
Activities of daily living	
Cognitive status and associated behavioral problems	
Clinical diagnoses including: diabetes, hypertension, stroke, cancer, or having had a fall	
Ability to manage medication	
Income	
Payment eligibility	
Need for special services	
Characteristics of the support system	
Family capability	
For married respondents, age of spouse	
Presence of responsible relative (usually adult child)	
Family structure of responsible relative	
Employment status of responsible relative	
Physician availability	
Amount of care currently received from family and others	
Community resources	
Formal community resources	
Informal support systems	
Presence of long-term care institutions	
Characteristics of long-term care institutions	

The care of nursing home residents is more complex than it used to be. Management of medical problems is geared toward optimizing function, physical activity, and overall quality of life. Clinical problems include such things as infections, falls, malnutrition, dehydration, incontinence, behavioral disturbances, drug side effects and interactions, and management of multiple comorbidities. Care management must be done in collaboration with the resident and family/caregiver wishes and must consider ethical issues and resource allocation.

Once in a nursing home, residents have high rates of hospitalization; approximately a quarter of all residents are likely to be transferred at least once per year to the hospital (Mor et al., 2010). Infection is the most common reason for this transfer, and it is believed that many transfers could be avoidable with appropriate systems of care and resources within the skilled facility. Interventions such as INTERACT II (<http://interact2.net>) are being used to decrease the rates of transfer (Ouslander et al., 2011).

With the growing number of older adults who have three or more chronic diseases, there is likely to be an increased need for the expertise of a geriatrician as well as care options to best manage not just single but multiple morbidities (Boyd and Fortin, 2011). Likewise, these individuals are going to need care that may not be best provided in a single individual home setting. Care options and choices will be important for health-care providers to understand and to share with patients and families. A more detailed guide to LTC resources is presented in Chapter 15.

REFERENCES

- Anderson RN, Smith BS. Deaths: leading causes for 2002. National Vital Statistics Report. 2005. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_17.pdf. Accessed November 28, 2012.
- Arling G, Kane RL, Cooke V, Lewis T. Targeting residents for transitions from nursing home to community. *Health Serv Res*. 2010;45:691-711.
- Boult C, Wieland GD. Comprehensive primary care for older patients with multiple chronic conditions: "nobody rushes you through." *JAMA*. 2010;30:1936-1943.
- Boyd C, Fortin M. Future of multimorbidity research: how should understanding of multimorbidity inform health system design? *Public Health Rev*. 2011;32:451-474.
- Census Data. Resident population. National population estimates for the 2000s. Monthly postcensal resident population, by single year of age, sex, race, and Hispanic origin, July to September 2010. 2010. Available at: <http://www.census.gov/popest/>. Accessed November 28, 2012.
- Centers for Disease Control and Prevention. National Ambulatory Medical Care Survey: 2008 summary tables. 2008. Available at: http://www.cdc.gov/nchs/data/ahcd/namcs_summary/2008_namcs_web_tables.pdf. Accessed November 28, 2012.
- Cubanksi J, Huang J, Camico A, Jacobson G, Neuman T. *Medicare Chartbook, Fourth Edition 2010*. 2010. Available at: <http://www.kff.org/medicare/upload/8103.pdf>. Accessed November 28, 2012.
- Cutler DM. Declining disability among the elderly. *Health Aff*. 2001;20(6):11-27.
- Day J. *Population Projections of the United States, by Age, Sex, Race, and Hispanic Origin: 1993 to 2050, Current Population Reports*. Washington, DC: U.S. Bureau of the Census, U.S. Government Printing Office; 1993:25-1104.

- Dramé M, Lang PO, Jolly D, et al. Nursing home admission in elderly subjects with dementia: predictive factors and future challenges. *J Am Med Dir Assoc.* 2012;13:17-20.
- Federal Interagency Forum on Aging-Related Statistics. Population: number of older Americans. 2010. Available at: http://www.agingstats.gov/Main_Site/Data/2010_Documents/docs/Population.pdf. Accessed November 28, 2012.
- Luppa M, Luck T, Weyerer S, König H, Brähler E, Riedel-Heller SG. Prediction of institutionalization in the elderly. A systematic review. *Age Ageing.* 2010;39:31-38.
- Mor V, Intrator I, Feng V, Grabowski DC. The revolving door of rehospitalization from skilled nursing facilities. *Health Aff.* 2010;29:57-64.
- Ouslander J, Lamb G, Tappen R, et al. Interventions to reduce hospitalizations from nursing homes: evaluation of the INTERACT II collaborative quality improvement project. *J Am Geriatr Soc.* 2011;59:745-753.
- Preston S, Stokes A. Contribution of obesity to international differences in life expectancy. *Am J Public Health.* 2011;101:2137-2143.
- van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. *Eur J Cardiovasc Prev Rehabil.* 2010;17(Suppl 1):S3-S8.
- von Bonsdorff M, Rantanen T. Benefits of formal voluntary work among older people. A review. *Aging Clin Exp Res.* 2011;23:162-169.
- Zhao J, Barclay S, Farquhar M, Kinmonth AL, Brayen C, Flemming J. The oldest old in the last year of life: population based findings from Cambridge City over-75s cohort study participants aged 85 and older at death. *J Am Geriatr Soc.* 2010;38:1-11.

SUGGESTED READINGS

- Anderson RN, Smith BS. Deaths: leading causes for 2002. National Vital Statistics Report. 2005. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_17.pdf. Accessed November 28, 2012.
- Arling G, Kane RL, Cooke V, Lewis T. Targeting residents for transitions from nursing home to community. *Health Serv Res.* 2010;45:691-711.
- Boult C, Wieland GD. Comprehensive primary care for older patients with multiple chronic conditions: "nobody rushes you through." *JAMA.* 2010;30:1936-1943.
- Boyd C, Fortin M. Future of multimorbidity research: how should understanding of multimorbidity inform health system design? *Public Health Rev.* 2011;32:451-474.
- Census Data. Resident population. National population estimates for the 2000s. Monthly postcensal resident population, by single year of age, sex, race, and Hispanic origin, July to September 2010. 2010. Available at: <http://www.census.gov/popest/>. Accessed November 28, 2012.
- Centers for Disease Control and Prevention. National Ambulatory Medical Care Survey: 2008 summary tables. 2008. Available at: http://www.cdc.gov/nchs/data/ahcd/namcs_summary/2008_namcs_web_tables.pdf. Accessed November 28, 2012.
- Cubanksi J, Huang J, Camico A, Jacobson G, Neuman T. *Medicare Chartbook, Fourth Edition 2010.* 2010. Available at: <http://www.kff.org/medicare/upload/8103.pdf>. Accessed November 28, 2012.
- Day J. *Population Projections of the United States, by Age, Sex, Race, and Hispanic Origin: 1993 to 2050, Current Population Reports.* Washington, DC: U.S. Bureau of the Census, U.S. Government Printing Office; 1993:25-1104.
- Dramé M, Lang PO, Jolly D, et al. Nursing home admission in elderly subjects with dementia: predictive factors and future challenges. *J Am Med Dir Assoc.* 2012;13:17-20.

- Federal Interagency Forum on Aging-Related Statistics. Population: number of older Americans. 2010. Available at: http://www.agingstats.gov/Main_Site/Data/2010_Documents/docs/Population.pdf. Accessed November 28, 2012.
- Luppa M, Luck T, Weyerer S, König H, Brähler E, Riedel-Heller SG. Prediction of institutionalization in the elderly. A systematic review. *Age Ageing*. 2010;39:31-38.
- Mor V, Intrator I, Feng V, Grabowski DC. The revolving door of rehospitalization from skilled nursing facilities. *Health Aff*. 2010;29:57-64.
- Ouslander J, Lamb G, Tappen R, et al. Interventions to reduce hospitalizations from nursing homes: evaluation of the INTERACT II collaborative quality improvement project. *J Am Geriatr Soc*. 2011;59:745-753.
- Preston S, Stokes A. Contribution of obesity to international differences in life expectancy. *Am J Public Health*. 2011;101:2137-2143.
- van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. *Eur J Cardiovasc Prev Rehabil*. 2010;17(Suppl 1):S3-S8.
- von Bonsdorff M, Rantanen T. Benefits of formal voluntary work among older people. A review. *Aging Clin Exp Res*. 2011;23:162-169.
- Zhao J, Barclay S, Farquhar M, Kinmonth AL, Brayen C, Flemming J. The oldest old in the last year of life: population based findings from Cambridge City over-75s cohort study participants aged 85 and older at death. *J Am Geriatr Soc*. 2010;38:1-11.

CHAPTER 3

Evaluating the Geriatric Patient

Comprehensive evaluation of an older individual's health status is one of the most challenging aspects of clinical geriatrics. It requires sensitivity to the concerns of people, awareness of the many unique aspects of their medical problems, ability to interact effectively with a variety of health professionals, and often a great deal of patience. Most importantly, it requires a perspective different from that used in the evaluation of younger individuals. Not only are the a priori probabilities of diagnoses different, but one must be attuned to more subtle findings. Progress may be measured on a finer scale. Special tools are needed to ascertain relatively small improvements in chronic conditions and overall function compared with the more dramatic cures of acute illnesses often possible in younger patients. Creativity is essential to incorporate these tools efficiently in a busy clinical practice.

Comprehensive geriatric assessment has been shown to improve both mortality and the chances of remaining in the community (Barer, 2011; Ellis et al., 2011). The challenge is to use it efficiently. Complex patients and those facing major long-term care decisions are strong candidates, but studies have also shown benefit for persons presumably at low risk. As described in Chapter 4, home visits to basically well older persons can prevent nursing home admissions and functional decline.

The purpose of the evaluation and the setting in which it takes place will determine its focus and extent. Considerations important in admitting a geriatric patient with a fractured hip and pneumonia to an acute care hospital during the middle of the night are obviously different from those in the evaluation of an older demented patient exhibiting disruptive behavior in a nursing home. Elements included in screening for treatable conditions in an ambulatory clinic are different from those in assessment of older individuals in their own homes or in long-term care facilities.

Despite the differences dictated by the purpose and setting of the evaluation, several essential aspects of evaluating older patients are common to all purposes and settings. [Figure 3-1](#) depicts these aspects. Several comments on addressing them are in order:

1. Physical, psychological, and socioeconomic factors interact in complex ways to influence the health and functional status of the geriatric population.
2. Comprehensive evaluation of an older individual's health status requires an assessment of each of these domains. The coordinated efforts of several different health-care professionals functioning as an interdisciplinary team are needed.
3. Functional abilities should be a central focus of the comprehensive evaluation of geriatric patients. Other more traditional measures of health status (such as diagnoses and physical and laboratory findings) are useful in dealing with underlying etiologies and detecting treatable conditions, but in the geriatric




FIGURE 3-1 Components of assessment of older patients.

population, measures of function are often essential in determining overall health, well-being, and the need for health and social services.

Just as function is the common language of geriatrics, assessment lies at the heart of its practice. Special techniques that address multiple problems and their functional consequences offer a way to structure the approach to complicated geriatric patients. The core of geriatric practice has been considered the comprehensive geriatric assessment, but its role has been actively debated. Geriatric assessment has been tested in a variety of forms. [Table 3-1](#) summarizes the findings from a number of randomized controlled trials of different approaches to geriatric assessment. Annual in-home comprehensive geriatric assessment as a preventive strategy demonstrated the potential to delay the development of disability and reduce permanent nursing home stays (Stuck et al., 2002). Controlled trials of approaches to hospitalized geriatric patients suggest comprehensive geriatric assessment by a consultation team with limited follow-up does not improve health or survival of selected geriatric patients (Reuben et al., 1995) but suggests that a special acute geriatric unit can improve function and reduce discharges to institutional care (Landefeld et al., 1995). A controlled multisite Veterans Affairs trial of inpatient geriatric evaluation and management demonstrated significant reductions in functional decline without increased costs (Cohen et al., 2002). Results of outpatient geriatric assessment have been mixed and less compelling (Cohen et al., 2002). However, a randomized trial of outpatient geriatric assessment showed that it prevented functional decline (Reuben et al., 1999).

There is considerable variation in approaches to the comprehensive assessment of geriatric patients. Various screening and targeting strategies have been used to identify appropriate patients for more comprehensive assessment. These strategies range from selection based on age to targeting patients with a certain number of

TABLE 3-1. Examples of Randomized Controlled Trials of Geriatric Assessment

Setting	Examples of assessment strategies	Selected outcomes*
Community/ outpatients	Social worker assessment and referral Nursing assessment and referral Annual in-home assessment by nurse practitioner Multidisciplinary clinic assessment	Reduced mortality Reduced hospital use Reduced permanent nursing home use Delayed development of disability
Hospital inpatient (specialized units)	Interdisciplinary teams with focus on function, geriatric syndromes, rehabilitation	Reduced mortality Improved function Reduced acute hospital and nursing home use
Hospital inpatient consultation	Geriatric consultation teams	Mixed results Some studies show improved function and lower shortterm mortality Other studies show no effects

*Not all studies show improvements in all outcomes. See text and Rubenstein et al., 1991.

impairments or specific conditions. Sites of assessment vary as well and include the clinic, the home, the hospital, and different levels of long-term care. Geriatric assessment also varies in terms of which discipline carries out the different components of the assessment as well as in the specific assessment tools used. Despite the dramatic variation in approach to targeting, personnel used, and measures employed, a clear pattern of effectiveness has emerged. Taken together, these results are both heartening and cautioning. Systematic approaches to patient care are obviously desirable. The issue is more how formalized these assessments should be. Research suggests that the specifics of the assessment process seem to be less important than the very act of systematically approaching older people with the belief that improvement is possible.

A major concern about such assessments is efficiency. Because of the multidimensional nature of geriatric patients' problems and the frequent presence of multiple interacting medical conditions, comprehensive evaluation of the geriatric patient can be time consuming and thus costly. It is important to reduce duplication of effort. It is possible to have interprofessional collaboration in determining what data should be collected, but the actual data collection is best delegated to one or, at most, a few team members. Additional expertise can be brought to bear if the initial screening uncovers an area that requires it. Another crucial lesson is that assessment without follow-up is unlikely to make any difference. Thus, the term "geriatric assessment" has given way to the concept of geriatric evaluation and management. There must be strong commitment to

act on the problems uncovered and to follow up long enough to be sure that they have responded to the treatment prescribed.

Strategies that can make the evaluation process more efficient include the following:

1. The development of a close-knit interdisciplinary team with minimal redundancy in the assessments performed.
2. Use of carefully designed questionnaires that reliable patients and/or caregivers can complete before an appointment.
3. Incorporation of screening tools that target the need for further, more in-depth assessment.
4. Use of assessment forms that can be readily incorporated into a computerized relational database.
5. Integration of the evaluation process with case management activities that target services based on the results of the assessment.

This chapter focuses on the general aspects of assessing geriatric patients; sections on geriatric consultation, preoperative evaluation, and environmental assessments are included in the chapter.

Chapter 14 includes information on case management and other health services, and Chapter 15 is devoted to the assessment and management of geriatric patients in the nursing home setting.

HISTORY

Sir William Osler's aphorism, "Listen to the patient, he'll give you the diagnosis," is as true in older patients as it is in younger patients. In the geriatric population, however, several factors make taking histories more challenging, difficult, and time consuming.

Table 3-2 lists difficulties commonly encountered in taking histories from geriatric patients, the factors involved, and some suggestions for overcoming these difficulties. Impaired hearing and vision (despite corrective devices) are common and can interfere with effective communication.

Techniques such as eliminating extraneous noises, speaking slowly and in deep tones while facing the patient, and providing adequate lighting can be helpful. The use of simple, inexpensive amplification devices with earphones can be especially effective, even among the severely hearing impaired. Patience is truly a virtue in obtaining a history; because thought and verbal processes are often slower in older than in younger individuals, patients should be allowed adequate time to answer in order not to miss potentially important information. At the same time, the cardinal rule of open-ended questions may need to be tempered to get the maximum amount of information in the time allocated.

Many older individuals underreport potentially important symptoms because of their cultural and educational backgrounds as well as their expectations of illness as a normal concomitant of aging. More aggressive probing may be necessary. Fear of illness and disability or depression accompanied by a lack of self-concern may also cause less

TABLE 3-2. Potential Difficulties in Taking Geriatric Histories

Difficulty	Factors involved	Suggestions
Communication	Diminished vision Diminished hearing Slowed psychomotor performance	Use well-lit room Eliminate extraneous noise Speak slowly in a deep tone Face patient, allowing patient to see your lips Use simple amplification device for severely hearing impaired If necessary, write questions in large print Leave enough time for the patient to answer
Underreporting of symptoms	Health beliefs Fear Depression Altered physical and physiological responses to disease process Cognitive impairment	Ask specific questions about potentially important symptoms (see Table 3-3) Use other sources of information (relatives, friends, other caregivers) to complete the history
Vague or nonspecific symptoms	Altered physical and physiological responses to disease process Altered presentation of specific diseases Cognitive impairment	Evaluate for treatable diseases, even if the symptoms (or signs) are not typical or specific when there has been a rapid change in function Use other sources of information to complete history
Multiple complaints	Prevalence of multiple coexisting diseases Somatization of emotions—"masked depression" (see Chap. 7)	Attend to all somatic symptoms, ruling out treatable conditions Get to know the patient's complaints; pay special attention to new or changing symptoms Interview the patient on several occasions to complete the history

frequent reporting of symptoms. Altered physical and physiological responses to disease processes (see Chapter 1) can result in the absence of symptoms (such as painless myocardial infarction or ulcer and pneumonia without cough). Symptoms of many diseases can be vague and nonspecific because of these age-related changes. Impairments of memory and other cognitive functions can result in an imprecise or inadequate history and compound these difficulties. Asking specifically about potentially important symptoms (such as those listed in [Table 3-3](#)) and using other sources

TABLE 3-3. Important Aspects of the Geriatric History

Social history

Living arrangements
Relationships with family and friends
Expectations of family or other caregivers
Economic status
Abilities to perform activities of daily living (see Table 3-8)
Social activities and hobbies
Mode of transportation
Advance directives (see Chap. 17)

Past medical history

Previous surgical procedures
Major illnesses and hospitalizations
Previous transfusions
Immunization status
 Influenza, pneumococcus, tetanus, zoster
Preventive health measures
 Mammography
 Papanicolaou (Pap) smear
 Flexible sigmoidoscopy
 Antimicrobial prophylaxis
 Estrogen replacement
Tuberculosis history and testing
Medications (use the “brown bag” technique; see text)
 Previous allergies
 Knowledge of current medication regimen
 Compliance
Perceived beneficial or adverse drug effects

Systems review

Ask questions about general symptoms that may indicate treatable underlying disease such as fatigue, anorexia, weight loss, insomnia, recent change in functional status
Attempt to elicit key symptoms in each organ system, including the following:

System	Key symptoms
Respiratory	Increasing dyspnea Persistent cough
Cardiovascular	Orthopnea Edema Angina Claudication Palpitations Dizziness Syncope
Gastrointestinal	Difficulty chewing Dysphagia Abdominal pain Change in bowel habit

(continued)

TABLE 3-3. Important Aspects of the Geriatric History (*continued*)

System	Key symptoms
Genitourinary	Frequency Urgency Nocturia Hesitancy, intermittent stream, straining to void Incontinence Hematuria Vaginal bleeding
Musculoskeletal	Focal or diffuse pain Focal or diffuse weakness
Neurological	Visual disturbances (transient or progressive) Progressive hearing loss Unsteadiness and/or falls Transient focal symptoms
Psychological	Depression Anxiety and/or agitation Paranoia Forgetfulness and/or confusion

of information (such as relatives, friends, and other caregivers) can be very helpful in collecting more precise and useful information in these situations.

At the other end of the spectrum, geriatric patients with multiple complaints can frustrate the health-care professional who is trying to sort them all out. The multiplicity of complaints can relate to the prevalence of coexisting chronic and acute conditions in many geriatric patients. These complaints may, however, be deceiving. Somatic symptoms may be manifestations of underlying emotional distress rather than symptoms of a physical illness, and symptoms of physical conditions may be exaggerated by emotional distress (see Chapter 5). Getting to know patients and their complaints and paying particular attention to new or changing symptoms are helpful in detecting potentially treatable conditions.

Clinicians may become impatient with the slow pace of older patients and their tendency to wander from the subject at hand. In desperation, they shift their focus to the accompanying family members who can provide a more lucid and linear history. But this tendency to bypass the older patient can have several serious effects. Not only does it diminish the self-image of the older patient and reinforce a message of dependency, it may miss important information that the patient knows but the family member does not.

Table 3-3 lists aspects of the history that are especially important in geriatric patients. It is often not feasible to gather all information in one session; shorter interviews in a few separate sessions may prove more effective in gathering these data from some geriatric patients.

Some topics that may be especially important to an older person's quality of life are often skipped over because they are embarrassing to the clinician or the patient. Issues like fecal and urinary incontinence and sexual dysfunction can be important areas to explore. Given its prevalence, vulnerability to treatment, and ability to complicate the care of other conditions, it is important to screen for depression. Chapter 7 reviews the measures available for depression screening in older patients.

Often shortchanged in medical evaluations, the social history is a critical component. Understanding the patient's socioeconomic environment and ability to function within it is crucial in determining the potential impact of an illness on an individual's overall health and need for health services. Especially important is the assessment of the family's feelings and expectations. Many family caregivers of frail geriatric patients have feelings of both anger (at having to care for a dependent family member) and guilt (over not being able or willing to do enough) and have unrealistic expectations. Such unrealistic expectations are often based on a lack of information and can interfere with care if not discussed. Unlike younger patients, older patients often have had multiple prior illnesses. Therefore, the past medical history is important in putting the patient's current problems in perspective; this can also be diagnostically important. For example, vomiting in an elderly patient who has had previous intra-abdominal surgery should raise the suspicion of intestinal obstruction from adhesions; nonspecific constitutional symptoms (such as fatigue, anorexia, and weight loss) in a patient with a history of depression should prompt consideration of a relapse. Because older individuals are often treated with multiple medications, they are at increased risk of noncompliance and adverse effects (see Chapter 14). A detailed medication history (including both prescribed and over-the-counter drugs) is essential.

The brown bag technique is very helpful in this regard; have the patient or caregiver empty the patient's medicine cabinet (prescribed and over-the-counter drugs as well as nontraditional remedies) into a brown paper bag and bring it to each visit. More often than not, one or more of these medications can, at least in theory, contribute to geriatric patients' symptoms. Clinicians should not hesitate to turn to pharmacists for help in determining potential drug interactions.

A complete systems review, focusing on potentially important and prevalent symptoms in the elderly, can help overcome many of the difficulties described earlier. Although not intended to be all-inclusive, Table 3-3 lists several of these symptoms.

General symptoms can be especially difficult to interpret. Fatigue can result from a number of common conditions such as depression, congestive heart failure, anemia, and hypothyroidism. Anorexia and weight loss can be symptoms of an underlying malignancy, depression, or poorly fitting dentures and diminished taste sensation. Age-related changes in sleep patterns, anxiety, gastroesophageal reflux, congestive heart failure with orthopnea, or nocturia can underlie complaints of insomnia. Because many frail geriatric patients limit their activity, some important symptoms may be missed. For example, such patients may deny angina and dyspnea but restrict their activity to avoid the symptoms. Questions such as "How far do you walk in a typical day?" and "What is the most common activity you carry out in a typical day?" can be helpful in patients suspected of limiting their activities to avoid certain symptoms.

PHYSICAL EXAMINATION

The common occurrence of multiple pathologic physical findings superimposed on age-related physical changes complicates interpretation of the physical examination. Table 3-4 lists common physical findings and their potential significance in the geriatric population.

An awareness of age-related physical changes is important to the interpretation of many physical findings and therefore subsequent decision making. For example, age-related changes in the skin and postural reflexes can influence the evaluation of hydration and volume status; age-related changes in the lung and lower-extremity edema secondary to venous insufficiency can complicate the evaluation of symptoms of heart failure.

Certain aspects of the physical examination are of particular importance in the geriatric population. Detection and further evaluation of impairments of vision and hearing can lead to improvements in quality of life. Walking performance can be a valuable indicator of a variety of problems. Evaluation of gait may uncover correctable causes of unsteadiness and thereby prevent potentially devastating falls (see Chapter 9). Careful palpation of the abdomen may reveal an aortic aneurysm, which, if large enough, might warrant consideration of surgical removal. The mental status examination is especially important; this aspect of the physical examination is discussed later and in Chapter 6.

LABORATORY ASSESSMENT

Abnormal laboratory findings are often attributed to “old age.” While it is true that abnormal findings are common in geriatric patients, few are true aging changes. Misinterpreting an abnormal laboratory value as an aging change may result in underdiagnosis and undertreatment of conditions such as anemia.

Table 3-5 lists those laboratory parameters unchanged in the elderly and those commonly abnormal. Abnormalities in the former group should prompt further evaluation; abnormalities in the latter group should be interpreted carefully. Table 3-5 also notes important considerations in interpreting commonly abnormal laboratory values.

FUNCTIONAL ASSESSMENT

General Concepts

Ability to function should be a central focus of the evaluation of geriatric patients (see Fig. 3-1). Medical history, physical examination, and laboratory findings are all of obvious importance in diagnosing and managing acute and chronic medical conditions in older people, as they are in all age groups. But once the dust settles, functional abilities are just as, if not more, important to the overall health, well-being, and potential need for services of older individuals. For example, in a patient with hemiparesis, the nature, location, and extent of the lesion may be important in the management, but whether the patient is continent and can climb the steps to an

TABLE 3-4. Common Physical Findings and Their Potential Significance in Geriatrics

Physical findings	Potential significance
Vital signs	
Elevated blood pressure	Increased risk for cardiovascular morbidity; therapy should be considered if repeated measurements are high (see Chap. 11)
Postural changes in blood pressure	May be asymptomatic and occur in the absence of volume depletion Aging changes, deconditioning, and drugs may play a role Can be exaggerated after meals Can be worsened and become symptomatic with antihypertensive, vasodilator, and tricyclic antidepressant therapy
Irregular pulse	Arrhythmias are relatively common in otherwise asymptomatic elderly; seldom need specific evaluation or treatment (see Chap. 11)
Tachypnea	Baseline rate should be accurately recorded to help assess future complaints (such as dyspnea) or conditions (such as pneumonia or heart failure)
Weight changes	Weight gain should prompt search for edema or ascites Gradual loss of small amounts of weight common; losses in excess of 5% of usual body weight over 12 months or less should prompt search of underlying disease
General appearance and behavior	
Poor personal grooming and hygiene (eg, poorly shaven, unkempt hair, soiled clothing)	Can be signs of poor overall function, caregiver's neglect, and/or depression; often indicates a need for intervention
Slow thought processes and speech	Usually represents an aging change; Parkinson disease and depression can also cause these signs
Ulcerations	Lower extremity vascular and neuropathic ulcers common Pressure ulcers common and easily overlooked in immobile patients
Diminished turgor	Often results from atrophy of subcutaneous tissues rather than volume depletion; when dehydration suspected, skin turgor over chest and abdomen most reliable
Ears (see Chap. 13)	
Diminished hearing	High-frequency hearing loss common; patients with difficulty hearing normal conversation or a whispered phrase next to the ear should be evaluated further Portable audioscopes can be helpful in screening for impairment

(continued)

TABLE 3-4. Common Physical Findings and Their Potential Significance in Geriatrics (*continued*)

Eyes (see Chap. 13)	
Decreased visual acuity (often despite corrective lenses)	May have multiple causes, all patients should have thorough optometric or ophthalmologic examination Hemianopsia is easily overlooked and can usually be ruled out by simple confrontation testing
Cataracts and other abnormalities	Fundoscopic examination often difficult and limited; if retinal pathology suspected, thorough ophthalmologic examination necessary
Mouth	
Missing teeth	Dentures often present; they should be removed to check for evidence of poor fit and other pathology in oral cavity Area under the tongue is a common site for early malignancies
Skin	
Multiple lesions	Actinic keratoses and basal cell carcinomas common; most other lesions benign
Chest	
Abnormal lung sounds	Crackles can be heard in the absence of pulmonary disease and heart failure; often indicate atelectasis
Cardiovascular (see Chap. 11)	
Irregular rhythms	See Vital Signs at the beginning of the table
Systolic murmurs	Common and most often benign; clinical history and bedside maneuvers can help to differentiate those needing further evaluation Carotid bruits may need further evaluation
Vascular bruits	Femoral bruits often present in patients with symptomatic peripheral vascular disease
Diminished distal pulses	Presence or absence should be recorded as this information may be diagnostically useful at a later time (eg, if symptoms of claudication or an embolism develop)
Abdomen	
Prominent aortic pulsation	Suspected abdominal aneurysms should be evaluated by ultrasound
Genitourinary (see Chap. 8)	
Atrophy	Testicular atrophy normal; atrophic vaginal tissue may cause symptoms (such as dyspareunia and dysuria) and treatment may be beneficial

TABLE 3-4. Common Physical Findings and Their Potential Significance in Geriatrics (continued)

Genitourinary (see Chap. 8)

Pelvic prolapse (cystocele, rectocele)	Common and may be unrelated to symptoms; gynecologic evaluation helpful if patient has bothersome, potentially related symptoms
--	---

Extremities

Periarticular pain	Can result from a variety of causes and is not always the result of degenerative joint disease; each area of pain should be carefully evaluated and treated (see Chap. 10)
Limited range of motion	Often caused by pain resulting from active inflammation, scarring from old injury, or neurological disease; if limitations impair function, a rehabilitation therapist could be consulted
Edema	Can result from venous insufficiency and/or heart failure; mild edema often a cosmetic problem; treatment necessary if impairing ambulation, contributing to nocturia, predisposing to skin breakdown, or causing discomfort Unilateral edema should prompt search for a proximal obstructive process

Neurological

Abnormal mental status (ie, confusion, depressed affect)	See Chaps. 6 and 7
Weakness	Arm drift may be the only sign of residual weakness from a stroke Proximal muscle weakness (eg, inability to get out of chair) should be further evaluated; physical therapy may be appropriate

apartment makes the difference between going home to live or going to a nursing home.

The concern about function as a core component of geriatrics deserves special comment. Functioning is the end result of the various efforts of the geriatric approach to care. Optimizing function necessitates integrating efforts on several fronts. It is helpful to think of functioning as an equation:

$$\text{Function} = \frac{(\text{physical capabilities} \quad \text{medical management} \quad \text{motivation})}{(\text{social, psychological, and physical environment})}$$

This admitted oversimplification is meant as a reminder that function can be influenced on at least three levels. The clinician's first task is to remediate the remediable.

TABLE 3-5. Laboratory Assessment of Geriatric Patients**Laboratory parameters unchanged***

Hemoglobin and hematocrit
 White blood cell count
 Platelet count
 Electrolytes (sodium, potassium, chloride, bicarbonate)
 Blood urea nitrogen
 Liver function tests (transaminases, bilirubin, prothrombin time)
 Free thyroxine index
 Thyroid-stimulating hormone
 Calcium
 Phosphorus

Common abnormal laboratory parameters†

Parameter	Clinical significance
Sedimentation rate	Mild elevations (10-20 mm) may be an age-related change
Glucose	Glucose tolerance decreases (see Chap. 12); elevations during acute illness are common
Creatinine	Because lean body mass and daily endogenous creatinine production decline, high-normal and minimally elevated values may indicate substantially reduced renal function
Albumin	Average values decline (<0.5 g/mL) with age, especially in acutely ill, but generally indicate undernutrition
Alkaline phosphatase	Mild asymptomatic elevations common; liver and Paget disease should be considered if moderately elevated
Serum iron, iron-binding capacity, ferritin	Decreased values are not an aging change and usually indicate undernutrition and/or gastrointestinal blood loss
Prostate-specific antigen	May be elevated in patients with benign prostatic hyperplasia. Marked elevation or increasing values when followed over time should prompt consideration of further evaluation in patients for whom specific therapy for prostate cancer would be undertaken if cancer were diagnosed
Urinalysis	Asymptomatic pyuria and bacteriuria are common and rarely warrant treatment; hematuria is abnormal and needs further evaluation (see Chap. 8)
Chest radiographs	Interstitial changes are a common age-related finding; diffusely diminished bone density generally indicates advanced osteoporosis (see Chap. 12)
Electrocardiogram	ST-segment and T-wave changes, atrial and ventricular arrhythmias, and various blocks are common in asymptomatic elderly and may not need specific evaluation or treatment (see Chap. 11)

*Aging changes do not occur in these parameters; abnormal values should prompt further evaluation.

†Includes normal aging and other age-related changes.

Careful medical diagnosis and appropriate treatment are essential in good geriatric care. Adequate medical management, however, is necessary but not sufficient. Once those conditions amenable to treatment have been addressed, the next step is to develop the environment that will best support the patient's autonomous function.

Environmental barriers can be both physical and psychological. It is important to recognize how physical barriers may complicate functioning for persons with various conditions (eg, stairs for a person with dyspnea, inaccessible cabinets for the wheelchair bound). Psychological barriers refer especially to the dangers of risk aversion. Those most concerned about the patient may restrict activity in the name of protecting the patient or the institution. For example, hospitals are notoriously averse to risk; older patients will be restricted to a wheelchair rather than risk them falling when walking.

This risk-averse behavior may be compounded by concerns about efficiency. Personal care is personnel intensive. It takes much more time and patience to work with patients to encourage them to do things for themselves than to step in and do the task. But that pseudoefficiency breeds dependence.

The third factor relates to the concept of motivation. If care providers believe that the patient cannot improve, they will likely induce despair and discouragement in their charges. The tendency toward functional decline may become a self-fulfilling prophecy. Indeed, the opposite belief—that improvement is quite likely with appropriate intervention—may account for at least part of the success of geriatric evaluation units. Belief in the possibility of improvement can play another critical role in geriatric care. Psychologists have developed a useful paradigm referred to as “the innocent victim.” The basic concept is that caregivers respond in a hostile manner to those they feel impotent to help. If given a sense of empowerment to approach the complex problems of older persons, perhaps assessment tools and intervention strategies such as the ones provided in this book, can help care providers feel more positive toward those individuals and be more willing to work with them rather than avoid them. The more an information system can provide feedback on accomplishments and progress toward improved function, the more positively the provider will feel about the older patient.

Table 3-6 summarizes several other important concepts about comprehensive functional assessment in the geriatric population, which were identified in a Consensus Development Conference at the National Institutes of Health (National Institutes of Health, 1988). To a large extent, the purpose, setting, and timing of the assessment dictate the nature of the assessment process. **Table 3-7** lists the different purposes and objectives of functional status measures. Generally, functional assessment begins with a case-finding or screening approach in order to identify individuals for whom more in-depth and interdisciplinary assessment might be of benefit. Assessment is often carried out at points of transition, such as a threatened or actual decline in health status or impending change in living situation. Without this type of targeting, the assessment of older people may be time consuming and not cost effective. Numerous standardized instruments are available to assist in the assessment process.

TABLE 3-6. Important Concepts for Geriatric Functional Assessment

1. The nature of the assessment should be dictated by its purpose, setting, and timing (see Table 3-7)
2. Input from multiple disciplines is often helpful, but routine multidisciplinary assessment is not cost-effective
3. Assessments should be targeted
 - a. Initial screening to identify disciplines needed
 - b. Times of threatened or actual decline in status, impending change in living situation, and other stressful situations
4. Standard instruments are useful, but there are numerous potential pitfalls
 - a. Instruments should be reliable, sensitive, and valid for the purposes and setting of the assessment
 - b. How questions are asked can be critically important (eg, performance vs. capability)
 - c. Discrepancies can arise between different informants (eg, self-report vs. caregiver's report)
 - d. Self- or caregiver's report of performance or direct observation of performance may not reflect what the individual does in everyday life
 - e. Many standard instruments have not been adequately tested for reliability and sensitivity to changes over time
5. Open-ended questions are helpful in complementing information from standardized instruments
6. The family's expectations, capabilities, and willingness to provide care must be explored
7. The patient's preferences and expectations should be elicited and considered paramount in planning services
8. A strong link must exist between the assessment process and follow-up in the provision of services

TABLE 3-7. Purposes and Objectives of Functional Status Measures

Purpose	Objectives
Description	Develop normative data Depict geriatric population along selected parameters Assess needs Describe outcomes associated with various interventions
Screening	Identify from among population at risk those individuals who should receive further assessment and by whom
Assessment	Make diagnosis Assign treatment
Monitoring	Observe changes in untreated conditions Review progress of those receiving treatment
Prediction	Permit scientifically based clinical interventions Make prognostic statements of expected outcomes on the basis of given conditions

Instruments designed for research use may not work in clinical practice, and vice versa. There are numerous potential pitfalls in the use of standardized assessment instruments (Kane and Kane, 2000) (see Table 3-6). The critical concept in using standardized instruments is that they should fit the purposes and settings for which they are intended, and there must be a solid link between the assessment process and the follow-up provision of services. In addition, the assessment process should include a clear discussion of the patient's preferences and expectations, as well as the family's expectations and willingness to provide care. The importance of functional status assessment is reflected in the ability of functional status measures to predict mortality in older hospitalized patients (Inouye et al., 1998).

■ **Assessment Tools for Functional Status**

This chapter focuses on the assessment of physical and mental function. Mental function is also discussed in Chapter 6. **Table 3-8** lists examples of measures of physical functioning. Physical functioning is measured along a spectrum. For disabled persons, one may focus on the ability to perform basic self-care tasks, often referred to as activities of daily living (ADLs). The patient is assessed on the ability to conduct each of a series of basic activities. Data usually come from the patient or from a caregiver (eg, a

TABLE 3-8. Examples of Measures of Physical Functioning
Basic ADLs
Feeding
Dressing
Ambulation
Toileting
Bathing
Transfer (from bed and toilet)
Continence
Grooming
Communication
IADLs
Writing
Reading
Cooking
Cleaning
Shopping
Doing laundry
Climbing stairs
Using telephone
Managing medication
Managing money
Ability to perform paid employment duties or outside work (eg, gardening)
Ability to travel (use public transportation, go out of town)

ADL, activity of daily living; IADL, instrumental ADL.

nurse or family member) who has had sufficient opportunity to observe the patient. In some cases, it may be more useful to have the patient actually demonstrate the ability to perform key tasks. Grading of performance is usually divided into three levels of dependency: (1) ability to perform the task without human assistance (one may wish to distinguish those persons who need mechanical aids like a walker but are still independent); (2) ability to perform the task with some human assistance; and (3) inability to perform the task, even with assistance. Distinguishing “independent without difficulty” from “independent with difficulty” may provide complementing prognostic information (Gill, Robinson, and Tinetti, 1998).

Different disciplines approach functional measurement differently. A physician, for example, may be content to ascertain whether a person can dress herself with or without assistance. By contrast, an occupational therapist might subdivide the act of getting dressed into a series of specific steps (eg, choosing appropriate clothes, getting them out of the closet or drawers, putting on different types of clothing, using various fasteners). Likewise, performance can be further assessed in terms of the time required to complete the task and the skill with which it was done.

There may be discrepancies between patients’ or caregivers’ reports and what the individuals actually do in their everyday life. Moreover, there may be differences between reported physical functional status and actual measures of physical performance. Reuben’s Physical Performance Test is one example of a practical assessment that provides insights into actual performance and prognostic information (Reuben and Siu, 1990). In general, performance tests measure what occurs under standardized conditions, whereas reports address what is done under actual living conditions; hence, the latter may offer insights into the effects of the environment as well as the patient’s abilities. Other performance-based assessments of gait and balance are discussed in Chapter 9.

In addition to these general geriatric measures of functional status, other functional assessment tools are commonly used in different settings. Examples include the following:

1. The Short Form-36 (SF-36)—a global measure of function and well-being that is increasingly being used in outpatient settings. This measure has a disadvantage in the frail geriatric population because of a ceiling effect—that is, it does not distinguish well between sick and very sick older people.
2. The Minimum Data Set (MDS)—a comprehensive assessment mandated on admission with quarterly updates in Medicare-/Medicaid-certified nursing facilities. The most current version is the MDS 3.0.
3. The Functional Independence Measure (FIM; now part of the Inpatient Rehabilitation Facility–Patient Assessment Instrument [IRF-PAI])—a detailed assessment tool commonly used to monitor functional status progress in rehabilitation settings.
4. The Outcome and Assessment Information Set (OASIS)—a comprehensive data collection system for use in home health care; it is mandatory for Medicare beneficiaries.

A new data system, Continuity Assessment Record and Evaluation (CARE) combines elements from MDS, OASIS, and IRF-PAI and introduces a common measurement system for all postacute care.

A structured assessment of cognitive function should be part of every complete geriatric functional assessment. Because of the high prevalence of cognitive impairment, the potential impact of such impairment on overall function and safety and the ability of patients with early impairments to mask their deficits, clinicians must specifically attend to this aspect of functional assessment. At a minimum, assessment should include a test for orientation and memory. Although these tests do not probe the variety of intellectual functions appropriate for a more detailed assessment, they are quick, easy, scorable, and reliable. More detailed assessment of cognitive function is discussed in Chapter 6.

ENVIRONMENTAL ASSESSMENT

We emphasized earlier that patient function is the result of innate ability and environment. The clinician must, therefore, be particularly concerned with the older patient's environment. For many patients, the assessment should include an evaluation of the available and potential resources to maintain functioning. Just as physicians comfortably prescribe drugs, they should also be prepared to prescribe environmental interventions when necessary.

Rehabilitation therapists (eg, physical, occupational, speech) are especially skilled at assessing function, developing and implementing rehabilitative plans of care targeted at potentially remediable functional impairments, and making specific recommendations about environmental modifications that can enhance safety and functional ability. An environmental prescription may include alterations in the physical environment (eg, ramps, grab bars, elevated toilet seats), special services (eg, meals on wheels, homemaking, home nursing), increased social contact (eg, friendly visits, telephone reassurance, participation in recreational activities), or provision of critical elements (eg, food, money). An environmental assessment by an occupational therapist for essentially asymptomatic older persons has been shown to significantly reduce subsequent hospital use (Clark et al., 1997).

The ability to identify the environmental interventions and function supports needed to maintain in the community may be the essential difference between enabling an older person to remain at home versus transferring the person to an institution. Although identifying the need is not tantamount to providing the resource, it is an important first step.

ASSESSMENT FOR PAIN

Guidelines published by the American Geriatrics Society recommend that on initial presentation or admission of an older person to any health-care service, the patient should be assessed for evidence of persistent pain (American Geriatrics Society Panel on Persistent Pain in Older Persons, 2002). Patients with persistent pain that may affect physical function, psychosocial function, or other aspects of quality

TABLE 3-9. Important Aspects of the History in Assessment of Pain

1. Characteristics of the pain
2. Relation of pain to impairments in physical and social function
3. Analgesic history (present, previous, prescribed, over-the-counter, alternative remedies, alcohol use, side effects)
4. Patient's attitudes and beliefs about pain and its management
5. Effectiveness of treatments
6. Satisfaction with current pain management
7. Social support and health-care accessibility

of life should undergo a comprehensive pain assessment. [Tables 3-9](#) and [3-10](#) list important aspects of the history and physical examination, respectively, in assessing pain. For patients who are cognitively intact, pain assessments should use direct questioning of the patient. Quantitative assessment of pain should be recorded by using a standard pain scale, such as a visual analog scale, where a patient can indicate where along the continuum their pain lies. A verbal scale of 0 to 10, with 0 meaning no pain and 10 meaning the worst pain possible, is frequently used. Other scales (pain thermometer and faces) studied in older populations are illustrated in [Figure 3-2](#). In cognitively impaired and nonverbal patients, pain assessment should be by direct observation or history from caregivers. Patients should be observed for pain-related behaviors during movement. Unusual behavior in a patient with severe dementia should trigger assessment for pain as a potential cause.


NUTRITIONAL ASSESSMENT

Several parameters are used in assessing nutritional status in older adults. Some anthropometric variables are probably effective estimators of major aspects of body composition ([Table 3-11](#)). They cannot provide a complete description of the nutritional status of an individual and are not highly correlated with biochemical or hematologic indicators of nutritional status.

Although weight is a global measure, it can be obtained easily from adults and is useful in the absence of edema. Body mass index ($\text{BMI} = \text{kg}/\text{m}^2$) is best correlated with total body fat. Triceps and subscapular skin folds are highly correlated with the percentage of body fat in older adults. Waist-to-hip ratio is a parameter

TABLE 3-10. Important Aspects of the Physical Examination in Assessment of Pain

1. Careful examination of the site of pain and common sites for pain referral
2. Focus on the musculoskeletal system
3. Focus on the neurological system including weakness and dysesthesia
4. Observation of physical function
5. Psychological function
6. Cognitive function



The Faces Pain Scale – Revised [1] (FPS-R) is a self-report measure of pain intensity developed for children. It was adapted from the Faces Pain Scale [2] in order to make it possible to score on the widely accepted 0-to-10 metric. It shows a close linear relationship with visual analog pain scales across the age range of 4-16 years. It is easy to administer and requires no equipment except for the photocopied faces. The absence of smiles and tears in this scale may be advantageous. It is particularly recommended for use with younger children. Numerical self-rating scales (0-10) can be used with most children over 8 years of age [3], and behavioral observation scales are required for those unable to provide a self-report.

In the following instructions, say "hurt" or "pain," whichever seems right for a particular child:
"These faces show how much something can hurt. This face [point to left-most face] shows no pain. The faces show more and more pain [point to each from left to right] up to this one [point to right-most face] - it shows very much pain. Point to the face that shows how much you hurt [right now] ."
Score the chosen face 0, 2, 4, 6, 8, or 10, counting left to right, so '0' = 'no pain' and '10' = 'very much pain.' Do not use words like 'happy' and 'sad.' This scale is intended to measure how children feel inside, not how their face looks.

FIGURE 3-2 Samples of two pain intensity scales that have been studied in older persons. Directions: Patients should view the figure without numbers. After the patient indicates the best representation of his or her pain, the appropriate numerical value can be assigned to facilitate clinical documentation and follow-up. (*Faces Pain Scale—Revised, ©2001, International Association for the Study of Pain.*)

of central adiposity. Upper arm circumference is correlated with lean body mass and may be particularly helpful in edematous patients in whom weight is misleading. The effect of the aging process on lean body mass is so great that it remains a poor reflection of nutritional status in older adults.

Serum albumin is a practical indicator of malnutrition in older adults. However, liver disease, proteinuria, and protein-losing enteropathies must be excluded. A low serum albumin may be indicative of malnutrition, but a normal or increased serum albumin concentration does not necessarily indicate normality. Thyroxine-binding prealbumin and/or retinol-binding protein are more sensitive indices than are albumin and transferrin.

In animals, dietary deprivation of protein results in anemia. Because anemia is one of the earliest manifestations of protein–calorie malnutrition, its presence should alert the physician to the possibility of malnutrition. Total lymphocyte count may be a very good marker for nutritional problems.

TABLE 3-11. Assessment of Body Composition	
Assessment	Component
Weight	Global
Body mass index	Total fat
Skin fold	Percent fat
Waist:hip ratio	Central adiposity
Upper arm circumference	Lean body mass

TABLE 3-12. Critical Questions in Assessing a Patient for Malnutrition

Is there any reason to suspect malnutrition?
 If so, of which nutrient(s) and to what extent?
 What are the pathophysiological mechanisms (eg, alteration in nutrient intake, digestion and absorption, metabolism, excretion, or requirements)?
 What etiology underlies the pathophysiological mechanism(s)?

Some important factors need to be considered in evaluating a given patient. **Table 3-12** presents some issues that should be considered in assessing older patients at risk for malnutrition. Individuals with such problems should have an evaluation of nutritional status. Some patients may have several concurrent diseases that impair nutritional status (**Table 3-13**). Protein–energy malnutrition may ensue and is associated with poor prognosis. The Mini Nutritional Assessment (MNA) and Subjective Global Assessment (SGA) predict mortality in geriatric patients (Persson et al., 2002) and are valuable tools for the assessment of nutritional status in older adults. The Short-Form Mini Nutritional Assessment (MNA-SF) can be used in a two-step screening process in which persons identified as at risk on the MNA-SF would receive additional assessment (Rubenstein et al., 2001) (**Table 3-14**). The MNA (Guigoz, Vellas, and Garry, 1996) may be advantageous for the latter since it classified fewer patients than the SGA as well-nourished and those identified as well-nourished on the MNA had a better 3-year survival than those classified as well-nourished by the SGA (Persson et al., 2002).

GERIATRIC CONSULTATION

Geriatric consultation may be requested to address specific clinical issues (eg, confusion, incontinence, recurrent falling), to perform a comprehensive geriatric assessment (often in the context of determining the need for placement in a difficult living setting), or to perform a preoperative evaluation of a high-risk geriatric patient. In this chapter, we discuss the latter two types of consultation.

TABLE 3-13. Factors That Place Older Adults at Risk for Malnutrition

Drugs (eg, reserpine, digoxin, antitumor agents)
 Chronic disease (eg, congestive heart failure, renal insufficiency, chronic gastrointestinal disease)
 Depression
 Dental and periodontal disease
 Decreased taste and smell
 Low socioeconomic level
 Physical weakness
 Isolation
 Food fads

TABLE 3-14. Mini Nutrition Assessment

A. Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing or swallowing difficulties? 0 = severe loss of appetite 1 = moderate loss of appetite 2 = no loss of appetite	<input type="checkbox"/>
B. Weight loss during last 3 months 0 = weight loss >3 kg (6.6 lb) 1 = does not know 2 = weight loss between 1 and 3 kg (2.2 and 6.6 lb) 3 = no weight loss	<input type="checkbox"/>
C. Mobility 0 = bed or chair bound 1 = able to get out of bed/chair but does not go out 2 = goes out	<input type="checkbox"/>
D. Has suffered psychological stress or acute disease in the past 3 months 0 = yes 2 = no	<input type="checkbox"/>
E. Neuropsychological problems 0 = severe dementia or depression 1 = mild dementia 2 = no psychological problems	<input type="checkbox"/>
F. Body mass index (BMI) (weight in kg)/(height in m) ² 0 = BMI <19 1 = BMI 19 to <21 2 = BMI 21 to <23 3 = BMI ≥23	<input type="checkbox"/>
Screening score (subtotal max. 14 points) 12 points or greater: Normal—no need for further assessment 11 points or below: Possible malnutrition—continue assessment	<input type="checkbox"/> <input type="checkbox"/>

Note: if greater specificity is desired consider 10 points or below as possible malnutrition.

Alternative height calculations using knee to heel measurements: with knee at 90° angle (foot flexed or flat on floor or bed board), measure from bottom of heel to top of knee.

Men = (2.02 × knee height, cm) × (0.04 × age) + 64.19

Women = (1.83 × knee height, cm) × (0.24 × age) + 84.88

Body weight calculations in amputees:

For amputations, increase weight by the percentage below for contribution of individual body parts to obtain the weight to use to determine body mass index.

Single below knee 6.0% Single at knee 9.0%

Single above knee 15.0% Single arm 6.5%

Single arm below elbow 3.6%

Reproduced with permission from Rubenstein et al., 2001.

■ Comprehensive Geriatric Consultation

A comprehensive geriatric consultation includes the following:

1. A geriatric-oriented history and physical examination attending to the issues reviewed earlier in this chapter
2. Medication review; in addition, geriatric patients should be questioned about alcohol abuse
3. Functional assessment
4. Environmental and social assessment, focusing especially on caregiver's support and other resources available to meet the patient's needs
5. Discussion of advance directives
6. A complete list of the patient's medical, functional, and psychosocial problems
7. Specific recommendations in each domain

A systematic screening process to identify potentially remediable geriatric problems may be a useful tool for the comprehensive consultation.

One such screening strategy is illustrated in [Table 3-15](#) (Moore and Siu, 1996). It may also be useful, especially in capitated systems, to use a tool that identifies risk for crises and expensive health-care utilization. The Probability of Repeated Admissions (Pra) instrument is one such tool ([Table 3-16](#)) (Pacala et al., 1997). Among frail, dependent geriatric patients, screening for risk factors and elder abuse is important. Elder abuse is more common among older people who are in poor health and who are physically and cognitively impaired. Additional risk factors include shared living arrangements with a relative or friend suspected of alcohol or substance abuse, mental illness, or a history of violence.

Frequent emergency room visits for injury or exacerbations of chronic illness should also raise suspicion about abuse. [Table 3-17](#) illustrates an example of an effective format for documenting the results of the consultation, listing the problems and recommendations.

PREOPERATIVE EVALUATION

Geriatricians are often called upon by surgeons and anesthesiologists to assess elderly patients before surgical procedures. [Table 3-18](#) lists several key factors involved in the preoperative evaluation of geriatric patients. Although older patients (age >70 years) have higher rates of major perioperative complications and mortality after nonemergent major noncardiac surgical procedures than do younger patients, mortality is low, even in patients 80 years of age or older (Polanczyk et al., 2001). Morbidity and mortality, however, are influenced to a greater extent by the presence and severity of systemic illnesses and whether the procedure is elective versus emergent. Thus, evaluating a geriatric patient's preoperative status and risk for surgery necessitates a thorough assessment of cardiopulmonary and renal function as well as nutritional and hydration status. Factors that increase the risk of perioperative cardiac complications in patients undergoing noncardiac surgery include ischemic heart disease, congestive heart failure, diabetes mellitus, and renal insufficiency (Lee et al., 1999).

TABLE 3-15. Example of a Screening Tool to Identify Potentially Remediable Geriatric Problems

Problem	Screening measure	Positive result
Poor vision	Ask, “Do you have difficulty driving, watching television, reading, or doing any of your daily activities because of your eyesight?” If yes, then test acuity with Snellen chart, with corrective lenses	Inability to read better than 20/40 on Snellen chart
Poor hearing	With audioscope set at 40 dB, test hearing at 1000 and 2000 Hz	Inability to hear 1000 or 2000 Hz in both ears or either frequency in one ear
Poor leg mobility	Time the patient after asking, “Rise from the chair. Walk 20 feet briskly, turn, walk back to the chair, and sit down.”	Unable to complete task in 15 s
Urinary incontinence	Ask, “In the past year, have you ever lost your urine and gotten wet?” If yes, then ask, “Have you lost urine on at least 6 separate days?”	Yes to both questions
Malnutrition and weight loss	Ask, “Have you lost 10 lb over the past 6 months without trying to do so?” and then weigh the patient	Yes to the question or weight <100 lb
Memory loss	Three-item recall	Unable to remember all three items after 1 min
Depression	Ask, “Do you often feel sad or depressed?”	Yes to the question
Physical disability	Ask six questions: “Are you able to: • Do strenuous activities such as fast walking or bicycling? • Do heavy work around the house like washing windows, walls, or floors? • Go shopping for groceries or clothes? • Get to places that are out of walking distance? • Bathe: either a sponge bath, tub bath, or shower? • Dress, including putting on a shirt, buttoning and zipping, and putting on shoes?”	No to any question

Reproduced with permission from Moore and Siu, 1996.

TABLE 3-16. Questions on the Probability of Repeated Admissions Instrument for Identifying Geriatric Patients at Risk for Health Service Use

1. In general, would you say your health is:
(excellent, very good, good, fair, poor)
2. In the previous 12 months, have you stayed overnight as a patient in a hospital?
(not at all, one time, two or three times, more than three times)
3. In the previous 12 months, how many times did you visit a physician or clinic?
(not at all, one time, two or three times, four to six times, more than six times)
4. In the previous 12 months, did you have diabetes?
(yes, no)
5. Have you ever had: Coronary heart disease? (yes, no)
Angina pectoris? (yes, no)
A myocardial infarction? (yes, no)
Any other heart attack? (yes, no)
6. Your sex?
(male, female)
7. Is there a friend, relative, or neighbor who would take care of you for a few days if necessary?
(yes, no)
8. Your date of birth?
(month , day , year)

Reproduced with permission from Pacala et al., 1997. Copyright © Regents of the University of Minnesota. All rights reserved.

TABLE 3-17. Suggested Format for Summarizing the Results of a Comprehensive Geriatric Consultation

1. Identifying data, including referring physician
2. Reason(s) for consultation
3. Problems
 - a. Medical problem list
 - b. Functional problem list
 - c. Psychosocial problem list
4. Recommendations
5. Standard documentation
 - a. History, including medications, significant past medical and surgical history, system review
 - b. Social and environmental information
 - c. Functional assessment
 - d. Advance directive status
 - e. Physical examination
 - f. Laboratory and other test data

TABLE 3-18. Key Factors in the Preoperative Evaluation of the Geriatric Patient

1. Age >70 is associated with an increased risk of complications and death
 - a. Risk varies with the type of procedure and local complication rates
 - b. Emergency procedures are associated with much higher risk
 - c. Comorbid conditions, especially cardiovascular, are more important risk factors than age per se
2. The appropriateness and risk-benefit ratio of the proposed surgery must be carefully considered
3. Underlying conditions must be evaluated and optimally managed before nonemergency surgery, eg:
 - a. Cardiovascular disease, especially heart failure
 - b. Pulmonary status
 - c. Renal function
 - d. Diabetes mellitus
 - e. Thyroid disease (which is often occult)
 - f. Anemia
 - g. Nutrition
 - h. Hydration and volume status, especially in patients on diuretics
4. Medication regimens should be carefully planned; some drugs should be continued, others should be withheld, and some necessitate dosage adjustments
5. Several cardiovascular conditions substantially increase risk, including:
 - a. Myocardial infarction within 6 months
 - b. Pulmonary edema
 - c. Angina (especially if unstable)
 - d. Severe aortic stenosis
6. Specific laboratory evaluations may be helpful in some situations, eg:
 - a. Pulmonary function tests and arterial blood gas with respiratory symptoms, obesity, chest deformity (eg, kyphoscoliosis), abnormal chest radiographs, planned thoracic or upper abdominal procedure
 - b. Noninvasive cardiac testing in high and intermediate risk for cardiac event patients
 - c. Creatinine clearance with unstable or borderline renal function, or the use of nephrotoxic or renally excreted drugs
7. The documented effectiveness, risks, and benefits of perioperative prophylactic measures should be considered:
 - a. β -Blocker administration*
 - b. Antithrombotic prophylaxis†
 - c. Antimicrobial prophylaxis‡

*See Fleisher and Eagle, 2001.

†See Geerts et al., 2001.

‡See Medical Letter on Drugs and Therapeutics, 1999.

Patients with a recent history of myocardial infarction, active angina, pulmonary edema, and severe aortic stenosis are at especially high risk (Mangano and Goldman, 1995). Preoperative pulmonary function tests and arterial blood gases are rarely of prognostic value. Assessment of exercise tolerance may be helpful, for example, the

ability to climb one flight of stairs. In patients at low risk for cardiac complications, no β -blockade is necessary. In patients at increased risk for cardiac complications, modified exercise testing, dipyridamole thallium scanning, or dobutamine echocardiography may be indicated (Palda and Detsky, 1997). Coronary artery bypass grafting or percutaneous coronary revascularization should be limited to patients who have a clearly defined need for the procedure that is independent of the need for noncardiac surgery (Fleisher and Eagle, 2001).

Underlying conditions that are prevalent in the geriatric population, such as hypertension, congestive heart failure, chronic obstructive lung disease, diabetes mellitus, anemia, and undernutrition, need particularly careful management in the preoperative period (Schiff and Emanuele, 1995; Thomas and Ritchie, 1995). Medication regimens should be scrutinized in order to determine whether specific drugs should be continued or withheld. Results from several well-designed clinical trials suggest that use of β -blockers perioperatively is associated with significant reductions in cardiac morbidity and mortality (Auerbach and Goldman, 2002). High and intermediate cardiac event risk patients with negative noninvasive test results should begin β -blockade therapy. Those with positive noninvasive test results should have consideration of additional therapies to reduce risk, for example, coronary revascularization. Careful consideration should also be given to perioperative prophylactic measures for the prevention of thromboembolism and infection, many of which have documented efficacy in specific situations (Geerts et al., 2001; Medical Letter on Drugs and Therapeutics, 1999).

Frailty (assessed by unintentional weight loss, decreased grip strength, decreased effort and motivation, low physical activity, and slow walking speed) independently predicted postoperative complications, length of stay, and discharge to a skilled or assisted living facility in older surgical patients (Makary et al., 2010). Preoperative impaired cognition, recent falls, lower albumin, greater anemia, functional dependence, and increased comorbidities were associated with higher mortality at 6 months (Robinson et al., 2009). There is growing awareness of the importance of preventing, or at least minimizing, postoperative delirium. One study found four items independently associated with delirium: prior stroke or transient ischemic attack, Mini-Mental State Examination score, abnormal serum albumin, and the Geriatric Depression Scale (Rudolph et al., 2009).

Many surgeons and anesthesiologists favor regional over general anesthesia for geriatric patients. Regional anesthesia (eg, epidural), however, may have several potential disadvantages. Patients may require added intravenous sedation and/or analgesia, thus increasing the risks of perioperative cardiovascular and mental status changes. Significant cardiovascular changes can, in fact, occur during regional anesthesia; thus, invasive monitoring may be required in some patients. Neither the incidence of deep vein thrombosis nor the amount of blood loss seems to be substantially decreased compared to general anesthesia. Thus, decisions about the type of anesthesia should be carefully individualized based on patient factors, the nature of the procedure, and the preferences of the surgical team.

REFERENCES

- American Geriatrics Society Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. *J Am Geriatr Soc.* 2002;50:S205-S224.
- Auerbach AD, Goldman L. Beta-blockers and reduction of cardiac events in noncardiac surgery: scientific review. *JAMA.* 2002;287:1435-1444.
- Barer D. ACP Journal Club. Review: inpatient comprehensive geriatric assessment improves the likelihood of living at home at 12 months. *Ann Intern Med.* 2011;155:JC6-2.
- Clark F, Azen SP, Zemke R, et al. Occupational therapy for independent-living older adults: a randomized controlled trial. *JAMA.* 1997;278:1321-1326.
- Cohen HJ, Feussner JR, Weinberger M, et al. A controlled trial of inpatient and outpatient geriatric evaluation and management. *N Engl J Med.* 2002;346:905-912.
- Ellis G, Whitehead MA, O'Neill D, Langhorne P, Robinson D. Comprehensive geriatric assessment for older adults admitted to hospital. *Cochrane Database Syst Rev.* 2011;7:CD006211.
- Fleisher LA, Eagle KA. Clinical practice. Lowering cardiac risk in noncardiac surgery. *N Engl J Med.* 2001;345:1677-1682.
- Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. *Chest.* 2001;119 (Suppl 1):132S-175S.
- Gill TM, Robinson JT, Tinetti ME. Difficulty and dependence: two components of the disability continuum among community-living older persons. *Ann Intern Med.* 1998;128:96-101.
- Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: the Mini Nutritional Assessment as part of the geriatric evaluation. *Nutr Rev.* 1996;54:S59-S65.
- Inouye SK, Peduzzi PN, Robinson JT, et al. Importance of functional measures in predicting mortality among older hospitalized patients. *JAMA.* 1998;279:1187-1193.
- Kane RL, Kane RA, eds. *Assessing Older Persons: Measures, Meaning, and Practical Applications.* New York, NY: Oxford University Press; 2000.
- Landefeld CS, Palmer RM, Kresevic DM, Fortinsky RH, Kowal J. A randomized trial of care in a hospital medical unit especially designed to improve the functional outcomes of acutely ill older patients. *N Engl J Med.* 1995;332:1338-1344.
- Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation.* 1999;100:1043-1049.
- Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. *J Am Coll Surg.* 2010;210:901-908.
- Mangano DT, Goldman L. Preoperative assessment of patients with known or suspected coronary disease. *N Engl J Med.* 1995;333:1750-1756.
- Medical Letter on Drugs and Therapeutics. Antimicrobial prophylaxis in surgery. *Med Lett.* 1999;41:75-80.
- Moore AA, Siu AL. Screening for common problems in ambulatory elderly: clinical confirmation of a screening instrument. *Am J Med.* 1996;100:438-443.
- National Institutes of Health. NIH Consensus Development Statement: geriatric assessment methods for clinical decision-making. *J Am Geriatr Soc.* 1988;36:342-347.
- Pacala JT, Boulton C, Reed RL, Aliberti E. Predictive validity of the Pra instrument among older recipients of managed care. *J Am Geriatr Soc.* 1997;45:614-617.
- Palda VA, Detsky AS. Perioperative assessment and management of risk from coronary artery disease. *Ann Intern Med.* 1997;127:313-328.

- Persson MD, Brismar KE, Katzarski KS, Nordenstrom J, Cederholm TE. Nutritional status using mini nutritional assessment and subjective global assessment predict mortality in geriatric patients. *J Am Geriatr Soc.* 2002;50:1996-2002.
- Polanczyk CA, Marcantonio E, Goldman L, et al. Impact of age on perioperative complications and length of stay in patients undergoing noncardiac surgery. *Ann Intern Med.* 2001;134:637-643.
- Reuben D, Siu A. An objective measure of physical function of elderly outpatients. The Physical Performance Test. *J Am Geriatr Soc.* 1990;38:1105-1112.
- Reuben DB, Borok GM, Wolde-Tsadik G, et al. A randomized trial of comprehensive geriatric assessment in the care of hospital patients. *N Engl J Med.* 1995;332:1345-1350.
- Reuben DB, Frank JC, Hirsch SH, McGuigan KA, Maly RC. A randomized clinical trial of outpatient comprehensive geriatric assessment coupled with an intervention to increase adherence to recommendations. *J Am Geriatr Soc.* 1999;47:269-276.
- Robinson TN, Eiseman B, Wallace JI, et al. Redefining geriatric preoperative assessment using frailty, disability and co-morbidity. *Ann Surg.* 2009;250:449-455.
- Rubenstein LZ, Harker JO, Salva A, Guigoz Y, Vellas B. Screening for undernutrition in geriatric practice: developing the Short-Form Mini-Nutritional Assessment (MNA-SF). *J Gerontol A Biol Sci Med Sci.* 2001;56:M366-M372.
- Rudolph JL, Jones RN, Levkoff SE, et al. Derivation and validation of a preoperative prediction rule for delirium after cardiac surgery. *Circulation.* 2009;119:229-236.
- Schiff RL, Emanuele MA. The surgical patient with diabetes mellitus: guidelines for management. *J Gen Intern Med.* 1995;10:154-161.
- Stuck AE, Egger M, Hammer A, Minder CE, Beck JC. Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. *JAMA.* 2002;287:1022-1028.
- Thomas DR, Ritchie CS. Preoperative assessment of older adults. *J Am Geriatr Soc.* 1995;43:811-821.

SUGGESTED READINGS

- Applegate WB, Blass JP, Williams TF. Instruments for functional assessment of older patients. *N Engl J Med.* 1990;322:1207-1214.
- Crum RM, Anthony SC, Bassett SS, et al. Population-based norms for the Mini-Mental State Examination by age and educational level. *JAMA.* 1993;269:2386-2391.
- Feinstein AR, Josephy BR, Wells CK. Scientific and clinical problems in indexes of functional disability. *Ann Intern Med.* 1986;105:413-420.
- Finch M, Kane RL, Philp I. Developing a new metric for ADLs. *J Am Geriatr Soc.* 1995;43:877-884.
- Fleming KC, Evans JM, Weber DC, et al. Practical functional assessment of elderly persons: a primary-care approach. *Mayo Clin Proc.* 1995;70:890-910.
- Folstein MF, Folstein S, McHuth PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res.* 1975;12:189-198.
- Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. *JAMA.* 1994;272:619-626.
- Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The Index of ADL: a standardized measure of biological and psychosocial function. *JAMA.* 1963;185:914-919.

- Reuben DB, Siu AL. An objective measure of physical function of elderly persons: the physical performance test. *J Am Geriatr Soc.* 1990;38:1105-1112.
- Scheitel SM, Fleming KC, Chutka DS, et al. Geriatric health maintenance. *Mayo Clin Proc.* 1996;71:289-302.
- Siu A. Screening for dementia and its causes. *Ann Intern Med.* 1991;115:122-132.
- Williams ME, Hadler N, Earp JA. Manual ability as a mark of dependency in geriatric women. *J Chronic Dis.* 1987;40:481-489.

CHAPTER 4

Chronic Disease Management

Geriatrics can be thought of as the intersection of gerontology and chronic disease management (Kane, Priester, and Totten, 2005). At a time when medical care in general is awakening to the importance of good chronic disease care, geriatrics has been doing it for years. Many of the principles of geriatrics are basically those of good chronic care. Chronic disease management has two basic components. The first aims at preventing catastrophes (ie, emergency room visits and hospitalizations) by proactively monitoring patients' conditions and intervening at the first sign of a change in the clinical course. Ideally these interventions prevent some hospitalizations, primarily by providing more effective primary care that prevents the event, but secondarily by managing crises, when they occur, without hospitalization. **Figure 4-1** illustrates the paths to chronic disease catastrophe. Multimorbidity is associated with polypharmacy, which, in turn, can lead to iatrogenic complications. The second basic component is palliative care. We tend to associate this type of care with end-of-life care, but its principles can be applied much more broadly.

Several models of chronic disease management have been promulgated. The most popular is the Wagner model, which envisions a productive interaction between an informed, activated patient (and caregiver) and a prepared, proactive practice team (Wagner, Austin, and Von Korff, 1996). Unfortunately the current health-care system is poorly organized to facilitate such care. Fee-for-service payments, driven by in-person encounters, provide exactly the wrong climate for proactive care that uses modern communication technology to track patient status. The basic tenets of good chronic care are summarized in **Table 4-1**.

Elderly patients are in danger of being dismissed as hopeless or not worth the effort based on their age. Physicians faced with the question of how much time and resources to spend in searching for a diagnosis will want to consider the probability of benefit from the investment. In some cases, older patients are better investments than younger ones. This apparent paradox occurs in the case of some preventive strategies when the high risk of susceptibility and the discounted benefits of future health favor older persons. But it also arises in situations where small increments of change can yield dramatic differences.

Perhaps the most striking example of the latter is found in the case of nursing home patients. Ironically, very modest changes in their routine, such as introducing a pet, giving them a plant to tend, or increasing their sense of control over their environment, can produce dramatic improvements in mood and morale.

At the same time, the risk–benefit ratio is different with older patients. Treatments that might be easily tolerated in younger patients may pose a much greater risk of producing harmful effects in older patients with multiple chronic illnesses. As shown in **Figure 4-2**, the therapeutic window that separates benefit from harm is narrower.




FIGURE 4-1 Paths to chronic disease catastrophe.

TABLE 4-1. Chronic Care Tenets
Aggressive primary care
Proactive monitoring
Early intervention to avoid catastrophes
Patient-centeredness, meaningful patient involvement in the care process
Use of information technology to track outcomes and trigger reevaluation
Teamwork, delegation
Efficient use of time
Assessing benefit in terms of slowing decline




FIGURE 4-2 Narrowing of the therapeutic window. This diagram portrays in a conceptual manner how the space between a therapeutic dose and a toxic dose narrows with age.

In effect, the dosage that will produce a positive effect more closely approaches one that can lead to a toxic effect. As noted earlier in this text, one of the hallmarks of aging is a loss of responsiveness to stress. In this context, treatment may be viewed as a stress.

Those who treat older patients must also consider the theory of competitive risks. Because older persons often suffer from multiple problems, treating one problem may provide an opportunity for more adverse effects from another. In essence, eliminating one cause of death increases the likelihood of death from other causes.

SYSTEM CHANGES

Professional roles need to be reexamined to look for opportunities to delegate to less expensive personnel many tasks formerly performed by more trained professionals. For example, nurse practitioners have been shown to be capable of providing a good deal of primary care that was formerly the exclusive purview of physicians (Horrocks, Anderson, and Salisbury, 2002; Munding et al., 2000). New models of collaborative care seem promising (Callahan et al., 2006; Counsell et al., 2006).

The enthusiasm for teams needs to be tempered by an appreciation of the skills needed to work cooperatively and the willingness to delegate tasks (Kane, Shamliyan, and McCarthy, 2011).

Expectations must be recalibrated. The familiar dichotomy of care versus cure must be expanded to recognize the role of disease management. Because the natural course of chronic illness is deterioration, successful care must be defined as doing better than would be expected otherwise. This phenomenon is illustrated in [Figure 4-3](#). The bold line represents the effects of good care. The dotted line represents




FIGURE 4-3 A conceptual model of the difference between expected and actual care. The heavier line represents what is usually observed in clinical chronic care. Despite good care, the patient's course deteriorates. The true benefit, represented by the area between the dark line and the dotted line, is invisible unless some means is found to display the expected course in the absence of good care. Such data could be developed based on clinical prognosis, or it could be derived from accumulated data once such a system is in place.

the effects of the absence of such care. Both lines show decline over time. The difference between them represents the effects of good care. Most of the time, this contrast is invisible—all that is seen is decline despite the best efforts. Improving care will require developing information systems that can contrast actual and expected clinical courses.

Appreciating this contrast is critical to both policy and morale. The importance of measuring success by comparing the actual clinical course to a generated expected course is central to concepts of quality in chronic disease. It is also important in maintaining the morale of workers in this field. People who see only decline despite their best efforts become discouraged (Lerner and Simmons, 1966). They need to appreciate the value of their care if they are to continue to give it in the face of so much frailty and disability. Slowing the rate of decline must be seen as positive achievement.

Likewise policymakers, and indeed the general public, are unlikely to support needed efforts to improve chronic care if they do not believe that such care can make a difference. They must be educated to appreciate these differences and be given the information to demonstrate these differences.

A good question is where to begin. Several targets present themselves. Complex cases use up large amounts of resources and are worth the investment in better management. This is the heart of geriatrics. Any type of hand-off is associated with errors and problems.

TRANSITIONAL CARE

Transitions from hospitals have been targeted for special attention. Currently, discharges, and other times when care is transferred, represent danger zones. There is great concern about the high rate of rehospitalizations, which represent signs of care failure and add to the costs of care. When medical regimens are changed, the relevant information may be poorly communicated (both between clinicians and with patients and families). Careful coordination and follow-up are associated with lower rates of rehospitalization and lower costs (Coleman et al., 2006; Naylor et al., 1994). Transitional care consists of a set of specific actions.

1. Prior to discharge, a coach meets with the patient and her family to establish a rapport and assist with discharge planning.
2. The coach meets with the patient soon after discharge to be sure she understands the discharge plan and is comfortable with her medication regimen and any other instructions.
3. The coach stays in close contact during the ensuing period to be sure things are going well.
4. The patient's primary care physician is urged to get involved soon after discharge and gets all relevant information.

END-OF-LIFE CARE

Eliminating excessive, futile, or unnecessary care and attention to preventing iatrogenic events can improve care and save money. Two ready targets are medications and end-of-life care, including palliative care. Medication management in

geriatric patients is discussed in detail in Chapter 14. In addition to the section that follows, end-of-life care is discussed in Chapters 16 and 17.

The physician's concern with the patient's functioning continues throughout the course of the chronic disease. Elderly patients will die. In many cases, death is not a reflection of medical failure. The approach to the dying patient will often raise difficult dilemmas. No simple answers suffice. Too often the dying patient is treated as an object. Ignored and isolated, the patient may be discussed in the third person.

Physicians who treat elderly patients must come to terms with death. Often the patients are more comfortable with the subject than are their physicians (and their families). Fleeing from the dying patient is inexcusable. Dying patients need their doctors. At a very basic level, everything should be done to keep the patient as comfortable as possible. One simple step is to identify the pattern of discomforting symptoms and arrange the dosage schedule of palliatives to prevent rather than respond to the symptoms.

Patients need an opportunity to talk about their death. Not everyone will take advantage of that chance, but a surprising number will respond to a genuine offer made without time pressure. Such discussions are not conducted on the run. Often several invitations accompanied by appropriate behavior (eg, sitting down at the bedside) are necessary.

Some physicians are unable to confront this aspect of practice. For them, the challenge is to recognize their own behavior and get appropriate help. Such help is available at various levels: help for the physician and for the patient. Groups and therapy are readily available to assist doctors to deal with their feelings. Patients of doctors who fear death need the help of other caregivers. Often other professionals (nurses, social workers) who are working with these patients already can play the lead role in helping them work through their feelings. But the active intervention of another caregiver is not a justification to ignore the patient.

The rise of the hospice movement has created a growing cadre of persons and settings to help with the dying patient. The lessons coming from this experience suggest that much can be done to facilitate this stage of life, although the formal studies done to evaluate hospice care do not show dramatic benefits.

Patients should be encouraged to be as active as possible and as interactive as they wish. Even more than in other aspects of care, the unique condition of the dying patient necessitates that the physician be prepared to listen carefully to the patient and to share decision making about how and when to do things.

Medical care has evolved in such a way that special exemptions are made for the period at the end of life. Hospice care was created to reverse the overuse of technology and denial of dying (see Chapter 18). It can be viewed as both a success and a failure. On the one hand, it is still probably used too little and too late, only after more drastic measures have been tried. At the same time, it has led to serious reconsideration of how medicine handles the process of dying. It has spawned the concept of palliative care, an idea that many aspects of support and comfort can be applied coincident with active treatment (Morrison and Meier, 2004). It has forced

a reassessment of how pain is managed, with more attention to proactive treatment in adequate doses. Palliative care is discussed in detail in Chapter 18.

SPECIAL ISSUES IN CHRONIC DISEASE MANAGEMENT

Clinical Glide Paths

Chronic care requires proactive primary care supported by better data systems. The whole approach to care needs to be rethought. The idea of scheduled revisits needs to be replaced with a system of ongoing monitoring and interventions when there is a significant change in the patient's condition. Information technology is probably the most important technological breakthrough for chronic care.

Structuring data helps to focus the clinician's attention on what is most relevant. The goal of a good information system should be to present clinicians with pertinent information at the right time in the form that will capture their attention. Identifying what is salient at the moment is critical, especially in view of the brief contact times allowed. Too much information can be as dysfunctional as too little, because the pertinent facts get lost in a sea of data.

Providing effective chronic care that avoids catastrophes relies on a longitudinally oriented information system that is sensitive to change. Each clinical encounter with a chronically ill patient is essentially a part of a continuing episode of care; it has a history and a future. Caring for a chronically ill patient, especially one with multiple problems, demands an enormous feat of memory as the patient's list of problems is unearthed and the history, treatments, and expectations associated with each are reviewed. Clinicians caring for such patients (often under enormous time pressures) may find themselves either overwhelmed with large volumes of data from which they must quickly extract the most salient facts or, alternatively, relying on inadequate data from which to reconstruct the patient's clinical course. Moreover, because patients live with their disease 24 hours a day, 7 days a week, they are best positioned to make regular observations about its progress. Such patient-constructive involvement responds to another principle of chronic care. These goals can be achieved using a simple information system that can focus the clinician's attention on salient parameters.

One approach to organizing clinical information and actively involving patients in their own care is the clinical glide path. The underlying concept is based on landing an airplane. Basically, the goal is to keep the patient within the expected trajectory to avoid the need for dramatic midcourse corrections. An expected clinical course (with provision for confidence intervals) is created. Ideally this clinical trajectory would be derived from a large statistical database that shows how similar patients have done previously. However, in the absence of such a database, the expected clinical path can be based on the clinician's experience and intuition. A separate glide path is used for each chronic problem. For each condition, the clinician selects one (or at the most two) clinical parameters to track. Ideally these should reflect how the problem manifests in that patient. The parameter can be a sign or a symptom, or even a laboratory value. The data on this parameter are collected regularly, several times a week or even daily.

In most cases, the patients can provide the information, having been taught to make careful, consistent observations. These are recorded on the equivalent of flow sheets, which can be entered into a computer program that produces a graphic display. The key to this monitoring is the early warning. Observations falling outside the confidence intervals prompt strong exception messages. Any pattern of deviation is the cue for action and early intervention to assess the patient's condition and to take appropriate action. These cases should be seen quickly and with enough time to evaluate the reasons for the changes in status. Figure 4-4 shows a hypothetical




FIGURE 4-4 Clinical glide path models. **(A)** In this model, the expected course (solid line) calls for gradual decline. The confidence intervals are shown as dotted lines. Actual measures that are within or better than the glide path are shown as "o's". When the patient's course is worse than expected, the "o" changes to an "x." The design shown uses confidence intervals with upper and lower bounds, but actually only the lower bound is pertinent. Any performance above the upper confidence interval boundary is very acceptable. **(B)** The design of the glide path can also take another form. It may be preferable to think in terms of reaching a threshold level within a given time window (eg, in recuperating from an illness) and then maintaining that level.

example of such a clinical glide path. The patient's progress (marked with "O's") is within the confidence interval (which indicates a path of gradual decline) until the last observation (noted with an "X," which falls outside the confidence interval and hence should trigger a warning.

Patients (or their caregivers) can be trained to make systematic observations about salient clinical parameters and to report meaningful changes (determined by established protocols) to their clinicians. Even better, they can enter such observations into a simple computerized data system that has been programmed to notify clinicians when the patterns exceed predetermined algorithms. Devices are available that automatically enter the data (such as self-reporting scales and sphygmomanometers), but patient involvement can be maximized by having them enter the data. In most instances nothing is done at data entry; routine data (which indicate the patient is staying on the trajectory) are not actionable, only meaningful changes.

The clinician's task is then to evaluate the meaning of such a change, when it occurs. The patient should be seen quickly (either by a physician or another clinician) to have the findings analyzed. The basic approach addresses three questions:

1. Are the data accurate? Has there been a real change?
2. Has the patient adhered to his/her prescribed regimen?
3. Has there been an intervening event (eg, infection, change in diet)?

The change really occurred; the patient was following her regimen, and there is no obvious explanation for the change, then a full assessment is warranted to determine the reason for the deviation.

The glide path approach meets several needs for chronic care. (1) It helps to focus physicians' attention on salient parameters. It provides an indication of early problems in time to make midcourse corrections. (2) It provides a means to involve patients more actively in their care. They learn about what is important and assume greater responsibility. (3) It is a basis for reapportioning time and effort to focus attention where an intervention is likely to produce a greater impact. Ideally, clinicians would stop making blanket return appointments, and instead track conditions and intervene when the circumstances change.

It is important to distinguish the clinical glide path approach from clinical pathways. The latter specify an expected course with specific milestones and dictate what care should be provided at specific junctures. This approach works well in very predictable situations such as postoperative recovery and even some instances of rehabilitation, but most of chronic care management is not as predictable. The glide path method specifies what data should be collected, not what actions should be taken. Its underlying premise holds that when clinicians can be aided in focusing their attention on a patient's salient parameters, they will be able to manage the chronic problems better.

Nursing home care has never attracted a great deal of physician enthusiasm, but this need not continue to be the case. If we can implement a new form of record keeping that provides better information to staff and demands better performance from them (such as clinical guidelines), we would see an improvement in morale and hence a more attractive atmosphere in which to practice.

■ Targeting and Tracking

Case management, which is used to target interventions and track and monitor outcomes, has received a lot of attention, although its efficacy has yet to be established. One of the problems in assessing the benefits of case management has been the multiple ways the term has been used. (For a discussion of case management, see Chapter 15.)

Focusing attention on the management of specific problems has become a consistent theme in the effort to improve the management of chronic illness. *Disease management* is most commonly used by health plans, which use the available administrative data from encounters, drug records, and laboratory tests to identify all enrollees with a given condition. Protocols can then be applied to look for errors of both omission and commission. In some cases, potential complications can be flagged and checks built in to try to avoid untoward events such as drug interactions.

A more active approach to disease management uses *case managers* for patients who are determined to need special attention, either because they have a diagnosis that suggests high risk of subsequent use or their history indicates problems in controlling their disease(s). These case managers work with the patients to be sure that they understand their regimens. They encourage the patients to raise any questions early. They telephonically monitor the course of the illness using parameters like those described earlier. They may make home visits to ascertain how the patients are doing and to ensure that they can function effectively in their natural habitats. The positive reports from trials of this approach have encouraged many replications.

Another variation on disease management being practiced in a few managed care organizations is *group care*. Here patients with a given disease (sometimes a more heterogeneous cluster of patients is assembled) are brought together for periodic sessions that include health education and group support, as well as individual clinical attention. It has proven more efficient to use groups in this way. The same sessions can draw upon specialists to see problematic cases more efficiently.

Particularly in the context of managed care, there is a strong incentive to try to identify high-risk patients in order to attend to them before they develop into high-cost cases. Various predictive models have been developed to identify such cases. One widely used model is the Probability of Repeated Admissions (Pra). (See Chapter 3.) This tool uses an eight-item questionnaire to flag older patients who are most likely to have two or more hospital admissions in the next several years (Boult et al., 1993). A modification of this method has been developed to use administrative databases as well. A similar approach is being developed to identify those at high risk for needing long-term care. Once these patients have been targeted, an intervention is needed to change the predicted course. The Pra model does not specify what actions should be taken; it was initially developed as a method for identifying those in need of a comprehensive geriatric examination.

Other efforts have sought to target high-risk groups. An analysis of the Medicare Current Beneficiary Survey identified a model that could identify older persons at risk

of death or functional decline (Saliba et al., 2001). Another index can identify older adults who have an increased risk of death 1 year after hospitalization (Walter et al., 2001). Changes in Medicare reimbursement have focused attention on 30-day hospital readmissions. Identifying predictors of 30-day readmissions other than a recent hospitalization has proven challenging (Kansagara et al., 2011).

Interventions have also been developed to address those at highest risk. Compressive geriatric assessment has been shown to improve survival and prolong living at home (Barer, 2011; Ellis et al., 2011). Some interventions seem surprisingly effective. Home visits to basically well older persons can prevent nursing home admissions and functional decline (Stuck et al., 2002). Likewise an in-home visit by an occupational therapist was associated with improved health, function, and quality of life (Clark et al., 1997). No single intervention has strong evidence for its effectiveness in reducing 30-day hospital readmissions (Hansen et al., 2011). Given the complexity of patients with multiple chronic diseases and the multiple factors that contribute to the decision to hospitalize them, multicomponent interventions will be needed to reduce preventable hospital admissions and readmissions in this population.

Function has proven to be an important predictive risk factor for both subsequent use of expensive services and outcomes in general. Poor functional status in hospital patients predicts later mortality over and above the effects of burden-of-illness measures.

ROLE OF OUTCOMES IN ASSURING QUALITY OF CHRONIC CARE

Quality of care remains a critical, if elusive, goal for chronic care. As we consider steps for resource allocation, we might first address the question of whether we are spending our current funds most wisely. There is at once a growing demand for more creativity and more accountability in care. It may be possible to reduce the regulatory burden, increase the meaningful accountability, and make the incentives within the system more rational. Progress in chronic care will require not only more innovation and creativity, but also accountability. Outcome monitoring (and ultimately outcome-based rewards) allows both to coexist.

Before we can talk about how to package care or how to buy it cheaper, we need a better understanding of what we are really buying. One hears more and more about the value of shifting attention from the process of care to the actual outcomes achieved in chronic care.

Two basic concepts must be kept in mind when discussing outcomes.

1. The term “outcomes” is used to mean the relationship between what is achieved and what is expected.
2. Because outcomes rely on probabilities, it is inappropriate to base assessments of outcomes on an individual case. Outcomes are averages and are always judged on the basis of group data.

Table 4-2 summarizes the reasons for looking toward outcomes as the way to assess and assure quality.

TABLE 4-2. Rationale for Using Outcomes

1. Outcomes encourage creativity by avoiding domination by current professional orthodoxies or powerful constituencies.
2. Outcomes permit flexibility in the modality of care.
3. Outcomes permit comparisons of efficacy across modalities of care.
4. Outcomes permit more flexible responses to different levels of performance, and thus avoid the “all-or-none” difficulties of many sanctions. At the same time, outcomes have some limitations.
5. Outcomes necessitate a single point of accountability; all the actors—facility operators, agencies, staff, physicians, patients, and family—contribute to them. Under this approach the role of the provider includes motivating others.
6. Outcomes are largely influenced by the patient’s status at the beginning of treatment. The easiest and most direct way to address this issue is to think of the relationship between achieved and expected outcomes as the measure of success.
7. Outcomes must also be cognizant of case mix. Predicting outcomes necessitates information about disease characteristics (eg, diagnosis, severity, comorbidity) and patient characteristics (eg, demographic factors, prior history, social support).

Nonetheless, clinicians frequently balk at being judged based on outcomes. This discomfort can be traced to several issues.

1. Virtually all of clinical training addresses the process of care. Clinicians are schooled in what to do for whom. They reasonably believe, therefore, that if they do the right thing well, they have provided a quality service. They do not like to discuss clusters of patients, preferring to review their care one patient at a time.
2. Many factors can affect the outcomes of care that are out of the clinicians’ control. They have difficulty with the concept of probability and prefer to either be responsible or not.
3. Outcomes are by their nature post hoc. Often, a long period can elapse between the time of an action and the report of its success. It is thus too late to intervene in that case.
4. Outcomes indicate a problem but offer no solution. Outcomes do not often point to specific actions that must be taken to correct the problems.

Hence, introducing outcomes, however rational, has not been easy. Making clinicians comfortable with an outcomes philosophy will require substantial training and new incentives. Physicians need to be trained to think in terms of both condition-specific and generic outcomes. They need access to data systems that can display the outcomes of their care for clinically relevant groups of patients under their care and compare them with what are reasonable outcomes for comparable patients receiving good care. [Table 4-3](#) summarizes the key issues in outcomes measurement and its applications.

TABLE 4-3. Outcomes Measurement Issues

Issue	Comments
Need outcome measures that are both clinically meaningful and psychometrically sound	Use combination of condition-specific and generic measures. Usually better to adapt extant measures than to develop measures de novo.
Outcomes are always post hoc	Expand outcomes information systems to include data on risk factors. These data should be useful in guiding clinicians to collect information that will identify potential problems. Use these data to create risk warnings to flag high-risk cases.
Every physician has all the tough cases	Need to include a wide variety of case-mix adjusters for severity and comorbidity. Ask clinicians in advance to identify potential risk adjusters. Collect almost any item that a clinician might want to see. Test the ability of the potential risk factor to predict outcomes and discard if it has little predictive power.
Because no two clinicians see the same cases, comparisons are unfair	Use risk adjustment to create clinically homogeneous subgroups; use risk propensities to create groups of patients with same a priori likelihood of developing the outcome
Cannot control for selection bias; patients may receive different treatments because of subtle differences	Adjust for all clinically identifiable differences Use statistical methods (eg, instrumental variables) to adjust for unmeasured differences

Outcomes should be used as the basis for quality assurance in long-term care. The outcomes approach can be used in several ways.

1. Outcome measures can be substituted for most of the current structure and process measures. It is appropriate to continue regulation in areas such as life safety. Concomitant with an outcomes emphasis would be the reduction of regulatory burden. It is important to recognize, however, that it is not appropriate to dictate structure, process, and outcome at the same time. Such a policy removes all degrees of freedom and stifles creativity at the point when we want to encourage it. Under an outcome-regulated approach, providers whose patients do better than expected are rewarded and are less worried about their style of caregiving, whereas those whose patients do relatively poorly are investigated more closely.
2. Outcomes can be incorporated into the payment structure to link payment with effects of care, but the outcomes must be adjusted to recognize differences in case mix. Payments, either in the form of bonuses and penalties or as a more fundamental part of the payment structure, can be used to reward and penalize

good and bad outcomes, respectively (eg, an outcomes approach might use a factor reflecting the overall achieved/expected ratio for a patient as a multiplier against the costs of care to develop a total price paid for that period of time; or one might use a similar ratio to weigh the amount of money going to a given provider from a fixed pool of dollars committed to such care). Such an approach must be viewed carefully within the context of our present case-mix reimbursement (such as that used in nursing homes), because the latter indirectly rewards deterioration in function. An outcomes approach to payment is compatible with a case-mix approach that is used at intake.

3. An outcomes approach can be incorporated into the basic caring process. Where the information base used in assessing patients and developing care plans is structured, the emphasis on outcomes can become a proactive force to guide care. Optimally, the information used to assess outcomes will come from the clinical records and will be the same information used to guide care. Using available computer technology, it is now feasible to collect such data, translate them into care plans, and aggregate these data for quality assurance at minimal additional cost. The great advantage of such a scheme is its potential both to provide a better information base with which to plan care and to reinforce the creative use of such information to achieve improvements in function. Much of the current efforts going into more traditional regulatory activities might be redirected to this effort, with assessors used to validate the assessment and to focus more intense efforts on the miscreants.

We have generally good consensus on the components of outcomes, which include elements of both quality of care and quality of life, but we are less clear about how to sum them to produce composite scores. The gerontological literature consistently cites the following categories of outcomes:

- Physiological function (eg, blood pressure control, lack of decubitus)
- Functional status (usually a measure of activities of daily living [ADLs])
- Pain and discomfort
- Cognition (intellectual activity)
- Affect (emotional activity)
- Social participation (based on preferences)
- Social relations (at least one person who can act as a confidant)
- Satisfaction (with care and living environment)

To these must be added more global outcomes, such as death and admission to hospital.

Current work has shown reasonable consensus across a variety of constituencies about the relative weights to be placed on them for different kinds of patients (eg, different levels of physical and cognitive function at baseline).

The outcomes approach offers significant assistance with a recurrent problem in regulation—the development of standards. This approach may avoid many of these difficulties by relying on empirical standards. Rather than arguing about what is a reasonable expectation, the standard can be empirically determined. Expectations can be

derived from the actual outcomes associated with real care given by those felt to represent a reasonable level of practice. This could include the entire field or a designated subset. Under this arrangement, providers would be comparing their achievements to each other's past records, with the possibility that everyone can do better.

TECHNOLOGY FOR QUALITY IMPROVEMENT

Ideally, one would like to see a measurement approach that:

- Can cover the spectrum of performance
- Is easy and rapid to administer
- Is sensitive to meaningful change in performance
- Is stable within the same patient over time when the patient has been clinically stable
- Performs consistently in different hands
- Cannot be manipulated to meet the needs of either the provider or the patient

The solution to this challenge is to create an assessment approach that incorporates the features designed to maximize these elements. To cover the broad spectrum sought and still be relatively quickly administered, an instrument should have multiple branch points. These permit the user to focus on the area along the continuum where the patient is most likely to function and to expand that part of the scale to measure meaningful levels of performance. Branching can also ensure that the assessment is comprehensive but not burdensome.

By using key questions to screen an area, interviewers can ascertain whether to obtain more detailed information in each relevant domain. Where the initial response is negative, they can go on to the next branch point. Reliability is more likely to be achieved when the items are expressed in a standardized fashion tied closely to explicit behaviors. Whenever possible, performance is preferred over reports of behavior.

One cannot expect to totally avoid the gaming of an assessment. If the patient knows that poor performance is needed to ensure eligibility, he or she may be motivated to achieve the requisite low level. One can use some test of reporting bias, such as measures of social desirability, but they will not prevent gaming the system or detect all cheating.

■ Computer Technology

Clinical medicine seems headed inevitably toward electronic medical records. This step could represent a major advance in the care of older people, if the opportunity is properly harnessed. Simply reproducing the current unstructured information set in a more legible and transmissible format will not suffice. Structured information provides the vehicle for assuring a more systematic evaluation and follow-up of cases. By distinguishing between missing and normal values, it can provide the structure to focus clinicians' attention on salient items.

Computer technology can dramatically reduce redundancy. Properly mobilized, computers can provide the structure needed to assure a comprehensive assessment

with no duplication of effort. Because they are interactive, they can carry out much of the desired branching and can even use simple algorithms to clarify areas of ambiguity and retest areas where some unreliability is suspected. Similar algorithms can look for inconsistency to screen for cheating.

Data stored on computers can be aggregated to display performance across patients by provider (eg, physician, nursing home, or agency). Data on a patient can be traced across time to look at changes in function and, in turn, can be aggregated.

The next important step in the progression is to move the focus from a single point of care to the linking of related elements of care. In an ideal system, patient information would be linked to permit tracing changes in status for that individual as they move from one treatment modality to another. Thus, hospital admission and discharge information, long-term care information, and primary care information would be merged into a common computer-linked record, which allows one to trace the patient's movements and status. The federal Office of the National Coordinator and other federal and state agencies are developing standards for transferring clinical information from one setting to another.

Finally, it would be desirable to have data on the process of care as well as the outcomes. This combination would permit analyses of what elements of care made a difference for which patients.

Such an approach to assuring quality is within our grasp if we are prepared to invest in data systems and to commit ourselves to collecting standardized information. It necessitates a shift in some of our fundamental paradigms from thinking about whether we did the right thing to deciding if it made any difference after all.

Two basic changes in thinking are necessary in order to establish an outcome-based philosophy, both of which are difficult for clinicians.

1. Thinking in the aggregate, using averages instead of examining each case: Outcomes do not work well for individual cases because there is always a chance that something will go wrong, and life does not provide a control group.
2. Attributing responsibility to the whole enterprise rather than placing blame on an individual: A pattern of poor outcomes will mandate closer inspection of the process of care, but outcomes per se are a collective responsibility.

Computerized records greatly facilitate the task of monitoring the outcomes of care. Ideally, such a record system should be proactive, directing the collection of clinical information to encourage adequate coverage of relevant material. Long-term care is actually ahead of acute care in this regard, with the federal requirement for computerized versions of the Minimum Data Set. Unfortunately, most of the systems in use are simply inputting mechanisms. They do not begin to tap the real potential of a computerized information system. Because long-term care depends heavily on poorly educated personnel for so much of its core services, the availability of an information support system, which can provide feedback and direction, is especially appropriate.

Computerization can provide both the flexibility and the brevity sought by using branching logic to expand a category when there is reason to explore it

more thoroughly. It can avoid duplication by displaying data already collected by others while still permitting the second observer to correct and challenge earlier entries. More important, it can display information to show change over time, thus permitting both the regulators and the caregivers to look at the effects of care.

Once the data are in electronic form, they are easily transmitted and manipulated. It is not hard to envision a large set of data derived from these systematic observations that would permit calculations of expected courses for different types of long-term care patients. These could then be compared to individual patients' courses to assess the potential impact of care on outcomes.

The computer's ability to compare observed and expected outcomes extends beyond its role as a regulatory device. It could be a major source of assistance to caregivers. One of the great frustrations in long-term care, especially in the trenches, is the difficulty in sensing whether the caregiver is making a difference. Because so many patients enter care when they are already declining, the benefits of care are often best expressed as a slowing of that decline curve. Without some measure of expected course in the absence of good care, those who render care daily may not appreciate how much they are accomplishing and thereby may forgo one of the important rewards of their labors.

Displaying information about the change in patient's condition over time, which is a simple task for a computer, will assist the long-term caregiver to think more in terms of the overall picture, rather than a series of separate snapshots in time. Given the computer's ability to translate data into graphics, it is a simple procedure to develop pictorial representations of the changes occurring for a given patient or group of patients and to contrast those with what might be reasonably expected.

Again the effort is directed toward changing perceptions about older persons, especially those in long-term care. For too long, long-term care has worked in a negative spiral—a self-fulfilling prophecy that expected patients to deteriorate—serving to discourage both care providers and patients. Such an attitude is hardly likely to attract the best and the brightest in any of the health professions. As noted earlier in this chapter, nursing home patients are among the most responsive to almost any form of intervention. Any information system that can reinforce a prospective view of long-term care, especially one that can display patient progress, represents an important adjunct to such care.

Assessing Care of Vulnerable Elders (ACOVE) has also made a number of recommendations about steps in providing better care, but none are supported by strong evidence (Wenger and Shekelle, 2007), although they make good clinical sense. These recommendations are summarized in [Table 4-4](#).

NEXT STEPS

It has long been recognized that fee-for-service payment is a major barrier to good chronic disease management. Several developments in the organization and financing of care, stimulated by the Patient Protection and Affordable Care Act of 2010, will have implications for changing that arrangement. The Accountable Care Organization proposal calls for developing a framework where clinicians would be

TABLE 4-4. ACOVE Recommendations

- All patients should be able to identify a physician or clinic to call for medical care and know how to reach them.
- After a new medication is prescribed for a chronic illness, the following should be noted at follow-up:
 - Medication is being taken as prescribed.
 - Patient was asked about the medication (eg, side effects, adherence, availability).
 - Medication was not started because it was not needed or changed.
- If a patient is seen by two or more physicians and a new medication is prescribed by one, the other(s) should be aware of the change.
- If a patient is referred to a consultant, the referring physician should show evidence of the consultant's findings and recommendations.
- If a diagnostic test is ordered, the following should be documented at the next visit:
 - Result of the test specifically acknowledged.
 - Note that the test was not needed or not performed and why.
 - Note that the test is pending.
- If a patient misses a scheduled preventive visit, there should be a reminder.
- When patients are seen in an emergency department (ED) or admitted to hospital, the continuity physician should be notified within 2 days.
- Patients discharged from hospital and who survive 6 weeks should have some contact with their continuity physician who should be aware of the hospitalization.
- When a patient is discharged to home from hospital and receives new chronic disease medication, the continuity physician should document the change in medication within 6 weeks.
- When a patient is discharged to home or to a nursing home from hospital and tests are pending, the results should be available within 6 weeks.
- When a patient is discharged to home or to a nursing home from hospital, there should be a discharge summary in the continuity physician's records.
- If a patient does not speak English, an interpreter or translated materials should be used.

paid in a manner that reflects, at least in part, their contribution to saving money by more efficient care. Likewise, medical/health-care homes will at least promote more comprehensive approaches to care, including some variant of case management (albeit many such programs do not focus on patients with chronic disease). Bundling payments for hospital and posthospital care will encourage transitional care and better choice of posthospital venues.

SUMMARY

In many respects, geriatrics is the epitome of chronic disease care. New paradigms are needed that recognize the changing role of patients in their own care, the need to think differently about the payoff horizons for investments in care, and the tracking of the course of disease to identify when intervention is needed. With geriatrics and chronic disease in general, the benefits of good care may be hard to discern because

they represent a slowing of decline. This effect is invisible unless there is some basis for forming an expected clinical course against which to compare the actual course.

Physicians caring for older patients need to think in prospective terms. They will enjoy their practices more if they can learn to set reasonable goals for patients, to record progress toward these goals, and to use the failure to achieve progress as an important clinical sign of the need for reevaluation.

REFERENCES

- Barer D. ACP Journal Club. Review: inpatient comprehensive geriatric assessment improves the likelihood of living at home at 12 months. *Ann Intern Med.* 2011;155:JC6-2.
- Boult C, Dowd B, McCaffrey D, Boult L, Hernandez R, Krulewicz H. Screening elders for risk of hospital admission. *J Am Geriatr Soc.* 1993;41:811-817.
- Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. *JAMA.* 2006;295:2148-2157.
- Clark F, Azen SP, Zemke R, et al. Occupational therapy for independent-living older adults: a randomized controlled trial. *JAMA.* 1997;278:1321-1326.
- Coleman EA, Parry C, Chalmers S, Min SJ. The care transitions intervention: results of a randomized controlled trial. *Arch Intern Med.* 2006;166:1822-1828.
- Counsell SR, Callahan CM, Buttar AB, Clark DO, Frank KI. Geriatric Resources for Assessment and Care of Elders (GRACE): a new model of primary care for low-income seniors. *J Am Geriatr Soc.* 2006;54:1136-1141.
- Ellis G, Whitehead MA, O'Neill D, Langhorne P, Robinson D. Comprehensive geriatric assessment for older adults admitted to hospital. *Cochrane Database Syst Rev.* 2011;7:CD006211.
- Hansen LO, Young RS, Hinami K, Leung A, Williams MV. Interventions to reduce 30-day rehospitalization: a systematic review. *Ann Intern Med.* 2011;155:520-528.
- Horrocks S, Anderson E, Salisbury C. Systematic review of whether nurse practitioners working in primary care can provide equivalent care to doctors. *Br Med J.* 2002;324:819-823.
- Kane RL, Priester R, Totten AM. *Meeting the Challenge of Chronic Illness.* Baltimore: Johns Hopkins University Press; 2005.
- Kane RL, Shamliyan T, McCarthy T. Do geriatric healthcare teams work? *Aging Health.* 2011;7:865-876.
- Kansagara D, Englander H, Salanitro A, et al. Risk prediction models for hospital readmission: a systematic review. *JAMA.* 2011;306:1688-1698.
- Lerner MJ, Simmons CH. Observer's reaction to the "innocent victim": compassion or rejection. *J Pers Soc Psychol.* 1966;4:203-210.
- Morrison RS, Meier DC. Clinical practice. Palliative care. *N Engl J Med.* 2004;350:2582-2590.
- Mundinger M, Kane R, Lenz E, et al. Primary care outcomes in patients treated by nurse practitioners or physicians: a randomized trial. *JAMA.* 2000;283:59-68.
- Naylor M, Brooten D, Jones R, Lavizzo-Mourey R, Mezey M, Pauly M. Comprehensive discharge planning for the hospitalized elderly: a randomized clinical trial. *Ann Intern Med.* 1994;120:999-1006.
- Saliba D, Elliott M, Rubenstein LZ, et al. The vulnerable elders survey: a tool for identifying vulnerable older people in the community. *J Am Geriatr Soc.* 2001;49:1691-1699.
- Stuck AE, Egger M, Hammer A, Minder CE, Beck JC. Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. *JAMA.* 2002;287:1022-1028.

- Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. *Milbank Q.* 1996;74:511-543.
- Walter LC, Brand RJ, Counsell SR, et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. *JAMA.* 2001;285:2987-2994.
- Wenger NS, Shekelle PG. Measuring medical care provided to vulnerable elders: the Assessing Care of Vulnerable Elders-3 (ACOVE-3) quality indicators. *J Am Geriatr Soc.* 2007;55(Suppl 2):S247-S487.

This page intentionally left blank

PART II

**DIFFERENTIAL DIAGNOSIS
AND MANAGEMENT**

This page intentionally left blank

CHAPTER 5

Prevention

GENERAL PRINCIPLES

Today's older people are increasingly interested in promoting healthy aging. The terms "health promotion" and "prevention" are used almost interchangeably. Prevention runs a gamut. For the most part, we think of prevention in terms of warding off disease or delaying its onset, but prevention can also involve simply avoiding bad events or complications of care. As noted in Chapter 4, in the context of chronic disease management, proactive primary care can be seen as a form of prevention (tertiary prevention, as defined later). Prevention is typically targeted at specific diseases or conditions, but some authors caution against such a single-disease approach to prevention among older persons, arguing that competitive risks will simply raise the rates for other diseases (Mangin, Sweeney, and Heath, 2007). Likewise, some preventive efforts, like stopping smoking and exercising, can affect many diseases.

Ageism may lead people to discount the value of prevention in caring for older persons, but the evidence suggests that many preventive strategies are effective in this age group. Ironically, the effects of prevention may be greatest in older people because the benefit of preventive activities depends on two basic factors: the prevalence of the problem and the likelihood of an effective intervention. Thus, flu shots may be less likely to work in older people if they are immune compromised, but osteoporosis prevention will be very cost-effective because the baseline levels of the problem, and of falling, are high. Plans for prevention in older people should consider the issues laid out in [Table 5-1](#). Perhaps the most preventable problem connected with caring for older persons is iatrogenic disease.

The major thesis here, as with much covered elsewhere in this book, is that age alone should not be a predominant factor in choosing an approach to a patient. A number of preventive strategies deserve serious consideration in light of their immediate and future benefits for many elderly patients.

Preventive activities can be divided into three types. *Primary prevention* refers to action taken to render the patient more resistant or the environment less harmful. It is basically a reduction in risk. The term *secondary prevention* is used in two ways. One implies screening or early detection for asymptomatic disease or early disease. The idea here is that finding a problem early allows more effective treatment. The second meaning of secondary prevention involves using the techniques of primary prevention on people who already have the disease in an effort to delay progression; for example, getting people who have had a heart attack to stop smoking. That behavior will not prevent heart disease, but it should reduce the risks of subsequent complications. *Tertiary prevention* involves efforts to improve care to avoid later complications; proactive chronic disease management is a good example of this approach. As noted in Chapter 4, tertiary prevention is a central part of good geriatric care,

TABLE 5-1. Considerations in Assessing Prevention in Older Patients

1. Baseline risk
 - The higher the baseline risk, the greater is the likelihood that an effective preventive intervention will have an impact. Hence, some preventive strategies may be paradoxically more effective with older patients.
2. Competing risks/limited life expectancy
 - Multimorbidity means that reducing the risk of one disease may leave older people vulnerable to others.
 - Limited life expectancy influences judgments about the expected course of benefits.
3. Time to achieving an effect
 - Interventions with long lag times for effects (as are typical in many behavioral changes) may run up against concerns about life expectancy.
4. Vulnerability/risk of harms
 - Older people have a narrower therapeutic window (see Chap. 4).
 - They may be susceptible to the side effects of prevention.
5. Response to intervention
 - The preventive intervention may not work as well in older patients.
 - Some older patients may have difficulty following the preventive regimen.
6. The value of the health gained
 - Other problems may reduce the benefit.
7. The cost of the preventive activity
 - Direct costs
 - Indirect costs, such as anxiety, restricted lifestyle, and false-positive results

which strives to minimize the progression of disease to disability. It requires a comprehensive effort to address both the physiological and environmental factors that can create dependency. All three areas are relevant to geriatric care. [Table 5-2](#) offers examples of activities in each category. Not all the items indicated in this table are supported by clear research findings. Some examples—such as seat belts, exercise, and social support—are based on prudent judgment.

The federal government has set health goals for various population groups, including older people. [Table 5-3](#) shows the indicators for older persons identified under the Healthy People program; these measures were selected because they can be derived from available national data sources.

The U.S. Preventive Services Task Force (USPSTF) is charged with reviewing the evidence on prevention and making recommendations. [Tables 5-4](#) and [5-5](#) contrast the USPSTF recommendations for topics relevant to older persons with current Medicare policy. It is interesting to note that there are several discrepancies in both directions; some recommended care is not covered, and some care that is not recommended is covered. For example, Medicare will cover prostate-specific antigen (PSA) screening, but the USPSTF does not recommend it.

In addressing prevention for older persons, it is important to bear in mind the goals pursued. The World Health Organization has provided a useful continuum,

TABLE 5-2. Preventive Strategies for Older Persons		
Primary	Secondary	Tertiary
Immunization	Papanicolaou (Pap) smear	Proactive primary care
Influenza	Breast examination	Comprehensive geriatric assessment
Pneumococcus	Breast self-examination	Foot care
Tetanus	Mammography	Dental care
Blood pressure	Fecal blood, colonoscopy	Toileting efforts
Smoking	Hypothyroidism	
Exercise	Depression	
Obesity	Vision	
Cholesterol	Hearing	
Sodium restriction	Oral cavity	
Social support	Tuberculosis	
Home environmental improvements	PSA	
Seat belts		
Medication review		

PSA, prostate specific antigen.

TABLE 5-3. Healthy People Report Card Items for Seniors	
Health status (minimize the following)	
Physically unhealthy days	
Frequent mental distress	
Complete tooth loss	
Disability (limitation in any way in physical, mental, or emotional problems; need for special equipment)	
Health behaviors	
Leisure time physical activity	
Eating 5+ fruits and vegetables daily	
Obesity	
Smoking	
Preventive care and screening	
Flu vaccine in past year	
Pneumonia vaccine ever	
Mammogram within past 2 years	
Sigmoidoscopy or colonoscopy ever	
Cholesterol checked within past 5 years	
Injuries	
Hip fracture hospitalizations	

Source: Centers for Disease Control and Prevention and The Merck Company Foundation. *The State of Aging and Health in America 2007*. Whitehouse Station, NJ: The Merck Company Foundation; 2007.

TABLE 5-4. U.S. Preventive Services Task Force (USPSTF) Recommendations for Screening Older Adults and Medicare Coverage

Services	USPSTF recommendation		Medicare coverage	
	Summary of recommendation	Grade	Coverage frequency	
Abdominal aortic aneurysm screening	The USPSTF recommends one-time screening for abdominal aortic aneurysm (AAA) by ultrasonography in men age 65 to 75 who have ever smoked.	B	A one-time screening ultrasound for persons with at least one of the following risk factors:	
	The USPSTF makes no recommendation for or against screening for AAA in men age 65 to 75 who have never smoked.	C	<ul style="list-style-type: none"> • A family history of abdominal aortic aneurysm • Must be a man age 65 to 75 who has smoked at least 100 cigarettes in his lifetime • Have never had an AAA ultrasound screening paid for by Medicare 	
	The USPSTF recommends against routine screening for AAA in women.	D		
Breast cancer screening	The USPSTF recommends biennial screening mammography for women age 50 to 74 years.	B	<ul style="list-style-type: none"> • All women with Medicare age 40 and older can get a breast cancer screening mammogram every 12 months. 	
	The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms.	C	<ul style="list-style-type: none"> • Medicare also covers digital technologies for screening mammograms. • Medicare also pays for one baseline mammogram for women with Medicare between age 35 and 39. 	
	The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years or older.	I		
	The USPSTF recommends against teaching breast self-examination (BSE).	D		
	The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older.	I		

	The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of either digital mammography or magnetic resonance imaging (MRI) instead of film mammography as screening modalities for breast cancer.	I	
Carotid artery stenosis screening	The USPSTF recommends against screening for asymptomatic carotid artery stenosis (CAS) in the general adult population.	D	
Cervical cancer screening	The USPSTF recommends screening for cervical cancer in women age 21 to 65 years with cytology (Pap smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years.	A	<ul style="list-style-type: none"> • One Pap test and pelvic exam to check for cervical, vaginal, and breast cancers every year for women who are of childbearing age and who had an exam that indicated cervical or vaginal cancer or other abnormalities in the past 3 years or are considered high risk for developing cervical or vaginal cancer. • One Pap test and pelvic exam every 2 years for women who are at low risk for cervical cancer. • A clinical breast exam is included as part of the pelvic exam.
	The USPSTF recommends against screening for cervical cancer in women younger than age 21 years.	D	
	The USPSTF recommends against screening for cervical cancer in women older than age 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer.	D	
	The USPSTF recommends against screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and who do not have a history of a high-grade precancerous lesion (ie, cervical intraepithelial neoplasia [CIN] grade 2 or 3) or cervical cancer.	D	
	The USPSTF recommends against screening for cervical cancer with HPV testing, alone or in combination with cytology, in women younger than age 30 years.	D	

(continued)

TABLE 5-4. U.S. Preventive Services Task Force (USPSTF) Recommendations for Screening Older Adults and Medicare Coverage (*continued*)

Services	USPSTF recommendation		Medicare coverage
	Summary of recommendation	Grade	Coverage frequency
Colorectal cancer screening	The USPSTF recommends screening for colorectal cancer (CRC) using fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults, beginning at age 50 years and continuing until age 75 years. The risks and benefits of these screening methods vary.	A	<ul style="list-style-type: none"> • Fecal occult blood test: Once every 12 months. • Flexible sigmoidoscopy: Generally, once every 48 months, or 120 months after a previous screening colonoscopy for people not at high risk.
	The USPSTF recommends against routine screening for colorectal cancer in adults age 76 to 85 years. There may be considerations that support colorectal cancer screening in an individual patient.	C	<ul style="list-style-type: none"> • Screening colonoscopy: Generally once every 120 months (once every 24 months if patient is at high risk), or 48 months after a previous flexible sigmoidoscopy.
	The USPSTF recommends against screening for colorectal cancer in adults older than age 85 years.	D	<ul style="list-style-type: none"> • Barium enema: Doctor can decide to use this test instead of a flexible sigmoidoscopy or colonoscopy. This test is covered every 24 months if people are at high risk for colorectal cancer and every 48 months if people are not at high risk.
	The USPSTF concludes that the evidence is insufficient to assess the benefits and harms of computed tomographic colonography and fecal DNA testing as screening modalities for colorectal cancer.	I	
Coronary heart disease screening	The USPSTF recommends against routine screening with resting electrocardiography (ECG), exercise treadmill test (ETT), or electron-beam computerized tomography (EBCT) scanning for coronary calcium for either the presence of severe coronary artery stenosis (CAS) or the prediction of coronary heart disease (CHD) events in adults at low risk for CHD events.	D	Check cholesterol and other lipid levels every 5 years: <ul style="list-style-type: none"> • Total cholesterol test; cholesterol test for high-density lipoproteins • Triglycerides test
		I	

	The USPSTF found insufficient evidence to recommend for or against routine screening with ECG, ETT, or EBCT scanning for coronary calcium for either the presence of severe CAS or the prediction of CHD events in adults at increased risk for CHD events.		
Dementia screening	The USPSTF concludes that the evidence is insufficient to recommend for or against routine screening for dementia in older adults.	I	
Hormone replacement therapy	The USPSTF recommends against the routine use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women.	D	
	The USPSTF recommends against the routine use of unopposed estrogen for the prevention of chronic conditions in postmenopausal women who have had a hysterectomy.	D	
Osteoporosis screening	The USPSTF recommends screening for osteoporosis in women age 65 years or older and in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors.	B	<ul style="list-style-type: none"> Once every 24 months (more often if medically necessary)
	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis in men.	I	
Ovarian cancer screening	The USPSTF recommends against routine screening for ovarian cancer.	D	
Peripheral arterial disease screening	The USPSTF recommends against routine screening for peripheral arterial disease (PAD).	D	

(continued)

TABLE 5-4. U.S. Preventive Services Task Force (USPSTF) Recommendations for Screening Older Adults and Medicare Coverage (*continued*)

Services	USPSTF recommendation		Medicare coverage
	Summary of recommendation	Grade	Coverage frequency
Prostate cancer screening	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of prostate cancer screening in men younger than age 75 years.	I	
	The USPSTF recommends against screening for prostate cancer in men age 75 years or older.	D	
Thyroid disease screening	The USPSTF concludes the evidence is insufficient to recommend for or against routine screening for thyroid disease in adults.	I	
Vision screening in older adults	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for visual acuity for the improvement of outcomes in older adults.	I	Once every 12 months, which includes: <ul style="list-style-type: none"> • A dilated eye exam with an intraocular pressure measurement • A direct ophthalmoscopy exam or a slit-lamp biomicroscopic exam

USPSTF recommendation codes:

A = strongly recommends in favor

B = recommends in favor

C = recommends against

D = strongly recommends against

I = evidence is insufficient

Sources: U.S. Preventive Services Task Force. Recommendations. Available at: <http://www.uspreventiveservicestaskforce.org/recommendations.htm>; Medicare.gov. Preventive and screening services. Available at: <http://www.medicare.gov/navigation/manage-your-health/preventive-services/preventive-service-overview.aspx>; Centers for Disease Control and Prevention. Immunization schedules. Available at: <http://www.cdc.gov/vaccines/schedules/index.html>. Accessed March 20, 2012.

TABLE 5-5. Additional Preventive Services From U.S. Preventive Services Task Force (USPSTF) (May Be Suitable for Older Adults) and Medicare Coverage

Services	USPSTF recommendation		Medicare coverage
	Summary of recommendation	Grade	Coverage frequency
Alcohol misuse screening and counseling	The USPSTF recommends screening and behavioral counseling interventions to reduce alcohol misuse by adults, including pregnant women, in primary care settings.	B	Medicare covers 1 alcohol misuse screening per year. People who screen positive can get up to 4 brief face-to-face counseling sessions per year.
Aspirin/NSAIDs for prevention of colorectal cancer	The USPSTF recommends against the routine use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) to prevent colorectal cancer in individuals at average risk for colorectal cancer.	D	
Cardiovascular disease (behavioral therapy)	The USPSTF recommends the use of aspirin for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarctions outweighs the potential harm due to an increase in gastrointestinal hemorrhage.	A	Medicare covers 1 visit per year to help lower risk for cardiovascular disease. During this visit, doctor may discuss aspirin use (if appropriate), check blood pressure, and give tips to make sure people are eating well.
Aspirin for the prevention of cardiovascular disease	The USPSTF recommends the use of aspirin for women age 55 to 79 years when the potential benefit of a reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal hemorrhage.	A	
	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of aspirin for cardiovascular disease prevention in men and women age 80 years or older.	I	
	The USPSTF recommends against the use of aspirin for stroke prevention in women younger than 55 years and for myocardial infarction prevention in men younger than 45 years.	D	

(continued)

TABLE 5-5. Additional Preventive Services From U.S. Preventive Services Task Force (USPSTF) (May Be Suitable for Older Adults) and Medicare Coverage (*continued*)

Services	USPSTF recommendation		Medicare coverage
	Summary of recommendation	Grade	Coverage frequency
Cholesterol abnormalities in adults (dyslipidemia, lipid disorders)	The USPSTF strongly recommends screening men age 35 and older for lipid disorders.	A	Check cholesterol and other lipid levels every 5 years: • Total cholesterol test; cholesterol test for high-density lipoproteins • Triglycerides test
	The USPSTF strongly recommends screening women age 45 and older for lipid disorders if they are at increased risk for coronary heart disease.	A	
	The USPSTF makes no recommendation for or against routine screening for lipid disorders in men age 20 to 35 or in women age 20 and older who are not at increased risk for coronary heart disease.	C	
Back pain, low (low back pain)	The USPSTF concludes that the evidence is insufficient to recommend for or against the routine use of interventions to prevent low back pain in adults in primary care settings.	I	
Bacteriuria	The USPSTF recommends against screening for asymptomatic bacteriuria in men and nonpregnant women.	D	
Bladder cancer	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for bladder cancer in asymptomatic adults.	I	
Blood pressure in adults (hypertension)	The USPSTF recommends screening for high blood pressure in adults age 18 and older.	A	

Breast cancer, <i>BRCA</i> testing (ovarian cancer)	The USPSTF recommends against routine referral for genetic counseling or routine breast cancer susceptibility gene (<i>BRCA</i>) testing for women whose family history is not associated with an increased risk for deleterious mutations in breast cancer susceptibility gene 1 (<i>BRCA1</i>) or breast cancer susceptibility gene 2 (<i>BRCA2</i>).	D	
	The USPSTF recommends that women whose family history is associated with an increased risk for deleterious mutations in <i>BRCA1</i> or <i>BRCA2</i> genes be referred for genetic counseling and evaluation for <i>BRCA</i> testing.	B	
Breast cancer	The USPSTF recommends against routine use of tamoxifen or raloxifene for the primary prevention of breast cancer in women at low or average risk for breast cancer.	D	
	The USPSTF recommends that clinicians discuss chemoprevention with women at high risk for breast cancer and at low risk for adverse effects of chemoprevention. Clinicians should inform patients of the potential benefits and harms of chemoprevention.	B	
Chlamydial infection	The USPSTF recommends screening for chlamydial infection for all sexually active nonpregnant young women age 24 and younger and for older nonpregnant women who are at increased risk.	A	Medicare covers sexually transmitted infection screenings for chlamydia, gonorrhea, syphilis, and/or hepatitis B for people who meet certain criteria once every 12 months or at certain times during pregnancy. Medicare also covers up to 2 individual behavioral counseling sessions each year for people who meet certain criteria.
	The USPSTF recommends against routinely providing screening for chlamydial infection for women age 25 and older, whether or not they are pregnant, if they are not at increased risk.	C	
	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydial infection for men.	I	

(continued)

TABLE 5-5. Additional Preventive Services From U.S. Preventive Services Task Force (USPSTF) (May Be Suitable for Older Adults) and Medicare Coverage (*continued*)

Services	USPSTF recommendation		Medicare coverage
	Summary of recommendation	Grade	Coverage frequency
Lipid disorders	The USPSTF strongly recommends screening women age 45 and older for lipid disorders if they are at increased risk for coronary heart disease.	A	Medicare does not pay for screening per se but will pay if there is a relevant diagnosis.
	The USPSTF makes no recommendation for or against routine screening for lipid disorders in men age 20 to 35 or in women age 20 and older who are not at increased risk for coronary heart disease.	C	
Chronic obstructive pulmonary disease	The USPSTF recommends against screening adults for chronic obstructive pulmonary disease (COPD) using spirometry.	D	
Depression in adults	The USPSTF recommends screening adults for depression when staff-assisted depression care supports are in place to assure accurate diagnosis, effective treatment, and follow-up.	B	One depression screening per year. The screening must be done in a primary care setting that can provide follow-up treatment and referrals.
	The USPSTF recommends against routinely screening adults for depression when staff-assisted depression care supports are not in place. There may be considerations that support screening for depression in an individual patient.	C	
Diabetes mellitus	The USPSTF recommends screening for type 2 diabetes in asymptomatic adults with sustained blood pressure (either treated or untreated) greater than 135/80 mm Hg.	B	Medicare covers up to 2 fasting blood glucose tests each year.
	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in asymptomatic adults with blood pressure of 135/80 mm Hg or lower.	I	

Diet (nutrition)	<p>The USPSTF concludes that the evidence is insufficient to recommend for or against routine behavioral counseling to promote a healthy diet in unselected patients in primary care settings.</p> <p>The USPSTF recommends intensive behavioral dietary counseling for adult patients with hyperlipidemia and other known risk factors for cardiovascular and diet-related chronic disease. Intensive counseling can be delivered by primary care clinicians or by referral to other specialists, such as nutritionists or dietitians.</p>	<p>I</p> <p>B</p>	<p>Medicare covers medical nutrition therapy services prescribed by a doctor for people with diabetes or kidney disease. This benefit includes: an initial assessment of nutrition and lifestyle assessment; nutrition counseling; information regarding managing lifestyle factors that affect diet; and follow-up visits to monitor progress managing diet. Medicare covers 3 hours of one-on-one counseling services the first year, and 2 hours each year after that.</p>
Drug use, illicit	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening adolescents, adults, and pregnant women for illicit drug use.	I	
Exercise (physical activity)	The USPSTF concludes that the evidence is insufficient to recommend for or against behavioral counseling in primary care settings to promote physical activity.	I	
Family violence	The USPSTF found insufficient evidence to recommend for or against routine screening of parents or guardians for the physical abuse or neglect of children, of women for intimate partner violence, or of older adults or their caregivers for elder abuse.	I	
Glaucoma	The USPSTF found insufficient evidence to recommend for or against screening adults for glaucoma.	I	<p>Once every 12 months, which includes:</p> <ul style="list-style-type: none"> • A dilated eye exam with an intraocular pressure measurement • A direct ophthalmoscopy exam or a slit-lamp biomicroscopic exam

(continued)

TABLE 5-5. Additional Preventive Services From U.S. Preventive Services Task Force (USPSTF) (May Be Suitable for Older Adults) and Medicare Coverage (*continued*)

Services	USPSTF recommendation		Medicare coverage
	Summary of recommendation	Grade	Coverage frequency
Gonorrhea	The USPSTF recommends that clinicians screen all sexually active women, including those who are pregnant, for gonorrhea infection if they are at increased risk for infection.	B	Medicare covers sexually transmitted infection screenings for chlamydia, gonorrhea, syphilis, and/or hepatitis B for people who meet certain criteria once every 12 months or at certain times during pregnancy. Medicare also covers up to 2 individual behavioral counseling sessions each year for people who meet certain criteria.
	The USPSTF found insufficient evidence to recommend for or against routine screening for gonorrhea infection in men at increased risk for infection.	I	
	The USPSTF recommends against routine screening for gonorrhea infection in men and women who are at low risk for infection.	D	
Hearing loss, older adults	NA	NA	
Hemochromatosis	The USPSTF recommends against routine genetic screening for hereditary hemochromatosis in the asymptomatic general population.	D	
Hepatitis B virus infection	The USPSTF recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection.	D	Medicare covers sexually transmitted infection screenings for chlamydia, gonorrhea, syphilis, and/or hepatitis B for people who meet certain criteria once every 12 months or at certain times during pregnancy. Medicare also covers up to 2 individual behavioral counseling sessions each year for people who meet certain criteria.

Hepatitis C virus infection	The USPSTF recommends against routine screening for hepatitis C virus (HCV) infection in asymptomatic adults who are not at increased risk (general population) for infection.	D	Medicare covers HIV screening once every 12 months.
	The USPSTF found insufficient evidence to recommend for or against routine screening for HCV infection in adults at high risk for infection.	I	
Herpes simplex, genital	The USPSTF recommends against routine serological screening for herpes simplex virus in asymptomatic adolescents and adults.	D	
Human immunodeficiency virus (HIV) infection	The USPSTF strongly recommends that clinicians screen for HIV in all adolescents and adults at increased risk for HIV infection.	A	
	The USPSTF makes no recommendation for or against routinely screening for HIV in adolescents and adults who are not at increased risk for HIV infection.	C	
Lung cancer	The USPSTF concludes that the evidence is insufficient to recommend for or against screening asymptomatic persons for lung cancer with either low-dose computed tomography (LDCT), chest x-ray (CXR), sputum cytology, or a combination of these tests.	I	Medicare covers intensive counseling to help lose weight. This counseling may be covered if people get it in a primary care setting, where it can be coordinated with the comprehensive prevention plan.
Obesity in adults	The USPSTF recommends that clinicians screen all adult patients for obesity and offer intensive counseling and behavioral interventions to promote sustained weight loss for obese adults.	B	

(continued)

TABLE 5-5. Additional Preventive Services From U.S. Preventive Services Task Force (USPSTF) (May Be Suitable for Older Adults) and Medicare Coverage (*continued*)

Services	USPSTF recommendation		Medicare coverage
	Summary of recommendation	Grade	Coverage frequency
Oral cancer	The USPSTF concludes that the evidence is insufficient to recommend for or against the use of moderate- or low-intensity counseling together with behavioral interventions to promote sustained weight loss in obese adults.		
	The USPSTF concludes that the evidence is insufficient to recommend for or against the use of counseling of any intensity and behavioral interventions to promote sustained weight loss in overweight adults.	I	
		I	
Pancreatic cancer	The USPSTF concludes that the evidence is insufficient to recommend for or against routinely screening adults for oral cancer.	I	
Pancreatic cancer	The USPSTF recommends against routine screening for pancreatic cancer in asymptomatic adults using abdominal palpation, ultrasonography, or serological markers.	D	
Sexually transmitted infections	The USPSTF recommends high-intensity behavioral counseling to prevent sexually transmitted infections (STIs) for all sexually active adolescents and for adults at increased risk for STIs.	B	Medicare covers STI screenings for chlamydia, gonorrhea, syphilis, and/or hepatitis B for people who meet certain criteria once every 12 months or at certain times during pregnancy. Medicare also covers up to 2 individual behavioral counseling sessions each year for people who meet certain criteria.
	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of behavioral counseling to prevent STIs in non-sexually active adolescents and in adults not at increased risk for STIs.	I	

Skin cancer	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of using a whole-body skin examination by a primary care clinician or patient skin self-examination for the early detection of cutaneous melanoma, basal cell cancer, or squamous cell skin cancer in the adult general population.	I	
	The USPSTF concludes that the evidence is insufficient to recommend for or against routine counseling by primary care clinicians to prevent skin cancer.	I	
Smoking (tobacco use)	The USPSTF recommends that clinicians ask all adults about tobacco use and provide tobacco cessation interventions for those who use tobacco products.	A	Medicare will cover up to 8 face-to-face visits during a 12-month period.
Suicide risk	The USPSTF concludes that the evidence is insufficient to recommend for or against routine screening by primary care clinicians to detect suicide risk in the general population.	I	
Syphilis	The USPSTF strongly recommends that clinicians screen persons at increased risk for syphilis infection.	A	Medicare covers STI screenings for chlamydia, gonorrhea, syphilis, and/or hepatitis B for people who meet certain criteria once every 12 months or at certain times during pregnancy. Medicare also covers up to 2 individual behavioral counseling sessions each year for people who meet certain criteria.
	The USPSTF recommends against routine screening of asymptomatic persons who are not at increased risk for syphilis infection.	D	
Testicular cancer	The USPSTF recommends against screening for testicular cancer in adolescent or adult males.	D	
Vitamin D supplementation to prevent cancer and fractures	NA	NA	

(continued)

TABLE 5-5. Additional Preventive Services From U.S. Preventive Services Task Force (USPSTF) (May Be Suitable for Older Adults) and Medicare Coverage (*continued*)

Services	USPSTF recommendation		Medicare coverage
	Summary of recommendation	Grade	Coverage frequency
Vitamin supplementation to prevent cancer and coronary heart disease	The USPSTF concludes that the evidence is insufficient to recommend for or against the use of supplements of vitamins A, C, or E; multivitamins with folic acid; or antioxidant combinations for the prevention of cancer or cardiovascular disease.	I	
	The USPSTF recommends against the use of beta-carotene supplements, either alone or in combination, for the prevention of cancer or cardiovascular disease.	D	

USPSTF recommendation codes:

A = strongly recommends in favor

B = recommends in favor

C = recommends against

D = strongly recommends against

I = evidence is insufficient

- A. The USPSTF strongly recommends that clinicians routinely provide (the service) to eligible patients. The USPSTF found good evidence that (the service) improves important health outcomes and concludes that benefits substantially outweigh harms.
 - B. The USPSTF recommends that clinicians routinely provide (the service) to eligible patients. The USPSTF found at least fair evidence that (the service) improves important health outcomes and concludes that benefits outweigh harms.
 - C. The USPSTF makes no recommendation for or against routine provision of (the service). The USPSTF found at least fair evidence that (the service) can improve health outcomes but concludes that the balance of benefits and harms is too close to justify a general recommendation.
 - D. The USPSTF recommends against routinely providing (the service) to asymptomatic patients. The USPSTF found at least fair evidence that (the service) is ineffective or that harms outweigh benefits.
 - I. The USPSTF concludes that the evidence is insufficient to recommend for or against routinely providing (the service). Evidence that the (service) is effective is lacking, of poor quality, or conflicting and the balance of benefits and harms cannot be determined.
- NA, not applicable.

Sources: U.S. Preventive Services Task Force. Recommendations. Available at: <http://www.uspreventiveservicestaskforce.org/recommendations.htm>; Medicare.gov. Preventive and screening services. Available at: <http://www.medicare.gov/navigation/manage-your-health/preventive-services/preventive-service-overview.aspx>; Centers for Disease Control and Prevention. Immunization schedules. Available at: <http://www.cdc.gov/vaccines/schedules/index.html>. Accessed March 20, 2012.

which progresses from disease to impairment to disability to handicap (although the latter term is no longer considered politically correct). Preventive efforts for older people can be productively targeted at several points along this spectrum. Efforts can seek to prevent disease, but they can also be designed to minimize its consequences by reducing the progression to disability. Slowing that transition is, in essence, the heart of geriatrics.

Preventive efforts on behalf of elderly patients have special characteristics beyond the emphasis on function. Some risk factors that strongly predict the onset of disease in younger persons may not be appropriate for modification in older persons. Perhaps the condition has already become well established and is resistant to change, or the factor may have already exerted its influence at an earlier stage of life. Conversely, older people represent survivors. People exposed to a risk factor for many years and still living into old age may be affected differently from those who succumb younger. Thus, questions are repeatedly raised about how enthusiastic one should be to stop smoking or reduce cholesterol levels in the oldest of the old.

While primary prevention is the most desirable approach, the nature of the changes required to achieve this end vary substantially. Some require a single brief contact (eg, immunization), but others imply sustained change in behaviors, such as changing eating habits or exercising. If a brief encounter can confer some form of long-lasting protection at minimal risk, such a strategy will be actively pursued. But the risk factors for most chronic diseases involve sustained behavior change, which is harder to achieve.

Many of the behaviors that need to change are pursued because they are pleasurable. In the case of older persons, we need to weigh the benefits against the costs, where the latter are defined in more than dollars. At what point is the benefit worth the cost? How much quality of life should be sacrificed in the name of health? Do we really want to put an 85-year-old diabetic on a strict diet, or even make that person forgo the sweets he or she craves? Conversely, how big a role does ageism play in deciding that it is not worth investing in prevention for older people? Just as with therapeutic decisions, thoughtful geriatricians struggle with the overall benefit of enforcing a major lifestyle change on someone who has both survived and has a finite life expectancy, with limited opportunities for pleasure. The task is made even harder when strong economic interests advertise the very products physicians seek to discourage.

One approach to risk reduction that fits with the predominant medical model is to transform the risk into a disease and treat it as such. For example, high blood pressure becomes hypertension; high cholesterol becomes hypercholesterolemia; thin bones become osteoporosis. When effective medications become available, as is the case in each of these scenarios, the drug companies now become active allies, preaching to both the medical profession and the consumers. From a societal perspective, the question becomes one of cost-effectiveness. If the medications are expensive (especially over a lifetime), how much should be spent on this form of prevention? Many of the calculations suggest that those strategies that involve costly medications are not cost-effective or that the strategy must be carefully targeted to those at highest risk.

Ironically, in some cases, such as osteoporosis, older people are more cost-effective targets than younger ones (Schousboe et al., 2005).

Because the number of activities that are both safe and effective is small, we must rely on the other two preventive strategies, each of which comes at a cost. Screening for one or another condition is useful when the disease process can be detected in advance of the condition's clinical appearance and there is evidence that earlier treatment produces real benefits (earlier diagnosis can create the appearance of longer survival simply by identifying the problem earlier), but such screening may be excessively costly if the number of treatable cases detected is low and the follow-up testing is expensive. Screening is usually judged on the criteria of sensitivity and specificity. The former refers to the proportion of actual cases correctly identified and the latter to the accuracy of labeling of noncases (individuals without the condition). Alas, the two factors are usually linked, so that an improvement in one comes at the cost of a decrement in the other (ie, as sensitivity increases, specificity decreases, and therefore, the number of false positives increases). The decision about where to set them relative to each other depends on the expected prevalence of the problem and the consequences of a false-positive and a false-negative finding with respect to a given clinical condition.

While older persons have been traditionally excluded from preventive trials, that situation is changing. As it does, findings suggest that primary prevention is often appropriate for older persons as well, but the problems associated with translating the results of clinical trials into practice are at least as great as with younger persons.

Even more broadly, the value of geriatric assessment suggests that important problems in primary care of older persons are being ignored or undertreated. Research has shown that a yearly visit by a nurse practitioner to unselected persons age 75 years and older can lead to substantial functional improvement and reduced nursing home admissions (Stuck et al., 2002). This research raises serious questions about how well the current primary care system is working. Likewise, a randomized trial showed that a home visit by an occupational therapist yielded benefits for a cross-section of independent-living older adults (Clark et al., 1997). For older patients with already diagnosed complex problems, the concept of geriatric assessment has given way to a model of geriatric evaluation and management (GEM), which allows for the geriatric team to assume responsibility for the patient's care for a period sufficient to permit stabilization of the patient's condition and, in some instance, therapeutic trials. The problem still remains that when the patient is returned to the care of their primary care physician, the benefits of this assessment may be lost unless provision is made to sustain the therapeutic changes. In the absence of this continuity, the investment represented by geriatric assessment may be threatened.

Clinicians' enthusiasm for prevention will be tempered by their ability to be paid for this work. Medicare's coverage of preventive services is modest. Although Medicare Part B does not pay for many preventive services, much can be done in prevention without special visits for that purpose. Most, if not all, of the procedures

can be performed by appropriately trained clinicians. Medicare does now cover an annual wellness examination that provides an opportunity for clinicians to review preventive strategies with their patients. Table 5-4 shows the extent of this coverage.

EFFECTIVENESS OF PREVENTION IN OLDER PEOPLE

Evaluating the efficacy of preventive activities for older persons raises a dilemma. Because older people were systematically excluded from many trials of prevention strategies, there are few hard data on which to base judgments. At the same time, there are strong feelings from both sides about the value of prevention. Active advocates for wellness among elderly people urge strenuous efforts to promote major life changes. They are allied with those who view many of the accoutrements of aging as acquired and hence capable of modification. They cite data showing that muscle strength and endurance can be regained with active training even at advanced ages. Another group argues that older people have already reached a stage in life where they have demonstrated a capacity to cope. They would accept many of the consequences of aging and note that the demonstrated gains are less strongly associated with major improvements in morbidity and function than with values derived from testing.

Appropriate treatment can do a great deal to keep such patients functional and stable. The USPSTF avoided the debate about false-positive results with regard to screening for glaucoma by recommending that the decision be made by an ophthalmologist, but the importance of vision in the overall functioning of the elderly patient argues strongly for attention to this area. In a similar vein, the potential for improving function by replacing cataracts with implanted lenses mandates greater attention to visual problems as well as concern about the excess use of surgery. However, the functional benefit is not realized by cognitively impaired persons. More recent practice has shifted diabetes care attention from the usual concerns about eyes and feet to a greater appreciation about the importance of cardiovascular disease. Because of the vascular effects of diabetes, close attention should be paid to the lipid profiles of diabetics.

Some preventive interventions seem intuitively worthwhile, but data can raise irksome questions. For example, vaccination against influenza is strongly recommended for older persons. Some studies show that immunization is associated with decreased use of hospitals (Nichol et al., 2007). Indeed, over the last several years, the rate of such immunization has increased dramatically. Ironically, the rate of hospitalizations among older persons for influenza and pneumonia has also gone up during the same period, raising perplexing questions about the value of this widely lauded preventive measure (Simonsen et al., 2007).

Pneumococcal vaccines are now in widespread use, and many consider them to be useful in the care of elderly persons at risk, especially those in institutions, but there remains an active controversy about their cost-effectiveness. Tuberculosis remains a problem among older people, especially those living in institutions. Special care must be taken in interpreting a lack of reaction to tuberculin skin tests in elderly persons because of the risk of anergy.

The value of screening depends on the availability of an effective intervention and the likelihood that the intervention will change the clinical course. There is reason to believe that some cancers may behave differently in older persons. Although the incidence (and certainly the prevalence) of many cancers increases with age, the rate of growth may be slower. Thus, there is great controversy around the efficacy of active screening for prostate and breast cancer in older persons. Analysis of data from clinical trials of mammography illustrates just how confusing this literature can be. One analysis suggests that screening with mammography after age 69 leads to a small gain in life expectancy and is modestly cost-effective (Kerlikowske et al., 1999). The controversy over PSA is even higher. The USPSTF recommendation not to screen for elevated PSA in men older than age 75 unleashed a firestorm of controversy (Welch, 2011). The issue of risk versus benefit becomes even more relevant when procedures like colonoscopy are considered (Lin et al., 2006). Most clinicians would not be enthusiastic about subjecting 85-year-old patients to a colonoscopy.

Some geriatricians question whether older patients can tolerate treatment for cancer; others believe that cancer in the elderly progresses more slowly than in younger patients. Cancer takes a toll on older people. The mean age of detection for the most common forms of cancer is about 68, and the mean age of death among those persons is about 72. Cancer foreshortens their lives. In the case of breast cancer, the median age of diagnosis is about 61, and the median age of death is around 69. Most recommendations call for stopping Pap smears at age 70 for women with no abnormalities. However, cervical cancer remains a serious risk for older women, and studies show that the risk of cancer increases with longer intervals between tests (Sawaya et al., 2003).

At the same time, some areas are well served by increased clinical attention. Greater physician sensitivity to identifying depression in older persons can detect an often remediable condition. Detection of mental problems is greatly enhanced by structured screening data. Awareness of the likelihood of alcoholism can lead to recognizing a problem that can be corrected.

There is more controversy about the desirability of increasing the recognition of cognitive impairment. Although standardized testing can detect cases that might otherwise be masked in older persons who have skillfully compensated for their loss, it is not immediately clear that there is great benefit in such early uncovering. Given the relatively small proportion of dementia cases that have reversible etiologies, screening for dementia would not seem to pass the first test of screening. However, some geriatricians suggest that the modest benefits of cholinesterase inhibitor therapy can gain at least months of function and postpone institutionalization, thus justifying an aggressive approach to screening. Moreover, they argue that earlier detection allows for better planning (McCarten et al., 2011) for the dementia and the management of other diseases. Others suggest that the jury is still out (Brayne, Fox, and Boustani, 2007). Increasing the period of time when a person knows they have dementia may be a mixed blessing at best. Nonetheless, the management of dementia in the primary care setting can be improved (Callahan et al., 2006) (see Chapter 6). There is growing interest in various types of cognitive training.

Basically extending the enthusiasm for physical activity, researchers have shown modest benefits from cognitive activity in maintaining cognitive prowess (Ball et al., 2002; Wolinsky et al., 2006). However, it is too early to claim major victories. By contrast, the benefits of aggressively identifying and bringing under treatment older persons with symptoms of depression have been demonstrated (Katon et al., 1995; von Korff et al., 2011).

Routine screening for geriatric populations tends to uncover problems that are already known. Among a group of elderly persons coming for a health screening, 95% had at least one positive finding. Approximately 55% were referred to a physician for further evaluation, and only 15% were treated for the finding (Rubenstein et al., 1986). Routine annual laboratory testing of nursing home residents has received mixed reviews. A modest panel—including a complete blood count, electrolytes, renal and thyroid function tests, and a urinalysis—may be useful (Levinstein et al., 1987).

Behavior change represents at once the most promising and the most frustrating component of prevention. While some may argue that you can't teach an old dog new tricks or that engrained habit patterns are hard to break, there is no evidence to support such pessimism. Quite to the contrary, anecdotal data about elderly people taking up exercise programs and changing their dietary habits provide reason for more optimism. The critical issue here is the degree to which such changes will sufficiently modify risk factors and change clinical courses to justify the disturbance.

In general, moderation seems safest. For example, data from the Alameda County study suggest that not smoking, modest physical activity, moderate weight, and regular meals are associated with lower mortality risks among older populations. [Figure 5-1](#)




FIGURE 5-1 Changes in health habits among persons 65 years and older. (Source: *Older Americans: Key Indicators of Well-Being*. Forum on Aging-Related Statistics, Washington DC, 2012.)

shows how several parameters of health frisks have changed among older persons between 2000 and 2010. Physical activity has increased but still remains low; only 10% of seniors reported participating in leisure-time aerobic and muscle-strengthening activities that meet the 2008 Federal physical activity guidelines. Smoking rates among older people are only about 10%, but overweight is an serious endemic issue; about 65% report meeting the recommendations of the *2005 Dietary Guidelines for Americans*.

The best preventive strategies for older persons are those associated with the least risk. The findings from the Trial of Nonpharmacologic Interventions in the Elderly (TONE) study, suggesting that weight loss and sodium restriction could effectively lower blood pressure in older persons, provide a good example of such an approach. Reducing dietary salt intake was shown to lower blood pressure in another study as well. Along the same lines, antioxidant vitamins have been suggested by epidemiological evidence as a means of reducing cardiovascular disease. Several studies have shown protective benefits from using vitamin E to prevent Alzheimer disease, although the definitive data for either have not yet been seen. Taking broad-spectrum vitamin supplements is probably a good idea for most older people (Fletcher and Fairfield, 2002).

Low-dose aspirin seems like a good idea, although its use has been targeted to younger persons. It has been shown to reduce the incidence of myocardial infarction, but not stroke, in men but to have the opposite result in women (Ridker et al., 2005).

Perhaps the greatest controversy around the value of epidemiological studies as the basis for preventive care recommendations has come in the area of hormone replacement therapy (HRT) in women. Based on observational studies, HRT was widely hailed as having multiple benefits including delaying osteoporosis, lowering cholesterol, and preventing Alzheimer disease. However, subsequent findings from randomized clinical trials showed that many of these benefits were exaggerated and that HRT (at least a combination of estrogen and progesterone, the treatment recommended to avoid risks of uterine cancer) may actually increase risks of heart disease and stroke as well as cancer. Now labeled a health hazard, instead of a preventive tool, the role of HRT in treating postmenopausal symptoms is still under evaluation and will likely become a decision based on risk aversion.

GENERIC APPROACHES TO PREVENTION

It is generally not a good strategy to assume that one can simply impose a comprehensive approach to health promotion and prevention on older people as a group. Older persons often have their own agendas about what is important to them and what they believe will benefit them.

After smoking, the behavior with potentially the greatest benefit is exercise, but the evidence can confuse both older persons and their clinicians. Overall, there is widespread belief that exercise will benefit an older individual. However, exercise is a heterogeneous group of activities. There are various types, and each is directed at a specific target. [Table 5-6](#) summarizes the major types of exercise and the intended

TABLE 5-6. Types of Exercise

Type	Purpose/expected benefit
Aerobic/anaerobic	Cardiovascular conditioning
Resistance/weights	Strength, tone, muscle mass
Antigravity	Prevent osteoporosis
Balance	Prevent falls
Stretching	Flexibility

benefits of each type. Different approaches to exercise should be pursued to achieve specific goals. Although its role in osteoporosis prevention remains controversial, exercise is generally recommended as a safe approach, with more possible benefits than risks. Less than a third of older persons report regular exercise, and fewer report vigorous activity. Although evidence suggests that active aerobic exercise is necessary to reduce risk of cardiovascular accidents, even modest amounts of exercise will improve strength, keep joints more limber, promote a sense of well-being, and improve sleep. Even severely compromised nursing home residents can benefit from carefully supervised and graded strength-training exercise. Both the direct benefits (eg, improved muscle strength and activity tolerance) and indirect effects (eg, being treated with more esteem) allowed residents to function more autonomously. Exercise appears to improve both overall well-being and older persons' sense of self-worth, but it can be hard to recruit people to undertake it and to sustain such regimens (Kerse et al., 2005; Pahor et al., 2006). Likewise, occupational therapy has been shown to produce beneficial results for a group of independently living older adults (Clark et al., 1997). Modest efforts at exercise can yield substantial rewards in terms of improved function and reduced use of long-term care.

Epidemiological data suggest that even among persons in their 70s, cessation of smoking will reduce mortality to levels of nonsmokers in a sufficiently short time to justify actively encouraging quitting. Smoking cessation has rapid benefits for risks of both vascular and lung disease.

There is growing enthusiasm for controlling even modest levels of both diastolic and systolic hypertension among the elderly (Law, Morris, and Wald, 2009). However, there is not consensus (Morley, 2010). It is important to distinguish carefully between the value of uncovering elevated blood pressure and the need to control it over a sustained period. Most older persons with hypertension are aware of it; the challenge is to maintain them in a safe range without producing significant side effects. Hypertension is very common among the elderly. Black females have the highest rates, and among white males, the rate approaches 40%.

The effects of dietary changes are less certain. Weight loss for obese persons makes sense in terms of reducing cardiovascular load and in the management of adult-onset diabetes and hypertension, but hard data suggest that the benefit may be over-sold, certainly for the former. The efficacy of changing diet, especially to reduce the

amount of fat consumed, has not yet been clearly established. There is increasing evidence that elevated weight (short of frank obesity) is in fact associated with longer life than being underweight (Kuk, 2009; Newman et al., 2001). Thus, putting older people on restrictive diets that impair their quality of life does not make sense.

High cholesterol and elevated low-density lipoproteins (LDLs) are risk factors for heart disease for general populations but have not been specifically tested in the elderly. However, elevated high-density lipoproteins have been shown to provide a protective factor for strokes in older people. More than 30% of white females have high-risk cholesterol levels (>268 mg/dL). Cholesterol-lowering therapy works in older persons as well as in the middle-aged who were generally included in such trials. Recommendations for using lipid-lowering drugs in older patients with a history of cardiac or vascular disease are countered by other claims that cholesterol is not a significant risk factor in older persons. At the same time, only approximately 50% of older persons put on lipid-lowering medications remain on the regimen after 5 years. The preponderance of support now seems to favor more aggressive treatment of elevated LDL cholesterol, even in quite elderly persons (Aronow, 2002). However, many older patients do not remain on the statin therapy regimens long enough to benefit from them (Benner et al., 2002).

In areas such as weight, cholesterol, and blood pressure, the clinician must weigh the benefits of intervention against the costs and risks. There is a compelling argument that overzealous activity in the name of prevention may cost more in quality of life than it gains in quality years. Some have suggested that the survivor effect should be taken more seriously. Persons who survive to old age may have demonstrated a biological ability that deserves more respect. At the very least, any determination to change lifestyle at this stage of life should be made by the patient after suitable counseling. Nonetheless, older persons should not be denied the opportunity to actively consider the benefits of primary prevention. The growing body of evidence about at least the possible value of primary prevention imposes a responsibility on clinicians to provide them with such information.

One area of behavior with great theoretical promise but little immediate practical application is social support. There is some evidence to suggest that older persons with strong social support systems, or at least perceived support, are at less risk for adverse events, but it is not yet clear how to build such a support system for those without one naturally. Social support likely plays at least two distinct roles: (1) Having (or perhaps just believing one has) a strong support system may reduce the risk of adverse events (through a yet-to-be-elucidated mechanism that likely involves stress). (2) For persons who are disabled and require assistance, having a real support system may prove the difference between staying in the community and needing to enter an institution. It is difficult to assess the availability of that support system in advance.

The perception, even the promise, of such support does not guarantee that the necessary support will be consistently and conveniently available when it is needed. Even well-intentioned family members may find the task too daunting to be able to maintain it.

PREVENTING DISABILITY

Although discussions of prevention tend to focus on the prevention of disease, the context of geriatrics—with its emphasis on functioning—urges a broader approach. When caring for older patients, equal attention must be paid to seeking means to keep them as active as possible. While there may be little that can be done to prevent the occurrence of a disease in an elderly person, much can be done to minimize the impact of that disease. Impairments cannot be allowed to become disabilities. Recent work in studying disability has raised new questions about the possible differences between transient and persistent disabled states. Studies that followed older people closely showed that many of them move in and out of transient states of disability. Hence, measures of disability over long periods may contain elements of both permanent and transient disability. This distinction is important because efforts to prevent disability may be falsely positive if they reflect transient conditions that would have improved on their own.

The overarching goal of geriatric practice is the improvement, or at least the preservation, of patients' function. In general, function can be thought of as being determined by three principal forces: (1) the patient's overall physical health, (2) the environment, and (3) the patient's motivation. Much of the discussion in this book deals with ways to maximize the patient's health status by proper diagnosis and treatment. Such steps are necessary, but not sufficient, for good geriatric care. It is essential to appreciate that a person's environment can play a critical role in affecting their functioning. Just imagine for a minute what it would be like to be in a country where you did not speak the language or even understand its symbols. Although your capabilities are intact, you cannot function effectively. By a similar token, even after therapy has achieved its maximal effect, a patient's environment can be crucial.

In the context of geriatrics, one central type of screening is comprehensive assessment. The general approaches of such programs are reviewed in Chapter 3. It is important to note that the composition of these programs varies. Table 3-1 in Chapter 3 summarizes the major randomized controlled trials using different approaches to assessment. Work on demonstrated performance, especially when combined with timed measures, is promising. This additional component provides a way to achieve more variability and may lead to better prediction. It offers a means to detect more subtle change. Interventions can be targeted at both the individual patient and the environment.

Environment in this case refers to both the physical and psychological setting. It is fairly easy to imagine the physical barriers to functioning. Narrow doorways, poor lighting, and stairs can all serve as barriers. The homes of older persons are often cluttered with obstacles and loose rugs, wires, and so on, which may increase the risk of tripping. Occupational therapists can be especially helpful in assessing the patient's environment to suggest modifications and adaptive equipment. Environment refers to the ways patients are treated and, especially, the extent to which they are encouraged to do as much for themselves as they can.

The psychological barriers are more subtle but perhaps more important. We noted earlier that a risk-averse environment can engender excessive dependency, so too can the pressure to be productive. As long as time is at a premium, care providers will be motivated to do things for patients, rather than encouraging them to perform those tasks themselves, especially if the latter course takes considerably longer. In the name of efficiency, we may be creating dependency. The effort to encourage self-sufficiency is precisely what is usually called rehabilitation, even when it occurs in a plain wrapper.

The third element of functional effects is the patient's motivation. Today's older patients place especially high trust in their physicians, whom they view as figures of authority. Thus, one of the most subtle but nonetheless important aspects of this approach to prevention—the prevention of inactivity and despair—is the physician's attitude. For the patient, a gain in function or an ability to deal with a chronic problem is essential. It is surely no mean feat. Such behavior should be encouraged and rewarded. Indifference may be enough to discourage the patient from trying.

Other programs can be mobilized on the patient's behalf. Self-help groups are available in many communities to offer support with chronic illness, including stress management and drugless pain-control techniques. Social activity can play an essential role in maintaining function. Pets have proved to be very effective in improving morale and maintaining function.

Special efforts may be necessary to deal with members of the patient's family. Their concern over potentially dangerous accidents may lead them to become overprotective and thus exaggerate the condition of dependency.

OSTEOPOROSIS AS A SPECIFIC EXAMPLE OF PREVENTION IN OLDER ADULTS

A good example of the complicated nature of prevention in older persons is the case of osteoporosis. (This topic is also addressed in Chapter 10.) Effective treatments are now available to delay the onset or halt the progression of this disease, which can lead to fractures and disabilities. Understanding the management of osteoporosis requires thinking systematically about the clinical goals. In this regard, the intellectual exercise is similar to that around hypertension. The real consideration is not necessarily attacking the primary disease but its ultimate effects. In the case of osteoporosis, the adverse outcomes are fractures of various types. However, once attention shifts to the actual outcomes of importance, new strategies emerge. For example, if the goal is to prevent hip fractures, wearing hip protectors may be as effective, perhaps more so, as improving bone density, because hip fracture is the combined effect of falling and osteoporosis (Sawka et al., 2007). The studies on the actual effectiveness of such devices suggest that they do not work as well as one might hope (van Schoor et al., 2007). Part of the failure may be attributed to older peoples' reluctance to wear them. It is not easy to convince older patients, especially those with cognitive impairment, to wear such devices.

Drugs can be used to treat osteoporosis effectively, and with modest side effects, but these drugs can be expensive, especially over a lifetime. (A common bisphosphonate, alendronate, is now available as a generic drug.) The first line of defense against

this disease is a regimen of calcium, vitamin D, and weight-bearing exercises, but this inexpensive and safe approach may be insufficient or hard to sustain. In these instances, drugs may be indicated (although the use of calcium, vitamin D, and weight-bearing exercise should be continued).

The prime target for osteoporosis screening is postmenopausal women, but the disease can also affect men. Screening is done by bone mineral density testing. The World Health Organization standard for osteoporosis is a value of 2.5 standard deviations (SDs) (often referred to as a T score) or more below the young adult mean value, but the National Osteoporosis Foundation recommends treating when T scores are ≤ 2 SDs below the young adult mean value.

HRT is effective in delaying the course of osteoporosis, but the effects last only as long as the treatment. Given the new evidence of multiple disease risks associated with HRT, this option has effectively been removed from the osteoporosis treatment repertoire.

The class of bisphosphonates shows great promise in increasing bone density and reducing fracture rates. The major side effects are gastrointestinal disturbances; therefore, these drugs must be taken on an empty stomach in an upright position. New monthly dosing regimens promise to reduce the side effects and the cost. The ultimate duration of this therapy is still not established. There is some evidence of a sustained effect for 5 years or more. Recommendations about how long to continue bisphosphonate treatment remain cautious. For many patients, 3 to 5 years of treatment may suffice, but those at highest risk (including older patients) may benefit from longer treatment (Black et al., 2012; Whitaker et al., 2012). A number of bisphosphonate products are emerging each year into this lucrative market, each with claims of improved benefits. In addition, other approaches are being actively explored. Nasally administered calcitonin is also approved by the Food and Drug Administration (FDA) for treatment of osteoporosis, but it has weak fracture prevention efficacy. An intriguing finding has been that the statins, which are used to treat high cholesterol, have appeared to show a positive effect on bone mass density. This therapeutic effect has not yet been tested in randomized trials. Moreover, no clear fracture reduction benefit from statins has been demonstrated. [Table 5-7](#) compares the effectiveness of the available bisphosphonates and other potential treatments. The fracture reduction benefit is disproportionately greater than the improvement in bone mineral density; this may be because of reduction of bone turnover from these drugs. Although parathyroid hormone (PTH) is the most potent approach, it is not widely used because of the cost and administration problems, as well as concern regarding its long-term safety. Although PTH side effects are few, concern remains about the risk of osteosarcoma from its use.

IATROGENESIS

Probably the most important preventable problems faced by older persons today are those associated with diagnostic tests and treatments. [Table 5-8](#) lists some of the iatrogenic problems elderly patients may suffer with.

TABLE 5-7. Relative Effectiveness of Various Osteoporosis Treatments					
	Mean % change in bone mass density at 12-18 months [‡]		Rate of fractures		
	Lumbar spine	Femoral neck	Vertebra	Nonspine	Hip
Alendronate (70 mg)*	+5	+3	↓	↓	↓
Risedronate (35 mg)*	+3	+2	↓	↓	↓
Ibandronate (150 mg)	+6	+3	↓	—	—
Ibandronate IV (3 mg)	+5	+3	↓	—	—
Zoledronate IV (5 mg)	+5	+3	↓	↓	↓
Raloxifene (60 mg)*	+3	+2	↓	—	—
Calcitonin (200 IU)*	+1	—	↓	—	—
Parathyroid hormone (20 mg)	+9	+4	↓	↓	—
Hormone replacement therapy [†]	+4	+1	↓	↓	↓

*Food and Drug Administration–approved agent for treating postmenopausal osteoporosis.

[†]No longer considered a realistic option.

[‡]Difference between drug and placebo.

↓Direct evidence from randomized trials.

Source: Information provided by John Schousboe, MD.

In some cases, these iatrogenic problems can be traced to oversights and omissions. In other cases, overzealous care can be blamed. Some of the problems are attributable to lack of expertise in managing older persons, but a substantial portion is caused by the inevitable problems of trying to titrate therapy in a person who is considerably less resilient. The more aggressive the treatment, the greater is the chance that it will produce adverse effects. [Figure 5-2](#) portrays in a conceptual manner this narrowing of the therapeutic window (ie, the space between a therapeutic dose and a toxic dose)

TABLE 5-8. Common Iatrogenic Problems of Older Persons
Overzealous labeling
Dementia
Incontinence
Underdiagnosis
Bed rest
Polypharmacy
Enforced dependency
Environmental hazards
Transfer trauma




FIGURE 5-2 Narrowing of the therapeutic window. This diagram portrays in a conceptual manner how the space between a therapeutic dose and a toxic dose narrows with age.

with age. As the response to therapy decreases, the susceptibility to toxic side effects increases. These changes are attributable to many factors, including the ability to metabolize drugs, changes in receptor behavior, and an altered chemical environment produced by other simultaneous drugs.

This narrowing of the therapeutic window is perhaps most easily recognized in the pharmacological treatment of older patients. In the face of reduced capacity for metabolizing and excreting many drugs, the older patient can develop high blood levels on “normal” dosages. Changes in receptors may alter sensitivity to chemicals in either direction.

Many older people are at risk of drug problems. A study of community-dwelling elders found that 20% of older people taking medications had inappropriate elements, such as potential drug–disease interactions and excessive duration of use. Another study found that more than 20% of older persons were taking drugs that an expert panel had identified as inappropriate for this age group. For example, several studies have shown that thrombolytics may have serious adverse consequences when used in elderly patients with acute myocardial infarctions. Although they are actively recommended for younger victims, their use in older persons must be monitored very closely.

Use of numerous drugs transforms the elderly patient into a living chemistry set. Because of their prevalence and importance, drugs are discussed separately in Chapter 14. There is good reason to believe that older people are overmedicated (Hajjar et al., 2005). In this chapter, we focus attention on some of the more subtle ways in which other types of treatment can adversely affect older people. In general, many drugs can be discontinued safely. However, there is one caveat. In the fear of overmedicating older patients, doctors may be tempted to discontinue drugs that were begun at an earlier time. While such a reevaluation is prudent, the decision to discontinue should be made carefully. One study showed that stopping long-term

diuretic medications in elderly patients resulted in an exacerbation of heart failure symptoms and a rise in their blood pressure (Walma et al., 1997).

SPECIAL RISKS OF HOSPITALS

Hospitals are dangerous places for any patient, as reflected in a report from the Institute of Medicine documenting the prevalence of medical errors (Kohn, Corrigan, and Donaldson, 2000). The Institute of Medicine has called for more stringent efforts to make hospitals safer places and eliminate the many deaths associated with imperfect care. Older patients are at special risk. Most of us are resilient enough to enter an acute care hospital and suffer the vicissitudes of care with the expectation that we will emerge better (certainly in the long run). Hospitalized patients over age 65 have a 5% chance of sustaining a disabling injury (Brennan et al., 1991). As shown in Table 5-9, age is a risk factor for bad outcomes in the hospital. The calculation of the balance between benefits received and risks undertaken needs to be more carefully thought through with older patients.

Just a little thought reveals the litany of familiar hazards of hospitalization—from the risk of nosocomial infection to getting the wrong drug to the stress of major surgery or the danger of certain diagnostic procedures. One meta-analysis estimated the high rate of adverse drug reactions in hospitalized patients in general at almost 7% (Lazarou, Pomeranz, and Corey, 1998). Hospitalized older people are at risk of being restrained and being catheterized, both with serious consequences. All these are imposed on the general hazards of bed rest discussed in Chapter 10, Table 10-2. Table 5-10 offers some examples of potential hazards in the hospital. They include problems of both overtreatment and undertreatment.

Elderly patients are more likely to experience an untoward event during a hospital stay. In part, this is because they present with more physical problems; however, they are also more vulnerable. Table 5-11 lists patient characteristics associated with increased risk of hospital iatrogenic complications. Source of admission and condition on admission are especially salient. Because elderly patients are more likely to come from nursing homes and to be in poor condition on admission, they should be considered at high risk for iatrogenic complications.

TABLE 5-9. Frequency of Patient Risk Factors for Iatrogenic Hospital Events		
	<65 years old	65+ years old
Adverse events (AE)	2.8%	5.3%
Preventable AEs	1.6%	3.0%
Procedure related	0.1%	0.7%
Drug related	0.2%	0.6%
Fall	0.01%	0.1%

Source: Adapted from Thomas and Brennan, 2000.

TABLE 5-10. The Hazards of Hospitalization

Risk factors	Potentially hazardous outcomes
Diagnostic procedures	Medication error
Cardiac catheterization	Drug–drug interaction
Arteriography	Drug reaction
Therapeutic procedures	Drug side effect
Intravenous therapy	Infection
Urinary catheters	Metabolic imbalance
Nasogastric tube	Malnutrition
Dialysis	Hypovolemia
Transfusion	Calcium metabolism
Drugs	Fecal impaction
Surgery	Urine incontinence
Anesthesia	Thromboembolism
Bed rest	Nosocomial infection
	Falls

Table 5-12 provides a simple rapid screening test for identifying older patients at risk of functional decline in the hospital. Delirium can be a serious problem in elderly hospitalized patients (see Chapter 6 for a discussion of this condition). The elderly patient’s vulnerability extends to a more subtle level. Admission to a hospital means entering an unfamiliar world. Moreover, the patient enters the hospital at a time of great stress. The anxiety of unknown consequences exists in addition to the physical stress of the illness.

The hospital presents physical and organizational barriers to which the patient must adapt. Not only the geography but the routines are different. The things we rely on to preserve our sense of identity—our clothing, our personal effects—are among the first things taken away. It is hardly surprising, then, that many elderly persons who are able to function in their familiar surroundings become disoriented and often agitated in the hospital. Just as a blind person can move flawlessly in familiar surroundings, an older person may have developed a host of adaptive mechanisms to function in their home situation, overcoming problems of memory loss and impaired vision.

Transferred into the sterile, rigid hospital room, such an individual may decompensate. The syndrome of “sundowning,” whereby older patients in the hospital

TABLE 5-11. Patient Risk Factors for Iatrogenic Hospital Events

Admission from nursing home or other hospital
Physician’s assessment of overall condition on admission
Age
Number of drugs
Length of stay

TABLE 5-12. Risk Factors for Functional Decline in Elderly Hospitalized Patients

Age 75+
Missing >15 of the first 21 MMSE items
Dependence in 2+ IADLs prior to admission
Pressure sore
Baseline functional dependency
History of low social activity

IADL, instrumental activity of daily living; MMSE, Mini-Mental State Examination.
Adapted from Inouye and Charpentier, 1996; and Sager et al., 1996.

become agitated and disoriented as dusk falls, is likely a function of visual or hearing impairments, diminished sensory stimuli, and resultant disorientation.

The older person accustomed to coping with nocturia may wander at night in the dark to where the bathroom at home ought to be and wet the floor. In the crisis of urinary urgency, the patient may be unable to scale the side rails and make it to the bathroom in time. To label an individual who suffers such environmentally exacerbated accidents as incontinent is to inflict double jeopardy.

We fail to appreciate the dangers of bed rest for elderly people. The bed is actually a very dangerous place for an older person! Besides the risk of falling out of bed, enforced immobility can produce much harm. Complications of bed rest are summarized in [Table 5-13](#) and detailed in Chapter 10.

The hospital breeds dependency. Even with younger patients, hospital personnel are accustomed to performing basic functions for the patient. Use of the bathroom is by prescription only. Bathing is often a supervised event. Patients are transported from one location to another. Although most of us as patients may have enjoyed being indulged for a while, we soon begin to rail against the imposed dependency. In older patients who need to be urged, encouraged, and cajoled into doing as much for themselves as possible, such an atmosphere can be especially debilitating.

TABLE 5-13. Potential Complications of Bed Rest in Older Persons

Pressure sores
Bone resorption
Hypercalcemia
Postural hypotension
Atelectasis and pneumonia
Thrombophlebitis and thromboembolism
Urinary and fecal incontinence
Constipation and fecal impaction
Decreased muscle strength/deconditioning
Decreased cardiac output/aerobic capacity
Contractures
Depression and anxiety

Encouraging patients to act independently necessitates patience and time; unfortunately, both are scarce in the acute care hospital. It is much faster and easier to do a task for a person who performs slowly and uncertainly than to take the time to encourage that person to do that task independently. Moreover, the result of a professionally performed task is usually neater and more in keeping with hospital standards. Thus, well-meaning staff bowing to the pressures for efficiency may be inclined to do things for elderly patients rather than urging the patients to do as much as possible for themselves. This well-intentioned behavior fosters dependency at a time when independent function is crucial.

Ironically, we have invested great effort in minimizing the trauma of hospitalization for children. Creativity in architecture and programs has gone into making pediatric wards as nonthreatening and homelike as possible. Although children are rarely hospitalized and geriatric patients are frequently hospitalized, no similar investment of creativity has been devoted to making the hospital less stressful for frail elderly patients. We know enough about perceptual and functional problems of aging to recognize that even simple architectural modifications can make a hospital stay easier. Use of primary colors, windows at lower heights, better-designed furniture, use of textures and patterns, and better design of rooms can all help the older patient retain maximum functioning capacity.

Special units for managing geriatric patients are beginning to emerge. Staffed by an interdisciplinary team, which may include a social worker, physician, physical or occupational therapist, and nurses, these units apply techniques of multidimensional functional evaluation to assess the diagnoses, needs, and capacity of the geriatric patient and develop treatment plans to address them.

Likewise, the reports of geriatric assessment units that took patients who had completed a course of acute care hospitalization and were otherwise destined for a nursing home and dramatically altered both their clinical state and their long-term care course, even reducing mortality rates, suggest that much more can be done for older persons while they are in a hospital. Such geriatric units can uncover treatable conditions, provide rehabilitation to improve functional capacity, and develop a plan of care that will allow elderly patients to remain in the community.

Hospitals can also lead to problems at the time of discharge. Decisions made under the pressure of time can commit older patients to an unnecessary lifetime of nursing home care. Poor transmission of information to the community care staff (or the nursing home) or the patient can create serious problems associated with high rates of readmission (Coleman, 2006; Naylor et al. 1994).

HOSPITAL DISCHARGE PLANNING

Clinicians admitting patients to nursing homes are responsible for assuring both themselves and their patients on several scores:

1. The patient truly needs care in such a setting and cannot reasonably get such care elsewhere.
2. The institution is capable of providing the needed care.
3. The patient is prepared for a transfer to the nursing home.

Hospital discharge planners are often put under great stress to move patients out quickly, leaving little time for careful considerations, options, or even what goals the family and patient want to maximize. Too often the first train leaving the station is the best one to be on. Availability of placements trumps careful consideration of options. Because nursing home discharges are easier to arrange, they are frequently used. Earlier discharges from hospitals promote the concept of recuperation in a nursing home.

Too frequently, hospital discharge to the nursing home compounds the trauma. Discharge planning is often begun too late. There is insufficient time to find the best facility for the patient's needs or to allow the patient and the patient's family a sufficient role in making the decision for nursing home placement.

Good discharge decision making should separate two major classes of decisions: (1) What types of care are most likely to achieve the primary goals for this patient? and (2) Having chosen the modality, what vendor can best provide those services? These two components require quite different sets of information. The former requires goal clarification and agreement within a family. Then one needs to know about the relative risks and benefits of each type of posthospital care. The choice of a vendor may involve quite different factors. Here, location, quality, and policies may be salient.

Making a good discharge decision includes at least six critical steps:

1. Adequate identification of those at risk of needing special arrangements on discharge
2. Assessment to identify problems and strengths
3. Clarification of what goals should be maximized
4. Determination of the risks and benefits associated with alternative modalities of care
5. Determination of the most suitable vendor among the modality of care selected
6. Transmission of adequate information to assure a successful transition

Patients and their families should play an active role in steps 3, 4, and 5. Ideally, they should make the choice after the information has been provided by professionals. In practice, this is rarely the case. Often, getting family members to agree on the most important goals for posthospital care (ie, Do concerns about recovery trump those of autonomy? Where does safety factor?) can be very time consuming and requires great skill. Older patients and their families may not agree. Old family histories and relationships may intrude.

Adequate information about the risks and benefits of alternative modalities may not be presented (it may not be known). Encouragement or assistance may not be provided to help patients and families determine precisely what outcomes they seek to maximize. Too often, insufficient time is allowed to weigh the complexities of the choice. When it comes to choosing among vendors of a given service, real choices may not exist because of the constraints of payment arrangements, including managed care.

As discussed in Chapter 16, the nature of nursing home care is changing. The pressure for earlier discharges from hospitals has created a new demand for what has been termed subacute care—in essence, care that was formerly provided in hospitals.

SUMMARY

Many useful steps can improve and protect the health of elderly patients. The elderly patient represents a different risk–benefit ratio than the younger patient. Actions well tolerated in others may produce serious consequences in the old. A bed is a dangerous place for the older patient; confinement to bed rest should be avoided whenever possible.

Clinicians must guard against several potential iatrogenic problems with elderly patients. Diagnostic labels implying incurable problems (such as dementia and incontinence) should not be used until a careful search for correctable causes has been undertaken. Special attention should be given to the tendency to create dependency through well-intentioned care. By keeping in mind the need to maintain the patient's functioning, the physician can remain sensitive to the effects of the environment to enhance or impede such activity.

REFERENCES

- Aronow WS. Should hypercholesterolemia in older persons be treated to reduce cardiovascular events? *J Gerontol A Biol Sci Med Sci*. 2002;57A:M411-M413.
- Ball K, Berch DB, Helmers KF, et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. *JAMA*. 2002;288:2271-2281.
- Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. *JAMA*. 2002;288:455-461.
- Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? *N Engl J Med*. 2012;366:2051-2053.
- Brayne C, Fox C, Boustani M. Dementia screening in primary care: is it time? *JAMA*. 2007;298:2409-2411.
- Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence care in hospitalized patients. *N Engl J Med*. 1991;324:370-376.
- Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. *JAMA*. 2006;295:2148-2157.
- Clark F, Azen SP, Zemke R, et al. Occupational therapy for independent-living older adults: a randomized controlled trial. *JAMA*. 1997;278:1321-1326.
- Coleman EA, and Berenson RA. Lost in transition: challenges and opportunities for improving the quality of transitional care. *Ann Intern Med*. 2004;141(7):533-536.
- Coleman, EA, Parry, C, Chalmers, S, and Min, SJ. The care transitions intervention: results of a randomized controlled trial. *Arch Intern Med*. 2006;166(17):1822-1828.
- Fletcher RH, Fairfield KM. Vitamins for chronic disease prevention in adults: clinical applications. *JAMA*. 2002;287:3127-3129.
- Hajjar ER, Hanlon JT, Sloane RJ, et al. Unnecessary drug use in frail older people at hospital discharge. *J Am Geriatr Soc*. 2005;53:1518-1523.
- Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. *JAMA*. 1996;275:852-857.
- Katon W, von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. *JAMA*. 1995;273:1026-1031.

- Kerlikowske K, Salzman P, Phillips KA, Cauley JA, Cummings SR. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. *JAMA*. 1999;282:2156-2163.
- Kerse N, Elley CR, Robinson E, Arroll B. Is physical activity counseling effective for older people? A cluster randomized, controlled trial in primary care. *J Am Geriatr Soc*. 2005;53:1951-1956.
- Kohn LT, Corrigan JM, Donaldson MS, eds. *To Err Is Human: Building a Safer Health System*. Washington, DC: National Academy Press; 2000.
- Kuk JL, Ardern CI. Influence of age on the association between various measures of obesity and all-cause mortality. *J Am Geriatr Soc*. 2009; 57(11):2077-2084.
- Law MR, Morris JK, and Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009;338:b1665.
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA*. 1998;279:1200-1205.
- Levinstein MR, Ouslander JG, Rubenstein LZ, Forsythe SB. Yield of routine annual laboratory tests in a skilled nursing home population. *JAMA*. 1987;258:1909-1915.
- Lin OS, Kozarek RA, Schembre DB, et al. Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy. *JAMA*. 2006;295:2357-2365.
- Mangin D, Sweeney K, Heath I. Preventive health care in elderly people needs rethinking. *BMJ*. 2007;335:285-287.
- McCarten JR, Anderson P, Kuskowski MA, McPherson SE, Borson S. Screening for cognitive impairment in an elderly veteran population: acceptability and results using different versions of the Mini-Cog. *J Am Geriatr Soc*. 2011;59:309-313.
- Morley JE. Hypertension: is it overtreated in the elderly? *J Am Med Dir Assoc*. 2010;11:147-152.
- Naylor M., Broton D, Jones R, Lavisso-Mourey R, Mezey M, Pauly M. Comprehensive discharge planning for the hospitalized elderly: a randomized clinical trial. *Ann Intern Med*. 1994;120(12):999-1006.
- Newman AB, Yanez D, Harris T, Duxbury A, Enright PL, Fried LP. Weight change in old age and its association with mortality. *J Am Geriatr Soc*. 2001;49:1309-1318.
- Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. *N Engl J Med*. 2007;357:1373-1381.
- Pahor M, Blair SN, Espeland M, et al. Effects of a physical activity intervention on measures of physical performance: results of the lifestyle interventions and independence for Elders Pilot (LIFE-P) study. *J Gerontol A Biol Sci Med Sci*. 2006;61:1157-1165.
- Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med*. 2005;352:1293-1304.
- Rubenstein LZ, Josephson KR, Nichol-Seamons M, Robbins AS. Comprehensive health screening of well elderly adults: an analysis of a community program. *J Gerontol*. 1986;41:342-352.
- Sager MA, Rudberg MA, Jalaluddin M, et al. Hospital Admission Risk Profile (HARP): identifying older patients at risk for functional decline following acute medical illness and hospitalization. *J Am Geriatr Soc*. 1996;44:251-257.
- Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. *N Engl J Med*. 2003;349:1501-1509.

- Sawka AM, Boulos P, Beattie K, et al. Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. *J Clin Epidemiol.* 2007;60:336-344.
- Schousboe JT, Ensrud KE, Nyman JA, Melton LJ, 3rd, Kane RL. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. *J Am Geriatr Soc.* 2005;53:1697-1704.
- Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. *Lancet Infect Dis.* 2007;7:658-666.
- Stuck AE, Egger M, Hammer A, Minder CE, Beck JC. Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. *JAMA.* 2002;287:1022-1028.
- Thomas EJ, Brennan TA. The incidence and types of preventable adverse events in the elderly. *Br Med J.* 2000;320:741-744.
- van Schoor NM, Smit JH, Bouter LM, Veenings B, Asma GB, Lips P. Maximum potential preventive effect of hip protectors. *J Am Geriatr Soc.* 2007;55:507-510.
- von Korf M, Katon WJ, Lin EHB, et al. Functional outcomes of multi-condition collaborative care and successful ageing: results of randomised trial. *BMJ.* 2011;343:d6612.
- Walma EP, Hoes AW, van Dooren C, Prins A, van der Does E. Withdrawal of long term diuretic medication in elderly patients: a double blind randomised trial. *Br Med J.* 1997;315:464-468.
- Welch HG. A piece of my mind. Making the call. *JAMA.* 2011;306:2649-2650.
- Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis—where do we go from here? *N Engl J Med.* 2012;366:2048-2051.
- Wolinsky FD, Unverzagt FW, Smith DM, Jones R, Stoddard A, Tennstedt SL. The ACTIVE cognitive training trial and health-related quality of life: protection that lasts for 5 years. *J Gerontol A Biol Sci Med Sci.* 2006;61:1324-1329.

SUGGESTED READINGS

- Fiatarone MA, O'Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. *N Engl J Med.* 1994;330:1769-1775.
- Gill TM, Williams CS, Mendes de Leon CF, et al. The role of change in physical performance in determining risk for dependence in activities of daily living among nondisabled community-living elderly persons. *J Clin Epidemiol.* 1997;50:765-777.
- Gillick MR, Serrell NA, Gillick LS. Adverse consequences of hospitalization in the elderly. *Soc Sci Med.* 1982;16:1033-1038.
- Hanlon JT, Schmadre KE, Boulton C, et al. Use of inappropriate prescription drugs by older people. *J Am Geriatr Soc.* 2002;50:26-34.
- Pham HH, Schrag D, Hargraves JL, Bach PB. Delivery of preventive services to older adults by primary care physicians. *JAMA.* 2005;294:473-481.
- Ross KS, Carter HB, Pearson JD, et al. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. *JAMA.* 2000;284:1399-1405.
- Schnelle JF, Alessi CA, Simmons SF, Al-Samarrai N, Beck JC, Ouslander JG. Translating clinical research into practice: a randomized controlled trial of exercise and incontinence care in nursing home residents. *J Am Geriatr Soc.* 2002;50:1476-1483.
- Singh MAF. Exercise comes of age: rationale and recommendations for a geriatric exercise prescription. *J Gerontol A Biol Sci Med Sci.* 2002;57A:M262-M282.

This page intentionally left blank

CHAPTER 6

Delirium and Dementia

Diagnosis and management of geriatric patients exhibiting symptoms and signs of impaired cognitive functioning can make a critical difference to their overall health and the ability to function independently. Impaired cognitive function can be acute in onset, or it can be manifest by slowly progressive cognitive impairment. The major causes of impaired cognition in the geriatric population are delirium and dementia. As more people live into the tenth decade of life, the chance that they will develop some form of dementia increases substantially. Community-based studies report a prevalence of dementia as high as 47% among those 85 years of age and older. Prevalence rates are, however, highly dependent on the criteria used to define dementia (Mayeux, 2010). Between 25% and 50% of older patients admitted to acute care medical and surgical services are delirious on admission or develop delirium during their hospital stay. In nursing homes, 50% to 80% of those older than age 65 years have some degree of cognitive impairment. Delirium is often superimposed on dementia in both hospital and community settings, can persist for days to weeks after discharge from an acute hospital, and is a risk factor for functional decline and mortality. Both dementia and delirium are associated with high health-care costs (Okie, 2011).

Misdiagnosis and inappropriate management of conditions leading to confusion in geriatric patients can cause substantial morbidity among the patients, hardship for their families, and excess health-care expenditures. This chapter provides a practical framework for diagnosing and managing geriatric patients who demonstrate “confusion” or signs of cognitive impairment. We focus on the most common causes of confusion in the geriatric population—delirium and dementia—although a variety of other disorders can cause the same or similar signs.

Imprecise definition of the abnormalities of cognitive function in older patients labeled as “confused” has led to problems in diagnosis and management. Descriptions such as impairment of cognitive function or cognitive impairment coupled with careful documentation of the timing and nature of specific abnormalities provide more precise and clinically useful information. Such documentation is best accomplished by screening and a thorough mental status examination, if indicated.

Screening for delirium can be accomplished with the confusion assessment method (CAM). The Mini-Cog is useful in screening for cognitive impairment and dementia. Both of these screening tests are discussed later in the chapter.

A thorough mental status examination has several basic components that are essential in diagnosing dementia, delirium, or other syndromes (Table 6-1). The examiner should focus on each of these components in a systematic manner. Recording observations in each area facilitates recognizing and evaluating changes over time. Standardized and validated measures of cognitive function (see Appendix) should be

TABLE 6-1. Key Aspects of Mental Status Examination

State of consciousness
General appearance and behavior
Orientation
Memory (short- and long-term)
Language
Visuospatial functions
Executive control functions (eg, planning and sequencing of tasks)
Other cognitive functions (eg, calculations, proverb interpretation)
Insight and judgment
Thought content
Mood and affect

used in diagnosis and subsequent monitoring. Several factors may, however, influence performance and interpretation of standard mental status tests, such as prior educational level, primary language other than English, severely impaired hearing, or poor baseline intellectual function. Thus, scores on these tests should not be used to replace a more comprehensive examination such as that in Table 6-1.

Important information can be gleaned unobtrusively from simply observing and interacting with the patient during the history. Is the patient alert and attentive? Does the patient respond appropriately to questions? How is the patient dressed and groomed? Does the patient repeat herself or give an imprecise social or medical history, suggesting memory impairment? Orientation, insight, and judgment can sometimes be assessed during the history as well.

Questions relating to specific areas of cognitive functioning should be introduced in a nonthreatening manner, because many patients with early deficits respond defensively. Each of the three basic components of memory should be tested: immediate recall (eg, repeating digits), recent memory (eg, recalling three objects after a few minutes), and remote memory (eg, ability to give details of early life). Language and other cognitive functions should be carefully evaluated. Is the patient's speech clear? Can the patient read (and understand) and write? Does there seem to be a good general fund of knowledge (eg, current events)? Other cognitive functions that can be tested easily include the ability to perform simple calculations (eg, one that relates to making change while shopping) and to copy diagrams. The ability to interpret proverbs abstractly and to list the names of animals (listing 12 names in 1 minute is normal) is a sensitive indicator of cognitive function and is easy to test.

Judgment and insight can usually be assessed during the examination without asking specific questions, although input from family members or other caregivers can be helpful, and is sometimes necessary. Any abnormal thought content should also be noted during the examination; bizarre ideas, mood-incongruent thoughts, and delusions (especially paranoid delusions) may be present in older patients with cognitive impairment and are important both diagnostically and therapeutically. Observations during the examination may also detect abnormalities of executive control.

Executive function involves the planning, sequencing, and execution of goal-directed activities. These functions are critical to the ability to perform instrumental activities of daily living (IADLs). Screening tests for executive dysfunction include a clock-drawing test, which is a component of the Mini-Cog (see later in this chapter).

Throughout the examination, the patient's mood and affect should be assessed. Depression, apathy, emotional lability, agitation, and aggression are common in older patients with cognitive impairment (Lyketsos et al., 2002), and failure to recognize these abnormalities can lead to improper diagnosis and management. In some patients—such as those who are very intelligent or poorly educated, or have low intelligence, as well as those in whom depression is suspected—more detailed neuropsychological testing by an experienced psychologist is helpful in precisely defining abnormalities in cognitive function and in differentiating between the many and often interacting underlying causes.

DIFFERENTIAL DIAGNOSIS

The causes of impaired cognitive function in the geriatric population are myriad. The differential diagnosis in an older patient who presents with confusion includes disorders of the brain (eg, stroke, dementia), a systemic illness presenting atypically (eg, infection, metabolic disturbance, myocardial infarction, congestive heart failure), sensory impairment (eg, hearing loss), and adverse effects of a variety of drugs or alcohol.

Similar to many other disorders in geriatric patients, cognitive impairment often results from multiple interacting processes rather than a single causative factor. Accurate diagnosis depends on specifically defining abnormalities in mental status and cognitive function and on consistent definitions for clinical syndromes. Disorders causing confusion in the geriatric population can be broadly categorized into three groups:

1. Acute disorders usually associated with acute illness, drugs, and environmental factors (ie, delirium)
2. More slowly progressive impairment of cognitive function as seen in most dementia syndromes
3. Impaired cognitive function associated with affective disorders and psychoses

Older patients have often been labeled “senile” because they are unable to answer a question or because they are not given adequate time to respond. Other age-associated disorders such as impaired hearing and Parkinson disease can also lead to mislabeling an older patient as confused or senile. Old age alone does not cause impairment of cognitive function of sufficient severity to render an individual dysfunctional. Slowed thinking and reaction time, mild recent memory loss, and impaired executive function can occur with increasing age and may or may not progress to dementia. *Mild cognitive impairment (MCI)* and *cognitive impairment, not dementia (CIND)* have been used to describe these deficits. Just over 20% of people age 71 and older in the United States have cognitive impairment without dementia (Plassman et al., 2008). The definitions, prevalence, prognosis, and treatment of MCI and CIND are being studied actively at the current time. Data suggest that up to 15% to 20% of

those diagnosed with MCI or CIND will progress to dementia over the course of a year (Petersen, 2011; Ravaglia et al., 2008; Ries et al., 2008; Sachdev et al., 2012). The therapeutic implications of MCI are subjects of intensive research, but at this time, no intervention has been shown to prevent progression to dementia.

Three questions are helpful in making an accurate diagnosis of the underlying cause(s) of confusion:

1. Has the onset of abnormalities been acute (ie, over a few hours or a few days)?
2. Are there physical factors (eg, medical illness, sensory deprivation, drugs) that may contribute to the abnormalities?
3. Are psychological factors (ie, depression and/or psychosis) contributing to or complicating the impairments in cognitive function?

These questions focus on identifying treatable conditions, which, when diagnosed and treated, might result in substantially improved cognitive function.

DELIRIUM

Delirium is an acute or subacute alteration in mental status especially common in the geriatric population. The prevalence of delirium in hospitalized geriatric patients is approximately 15% on admission, and the incidence in this setting may be up to one-third. Delirium may persist for days or weeks and is, therefore, common in post-acute care settings. Many factors predispose geriatric patients to the development of delirium, including impaired sensory functioning and sensory deprivation, sleep deprivation, immobilization, and transfer to an unfamiliar environment.

The *Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV-TR) (American Psychiatric Association, 2000) defines diagnostic criteria for delirium (Table 6-2). The key features of this disorder include the following:

- Disturbance of consciousness
- Change in cognition not better accounted for by dementia

TABLE 6-2. Diagnostic Criteria for Delirium
<div><div>1. Disturbance of consciousness (ie, reduced clarity of awareness of the environment) in conjunction with reduced ability to focus, sustain, or shift attention</div><div>2. A change in cognition (such as memory deficit, disorientation, or language disturbance) or the development of a perceptual disturbance that is not better accounted for by a preexisting, established, or evolving dementia</div><div>3. Development of the disturbance during a brief period (usually hours to days) and a tendency for fluctuation during the course of the day</div><div>4. Evidence from the history, physical examination, or laboratory findings that the disturbance is caused by<div><div>a. A general medical condition</div><div>b. A substance intoxication, side effect, or withdrawal</div></div></div></div>

Source: Reproduced with permission from the American Psychiatric Association, 2000.

- Symptoms and signs developing over a short period of time (hours to days)
- Fluctuation of the symptoms and signs
- Evidence that the disturbances are caused by the physiological consequences of a medical condition

The disturbances of consciousness and attention, with sudden onset and fluctuating cognitive status, are the major features that distinguish delirium from other causes of impaired cognitive function. Delirium is characterized by difficulty in sustaining attention to external and internal stimuli, sensory misperceptions (eg, illusions), and a fragmented or disordered stream of thought. Disturbances of psychomotor activity (eg, restlessness, picking at bedclothes, attempting to get out of bed, sluggishness, drowsiness, and generally decreased psychomotor activity) and emotional disturbances (eg, anxiety, fear, irritability, anger, apathy) are common in delirious patients. Neurological signs (except asterixis) are uncommon in delirium.

Among hospitalized geriatric patients, many factors are associated with the development of delirium (Inouye and Charpentier, 1996), including:

- Age greater than 80 years
- Male sex
- Preexisting dementia
- Fracture
- Symptomatic infection
- Malnutrition
- Addition of three or more medications
- Use of neuroleptics and narcotics
- Use of restraints
- Bladder catheters

Rapid recognition of delirium is critical because it is often related to other reversible conditions and its development may be a poor prognostic sign for adverse outcomes including nursing home placement and death. CAM is a validated tool to screen for delirium (Inouye et al., 1990). The diagnosis of delirium by the CAM requires the presence of:

- Acute onset and fluctuating course *and*
- Inattention *and*
- Disorganized thinking *or*
- Altered level of consciousness

Differentiating delirium from dementia is important, because the latter is not immediately life threatening, and inappropriately labeling a delirious patient as demented may delay the diagnosis of serious and treatable underlying medical conditions. It is not possible to make the diagnosis of dementia when delirium is present in a patient with previously normal or unknown cognitive function. The diagnosis of dementia must await the treatment of all of the potentially reversible causes of delirium, as discussed later. [Table 6-3](#) shows some of the key clinical features that

TABLE 6-3. Comparison of Presentation of Delirium and Dementia

Delirium	Dementia
Marked psychomotor changes (hyperactive or hypoactive, lethargic or agitated)	Generally unchanged psychomotor behavior (patient’s baseline activity)
Altered and changing levels of consciousness	No change in level of consciousness
Short attention span	No change in attention span
Speech is often incoherent	Difficulty finding words or aphasic (in multi-infarct dementia)
Hallucinations (usually visual) and illusions common	Hallucinations unusual until later stages except in patients with dementia with Lewy bodies
Sleep-wake cycle disrupted	Sleep may be disturbed, but sleep-wake cycle less commonly affected
Positive screen on Confusion Assessment Method	Negative screen for delirium Confusion Assessment Method
Symptoms develop over a short period of time and last days to weeks	Symptoms usually gradual in onset and progress over years
Symptoms and signs can show marked fluctuation	Symptoms may vary throughout the day, but fluctuation not as prominent
Generally evidence of an acute illness and/or medication side effect	No evidence of acute illness

are helpful in differentiating delirium from dementia. *Sundowning* is a term that describes an increase in confusion that commonly occurs in geriatric patients, especially those with preexisting dementia, at night. This condition is probably related to sensory deprivation in unfamiliar surroundings (such as the acute care hospital), and patients who sundown may actually meet the criteria for delirium.

A complete list of conditions that can cause delirium in the geriatric population would be too long to be useful in a clinical setting. [Table 6-4](#) lists some of the common causes of this disorder. Several of them deserve further attention. Each geriatric patient who becomes acutely confused should be evaluated to rule out treatable conditions such as metabolic disorders, infections, and causes for decreased cardiac output (ie, dehydration, acute blood loss, heart failure). The evaluation should include vital signs (including pulse oximetry and a finger-stick glucose determination in diabetics), a careful physical examination, a complete blood count and basic metabolic panel, and other diagnostic tests as indicated by the findings and the patient’s comorbidities.

Sometimes this workup is unrevealing. Small cortical strokes, which do not produce focal symptoms or signs, can cause delirium. These events may be difficult or impossible to diagnose with certainty, but there should be a high index of suspicion

TABLE 6-4. Common Causes of Delirium in Geriatric Patients

Metabolic disorders
Hypoxia
Hypercarbia
Hypo- or hyperglycemia
Hyponatremia
Azotemia
Infections
Decreased cardiac output
Dehydration
Acute blood loss
Acute myocardial infarction
Congestive heart failure
Stroke (small cortical)
Drugs (see Table 6-5)
Intoxication (alcohol, other)
Hypo- or hyperthermia
Acute psychoses
Transfer to unfamiliar surroundings (especially when sensory input is diminished)
Other
Fecal impaction
Urinary retention

for this diagnosis in certain subgroups of patients—especially those with a history of hypertension, previous strokes, transient ischemic attacks, or cardiac arrhythmias. If delirium recurs, a source of emboli should be sought, and associated conditions (such as hypertension) should be treated optimally. Fecal impaction and urinary retention, common in geriatric patients in acute care hospitals, can have dramatic effects on cognitive function and may be causes of acute confusion. The response to relief from these conditions can be just as impressive.

Drugs are a major cause of acute and chronic impairment of cognitive function in older patients. Anesthesia poses a special risk. [Table 6-5](#) lists selected drugs that can cause or contribute to delirium. Every attempt should be made to avoid or discontinue any medication that may be worsening cognitive function in a delirious geriatric patient. Environmental factors, especially rapid changes in location (such as being hospitalized, going on vacation, or entering a nursing home) and sensory deprivation, can precipitate delirium. This is especially true of those with early forms of dementia (see next section). Measures such as preparing older patients for changes in location; placing familiar objects in the surroundings; and maximizing sensory input with lighting, clocks, and calendars may help prevent or manage delirium in some patients. A Hospital Elder Life Program has been described that may help prevent delirium and cognitive and functional decline among high-risk older patients in acute hospitals (Inouye et al., 1999; Inouye et al., 2000; see <http://hospitalelderlifeprogram.org/public/public-main.php>). This program incorporates

TABLE 6-5. Drugs That Can Cause or Contribute to Delirium and Dementia*

Analgesics	Cardiovascular
Narcotic	Antiarrhythmics
Nonnarcotic	Digoxin
Nonsteroidal anti-inflammatory agents	H ₂ receptor antagonists
Anticholinergics/antihistamines	Psychotropic drugs
Anticonvulsants	Antianxiety drugs
Antihypertensives	Antidepressant drugs
	Antipsychotics
Antiparkinsonism drugs	Sedatives/hypnotics
Alcohol	Skeletal muscle relaxants
	Steroids

*Other drugs may contribute but are less common.

several strategies for identifying potentially reversible causes of delirium and medical behavioral and environmental interventions for patients who develop delirium and has been shown to be sustainable in a community hospital setting (Rubin et al., 2011).

DEMENTIA

Dementia is a clinical syndrome involving a sustained loss of intellectual functions and memory of sufficient severity to cause dysfunction in daily living. Loss of functional ability due to impaired cognition is the key feature that distinguishes dementia from MCI. Its key features include:

- A gradually progressing course (usually over months to years)
- No disturbance of consciousness

Dementia in the geriatric population can be grouped into two broad categories:

1. Reversible or partially reversible dementias
2. Nonreversible dementias

Reversible Dementias

While it is important to rule out treatable and potentially reversible causes of dementia in individual patients, these dementias account for a very small proportion of dementias (Clarfield, 2003). Moreover, finding a reversible cause does not guarantee that the dementia will improve after the putative cause has been treated.

Table 6-6 lists reported causes of reversible dementia. These disorders can be detected by careful history, physical examination, and selected laboratory studies. Drugs known to cause abnormalities in cognitive function (see Table 6-5) should be discontinued whenever feasible. There should be a high index of suspicion regarding excessive alcohol intake in older patients. The incidence of alcohol

TABLE 6-6. Causes of Potentially Reversible Dementias	
Neoplasms	Autoimmune disorders
Metabolic disorders	Central nervous system vasculitis, temporal arteritis
Trauma	Disseminated lupus erythematosus
Toxins	Multiple sclerosis
Alcoholism	Drugs (see Table 6-5)
Heavy metals	Nutritional disorders
Organic poisons	Psychiatric disorders
Infections	Depression
Viral, including HIV	Other disorders (eg, normal-pressure hydrocephalus)

Source: Reproduced with permission from Costa et al., 1996.
HIV, human immunodeficiency virus.

consumption varies considerably in different populations but is easily missed and can cause dementia as well as delirium, depression, falls, and other medical complications.

“Depressive pseudodementia” is a term that has been used to refer to patients who have reversible or partially reversible impairments of cognitive function caused by depression. Depression may coexist with dementia in more than one-third of outpatients with dementia and in an even greater proportion in nursing homes. The interrelationship between depression and dementia is complex. Many patients with early forms of dementia become depressed, and depression may be diagnosed in many patients before they become demented. Sorting out how much of the cognitive impairment is caused by depression and how much by an organic factor (or factors) can be difficult. Some clinical characteristics can be helpful in diagnosis including prominent complaints of memory loss, patchy and inconsistent cognitive deficits on examination, and frequent “don’t know” answers. Detailed neuropsychological testing, performed by a psychologist or other health-care professional skilled in the use of these tools, can be helpful in many patients. At times, even after a complete assessment, uncertainty still exists regarding the role of depression in producing intellectual deficits. Under these circumstances, a careful trial of an antidepressant is justified to facilitate the diagnosis and may help improve overall functioning and quality of life. Older patients who develop reversible cognitive impairment while depressed appear at relatively high risk for developing dementia over the following few years, and their cognitive function should be followed closely over time.

■ Nonreversible Dementias

Several different classifications have been recommended for the nonreversible dementias (Table 6-7):

- 1. Degenerative diseases of the central nervous system
- 2. Vascular disorders

TABLE 6-7. Causes of Nonreversible Dementias

Degenerative diseases of the central nervous system
Alzheimer disease
Dementia associated with Lewy bodies
Parkinson disease
Pick disease
Huntington disease
Progressive supranuclear palsy
Others
Vascular dementias
Cerebrovascular disease (multi-infarct dementia)
Binswanger disease
Arteritis
Anoxia secondary to cardiac arrest, cardiac failure of carbon monoxide intoxication
Traumatic dementia
Craniocerebral injury, including dementia pugilistica
Infections
Acquired immunodeficiency syndrome
Opportunistic infections
Creutzfeldt-Jakob disease
Progressive multifocal leukoencephalopathy
Postencephalitic dementia

Source: Adapted from Katzman, Lasker, and Bernstein, 1988.

- 3. Trauma
- 4. Infections

Alzheimer disease (AD), other degenerative disorders, and vascular dementias account for a vast majority of dementias in the geriatric population and are the focus of discussion in this chapter.

Alzheimer and Other Degenerative Diseases

AD and multi-infarct dementia account for the vast majority of dementias in the geriatric population. They frequently coexist in the same patient (Snowden et al., 1997; Langa, Foster, and Larson, 2004). Dementia with Lewy bodies (DLB) accounts for up to 25% of dementias in some series, and the symptoms may overlap with Alzheimer and Parkinson dementias. Some data suggest that iodine-123 metaiodobenzylguanidine cardiac scintigraphy may be helpful in distinguishing DLB from AD (Yoshita et al., 2006), but this remains a research diagnostic tool. In addition to the characteristic pathologic findings, DLB is characterized by:

- Visual hallucinations
- Parkinsonian signs
- Alterations of alertness and attention

TABLE 6-8. Diagnostic Criteria for Alzheimer Dementia

- A. The development of multiple cognitive deficits manifested by both
 1. Memory impairment (impaired ability to learn new information or to recall previously learned information)
 2. One (or more) of the following cognitive disturbances:
 - a. Aphasia (language disturbance)
 - b. Apraxia (impaired ability to perform motor activities despite intact motor function)
 - c. Agnosia (failure to recognize or identify objects despite intact sensory function)
 - d. Disturbance in executive functioning (ie, planning, organizing, sequencing, abstracting)
- B. The cognitive deficits cause severe impairment in social or occupational functioning and represent a major decline from a previous level of functioning
- C. The course is characterized by gradual onset and continuing cognitive decline
- D. The cognitive deficits are not because of any of the following:
 1. Other central nervous system conditions that cause progressive deficits in memory and cognition (eg, cerebrovascular disease, Parkinson disease, Huntington disease, subdural hematoma, normal-pressure hydrocephalus, brain tumor)
 2. Systemic conditions known to cause dementia (eg, hypothyroidism, vitamin deficiencies, hypercalcemia, neurosyphilis, HIV infection)
- E. The deficits do not occur exclusively during the course of a delirium
- F. The disturbance is not better accounted for by another axis I disorder (eg, major depressive disorder, schizophrenia)

Source: Reproduced with permission from the American Psychiatric Association, 2000.
HIV, human immunodeficiency syndrome.

Table 6-8 lists the diagnostic criteria for AD dementia. Family history and increasing age are its primary risk factors. Approximately 6% to 8% of persons older than age 65 have AD. The prevalence doubles every 5 years, so that nearly 30% of the population older than age 85 has AD. By the age of 90, almost 50% of persons with a first-degree relative suffering from AD might develop the disease themselves. Rare genetic mutations on chromosomes 1, 14, and 21 cause early-onset familial forms of AD, and some forms of late-onset AD are linked to chromosome 12. The strongest genetic linkage with late-onset AD identified thus far is the apolipoprotein E epsilon 4 (apo E-E4) allele on chromosome 19. The relative risk of AD associated with one or more copies of this allele in whites is approximately 2.5. However, apo E-E4 does not appear to confer increased risk for AD among African Americans or Hispanics. Because the presence of one or more apo E-E4 alleles is neither sensitive nor specific, there is no agreement on recommending it as a screening test for AD. Thus, routine screening, even among high-risk populations, is generally not recommended.

Other possible risk factors for AD include previous head injury, female sex, lower education level, and other yet-to-be-identified susceptibility genes. Studies on the

protective effects of antihypertensive medications, omega-3 fatty acids, physical activity, and cognitive engagement are ongoing; these factors may help prevent or delay cognitive decline or AD, but no firm conclusions can be drawn at this time (National Institutes of Health, 2010).

Vascular Dementias

Vascular dementias predominately caused by multiple infarcts (multi-infarct dementia) are common in the geriatric population. Multi-infarct dementia can occur alone or in combination with other disorders that cause dementia (Zekry, Hauw, and Gold, 2002). Autopsy studies suggest that cerebrovascular disease may play an important role in the presence and severity of symptoms of AD (Snowden et al., 1997). Multi-infarct dementia results when a patient has sustained recurrent cortical or subcortical strokes. Many of these strokes are too small to cause permanent or residual focal neurological deficits or evidence of strokes on computed tomography (CT). Magnetic resonance imaging (MRI) may be more sensitive in detecting small infarcts, but there has been a tendency to overinterpret some of these findings as more MRI scans are being done. Table 6-9 identifies characteristics of patients likely

TABLE 6-9. Alzheimer Disease Versus Multi-Infarct Dementia: Comparison of Clinical Characteristics		
Characteristics	Alzheimer disease	Multi-infarct dementia
Demographic		
Sex	Women more commonly affected	Men more commonly affected
Age	Generally over age 75 years	Generally over age 60 years
History		
Time course of deficits	Gradually progressive	Stuttering or episodic, with stepwise deterioration
History of hypertension	Less common	Common
History of stroke(s), transient ischemic attack(s), or other focal neurological symptoms	Less common	Common
Examination		
Hypertension	Less common	Common
Focal neurological signs	Uncommon	Common
Signs of atherosclerotic cardiovascular disease	Less common	Common
Emotional lability	Less common	More common




FIGURE 6-1 Primary degenerative dementia versus multi-infarct dementia: comparison of time courses. (1) Recognized by patient, but only detectable on detailed testing. (2) Deficits recognized by family and friends. (3) See text for explanation. (4) Exact time courses are variable; see text.

to have multi-infarct dementia and compares the clinical characteristics of primary degenerative and multi-infarct dementias. A key feature of multi-infarct dementia is the stepwise deterioration in cognitive functioning, as illustrated in [Figure 6-1](#).

EVALUATION

The first step in diagnosing dementia is to recognize clues that dementia may be present. The Mini-Cog assessment is a useful screening tool in identifying patients who should undergo further assessment. It screens both memory (three-item recall) and executive function (clock drawing) (Borson et al., 2003). The value of screening for cognitive impairment has been debated. Despite the lack of specific therapies, screening can identify impairments that should be followed over time, which will in turn help guide support and education of the patient and family.

[Table 6-10](#) lists symptoms that should suggest further evaluation. Patients exhibiting one or more of these symptoms should be considered for the following evaluation:

- Focused history and physical examination, including assessment for delirium and depression and identification of comorbid conditions (eg, sensory impairment)
- A functional status assessment (see Chapter 3)
- A mental status examination (see Table 6-1)
- Selected laboratory studies to rule out reversible dementia and delirium

[Table 6-11](#) outlines key aspects of the history. Because many physical illnesses and drugs can cause cognitive dysfunction, active medical problems and use of

TABLE 6-10. Symptoms That May Indicate Dementia

- Learning and retaining new information
Is repetitious; has trouble remembering recent conversations, events, appointments; frequently misplaces objects
- Handling complex tasks
Has trouble following a complex train of thought or performing tasks that require many steps, such as balancing a checkbook or cooking a meal
- Reasoning ability
Is unable to respond with a reasonable plan to problems at work or home, such as knowing what to do if the bathroom is flooded; shows uncharacteristic disregard for rules of social conduct
- Spatial ability and orientation
Has trouble driving, organizing objects around the house, finding their way around familiar places
- Language
Has increasing difficulty with finding the words to express what they want to say and with following conversations
- Behavior
Appears more passive and less responsive, is more irritable than usual, is more suspicious than usual, misinterprets visual or auditory stimuli

Source: Reproduced from Costa et al., 1996.

prescription and nonprescription drugs (including alcohol) should be reviewed. The nature and severity of the symptoms should be characterized. What are the deficits? Does the patient admit to them, or is the family member describing them? How is the patient reacting to the problems? The responses to these questions can be helpful in differentiating between dementia, depressive, and mixed condition. The onset of symptoms and the rate of progression are particularly important. The sudden onset of cognitive impairment (over a few days) should prompt a search for one of the underlying causes of delirium listed in Table 6-4. Irregular, stepwise decrements in cognitive function (as opposed to a more even and gradual loss) favor a diagnosis of multi-infarct dementia (see Table 6-9 and Fig. 6-1). Patients with dementia are often brought for evaluation at a time of sudden worsening of cognitive function (as illustrated by the broken line in Fig. 6-1) and may even meet the criteria for delirium. These sudden changes may be triggered by a number of acute events (a small stroke without focal signs, acute physical illness, drugs, changes in environment, or personal loss such as the death or departure of a relative). Only a careful history (or familiarity with the patient) will help to determine when an acute event has been superimposed on a preexisting dementia. Appropriate management of the acute event may result in improvement in cognitive function (see Fig. 6-1, broken line).

TABLE 6-11. Evaluating Dementia: The History

Summarize active medical problems and current physical complaints
List drugs (including over-the-counter preparations and alcohol)
Cardiovascular and neurological history
Characterize the symptoms
Nature of deficits (memory vs. other cognitive functions)
Onset and rate of progression
Impaired function (eg, managing money or medications)
Associated psychological symptoms
Depression
Anxiety or agitation
Paranoid ideation
Psychotic thought processes (delusions and/or hallucinations)
Ask about special problems
Wandering (and getting lost)
Dangerous driving and car crashes
Disruptive or self-endangering behaviors
Verbal agitation
Physical aggression
Insomnia
Poor hygiene
Malnutrition
Incontinence
Assess the social situation
Living arrangements
Social supports
Availability of relatives and other caregivers
Employment and health of caregivers

The history should also include specific questions about common problems requiring special attention in patients with dementia. These problems may include wandering, dangerous driving and car crashes, disruptive behavior (eg, verbal agitation, physical aggression, and nighttime agitation), delusions or hallucinations, insomnia, poor hygiene, malnutrition, and incontinence (Lyketsos et al., 2002). They require careful management and most often substantial involvement of family or other caregivers.

A social history is especially important in patients with dementia. Living arrangements and social supports should be assessed. Along with functional status, these factors play a major role in the management of patients with dementia and are of critical importance in determining the possible necessity for institutionalization. A patient with dementia and weak social supports may require institutionalization at a higher level of function than a patient with strong social supports. In addition to the lack of availability of a spouse, child, or other relative who can serve as a caregiver, the caregiver's employment and/or poor health can play an important role in determining the need for institutional care.

A general physical examination should focus particularly on cardiovascular and neurological assessment. Hypertension and other cardiovascular findings and focal neurological signs (eg, unilateral weakness or sensory deficit, hemianopsia, Babinski reflex) favor a diagnosis of multi-infarct dementia. Pathologic reflexes (eg, the glabellar and palmomental reflexes) are nonspecific and occur in many forms of dementia as well as in a small proportion of normal-aged persons. These frontal lobe release signs—as well as impaired stereognosis or graphesthesia, gait disorder, and abnormalities on cerebellar testing—are significantly more common in patients with AD than in age-matched controls. Parkinsonian signs (tremor, bradykinesia, muscle rigidity) should be sought because they may indicate either DLB or frank Parkinson disease.

A careful mental status examination (see Table 6-1) and a standardized mental status test should be performed (see Appendix). Neuropsychological testing can be helpful when there is a normal mental status score but also functional and/or behavioral changes (this can occur in patients with high baseline intelligence) or when there is a low score without functional deficits (this can occur in patients with lower educational levels). Neuropsychological testing can also be helpful in differentiating depression and dementia and in pinpointing specific cognitive strengths and weaknesses for patients, families, and health-care providers.

Selected diagnostic studies are useful in ruling out reversible forms of dementia (Table 6-12). Although CT and MRI scans of the head are expensive, they are generally readily available and should be done to exclude unsuspected correctable structural lesions for patients with dementia of recent onset in whom no other clinical findings explain the dementia and in those with focal neurological signs or symptoms. Cerebral atrophy on one of these scans does not establish the diagnosis of AD; it can occur with normal aging as well as with several specific disease processes. The scan is thus recommended to rule out treatable causes (eg, subdural hematoma,

TABLE 6-12. Evaluating Dementia: Recommended Diagnostic Studies	
Blood studies	
Complete blood count	
Glucose	
Urea nitrogen	
Electrolytes	
Calcium and phosphorous	
Liver function tests	
Thyroid-stimulating hormone	
Vitamin B ₁₂	
Serologic test for syphilis (if suspected)	
Human immunodeficiency virus antibodies (if suspected)	
Radiographic studies	
Computed tomography (or magnetic resonance imaging) of the head	
Other studies	
Neuropsychological testing (selected patients; see text)	

tumors, normal-pressure hydrocephalus). CT and MRI each have advantages and disadvantages. They are roughly equivalent in the detection of most remediable structural lesions. MRI will demonstrate more lesions than CT in patients with multi-infarct dementia, but will also demonstrate white matter changes of uncertain clinical significance. Position emission tomography (PET) scan abnormalities of glucose metabolism can precede the development of clinical deficits by several years in patients at risk for AD. However, PET scanning using glucose metabolism or the presence of amyloid-containing plaques remains largely a research tool rather than a clinical practice tool. The blood tests recommended are directed at finding common comorbidities as opposed to identifying the cause of the underlying dementia. For example, thyroid hormone and/or vitamin B₁₂ replacement may be important for a patient's health but have not been shown to reverse cognitive deficits (Clarfield, 2003; Balk et al., 2007).

MANAGEMENT OF DEMENTIA

■ General Principles

Table 6-13 outlines key principles for the management of dementia. Optimizing therapy for comorbid conditions in the context of dementia, counseling families about the stages of dementia and avoidance of certain drugs and excessive alcohol, discussing strategies to manage behavioral symptoms if they arise and advance directives, and planning for the future are critical early steps in management.

Although complete cure is not available for the vast majority of dementias, optimal management can provide improvements in the ability of these patients to function, as well as in their overall well-being and that of their families and other caregivers.

If causes of reversible or partially reversible forms of dementia are identified (see Table 6-6), they should be specifically treated. Small strokes (lacunar infarcts), which can cause further deterioration of cognitive function in patients with AD, as well as those with vascular dementia, may be prevented by controlling hypertension; thus, hypertension should be treated in patients with dementia as long as side effects can be avoided. Other specific diseases such as Parkinson disease and diabetes should be optimally managed. The treatment of these and other medical conditions is especially challenging because drug side effects may adversely affect cognitive function.

■ Pharmacological Treatment of Dementia

There are four basic approaches to the pharmacological treatment of dementia:

1. Avoid drugs that can worsen cognitive function, mainly those with strong anticholinergic activity
2. Agents that enhance cognition and function
3. Drug treatment of coexisting depression
4. Pharmacological treatment of complications such as paranoia, delusions, psychosis, and behavioral symptoms such as agitation (verbal and physical)

TABLE 6-13. Key Principles in the Management of Dementia

- Optimize the patient’s physical and mental function through physical activity and mind plasticity principals and activities
 - Treatment underlying medical and other conditions (eg, hypertension, Parkinson disease, depression [Chap. 7])
 - Avoid use of drugs with central nervous system side effects (unless required for management of psychological or behavioral disturbances—see Chap. 14)
 - Assess the environment and suggest alterations, if necessary
 - Encourage physical and mental activity
 - Avoid situations stressing intellectual capabilities; use memory aids whenever possible
 - Prepare the patient for changes in location
 - Emphasize good nutrition
- Identify and manage behavioral symptoms and complications
 - Wandering
 - Dangerous driving
 - Behavioral disorders
 - Depression (see Chap. 7)
 - Agitation or aggressiveness
 - Psychosis (delusions, hallucinations)
 - Malnutrition
 - Incontinence (see Chap. 8)
- Provide ongoing care
 - Reassessment of cognitive and physical function
 - Treatment of medical conditions
- Provide information to patient and family
 - Nature of the disease
 - Extent of impairment
 - Prognosis
- Provide social service information to patient and family
 - Local Alzheimer’s Association
 - Community health-care resources (day centers, homemakers, home health aides)
 - Legal and financial counseling
 - Use of advance directives
- Provide family counseling for:
 - Setting realistic goals and expectations
 - Identification and resolution of family conflicts
 - Handling anger and guilt
 - Decisions on respite or institutional care
 - Legal concerns
 - Ethical concerns (see Chap. 17)
 - Consideration of palliative and hospice care (see Chap. 18)

Drug treatment of depression may provide substantial benefits in patients with dementia (Lyketsos et al., 2003) and is discussed in detail in Chapter 7. The use of antipsychotics to treat the neuropsychiatric symptoms of dementia is highly controversial (Sink, Holden, and Yaffe, 2005; Schneider et al., 2006; Ayalon et al., 2006; Maher et al., 2011). Most experts and guidelines recommend avoiding these drugs and using nonpharmacological strategies unless patients are a danger to themselves and others or if nonpharmacological interventions have failed. Atypical antipsychotics are associated with weight gain and now have black box warnings from the U.S. Food and Drug Administration because of the increased risk of death associated with their use. Moreover, the U.S. Centers for Medicare and Medicaid Services have begun a campaign to improve the appropriateness and reduce the use of these drugs in nursing homes. Patients with new or worsening behavioral symptoms associated with dementia should have a medical evaluation to identify potentially treatable precipitating conditions. Pain may be especially hard to detect. For severely demented patients who develop physical or verbal agitation without an obvious underlying cause, empiric treatment with acetaminophen has shown some efficacy (Husebo et al., 2011). Nonpharmacological approaches should be used before psychotropic drugs are prescribed, unless patients are clearly psychotic and/or an immediate danger to themselves or others around them. Pharmacological treatments, including antipsychotics, are discussed further in Chapter 14.

The primary pharmacological approach to the treatment of AD has been the use of cholinesterase inhibitors. Their effectiveness in improving function and quality of life remains controversial, and the potential benefits of these drugs versus their risks and costs must be weighed carefully in individual patients. Some evidence suggests that these drugs may also have some efficacy for multi-infarct dementia and DLB. There are four approved drugs of this class on the market: tacrine, donepezil, rivastigmine, and galantamine. Randomized placebo-controlled clinical trials suggest that these drugs can have positive effects on cognitive function and may improve or prevent decline in overall function and potentially delay nursing home admission (Ritchie et al., 2004; Carson, McDonagh, and Peterson, 2006; Winblad et al., 2006). The clinical importance of these improvements may be marginal in many patients (Raina et al., 2008). Tacrine is potentially hepatotoxic and is generally not prescribed for this reason. Gastrointestinal side effects can be problematic and include nausea, vomiting, and diarrhea; nightmares can be bothersome as well. However, the benefits of these drugs include slight improvements in cognitive function and up to a several-month delay in the progression of cognitive impairment and the development of related behavioral symptoms. While these drugs have been used to help manage behavioral symptoms associated with dementia, at least one controlled study of one of them (donepezil) failed to demonstrate efficacy for this purpose (Howard et al., 2007).

Other drugs, including estrogen (in women), vitamin E, ginkgo biloba, and non-steroidal anti-inflammatory drugs, have been used to prevent and/or treat dementia. There is, however, no evidence that these drugs are effective in preventing or treating dementia (most evidence suggests they are not). There is also no evidence that

vitamin B₁₂, vitamin B₆, or folic acid supplementation improves cognitive function (Balk et al., 2007).

■ Nonpharmacological Management

A variety of supportive measures and other nonpharmacological management strategies are useful in improving the overall function and well-being of patients with dementia and their families (see Table 6-13). These interventions range from specific recommendations for caregivers, such as alterations in the physical environment, the use of memory aids, the avoidance of stressful tasks, and preparation for the patient's move to another living setting with a higher level of care, to more general techniques, such as providing information and counseling services (Ayalon et al., 2006). Resources are available through the Alzheimer's Association and the Rosalyn Carter Institute's Savvy Caregiver Program to assist caregivers (see websites at end of chapter). Many nursing homes have developed special care units for dementia patients. However, there is little evidence that such units improve outcomes (Phillips et al., 1997; Rovner et al., 1996). Nonpharmacologic treatment of agitation can, however, be effective in this setting (Cohen-Mansfield, Libin, and Marx, 2007). Assisted-living facilities have also developed specialized dementia units, with specially designed environments, trained staff, and intensive activities programming, and without the more hospital-like environment typical of many nursing homes. The effectiveness of such units and whether people with advanced dementia can optimally be cared for in them have not been well studied.

Symptoms commonly associated with moderate to severe cognitive impairment, such as memory loss, aphasia, motor apraxia, visual agnosia, and apathy, make it challenging for caregivers to interact, motivate, and implement restorative care interventions. In addition to functional and motivational challenges, problematic behavioral symptoms, such as verbal and physical aggression, sleep disturbance, depression, delusions, hallucinations, and resistance to care, occur in at least 50% to 80% of individuals diagnosed with dementia at some time during the course of their illness. Caregivers in home settings commonly suffer from severe stress, and caregiving for people with dementia can impair the caregiver's quality of life and health. Thus, recommending and assisting in locating resources to reduce caregiver burden are essential aspects of managing dementia. Nursing assistants, who provide the majority of hands-on care in long-term care settings, are frequently challenged by the agitated and uncooperative behaviors of cognitively impaired residents. There are, however, a variety of techniques that have been shown to be effective in engaging these individuals in functional activities while managing behavioral problems. These include such things as getting to know individuals and drawing on their past experiences and patterns (eg, memory boxes outside rooms in dementia units, giving a housewife household activities to do), using humor, providing simple repetitive activities, encouraging mimicking by demonstrating the behavior/activity that you want the individual to perform, communicating face on, and using multiple sources of input (eg, verbal and written).

Providing ongoing care is especially important in the management of dementia patients. Reassessment of the patient's cognitive abilities can be helpful in identifying potentially reversible causes for deteriorating function and in making specific recommendations to family and other caregivers about remaining capabilities. The family is the primary target of strategies to help manage dementia patients in non-institutional settings. Caring for relatives with dementia is physically, emotionally, and financially stressful. Information on the disease itself and the extent of impairment and on community resources helpful in managing these patients can be of critical importance to family and caregivers. The local chapter of the Alzheimer's Association and the Area Agency on Aging are examples of community resources that can provide education and linkages with appropriate services. Anticipating and teaching family members strategies to cope with common behavioral problems associated with dementia—such as wandering, incontinence, day–night reversal, and nighttime agitation—can be of critical importance. Hazardous driving can result in car crashes and is an especially troublesome problem. Better validated screening methods for identifying individuals who may be unable to drive safely are now available (Carr et al., 2011). Several states require reporting patients with dementia who maintain drivers' licenses. Wandering may be especially hazardous for the dementia patient's safety and is associated with falls. Incontinence is common and often very difficult for families to manage (see Chapter 8). Books providing information and suggestions for family management techniques are very useful (see Suggested Readings). Support groups for families of patients with AD through the Alzheimer's Association are available in most large cities. Family counseling can be helpful in dealing with a variety of issues such as anger, guilt, decisions on institutionalization, handling the patient's assets, and terminal care. Dementia patients and their families should also be encouraged to discuss and document their wishes, using a durable power of attorney for health care or an equivalent mechanism early in the course of the illness (see Chapter 17). Family members should be encouraged to seek respite care periodically to provide time for themselves. Some communities have formal respite care programs available. In the absence of such programs, informal arrangements can often be made to relieve the primary family caregivers for short periods of time at regular intervals. Such relief will help the caregiver to cope with what is generally a very stressful situation. Often a multidisciplinary group of health professionals—made up of a physician, a nurse, a social worker, and, when needed, rehabilitation therapists, a lawyer, and a clergy member—must coordinate efforts to manage these patients and provide support to family and caregivers.

Dementia is now recognized as a terminal illness, and many diagnostic and therapeutic interventions have been shown to be burdensome without benefits on quality of life and function in patients with end-stage dementia. Advanced care planning and establishing advance directives with designated surrogate decision makers is a critical aspect of managing this patient population. Advanced dementia is the subject of a recent review by several experts in this area (Mitchell et al., 2012), and management of these patients is addressed in Chapters 16, 17, and 18.

Evidence Summary

Do's

- Assess for correctable underlying causes of delirium, dementia, and new or worsening behavioral symptoms associated with dementia.
- Carefully review medication regimens to determine if one or more medication can affect cognitive function and try to eliminate potential offenders.
- Screen for behaviors and symptoms that put demented patients at risk (eg, trying to cook unattended, driving, wandering at night).
- Screen older patients with dementia for depression, which can exacerbate cognitive impairment.
- Pay attention to the health and emotional status of caregivers.
- Discuss advance care planning and set realistic goals and expectations for patients and caregivers.

Don'ts

- Automatically do brain imaging in every patient with cognitive impairment.
- Use psychoactive drugs if they can be avoided in patients with cognitive impairment.
- Prescribe antipsychotics for behavioral symptoms associated with dementia unless underlying treatable conditions have been excluded and nonpharmacological interventions have failed or unless patients are an immediate danger to themselves or others around them.
- Use physical restraints in hospitalized older patients with delirium or dementia unless essential for their safety and medical care.

Consider

- Formal neuropsychological testing if the diagnosis is uncertain, or if the patient or family wants to better understand cognitive capabilities
- A trial of a cholinesterase inhibitor for older patients with dementia
- Judicious use of antidepressants for dementia patients with concomitant depression
- Referring family members for support groups, in-home help, and respite programs when appropriate

REFERENCES

- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. Text Revision, 4th ed. Washington, DC: American Psychiatric Association; 2000.
- Ayalon L, Gum AM, Feliciano L, et al. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia. *Arch Intern Med*. 2006;166:2182-2188.
- Balk EM, Raman G, Tatsioni A, et al. Vitamin B₆, B₁₂, and folic acid supplementation and cognitive function. *Arch Intern Med*. 2007;167:21-30.
- Borson S, Scanlan JM, Chen P, et al. The Mini-Cog as a screen for dementia: validation in a population-based sample. *J Am Geriatr Soc*. 2003;51:1451-1454.
- Carr DB, Barco PP, Wallendorf MJ, et al. Predicting road test performance in drivers with dementia. *J Am Geriatr Soc*. 2011;59:2112-2117.
- Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. *J Am Geriatr Soc*. 2006;54:354-361.

- Clarfield AM. The decreasing prevalence of reversible dementias: an updated meta-analysis. *Arch Intern Med.* 2003;163:2219-2229.
- Cohen-Mansfield J, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. *J Gerontol Med Sci.* 2007;62A: 908-916.
- Costa PT Jr, Williams TF, Somerfield M, et al. *Recognition and Initial Assessment of Alzheimer's Disease and Related Dementias*. Clinical Practice Guideline No. 19. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; November 1996; AHCPR Publication No. 97-0702.
- Howard RJ, Juszcak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. *N Engl J Med.* 2007;357:1382-1392.
- Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy or treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomized trial. *BMJ.* 2011;343:d4065.
- Inouye SK, Bogardus ST, Baker DI, et al. The hospital elder life program: a model of care to prevent cognitive and functional decline in older hospitalized patients. *J Am Geriatr Soc.* 2000;48:1697-1706.
- Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. *N Engl J Med.* 1999;340:669-676.
- Inouye SK, Charpentier PA. Precipitating factors of delirium in hospitalized elderly persons: predictive model and interrelationship with baseline vulnerability. *JAMA.* 1996;275:852-857.
- Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method: a new method for detection of delirium. *Ann Intern Med.* 1990;113:941-948.
- Katzman R, Lasker B, Bernstein N. Advances in the diagnosis of dementia: accuracy of diagnosis and consequences of misdiagnosis of disorders causing dementia. In: Terry RD, ed. *Aging and the Brain*. New York, NY: Raven Press; 1988:17-62.
- Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and therapeutic implications. *JAMA.* 2004;292:2901-2908.
- Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. *Arch Gen Psychiatry.* 2003;60:737-746.
- Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. *JAMA.* 2002;288:1475-1483.
- Maher M, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults. *JAMA.* 2011;306:1359-1369.
- Mayeux R. Early Alzheimer's disease. *N Engl J Med.* 2010;362:2194-2201.
- Mitchell SL, Black BS, Ersek M, et al. Advanced dementia: state of the art and priorities in the next decade. *Ann Intern Med.* 2012;156:45-51.
- National Institutes of Health. Preventing Alzheimer's disease and cognitive decline. Available at: <http://consensus.nih.gov/2010/alzstatement.htm>. Accessed December 4, 2012.
- Okie S. Confronting Alzheimer's disease. *N Engl J Med.* 2011;365:1069-1072.
- Peterson, RC. Mild cognitive impairment. *N Engl J Med.* 2011;364:2227-2234.
- Phillips C, Sloane P, Hawes C, et al. Effects of residence in Alzheimer disease special care units on functional outcomes. *JAMA.* 1997;278:1340-1344.
- Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. *Ann Intern Med.* 2008;148:427-434.
- Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for clinical practice guideline. *Ann Intern Med.* 2008;148:379-397.

- Ravaglia G, Forti P, Montesi F, et al. Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population. *J Am Geriatr Soc.* 2008;56:51-58.
- Ries ML, Carlsson CM, Rowley HA, et al. Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review. *J Am Geriatr Soc.* 2008;56:920-934.
- Ritchie CW, Ames D, Clayton T, et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. *Am J Geriatr Psychiatry.* 2004;12:358-369.
- Rovner BW, Steele CD, Shmueli Y, et al. A randomized trial of dementia care in nursing homes. *J Am Geriatr Soc.* 1996;44:7-13.
- Rubin FL, Neal K, Fenlon K, et al. Sustainability and scalability of the Hospital Elder Life Program at a community hospital. *J Am Geriatr Soc.* 2011;59:359-365.
- Sachdev PS, Lipnicki DM, Crawford J, et al. Risk profiles of subtypes of mild cognitive impairment: The Sydney memory and ageing study. *J Amer Geriatr Soc.* 2012;60:24-33.
- Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *N Engl J Med.* 2006;355:1525-1538.
- Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. *JAMA.* 2005;293:596-608.
- Snowden DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer's disease: the nun study. *JAMA.* 1997;277:813-817.
- Winblad B, Kilander L, Erikson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. *Lancet.* 2006;367:1057-1165.
- Yoshita M, Taki J, Yokoyama K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. *Neurology.* 2006;66:1850-1854.
- Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. *J Am Geriatr Soc.* 2002;50:1431-1438.

SUGGESTED READINGS

- American Geriatrics Society, American Association for Geriatric Psychiatry. Consensus statement on improving the quality of mental health care in U.S. nursing homes: management of depression and behavioral symptoms associated with dementia. *J Am Geriatr Soc.* 2003;51:1287-1298.
- Cummings JL. Alzheimer's disease. *N Engl J Med.* 2004;351:56-67.
- Holsinger T, Deveau J, Boustani M, et al. Does this patient have dementia? *JAMA.* 2007;297:2391-2404.
- Inouye SK. Delirium in older persons. *N Engl J Med.* 2006;354:1157-1165.
- Kane RL. The Good Caregiver. Available at: <http://www.thegoodcaregiver.com>. Accessed December 4, 2012.
- Lyketsos G, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. *Am J Geriatr Psychiatry.* 2006;14:561-573.
- Mitchell SL. A 93-year-old man with advanced dementia and eating problems. *JAMA.* 2007;298:2527-2536.
- Robins P, Lyketsos C, Steele C. *Practical Dementia Care*. New York, NY: Oxford University Press; 2006.
- Wenger NS, Solomon DH, Roth CP, et al. Application of assessing care of vulnerable elders-3 quality indicators to patients with advanced dementia and poor prognosis. *J Am Geriatr Soc.* 2007;55:S457-S463.

SELECTED WEBSITES (ACCESSED MARCH 16, 2008)

<http://www.alz.org>
<http://alzheimers.org.uk/>
http://consultgerirn.org/topics/delirium/need_help_stat/
http://consultgerirn.org/topics/dementia/want_to_know_more
<http://www.nia.nih.gov/alzheimers>
http://www.rosalynncarter.org/caregiver_resources

TOOLS**Mini-Cog**

http://www.hospitalmedicine.org/geriresource/toolbox/mini_cog.htm (accessed on July 12, 2012)

Confusion assessment method

<http://www.hospitalelderlifeprogram.org/pdf/The%20Confusion%20Assessment%20Method.pdf> (accessed on July 12, 2012)

Montreal Cognitive Assessment

<http://www.mocatest.org/> (accessed on July 12, 2012)

Saint Louis University Mental Status Examination (SLUMS)

<http://aging.slu.edu/index.php?page=saint-louis-university-mental-status-slums-exam> (accessed on July 12, 2012)

This page intentionally left blank

CHAPTER 7

Diagnosis and Management of Depression

Depression in older adults is a persistent or recurrent disorder resulting from psychosocial stress or the physiological effects of disease. This psychological problem can lead to disability, cognitive impairment, exacerbation of medical problems, increased use of health-care services, increased suicide, and increased risk of falls (Brown and Roose, 2011; Eggermont et al., 2012). It complicates the treatment of other physiological problems. Unfortunately, depression is severely under-recognized and under-treated. This lack of identification and treatment can be traced to providers assuming that the signs and symptoms of depression are normal age changes and/or normal responses to life events or medical problems.

Older individuals do not present with the typical symptoms of depression, such as depressed mood or sadness. They may, however, respond to focused questions about whether or not they feel depressed. Thus, it is important to ask older individuals directly about depression using brief screening tools or even by just asking if they feel depressed. The signs and symptoms indicative of depression that are reported may be related to a physical illness and exacerbated or exaggerated by the depression. While it is sometimes a slow and difficult diagnostic process, it is critical to rule out medical problems (acute or chronic) prior to a definitive diagnosis of depression. Once identified, depression is often not treated due to concerns about drug side effects associated with antidepressants and polypharmacy and beliefs that psychotherapy and other nonpharmacological interventions will not be effective for older individuals. While side effect concerns are appropriate, it is important to appreciate that depression in older patients is treatable.

Sorting out the complex interrelationships between symptoms and signs of depression caused by physical illnesses and those caused primarily by an affective disorder or related psychiatric diagnosis is challenging for health-care providers. Recognition and appropriate management of depression are critical, however, to optimize the management of comorbidities, maintain function and quality of life, reduce the need for health-care resources, and prevent further morbidity and even mortality. This chapter addresses these issues from the perspective of the nonpsychiatrist, highlighting diagnostic techniques and initial management options. It should be recognized, however, that the management of some older adults will best be done by involving psychiatrists and psychologists and possibly an integrated care model approach (Ellison, Kyomen, and Harper, 2012).

AGING AND DEPRESSION

The prevalence of major depression among older adults actually decreases with age, with this rate being approximately 5% to 10% of older person living in the

community and presenting to primary care practices have diagnosable depression. Although an additional 2% of older individuals experience dysthymia (a chronic depressive disorder characterized by functional impairment and at least 2 years of depressive symptoms), this disorder also decreases with age. Major depression is found in 16% to 50% of older adults in nursing homes or acute care settings. The lower rate of major depression among community-living older individuals may be caused by selective mortality, institutionalization, missed diagnoses, and/or cohort effects (ie, older individuals tend to deny mental health problems such as depression). The prevalence of subsyndromal depression (ie, symptoms of depression that do not meet standard criteria for major depression), however, steadily increases with age and ranges from 10% to 25% among community-dwelling adults and increases to 50% among those in nursing homes or acute care settings (Meeks et al., 2011).

The implications of depression are substantial and include increased mortality and morbidity including increased incidence of metabolic syndrome, weight changes, and declines in function and impaired cognition. When depression is associated with other medical problems (eg, hip fracture or osteoarthritis), there is often an exacerbation of associated pain, poor compliance and motivation, and impaired recovery and function. Persons age 65 and over account for 25% of all suicides, and as many as 75% of older adults who commit suicide suffer from depression. Approximately 10% of community-dwelling older adults report passive thoughts about suicide, and 1% have had active suicidal ideation. Several factors are associated with suicide in the geriatric population ([Table 7-1](#)).

Lifelong bipolar affective disorder is not uncommon in the elderly persons; these disorders account for 10% to 25% of all geriatric patients with mood disorders and 5% of patients admitted to geropsychiatric inpatient units. The incidence of late-onset bipolar disease, however, decreases with age and presents differently than it does in younger individuals. The most important differences in presentation are that older adults tend to present with better psychosocial function, less severe psychopathology, and a higher frequency of neurological etiologies than younger individuals. Elderly patients with bipolar disorder are more likely to have a mixture of depression and marked irritability. Pressured speech that tends to go off on tangents is common, although the severity of thinking disturbance is less pronounced than in young adults and flight of ideas is less common. Hypersexuality and grandiosity may be present but also tend to be less prominent in older adults. Manic-like syndromes in late life are distinguished by a greater likelihood of confusion, often a reflection of an underlying cognitive disturbance, such as an incipient dementia.

Several biological, physical, psychological, and sociological factors predispose older persons to depression ([Table 7-2](#)). Aging changes in the central nervous system, such as changes in neurotransmitter concentrations (especially catecholaminergic neurotransmitters), may play a role in the development of geriatric depression. Vascular depression, commonly seen in about 30% of stroke survivors, is linked to white-matter hyperintensities, which are bright regions seen in the brain parenchyma on T2-weighted magnetic resonance imaging (MRI). Inflammatory markers such as

TABLE 7-1. Factors Associated with Suicide in the Geriatric Population

Factor	High risk	Low risk
Sex	Male	Female
Religion	Protestant	Catholic or Jewish
Race	White	Nonwhite
Marital status	Widowed or divorced Recent death of a spouse	Married
Occupational background	Blue-collar low-paying job	Professional or white-collar job
Current employment status	Retired or unemployed	Employed full- or part-time
Living environment	Urban Living alone Isolated Recent move	Rural Living with spouse or other relatives Living in close-knit neighborhood
Physical health	Poor health Terminal illness Pain and suffering Multiple comorbid conditions	Good health
Mental health	Depression (current or previous) Alcoholism Low self-esteem Loneliness Feeling rejected, unloved Poor quality of life	Happy and well adjusted Positive self-concept and outlook Sense of personal control over life
Personal background	Broken home Dependent personality History of poor interpersonal relationships Family history of mental illness Poor marital history Poor work record	Intact family of origin Independent, assertive, flexible personality History of close friendships No family history of mental illness No previous suicide attempts No history of suicide in family Good marital history Good work record

interleukin 6 (IL-6) have likewise been associated with depression, as has vitamin D deficiency. Other physical problems such as impaired vision and chronic pain and mild cognitive impairment are similarly associated with depression. There are several medical diagnoses that increase the risk for depression in older adults. These include

TABLE 7-2. Factors Predisposing Older People to Depression

Biological
Family history (genetic predisposition)
Prior episode(s) of depression
Aging changes in neurotransmission
Physical
Specific diseases (see Table 7-5)
Chronic medical conditions (especially with pain or loss of function)
Exposure to drugs (see Table 7-6)
Sensory deprivation (loss of vision or hearing)
Loss of physical function
Psychological
Unresolved conflicts (eg, anger, guilt)
Memory loss and dementia
Personality disorders
Social
Losses of family and friends (bereavement)
Isolation
Loss of job
Loss of income

cardiovascular disease, cancer, Parkinson disease, stroke, lung disease, arthritis, loss of hearing, and dementia (Winter et al., 2011).

Many psychosocial factors increase the likely occurrence of depression in older adults. These factors include being unmarried, living alone, having limited or no social support, recent loss and prolonged bereavement, being a caregiver, and having a low socioeconomic status (Barua et al., 2010; Clark et al., 2013). Risk for depression is further increased if there is a family history of depression, current or past substance abuse, or the individual had a prior depressive episode or suicide attempt. Losses, whether real or perceived, are common in the geriatric population and can be a contributory factor to depression. Loss of job, income, and social supports (especially the death of family members and friends) increase with age and can result in social isolation and subsequent ongoing bereavement and frank depression. Loss of independence, which occurs with the loss of a driver's license or acute declines in function, can further cause depression. Other psychosocial factors such as impaired spiritual well-being and a perceived sense of unmet needs have similarly been noted to contribute to depression.

SYMPTOMS AND SIGNS OF DEPRESSION

Major depression typically is diagnosed by evidence of depressed mood and/or loss of interest or pleasure. There may also be an associated appetite change, particularly a loss of appetite, insomnia or hypersomnia, psychomotor agitation or retardation, loss

of energy and fatigue, feelings of worthlessness, difficulties with concentration, and/or recurrent thoughts of death or suicide. These typical signs and symptoms are often not noted in older adults or assumed to be due to normal aging or other comorbidities. Older depressed patients are more likely to present with a preoccupation with somatic and cognitive symptoms and will less frequently report depressed mood and guilty preoccupations, have crying spells, sadness, fear, or feelings that their life has been a failure (Ellison, Kyomen, and Harper, 2012). They commonly report poor self-perception of health and complain repeatedly about constipation or urinary frequency. These individuals may not acknowledge sustained feelings of sadness. They will, however, report a persistent loss of pleasure and interest in previously enjoyable activities (anhedonia). Generally, older individuals do not exhibit the signs and symptoms of depressed mood that meet the criteria for a major depressive disorder.

Minor, or subsyndromal, depression is more common than major depression. It is defined as one or more periods of depressive symptoms that are identical to major depressive episodes in duration (2 weeks or longer) but that involve fewer symptoms and less impairment. An episode of subsyndromal depression involves either a sad/depressed mood or loss of interest/pleasure in nearly all activities.

The diagnosis of depression, whether major or minor, in older persons is complicated by the overlap of physical illness. Patients with serious medical illness may be preoccupied, for example, with thoughts about death or worthlessness because of concomitant disability. Older adults with depression also tend to have a higher rate of anxiety, nervousness, and irritability than their younger counterparts. They may engage in somatization and put themselves at risk for iatrogenic disease that occurs due to unnecessary tests and treatments. As noted earlier, rigorous steps must be taken to exclude any possible cause of their symptoms prior to concluding that depression is the primary diagnosis. However, this workup must consider the risks and benefits of any procedure or test for each individual.

Recognizing the signs and symptoms of depression and identifying depression disorders in older adults is complicated by many factors, including:

- The presence of common medical conditions (eg, Parkinson disease, congestive heart failure) that can result in the individual appearing depressed, even when depression is not present.
- Nonspecific physical symptoms (eg, fatigue, weakness, anorexia, diffuse pain) that are commonly associated with comorbid conditions.
- Specific physical symptoms, relating to every major organ system, can represent depression as well as physical illness in geriatric patients.
- Depression can exacerbate symptoms of coexisting physical illnesses such as exacerbation of memory changes or pain associated with arthritis.
- Pharmacologically induced depressive symptoms from substance use, particularly alcohol, and abuse or prescribed or over-the-counter medications.

The physical appearance of older patients suspected of being depressed should be interpreted cautiously. Normal age changes such as pale, thin, wrinkled skin; loss of teeth; kyphosis; and a wide-based slow gait, alone or in addition to the presence of

diseases such as anemia or Parkinson disease, may make the older individual look depressed. Parkinson disease, which manifests by masked facies, bradykinesia, and stooped posture, can be misinterpreted as depression. Patients with sensory changes resulting in impaired vision and hearing may appear withdrawn and disinterested simply because they cannot see or hear you or others and, therefore, withdraw from social interactions. The psychomotor retardation of hypothyroidism may offer the physical appearance of depression. Systemic illnesses such as malignancy, dehydration, malnutrition, or chronic obstructive pulmonary disease can produce a depressed appearance with a flat affect or decreased energy. It is possible that the older individual will present with both medical problems and associated depression. In this scenario, it is critical that the medical management be optimized for each of the underlying problems and the depression treated so that quality of life and symptom management of the medical problems are optimized. [Table 7-3](#) provides an overview of some common examples of somatic symptoms that may actually represent, or be exacerbated by, depression in older patients.

TABLE 7-3. Examples of Physical Symptoms That Can Represent Depression	
System	Symptom
General	Fatigue
	Weakness
	Anorexia
	Weight loss
	Anxiety
	Insomnia (see Table 7-4)
	“Pain all over”
	Apathy
Cardiopulmonary	Chest pain
	Shortness of breath
	Palpitations
	Dizziness
Gastrointestinal	Abdominal pain
	Constipation
	Diarrhea
Genitourinary	Frequency
	Urgency
	Incontinence
Musculoskeletal	Diffuse pain
	Back pain
Neurological	Headache
	Memory disturbance
	Dizziness
	Paresthesias

■ Insomnia

Older adults with mental health problems such as undiagnosed depression or anxiety may initially present with complaints of sleep disorders. Those with underlying shortness of breath, paroxysmal nocturnal dyspnea, anxiety and restlessness, and gastroesophageal reflux disease are likely to suffer from insomnia because these medical problems are exacerbated by a recumbent posture and may interfere with falling or staying asleep. Although it is one of the key symptoms in diagnosing different forms of depression, a variety of factors may underlie insomnia (Table 7-4). Insomnia can also be caused by the effects of (or withdrawal from) several medications or use of alcohol or late-night caffeine.

TABLE 7-4. Key Factors in Evaluating the Complaint of Insomnia

Sleep disturbance should be carefully characterized
Delayed sleep onset
Frequent awakenings
Early morning awakenings
Physical symptoms can underlie insomnia (from patient and bed partner)
Symptoms of physical illnesses
Pain from musculoskeletal disorders
Orthopnea, paroxysmal nocturnal dyspnea, or cough
Nocturia
Gastroesophageal reflux
Symptoms suggestive of periodic leg movements
Uncomfortable sensations in legs with a desire to move the legs
Symptoms suggestive of sleep apnea
Loud or irregular snoring
Awakening sweating, anxious, tachycardiac
Excessive movement
Morning drowsiness
Aging changes occurring in sleep patterns
Increased sleep latency
Decreased time in deeper stages of sleep
Increased awakenings
Behavioral factors can affect sleep patterns
Daytime naps >30 min
Earlier bedtime
Increased time spent in bed not sleeping
Medications can affect sleep
Hypnotic withdrawal
Caffeine
Alcohol (causes sleep fragmentation)
Certain antidepressants
Diuretics
Steroids

Older adults may complain of sleep problems caused by underlying physiological or psychological problems such as pain, anxiety, depression, shortness of breath, gastritis, or unrealistic sleep expectations (eg, belief in the need to sleep for a straight 8 hours). In addition, a number of specific sleep disorders are known to present more frequently in older individuals. Obstructive sleep apnea (OSA), which results in abnormal breathing, is the most common sleep-related problem. The development of OSA seems to be age dependent and male dominant. The incidence is also higher in individuals who are obese and have enlarged neck circumferences. The risks associated with untreated OSA include nighttime hypoxia with associated risks for cardiac arrhythmias and myocardial and cerebral infarction. Specific signs such as loud snoring, which are often elicited from the bed partner, should prompt the provider to refer the older individual to a sleep center for further workup. Once diagnosed, the treatment for OSA includes continuous positive airway pressure, dental appliances, and uvulopalatopharyngoplasty. Another common sleep disorder that can cause insomnia is restless leg syndrome (RLS). The incidence of RLS increases to 20% of those 80 years of age or older. Female gender, being retired, and unemployment were independent risk factors for RLS (Angelini et al., 2011). Patients with RLS have uncomfortable sensations in the lower extremities that they attempt to relieve by moving their legs during sleep or by rising and walking around. Managing RLS is challenging but can be achieved with medications.

Even without disease, aging is associated with changes in sleep patterns, such as daytime naps, early bedtime, increased time until onset of sleep, decreases in the absolute and relative amounts of the deeper stages of sleep, and increased periods of wakefulness, all of which contribute to the complaint of insomnia. Insomnia is a good example of how a primary symptom of depression must be evaluated to first determine that there is not an important and treatable underlying cause. It is important to avoid assuming or blaming the symptom on age or depression before a comprehensive medical workup has been completed.

DEPRESSIVE SYMPTOMS ASSOCIATED WITH MEDICAL CONDITIONS

Medical disorders that may imitate depressive symptoms are particularly important to consider in elderly patients because of the increased vulnerability of this population to physical illnesses. Hyperthyroidism, for example, may present with apathy and diminished energy that mimics depression.

Symptoms and signs of depression are associated with medical conditions in the geriatric population as evidenced by the following:

- Some diseases can result in the physical appearance of depression, even when depression is not present (eg, Parkinson disease).
- Many diseases can either directly cause depression or elicit a reaction of depression. The latter is especially true of conditions that cause or produce fear of chronic pain, disability, and dependence.

- Drugs used to treat medical conditions can cause symptoms and signs of depression.
- Changes in living environment, such as entering a nursing home or assisted living facility, can predispose to depression.

A wide variety of physical illnesses can present with or be accompanied by symptoms and signs of depression (Table 7-5). Any medical condition associated with systemic involvement and metabolic disturbances can have profound effects on mental

TABLE 7-5. Medical Illnesses Associated with Depression

Metabolic disturbances
Dehydration
Azotemia, uremia
Acid-base disturbances
Hypoxia
Hypo- and hypernatremia
Hypo- and hyperglycemia
Hypo- and hypercalcemia
Endocrine
Hypo- and hyperthyroidism
Hyperparathyroidism
Diabetes mellitus
Cushing disease
Addison disease
Infections
Cardiovascular
Congestive heart failure
Myocardial infarction
Pulmonary
Chronic obstructive lung disease
Malignancy
Gastrointestinal
Malignancy (especially pancreatic)
Irritable bowel
Genitourinary
Urinary incontinence
Musculoskeletal
Degenerative arthritis
Osteoporosis with vertebral compression or hip fracture
Polymyalgia rheumatica
Paget disease
Neurological
Dementia (all types)
Parkinson disease
Stroke
Tumors
Other
Anemia (of any cause)
Vitamin deficiencies
Hematological or other systemic malignancy

Source: Adapted with permission from Levenson AJ, Hall RCW, eds. *Neuropsychiatric Manifestations of Physical Disease in the Elderly*. New York: Raven Press; 1981.

function and affect. The most common among these are fever, dehydration, decreased cardiac output, electrolyte disturbances, and hypoxia. Hyponatremia (whether from a disease process or drugs) and hypercalcemia (associated with malignancy) may also cause older patients to appear depressed. Systemic diseases, especially malignancies and endocrine disorders such as diabetes, are often associated with symptoms of depression. Depression—accompanied by anorexia, weight loss, and back pain—is commonly present in patients with cancer of the pancreas. Among the endocrine disorders, thyroid and parathyroid conditions are most commonly accompanied by symptoms of depression. Most hypothyroid patients manifest psychomotor retardation, irritability, or depression. Hyperthyroidism may also present as withdrawal and depression in older patients—so-called apathetic thyrotoxicosis. Hyperparathyroidism with attendant hypercalcemia can simulate depression and is often manifest by apathy, fatigue, bone pain, and constipation. Other systemic physical conditions, such as infectious diseases, anemia, and nutritional deficiencies, can also have prominent manifestations of depression in the geriatric population.

Alternatively, some diseases, like cardiovascular and nervous system diseases, can precipitate depression. Because these diseases are threatening and potentially disabling, they can bring on symptoms of depression. For example, myocardial infarction, with attendant fear of shortened life span and restricted lifestyle, commonly precipitates depression. Stroke is often accompanied by depression, although the depression may not always correlate with the extent of physical disability. Stroke patients who are substantially disabled (eg, hemiparesis, aphasia) can become depressed in response to their loss of function; others may become depressed because of vascular depression after stroke. Other causes of brain damage, especially in the frontal lobes, such as tumors and subdural hematomas, can likewise be associated with depression. Older individuals with dementia, both Alzheimer and multi-infarct dementia, may have prominent symptoms of depression (see Chapter 6). Patients with Parkinson disease also have a high incidence of clinically diagnosed depression. Overall, being functionally dependent and medically ill with shorter life expectancy significantly increases the likelihood that the older individual will be depressed (Samad, Brealey, and Gilbody, 2011).

Symptoms of depression associated with medical problems may simply be a response to the disease. For example, hospitalizations associated with medical illnesses can result in feelings of isolation, sensory deprivation, and immobilization and contribute or cause depressive symptoms. Likewise, iatrogenic complications such as functional impairment, constipation and fecal impaction, a urinary tract infection, or urinary retention that causes new-onset incontinence or pressure ulcers with subsequent pain can also cause depression. Drugs are the most common cause of treatment-induced depression. Although a wide variety of pharmacological agents can produce symptoms of depression (Table 7-6), antihypertensive agents, antilipids, antiepilepsy medications, selective estrogen receptor modulators, H_2 -receptor antagonists, corticosteroids, and in some cases, nonsteroidal anti-inflammatory drugs and sedative-hypnotics are the most common groups of drugs that cause depression among older adults (Rodda, 2011). The true impact of

TABLE 7-6. Drugs That Can Cause Symptoms of Depression

Antihypertensives	Antipsychotics
Angiotensin-converting enzyme inhibitors	Chlorpromazine
Calcium channel blockers (verapamil)	Haloperidol
Clonidine	Thiothixene
Hydralazine	Hypnotics
β -Blockers (eg, propranolol)	Chloral hydrate
Reserpine	Benzodiazepines
Analgesics	Steroids
Narcotics	Corticosteroids
Antiparkinsonism drugs	Estrogens
Levodopa	Anticonvulsants
Bromocriptine	Celontin
Antimicrobials	Zarontin
Sulfonamides	Antiviral
Isoniazid	Zovirax
Cardiovascular preparations	Antibiotics
Digitalis	Ciprofloxacin
Diuretics	Statins
Lidocaine	Pravachol
Hypoglycemic agents	Others
Psychotropic agents	Alcohol
Sedatives	Cancer chemotherapeutic agents
Barbiturates	Cimetidine
Benzodiazepines	
Meprobamate	

Sources: Adapted from Levenson AJ, Hall RCW, eds. *Neuropsychiatric Manifestations of Physical Disease in the Elderly*. New York: Raven Press; 1981; Medical Letter. Drugs that may cause psychiatric symptoms. *Med Lett*. 2002; 44(1134):59-62.

medications on the development of depression is inconsistent, however, and it has been projected that there may be genetic differences among individuals that impact the side effects of these medications (Parker et al., 2010). Given the individual impact of medications, whenever possible, drugs that can potentially exacerbate depression should be discontinued.

DIAGNOSING DEPRESSION

The interrelationship between depression and its signs and symptoms, medical illnesses, and treatment effects makes diagnosing depression particularly challenging. The following are some general guidelines to help with the differential diagnosis between depression and other causes of the associated signs and symptoms reported by older adults:

- Screening tools (eg, Geriatric Depression Scale) that screen for depressive symptoms may be helpful in identifying depressed geriatric patients. However, somatic

components of many depression scales are less useful in older patients because of the high prevalence of physical symptoms and medical illnesses.

- Consideration should be given to using a simple, brief screening question(s) to help identify those who might be at risk for depression (see later discussion of the Patient Health Questionnaire). A more comprehensive tool can then be used to provide additional information to confirm or refute a diagnosis.
- Nonspecific or multiple somatic symptoms that are suggestive of depression should not be diagnosed as such until physical illnesses have been excluded.
- Somatic symptoms unexplained by physical findings or diagnostic studies, especially those of relatively sudden onset in an older person who is not usually hypochondriacal, should raise the suspicion of depression.
- Drugs used to treat medical illnesses (see Table 7-6), sedative-hypnotics, and alcohol abuse should be considered as potential causes for symptoms and signs of depression.
- Standard diagnostic criteria should form the basis for diagnosing various forms of depression in the geriatric population, but several differences may distinguish depression in older, as opposed to younger, patients.
- Major depressive episodes should be differentiated from other diagnoses such as uncomplicated bereavement, bipolar disorder, dysthymic disorder, minor depression, and adjustment disorders with a depressed mood.
- Consultation with experienced geriatric psychiatrists, psychologists, or psychiatric nurse practitioners should be obtained whenever possible to help diagnose and manage depressive disorders.
- Whenever there is uncertainty about the diagnosis, or while medical workup is being initiated, the depression and associated symptoms should be treated with a judicious (but adequate) therapeutic trial of an antidepressant.

Several differences in the presentation of depression can make the diagnosis much more challenging and difficult in older people, as compared to younger people (Table 7-7). The most common clinical problem is differentiating major depressive episodes from other forms of depression. Table 7-8 outlines the criteria for

TABLE 7-7. Some Differences in the Presentation of Depression in the Older Population, as Compared with the Younger Population

1. Somatic complaints, rather than psychological symptoms, often predominate in the clinical picture.
2. Older patients often deny having a dysphoric mood.
3. Apathy and withdrawal are common.
4. Feelings of guilt are less common.
5. Loss of self-esteem is prominent.
6. Inability to concentrate with resultant impairment of memory and other cognitive functions is common (see Chap. 6).

major depression based on the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV) (American Psychiatric Association, 1994). The DSM-IV criteria require that the depressive symptoms are not a direct effect of a general medical condition or medication and that patients have at least one core symptom (depressed mood or loss of interest or pleasure) and that five or more symptoms have occurred nearly every day for most of the day for at least 2 weeks. The symptoms must be causing significant distress or impaired functioning. DSM-V is currently under development, and consideration for the addition of laboratory values is in process. Table 7-9 lists

TABLE 7-8. Summary Criteria for Major Depressive Episode*

- A. Five (or more) of the following symptoms have been present nearly every day during the same 2-week period and represent a change from previous functioning; at least one is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms that are clearly caused by a general medical condition should not be counted
 - (1) Depressed mood most of the day*
 - (2) Markedly diminished interest or pleasure in all, or almost all, activities most of the day
 - (3) Significant weight loss when not dieting or weight gain, or decrease or increase in appetite
 - (4) Insomnia or hypersomnia
 - (5) Psychomotor agitation or retardation
 - (6) Fatigue or loss of energy
 - (7) Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional)
 - (8) Diminished ability to think or concentrate, or indecisiveness
 - (9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide
- The symptoms
- B. Do not meet criteria for a mixed episode
- C. Cause clinically significant stress or impairment in social, occupational, or other important areas of functioning
- D. Are not due to the direct physiological effects of a substance or a general medical condition
- E. Are not better accounted for by bereavement; the symptoms persist for longer than 2 months or are characterized by marked functional impairment, morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or psychomotor retardation

*Core symptom: For a diagnosis of major depression, the individual must have at least one core symptom, and five or more symptoms must have occurred nearly every day for most of the day for at least 2 weeks. The symptoms must be causing significant distress or impaired functioning and must not be due to a direct physiological cause. Data from the American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed. Washington, DC: American Psychiatric Association; 1994.

TABLE 7-9. Major Depression Versus Other Forms of Depression	
Diagnostic classification	Key features distinguishing from major depression
Bipolar disorder	The patient may meet, or have met in the past, criteria for major depression but is having or has had one or more manic episode; the latter are characterized by distinct periods of a relatively persistent elevated or irritable mood and other symptoms such as increased activity, restlessness, talkativeness, flight of ideas, inflated self-esteem, and distractibility
Cyclothymic disorder	There are numerous periods during which symptoms of depression and mania are present but not of sufficient severity or duration to meet the criteria for a major depressive or manic episode; in addition to a loss of interest and pleasure in most activities, the periods of depression are accompanied by other symptoms such as fatigue, insomnia or hypersomnia, social withdrawal, pessimism, and tearfulness
Dysthymic disorder	Patient usually exhibits a prominently depressed mood, marked loss of interest or pleasure in most activities, and other symptoms of depression; the symptoms are not of sufficient severity or duration to meet the criteria for a major depressive episode, and the periods of depression may be separated by up to a few months of normal mood
Adjustment disorder with depressed mood	The patient exhibits a depressed mood, tearfulness, hopelessness, or other symptoms in excess of a normal response to an identifiable psychosocial or physical stressor; the response is not an exacerbation of another psychiatric condition, occurs within 3 months of the onset of the stressor, eventually remits after the stressor ceases (or the patient adapts to the stressor), and does not meet the criteria for other forms of depression or uncomplicated bereavement
Uncomplicated bereavement	This is a depressive syndrome that arises in response to the death of a loved one—its onset is not more than 2-3 months after the death, and the symptoms last for variable periods of time; the patient generally regards the depression as a normal response—guilt and thoughts of death refer directly to the loved one; morbid preoccupation with worthlessness, marked or prolonged functional impairment, and marked psychomotor retardation are uncommon and suggest the development of major depression

TABLE 7-10. Examples of Screening Tools for Depression

1. Centers for Epidemiological Studies Depression Scale
(<http://www.chcr.brown.edu/pcoc/cesdscale.pdf>)
2. Geriatric Depression Scale
(<http://www.stanford.edu/~yesavage/GDS.html>)
3. Beck Depression Inventory
(<http://www.fpnotebook.com/Psych/Exam/BckDprsnInvntry.htm>)
4. Cornell Scale for Depression in Dementia
(<http://qmweb.dads.State.tx.US/Depression/CSDD.htm>)

some of the key features that can aid in distinguishing major depression from other conditions.

There are several valid and reliable measures to screen older adults for depression. **Table 7-10** provides a listing of these measures. Most commonly used is the Geriatric Depression Scale, which is available in a longer 30-item measure and 15-item, 5-item, and 2-item measures. The two-item measure can be used for preliminary screening followed with a longer measure if the individual answer suggests that the patient may be depressed.

Some depression tools have been developed for use with specific diseases. It is important to differentiate between depression and dementia in many patients. The Cornell Depression Scale (Alexopoulos et al., 1988) was developed to screen for depression in older adults with dementia. The Stroke Aphasic Depression Questionnaire, Signs of Depression Scale, and the Visual Analogue Mood Scale have all been used to assess for depression in older adults with stroke (Bennett et al., 2007). For the primary care setting, the Primary Care Evaluation of Mental Disorders (Spitzer, Williams, and Kroenke, 1994) was developed. This measure consists of five questions that address the diagnostic categories of the DSM-IV. Given the high prevalence of depression and the risk for missing a diagnosis, screening should be incorporated into all routine examinations. The Patient Health Questionnaire (PHQ) has increasingly been used to evaluate depression because this short nine-item scale assesses the patient's symptoms and functional impairment and includes another section that establishes a severity score (Kroenke, 2001). There is also a two-item PHQ. The two items included asking individuals to respond to how often in the last 2 weeks they experienced (1) little interest or pleasure in doing things; and (2) feeling down, depressed, or hopeless. Responses include the following options: not at all; several days; more than half the days; and nearly every day. Participants can score from 0 to 6, with scores of 3 or greater indicating depression.

Because of the overlap of symptoms and signs of depression and physical illness and the close association between many medical conditions and depression, older patients presenting with what appears to be a depression should have physical illnesses carefully excluded. This is important as well to develop trust with patients and their families and to assure these individuals that a comprehensive evaluation

TABLE 7-11. Diagnostic Studies Helpful in Evaluating Depressed Geriatric Patients with Somatic Symptoms

Basic evaluation

- History
- Physical examination
- Complete blood count
- Erythrocyte sedimentation rate
- Serum electrolytes, glucose, and calcium
- Renal function tests
- Liver function tests
- Thyroid function tests
- Calcium and vitamin D
- Serum B₁₂ or methylmalonic acid
- Folate
- Syphilis serology
- Urinalysis

Examples of other potentially helpful studies

Symptom or sign	Diagnostic study
Pain	Evaluation for underlying cause (eg, appropriate radiological procedure such as bone film, bone scan, GI series)
Chest pain	ECG, noninvasive cardiovascular studies (eg, exercise stress test, echocardiography, radionuclide scans)
Shortness of breath	Chest films, pulmonary function tests, pulse oximetry arterial blood gases
Constipation	Test for occult blood in stool, colonoscopy, abdominal x-ray, thyroid function tests
Focal neurological signs or symptoms	CT or MRI scan, EEG

CT, computed tomography; ECG, electrocardiography; EEG, electroencephalography; GI, gastrointestinal; MRI, magnetic resonance imaging.

of the symptoms has been done. This evaluation can usually be accomplished by a thorough history, physical examination, and basic laboratory studies (Table 7-11). Complaints of fatigue, for example, could be explored by checking the thyroid-stimulating hormone level. Sometimes the assurance that there are no acute medical problems will help the individual recognize that the symptoms may be caused by mood and the focused depression treatment can be initiated. Other diagnostic studies can provide helpful objective data for particularly difficult to distinguish persistent somatic symptoms/complaints such as shortness of breath or fatigue. For example, echocardiography and radionuclide cardiac scans can help rule out organic heart disease as a basis for these symptoms.

MANAGEMENT

General Considerations

Several treatment modalities are available to manage depression in older persons (Table 7-12). Pharmacological and behavioral interventions and psychotherapy have been effective in mild to moderate depression (Areal et al., 2010). A Cochrane

TABLE 7-12. Evidence-Based Treatment Modalities for Depression		
Treatment	Evidence level	Description of the intervention
Cognitive behavior therapy	A	Active time-limited therapy that aims to change the thinking and behavior of individuals that influences their depression. Effective when compared to no treatment
Medication	A	Tricyclic antidepressants Selective serotonin reuptake inhibitors Monoamine oxidase inhibitors can all effectively treat depression
Hormone therapy	C	Estrogen use in females given as a patch, cream, injection, implant, or suppository Was effective only in women post hysterectomy Use of testosterone in men orally, by injection, as skin patches, or as a gel Single group study showed decrease in depression among a small group of older men
Exercise	B	Two main types of exercise: aerobic activity such as running or brisk walking and resistance training focused on muscle strengthening activity Aerobic activity was found to be more effective than education in lowering depression scores Resistance exercise alone has been less effective
ECT	A	Involves delivering a brief electric current to the brain to produce a cerebral seizure ECT was better than placebo (sham ECT)
St. John's wort	B	Herb available as a tablet, capsule, or liquid forms Reduces symptoms equally when compared to antidepressants, although the effectiveness may only be short term

A, supported by one or more high quality randomized trials; B, supported by one or more high-quality nonrandomized cohort studies or low-quality RCTs; C, supported by one or more case series and/or poor quality cohort and/or case-control studies; D, supported by expert opinion and/or extrapolation from studies in other populations or settings; X, evidence supports the treatment being ineffective or harmful.

There is insufficient evidence to support multiple herbal remedies (with the exception of St. John's wort), acupuncture, music therapy, or vitamins.

ECT, electroconvulsive therapy; RCT, randomized controlled trials.

review on pharmacological management of depression concluded that selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are equally effective. There are, however, more side effects and risks associated with use of TCAs when compared with SSRIs. Behavioral interventions such as the use of exercise and cognitive behavioral therapy (CBT) or problem-solving therapy (PST), are particularly effective for those with evidence of executive dysfunction (Arean et al., 2010). Behavioral interventions often need to be adapted to the special needs of older adults and adjusted to different sites of care and living situations. For example, information may need to be repeated or provided at a slower pace. There may also need for an external stimulus to engage in the behavioral intervention (eg, a reminder to go to an exercise class).

Overall treatment using pharmacotherapy and psychotherapy renders similar, moderate to large effect sizes in the treatment of late life depression. Unfortunately, although treatment is quite effective in reducing the symptoms of depression, we have been less successful in maintaining remission of depression for those who are older, and relapse rates tend to be higher in older individuals. The choice of treatment(s) for an individual patient depends on many factors, including the primary disorder causing the depression, the severity of symptoms, the availability and practicality of the various treatment modalities, and underlying conditions that might contraindicate a specific form of treatment (eg, cognitive issues that may make psychotherapy more difficult, underlying medical problems that increase the risk of medication management). There is increasing interest in the genetic factors that predispose one to depression and gene–environment interactions. Much of the genetic impetus is based on the fact that despite exposure to many of the common physical and psychosocial challenges and losses associated with aging, only a minority of older adults become depressed. Conversely, the heritability for major depressive disorders is only 37%. While only limited research has been done in this area, it is anticipated that particular genes interact with the physical and psychosocial environment of the individual and influence the development of depression (Lotrich, 2011). The first step in any treatment approach is to remove the underlying cause of depression, whether this is medical or situational. For example, if a specific pharmacological treatment is being given that may cause depression, attempts should be made to remove this agent. While difficult to achieve, strategies to alleviate multiple losses (such as death of loved ones and pets or change in living locations) can be considered. Likewise, attempts to resolve acute illness, or exacerbations of chronic illness, are needed to assure that the individual is at his or her optimal state of health. These interventions should be implemented before other therapies are initiated unless the depression is severe enough to warrant immediate treatment (eg, the patient is delusional or suicidal).

The course of treatment for depression, particularly major depression, should proceed as follows: acute treatment to reverse the current episode, continuation of treatment to prevent relapse, and maintenance treatment to prevent recurrence. Continuation treatment to stabilize the recovery involves ongoing antidepressant therapy for up to 2 years (Andreescu and Reynolds, 2011). Predictors of treatment

response include evidence of early symptom resolution, lower levels of baseline anxiety, and later age at onset of the first episode of depression.

■ Nonpharmacological Management

Exercise, psychotherapy and other behavioral interventions, electroconvulsive therapy (ECT), transcranial magnetic stimulation, deep brain stimulation, vagus nerve stimulation, and magnetic seizure therapy are all treatment options for depression, with varying amounts of support for efficacy as shown in Table 7-12.

Psychotherapy

Most guidelines encourage using psychotherapy as adjunctive treatment to pharmacotherapy, but this can be tried as first-line therapy as well, especially when there are concerns about risk of drug side effects. The most common and most effective psychotherapies include CBT, PST, psychodynamic therapy, and supportive therapy. PST involves working with the patient to identify practical life difficulties that are causing distress and provide guidance to help the patient identify solutions. The treatment is delivered generally in six to eight meetings spaced 1 to 2 weeks apart. PST is often combined with behavioral activation and involves encouraging older adults to select and solve daily problems as a way of increasing confidence and decreasing the sense of helplessness that are common symptoms of depression. Although the studies done using psychotherapy have been relatively small, there is consistent evidence that, when compared with control or supportive therapy only, psychotherapy using CBT is effective.

Exercise

Based on a systematic review of current research, there is evidence that exercise interventions and ongoing physical activity can improve depression in older adults (Blake et al., 2009; Heesch, Burton, and Brown, 2011; Martins et al., 2011). These studies have used aerobic and resistive activities to effectively decrease depression in individuals who did not respond to medication alone. There was a trend for higher remission rates in the higher-dose exercise group. Significant differences between groups were found when the moderating effects of gender and family history of mental illness were taken into account and suggest that higher-dose exercise may be better for all men and women without a family history of mental illness. The reason for the decrease in depression following exercise is not known specifically. It may be a result of the benefits older adults experience in terms of weight loss or improvement in physical and functional health and performance or simply a result of the sense of overall well-being that occurs with regular physical activity.

■ Pharmacological Treatment

When symptoms and signs of depression are of sufficient severity and duration to meet the criteria for major depression (see Table 7-8), if the depression is producing marked functional disability or interfering with recovery from other illnesses (eg, not participating in rehabilitation services), or when the patient is not responding to nonpharmacological interventions alone, drug treatment should be considered.

There are numerous classes of pharmacologic agents for treatment of depression including heterocyclic antidepressants, monoamine oxidase inhibitors (MAOIs), SSRIs, serotonin norepinephrine reuptake inhibitors (SNRIs), and serotonin antagonist/reuptake inhibitors. Single agents include noradrenergic and specific serotonergic antidepressants, norepinephrine and dopamine reuptake inhibitors, norepinephrine reuptake inhibitors, and serotonin reuptake enhancers. Lastly, stimulants have also been used to treat depression. Examples of drugs that fall within these groups are shown in [Table 7-13](#). The choice of agent depends on the patient's comorbid medical conditions, the side effect profile of the antidepressant, and the individual patient's sensitivity to these effects. Briefly, the SSRIs can cause hyponatremia in some individuals, delayed ejaculation in men and failure to achieve orgasm in women, changes in appetite and sleep patterns, fatigue, and altered bowel function. The SNRIs can cause a rise in blood pressure, and overdose can be dangerous or fatal. In addition, some SNRIs may cause nausea, dry mouth, and constipation. Atypical antidepressants cause fewer sexual side effects than other antidepressants do. They may, however, cause sedation and weight gain. In light of those side effects, they are often used to treat individuals who are believed to be depressed and also have difficulty with sleeping and/or a decrease in appetite or weight loss. TCAs have substantial and often quite bothersome anticholinergic side effects including dry mouth, constipation, difficulty urinating, sedation, weight gain, and changes in sexual ability. MAOIs are not commonly used because they also have unpleasant side effects and can be potentially dangerous. The side effects include dizziness, dry mouth, upset stomach, difficulty with urination, twitching muscles, sexual side effects, drowsiness, and sleep problems. MAOIs can cause potentially fatal high blood pressure when combined with certain foods and beverages and certain other medications.

Potential interactions with other medications and prior use of antidepressant medications also should be considered. Current complaints of sleep disturbance, anxiety, poor appetite or weight changes, or psychomotor retardation help to further direct the practitioner's choice of a therapeutic agent. For individuals who do not sleep well, for example, a drug that is more sedating would be appropriate. There is evidence to support that treatment using either TCAs or SSRIs is effective in older adults, although TCAs are well known to have more side effects.

Common side effects of concern associated with antidepressants when used with older adults include anticholinergic effects, postural hypotension, and sedation. The risk of hyponatremia induced by antidepressants increases with age and is associated with being female, having low body weight, renal failure, and exacerbation with other drugs and treatments that cause hyponatremia. Use of SSRIs has also been associated with gastrointestinal bleeding. Citalopram, mirtazapine, bupropion, escitalopram, paroxetine, sertraline, venlafaxine, and duloxetine have been described as preferred agents for older adults based on efficacy and side effect profiles. Citalopram, escitalopram, and sertraline are the safest with regard to drug-drug interactions and impact on the cytochrome P450 enzymes. Table 7-13 provides a detailed summary of dosing, formulations, precautions, and advantages of the individual antidepressants. Although SSRIs are generally free of severe side effects, a small proportion of

TABLE 7-13. Antidepressants for Geriatric Patients

Drug group generic name (brand name)	Drug group side effects	Special concerns with older adults
Tricyclic antidepressants		
Amitriptyline (Elavil)	Dry mouth	These drugs are best avoided because of the side effects Amoxapine can cause extrapyramidal effects
Amoxapine (Asendin)	Blurred vision	
Clomipramine (Anafranil)	Constipation	
Desipramine (Norpramin or Pertofrane)	Difficulty urinating	
Doxepin (Sinequan or Adapin)	Increased heart rate	
Imipramine (Tofranil)	Loss of sex drive and erectile failure	
Maprotiline (Ludiomil)	Increased sensitivity to the sun	
Nortriptyline (Pamelor or Aventyl)	Weight gain	
Protriptyline (Vivactil)	Drowsiness	
Trimipramine (Surmontil)	Dizziness and nausea	
MAOIs		
Phenelzine (Nardil)	Light-headedness upon standing	All foods and drinks containing tyramine must be avoided, or the patient may experience a hypertensive crisis, stroke, or myocardial infarction
Tranylcypromine (Parnate)	Dizziness	
Isocarboxazid (Marplan)	Insomnia	
Selegiline (Emsam)	Weight gain	
	Headaches	
	Insomnia	
	Sexual problems such as impotence	
	Sleepiness	
SSRIs		
Fluoxetine (Prozac)	Nausea	SSRIs can cause an increase in suicidal thoughts and behaviors SSRIs also carry a risk for increased hostility, agitation, and anxiety SSRIs should not be taken at the same time as MAOIs Taking an SSRI within 2 weeks of an MAOI can cause a fatal reaction In adults 65 and older, SSRIs increase the risk for falls, fractures, and bone loss Mirtazapine causes significant sedation and weight gain so is effective for those with sleep disorders and weight loss
Fluvoxamine (Luvox)	Insomnia	
Sertraline (Zoloft)	Anxiety and restlessness	
Paroxetine (Paxil)	Decreased sex drive	
Escitalopram (Lexapro)	Dizziness	
Citalopram (Celexa)	Weight gain or weight loss	
	Tremors	
	Sweating	
	Drowsiness or fatigue	
	Dry mouth	
	Diarrhea or constipation	
	Headaches	
Duloxetine (Cymbalta)	Nausea	
Mirtazapine (Remeron)	Nervousness	

(continued)

TABLE 7-13. Antidepressants for Geriatric Patients (*continued*)

Drug group generic name (brand name)	Drug group side effects	Special concerns with older adults
Atypical antidepressants		
Bupropion (Wellbutrin)	Sexual dysfunction	Venlafaxine should not be used in those with hypertension
Trazodone (Desyrel)	Dry mouth	Duloxetine may be effective in those suffering from both depression and pain
Venlafaxine (Effexor)	Fatigue	Nefazodone may cause hepatotoxicity
Nefazodone (Serzone)	Sleepiness	
	Weight gain	
	Blurred vision	

MAOIs, monoamine oxidase inhibitors; SSRIs, selective serotonin reuptake inhibitors.

elderly patients develop hyponatremia because of the syndrome of inappropriate antidiuretic hormone secretion, and some experience anxiety, sleep disturbance, or agitation. Sexual side effects and weight gain or loss occur commonly with all SSRIs and may be a reason for poor treatment adherence.

SSRIs inhibit the hepatic isoenzyme *CYP2D6*, which can interfere with the oxidative metabolism of many drugs. The most frequent interactions involving the *CYP2D6* system involve fluoxetine and fluvoxamine, whereas drug interactions are less common with citalopram. SSRIs may increase the anticoagulant effects of medications such as warfarin, potentially through cytochrome isoenzyme inhibition or the inhibition of platelet activity. Careful monitoring of blood clotting is indicated following the introduction of an SSRI to patients being treated with warfarin. Fluoxetine causes substantial inhibition of *CYP2C19* and consequently inhibits the metabolism of alprazolam, quinidine, calcium channel blockers, TCAs, and carbamazepine via the cytochrome P450 (CYP) 3A4 subsystem.

Serotonin syndrome is a potentially life-threatening adverse reaction to use of SSRIs. Symptoms include mental status changes, agitation, myoclonus, hyperreflexia, tachycardia, sweating, shivering, tremor, diarrhea, lack of coordination, fever, and even death. The risk of serotonin syndrome is increased in individuals with deficits in peripheral 5-hydroxytryptamine (5-HT) metabolism from cardiovascular, liver, or pulmonary diseases; with tobacco use; or when SSRIs are used with nefazodone, venlafaxine, mirtazapine, and MAOIs, TCAs, SSRIs, meperidine, opioids, St. John's wort, or tramadol. Following the discontinuation of an SSRI, there have been reports of a serotonergic withdrawal syndrome. This may last for 2 to 3 weeks and is characterized by light-headedness, insomnia, agitation, nausea, headache, and sensory disturbances. Mood disturbance may also occur. The shorter-acting SSRIs (sertraline, paroxetine) appear to induce this syndrome, but venlafaxine and other SSRIs have also been implicated. Therefore, these agents should be tapered rather than stopped abruptly.

Tricyclic Antidepressants

The TCAs nortriptyline and desipramine are the most appropriate for use in older persons. Table 7-13 provides a detailed summary of drug names, side effects, and special issues concerning usage in older adults. They are effective but are associated with anticholinergic side effects and have a quinidine-like effect that delays ventricular conduction. Therapeutic response is associated with blood levels between 50 and 150 ng/mL for nortriptyline and levels above 120 ng/mL for desipramine. Over 60% of patients with nonpsychotic major depression or with depression that is not associated with dementia respond within 6 weeks to levels in these ranges. Although 5% of the population requires lower dosing because of the absence of the enzyme required to metabolize secondary amine tricyclics, most patients achieve target concentrations at dosages of 50 to 75 mg/day of nortriptyline and 100 to 150 mg/day of desipramine.

Other Antidepressants

Table 7-14 provides a summary of dosing, formulations, precautions, and advantages of other common pharmacological agents used to treat depression. Bupropion is generally safe, free of sexual side effects, and well tolerated when used at recommended doses. Bupropion can be activating in some individuals and has been associated with a 0.4% risk of seizures, which is much higher when recommended doses are exceeded. Bupropion, therefore, is contraindicated in persons with a seizure disorder. Bupropion appears to act by increasing the activity of dopamine and norepinephrine and therefore has stimulant-like qualities. Venlafaxine acts as an SSRI at lower doses, while also inhibiting the reuptake of norepinephrine at the high end of the therapeutic range of 75 to 225 mg/day. Venlafaxine is effective for both generalized anxiety and major depression. Blood pressure should be monitored in individuals receiving high dosages of this drug. Patients requiring doses at the high end of the therapeutic range should have blood pressure monitoring. Venlafaxine should be discontinued by gradual tapering to avoid the risk of flu-like discontinuation symptoms.

Duloxetine was approved for the treatment of both depression and neuropathic pain secondary to diabetes mellitus. Duloxetine is a serotonin and norepinephrine reuptake inhibitor, and its pharmacodynamic characteristics are generally like those of venlafaxine, although it is structurally unique. Because of its effects of increasing neural sphincter activity and bladder capacity, it has also been approved for the treatment of urinary incontinence and has been shown to reduce stress incontinence in women. These features may make duloxetine advantageous for the older patient.

Mirtazapine is a norepinephrine, 5-HT₂, and 5-HT₃ antagonist and consistently has the side effects of sedation and weight gain. Therefore, this drug is often used to treat depression while managing associated symptoms. The MAOIs are an older group of antidepressants that have significant side effects, such as orthostatic hypotension, and require careful food restriction of those foods with tyramine (eg, cheese)

TABLE 7-14. Characteristics of Selected Antidepressants for Geriatric Patients

Drug*	Recommended starting daily dosage	Daily dosage range	Level of sedation	Elimination half-life†	Comments
Selective serotonin reuptake inhibitors					
Citalopram (Celexa)	10-20 mg	20-30 mg	Very low	Very long	Less inhibition of hepatic cytochrome P450 May cause somnolence, insomnia, anorexia
Escitalopram (Lexapro)	10 mg	10 mg	Very low	Very long	Side effects as for citalopram
Fluoxetine (Prozac)	5-10 mg	20-60 mg	Very low	Very long	Inhibits hepatic cytochrome P450‡ Must be discontinued 6 weeks before initiating monoamine oxidase inhibitor
Paroxetine (Paxil)	10 mg	10-50 mg	Very low	Long	Inhibits hepatic cytochrome P450‡ Has anticholinergic side effects
Sertraline (Zoloft)	25 mg	50-200 mg	Very low	Very long	Less inhibition of cytochrome P450
Serotonin-norepinephrine reuptake blockers					
Venlafaxine (Effexor)	25 mg	75-225 mg	Very low	Intermediate	Reduced clearance with renal or hepatic impairment Can cause dose-related hypertension Must be tapered over 1-2 weeks when discontinuing

Tricyclic antidepressants					
Nortriptyline (Pamelor, others)	10-30 mg	25-150 mg	Mild	Long	Lower but still substantial anticholinergic effects [§] Blood levels can be monitored
Other agents [†]					
Bupropion (Wellbutrin)	50-100 mg	150-450 mg	Mild	Intermediate	Divided doses necessary
Mirtazapine (Remeron)	15 mg	15-45 mg	Mild	Long	Reduced clearance with renal impairment May cause or exacerbate hypertension
Nefazodone (Serzone)	100 mg	200-400 mg	Mild	Short	Potent inhibitor of cytochrome P450 [‡] Can increase concentrations of terfenadine, astemizole, and cisapride Has antianxiety effects
Trazodone (Desyrel)	25-50 mg	75-400 mg	Moderate– high	Short	Can cause hypotension May be useful in low doses as a hypnotic

*Other less commonly used antidepressants are discussed in the text.

[†]Short = <8 h; intermediate = 8-20 h; long = 20-30 h; very long = >30 h. Half-lives may vary in older patients, and some drugs have active metabolites.

[‡]See text for drug interactions.

[§]See text for anticholinergic side effects.

and avoidance of pseudoephedrine or pressor amines because these can cause a life-threatening hypertensive crisis. The use of MAOIs with an SSRI or meperidine can cause a fatal serotonin syndrome associated with delirium and hyperthermia. Methylphenidate and other stimulants have been used to treat major depression in older adults. There is limited evidence to support the effectiveness of this treatment, and generally, use is on a case-by-case basis.

Management of Bipolar Disorders

Most persons with bipolar disorders have a history of episodes in early adulthood and often receive chronic treatment with mood stabilizers versus antidepressants. Occasionally, this regimen may need adjustment if a new episode of mania emerges. In a comprehensive review of interventions to treat bipolar disorders in the elderly, it was noted that treatment with lithium, divalproex sodium, carbamazepine, lamotrigine, atypical antipsychotics, and antidepressants has been found to be beneficial. Prior to starting treatment with an antidepressant, however, careful evaluation of patients for evidence of motor activation, pressured speech, and racing thoughts is recommended to avoid possible exacerbation of manias (Frye et al., 2009). Although there are no specific guidelines for the treatment of these patients, monotherapy followed by combination therapy of the various classes of drugs may help with the resolution of symptoms. ECT and psychotherapy may be useful in the treatment of refractory disease.

Summary of Evidence-Based Recommendations for Depression Interventions
Do's
<ul style="list-style-type: none">• Individual cognitive behavioral therapy, particularly problem-solving therapy.• Depression care management with medications, with treatment decisions based on side effect profile of drugs.• Initial screening for depression using a brief questionnaire such as the two-item patient health questionnaire and then followed by a longer screening tool if there is an indication that the patient is depressed.
Don't Do
<ul style="list-style-type: none">• Physical rehabilitation and occupational therapy• Nutrition interventions• Peer support
Consider
<ul style="list-style-type: none">• Individual therapy other than cognitive behavioral therapy• Exercise interventions• Combined exercise with medications when either is ineffective alone• Suicide prevention• Geriatric health evaluation and skills training• Bereavement therapy

REFERENCES

- Alexopoulos GA, Abrams RC, Young RC, et al. Cornell scale for depression in dementia. *Biol Psychol.* 1988;23:271-284.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed. Washington, DC: American Psychiatric Association; 1994.
- Andresescu C, Reynolds CF. Late life depression: evidence based treatment and promising new directions for research and clinical practice. *Psychiatr Clin North Am.* 2011;34:335-355.
- Angelini M, Negrotti A, Marchesi E, Bonavina G, Calzetti S. A study of the prevalence of restless legs syndrome in previously untreated Parkinson's disease patients: absence of comorbid association. *J Neurol Sci.* 2011;310:268-288.
- Arean P, Raue P, Mackin RS, et al. Problem solving therapy and supportive therapy in older adults with major depression and executive dysfunction. *Am J Psychiatry.* 2010;167:1391-1396.
- Barua A, Ghosh MK, Kar N, et al. Socio-demographic factors of geriatric depression. *Indian J Psychol Med.* 2010;32:87-92.
- Bennett H, Thomas S, Austen R, Morris A, Lincoln N. Validation of screening measures for assessing mood in stroke patients. *Br J Clin Psychol.* 2007;46:367-376.
- Blake H, Mo P, Malik S, Thomas S. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. *Clin Rehabil.* 2009;23:873-887.
- Brown P, Roose SP. Age and anxiety and depressive symptoms: the effect on domains of quality of life. *Int J Geriatr Psychiatry.* 2011;26:1260-1266.
- Clark M, Nicholas JM, Wassira LN, et al. Psychosocial and biological indicators of depression in the caregiving population. *Biol Res Nurs.* 2013;15:112-121.
- Eggermont L, Penninx BW, Jones RN, Leveille SG. Depressive symptoms, chronic pain, and falls in older community-dwelling adults: the MOBILIZE Boston Study. *J Am Geriatr Soc.* 2012;60:230-237.
- Ellison J, Kyomen HH, Harper DG. Depression in later life: an overview with treatment recommendations. *Psychiatr Clin North Am.* 2012;35:203-229.
- Frye M, Helleman G, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. *Am J Psychiatry.* 2009;166:164-167.
- Heesch K, Burton NW, Brown WJ. Concurrent and prospective associations between physical activity, walking and mental health in older women. *J Epidemiol Commun Health.* 2011;65:807-813.
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med.* 2001 Sep;16(9):606-13.
- Lotrich F. Gene-environment interactions in geriatric depression. *Psychiatr Clin North Am.* 2011;34:357-376.
- Martins R, Coelho E, Silva M, et al. Effects of strength and aerobic-based training on functional fitness, mood and the relationship between fatness and mood in older adults. *J Sports Med Phys Fitness.* 2011;51:489-496.
- Meeks T, Vahia IV, Lavretsky H, Kulkarni G, Jeste DV. A tune in "a minor" can "b major": a review of epidemiology, illness course, and public health implications of subthreshold depression in older adults. *J Affect Disord.* 2011;129:126-142.
- Parker G, Rowe M, Mehta F, Kumar S. Will a new genotyping test help the clinician predict response to antidepressant drugs? *Australas Psychiatry.* 2010;18:413-416.
- Rodda J. Depression in older adults. *Br Med J.* 2011;343:1-7.

- Samad Z, Brealey S, Gilbody S. The effectiveness of behavioural therapy for the treatment of depression in older adults: a meta-analysis. *Int J Geriatr Psychiatry*. 2011;26:1211-1220.
- Spitzer RI, Williams J, Kroenke K. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. *JAMA*. 1994;272:1749-1756.
- Winter Y, Korchounov A, Zhukova TV, Bertschi NE. Depression in elderly patients with Alzheimer dementia or vascular dementia and its influence on their quality of life. *J Neurosci Rural Pract*. 2011;2:27-32.

SUGGESTED READINGS

- Andresescu C, Reynolds CF. Late life depression: evidence based treatment and promising new directions for research and clinical practice. *Psychiatr Clin North Am*. 2011;34:335-355.
- Eggermont L, Penninx BW, Jones RN, Leveille SG. Depressive symptoms, chronic pain, and falls in older community-dwelling adults: the MOBILIZE Boston Study. *J Am Geriatr Soc*. 2012;60:230-237.
- Ellison J, Kyomen HH, Harper DG. Depression in later life: an overview with treatment recommendations. *Psychiatr Clin North Am*. 2012;35:203-229.
- Lotrich F. Gene-environment interactions in geriatric depression. *Psychiatr Clin North Am*. 2011;34:357-376.
- Meeks T, Vahia IV, Lavretsky H, Kulkarni G, Jeste DV. A tune in “a minor” can “b major”: a review of epidemiology, illness course, and public health implications of subthreshold depression in older adults. *J Affect Disord*. 2011;129:126-142.
- Rodda J. Depression in older adults. *Br Med J*. 2011;343:1-7.
- Samad Z, Brealey S, Gilbody S. The effectiveness of behavioural therapy for the treatment of depression in older adults: a meta-analysis. *Int J Geriatr Psychiatry*. 2011;26:1211-1220.
- Serfaty M, Haworth D, Blanchard M, et al. Clinical effectiveness of individual cognitive behavioral therapy for depressed older people in primary care: a randomized controlled trial. *Arch Gen Psychiatry*. 2009;66:1332-1340.

WEBSITES

- Centers for Epidemiological Studies Depression Scale (<http://www.chcr.brown.edu/pcoc/cesdscale.pdf>)
- Geriatric Depression Scale (<http://www.stanford.edu/~yesavage/GDS.html>)
- Beck Depression Inventory (<http://www.fpnotebook.com/Psych/Exam/BckDprsnInvntry.htm>)
- Cornell Scale for Depression in Dementia (<http://qmweb.dads.state.tx.us/Depression/CSDD.htm>)
- The Patient Health Questionnaire-2 (http://www.cqaimh.org/pdf/tool_phq2.pdf)
- Hospital Anxiety and Depression Scale (HADS) (<http://www.scireproject.com/outcome-measures/hospital-anxiety-and-depression-scale-hads>)
- Montgomery and Asberg Depression Rating Scale (MADRS) (<http://farmacologiaclinica.info/scales/MADRS/>)

CHAPTER 8

Incontinence

Incontinence is a common, bothersome, and potentially disabling condition in the geriatric population. It is defined as the involuntary loss of urine or stool in sufficient amount or frequency to constitute a social and/or health problem. [Figure 8-1](#) illustrates the prevalence of urinary incontinence across various settings. The prevalence depends on the definition used. Incontinence ranges in severity from occasional episodes of dribbling small amounts of urine to continuous urinary incontinence with concomitant fecal incontinence.

Approximately one in three women and 15% to 20% of men older than age 65 years have some degree of urinary incontinence. Between 5% and 10% of community-dwelling older adults have incontinence more often than weekly and/or use a pad for protection from urinary accidents. The prevalence is as high as 60% to 80% in many nursing homes, where residents often have both urinary and stool incontinence. In both community and institutional settings, incontinence is associated with both impaired mobility and poor cognition.

Physical health, psychological well-being, social status, and the costs of health care can all be adversely affected by incontinence ([Table 8-1](#)). Urinary incontinence is curable or controllable in many geriatric patients, especially those who have adequate mobility and mental functioning. Even when it is not curable, incontinence can always be managed in a manner that keeps people comfortable, makes life easier for caregivers, and minimizes the costs of caring for the condition and its complications.

Despite some change in the social perception of incontinence because of television advertisements and public media and educational efforts, many older people are embarrassed and frustrated by their incontinence and either deny it or do not discuss it with a health professional. It is therefore essential that specific questions about incontinence be included in periodic assessments and that incontinence be noted as a problem when it is detected in institutional settings. Examples of such questions include the following:

“Do you have trouble with your bladder?”

“Do you ever lose urine when you don’t want to?”

“Do you ever wear padding to protect yourself in case you lose urine?”

This chapter briefly reviews the pathophysiology of geriatric incontinence and provides detailed information on the evaluation and management of this condition. Although most of the chapter focuses on urinary incontinence, some of the pathophysiology also applies to fecal incontinence, which is briefly addressed at the end of the chapter.




FIGURE 8-1 Prevalence of urinary incontinence (UI) in the geriatric population. “Regular UI” is more often than weekly and/or the use of a pad. (Percentages range in various studies; those shown reflect approximate averages from multiple sources.)

NORMAL URINATION

Continence requires effective functioning of the lower urinary tract, adequate cognitive and physical functioning, motivation, and an appropriate environment (Table 8-2). Thus, the pathophysiology of geriatric incontinence can relate to the anatomy and physiology of the lower urinary tract as well as to functional, psychological, and environmental factors. Several anatomic components participate in normal urination (Fig. 8-2). Urination is influenced by reflexes centered in the sacral micturition center. Afferent pathways (via somatic and autonomic nerves) carry information on bladder volume to the spinal cord as the bladder fills. Motor output is adjusted accordingly

TABLE 8-1. Potential Adverse Effects of Urinary Incontinence
Physical health
Skin irritation and breakdown
Recurrent urinary tract infections
Falls (especially with nighttime incontinence)
Psychological health
Isolation
Depression
Dependency
Social consequences
Stress on family, friends, and caregivers
Predisposition to institutionalization
Economic costs
Supplies (padding, catheters, etc.)
Laundry
Labor (nurses, housekeepers)
Management of complications

TABLE 8-2. Requirements for Continence

Effective lower urinary tract function

Storage

- Accommodation by bladder of increasing volumes of urine under low pressure
- Closed bladder outlet
- Appropriate sensation of bladder fullness
- Absence of involuntary bladder contractions

Emptying

- Bladder capable of contraction
- Lack of anatomic obstruction to urine flow
- Coordinated lowering of outlet resistance with bladder contractions

Adequate mobility and dexterity to use toilet or toilet substitute and to manage clothing

Adequate cognitive function to recognize toileting needs and to find a toilet or toilet substitute

Motivation to be continent

Absence of environmental and iatrogenic barriers such as inaccessible toilets or toilet substitutes, unavailable caregivers, or drug side effects

(Fig. 8-3). Thus, as the bladder fills, sympathetic tone closes the bladder neck, relaxes the dome of the bladder, and inhibits parasympathetic tone; somatic innervation maintains tone in the pelvic floor musculature (including striated muscle around the urethra). When urination occurs, sympathetic and somatic tones diminish, and parasympathetic cholinergically mediated impulses cause the bladder to contract. All these processes are under the influence of higher centers in the brain stem, cerebral cortex, and cerebellum.

This is a simplified description of a very complex process, and the neurophysiology of urination remains incompletely understood. The cerebral cortex exerts a predominantly inhibitory influence, and the brain stem facilitates urination. Thus, loss of the central cortical inhibiting influences over the sacral micturition center from diseases such as dementia, stroke, and parkinsonism can cause incontinence. Disorders of the brain stem and suprasacral spinal cord can interfere with the coordination of bladder contractions and lowering of urethral resistance, and interruptions of the sacral innervation can cause impaired bladder contraction and problems with continence.

Normal urination is a dynamic process, requiring the coordination of several physiological processes. Figure 8-4 depicts a simplified schematic diagram of the pressure–volume relationships in the lower urinary tract, similar to measurements made in urodynamic studies. Under normal circumstances, as the bladder fills, bladder pressure remains low (eg, <15 cm H₂O). The first urge to void is variable but generally occurs between 150 and 300 mL, and normal bladder capacity is 300 to 600 mL. When normal urination is initiated, true detrusor pressure (bladder pressure minus intra-abdominal pressure) increases, urethral resistance decreases, and urine flow occurs when detrusor pressure exceeds urethral resistance. If at any time




FIGURE 8-2 Structural components of normal micturition.

during bladder filling total intravesicular pressure (which includes intra-abdominal pressure) exceeds outlet resistance, urinary leakage will occur. This will happen if, for example, intra-abdominal pressure rises without a rise in true detrusor pressure when someone with low outlet or urethral sphincter weakness coughs or sneezes. This would be defined as genuine stress incontinence in urodynamic terminology. Alternatively, the bladder can contract involuntarily and cause urinary leakage.

CAUSES AND TYPES OF INCONTINENCE

Basic Causes

There are four basic categories of causes for geriatric urinary incontinence (Fig. 8-5). Determining the cause(s) is essential to proper management. It is important to distinguish between urological and neurological disorders that cause incontinence and




FIGURE 8-3 Peripheral nerves involved in micturition.

other problems (such as diminished mobility and/or mental function, inaccessible toilets, and psychological problems) that can cause or contribute to the condition. As is the case for a number of other common geriatric problems discussed in this text, multiple disorders often interact to cause urinary incontinence, as depicted in Figure 8-5.

Aging alone does not cause urinary incontinence. Several age-related changes can, however, contribute to its development. In general, with age, bladder capacity declines, residual urine increases, and involuntary bladder contractions become more common. Aging is also associated with a decline in bladder outlet and urethral resistance pressure in women. This decline is related to diminished estrogen influence and laxity of pelvic floor structures associated with prior childbirths, surgeries, and deconditioned muscles, which predisposes to the development of stress incontinence (Fig. 8-6). Decreased estrogen can also cause atrophic vaginitis and urethritis, which can, in turn, cause symptoms of dysuria and urgency and predispose to the development of urinary infection and urgency incontinence. In men, prostatic enlargement is associated with decreased urine flow rates and involuntary bladder contractions and can lead to urgency and/or overflow types of incontinence (discussed later). Aging is also associated with abnormalities of




FIGURE 8-4 Simplified schematic of the dynamic function of the lower urinary tract during bladder filling (*left*) and emptying (*right*). As the bladder fills, true detrusor pressure (*thick line at bottom*) remains low (<15 cm H_2O) and does not exceed urethral resistance pressure (*thin line at bottom*). As the bladder fills to capacity (generally 300–600 mL), pelvic floor and sphincter activity increase as measured by electromyography (EMG). Involuntary detrusor contractions (illustrated by *dashed lines*) occur commonly among incontinent geriatric patients (see text). They may be accompanied by increased EMG activity in attempts to prevent leakage (*dashed lines at top*). If detrusor pressure exceeds urethral pressure during an involuntary contraction, as shown, urine will flow. During bladder emptying, detrusor pressure rises, urethral pressure falls, and EMG activity ceases in order for normal urine flow to occur (*right side of figure*).

arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) levels. Lack of the normal diurnal rhythm of AVP secretion and increased levels of ANP may contribute to nocturnal polyuria and predispose many older people to nighttime incontinence.

■ Reversible Factors Causing or Contributing to Incontinence

Numerous potentially reversible conditions and medications may cause or contribute to geriatric incontinence (**Tables 8-3** and **8-4**). The term *acute incontinence* refers to those situations when the incontinence is of sudden onset, usually related to an acute illness or an iatrogenic problem, and subsides once the illness or medication problem has been resolved (this has also been termed *transient incontinence*). Persistent incontinence refers to incontinence that is unrelated to an acute illness and persists over time.




FIGURE 8-5 Basic underlying causes of geriatric urinary incontinence.

Potentially reversible conditions can play a role in both acute and persistent incontinence. A search for these factors should be undertaken in all incontinent geriatric patients. The causes of acute and reversible forms of urinary incontinence can be remembered by the mnemonic DRIP ([Table 8-5](#)).

Many older persons, because of urinary frequency and urgency, especially when they are limited in mobility, carefully arrange their schedules (and may even limit social activities) in order to be close to a toilet. Thus, any acute illness can precipitate incontinence by disrupting this delicate balance. Hospitalization with its attendant




FIGURE 8-6 Simplified schematic depicting age-associated changes in pelvic floor muscle, bladder, and urethra-vesicle position, predisposing to stress incontinence. Normally (*left*), the bladder and outlet remain anatomically inside the intra-abdominal cavity, and rises in pressure contribute to bladder outlet closure. Age-associated changes (eg, estrogen deficiency, surgeries, childbirth) can weaken the structures maintaining bladder position (*right*); in this situation, increases in intra-abdominal pressure can cause urine loss (stress incontinence).

TABLE 8-3. Reversible Conditions That Cause or Contribute to Geriatric Urinary Incontinence

Condition	Management
Conditions affecting the lower urinary tract	
Urinary tract infection (symptomatic with frequency, urgency, dysuria, etc.)	Antimicrobial therapy
Atrophic vaginitis/urethritis	Topical estrogen
Stool impaction	Disimpaction; appropriate use of stool softeners, bulk-forming agents, and laxatives if necessary; implement high fiber intake, adequate mobility, and fluid intake (see Table 8-21)
Drug side effect (see Table 8-4)	Discontinue or change therapy if clinically appropriate. Dosage reduction or modification (eg, flexible scheduling of rapid-acting diuretics) may also help
Increased urine production	
Metabolic (hyperglycemia, hypercalcemia)	Better control of diabetes mellitus Therapy for hypercalcemia depends on underlying cause
Excess fluid intake	Reduction in intake of diuretic fluids (eg, caffeinated beverages)
Volume overload	Support stockings
Venous insufficiency with edema	Leg elevation Sodium restriction Diuretic therapy
Congestive heart failure	Medical therapy
Impaired ability or willingness to reach a toilet	
Delirium	Diagnosis and treatment of underlying cause(s)
Chronic illness, injury, or restraint that interferes with mobility	Regular toileting Use of toilet substitutes Environmental alterations (eg, bedside commode, urinal) Remove restraints if possible
Psychological	Appropriate nonpharmacologic and/or pharmacologic treatment

Reproduced from Fantl et al., 1996.

TABLE 8-4. Medications That Can Cause or Contribute to Urinary Incontinence

Type of medication	Potential effects on incontinence
Diuretics	Polyuria, frequency, urgency
Anticholinergics	Urinary retention, overflow incontinence, stool impaction
Psychotropics	
Tricyclic antidepressants	Anticholinergic actions, sedation
Antipsychotics	Anticholinergic actions, sedation, immobility
Sedative-hypnotics	Sedation, delirium, immobility, muscle relaxation
Narcotic analgesics	Urinary retention, fecal impaction, sedation, delirium
α -Adrenergic blockers	Urethral relaxation
α -Adrenergic agonists	Urinary retention
Cholinesterase inhibitors	Urinary frequency, urgency
Angiotensin-converting enzyme inhibitors	Cough precipitating stress incontinence
β -Adrenergic agonists	Urinary retention
Calcium channel blockers	Urinary retention, edema (nocturia)
Gabapentin, pregabalin, glitazones	Edema (nocturia)
Alcohol	Polyuria, frequency, urgency, sedation, delirium, immobility
Caffeine	Polyuria, bladder irritation

environmental barriers (eg, bed rails, poorly lit rooms) and the immobility that often accompanies acute illnesses can precipitate acute incontinence. Incontinence in these situations is likely to resolve with resolution of the underlying acute illness and hospitalization. Hospital-acquired urinary incontinence can often be prevented. Unless an indwelling or external catheter is necessary during an acute illness to record urine output accurately, this type of incontinence should be managed by environmental manipulation, scheduled toileting, appropriate use of toilet substitutes (eg, urinals, bedside commodes, pads), and careful attention to skin care. Fecal impaction is

TABLE 8-5. Mnemonic for Potentially Reversible Conditions*

D	Delirium
R	Restricted mobility, retention
I	Infection, inflammation, impaction
P	Polyuria, pharmaceuticals

*See Tables 8-3 and 8-4.

a common problem in both acutely and chronically ill geriatric patients. Large impactions may cause mechanical obstruction of the bladder outlet in women and may stimulate involuntary bladder contractions induced by sensory input related to rectal distention. Relief of fecal impaction can improve and sometimes resolve the urinary incontinence.

Urinary retention with overflow incontinence should be considered in any patient who suddenly develops urinary incontinence. Immobility, anticholinergic and narcotic drugs, and fecal impaction can all precipitate urinary retention and overflow incontinence in geriatric patients. In addition, this condition may be a manifestation of an underlying acute process causing spinal cord compression.

Any acute inflammatory condition in the lower urinary tract that causes frequency and urgency can precipitate incontinence. Treatment of acute cystitis, atrophic vaginitis, or urethritis can restore continence.

Conditions that cause polyuria, including hyperglycemia and hypercalcemia, as well as diuretics (especially the rapid-acting loop diuretics), can precipitate acute incontinence. Some older people drink excessive amounts of fluids, and others ingest a large amount of caffeine without understanding the effects it can have on the bladder. Patients with volume-expanded states, such as congestive heart failure and lower extremity venous insufficiency, may have polyuria at night, which can contribute to nocturia and nocturnal incontinence.

As in the case of many other conditions discussed throughout this text, a wide variety of medications can play a role in the development of incontinence in elderly patients via several different mechanisms (see Table 8-4). Whether the incontinence is acute or persistent, the potential role of these medications in causing or contributing to patients' incontinence should be considered. When feasible, stopping the medication, switching to an alternative, or modifying the dosage schedule can be helpful in restoring continence.

■ Persistent Incontinence

Persistent forms of incontinence can be classified clinically into four basic types. As depicted in [Figure 8-7](#), an individual patient may have more than one type simultaneously. Although this classification does not include all the neurophysiological abnormalities associated with incontinence, it is helpful in approaching the clinical assessment and treatment of incontinence in the geriatric population.

Incontinence can result from one or a combination of the two basic abnormalities in lower genitourinary tract function: (1) failure to store urine, caused by an overactive or poorly compliant bladder or by diminished outflow resistance; and/or (2) failure to empty the bladder, caused by a poorly contractile bladder or by increased outflow resistance. [Table 8-6](#) shows the clinical definitions and common causes of persistent urinary incontinence.

Stress incontinence is common in older women, especially in ambulatory settings. It may be infrequent and involve very small amounts of urine and need no specific treatment in women who are not bothered by it. On the other hand, it may be so severe and bothersome that it necessitates surgical correction. It is most often




FIGURE 8-7 Basic types of persistent geriatric urinary incontinence.

associated with weakened supporting tissues (of the pelvic floor) and consequent hypermobility of the bladder outlet and urethra caused by lack of estrogen and/or previous vaginal deliveries or surgery (see Fig. 8-6). Obesity and chronic coughing can exacerbate this condition. Women who have had previous vaginal repair and/or surgical bladder neck suspension may develop a weak urethra (intrinsic sphincter deficiency [ISD]). These women generally present with severe incontinence and symptoms of urinary loss with any activity. This condition should be suspected during office evaluation if a woman loses urine involuntarily with coughing in the supine position during a pelvic examination when her bladder is relatively empty. In general, women with ISD are less responsive to nonsurgical treatment but may benefit from periurethral injections or a surgical sling procedure. Stress incontinence is unusual in men but can occur after transurethral surgery and/or radiation therapy for lower urinary tract malignancy when the anatomic sphincters are damaged.

Urgency incontinence can be caused by a variety of lower genitourinary and neurological disorders (see Table 8-6). Patients with urgency incontinence typically present with irritating symptoms of an overactive bladder, including frequency (voiding more than every 2 hours), urgency, and nocturia (two or more voids during usual sleeping hours). Urgency incontinence is most often, but not always, associated with involuntary bladder contractions on urodynamic testing (see Fig. 8-4). Some patients have a poorly compliant bladder without involuntary contractions (eg, as a result of radiation or interstitial cystitis, both relatively unusual conditions).

Other patients have symptoms of urgency incontinence but do not exhibit involuntary bladder contractions on urodynamic testing. Some patients with neurological disorders have involuntary bladder contractions on urodynamic testing but do not have urgency and are incontinent without any warning symptoms. These patients are generally treated as if they had urgency incontinence if they empty their bladders and do not have other correctable genitourinary pathology. A subgroup of older

TABLE 8-6. Basic Types and Causes of Persistent Urinary Incontinence

Types	Definition	Common causes
Stress	Involuntary loss of urine (usually small amounts) with increases in intra-abdominal pressure (eg, cough, laugh, exercise)	Weakness of pelvic floor musculature and urethral hypermobility Bladder outlet or urethral sphincter weakness
Urge	Leakage of urine (variable but often larger volumes) because of inability to delay voiding after sensation of bladder fullness is perceived	Detrusor overactivity, isolated or associated with one or more of the following: Local genitourinary condition such as tumors, stones, diverticula, or outflow obstruction Central nervous system disorders such as stroke, dementia, parkinsonism, spinal cord injury
Overflow (incontinence associated with incomplete bladder emptying)	Symptoms are variable and nonspecific Classic “overflow” incontinence involves leakage of urine (usually small amounts) resulting from mechanical forces on an overdistended bladder	Anatomic obstruction by prostate, stricture, cystocele Acontractile bladder associated with diabetes mellitus or spinal cord injury Neurogenic (detrusor-sphincter dyssynergy), associated with multiple sclerosis and other suprasacral spinal cord lesions
Functional	Urinary incontinence associated with inability to toilet because of impairment of cognitive and/or physical functioning, psychological unwillingness, or environmental barriers	Severe dementia and other neurological disorders Psychological factors such as depression and hostility

incontinent patients with an overactive bladder also have impaired bladder contractility—emptying less than one-third of their bladder volume with involuntary contractions on urodynamic testing (Resnick and Yalla, 1987; Elbadawi, Yalla, and Resnick, 1993). This condition has been termed *detrusor hyperactivity with impaired contractility* (DHIC). Patients with DHIC may present with symptoms that are not typical of urge incontinence and may strain to complete voiding. These patients may be challenging to manage because of their incomplete bladder emptying (Taylor and Kuchel, 2006).

Some older patients suffer from an overactive bladder but are not incontinent. The hallmark symptom of overactive bladder is urinary urgency. Patients with overactive

bladder usually also complain of urinary frequency (more than eight voids in 24 hours) and nocturia (awakening from sleep to void). Overactive bladder symptoms are common in the elderly; approximately 30% of women and 40% of men age 75 and older admit to these symptoms, most of whom also have urgency incontinence. The conditions that contribute to symptoms of overactive bladder as well as the diagnostic evaluation and management of this symptom complex are the same as for urgency incontinence (Ouslander, 2004).

Incontinence associated with incomplete bladder emptying can result from anatomic or neurogenic outflow obstruction, a hypotonic or acontractile bladder, or both. The most common causes include prostatic enlargement, diabetic neuropathic bladder, and urethral stricture. Low spinal cord injury and anatomic obstruction in females (caused by pelvic prolapse and urethral distortion) are less common causes of overflow incontinence. Several types of drugs can also contribute to this type of persistent incontinence (see Table 8-4). Some patients with suprasacral spinal cord lesions (eg, multiple sclerosis) develop detrusor-sphincter dyssynergy and consequent urinary retention, which must be treated in a similar manner as overflow incontinence; in some instances, a sphincterotomy is necessary. The symptoms of this type of incontinence are nonspecific, and urinary retention is easily missed on physical examination. Thus, a postvoid residual determination must be performed to exclude this condition.

The term *functional incontinence* refers to incontinence associated with the inability or lack of motivation to reach a toilet on time. Factors that contribute to functional incontinence (such as inaccessible toilets and psychological disorders, especially dementia) can also exacerbate other types of persistent incontinence. Patients with incontinence that appears to be predominantly related to functional factors may also have abnormalities of the lower genitourinary tract. In some patients, it can be very difficult to determine whether the functional factors or the genitourinary factors predominate without a trial of specific types of treatment. However, no matter what specific treatments are prescribed, patients with functional incontinence require systematic toileting assistance as a component of their management plan.

These basic types of incontinence may occur in combination in an individual patient, as depicted by the overlap in Figure 8-7. Older women commonly have a combination of stress and urgency incontinence (generally referred to as mixed incontinence). Frail geriatric patients often have urgency incontinence as well as functional disabilities that contribute to their incontinence.

EVALUATION

■ Basic Evaluation

The first step in evaluating incontinent patients is to identify the incontinence by direct observation or using the screening questions discussed earlier. In patients with the sudden onset of incontinence (especially when associated with an acute medical condition and hospitalization), the common reversible factors that can cause acute incontinence (see Tables 8-3, 8-4 and 8-5) can be ruled out by a brief history,

physical examination, postvoid residual determination, and basic laboratory studies (urinalysis, culture, and serum glucose).

Table 8-7 shows the components of the basic evaluation of persistent urinary incontinence. Practice guidelines suggest that the basic evaluation should include a focused history, targeted physical examination, urinalysis, and postvoiding residual (PVR) determination in most patients (Fantl et al., 1996; American Medical Directors Association, 2006; Fung et al., 2007). The history should focus on the characteristics of the incontinence, current medical problems and medications, the most bothersome symptom(s), and the impact of the incontinence on the patient and caregivers (**Table 8-8**). Bladder records or voiding diaries such as those shown in **Figure 8-8** (for outpatients) and **Figure 8-9** (for institutionalized patients) can be helpful in initially characterizing symptoms as well as in following the response to treatment.

TABLE 8-7. Components of the Diagnostic Evaluation of Persistent Urinary Incontinence	
All patients	
	History, including bladder record
	Physical examination
	Urinalysis
	Postvoid residual determination*
Selected patients†	
	Laboratory studies
	Urine culture
	Urine cytology
	Blood glucose, calcium
	Renal function tests
	Renal ultrasonography
	Gynecological evaluation
	Urological evaluation
	Cystourethroscopy
	Urodynamic tests
	Simple
	Observation of voiding
	Cough test for stress incontinence
	Complex
	Urine flowmetry‡
	Multichannel cystometrogram
	Pressure-flow study
	Leak-point pressure
	Urethral pressure profilometry
	Sphincter electromyography
	Video urodynamics

*Postvoid residual determination may not be necessary in carefully selected patients (see text).

†See text and Table 8-9.

‡Urine flowmetry is a useful screening test in older men (see text).

Physical examination should focus on abdominal, rectal, and genital examinations and an evaluation of lumbosacral innervation (Table 8-9). During the history and physical examination, special attention should be given to factors such as mobility, mental status, medications, and accessibility of toilets that may either be causing the incontinence or interacting with urological and neurological disorders to worsen the condition. The pelvic examination in women should include careful inspections of the labia and vagina for signs of inflammation suggestive of atrophic vaginitis and for pelvic prolapse. Most older women have some degree of pelvic prolapse (eg, grade 1 or 2 cystocele as depicted in Fig. 8-10). Not all incontinent older women with these degrees of prolapse need gynecological evaluation (see later discussion).

TABLE 8-8. Key Aspects of an Incontinent Patient's History

Active medical conditions, especially neurological disorders, diabetes mellitus, congestive heart failure, venous insufficiency
Medications (see Table 8-4)
Fluid intake pattern <ul style="list-style-type: none"> Type and amount of fluid (especially caffeine and fluids before bedtime)
Past genitourinary history, especially childbirth, surgery, dilatations, urinary retention, recurrent urinary tract infections
Symptoms of incontinence <ul style="list-style-type: none"> Onset and duration Type—stress vs. urge vs. mixed vs. other Frequency, timing, and amount of incontinence episodes and of continent voids (see Figs. 8-8 and 8-9)
Other lower urinary tract symptoms <ul style="list-style-type: none"> Irritative—dysuria, frequency, urgency, nocturia Voiding difficulty—hesitancy, slow or interrupted stream, straining, incomplete emptying Other—hematuria, suprapubic discomfort
Other symptoms <ul style="list-style-type: none"> Neurological (indicative of stroke, dementia, parkinsonism, normal-pressure hydrocephalus, spinal cord compression, multiple sclerosis) Psychological (depression) Bowel (constipation, stool incontinence) Symptoms suggestive of volume-expanded state (eg, lower extremity edema, shortness of breath while horizontal or with exertion)
Environmental factors <ul style="list-style-type: none"> Location and structure of bathroom Availability of toilet substitutes
Perceptions of incontinence <ul style="list-style-type: none"> Patient's concerns or ideas about underlying cause(s) Most bothersome symptom(s) Interference with daily life Severity (eg, is it enough of a problem for you to consider surgery?)

BLADDER RECORD

Day: _____

Date: _____/_____/_____.
month day

INSTRUCTIONS:

(1) In the 1st column make a mark every time during the 2-hour period you urinate into the toilet

(2) Use the 2nd column to record the amount you urinate (if you are measuring amounts)

(3) In the 3rd or 4th column, make a mark every time you accidentally leak urine

Time interval	Urinated in toilet	Amount	Leaking accident	or	Large accident	Reason for accident *
6-8 AM	_____	_____	_____	_____	_____	_____
8-10 AM	_____	_____	_____	_____	_____	_____
2-4 PM	_____	_____	_____	_____	_____	_____
4-6 PM	_____	_____	_____	_____	_____	_____
6-8 PM	_____	_____	_____	_____	_____	_____
8-10 PM	_____	_____	_____	_____	_____	_____
10-12 PM	_____	_____	_____	_____	_____	_____
Overnight	_____	_____	_____	_____	_____	_____

Number of pads used today: _____

* For example, if you coughed and have a leaking accident, write "cough".

If you had a large accident after a strong urge to urinate, write "urge".

FIGURE 8-8 Example of a bladder record for ambulatory care settings.

A clean urine sample should be collected for urinalysis. For men who are frequently incontinent, making a “clean-catch” specimen difficult to obtain, a clean specimen can be obtained using a condom catheter after cleaning the penis. For cognitively and functionally impaired women, a clean specimen can be obtained by cleaning the urethral and perineal area and having the patient void into a disinfected bedpan as an alternative to in-and-out catheterization. Persistent microscopic hematuria (>5 red blood cells per high-power field) in the absence of infection is an indication for further evaluation to exclude a tumor or other urinary tract pathology.

Because the prevalence of “asymptomatic bacteriuria” roughly parallels the prevalence of incontinence, incontinent geriatric patients commonly have significant bacteriuria. In the initial evaluation of incontinent noninstitutionalized patients, especially those in whom the incontinence is new or worsening, bacteriuria should be treated before further evaluation is undertaken. In the nursing home population,

INCONTINENCE MONITORING RECORD

INSTRUCTIONS: EACH TIME THE PATIENT IS CHECKED.

1) Mark one of the circles in the BLADDER section at the hour closest to the time the patient is checked.

2) Make an X in the BOWEL section if the patient has had an incontinent or normal bowel movement.

● = Incontinent, small amount

○ = Dry

X = Incontinent BOWEL

● = Incontinent, large amount

△ = Voided correctly

X = Normal BOWEL

PATIENT NAME _____ ROOM # _____ DATE _____

	BLADDER			BOWEL		INITIALS	COMMENTS
	INCONTINENT OF URINE	DRY	VOIDED CORRECTLY	INCONTINENT X	NORMAL X		
12 AM	● ●	○	△ cc ____				
1	● ●	○	△ cc ____				
2	● ●	○	△ cc ____				
3	● ●	○	△ cc ____				
4	● ●	○	△ cc ____				
5	● ●	○	△ cc ____				
6	● ●	○	△ cc ____				
7	● ●	○	△ cc ____				
8	● ●	○	△ cc ____				
9	● ●	○	△ cc ____				
10	● ●	○	△ cc ____				
11	● ●	○	△ cc ____				
12 PM	● ●	○	△ cc ____				
1	● ●	○	△ cc ____				
2	● ●	○	△ cc ____				
3	● ●	○	△ cc ____				
4	● ●	○	△ cc ____				
5	● ●	○	△ cc ____				
6	● ●	○	△ cc ____				
7	● ●	○	△ cc ____				
8	● ●	○	△ cc ____				
9	● ●	○	△ cc ____				
10	● ●	○	△ cc ____				
11	● ●	○	△ cc ____				
TOTALS:							

FIGURE 8-9 Example of a record to monitor bladder and bowel functions in institutional settings. This type of record is especially useful for implementing and following the results of various training procedures and other treatment protocols. (*Reproduced with permission from Ouslander, Uman, and Urman, 1986.*)

eradicating bacteriuria does not affect the severity of chronic, stable incontinence (Ouslander et al., 1995). However, new onset of incontinence, worsening incontinence, unexplained fever, and declines in mental and/or functional status may be the manifestations of a urinary tract infection in this population.

TABLE 8-9. Key Aspects of an Incontinent Patient’s Physical Examination

Mobility and dexterity
Functional status compatible with ability to self-toilet
Gait disturbance (parkinsonism, normal-pressure hydrocephalus)
Mental status
Cognitive function compatible with ability to self-toilet
Motivation
Mood and effect
Neurological
Focal signs (especially in lower extremities)
Signs of parkinsonism
Sacral arc reflexes
Abdominal
Bladder distension
Suprapubic tenderness
Lower abdominal mass
Rectal
Perianal sensation
Sphincter tone (resting and active)
Impaction
Masses
Size and contour of prostate
Pelvic
Perineal skin condition
Perineal sensation
Atrophic vaginitis (friability, inflammation, bleeding)
Pelvic prolapse (ie, cystocele, rectocele; see Fig. 8-10)
Pelvic mass
Other anatomic abnormality
Other
Lower extremity edema or signs of congestive heart failure (if nocturia is a prominent complaint)

A PVR determination can be done either by catheterization or using a portable ultrasound to detect urinary retention, which cannot always be detected by physical examination. Although the symptoms of incontinence associated with urinary retention can be nonspecific and significant residual urine can be easily missed on physical examination, some elderly incontinent patients may not need a PVR before a trial of treatment. Examples of such patients include those with pure symptoms of stress incontinence, urgency incontinence, or overactive bladder who have no symptoms of voiding difficulty and have no risk factors or urinary retention (eg, diabetes, spinal cord disease).

Patients with residual volumes of more than 200 mL should be considered for further evaluation. The need for further evaluation in patients with lesser degrees of retention should be determined on an individual basis, considering the patient’s symptoms and the degree to which they complain of straining or are observed to strain with voiding.




FIGURE 8-10 Example of a simplified grading system for cystoceles.

In older men, a noninvasive flow rate determination can be very helpful in screening for impaired bladder contractility or obstruction. Very low peak urinary flow rates (eg, <10 mL/s) after an adequate void (eg, >150 mL) are suggestive of one of these conditions. Uroflowmeters are relatively inexpensive but are rare in physicians' offices (except for urologists).

Further Evaluation

The need for further evaluation and the specific diagnostic procedures listed in Table 8-7 should be determined on an individual basis. Clinical practice guidelines state that not all incontinent geriatric patients require further evaluation. Patients who have unexplained polyuria should have their blood glucose and calcium levels determined. Patients with significant urinary retention should have renal function tests and be considered for renal ultrasound and urodynamic testing to determine whether obstruction, impaired bladder contractility, or both are present. Persistent microscopic hematuria in the absence of infection is an indication for urine cytology and urological evaluation, including cystoscopy. Even in the absence of hematuria, patients with the recent and sudden onset of irritative urinary symptoms who have risk factors for bladder cancer (heavy smoking, industrial exposure to aniline dyes) should be considered for these evaluations. Women with marked pelvic prolapse (see Fig. 8-10) should be referred for gynecological evaluation.

Complex urodynamic testing is helpful in guiding treatment in selected patients and is essential to determine the cause(s) of urinary retention and for any older patient for whom surgical intervention is being considered. [Table 8-10](#) summarizes criteria for referral for further evaluation, and [Figure 8-11](#) summarizes the overall approach to the evaluation of geriatric urinary incontinence.

MANAGEMENT

General Principles

Several therapeutic modalities can be used in managing incontinent geriatric patients ([Table 8-11](#)). Treatment can be especially helpful if specific diagnoses are made and attention is paid to all factors that may be contributing to the incontinence in a given patient. Even when cure is not possible, risks of complications can be reduced, and the comfort and satisfaction of both patients and caregivers can almost always be enhanced.

Acute incontinence may be transient if managed appropriately. All of the potential reversible factors that can cause or contribute to incontinence (see [Tables 8-3, 8-4](#) and [8-5](#)) should be attended to in order to maximize the potential for regaining continence. The most common approach to incontinent geriatric patients in acute care hospitals is indwelling catheterization. In some instances, this is justified by the need for accurate measurement of urine output during the acute phase of an illness. In many instances, however, it is unnecessary and poses a substantial and unwarranted risk of catheter-induced infection. Although it may be more difficult and time consuming, making toilets and toilet substitutes accessible and combining this with some form of scheduled toileting is probably a more appropriate approach in patients who do not require indwelling catheterization. Launderable or disposable and highly absorbent bed pads and undergarments may also be helpful in managing these patients and may result in less potential morbidity (and, therefore, overall cost) in the long run.

Supportive measures are critical in managing all forms of incontinence and should be used in conjunction with other, more specific treatment modalities.

Education (available in many booklets and on many websites), environmental manipulation, appropriate use of toilet substitutes, avoidance of iatrogenic contributions to incontinence, modifications of diuretic and fluid intake patterns, and good skin care are all important. Specially designed incontinence undergarments and pads can be very helpful in many patients but must be used appropriately. Although they can be effective, several caveats should be noted:

1. Garments and pads are a nonspecific treatment. They should not be used as the first response to incontinence or before some type of diagnostic evaluation is done.
2. Many patients are curable if treated with specific therapies, and some have potentially serious factors underlying their incontinence that must be diagnosed and treated.

TABLE 8-10. Criteria for Considering Referral of Incontinent Patients for Urological, Gynecological, or Urodynamic Evaluation

Criteria	Definition	Rationale
History		
Recent history of lower urinary tract or pelvic surgery or irradiation	Surgery or irradiation involving the pelvic area or lower urinary tract within the past 6 months.	A structural abnormality relating to the recent procedure should be sought.
Recurrent symptomatic urinary tract infections	Two or more symptomatic episodes in a 12-month period.	A structural abnormality or pathologic condition in the urinary tract predisposing to infection should be excluded.
Risk factors for bladder cancer	Recent or sudden onset of irritative symptoms, history of heavy smoking, or exposure to aniline dyes.	Urine for cytology and cystoscopy to exclude bladder cancer should be considered.
Physical examination		
Marked pelvic prolapse	A prominent cystocele that descends the entire height of the vaginal vault with coughing during speculum examination.	Anatomic abnormality may underlie the pathophysiology of the incontinence, and selected patients may benefit from a pessary or surgical repair.
Marked prostatic enlargement and/or suspicion of cancer	Gross enlargement of the prostate on digital examination; prominent induration or asymmetry of the lobes.	An evaluation to exclude prostate cancer may be appropriate and have therapeutic implications.
Postvoid residual		
Difficulty passing a 14-F straight catheter	Impossible catheter passage, or passage requiring considerable force, or a larger, more rigid catheter.	Anatomic blockage of the urethra or bladder neck may be present.
Postvoid residual volume >200	Volume of urine remaining in the bladder within a few minutes after the patient voids spontaneously in as normal a fashion as possible.	Anatomic or neurogenic obstruction or poor bladder contractility may be present.

(continued)

TABLE 8-10. Criteria for Considering Referral of Incontinent Patients for Urological, Gynecological, or Urodynamic Evaluation (*continued*)

Criteria	Definition	Rationale
Urinalysis		
Hematuria	>5 red blood cells per high-power field on repeated microscopic examinations in the absence of infection.	A pathologic condition in the urinary tract should be excluded.
Therapeutic trial		
Failure to respond	Persistent symptoms that are bothersome to the patient after adequate trials of behavioral and/or drug therapy.	Urodynamic evaluation may help guide specific therapy.

- 3. Underpants and pads can interfere with attempts at behavioral intervention and thereby foster dependency.
- 4. Many disposable products are relatively expensive and are not covered by Medicare or other insurance.

To a large extent, the optimal treatment of persistent incontinence depends on identifying the type(s). [Table 8-12](#) outlines the primary treatments for the basic types of persistent incontinence in the geriatric population. Each treatment modality is briefly discussed in the following sections. Behavioral interventions have been well studied in the geriatric population. These interventions are generally recommended by guidelines as an initial approach to therapy in many patients because they are generally noninvasive and nonspecific (ie, patients with stress and/or urgency incontinence respond equally well).

■ **Behavioral Interventions**

Many types of behavioral interventions are effective in the management of urinary incontinence (Shamliyan et al., 2008). The term *bladder training* has been used to encompass a wide variety of techniques. It is, however, important to distinguish between procedures that are patient dependent (ie, necessitate adequate function, learning capability, and motivation of the patient), in which the goal is to restore a normal pattern of voiding and continence, and procedures that are caregiver dependent that can be used for functionally disabled patients, in which the goal is to keep the patient and environment dry. [Table 8-13](#) summarizes behavioral interventions. All of the patient-dependent procedures generally involve the patient’s continuous self-monitoring, using a record such as the one depicted in [Figure 8-8](#); the caregiver-dependent procedures usually involve a record such as the one shown in [Figure 8-9](#).




FIGURE 8-11 Algorithm protocol for evaluating incontinence.

Pelvic floor muscle (Kegel) exercises are an essential component of patient-dependent behavioral interventions. They have been shown to produce the greatest benefit in treating urinary incontinence (Shamliyan et al., 2008). The exercises consist of repetitive contractions and relaxations of the pelvic floor muscles. The exercises may

TABLE 8-11. Treatment Options for Geriatric Urinary Incontinence

Nonspecific supportive measures
Education
Modifications of fluid (eg, caffeine) and medication intake
Use of toilet substitutes
Environmental manipulations
Garments and pads
Behavioral interventions (see Table 8-13)
Patient dependent
Pelvic muscle exercises
Bladder training
Bladder retraining (see Table 8-14)
Caregiver dependent
Scheduled toileting
Habit training
Prompted voiding (see Table 8-15)
Drugs (see Table 8-16)
Antimuscarinics (bladder relaxants)
α-Antagonists
α-Agonists
Estrogen
Periurethral injections
Surgery
Bladder neck suspension or sling
Removal of obstruction or pathologic lesion
Mechanical devices
Penile clamps
Artificial sphincters
Sacral nerve stimulators
Catheters
External
Intermittent
Indwelling

be taught by having the patient interrupt voiding to get a sense of the muscles being used or by having women squeeze the examiner's fingers during a vaginal examination (without doing a Valsalva maneuver, which is the opposite of the intended effect). A randomized trial has documented that many young-old women (mean age in the mid to upper 60s) can be taught these exercises during an in-office examination and derive significant reductions in incontinence (Burgio et al., 2002). Many women, however, especially those older than age 75, require biofeedback to help them identify the muscles and practice the exercises. One full exercise is a 10-second squeeze and a 10-second relaxation. Most older women will have to build endurance gradually to this level. Once learned, the exercises should be practiced many

TABLE 8-12. Primary Treatments for Different Types of Geriatric Urinary Incontinence

Type of incontinence	Primary treatments
Stress	Pelvic muscle (Kegel) exercises Other behavioral interventions (see Table 8-13) α -Adrenergic agonists Topical estrogen (not alone) Periurethral injections Surgical bladder neck suspension or sling
Urge	Bladder relaxants Topical estrogen (if atrophic vaginitis present) Bladder training (including pelvic muscle exercises)
Overflow	Surgical removal of obstruction Bladder retraining (see Table 8-14) Intermittent catheterization Indwelling catheterization
Functional	Behavioral interventions (caregiver dependent; see Tables 8-13 and 8-15) Environmental manipulations Incontinence undergarments and pads

times throughout the day (up to 40 exercises per day) and, importantly, should be used in everyday life during situations (eg, coughing, standing up, hearing running water) that might precipitate incontinence. Older men respond to pelvic muscle and bladder training techniques as well, and it should be considered as an alternative or adjunctive therapy for overactive bladder and urgency incontinence in the male population (Burgio et al., 2011). Biofeedback can be very effective for teaching pelvic floor muscle exercises. It generally involves the use of vaginal (or rectal) pressure or electromyography (EMG) with or without abdominal muscle EMG recordings to train patients to contract pelvic floor muscles and relax the abdomen. Studies show that these techniques improve management of both stress and urgency incontinence in the geriatric population. Numerous software packages are available to assist with biofeedback training.

Other forms of patient-dependent interventions include bladder training and bladder retraining. Bladder training involves education, pelvic muscle exercises (with or without biofeedback), strategies to manage urgency, and the regular use of bladder records (see Fig. 8-8). Bladder training is highly effective in selected community-dwelling patients, especially those who are motivated and functional.

Table 8-14 provides an example of a bladder retraining protocol. This protocol is applicable to patients who have had indwelling catheterization for monitoring of urinary output during a period of acute illness or for treatment of urinary retention

TABLE 8-13. Examples of Behavioral Interventions for Urinary Incontinence			
Procedure	Definition	Types of incontinence	Comments
Patient dependent			
Pelvic muscle (Kegel) exercises	Repetitive contraction and relaxation of pelvic floor muscles	Stress and urge	Requires adequate function and motivation and ability to learn Biofeedback often helpful in teaching the exercise
Bladder training	Use of education, bladder records, pelvic muscle, and other behavioral techniques	Stress and urge	Requires trained therapist, adequate cognitive and physical functioning, and motivation
Bladder retraining	Progressive lengthening or shortening of intervoiding interval, with intermittent catheterization used in patients recovering from overdistention injuries with persistent retention (see Table 8-14)	Acute (eg, postcatheterization with urge or overflow, poststroke)	Goal is to restore normal pattern of voiding and continence Requires adequate cognitive and physical function and motivation
Caregiver dependent			
Scheduled toileting	Routine toileting at regular intervals (scheduled toileting)	Urge and functional	Goal is to prevent wetting episodes Can be used in patients with impaired cognitive or physical functioning Requires staff or caregiver availability and motivation

(continued)

TABLE 8-13. Examples of Behavioral Interventions for Urinary Incontinence (*continued*)

Procedure	Definition	Types of incontinence	Comments
Habit training	Variable toileting schedule based on patient's voiding patterns	Urge and functional	Goal is to prevent wetting episodes Can be used in patients with impaired cognitive or physical functioning Requires staff or caregiver availability and motivation
Prompted voiding	Offer opportunity to toilet every 2 hours during the day; toilet only on request; social reinforcement; routine offering of fluids (see Table 8-15); individualize toileting at night based on patient preferences and degree of bother and risk for falls	Urge, stress, mixed, functional	Same as above 25%-40% of nursing home residents respond well during the day and can be identified during a 3-day trial (see text and Table 8-15)

with overflow incontinence. Such catheters should be removed as soon as possible, and this type of bladder retraining protocol should enable most indwelling catheters to be removed from patients in acute care hospitals as well as some in long-term care settings. A patient who continues to have difficulty voiding after 1 to 2 weeks of bladder retraining should be examined for other potentially reversible causes of voiding difficulties, such as those mentioned in the preceding discussion of acute incontinence. When difficulties persist, a urological referral should be considered to rule out correctable lower genitourinary pathology.

The goal of caregiver-dependent interventions is to prevent incontinence episodes rather than to restore normal patterns of voiding and complete continence. Such procedures are effective in reducing incontinence in selected nursing home residents. In its simplest form, scheduled toileting involves toileting the patient at regular intervals, usually every 2 hours during the day and every 4 hours during the evening and night. Habit training involves a schedule of toiletings or prompted voidings that is modified according to the patient's pattern of continent voids and

TABLE 8-14. Example of a Bladder Retraining Protocol

Objective: To restore a normal pattern of voiding and continence after the removal of an indwelling catheter

1. Remove the indwelling catheter (clamping the catheter before removal is not necessary)
2. Treat urinary tract infection if present
3. Initiate a toileting schedule. Begin by toileting the patient:
 - a. Upon awakening
 - b. Every 2 hours during the day and evening
 - c. Before getting into bed
 - d. Every 4 hours at night
4. Monitor the patient's voiding and continence pattern with a record that allows for the recording of:
 - a. Frequency, timing, and amount of continent voids
 - b. Frequency, timing, and amount of incontinence episodes
 - c. Fluid intake pattern
 - d. Postvoid catheter volume
5. If the patient is having difficulty voiding (complete urinary retention or very low urine outputs, eg, 240 mL in an 8-hour period while fluid intake is adequate):
 - a. Perform bladder ultrasound or in-and-out catheterization, recording volume obtained, every 6-8 hours until residual values are 200 mL
 - b. Instruct the patient on techniques to trigger voiding (eg, running water, stroking inner thigh, suprapubic tapping) and to help completely empty bladder (eg, bending forward, suprapubic pressure, double voiding)
 - c. If the patient continues to have high residual volumes after 1-2 weeks, consider urodynamic evaluation
6. If the patient is voiding frequently (ie, more often than every 2 hours):
 - a. Perform postvoid residual determination to ensure the patient is completely emptying the bladder
 - b. Encourage the patient to delay voiding as long as possible, and instruct the patient to use techniques to help completely empty bladder and pelvic muscle exercises
 - c. If the patient continues to have frequency and nocturia with or without urgency and incontinence:
 1. Rule out other reversible causes (eg, urinary tract infection, medication effects, hyperglycemia, and congestive heart failure)
 2. Consider further evaluation to rule out other pathology

incontinence episodes as demonstrated by a monitoring record such as that shown in Figure 8-9. Adjunctive techniques to prompt voiding (eg, running tap water, stroking the inner thigh, or suprapubic tapping) and to facilitate complete emptying of the bladder (eg, bending forward after completion of voiding) may be helpful in some patients. Prompted voiding has been the best studied of these procedures. [Table 8-15](#) provides an example of a prompted voiding protocol. Up to 40% of incontinent nursing home residents may be essentially dry during the day with

a consistent prompted voiding program. The success of these interventions is largely dependent on the knowledge and motivation of the caregivers who are implementing them, rather than on the physical functional and mental status of the incontinent patient. Targeting of prompted voiding to selected patients after a 3-day trial may enhance its cost-effectiveness (see Table 8-15). Quality improvement methods, based on principles of industrial statistical quality control, have been shown to be helpful

TABLE 8-15. Example of a Prompted Voiding Protocol for a Nursing Home

Assessment period (3-5 days)

1. Contact resident every hour from 7 AM to 7 PM for 2-3 days, then every 2 hours for 2-3 days
2. Focus attention on voiding by asking them whether they are wet or dry
3. Check residents for wetness, record results on bladder record, and give feedback on whether response was correct or incorrect
4. Whether wet or dry, ask residents if they would like to use the toilet or urinal. If they say yes:
 - Offer assistance
 - Record results on bladder record
 - Give positive reinforcement by spending extra time talking with them

If they say no:

- Repeat the question once or twice
- Inform them that you will be back in 1 hour and request that they try to delay voiding until then
- If there has been no attempt to void in the last 2-3 hours, repeat the request to use the toilet at least twice more before leaving

5. Offer fluids

Targeting

1. Prompted voiding is more effective in some residents than others
2. The best candidates are residents who show the following characteristics during the assessment period:
 - Void in the toilet, commode, or urinal (as opposed to being incontinent in a pad or garment) more than two-thirds of the time
 - Wet on $\leq 20\%$ of checks
 - Show substantial reduction in incontinence frequency on 2-hour prompts
3. Residents who do not show any of these characteristics may be candidates for either:
 - Further evaluation to determine the specific type of incontinence if they attempt to toilet but remain frequently wet
 - Supportive management by padding and adult diapers, and a checking-and-changing protocol if they do not cooperate with prompting

Prompted voiding (ongoing protocol)

1. Contact the resident every 2 hours from 7 AM to 7 PM
2. Use same procedures as for the assessment period
3. For nighttime management, use either modified prompted voiding schedule or padding, depending on resident's sleep pattern and preferences
4. If a resident who has been responding well has an increase in incontinence frequency despite adequate staff implementation of the protocol, the resident should be evaluated for reversible factors

in maintaining the effectiveness of prompted voiding in nursing homes (Ouslander, 2007). However, unless adequate staffing, training, and administrative support for the program persist, the effectiveness of prompted voiding will not be maintained in an institutional setting.

Toileting at night should be individualized, because prompted voiding and other similar interventions can disrupt sleep. Many functionally dependent patients are appropriately managed supportively at night with pads and adults diapers. This type of supportive management is appropriate for incontinent patients whose sleep is not disrupted and whose skin is not irritated.

■ Drug Treatment

Table 8-16 lists the drugs used to treat various types of incontinence. Several clinical trials show that the efficacy of drug treatment in the geriatric population is similar to that in younger populations (Shamliyan et al., 2012). Drug treatment can be prescribed in conjunction with various behavioral interventions. Treatment decisions should be individualized and will depend in large part on the characteristics and preferences of the patient (including risks and costs) and the preference of the health-care professional.

For urgency incontinence, antimuscarinic drugs with anticholinergic and relaxant effects on the bladder smooth muscle are used. All of them have proven efficacy in older patients, but they can have bothersome systemic anticholinergic side effects, especially dry mouth and constipation. Dry mouth can be relieved by small sips of water, hard candy, or over-the-counter oral lubricants. Constipation can be managed proactively (see “Fecal Incontinence” section). Patients should be warned about exacerbation of gastroesophageal reflux and glaucoma. Although open-angle glaucoma is not an absolute contraindication, patients being treated for glaucoma should be instructed to consult their ophthalmologist before initiating treatment.

All antimuscarinic drugs have anticholinergic properties and can theoretically cause problems with memory and other central nervous system side effects. Many older incontinent patients with urgency incontinence or overactive bladder have memory loss or early dementia and are already on cholinesterase inhibitors. In these patients, the decision to add an antimuscarinic for the bladder must be based on careful weighing of the bother of the symptoms versus the potential risks of the drugs.

The maximum effect of antimuscarinic drugs may not be achieved for up to 1 to 2 months. Therefore, patients should be educated to prevent unrealistic expectations about a quick cure and complete dryness. To maximize adherence, they should be told that many patients benefit from these drugs and some are cured, and that it may take a couple of months to achieve the desired effect. As with many other therapeutic agents, some patients respond to one drug better than others in the same class, so patients who are bothered and not responsive to one drug could be given a trial of another drug.

Among older men, symptoms of overactive bladder, including urgency incontinence, overlap with the irritative symptoms of benign prostatic hyperplasia (BPH). Men with large prostate glands (eg, estimated volume >30 g) may benefit from

TABLE 8-16. Drug Treatment for Urinary Incontinence and Overactive Bladder				
Drugs	Dosages	Mechanisms of action	Type of incontinence	Potential common adverse effects
Antimuscarinic				
Darifenacin	7.5-15 mg daily	Increase bladder capacity and diminish involuntary bladder contractions	Urge or mixed with urge predominant	Dry mouth, constipation, blurry vision, elevated intraocular pressure, cognitive impairment, delirium
Fesoterodine	4-8 mg daily		Overactive bladder with incontinence	
Oxybutynin				
Short-acting	2.5-5 mg tid			
Long-acting	5-30 mg daily			
Transdermal	3.9-mg patch changed after each 3 days			
Solifenacin	5-10 mg daily			
Tolterodine				
Short-acting	2 mg bid			
Long-acting	4 mg daily			
Trospium				
Short-acting	20 mg bid			
Long-acting	60 mg daily			

(continued)

TABLE 8-16. Drug Treatment for Urinary Incontinence and Overactive Bladder (*continued*)

Drugs	Dosages	Mechanisms of action	Type of incontinence	Potential common adverse effects
α-Adrenergic antagonists		Relax smooth muscle of urethra and prostatic capsule	Urge incontinence and related irritative symptoms associated with benign prostatic enlargement	Postural hypotension
Alfuzosin	10 mg qd		May be more effective	
Silodosin	4 mg daily		in combination with an	
Tamsulosin	0.4 mg qd		antimuscarinic drug	
α-Adrenergic agonists*				
Pseudoephedrine	30-60 mg tid or 60-120 mg, long acting	Stimulates contraction of urethral smooth muscle	Stress	Headache, tachycardia, elevation of blood pressure
Duloxetine	20-40 mg daily	Increases α -adrenergic tone to the urethra		Nausea
Topical estrogen [†]				
Topical cream	0.5-1.0 g/day for 2 weeks, then twice weekly	Strengthen periurethral tissues	Urge associated with severe vaginal atrophy or atrophic vaginitis	Local irritation
Vaginal estradiol ring	One ring every 3 months	Increase periurethral blood flow	Stress	
Arginine vasopressin [‡]				

DDAVP oral	0.1-0.4 mg at night	Prevents water loss from the kidney	Nocturia that is bothersome and does not respond to other treatments	Hyponatremia (serum sodium must be monitored closely at the onset of treatment)
Nasal spray	10-20 µg of nasal spray in each nostril at night			Flushing, nausea, rhinitis
Cholinergic agonist [§]				
Bethanechol	10-30 mg tid	Stimulate bladder contraction	Acute incontinence associated with incomplete bladder emptying in the absence of obstruction	Bradycardia, hypotension, bronchoconstriction, gastric acid secretion, diarrhea

* α -Adrenergic agonists are not approved by the U.S. Food and Drug Administration for this indication.

[†]Topical estrogen alone is not effective in relieving symptoms and should be considered an adjunctive treatment. There is also evidence that estrogen (given orally) may worsen incontinence in some women (Hendrix et al., 2005).

[‡]DDAVP is not approved by the U.S. Food and Drug Administration for this indication.

[§]Bethanechol may be helpful in selected patients after an episode of acute urinary retention; there is no evidence that it is useful on a chronic basis.

a 5- α reductase inhibitor. α -Adrenergic blockers (listed in Table 8-16) are effective for many older men for lower urinary tract symptoms associated with BPH but must be used carefully because of their potential to cause postural hypotension, especially among men already on cardiovascular medications. Combining an α -blocker with an antimuscarinic drug appears to be more efficacious than either alone, and the incidence of significant urinary retention with combination is very low (Kaplan et al., 2006).

Carefully selected patients with bothersome nocturia and/or nocturnal incontinence may benefit from a careful trial of intranasal arginine vasopressin (DDAVP) (see Table 8-16). However, the incidence of hyponatremia with this agent is very high in the elderly, and treated patients must be carefully monitored for its development. Currently, this would be an off-label use of this drug.

For stress incontinence, there are no drug treatments approved by the U.S. Food and Drug Administration (FDA). If drug treatment is considered, it usually involves a combination of an α -agonist and estrogen. Drug treatment is appropriate for motivated patients who have mild to moderate degrees of stress incontinence, do not have a major anatomic abnormality (eg, grade 3 cystocele or ISD), and do not have any contraindications to these drugs. Pseudoephedrine is contraindicated in elderly patients with hypertension. Duloxetine, a selective serotonin reuptake inhibitor antidepressant, increases α -adrenergic tone to the lower urinary tract through a spinal cord mechanism. It is approved in some countries for the treatment of stress incontinence. Neither pseudoephedrine nor duloxetine is FDA approved for stress incontinence and would be used off label for this indication. Patients with stress incontinence may also respond to concomitant behavioral interventions, as described earlier.

For stress incontinence, estrogen alone is not as effective as it is in combination with an α -agonist. Estrogen is also used for the treatment of irritative voiding symptoms and urgency incontinence in women with atrophic vaginitis and urethritis. Oral estrogen is not effective, and thus, topical estrogen must be used for these symptoms; in fact, oral estrogen may actually worsen incontinence in some women (Hendrix et al., 2005). Vaginal estrogen can be prescribed five nights per week for 1 to 2 months initially and then reduced to a maintenance dose of one to three times per week. A vaginal ring that slowly releases estradiol and vaginal tablets are also available. Drug treatment for chronic overflow incontinence using a cholinergic agonist or an α -adrenergic antagonist is rarely efficacious. Bethanechol may be helpful when given for a brief period subcutaneously in patients with persistent bladder contractility problems after an overdistention injury, but it is seldom effective when given over the long term orally. It can cause bradycardia and bronchoconstriction. α -Adrenergic blockers may be helpful in relieving symptoms associated with outflow obstruction in some patients but are probably not efficacious for long-term treatment of overflow incontinence.

■ Surgery

Surgery should be considered for older women with stress incontinence that continues to be bothersome after attempts at nonsurgical treatment and in women with a

significant degree of pelvic prolapse or ISD. As with many other surgical procedures, patient selection and the experience of the surgeon are critical to success. All women being considered for surgical therapy should have a thorough evaluation, including urodynamic tests, before undergoing the procedure.

Women with mixed stress incontinence and detrusor overactivity may also benefit from surgery, especially if the clinical history and urodynamic findings suggest that stress incontinence is the predominant problem. A randomized controlled trial has demonstrated that women with a clear history of pure stress incontinence do not necessarily need urodynamic testing before surgery (Nager et al., 2012). Many modified techniques of bladder neck suspension can be done with minimal risk and are successful in achieving continence over about a 5-year period. Urinary retention can occur after surgery, but it is usually transient and can be managed by a brief period of suprapubic catheterization. Data suggest that a fascial sling is more efficacious than a Burch colposuspension, but it is also associated with more postoperative complications (Albo et al., 2007). Periurethral injection of collagen and other materials is now available and may offer patients with ISD an alternative to surgery.

Surgery may be indicated in men in whom incontinence is associated with anatomically and/or uroynamically documented outflow obstruction. Men who have experienced an episode of complete urinary retention without any clear precipitant are likely to have another episode within a short period of time and should have a prostatic resection, as should men with incontinence associated with a sufficient amount of residual urine to be causing recurrent symptomatic infections or hydronephrosis. The decision about surgery in men who do not meet these criteria must be an individual one, weighing carefully the degree to which the symptoms bother the patient, the potential benefits of surgery (obstructive symptoms often respond better than irritative symptoms), and the risks of surgery, which may be minimal with newer prostate resection techniques. A small number of older patients, especially men who have stress incontinence related to sphincter damage caused by previous transurethral surgery, may benefit from the surgical implantation of an artificial urinary sphincter.

■ Catheters and Catheter Care

Catheters should be avoided in managing incontinence, unless specific indications are present. Three basic types of catheters and catheterization procedures are used for the management of urinary incontinence: external catheters, intermittent straight catheterization, and chronic indwelling catheterization.

External catheters generally consist of some type of condom connected to a drainage system. Sound design and observance of proper procedure and skin care when applying the catheter will decrease the risk of skin irritation as well as the frequency with which the catheter falls off. Patients with external catheters are at increased risk of developing symptomatic infection. External catheters should be used only to manage intractable incontinence in male patients who do not have urinary retention and who are extremely physically dependent. As with incontinence undergarments and padding, these devices should not be used as a matter of convenience because they may foster dependency.

Intermittent catheterization can help in the management of patients with incontinence associated with urinary retention. The procedure can be carried out by either the patient or a caregiver and involves straight catheterization two to four times daily, depending on catheter urine volumes and patient tolerance. In general, bladder volume should be kept to less than 400 mL. In the home setting, the catheter should be kept clean (but not necessarily sterile).

Intermittent catheterization may be useful for certain patients in acute care hospitals and nursing homes, for example, following removal of an indwelling catheter in a bladder retraining protocol (see Table 8-14). Nursing home residents, however, may be difficult to catheterize, and the anatomic abnormalities commonly found in older patients' lower urinary tracts may increase the risk of infection as a consequence of repeated straight catheterizations. In addition, using this technique in an institutional setting (which may have an abundance of organisms that are relatively resistant to many commonly used antimicrobial agents) may yield an unacceptable risk of nosocomial infections, and using sterile catheter trays for these procedures would be very expensive; thus, it may be extremely difficult to implement such a program in a typical nursing home setting.

Indwelling catheterization is still overused in acute hospital settings and increases the incidence of a number of complications, including chronic bacteriuria, bladder stones, periurethral abscesses, and even bladder cancer with long-term use. Nursing home residents, especially men, managed by chronic catheterization are at relatively high risk of developing symptomatic infections. Given these risks, it seems appropriate to recommend that the use of chronic indwelling catheters be limited to certain specific situations (Table 8-17). When indwelling catheterization is used, sound principles of catheter care should be observed to attempt to minimize complications (Table 8-18).

FECAL INCONTINENCE

Fecal incontinence is less common than urinary incontinence. Its occurrence is relatively unusual in older patients who are continent with regard to urine; however, 30% to 50% of geriatric patients with frequent urinary incontinence also have episodes of fecal incontinence, especially in the nursing home population. This coexistence suggests common pathophysiological mechanisms. Evidence-based reviews are now available on this topic (Shamliyan et al., 2007; Wald, 2007).

Defecation, like urination, is a physiological process that involves smooth and striated muscles, central and peripheral innervation, coordination of reflex responses, mental awareness, and physical ability to get to a toilet. Disruption of any of these factors can lead to fecal incontinence. The most common causes of fecal incontinence are problems with constipation and laxative use, unrecognized lactose intolerance, neurological disorders, and colorectal disorders (Table 8-19). Constipation is extremely common in the geriatric population and, when chronic, can lead to fecal impaction and incontinence. The hard stool (or scybalum) of fecal impaction irritates the rectum and results in the production of mucus and fluid. This fluid leaks

TABLE 8-17. Indications for Chronic Indwelling Catheter Use

Urinary retention that:

- Is causing persistent overflow incontinence, symptomatic infections, or renal dysfunction

- Cannot be corrected surgically or medically

- Cannot be managed practically with intermittent catheterization

Skin wounds, pressure ulcers, or irritations that are being contaminated by incontinent urine

Care of terminally ill or severely impaired patients for whom bed and clothing changes are uncomfortable or disruptive

Preference of patient when toileting or changing causes excessive discomfort

around the mass of impacted stool and precipitates incontinence. Constipation technically indicates less than three bowel movements per week, although many patients use the term to describe difficult passage of hard stools or a feeling of incomplete evacuation. Poor dietary and toilet habits, immobility, and chronic laxative abuse are the most common causes of constipation in geriatric patients ([Table 8-20](#)).

TABLE 8-18. Key Principles of Chronic Indwelling Catheter Care

1. Maintain sterile, closed gravity-drainage system.
2. Avoid breaking the closed system.
3. Use clean techniques in emptying and changing the drainage system; wash hands between patients in institutionalized setting.
4. Secure the catheter to the upper thigh or lower abdomen to avoid perineal contamination and urethral irritation because of movement of the catheter.
5. Avoid frequent and vigorous cleaning of the catheter entry site; washing with soapy water once per day is sufficient.
6. Do not routinely irrigate.
7. If bypassing occurs in the absence of obstruction, consider the possibility of a bladder spasm, which can be treated with a bladder relaxant.
8. If catheter obstruction occurs frequently, increase the patient's fluid intake and acidify the urine with dilute acetic acid irrigations.
9. Do not routinely use prophylactic or suppressive urinary antiseptics or antimicrobials.
10. Do not do surveillance cultures to guide management of individual patients because all chronically catheterized patients have bacteriuria (which is often polymicrobial) and the organisms change frequently.
11. Do not treat infection unless the patient develops symptoms; symptoms may be nonspecific, and other possible sources of infection should be carefully excluded before attributing symptoms to the urinary tract.
12. If a patient develops frequent symptomatic urinary tract infections, a genitourinary evaluation should be considered to rule out pathology such as stones, periurethral or prostatic abscesses, and chronic pyelonephritis.

TABLE 8-19. Causes of Fecal Incontinence

Fecal impaction
Laxative overuse or abuse
Neurological disorders
Dementia
Stroke
Spinal cord disease/injury
Colorectal disorders
Diarrheal illnesses
Lactose intolerance
Diabetic autonomic neuropathy
Rectal sphincter damage

Appropriate management of constipation will prevent fecal impaction and resultant fecal incontinence. The first step in managing constipation is the identification of all possible contributory factors. If the constipation is a new complaint and represents a recent change in bowel habit, then colonic disease, endocrine or metabolic disorders, depression, or drug side effects should be considered (see Table 8-19).

Proper diet, including adequate fluid intake and bulk, is important in preventing constipation. Crude fiber in amounts of 4 to 6 g/day (equivalent to three or four tablespoons of bran) is generally recommended. Improving mobility, positioning of body during toileting, and the timing and setting of toileting are all important in managing constipation.

TABLE 8-20. Causes of Constipation

Diet low in bulk and fluid
Poor toilet habits
Immobility
Laxative abuse
Colorectal disorders
Colonic tumor, stricture, volvulus
Painful anal and rectal conditions (hemorrhoids, fissures)
Depression
Drugs
Anticholinergic
Narcotic
Diabetic autonomic neuropathy
Endocrine or metabolic
Hypothyroidism
Hypercalcemia
Hypokalemia

Defecation should optimally take place in a private, unrushed atmosphere and should take advantage of the gastrocolic reflex, which occurs a few minutes after eating. These factors are often overlooked, especially in nursing home settings.

A variety of drugs can be used to treat constipation (Table 8-21). These drugs are often overused; in fact, their overuse may cause an atonic colon and contribute to chronic constipation (“cathartic colon”).

Laxative drugs can also contribute to fecal incontinence. Rational use of these drugs necessitates knowing the nature of the constipation and quality of the stool. For example, stool softeners will not help a patient with a large mass of already soft stool in the rectum. These patients would benefit from glycerin or irritant suppositories. The use of osmotic and irritant laxatives should be limited to no more than three or four times a week.

Fecal incontinence from neurological disorders is sometimes amenable to pelvic floor muscle training, although most severely demented patients are unable to cooperate.

TABLE 8-21. Drugs Used to Treat Constipation

Type	Examples	Mechanism of action
Stool softeners and lubricants	Dioctyl sodium succinate Mineral oil	Soften and lubricate fecal mass
Bulk-forming agents	Bran Psyllium mucilloid	Increase fecal bulk and retain fluid in bowel lumen
Osmotic cathartics	Milk of magnesia Magnesium sulfate/ citrate Lactulose Polyethylene glycol Sorbitol	Poorly absorbed and retain fluid in bowel lumen; increase net secretions of fluid in small intestine
Stimulants and irritants	Cascara Senna Bisacodyl Phenolphthalein	Alter intestinal mucosal permeability; stimulate muscle activity and fluid secretions
Enemas	Tap water Saline Sodium phosphate Oil	Induce reflex evacuations
Suppositories	Glycerin Bisacodyl	Cause mucosal irritation
Chloride ion activator	Lubiprostone	Enhances intestinal secretion; used for chronic idiopathic constipation
Opioid antagonists	Methylnaltrexone	Peripherally acting opioid antagonist for opioid-induced constipation

Evidence Summary	
Do's	
<ul style="list-style-type: none">• Assess for correctable underlying causes of overactive bladder and incontinence by history and targeted physical examination.• Manage constipation.• Utilize education and simple behavioral interventions for all incontinent patients.• Consider drug therapy for overactive bladder and/or urge continence in women (antimuscarinic) and men (selective α-adrenergic blocker with or without an antimuscarinic).• Follow symptomatic response and satisfaction with treatment after a 4- to 6-week period to determine the need to adjust the treatment plan.	
Don'ts	
<ul style="list-style-type: none">• Send all patients for specialist consultation or urodynamics.• Automatically prescribe medication for all older patients with symptoms of overactive bladder and incontinence.• Prescribe oral estrogen.	
Consider	
<ul style="list-style-type: none">• Referring selected patients for further urological, gynecological, and/or urodynamic evaluation.• A careful trial of pharmacological therapy for older patients with overactive bladder and urge incontinence who have cognitive impairment by carefully weighing the potential for benefit on bothersome symptoms vs. the potential cognitive side effects of anticholinergic agents.	

For patients with end-stage dementia who fail to respond to a regular toileting program and suppositories, a program of alternating constipating agents (if necessary) and laxatives on a routine schedule (such as giving laxatives or enemas three times a week) is often effective in controlling defecation.

Experience suggests that these measures should permit management of even severely demented patients. As a last resort, specially designed incontinence undergarments are sometimes helpful in managing fecal incontinence and preventing complications. Frequent changing is essential, because fecal material, especially in the presence of incontinent urine, can cause skin irritation and predispose to pressure ulcers.

REFERENCES
Albo ME, Richter HE, Brubaker L, et al. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. <i>N Engl J Med.</i> 2007;356:2143-2155.
American Medical Directors Association. <i>Urinary Incontinence: Clinical Practice Guideline.</i> Columbia, MD: AMDA; 2006.
Burgio KL, Goode PS, Johnson TM, et al. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. <i>J Am Geriatr Soc.</i> 2011;59:2209-2216.

- Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women. *JAMA*. 2002;288:2293-2299.
- Elbadawi A, Yalla SV, Resnick N. Structural basis of geriatric voiding dysfunction: I. Methods of a prospective ultrastructural/urodynamic study and an overview of the findings. *J Urol*. 1993;150:1650-1656.
- Fantl JA, Newman DK, Colling J, et al. *Urinary Incontinence in Adults: Acute and Chronic Management*. Clinical Practice Guideline No. 2, 1996, Update (AHCPR Publication No. 96-0682). Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1996.
- Fung CH, Spencer B, Eslami M, et al. Quality indicators for the screening and care of urinary incontinence in vulnerable elders. *J Am Geriatr Soc*. 2007;55:S443-S449.
- Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. *JAMA*. 2005;293:935-948.
- Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. *JAMA*. 2006;296:2319-2328.
- Nager CW, Brubaker L, Litman HJ, et al. A randomized trial of urodynamic testing before stress-incontinence surgery. *N Engl J Med*. 2012;366:1987-1997.
- Ouslander JG. Management of overactive bladder. *N Engl J Med*. 2004;350:786-799.
- Ouslander JG. Quality improvement initiatives for urinary incontinence in nursing homes. *J Am Med Dir Assoc*. 2007;8:S6-S11.
- Ouslander JG, Schapira M, Schnelle J, et al. Does eradicating bacteriuria affect the severity of chronic urinary incontinence among nursing home residents? *Ann Intern Med*. 1995;122:749-754.
- Ouslander JG, Uman GC, Urman HN. Development and testing of an incontinence monitoring record. *J Am Geriatr Soc*. 1986;34:83-90.
- Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function: an unrecognized but common cause of incontinence in elderly patients. *JAMA*. 1987;257:3076-3081.
- Shamliyan TA, Kane RL, Wyman J, Wilt TW. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. *Ann Intern Med*. 2008;148:459-473.
- Shamliyan T, Wyman J, Bliss DZ, et al. Prevention of Urinary and Fecal Incontinence in Adults. Rockville, MD: Prepared by the Minnesota Evidence-based Practice Center for the Agency for Healthcare Research and Quality under Contract No. 290-02-0009; Evidence Report/Technology Assessment No. 161, AHRQ Publication No. 08-E003. December 2007. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK38514/>.
- Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. *Ann Intern Med*. 2012;156:861-874.
- Taylor JA, Kuchel GA. Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition. *J Am Geriatr Soc*. 2006;54:1920-1932.
- Wald A. Fecal incontinence in adults. *N Engl J Med*. 2007;356:1648-1655.

SUGGESTED READINGS

- Boudreau DM, Onchee Y, Gray SI, et al. Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. *J Am Geriatr Soc*. 2011;59:2069-2076.
- Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? *J Am Geriatr Soc*. 2000;48:721-725.

- DuBeau CE. Therapeutic/pharmacologic approaches to urinary incontinence in older adults. *Clin Pharmacol Ther.* 2009;85:98-102.
- Fink HA, Taylor BC, Tacklind JW, Rutks IR, Wilt TJ. Treatment interventions in nursing home residents with urinary incontinence: a systematic review of randomized trials. *Mayo Clin Proc.* 2008;83:1332-1343.
- Fleming V, Wade WW. Overview of laxative therapies for treatment of chronic constipation in older adults. *Am J Geriatr Pharmacother.* 2010;8:514-550.
- Gibbs CF, Johnson TM II, Ouslander JG. Office management of geriatric urinary incontinence. *Am J Med.* 2007;120:211-220.
- Häggglund D. A systematic literature review of incontinence care for persons with dementia: the research evidence. *J Clin Nurs.* 2010;19:303-312.
- Kay GG, Abou-Donia MB, Messer WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. *J Am Geriatr Soc.* 2005;53:2195-2201.
- Lembo A, Camilleri M. Chronic constipation. *N Engl J Med.* 2003;349:1360-1368.
- Malmstrom TK, Andresen EM, Wolinsky FD, et al. Urinary and fecal incontinence and quality of life in African Americans. *J Am Geriatr Soc.* 2010;58:1941-1945.
- Markland AD, Vaughan CP, Johnson TM, et al. Incontinence. *Med Clin North Am.* 2011;95:539-554.
- Ouslander JG, Schnelle JF. Incontinence in the nursing home. *Ann Intern Med.* 1995;122:438-449.
- Talley KM, Wyman JF, Shamliyan TA. State of the science: conservative interventions for urinary incontinence in frail community-dwelling older adults. *Nurs Outlook.* 2011;59:215-220.
- Zarowitz BJ, Ouslander JG. The application of evidence-based principles of care in older persons (issue 6): urinary incontinence. *J Am Med Dir Assoc.* 2007;8:35-45.

SELECTED WEBSITES (ACCESSED SEPTEMBER 2012)

<http://www.nafc.org/>
<http://www.simonfoundation.org/>

CHAPTER 9

Falls

Falls are a major cause of morbidity in the geriatric population. Close to one-third of those age 65 years and older living at home suffer a fall each year. Among nursing homes residents, as many as half suffer a fall each year; 10% to 25% cause serious injuries. Accidents are the fifth leading cause of death in persons older than age 65, and falls account for two-thirds of these accidental deaths. Of deaths from falls in the United States, more than 70% occur in the population older than age 65. Fear of falling can adversely affect older persons' functional status and overall quality of life. Repeated falls and consequent injuries can be important factors in the decision to institutionalize an older person.

Table 9-1 lists potential complications of falls. Fractures of the hip, femur, humerus, wrist, and ribs and painful soft tissue injuries are the most frequent physical complications. Many of these injuries will result in hospitalization, with the attendant risks of immobilization and iatrogenic illnesses (see Chapter 10). Fractures of the hip and lower extremities often lead to prolonged disability because of impaired mobility. A less common, but important, injury is subdural hematoma. Neurological symptoms and signs that develop days to weeks after a fall should prompt consideration of this treatable problem.

Even when the fall does not result in serious injury, substantial disability may result from fear of falling, loss of self-confidence, and restricted ambulation (either self-imposed or imposed by caregivers).

Many studies suggest that some falls can be prevented. The potential for prevention together with the use of falling as an indicator of underlying risk for disability make an understanding of the causes of falls and a practical approach to the evaluation and management of gait instability and fall risk important components of geriatric care. Similar to many other conditions in the geriatric population, factors that can contribute to or cause falls are multiple, and very often more than one of these factors play an important role in an individual fall (**Fig. 9-1**).

AGING AND INSTABILITY

Several age-related factors contribute to instability and falls (**Table 9-2**). Most "accidental" falls are caused by one or a combination of these factors interacting with environmental hazards.

Aging changes in postural control and gait probably play a major role in many falls among older persons. Increasing age is associated with diminished proprioceptive input, slower righting reflexes, diminished strength of muscles important in maintaining posture, and increased postural sway. All these changes can contribute to falling—especially the ability to avoid a fall after encountering an environmental

TABLE 9-1. Complications of Falls in Elderly Patients

Injuries
Painful soft tissue injuries
Fractures
Hip
Femur
Humerus
Wrist
Ribs
Subdural hematoma
Hospitalization
Complications of immobilization (see Chap. 10)
Risk of iatrogenic illnesses (see Chap. 5)
Disability
Impaired mobility because of physical injury
Impaired mobility from fear, loss of self-confidence, and restriction of ambulation
Increased risk of institutionalization
Increased risk of death

hazard or an unexpected trip. Changes in gait also occur with increasing age. Although these changes may not be sufficient to be labeled truly pathologic, they can increase susceptibility to falls. In general, elderly people do not pick their feet up as high, thus increasing the tendency to trip. Elderly men tend to develop wide-based, short-stepped gaits; elderly women often walk with a narrow-based, waddling gait. These gait changes have been associated with white matter changes in the brain on magnetic resonance imaging (MRI) and with subsequent development of cognitive impairment.




FIGURE 9-1 Multifactorial causes and potential contributors to falls in older persons.

TABLE 9-2. Age-Related Factors Contributing to Instability and Falls

Changes in postural control and blood pressure
Decreased proprioception
Slower righting reflexes
Decreased muscle tone
Increased postural sway
Orthostatic hypotension
Postprandial hypotension
Changes in gait
Feet not picked up as high
Men develop flexed posture and wide-based, short-stepped gait
Women develop narrow-based, waddling gait
Increased prevalence of pathologic conditions predisposing to instability
Degenerative joint disease
Fractures of hip and femur
Stroke with residual deficits
Muscle weakness from disuse and deconditioning
Peripheral neuropathy
Diseases or deformities of the feet
Impaired vision
Impaired hearing
Impaired cognition and judgment
Other specific disease processes (eg, cardiovascular disease, parkinsonism—see Table 9-3)
Increased prevalence of conditions causing nocturia (eg, congestive heart failure, venous insufficiency)
Increased prevalence of dementia

Orthostatic hypotension (defined as a drop in systolic blood pressure of 20 mm Hg or more when moving from a lying to a standing position) occurs in approximately 20% of older persons. Although not all older individuals with orthostatic hypotension are symptomatic, this impaired physiological response could play a role in causing instability and precipitating falls in a substantial proportion of patients. Older people can experience a postprandial fall in blood pressure as well. People with orthostatic and/or postprandial hypotension are at particular risk for near syncope and falls when treated with diuretics and antihypertensive drugs.

Several pathologic conditions that increase in prevalence with increasing age can contribute to instability and falling. Degenerative joint disease (especially of the neck, the lumbosacral spine, and the lower extremities) can cause pain, unstable joints, muscle weakness, and neurological disturbances. Healed fractures of the hip and femur can cause an abnormal and less steady gait. Residual muscle weakness or sensory deficits from a recent or remote stroke can also cause instability.

Muscle weakness as a result of disuse and deconditioning (caused by pain and/or lack of exercise) can contribute to an unsteady gait and impair the ability to right oneself after a loss of balance. Diminished sensory input, such as in diabetes and other peripheral neuropathies, visual disturbances, and impaired hearing diminish cues from the environment that normally contribute to stability and thus predispose to falls. Impaired cognitive function may result in the creation of, or wandering into, unsafe environments and may lead to falls. Podiatric problems (bunions, calluses, nail disease, joint deformities, etc.) that cause pain, deformities, and alterations in gait are common, correctable causes of instability. Other specific disease processes common in older people (such as Parkinson disease and cardiovascular disorders) can cause instability and falls and are discussed later in the chapter.

CAUSES OF FALLS IN OLDER PERSONS

Table 9-3 outlines the multiple and often interacting causes of falls among older persons. More than half of all falls are related to medically diagnosed conditions, emphasizing the importance of a careful medical assessment for patients who fall (see below). Several studies have found a variety of risk factors for falls, including cognitive impairment, impaired lower extremity strength or function, gait and balance abnormalities, visual impairment, nocturia, and the number and nature of medications being taken. Frequently overlooked, environmental factors can increase susceptibility to falls and other accidents. Homes of elderly people are often full of environmental hazards (**Table 9-4**). Unstable furniture, rickety stairs with inadequate railings, throw rugs and frayed carpets, and poor lighting should be identified on home visits. Several factors are associated with falls among older nursing home residents (**Table 9-5**). Awareness of these factors can help prevent morbidity and mortality in these settings. Several factors can hinder precise identification of the specific causes for falls. These factors include lack of witnesses, inability of the older person to recall the circumstances surrounding the event, the transient nature of several causes (eg, arrhythmia, transient ischemic attack [TIA], postural hypotension), and the fact that the majority of elderly people who fall do not seek medical attention. Somewhat more detailed information is available on the circumstances surrounding falls in nursing homes (see **Table 9-5**).

Close to half of all falls can be classified as accidental. Usually an accidental trip or a slip can be precipitated by an environmental hazard, often in conjunction with factors listed in **Table 9-2**. Addressing the environmental hazards begins with a careful assessment of the environment. Some older persons have developed a strong attachment to their cluttered surroundings and may need active encouragement to make the necessary changes, but many may simply take such environmental risks for granted until they are specifically identified.

Syncope, “drop attacks,” and “dizziness” are commonly cited causes of falls in older persons. If there is a clear history of loss of consciousness, a cause for true syncope should be sought. Although the complete differential diagnosis of syncope is beyond the scope of this chapter, some of the more common causes of syncope in

TABLE 9-3. Causes of Falls**Accidents**

- True accidents (trips, slips, etc.)
- Interactions between environmental hazards and factors increasing susceptibility (see Table 9-2)

Syncope (sudden loss of consciousness)

- Drop attacks (sudden leg weaknesses without loss of consciousness)

Dizziness and/or vertigo

- Vestibular disease
- Central nervous system disease

Orthostatic hypotension

- Hypovolemia or low cardiac output
- Autonomic dysfunction
- Impaired venous return
- Prolonged bed rest
- Drug-induced hypotension
- Postprandial hypotension

Drug-related causes

- Antihypertensives
- Antidepressants
- Antiparkinsonian
- Diuretics
- Sedatives
- Antipsychotics
- Hypoglycemics
- Alcohol

Specific disease processes

- Acute illness of any kind ("premonitory fall")

Cardiovascular

- Arrhythmias
- Valvular heart disease (aortic stenosis)
- Carotid sinus hypersensitivity

Neurological causes

- TIA
- Stroke (acute)
- Seizure disorder
- Parkinson disease
- Cervical or lumbar spondylosis (with spinal cord or nerve root compression)
- Cerebellar disease
- Normal-pressure hydrocephalus (gait disorder)
- Central nervous system lesions (eg, tumor, subdural hematoma)

Urinary

- Overactive bladder
- Urge incontinence
- Nocturia

TIA, transient ischemic attack.

TABLE 9-4. Common Environmental Hazards

Old, unstable, and low-lying furniture
Beds and toilets of inappropriate height
Unavailability of grab bars
Uneven or poorly demarcated stairs and inadequate railing
Throw rugs, frayed carpets, cords, wires
Slippery floors and bathtubs
Inadequate lighting, glare
Cracked and uneven sidewalks
Pets that get under foot

older people include vasovagal responses, carotid sinus hypersensitivity, cardiovascular disorders (eg, bradycardia, tachyarrhythmias, aortic stenosis), acute neurological events (eg, TIA, stroke, seizure), pulmonary embolus, and metabolic disturbances (eg, hypoxia, hypoglycemia). A precise cause for syncope may remain unidentified in 40% to 60% of older patients.

Drop attacks, described as sudden leg weakness causing a fall without loss of consciousness, are often attributed to vertebrobasilar insufficiency and often precipitated by a change in head position. Only a small proportion of older people who fall have truly had a drop attack; the underlying pathophysiology is poorly understood, and care should be taken to rule out other causes.

Dizziness and unsteadiness are common complaints among elderly people who fall (as well as those who do not). A feeling of light-headedness can be associated with several different disorders but is a nonspecific symptom and should be interpreted with caution. Patients complaining of light-headedness should be carefully evaluated for postural hypotension and intravascular volume depletion.

Vertigo (a sensation of rotational movement), on the other hand, is a more specific symptom and is probably an uncommon precipitant of falls in the elderly. It is most

TABLE 9-5. Factors Associated with Falls Among Older Nursing Home Residents

Recent admission
Dementia
Hip flexor muscle weakness
Certain activities (toileting, getting out of bed)
Psychotropic drugs causing daytime sedation
Cardiovascular medications (vasodilators, antihypertensives, diuretics)
Polypharmacy
Low staff-patient ratio
Unsupervised activities
Unsafe furniture
Slippery floors

commonly associated with disorders of the inner ear, such as acute labyrinthitis, Ménière disease, and benign positional vertigo. Vertebrobasilar ischemia and infarction and cerebellar infarction can also cause vertigo. Patients with vertigo caused by organic disorders often have nystagmus, which can be observed by having the patient quickly lie down and turning the patient's head to the side in one motion. Many older patients with symptoms of dizziness and unsteadiness are anxious, depressed, and chronically afraid of falling, and the evaluation of their symptoms is quite difficult. Some patients, especially those with symptoms suggestive of vertigo, will benefit from a thorough otological examination including auditory testing, which may help clarify the symptoms and differentiate inner ear from central nervous system (CNS) involvement.

Orthostatic hypotension is best detected by taking the blood pressure and pulse rate in supine position, after 1 minute in the sitting position, and after 1 and 3 minutes in the standing position. A drop of more than 20 mm Hg in systolic blood pressure is generally considered to represent significant orthostatic hypotension. In many instances, this condition is asymptomatic; however, several conditions can cause orthostatic hypotension or worsen it to a severity sufficient to precipitate a fall. These conditions include low cardiac output from heart failure or hypovolemia, overtreatment with cardiovascular medications, autonomic dysfunction (which can result from diabetes or Parkinson disease), impaired venous return (eg, venous insufficiency), and prolonged bed rest with deconditioning of muscles and reflexes. Simply eating a full meal can precipitate a reduction in blood pressure in an older person that may be worsened when the person stands up and lead to a fall.

Drugs that should be suspected of playing a role in falls include diuretics (hypovolemia), antihypertensives (hypotension), antidepressants (postural hypotension), sedatives (excessive sedation), antipsychotics (sedation, muscle rigidity, postural hypotension), hypoglycemics (acute hypoglycemia), and alcohol (intoxication). Combinations of these drug types may greatly increase the risk of a fall. Many older patients are on a diuretic and one or two other antihypertensives, with consequent hypotension or postural hypotension that may precipitate a fall. Psychotropic drugs are commonly prescribed and appear to substantially increase the risk of falls and hip fractures, especially in patients concomitantly prescribed antidepressants.

Many disease processes, especially of the cardiovascular and neurological systems, are associated with falls. Cardiac arrhythmias are common in ambulatory elderly persons and may be difficult to associate directly with a fall or syncope. In general, cardiac monitoring should document a temporal association between a specific arrhythmia and symptoms (or a fall) before the arrhythmia is diagnosed (and treated) as the cause of falls.

Syncope is a symptom of aortic stenosis and is an indication to evaluate a patient suspected of having significant aortic stenosis for valve replacement. Aortic stenosis is difficult to diagnose by physical examination alone; all patients suspected of having this condition should have an echocardiogram.

Some elderly individuals have sensitive carotid baroreceptors and are susceptible to syncope resulting from reflex increase in vagal tone (caused by cough, straining at stool, micturition, etc.), which leads to bradycardia and hypotension. Carotid sinus sensitivity can be detected by bedside maneuvers (see below).

Cerebrovascular disease is often implicated as a cause or contributing factor for falls in older patients. Although cerebral blood flow and cerebrovascular autoregulation may be diminished, these aging changes alone are not enough to cause unsteadiness or falls. They may, however, render the elderly person more susceptible to stresses such as diminished cardiac output, which will more easily precipitate symptoms. Acute strokes (caused by thrombosis, hemorrhage, or embolus) can cause, and may initially manifest themselves in, falls. TIAs of both the anterior and posterior circulations frequently last only minutes and are often poorly described. Thus, care must be taken in making these diagnoses. Anterior circulation TIAs may cause unilateral weakness and thus precipitate a fall. Vertebrobasilar (posterior circulation) TIAs may cause vertigo, but a history of transient vertigo alone is not a sufficient basis for the diagnosis of TIA. The diagnosis of posterior circulation TIA necessitates that one or more other symptoms (visual field cuts, dysarthria, ataxia, or limb weakness, which can be bilateral) are associated with vertigo. Vertebrobasilar insufficiency, as mentioned earlier, is often cited as a cause of drop attacks; in addition, mechanical compression of the vertebral arteries by osteophytes of the cervical spine when the head is turned has also been proposed as a cause of unsteadiness and falling. Both of these conditions are poorly documented, are probably overdiagnosed, and should not be used as causes of a fall simply because nothing else can be found.

Other diseases of the brain and CNS can also cause falls. Parkinson disease and normal-pressure hydrocephalus can cause disturbances of gait, which lead to instability and falls. Cerebellar disorders, intracranial tumors, and subdural hematomas can cause unsteadiness, with a tendency to fall. A slowly progressive gait disability with a tendency to fall, especially in the presence of spasticity or hyperactive reflexes in the lower extremities, should prompt consideration of cervical spondylosis and spinal cord compression. It is especially important to consider these diagnoses because treatment may improve the condition before permanent disability ensues.

Urinary tract disorders including overactive bladder, urgency incontinence, and nocturia are also associated with falling. Urinary urgency may cause a distraction, similar to the “dual-tasking” studies mentioned earlier, and thereby predispose to falls. Awakening at night to void, especially among people who have taken hypnotics or other psychotropic drugs, may substantially increase the risk of falls.

Despite this long list, the precise causes of many falls will remain unknown, even after a thorough evaluation. The ultimate test of the etiology for falls is its reversibility. As noted earlier in the text, we are often better at finding putative causes of geriatric conditions than in correcting them.

EVALUATING THE ELDERLY PATIENT WHO FALLS

Updated quality indicators for the identification, evaluation, and management of vulnerable elderly people with falls and mobility problems have recently been

published as a component of the Assessing Care of Vulnerable Elders (ACOVE) project (Chang and Ganz, 2007).

Older patients who report a fall (or recurrent falls) that is not clearly the result of an accidental trip or slip should be carefully evaluated, even if the fall has not resulted in serious physical injury. A jointly developed set of recommendations for assessing people who fall has been issued by the American Geriatrics Society, the British Geriatrics Society, and the American Academy of Orthopaedic Surgeons (2010). A thorough fall evaluation basically consists of a focused history, targeted physical examination, gait and balance assessment, and, in certain instances, selected laboratory studies.

The history should focus on the general medical history and medications; the patient's thoughts about what caused the fall; the circumstances surrounding it, including ingestion of a meal and/or medication; any premonitory or associated symptoms (such as palpitations caused by a transient arrhythmia or focal neurological symptoms caused by a TIA); and whether there was loss of consciousness (Table 9-6). A history of loss of consciousness after the fall (which is often difficult to document) is important and should raise the suspicion of a cardiac event (transient arrhythmia or heart block) that caused syncope or near-syncope or a seizure (especially if there has been incontinence). Falls are often unwitnessed, and older patients may not recall any details of the circumstances surrounding the event. Detailed questioning can sometimes lead to identification of environmental factors that may have played a role in the fall and to symptoms that may lead to a specific diagnosis. Many older patients will not be able to give details about an unwitnessed fall and will simply report, "I just fell down; I don't know what happened." The skin, extremities, and painful soft tissue areas should be assessed to detect any injury that may have resulted from a fall.

Several other aspects of the physical examination can be helpful in determining the cause(s) (Table 9-7). Because a fall can herald the onset of a variety of acute illnesses (premonitory falls), careful attention should be given to vital signs. Fever, tachypnea, tachycardia, and hypotension should prompt a search for an acute illness (such as pneumonia or sepsis, myocardial infarction, pulmonary embolus, or gastrointestinal bleeding). Postural blood pressure and pulse determinations taken supine, sitting, and standing (after 1 and 3 minutes) are critical in the diagnosis and management of falls in older patients. As noted earlier, postural hypotension occurs in a substantial number of healthy, asymptomatic elderly persons as well as in those who are deconditioned from immobility or have venous insufficiency. This finding can also be a sign of dehydration, acute blood loss (occult gastrointestinal bleeding), or a drug side effect (especially with cardiovascular medications and anti-depressants). Visual acuity should be assessed for any possible uncorrected vision impairment that may have contributed to instability and falls. The cardiovascular examination should focus on the presence of arrhythmias (many of which are easily missed during a brief examination) and signs of aortic stenosis. Because both of these conditions are potentially serious and treatable, yet difficult to diagnose by physical examination, the patient should be referred for continuous monitoring and echocardiography if they are suspected. If the history suggests carotid sinus

TABLE 9-6. Evaluating the Elderly Patient Who Falls: Key Points in the History

General medical history
History of previous falls
Medications (especially antihypertensive and psychotropic agents)
Patient’s thoughts on the cause of the fall
Was patient aware of impending fall?
Was it totally unexpected?
Did patient trip or slip?
Circumstances surrounding the fall
Location and time of day
Activity
Situation: alone or not alone at the time of the fall
Witnesses
Relationship to changes in posture, turning of head, cough, urination, a meal, medication intake
Premonitory or associated symptoms
Light-headedness, dizziness, vertigo
Palpitations, chest pain, shortness of breath
Sudden focal neurological symptoms (weakness, sensory disturbance, dysarthria, ataxia, confusion, aphasia)
Aura
Incontinence of urine or stool
Loss of consciousness
What is remembered immediately after the fall?
Could the patient get up, and if so, how long did it take?
Can loss of consciousness be verified by a witness?

sensitivity, the carotid can be gently massaged for 5 seconds to observe whether this precipitates a profound bradycardia (50% reduction in heart rate) or a long pause (2 seconds). The extremities should be examined for evidence of deformities, limits to range of motion, or active inflammation that might underlie instability and cause a fall.

Special attention should be given to the feet because of deformities; painful lesions (calluses, bunions, ulcers); and poorly fitting, inappropriate, or worn-out shoes are common and can contribute to instability and falls.

Neurological examination is also an important aspect of this physical assessment. Mental status should be assessed (see Chapter 6), with a careful search for focal neurological signs. Evidence of muscle weakness, rigidity, or spasticity should be noted, and signs of peripheral neuropathy (especially posterior column signs such as loss of position or vibratory sensation) should be ruled out. Abnormalities in cerebellar function (especially heel-to-shin testing and heel tapping) and signs of Parkinson disease (such as resting tremor, muscle rigidity, and bradykinesia) should be sought.

TABLE 9-7. Evaluating the Elderly Patient Who Falls: Key Aspects of the Physical Examination

Vital signs
Fever, hypothermia
Respiratory rate
Pulse and blood pressure (lying, sitting, standing)
Skin
Turgor (over the chest; other areas unreliable)
Pallor
Trauma
Eyes
Visual acuity
Cardiovascular
Arrhythmias
Carotid bruits
Signs of aortic stenosis
Carotid sinus sensitivity
Extremities
Degenerative joint disease
Range of motion
Deformities
Fractures
Podiatric problems (calluses; bunions; ulcerations; poorly fitted, inappropriate, or worn-out shoes)
Neurological
Mental status
Focal signs
Muscles (weakness, rigidity, spasticity)
Peripheral innervation (especially position sense)
Cerebellar (especially heel-to-shin testing)
Resting tremor, bradykinesia, other involuntary movements
Observation of gait and balance
Get up and go test (Table 9-10)
Evaluation of assistive devices for hazards, such as missing tips on canes and walkers, impaired locking devices, or broken footrests on wheelchairs

Gait and balance assessments are a critical component of the examination and are probably more useful in identifying remediable problems than is the standard neuromuscular examination. Although sophisticated techniques have been developed to assess gait and balance, careful observation of a series of maneuvers is the most practical and useful assessment technique. The “get up and go” test and other practical performance-based balance and gait assessments have been developed (Table 9-8). While timing of this test has been used in research, timing in clinical practice is not essential and may distract the observer from careful

TABLE 9-8. Example of a Performance-Based Assessment of Gait and Balance (Get Up and Go)

Maneuver	Normal	Adaptive	Abnormal
Sitting balance	Steady, stable	Holds onto chair to keep upright	Leans, slides down in chair
Arising from chair	Able to arise in a single movement without using arms	Uses arms (on chair or walking aid) to pull or push up and/or moves forward in chair before attempting to rise	Multiple attempts required or unable without human assistance
Immediate standing balance (first 3-5 s)	Steady without holding onto walking aid or other object for support	Steady, but uses walking aid or support grabbing objects for support	Any sign of unsteadiness (eg, other object for staggering, more than minimal trunk sway)
Standing balance	Steady, able to stand with feet together without holding onto an object for support	Steady, but cannot put feet together	
Balance with eyes closed (Romberg test)	Steady without holding onto any object with feet together	Steady with feet apart	Any sign of unsteadiness or needs to hold onto an object
Nudge on sternum (patient standing with eyes closed; examiner pushes with light, even pressure over sternum three times; reflects ability to withstand displacement)	Steady, able to withstand pressure	Needs to move feet, but able to maintain balance	Begins to fall, or examiner has to help maintain balance
Walking (usual pace with assistive device if used)	Stable, smooth gait	Use of cane, walker, holding onto furniture	Decreased step height and/or step length; unsteadiness or staggering gait

Turning balance (360°)	No grabbing or staggering; no need to hold onto any objects; steps are continuous (turn is a flowing movement)	Steps are discontinuous (patient puts one foot completely on floor before raising other foot)	Any sign of unsteadiness or holds onto an object; more than four steps to turn 360°
Neck turning (patient asked to turn head side to side and look up while standing with feet as close together as possible)	Able to turn head at least halfway side to side and able to bend head back to look at ceiling; no staggering, grabbing, or symptoms of light-headedness, unsteadiness, or pain	Decreased ability to turn side to side to extend neck, but no staggering, grabbing, or symptoms of light-headedness, unsteadiness, or pain	Any sign of unsteadiness or symptoms when turning head or extending neck
Back extension (ask patient to lean back as far as possible, without holding onto object if possible)	Good extension without holding object or staggering	Tries to extend, but range of motion is decreased or needs to hold object to attempt extension	Will not attempt, no extension seen, or staggers
Reaching up (have patient attempt to remove an object from a shelf high enough to necessitate stretching or standing on toes)	Able to take down object without needing to hold onto other object for support and without becoming unsteady	Able to get object but needs to steady self by holding onto something for support	Unable or unsteady
Bending down (patient is asked to pick up small objects, such as pen, from the floor)	Able to bend down and pick up the object and able to get up easily in single attempt without needing to pull self up with arms	Able to get object and get upright in single attempt but needs to pull self up with arms or hold onto something for support	Unable to bend down or unable to get upright after bending down or takes multiple attempts to upright self
Sitting down	Able to sit down in one smooth movement	Needs to use arms to guide self into chair or not a smooth movement	Falls into chair, misjudges distances (lands off center)

assessment of gait and balance. Abnormalities on this assessment may be helpful in identifying patients who are likely to fall again and potentially remediable problems that might prevent future falls.

There is no specific laboratory workup for an elderly patient who falls. Laboratory studies should be ordered based on information gleaned from the history and physical examination. If the cause of the fall is obvious (such as a slip or a trip) and no suspicious symptoms or signs are detected, laboratory studies are unwarranted. If the history or physical examination (especially vital signs) suggests an acute illness, appropriate laboratory studies (eg, complete blood count, electrolytes, blood urea nitrogen, chest film, electrocardiogram) should be ordered. Because evidence suggests that vitamin D may be helpful in preventing falls (Bischoff-Ferrari et al., 2004; Kalyani et al., 2010), evaluating patients who fall recurrently for vitamin D deficiency is appropriate. If a transient arrhythmia or heart block is suspected, ambulatory electrocardiographic monitoring should be done. Although the sensitivity and specificity of this procedure for determining the cause of falls in the elderly are unknown, and many elderly people have asymptomatic ectopy, cardiac abnormalities detected on continuous monitoring that are clearly related to symptoms should be treated.

Because it is difficult to diagnose aortic stenosis on physical examination, echocardiography should be considered in all patients with suggestive histories and a systolic heart murmur or those who have a delay in the carotid upstroke. If the history suggests anterior circulation TIA, noninvasive vascular studies should be considered to rule out treatable vascular lesions. Computed tomography (CT) scans or MRI scans should be reserved for patients in whom there is a high suspicion of an intracranial lesion or seizure disorder.

MANAGEMENT

Table 9-9 outlines the basic principles of managing elderly patients with instability and a history of falls. Assessment and treatment of physical injury should not be overlooked because it may be helpful in preventing recurrent falls. The American Geriatrics Society has updated its clinical practice guideline on falls (American Geriatrics Society and British Geriatrics Society Panel on Prevention of Falls in Older Persons, 2011), and several meta-analyses have documented the effectiveness of a variety of interventions, including multicomponent programs, exercise, tai chi, and vitamin D (Bischoff-Ferrari et al., 2004; Chang et al., 2004; Coussement et al., 2007; Cameron et al., 2010; Kalyani et al., 2010; Leung et al., 2011, Sherrington et al., 2011)

When specific conditions are identified by history, physical examination, and laboratory studies, they should be treated in order to minimize the risk of subsequent falls, morbidity, and mortality. **Table 9-10** lists examples of treatments for some of the more common conditions. This table is meant only as a general outline; most of these topics are discussed in detail in general textbooks of medicine. Because the cause of a fall in an individual person is often multifactorial, multicomponent interventions are often necessary to reduce fall risk.

TABLE 9-9. Principles of Management for Elderly Patients with Complaints of Instability and/or Falls

Assess and treat physical injury
Treat underlying conditions (Table 9-10)
Prevent future falls
Provide physical therapy and education
Gait and balance retraining
Muscle strengthening
Aids to ambulation
Properly fitted shoes
Adaptive behaviors
Alter the environment
Safe and proper-size furniture
Elimination of obstacles (loose rugs, etc.)
Proper lighting
Rails (stairs, bathroom)

Physical therapy and patient education are important aspects of the management. Gait training, muscle strengthening, the use of assistive devices, and adaptive behaviors (such as rising slowly, using rails or furniture for balance, and techniques of getting up after a fall) are all helpful in preventing subsequent morbidity from instability and falls.

Environmental manipulations can be critical in preventing further falls in individual patients. The environments of the elderly are often unsafe (see Table 9-4), and appropriate interventions can often be instituted to improve safety (see Table 9-10). Physical restraints (eg, vests, belts, mittens, geri-chairs) have been used in institutional settings for those felt to be at high risk of falling, but research demonstrating no benefit or increased risk with restraints (Tinetti, Liu, and Ginter, 1992; Neufeld et al., 1999) and federal nursing home regulations and quality improvement initiatives have led to dramatically reduced use of these devices in many institutional settings; most nursing homes now aspire to be restraint free. Multifaceted interventions for fall prevention in long-term care settings have been designed and tested, but the results of these trials have been mixed (Ray et al., 1997; Taylor, 2002; Ray et al., 2005; Rask et al., 2007).

For elderly patients who are at high risk for falls and hip fractures, the use of hip protectors should be considered. Numerous clinical trials and meta-analyses (Kannus et al., 2000; Parker, Gillespie, and Gillespie, 2003; Honkanen et al., 2006; Kiel et al., 2007; Sawka et al., 2007; van Schoor et al., 2007), have not shown definitive evidence that hip protectors reduce morbidity in a population of fallers. However, in individual high-risk patients who will wear them, hip protectors may be a simple and relatively inexpensive preventive intervention to consider.

TABLE 9-10. Examples of Treatment for Underlying Causes of Falls	
Condition and cause	Potential treatment
Cardiovascular	
Tachyarrhythmias	Antiarrhythmics*
Bradyarrhythmias	Pacemaker*
Aortic stenosis	Valve surgery (for syncope)
Postural hypotension	
Drug-related	Elimination of drugs(s) that may contribute
Intravascular volume depletion	Rehydrate as appropriate
	Evaluate for blood loss if indicated
With venous insufficiency	Support stockings
	Leg elevation
	Adaptive behaviors
Neurologic	
Autonomic dysfunction or idiopathic	Support stockings
	Mineralocorticoids
	Midodrine hydrochloride
	Adaptive behaviors (eg, pausing and getting up slowly)
TIA	Aspirin and/or surgery†
Cervical spondylosis (with spinal cord compression)	Physical therapy
	Neck brace
	Surgery
Parkinson disease	Antiparkinsonian drugs
Visual impairment	Ophthalmological evaluation and specific treatment
Seizure disorder	Anticonvulsants
Normal-pressure hydrocephalus	Surgery (shunt)†
Dementia	Supervised activities
	Hazard-free environment
Benign positional vertigo	Habituation exercises
	Antivertiginous medication
Others	
Foot disorders	Podiatric evaluation and treatment
Gait and balance disorders (miscellaneous)	Properly fitted shoes
	Physical therapy
	Exercise with balance training (eg, tai chi)
Muscle weakness, deconditioning	Lower extremity strength training
Drug overuse (eg, sedatives, alcohol, other psychotropic drugs, antihypertensives)	Elimination of drug(s)
Vitamin D deficiency	Vitamin D supplementation
Recurrent falls in high-risk patients	Consider hip protectors

*These treatments may be indicated only if the cardiac disturbance is clearly related to symptoms.
†Risk-benefit ratio must be carefully assessed.
TIA, transient ischemic attack.

Evidence Summary

Do's

- Distinguish between falls, syncope, and seizure.
- Distinguish between “dizziness” and true vertigo.
- Assess for correctable underlying causes of falls by history and targeted physical examination.
- Pay particular attention to:
 - Uncorrected vision impairment
 - Postural vital signs
 - Psychotropic medications
 - Gait and balance abnormalities
 - Inappropriate footwear
 - Incorrect use of canes and other assistive devices
 - Environmental hazards
 - A simple “get up and go” test on all patients who have fallen
- Ensure safety in recurrent fallers by urgent intervention(s) to prevent injury.
- Refer patients to rehabilitation therapists (physical and occupational) whenever appropriate for detailed environmental and safety assessments, strengthening, and proper prescription and use of assistive devices.
- Prescribe vitamin D in doses of at least 800 IU per day.

Don'ts

- Send all patients for extensive diagnostic studies or cardiac monitoring.

Consider

- Referring selected patients for tai chi if they have balance problems and classes are available.
- Recommending hip protectors in carefully selected patients who are at high risk for fracture and who are recurrently falling.

REFERENCES

- American Geriatrics Society and British Geriatrics Society Panel on Prevention of Falls in Older Persons. Summary of the Updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. *J Am Geriatr Soc.* 2011;59:148-157.
- American Geriatrics Society, British Geriatrics Society, American Academy of Orthopaedic Surgeons Panel on Falls Prevention. Guideline for the prevention of falls in older persons. 2010. Available at: http://www.americangeriatrics.org/health_care_professionals/clinical_practice/clinical_guidelines_recommendations/2010. Accessed June 16, 2012.
- Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. *JAMA.* 2004;291:1999-2006.
- Cameron ID, Murray GR, Gillespie LD, et al. Interventions for preventing falls in older people in nursing care facilities and hospitals. *Cochrane Database Syst Rev.* 2010;1:CD005465.
- Chang JT, Ganz D. Quality indicators for falls and mobility problems in vulnerable elders. *J Am Geriatr Soc.* 2007;55:S327-S334.

- Chang JT, Morton SC, Rubenstein LZ, et al. Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials. *BMJ*. 2004;328:680.
- Coussement J, De Paepe L, Schwendimann R, et al. Interventions for preventing falls in acute- and chronic-care hospitals: a systematic review and meta-analysis. *J Am Geriatr Soc*. 2007;56:29-36.
- Honkanen LA, Mushlin AI, Lachs M, et al. Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations? *J Am Geriatr Soc*. 2006;54:1658-1665.
- Kannus P, Parkkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. *N Engl J Med*. 2000;343:1506-1513.
- Kalyani RR, Stein B, Valiyl R, et al. Vitamin D treatment for the prevention of falls in older adults: systematic review and meta-analysis. *J Am Geriatr Soc*. 2010;58:1299-1310.
- Kiel DP, Magaziner J, Zimmerman S, et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. *JAMA*. 2007;298:413-422.
- Leung DP, Chan CK, et al. Tai chi as an intervention to improve balance and reduce falls in older adults: a systematic and meta-analytical review. *Altern Ther Health Med*. 2011;17:40-48.
- Neufeld RR, Libow LS, Foley WJ, et al. Restraint reduction reduces serious injuries among nursing home residents. *J Am Geriatr Soc*. 1999;47:1202-1207.
- Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. *Cochrane Database Syst Rev*. 2003;3:CD001255.
- Rask K, Parmelee P, Taylor JA, et al. Implementation and evaluation of a fall management program. *J Am Geriatr Soc*. 2007;55:342-349.
- Ray WA, Taylor JA, Brown AK, et al. Prevention of fall-related injuries in long-term care: a randomized controlled trial of staff education. *Arch Intern Med*. 2005;165:2293-2298.
- Ray WA, Taylor JA, Meador KG, et al. A randomized trial of a consultation service to reduce falls in nursing homes. *JAMA*. 1997;278:557-562.
- Sawka AM, Boulos P, Beattie K, et al. Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. *J Clin Epidemiol*. 2007;60:336-344.
- Sherrington C, Tiedemann A, Fairhall N, et al. Exercise to prevent falls in older adults: an updated meta-analysis and best practice recommendations. *N S W Public Health Bull*. 2011;22:78-83.
- Taylor JA. The Vanderbilt fall prevention program for long-term care: eight years of field experience with nursing home staff. *J Am Med Dir Assoc*. 2002;3:180-185.
- Tinetti ME, Liu W, Ginter SF. Mechanical restraint use and fall-related injuries among residents of skilled nursing facilities. *Ann Intern Med*. 1992;116:369-374.
- van Schoor NM, Smit JH, Bouter LM, et al. Maximum potential preventive effect of hip protectors. *J Am Geriatr Soc*. 2007;55:507-510.

SUGGESTED READINGS

- Agostini JV, Baker DI, Bogardus STJ. *Prevention of Falls in Hospitalized and Institutionalized Older People: Making Health Care Safer: A Critical Analysis of Patient Safety Practices*. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
- Alexander N. Gait disorders in older adults. *J Am Geriatr Soc*. 1996;44:434-451.
- National Council on Aging. *Falls Free™ National Action Plan: A Progress Report*. Washington, DC: National Council on Aging; 2007.
- Tinetti ME. Preventing falls in elderly persons. *N Engl J Med*. 2003;348:42-49.
- Tinetti ME, Williams CS, Gill TM. Dizziness among older adults: a possible geriatric syndrome. *Ann Intern Med*. 2000;132:337-344.

CHAPTER 10

Immobility

Although mobility can be achieved by using various devices, the discussion here emphasizes walking. Immobility refers to the state in which an individual has a limitation in independent, purposeful physical movement of the body or of one or more lower extremities. Immobility can trigger a series of subsequent diseases and problems in older individuals that produce further pain, disability, and impaired quality of life. Optimizing mobility should be the goal of all members of the health-care team working with older adults. Small improvements in mobility can decrease the incidence and severity of complications, improve the patient's well-being, and decrease the cost and burden of caregiving.

This chapter outlines the common causes and complications of immobility and reviews the principles of management for some of the more common conditions associated with immobility in the older population.

CAUSES

Immobility can be caused by a wide variety of factors. The causes of immobility can be divided into intrapersonal factors including psychological factors (eg, depression, fear of falling or getting hurt, motivation), physical changes (cardiovascular, neurological, and musculoskeletal disorders, and associated pain), and environmental causes. Examples of these physical, psychological, and environmental factors include inappropriate caregiving, paralysis, lack of access to appropriate assistive devices, and environmental barriers such as lack of handrails on stairs or grab bars around a commode ([Table 10-1](#)).

The incidence of degenerative joint disease (DJD) is particularly high in older adults, although symptoms of disease may not manifest in all individuals who have radiographic changes (Lawrence et al., 2008). The pain and musculoskeletal changes associated with DJD can result in contractures and progressive immobility if not appropriately treated. In addition, podiatric problems associated with degenerative changes in the feet (eg, bunions and hammertoes) can likewise cause pain and contractures. These changes can result in painful ambulation and a subsequent decrease in the older individual's willingness and ability to ambulate. Patients who have had a stroke resulting in partial or complete hemiparesis/paralysis, spinal cord injury resulting in paraplegia or quadriplegia, fracture or musculoskeletal disorder limiting function, or prolonged bed rest after surgery or acute illness are considered immobilized. Approximately 8% of older adults in the 60- to 79-year age group experience a stroke, and this rate doubles in adults age 80 and above (American Heart Association and the American Stroke Association, 2012). About half of the individuals who suffer a stroke have residual deficits for which they require assistance, and often these deficits result in immobility. Parkinson disease (PD), another common neurological

TABLE 10-1. Common Causes of Immobility in Older Adults

Musculoskeletal disorders
Arthritides
Osteoporosis
Fractures (especially hip and femur)
Podiatric problems
Other (eg, Paget disease)
Neurological disorders
Stroke
Parkinson disease
Neuropathies
Normal-pressure hydrocephalus
Dementias
Other (cerebellar dysfunction, neuropathies)
Cardiovascular disease
Congestive heart failure (severe)
Coronary artery disease (frequent angina)
Peripheral vascular disease (frequent claudication)
Pulmonary disease
Chronic obstructive lung disease (severe)
Sensory factors
Impairment of vision
Decreased kinesthetic sense
Decreased peripheral sensation
Environmental causes
Forced immobility (in hospitals and nursing homes)
Inadequate aids for mobility
Acute and chronic pain
Other
Deconditioning (after prolonged bed rest from acute illness)
Malnutrition
Severe systemic illness (eg, widespread malignancy)
Depression
Drug side effects (eg, antipsychotic-induced rigidity)
Fear of falling
Apathy and lack of motivation

disorder found in older adults, can cause severe limitations in mobility. PD is a progressive neurological disorder that affects approximately 1% of the population over the age of 60 (European Parkinson’s Disease Association, 2012). As the disease progresses, it has a major impact on the individual’s function caused by the associated bradykinesia (slow movement) or akinesia (absence of movement), resting tremor, and muscle rigidity, as well as cognitive changes.

Severe congestive heart failure, coronary artery disease with frequent angina, peripheral vascular disease with frequent claudication, orthostatic hypotension, and severe chronic lung disease can restrict activity and mobility in many elderly patients because of lack of cardiovascular endurance. Peripheral vascular disease, especially in older diabetics, can cause claudication, peripheral neuropathy, and altered balance, all of which limit ambulation.

The psychological and environmental factors that influence immobility are as important as the physical changes noted. Depression, lack of motivation, apathy, fear of falling, and health beliefs (ie, a belief that rest and immobility are beneficial to recovery) can all influence mobility in older adults. Both the social and physical environment can have a major impact on mobility. Well-meaning formal and informal caregivers may provide care for older individuals rather than help the individual optimize their underlying function. Inappropriate use of wheelchairs, bathing, and dressing of individuals who have the underlying capability to engage in these activities results in deconditioning and immobility. Lack of mobility aids (eg, canes, walkers, and appropriately placed railings), cluttered environments, uneven surfaces, and the shape of and positioning of chairs and beds can further lead to immobility. Negotiating stairs can be a special challenge.

Drug side effects may also contribute to immobility. Sedatives and hypnotics can result in drowsiness, dizziness, delirium, and ataxia, and can impair mobility. Antipsychotic drugs (especially the typical antipsychotic agents) have prominent extrapyramidal effects and can cause muscle rigidity and diminished mobility. The treatment of hypertension can result in orthostatic hypotension or bradycardia such that the individual experiences dizziness and is unable to ambulate independently.

COMPLICATIONS

Immobility can lead to complications in almost every major organ system (Table 10-2). Prolonged inactivity or bed rest has adverse physical and psychological consequences. Metabolic effects include a negative nitrogen and calcium balance and impaired glucose tolerance. Older individuals can also experience diminished plasma volume and subsequent changes in drug pharmacokinetics. Immobilized older patients often become depressed, are deprived of environmental stimulation, and, in some instances, become delirious. Deconditioning can occur rapidly, especially among older individuals who have little physiological reserve.

Musculoskeletal complications associated with immobility include loss of muscle strength and endurance; reduced skeletal muscle fiber size, diameter, and capillarity; contractures; disuse osteoporosis; and DJD. The severity of muscle atrophy is related to the duration and magnitude of activity limitation. If left unchecked, this muscle wasting can lead to long-term sequelae, including impaired functional capacity and permanent muscle damage. Moreover, immobility exacerbates bone turnover by resulting in a rapid and sustained increase in bone resorption and a decrease in bone formation. The impact of immobility on skin can also be devastating. Varying degrees of immobility and decreased serum albumin significantly increase the risk for pressure ulcer development. Prolonged immobility results in cardiovascular deconditioning; the combination of deconditioned cardiovascular reflexes and diminished plasma volume can lead to postural hypotension. Postural hypotension may not only impair rehabilitative efforts but also predispose to falls and serious cardiovascular events such as stroke and myocardial infarction. Likewise, deep venous thrombosis and pulmonary embolism are well-known complications. Immobility, especially bed rest, also impairs

TABLE 10-2. Complications of Immobility

Skin
Pressure ulcers
Musculoskeletal
Muscular deconditioning and atrophy
Contractures
Bone loss (osteoporosis)
Cardiovascular
Deconditioning
Orthostatic hypotension
Venous thrombosis, embolism
Pulmonary
Decreased ventilation
Atelectasis
Aspiration pneumonia
Gastrointestinal
Anorexia
Constipation
Fecal impaction, incontinence
Genitourinary
Urinary infection
Urinary retention
Bladder calculi
Incontinence
Metabolic
Altered body composition (eg, decreased plasma volume)
Negative nitrogen balance
Impaired glucose tolerance
Altered drug pharmacokinetics
Psychological
Sensory deprivation
Delirium
Depression

pulmonary function. Tidal volume is diminished; atelectasis may occur, which, when combined with the supine position, predisposes to developing aspiration pneumonia.

Gastrointestinal and genitourinary problems are likewise influenced by immobility. Constipation and fecal impaction may occur because of decreased mobility and inappropriate positioning to optimize defecation. Urinary retention can result from inability to void lying down and/or rectal impaction impairing the flow of urine. These conditions and their management are discussed in Chapter 8. Immobility and spending more time in sedentary activity has also been associated with all-cause mortality (Bankoski et al., 2011).

ASSESSING IMMOBILE PATIENTS

Several aspects of the history and physical examination are important in assessing immobile patients (Table 10-3). Focused histories should address the intrapersonal aspect as well as the environmental issues associated with immobility. It is important to explore the underlying cause, or perceived cause, of the immobility on the part of the patient and caregiver. Specific contributing factors to explore include medical conditions, treatments (eg, medications, associated treatments such as intravenous lines), pain, psychological (eg, mood and fear) state, and motivational factors. Nutrition status, particularly protein levels and evaluation of 25-hydroxy vitamin D, is particularly useful to consider when evaluating the older patient because these have been associated with muscle weakness, poor physical performance, balance problems, and falls. An assessment of the environment is critical and should include both the patient's physical and social environment (particularly caregiving interactions). Any and all of these factors can decrease the individual's willingness to engage in activities. Although a comprehensive assessment is critical, other members of the health-care team (eg, social work, physical therapy) can facilitate these evaluations and provide at least an aspect of that assessment.

TABLE 10-3. Assessment of Immobile Older Patients	
History	
	Nature and duration of disabilities causing immobility
	Medical conditions contributing to immobility
	Pain
	Drugs that can affect mobility
	Motivation and other psychological factors
	Environment
Physical examination	
	Skin
	Cardiopulmonary status
Musculoskeletal assessment	
	Muscle tone and strength (see Table 10-4)
	Joint range of motion
	Foot deformities and lesions
Neurological deficits	
	Focal weakness
	Sensory and perceptual evaluation
Levels of mobility	
	Bed mobility
	Ability to transfer (bed to chair)
	Wheelchair mobility
	Standing balance
	Gait (see Chap. 9)
	Pain with movement

TABLE 10-4. Example of How to Grade Muscle Strength in Immobile Older Patients

- 0 = Flaccid
- 1 = Trace/slight contractility but no movement
- 2 = Weak with movement possible when gravity is eliminated
- 3 = Fair movement against gravity but not against resistance
- 4 = Good with movement against gravity with some resistance
- 5 = Normal with movement against gravity and some resistance

Upper extremity:

Shoulder extension: Have the individual hold up their arm at 90°. Place your hand on the individual's upper arm between elbow and shoulder and tell the individual not to let you push down their arm.

Elbow flexion: Have the individual bend their elbow fully and attempt to straighten the arm out while telling the individual not to let you pull the arm down.

Elbow extension: While the individual still has the elbow flexed, tell them to try and straighten out the arm while you resist.

Lower extremity:

Hip flexion: Place your hand on the individual's anterior thigh and ask them to raise the leg against your resisting hand (say to individual: don't let me push your leg down).

Knee extension: Have the individual bend their leg on the bed and place one of your hands just below the individual's knee and tell the individual to try and straighten out the leg as you resist.

Ankle plantar flexion: Have the individual extend their foot against your hand.

Ankle dorsiflexion: Have the individual pull their foot up against your hand.

In addition to the potential causes of immobility, the impact of immobility in older adults must always be considered. A comprehensive skin assessment should be done with a particular focus on bony prominences and areas of pressure against the bed, chair, splint, shoe, or any type of immobilizing device. Evaluation of lower extremities among those with known arterial insufficiency is critical. Cardiopulmonary status, especially intravascular volume, and postural changes in blood pressure and pulse are important to consider, particularly as these may further limit mobility. A detailed musculoskeletal examination, including evaluation of muscle tone and strength, evaluation of joint range of motion, and assessment of podiatric problems that may cause pain, should be performed. Standardized and repeated measures of muscle strength can be helpful in gauging a patient's progress (Table 10-4). The neurological examination should identify focal weakness as well as cognitive, sensory, and perceptual problems that can impair mobility and influence rehabilitative efforts.

Most importantly, the patient's function and mobility should be assessed and reevaluated on an ongoing basis. Assessments should include bed mobility; transfers, including toilet transfers; and ambulation and stair climbing (see Table 10-3). Pain, fear, resistance to activity, and endurance should simultaneously be considered during these evaluations. As previously noted, other members of the health-care team (eg, physical therapy, occupational therapy, and nursing) are skilled in completion of these assessments and are critical to the comprehensive evaluation of the patient.

MANAGEMENT OF IMMOBILITY

The goal in the management of any older adult is to optimize function and mobility to the individual's highest level. Medical management is central to assuring this goal because optimal management of underlying acute and chronic disease must be addressed to assure success. It is beyond the scope of this text to detail the management of all conditions associated with immobility in older adults; however, important general principles of the management of the most common of these conditions are reviewed. Brief sections at the end of the chapter provide an overview of key principles in the management of pain and the rehabilitation of geriatric patients.

■ Arthritis

Arthritis includes a heterogeneous group of related joint disorders that have a variety of causes such as metabolism, joint malformation, joint trauma, or joint damage. The pathology of osteoarthritis (OA) is characterized by cartilage destruction with subsequent joint space loss, osteophyte formation, and subchondral sclerosis. OA is the most common joint disease among older adults and is the major cause of knee, hip, and back pain. OA is not, by definition, inflammatory, although hypertrophy of synovium and accumulation of joint effusions are typical. It is currently believed that the pathogenesis of OA progression revolves around a complex interplay of numerous factors: chondrocyte regulation of the extracellular matrix, genetic influences, local mechanical factors, and inflammation.

Plain film radiography has been the main diagnostic modality for assessing the severity and progression of OA. Magnetic resonance imaging (MRI) and ultrasound, however, have been noted to be more accurate and comprehensive measures of joint changes. Once diagnosed, a wide variety of modalities can be used to treat OA as well as other painful musculoskeletal conditions. Treatment can be separated into three different categories: nonpharmacological, pharmacological, and surgical. Nonpharmacological management should be the focus of interventions and include weight loss, physical therapy to strengthen related musculature, use of local ice and heat, acupuncture, and use of exercise programs to maintain strength and function.

Pharmacological management is targeted toward symptomatic relief and includes use of analgesics (discussed further later), nonsteroidal anti-inflammatory drugs (NSAIDs), intraocular steroid injections, and viscosupplementation. In addition, topical nonsteroidals, arthroscopic irrigation, acupuncture, and nutraceuticals, which are a combination of pharmaceutical and nutritional supplements, have also been used. The most common nutraceuticals include glucosamine and chondroitin (Simon et al., 2010). Although there may be a placebo effect resulting in benefit to patients using glucosamine and chondroitin, there is no evidence of a significant improvement in pain (Simon et al., 2010). Likewise there is no evidence that vitamin D decreases pain or facilitates repair of structural damage among individuals with OA (Felson et al., 2007). Arthroscopic interventions have been recommended for situations in which there is known inflammation and when other noninvasive interventions have failed. Options include debridement and lavage, osteotomy, cartilage transplant,

and arthroplasty. There is little evidence, however, to support their efficacy (Moseley et al., 2002). Joint replacement should be reserved for individuals with severe symptomatic disease who do not respond to more conservative interventions. Patients referred for joint replacement should have stable medical conditions and be encouraged to lose weight and strengthen relevant muscles before the procedure. Optimal management often involves the use of multiple treatment modalities, and the best combination of treatments will vary from patient to patient.

Treating arthritis optimally requires a differential diagnosis because there are multiple different types of arthritic conditions and treatments may vary. For example, polymyalgia rheumatica is a common musculoskeletal problem for older women with symptoms that include weight loss; fever; muscle pain; aching of the neck, shoulder, and hip; and morning stiffness. Treatment involves use of steroids, such as prednisone, although methotrexate has been used as a corticosteroid-sparing agent and may be useful for patients with frequent disease relapses and/or corticosteroid-related toxicity. Conversely, infliximab has not been shown to be beneficial in terms of pain management or disease progression and thus is not currently recommended (Hernández-Rodríguez et al., 2009). Because of the close association between polymyalgia rheumatica and temporal arteritis, any symptoms suggestive of involvement of the temporal artery—headache, jaw claudication, recent changes in vision—especially when the sedimentation rate is very high (>75 mm/h), should prompt consideration of temporal artery biopsy. Acute treatment of temporal arteritis with high-dose steroids is needed to prevent blindness. The history and physical examination can be helpful in differentiating OA from inflammatory arthritis (Table 10-5); however, other procedures are often essential.

Gout, one of the oldest recognized forms of arthritis, is characterized by intra-articular monosodium urate crystals. Gout generally presents as acute, affecting the first metatarsal phalangeal joint, mid foot, or ankle, although the knee, elbow, or wrist can also be involved. Tophi, which are subcutaneous urate deposits on extensor surfaces, can develop in later phases of the disease and are sometimes confused with rheumatoid arthritis and associated nodules. Radiographs may reveal well-defined

TABLE 10-5. Clinical Features of Osteoarthritis Versus Inflammatory Arthritis		
Clinical feature	Osteoarthritis	Inflammatory arthritis
Duration of stiffness	Minutes	Hours
Pain	Usually with activity	Occurs even at rest and at night
Fatigue	Unusual	Common
Swelling	Common but little synovial reaction	Very common, with synovial proliferation and thickening
Erythema and warmth	Unusual	Common

gouty erosions in or around joints. Some patients will have elevated uric acid levels. The definitive diagnosis of gout is established by observing the presence of needle-shaped crystals in the involved joint. The goal of treatment is to terminate the acute attack and then prevent future attacks by considering underlying causes (eg, considering hypouricemic therapy). The acute phase of gout should be managed using short-term NSAIDs, colchicine, corticotrophin, and corticosteroids. Treatment choices should be based on patient comorbidities (eg, renal function, gastrointestinal disease). Treatment to decrease uric acid levels should not be initiated during the acute phase because drugs such as allopurinol or probenecid may exacerbate the acute attack. Due to renal changes associated with aging, allopurinol is recommended over probenecid in older individuals. Colchicine can be used for acute management as well as for prophylaxis. More recently, interleukin inhibitors have been found to be effective in the management of gout, particularly for individuals who cannot tolerate allopurinol (Stamp and Jordan, 2011).

In addition to making specific diagnoses of rheumatological disorders whenever possible, careful physical examination can detect treatable nonarticular conditions such as tendinitis and bursitis. Bicipital tendinitis and olecranon and trochanteric bursitis are common in geriatric patients. Dramatic relief from pain and disability from these conditions can be achieved by local treatments such as the injection of steroids.

Carpal tunnel syndrome is another common musculoskeletal disorder among older adults and can be confused for gout, rheumatoid arthritis, or pseudogout. Carpal tunnel syndrome involves the entrapment of the median nerve where it passes through the carpal tunnel of the wrist and thereby causes nocturnal hand pain, numbness, and tingling affecting the median nerve distribution in the hand. Further atrophy of the thenar eminence can develop when there has been persistent nerve compression. Nerve conduction studies are needed to make the diagnosis, and surgical intervention is often needed to relieve the nerve compression. For more conservative interventions, cock-up wrist splints, usually worn at night, isometric flexion exercises of metacarpal phalangeal joints, and steroid injections have been implemented.

■ Hip Fracture

Worldwide, the total number of hip fractures is expected to surpass 6 million by the year 2050. This varies, however, based on country and demographic factors such as gender and ethnicity. Recent evidence suggests, however, that there is a decline in incidence of hip fracture among both men and women in the United States and that mortality rates associated with these events are likewise decreasing (Brauer et al., 2009). It is not clear why these declines have occurred, although there is speculation that this is associated with the increased use of bisphosphonates for osteoporosis.

In the first year post hip fracture, older adults have a five- to eight-fold increased risk for all-cause mortality. Excess annual mortality persists over time for both women and men, but at any given age, excess annual mortality after hip fracture is higher in men than in women (Haentjens et al., 2010) and higher in the first year

after fracture. One year after hip fracture, approximately half of affected individuals do not regain their prefracture function with regard to activities of daily living or their ability to ambulate. After 3 months, there is generally no further improvement in overall function. Individuals do, however, improve their ability to ambulate across the first 12-month recovery period. The assessment and management of falls, the major cause of hip fracture, are discussed in Chapter 9.

The degree of immobility and disability caused by a hip fracture depends on several factors, including coexisting medical conditions, patient motivation, the nature of the fracture, and the techniques of management. Preexisting comorbid conditions such as OA, heart failure, or stroke make the recovery process all the more challenging. Patients with these underlying conditions and those with dementia are at especially high risk for poor functional recovery. There is evidence, however, that those with cognitive impairment who are exposed to rehabilitation services do improve functionally in a manner similar to those without impairment (Muir and Yohannes, 2009). The location of the fracture is especially important in determining the most appropriate management plan (Fig. 10-1). Subcapital fractures (which are inside the joint capsule) disrupt the blood supply to the proximal femoral head, thus resulting in a higher probability of necrosis of the femoral head and nonunion of the fracture. Replacement of the femoral head is often warranted in these cases. Inter- and




FIGURE 10-1 Characteristics of different types of hip fractures.

subtrochanteric fractures generally do not disrupt the blood supply to the femoral head, and open reduction and pinning are usually successful. Generally, arthroplasty has been shown to be more clinically effective and probably less costly over a 2-year period post surgery when compared with open reduction and fixation, bipolar hemiarthroplasty, and total arthroplasty (Butler et al., 2009; Carroll et al., 2011).

Generally, the current trend in hip fracture management is to stabilize any associated comorbid or acute medical conditions; surgically repair the hip, ideally with spinal anesthesia; and encourage early ambulation and aggressive rehabilitation. The current standard of care is for patients to receive prophylactic anticoagulation to prevent thromboembolic complications (Falck-Ytter et al., 2012) using low-molecular-weight heparin; fondaparinux; dabigatran, apixaban, or rivaroxaban (for total hip arthroplasty or total knee arthroplasty but not hip fracture surgery); low-dose unfractionated heparin; adjusted-dose vitamin K antagonist; aspirin (all grade 1B); or an intermittent pneumatic compression device for those who refuse treatment or are at increased risk for bleeding. Treatment should be for at least 10 to 14 days and ideally up to 35 days.

■ Parkinson Disease

The first step in successful management of Parkinson Disease (PD) is to recognize its presence. Pathologically, PD is associated with a progressive loss of dopamine-producing cells, especially in the substantia nigra, which sends dopamine to the corpus striatum. These structures, located in the basal ganglia, are stimulated by the neurotransmitter dopamine and are responsible for planning and controlling automatic movements of the body, such as walking, writing, or rising from a seated position. Once the level of dopamine loss has reached a threshold, individuals typically develop a triad of symptoms: bradykinesia (slow movement) or akinesia (absence of movement), resting tremor, and muscle rigidity. Many elderly patients, especially in long-term care institutions, have undiagnosed, treatable forms of parkinsonism. Some of these individuals have drug-induced parkinsonism resulting from the extrapyramidal side effects of antipsychotics (see Chapter 14). Nonmotor symptoms of PD are also common and include depression, psychosis, anxiety, sleep disturbances, dysautonomia, dementia, and others. Left untreated, parkinsonian patients eventually become immobile and can develop flexion contractures, pressure sores, malnutrition, and aspiration pneumonia.

Pharmacological treatment of PD is based on an attempt to increase the ratio of dopamine to acetylcholine in the central nervous system, specifically the nigrostriatal system. There are many drugs that are used in the treatment of the disease including amantadine, anticholinergic drugs, levodopa, monoamine oxidase inhibitors B (MAO-B), catechol O-methyltransferase (COMT), and dopamine agonists (Table 10-6). Clinical response may take several weeks; side effects are common and often limit pharmacological treatment. Wide variations in response can also occur, including morning akinesia, peak-dose dyskinesias, and freezing episodes (sometimes referred to as the “on–off phenomenon”). Excessive dopamine can also cause sleep disturbances, delirium, and psychosis. Alternative modes of drug delivery have been

TABLE 10-6. Drugs Used to Treat Parkinson Disease

Drug (brand name)	Usual dosages	Mechanism of action	Potential side effects
Carbidopa, levodopa (Sinemet)	40/400-200/2000 mg/day in divided doses*	Increases dopamine availability and decreases peripheral dopamine metabolism	Nausea, vomiting, anorexia Dyskinesias Orthostatic hypotension Behavioral disturbances Vivid dreams and hallucinations
Amantadine (Symmetrel)	100-300 mg/day†	Increases dopamine release	Delirium and hallucinations
Bromocriptine (Parlodel)	1-1.5 mg tid or qid (initial); gradually increase to maximum of 30-40 mg in divided doses	Directly activates dopaminergic receptors	Behavioral changes Hypotension Nausea
Pramipexole (Mirapex)	0.5-1.5 mg tid	Dopamine agonist	Hallucinations Nausea Somnolence
Ropinirole (Requip)	3-8 mg tid	Dopamine agonist	Orthostatic hypotension Syncope Nausea Somnolence
Anticholinergic agents,‡ trihexyphenidyl (Artane, Tremin)	2-20 mg/day in divided doses	Decreases effects of acetylcholine and helps to restore balance between cholinergic and dopaminergic systems	Dry mouth Constipation Urinary retention Blurred vision Exacerbation of glaucoma Tachycardia Confusion Behavioral changes

Benztropine mesylate (Cogentin)	0.5-8.0 mg/day in divided doses		
Selegiline (Eldepryl)	10 mg/day in one dose	MAO-B inhibitor	As above Nausea Confusion Agitation Insomnia Involuntary movements
Rasagiline (Azilect)	1 mg/day in one dose	Selective, irreversible MAO-B inhibitor	Balance difficulties Anorexia Vomiting Weight loss Depressive symptoms No dietary restrictions
Entacapone (Comtan)	200 mg with each dose of levodopa	Inhibits catechol methyltransferase	Nausea Dyskinesias Orthostatic hypotension Diarrhea
Tolcapone (Tasmar)	100-200 mg tid		Liver dysfunction [§]

*Top number represents carbidopa; bottom number, levodopa.

[†]Eliminated by kidney; dosages should be adjusted when renal function is diminished.

[‡]Several other anticholinergic agents are available.

MAO-B, monoamine oxidase type B.

considered in the treatment of PD. Rotigotine transdermal patch (Neupro®), which is a nonergolinic dopamine agonist, is being used in Europe in combination with levodopa. The ease of administration and maintenance of blood levels may have some benefit over other modes of administration. In addition, there is evidence to support the use of cholinesterase inhibitors in patients with PD-associated dementia, with a positive impact on global assessment (Rolinski et al., 2012). Several preliminary studies have demonstrated that coenzyme Q10 can protect the nigrostriatal dopaminergic system among patients with PD, although further research is needed (Liu et al., 2011). Given the variability noted in response to drug therapy, there is an increased interest in pharmacogenetics with regard to management of PD. More individualized approaches to medication management are anticipated in the future (Kalinderi et al., 2011).

Surgical options are also gaining more attention and are a viable choice for a select group of individuals, including thalamotomy, pallidotomy, and deep brain stimulation interventions (Murdoch, 2010). Although less common, intraputamenal fetal mesencephalic allografts have also been used to treat patients with PD.

Despite the many challenges to engaging older adults in exercise activities and to demonstrating outcomes, there is some evidence to support the benefits of exercise among patients with PD (Goodwin et al., 2011). Specifically, combinations of aerobic, strengthening, balance, and stretching exercise programs can improve balance among those with PD.

■ Stroke

To prevent the progression of immobility moving toward disability and subsequent complications, patients with completed strokes should receive prompt and intensive rehabilitative therapy. (Stroke is also discussed in Chapter 11.) In many elderly patients, coexisting medical conditions (eg, cardiovascular disease) limit the intensity of rehabilitation treatment that can be tolerated in order to qualify for Medicare coverage in an acute inpatient or skilled nursing facility. However, all patients should be evaluated and managed as actively as possible during the first several weeks after a stroke. Although all stroke patients deserve an assessment and consideration for intensive rehabilitation, the cost-effectiveness of various approaches to stroke rehabilitation is controversial, and there is no evidence to support or guide the amount of time spent in therapy sessions. Whether the rehabilitative efforts occur in the acute care hospital, special rehabilitation unit, nursing home, or at home, these efforts should involve a multidisciplinary rehabilitation team, and the basic principles remain the same (see Rehabilitation later in this chapter).

Despite the lack of data from controlled trials, even some of the most severely affected stroke patients can achieve meaningful improvements in functional status by early rehabilitative efforts. Although complete functional recovery occurs in less than half of stroke patients, immobility and its attendant complications can almost always be prevented or minimized. Treadmill training, for example, has repeatedly shown significant benefits in gait and balance among stroke survivors. There is interest in using brain-computer interfaces to facilitate rehabilitation after stroke. Innovative interventions with motor

training consisting of voluntary movements assisted by a robot device have been tested with some positive benefits noted (Yang et al., 2012). In addition to innovative and intensive rehabilitation in the immediate poststroke period, ongoing exercise and physical activity are critical after stroke to maintain optimal function and quality of life and to prevent future strokes. The management of older patients with cerebrovascular disease is discussed further in Chapter 11.

■ Pressure Ulcers

A pressure ulcer is defined as damage caused to the skin and underlying soft tissue by unrelieved pressure when the tissue is compressed between a bony prominence and external surface over a period of time. Three main factors contribute to the development of pressure sores: pressure, shearing forces, and friction. The amount of pressure necessary to occlude blood supply to the skin (and thus predispose to irreversible tissue damage) depends on the quality of the tissue, blood flow to the area, and the amount of pressure applied. For example, in a patient with peripheral artery disease, heel pressure over a relatively short period of time may cause an ulceration to occur.

Shearing forces (such as those created when the head of a bed is elevated and the torso slides down and transmits pressure to the sacral area) contribute to the stretching and angulation of subcutaneous tissues. Friction, caused by the repeated movement of skin across surfaces such as bed sheets or clothing, increases the shearing force. This can eventually lead to thrombosis of small blood vessels, thus undermining and then destroying skin. Shearing forces and friction are worsened by loose, folded skin, which is common in the elderly because of loss of subcutaneous tissue and/or dehydration. Moisture from bathing, sweat, urine, and feces compounds the damage. In light of the many risk factors and their variable influence, numerous scales have been developed to quantify a person's risk of developing pressure ulcers. The two most commonly used scales are the Braden scale (<http://www.bradenscale.com/>) and the Norton scale (<http://www.orthotecmedical.com/pdfs/Norton.pdf>). Pressure ulcers can be classified into four stages, depending on their clinical appearance and extent (Table 10-7) (Reed, 2012). The area of damage below the pressure ulcer can be much larger than the ulcer itself. This is caused by the manner in which pressure and shearing forces are transmitted to subcutaneous tissues. More than 90% of pressure ulcers occur in the lower body—mainly in the sacral and coccygeal areas, at the ischial tuberosities, and in the greater trochanter area.

The cornerstone of management of the skin in immobile patients is prevention of pressure ulcers (Table 10-8) (European Pressure Ulcer Advisory Panel, 2010). Once a stage I or II pressure ulcer develops, all preventive measures listed in Table 10-8 should be used to avoid progression of the ulcer, and intensive local skin care must be instituted. Many techniques have been advocated for local skin care; none is more successful than the others. The most important factor in all these techniques is the attention that the skin gets, including relief from pressure. Almost any technique that involves removing pressure from the area and regularly cleansing and drying the skin will work. Alternating pressure mattresses and alternating pressure overlays

TABLE 10-7. Clinical Characteristics of Pressure Sores	
Characteristics	Diagnostic tips
Stage I Acute inflammatory response limited to epidermis Presents as irregular area of erythema, induration, edema; may be firm or boggy Often over a bony prominence Skin is unbroken	Pressure areas at stage I do not blanch when pressed May be different with different skin pigments Redness with pressure persists after 30 min; in dark skin the color may be red, blue, or a purple hue
Stage II Extension of acute inflammatory response through dermis to the junction of subcutaneous fat Appears as a blister, abrasion, or shallow ulcer with more distinct edges Early fibrosis and pigment changes occur	May look like an abrasion or a blister
Stage III Full-thickness skin ulcer extending through subcutaneous fat. This may extend down to but not through the underlying fascia The skin may have undermining Base of ulcer infected, often with necrotic, foul-smelling tissue	This presents like a crater and may have undermining of the adjacent tissue
Stage IV Extension of ulcer through deep fascia, so that bone is visible at base of ulcer Osteomyelitis and septic arthritis can be present	Undermining is even more common and there may be sinus tracts

are equally effective in terms of prevention and management of pressure ulcers. Likewise, addressing nutrition and hydration of the patient is critical.

Treatment of pressure ulcers includes the use of a variety of occlusive dressings depending on the stage of the wound, degree of drainage, and evidence of infection. Several forms of energy have been used in the management of pressure ulcers. These include acoustic, mechanical, and kinetic energy, as well as energy from the electromagnetic spectrum (EMS). Infrared (thermal) radiation, ultraviolet light (invisible light), and laser (coherent and monochromatic light) are all part of the EMS, as is electrical/electromagnetic stimulation. Phototherapy (including laser, infrared, and

TABLE 10-8. Principles of Skin Care in Immobile Older Patients**Preventive**

- Identify patients at risk
- Decrease pressure, friction, and skin folding
- Keep skin clean and dry
- Avoid excessive bed rest: optimize and encourage function
- Avoid oversedation

Provide adequate nutrition and hydration (30-35 kcal/kg) overall, protein (1-1.5 g/kg), and fluid (1 mL/kcal)

Stages I and II pressure sores

- Clean wounds with warm, normal saline or water
- Avoid pressure and moisture
- Cover open wounds with an occlusive dressing: determined based on ulcer condition (eg, presence of granulation, necrotic tissue), type and amount of drainage, surrounding tissue, and evidence of infection
- Prevent further injury and infection: use antibiotics very judiciously
- Provide intensive local skin care*
- Manage associated pain

Stage III pressure sores

- Debride necrotic tissue: autolytic, chemical, mechanical, sharp, or surgical options
- Cleanse and dress wound as above*
- Culture wound: treat only in cases of confirmed bacteremia, sepsis, osteomyelitis, and cellulitis†
- Manage associated pain

Stage IV pressure sores

- Take tissue biopsy for culture
- Use systemic antimicrobials as noted in stage III
- Cleanse and dress wound as above
- Have surgical consultation to consider surgical repair
- Manage associated pain

*Many techniques are effective (see text).

†Cultures and topical antimicrobials should not be used routinely (see text).

ultraviolet), hydrotherapy, whirlpool, and pulsatile lavage with suction oxygen also are effective options for treating pressure ulcers. There is not, however, sufficient evidence to support the use of hyperbaric oxygen therapy, topical oxygen therapy, or biological dressings in the treatment of pressure ulcers. There is some clinical evidence to support the use of platelet-derived growth factor, although the evidence is not sufficient to recommend that this be used routinely.

The management of stage III and IV pressure ulcers is more complicated. Debridement of necrotic tissue and frequent irrigation (two to three times daily), cleansing (with saline or peroxide), and dressing of the wound are essential. Eschars should be undermined and removed if they are suspected of hiding large amounts of necrotic and infected tissue. Chemical debriding agents can be helpful. The role of

wound cultures and antimicrobials in the management of stage III pressure ulcers is controversial. Topical antimicrobials may be useful, especially when bacterial colony counts are high, but they are generally not recommended. Systemic antimicrobials should not be used because they do not reach sufficient concentrations in the area of the ulcer; topical therapy will be more effective unless cellulitis is present. Routine wound cultures are probably not warranted for stage III lesions because they almost always grow several different organisms and do not detect anaerobic bacteria, which are often pathogenic. Results of such cultures generally reflect colonization rather than infection. Once a lesion has progressed to stage IV, systemic antimicrobials are often necessary. Routine and anaerobic cultures of tissue or bone are most helpful in directing antimicrobial therapy. Patients with large pressure ulcers that become septic should be treated with broad-spectrum antimicrobials that will cover anaerobes, gram-negative organisms, and *Staphylococcus aureus*. In selected instances, consideration of plastic surgery for stage IV lesions is warranted.

Documentation of pressure sores is critical and should include the following components: (1) the type of ulcer, how long it has been present, and in what setting it occurred; (2) the size measured as length \times width \times depth in centimeters (area of the wound bed that is deepest, without a tract); (3) the color as percentage, with red indicating amount of granulation tissue, yellow indicating the amount of slough present, and black being necrotic tissue or eschar; (4) exudate as serous, serosanguinous, sanguinous, or purulent; (5) the presence or absence of odor in the wound (this should be determined after the wound is thoroughly cleaned); (6) description of the periwound tissues (eg, viable, macerated, inflamed, or hyperkeratotic); and (7) evidence of undermining (undermining is a separation of the tissues between the surface and the subcutaneous tissues).

PAIN MANAGEMENT

Pain is a major cause of immobility in older adults. Immobility, in turn, can exacerbate painful conditions and create a vicious cycle of pain, decreased mobility, and increased pain. The American Geriatrics Society has published recommendations of an expert panel for the management of persistent pain in older adults, and readers are referred to this publication for more details (American Geriatrics Society, 2009). (Pain is also discussed in Chapter 3.). Pain assessment and management tools are available at the Sigma Theta Tau Geriatric Pain website (<http://www.geriatricpain.org/Pages/home.aspx>).

Pain in older persons is commonly underdiagnosed and undertreated despite the availability of many assessment tools and effective therapeutic interventions. Pain is now viewed as a “fifth vital sign,” and health professionals are encouraged to routinely inquire about pain. When pain is identified, it should be carefully characterized. In addition to the standard questions about location, timing, aggravating factors, and the like, a simple standardized pain scale can be helpful in rating the severity of pain. Several such scales are available, as noted earlier, with some scales being more appropriate for those with cognitive impairment who may be less able

to communicate and describe their pain (<http://www.geriatricpain.org/Pages/home.aspx>). Pain during any type of activity may be diagnosed in these individuals based on evidence of agitation, moaning, becoming tense or rigid during movement, grimacing, or hitting or pushing the caregiver away, among other types of behaviors.

The degree to which pain interferes with activities of daily living and sleep is especially important to explore among older adults. Recurrent or persistent pain can result in complications such as a predisposition to falling because of deconditioning, fatigue, behavioral problems, depression, and impaired quality of life. It is important to discuss pain management options with older adults and to assess pain on an ongoing basis to determine if it has been resolved, if treatment is tolerable (ie, drug side effects), or if there is a need to alter the pain management regimen.

It is useful to differentiate between nociceptive pain and neuropathic pain. The former, includes somatic pain arising from the skin, bone, joint, muscle, or connective tissue and is often described as throbbing; visceral pain, which arises from internal organs such as the large intestine or pancreas. The latter is pain sustained by abnormal processing of sensory input by the peripheral or central nervous system. Neuropathic pain is generally described as burning, tingling, shock-like, or shooting. Differentiating pain helps to guide management strategies and assures more efficient pain relief. Pain management should consider nonpharmacological and pharmacological approaches. Nonpharmacological approaches include cold therapy, breathing exercises and guided imagery, distraction, heat, massage, music, positioning, acupuncture, relaxation, and physical activity, particularly exercises that focus on strengthening muscles around the joint.

The mainstay of pain management is drug therapy (American Geriatrics Society, 2009). **Table 10-9** lists drugs that can be helpful in managing pain in older adults. For persistent pain, most experts recommend initiating treatment with acetaminophen and the use of topical treatments such as capsaicin or ketamine gel or combination gels, lidocaine patches, or local intra-articular corticosteroid injections. Nonselective NSAIDs and cyclooxygenase-2 (COX-2) selective inhibitors should be avoided and only considered rarely, with caution, in highly selected individuals. If pain management is not controlled with nonpharmacological interventions and acetaminophen, consideration should be given to adding an opioid when pain is impacting function and quality of life (see Table 10-9). The side effects of opioids are well known and include respiratory depression, sedation, constipation, nausea, vomiting, and delirium. Side effects should be anticipated and a plan of care is initiated as prevention (<http://www.geriatricpain.org/Content/Management/Interventions/Documents/Side%20Effects.pdf>).

Nonopioid medications to treat persistent pain include a group of treatment options referred to as adjuvant therapy and include antidepressants such as the selective serotonin reuptake inhibitors (SSRIs) and tricyclics and anticonvulsants. Tricyclic antidepressants were the first drugs used in this way, but due to their significant anticholinergic side effects including dry mouth, urinary retention, constipation, delirium, tachycardia, and blurred vision, they are contraindicated in older adults. SSRIs and mixed serotonin and norepinephrine reuptake inhibitors (SNRIs)

TABLE 10-9. Types of Pain, Examples, and Treatment

Type of pain and examples	Source of pain	Typical description	Effective drug classes and treatment
Nociceptive: somatic			
Arthritis, acute postoperative, fracture, bone metastases	Tissue injury, eg, bones, soft tissue, joints, muscles	Well localized, constant; aching, stabbing, gnawing, throbbing	Nonopioids, NSAIDs, opioids Physical and cognitive-behavioral therapies
Nociceptive: visceral			
Renal colic, bowel obstruction	Viscera	Diffuse, poorly localized, referred to other sites, intermittent, paroxysmal; dull, colicky, squeezing, deep, cramping; often accompanied by nausea, vomiting, diaphoresis	Treatment of underlying cause, APAP, opioids Physical and cognitive-behavioral therapies
Neuropathic			
Cervical or lumbar radiculopathy, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, poststroke syndrome, herniated intervertebral disc	Peripheral or central nervous system	Prolonged, usually constant, but can be paroxysmal; sharp, burning, pricking, tingling, squeezing; associated with other sensory disturbances, eg, paresthesias and dysesthesias; allodynia, hyperalgesia, impaired motor function, atrophy, or abnormal deep tendon reflexes	Tricyclic antidepressants, anticonvulsants, opioids, topical anesthetics Physical and cognitive-behavioral therapies
Undetermined			
Myofascial pain syndrome, somatoform pain disorders	Poorly understood	No identifiable pathologic processes or symptoms out of proportion to identifiable organic pathology; widespread musculoskeletal pain, stiffness, and weakness	Antidepressants, antianxiety agents Physical, cognitive-behavioral, and psychological therapies

Reprinted with permission from Reuben DB, Herr KA, Pacala JT, et al. *Geriatrics at Your Fingertips: 2012*, 14th ed. New York, NY: The American Geriatrics Society; 2012.

are more effective in the treatment of pain, particularly neuropathic pain, and have much better side effect profiles. Anticonvulsant drugs, such as gabapentin and pregabalin, are also effective for neuropathic pain and tend to have fewer side effects than some of the older anticonvulsants. Corticosteroids are long known to be effective in the management of pain, particularly when there is associated inflammation. Adverse effects with the short-term use of steroids include delirium, fluid retention, hyperglycemia, and immunosuppression.

A few drugs should be avoided when managing pain in older adults, unless no other alternative is effective. Muscle relaxant drugs such as cyclobenzaprine, carisoprodol, and chlorzoxazone, among others, have not been shown to be effective for muscle spasm and pain and should be avoided because of the associated fall risk when they are used. Likewise benzodiazepines are not likely to be effective for pain management unless used on a trial basis to treat muscle spasm. Meperidine is metabolized to normeperidine, a substance that has no analgesic properties but may impair kidney function and cause tremulousness, myoclonus, and seizures. Tramadol, a drug that combines opioid-receptor binding and norepinephrine and serotonin reuptake inhibition, lowers the seizure threshold and should not be given when the individual is taking other medications with serotonergic properties.

EXERCISE

Exercise is a critical intervention for preventing immobility and its complications and is also discussed in Chapter 5. Meta-analytic reviews have provided strong evidence that participation in either nonspecific physical activity or specific aerobic or resistive exercise is associated with decreased progression of DJD, which is critical for maintaining mobility.

The specific amount of exercise needed to achieve the desired benefit varies based on individual goals and capabilities. Combining recommendations from the American College of Sports Medicine, the Centers for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH), health-care providers should recommend that older adults engage in 30 minutes of physical activity *daily*, and this activity should incorporate aerobic activity (walking, dancing, swimming, biking), resistance training, and flexibility. Exercises can be done individually or in group settings depending on the individual's preference, cognitive ability, and motivational level.

In light of the many benefits of physical activity and the relatively low risk of serious adverse events associated with low- and moderate-intensity physical activity, current guidelines from a consensus group from the American Heart Association and the American College of Cardiology (U.S. Preventive Services Task Force, 2004) no longer recommend routine stress testing for those initiating a physical activity. For sedentary older people who are asymptomatic, low-intensity physical activity can be safely initiated regardless of whether an older adult has had a recent medical evaluation. Moreover, sedentary behavior may create more of a risk than moderate-level physical activity. Resources are readily available for older adults interested in getting more information about the type and amount of exercise to do. For example, the

National Institute of Aging provides free exercise booklets that cover a basic exercise program including resistive, stretching, balance, and aerobic activities, and Go4Life DVD, video, and printed materials are likewise available at no cost (<http://www.nia.nih.gov/health/publication/go4life-dvd-everyday-exercises-national-institute-aging>).

REHABILITATION

The goal of rehabilitation is to restore function and prevent further disability. The goal of restorative care is to continue to focus on the restoration and/or maintenance of physical function by compensating for functional impairments so that the individual maintains his or her highest level of function and increases time spent in physical activity. Maintaining a restorative philosophy of care is therefore a core element of geriatric practice, especially for immobile elderly patients. Implementing this philosophy of care necessitates a team effort. Psychiatrists and physical and/or occupational therapists can be very helpful in developing appropriate and optimal rehabilitative and restorative plans for older adults across the care continuum. It is beyond the scope of this text to provide a detailed discussion of rehabilitation in the older adult. **Table 10-10** outlines some of the key principles. Careful assessment of a patient’s function and underlying capability, the setting of realistic goals, prevention of secondary disabilities and complications of immobility, evaluation of the environment, and adapting the environment to the patients’ abilities (and vice versa) are all essential elements of the rehabilitation process. Moreover, ongoing motivation of the older individual as well as the caregivers is critical to successful rehabilitation and restoration of function (Resnick, 2011). The expertise of an interdisciplinary team, specifically physical and occupational therapists, can be extremely valuable in

TABLE 10-10. Basic Principles of Rehabilitation in Older Patients
Optimize the treatment of underlying diseases, nutrition and hydration, and psychosocial situation
Optimize the physical environment with regard to encouraging function and physical activity (eg, handrails, open access)
Optimize the care environment so that patient participation in functional activities and physical activities is optimized (eg, so that care is not task focused)
Prevent secondary disabilities and complications of immobility
Treat primary disabilities
Set realistic, individualized goals
Emphasize functional independence
Set measurable goals related to functional performance
Enhance residual functional capacities
Provide adaptive tools to maximize function
Adapt the environment to the patient’s functional disabilities when feasible
Attend to motivation and other psychological factors of both patients and caregivers
Use a team approach

assessing, treating, motivating, and monitoring patients whose mobility is impaired. Physical therapists generally attend to the relief of pain, muscle strength and endurance, joint range of motion, and gait. They use a variety of treatment modalities (Table 10-11). Occupational therapists focus on functional abilities, especially as they relate to activities of daily living. They make detailed assessments of mobility and help patients improve or adapt to their abilities to perform basic and instrumental activities of daily living. Even when mobility and function remain impaired, occupational therapists can make life easier for these patients by performing environmental assessments and recommending modifications and assistive devices that will improve the patients' ability to function independently (Table 10-12). Speech therapists are helpful in assessing and implementing rehabilitation for disorders of communication and swallowing. Nursing and informal caregivers have the responsibility of ongoing encouragement of older adults to engage in the activities recommended by these therapists (eg, walking to the bathroom, participating in exercise classes, or completing specific strength training activities).

Rehabilitation services can occur in an acute hospital, skilled nursing facility, an outpatient clinical setting, or at home. Rehabilitation provided at an acute level of care, such as in stroke rehabilitation, is generally limited in terms of length of stay and depends on the older individual's goals and demonstration of progress toward goal achievement. Inpatient rehabilitation covered by Medicare requires 3 hours a day of therapy by at least two out of the three therapists (physical, occupational,

TABLE 10-11. Physical Therapy in the Management of Immobile Older Patients

Objectives
Relieve pain
Evaluate, maintain, and improve joint range of motion
Evaluate and improve strength, endurance, motor skills, and coordination
Evaluate and improve gait and stability
Assess the need for and teach the use of assistive devices for ambulation (wheelchairs, walkers, canes)
Treatment modalities
Exercise
Active (isometric and isotonic)
Passive
Encourage sitting exercise programs
Heat
Hot packs
Paraffin
Diathermy
Ultrasound
Hydrotherapy
Ultrasound
Transcutaneous electrical nerve stimulation

TABLE 10-12. Occupational Therapy in the Management of Immobile Older Patients

Objectives

- Restore, maintain, and improve ability to function independently
- Evaluate and improve sensory and perceptual motor function
- Evaluate and improve ability to perform ADLs
- Fabricate and fit splints for upper extremities
- Improve coping and problem-solving skills
- Improve use of leisure time

Modalities

- Assessment of mobility
 - Bed mobility
 - Transfers
 - Wheelchair propulsion
- Assessment of other ADLs using actual or simulated environments
 - Dressing
 - Toileting
 - Bathing and personal hygiene
 - Cooking and cleaning

- Visit home for environmental assessment and recommendations for adaptation
- Provide task-oriented activities (eg, crafts, projects)
- Recommend and teach use of assistive devices (eg, long-handled reachers, special eating and cooking utensils, sock aids)
- Recommend and teach use of safety devices (eg, grab bars and railing, raised toilet seats, shower chairs)

ADLs, activities of daily living.

or speech therapy). At this level of care, the patient is seen by a physician or designated provider daily and receives 24-hour nursing rehabilitation care. Reimbursement is based on case-mix groups using the Functional Independence Measure. At the skilled level of care (Medicare Part A), rehabilitation is somewhat less rigorous, although most Medicare intermediaries will require that a patient show significant rehabilitation potential and steady improvement toward some predetermined goal. At this level, a physician must supervise the care, but daily visits are not required. Reimbursement is based on prospective payment according to resource utilization groups (obtained from the Minimum Data Set). Once the older individuals' goals are achieved, continued rehabilitation services can occur under Medicare Part B 3 days a week at home or in an institutional setting.

The benefit of rehabilitation services in one site, or at one level, versus another has not been well established. Some of the variation may depend on the specific facility in which the care is provided and the philosophy of care that is implemented by the direct caregivers. For example, in inpatient rehabilitation settings, it is critical that the time spent outside of therapy should continue to implement a rehabilitation focus of care in which the older adults are encouraged to practice activities such as bathing, dressing, and ambulation in their real-world settings (Resnick, 2011).

Summary of Evidence

Do's

- Focus on nonpharmacological management of arthritis such as weight loss, physical therapy, exercise, local ice/heat treatment, and acupuncture.
- Treat the acute phase of gout with pharmacological interventions to manage symptoms including nonsteroidals, colchicines, or corticosteroids, as tolerated by the patient.
- Treat Parkinson disease with pharmacological interventions to increase the ratio of dopamine to acetylcholine in the central nervous system.
- Encourage exercise interventions in patients with stroke to improve balance and recovery.

Don'ts

- Recommend surgical interventions for arthritis such as debridement, lavage, ostomy, cartilage transplant, or arthroplasty.
- Start treatments to decrease uric acid levels during acute gout attacks.
- Use hyperbaric oxygen, topical oxygen, or biological dressings to treat pressure ulcers.

Consider

- Joint replacement for individuals with severe arthritis.
- Exercise as a treatment option in patients with Parkinson disease to improve balance, function, and quality of life.
- Innovative interventions after stroke using motor training via robotics.

If formal or informal caregivers provide the care (eg, bathe and dress) for the individual who has independent goals, it is unlikely that the goals will be achieved. Similarly, exemplary rehabilitation services are of little value if after completion of rehabilitation the individual is no longer encouraged to do such things as walk to the dining room. While the caregivers may be well intended and believe that “helping” and demonstrating “caring” is best shown by providing hands-on care services, this type of care only creates deconditioning and dependency, along with contractures and the other sequelae of immobility. Therefore, regardless of site of service, a rehabilitative or restorative philosophy of care should be implemented so as to maintain and optimize the function of each older individual.

REFERENCES

- American Geriatrics Society. AGS clinical practice guideline: pharmacological management of persistent pain in older persons. 2009. Available at: http://www.americangeriatrics.org/health_care_professionals/clinical_practice/clinical_guidelines_recommendations/2009/. Accessed December 9, 2012.
- American Heart Association and the American Stroke Association. Statistical Fact Sheet 2012 Update: older Americans and cardiovascular diseases. 2012. Available at: http://www.heart.org/idc/groups/heart-public/@wcm/@sop/@smd/documents/downloadable/ucm_319574.pdf. Accessed December 9, 2012.

- Bankoski A, Harris TB, McClain JJ, et al. Sedentary activity associated with metabolic syndrome independent of physical activity. *Diabetes Care*. 2011;34:497-503.
- Brauer C, Coca-Perraillon M, Cutler DM, et al. Incidence and mortality of hip fractures in the United States. *JAMA*. 2009;302:1573-1579.
- Butler M, Forte M, Kane RL, et al. Treatment of common hip fractures. Rockville, MD: Prepared by the Minnesota Evidence-Based Practice Center for the Agency for Healthcare Research and Quality under Contract No. 290-2007-10064-1; Evidence Report/Technology Assessment No. 184, AHRQ Publication No. 09-E-13; 2009.
- Carroll C, Stevenson M, Scope A, Evans P, Buckley S. Hemiarthroplasty and total hip arthroplasty for treating primary intracapsular fracture of the hip: a systematic review and cost-effectiveness analysis. *Health Technol Assess*. 2011;15:1-74.
- European Parkinson's Disease Association. Prevalence of Parkinson's disease. 2012. Available at: <http://www.parkinsonsawareness.eu.com/en/campaign-literature/prevalence-of-parkinsons-disease/>. Accessed December 9, 2012.
- European Pressure Ulcer Advisory Panel (EPUAP). Pressure ulcer prevention: quick reference guide. 2010. Available at: http://www.npuap.org/Final_Quick_Prevention_for_web_2010.pdf. Accessed December 9, 2012.
- Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141:e278S-e325S.
- Felson D, Niu J, Clancy M, et al. Low levels of vitamin D and worsening of knee osteoarthritis: results of two longitudinal studies. *Arthritis Rheum*. 2007;56:129-136.
- Goodwin V, Richards SH, Henley W, et al. An exercise intervention to prevent falls in Parkinson's disease: a randomized controlled trial. *J Neurol Neurosurg Psychiatry*. 2011;82:1185-1186.
- Haentjens P, Magaziner J, Colón-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. *Arch Intern Med*. 2010;152:380-390.
- Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X. Treatment of polymyalgia rheumatica: a systematic review. *Arch Intern Med*. 2009;169:1839-1850.
- Kalinderi K, Fidani L, Katsarou Z, Bostantjopoulou S. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. *Int J Clin Pract*. 2011;65:1289-1294.
- Lawrence R, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. *Arthritis Rheum*. 2008;58:26-35.
- Liu J, Wang L, Zhan S, Xia Y. Coenzyme Q10 for Parkinson's disease. *Cochrane Database Syst Rev*. 2011;12: CD008150.
- Moseley JB, O'Malley K, Petersen NJ, et al. A Controlled Trial of Arthroscopic Surgery for Osteoarthritis of the Knee. *N Engl J Med*. 2002;347:81-88.
- Muir S, Yohannes AM. The impact of cognitive impairment on rehabilitation outcomes in elderly patients admitted with a femoral neck fracture: a systematic review. *J Geriatr Phys Ther*. 2009;32:24-32.
- Murdoch B. Surgical approaches to treatment of Parkinson's disease: implications for speech function. *Int J Speech Lang Pathol*. 2010;12:375-384.
- Reed L. Test your pressure sore knowledge: slideshow to grade ulcers. 2012. Available at: <http://reference.medscape.com/features/slideshow/pressure-ulcers>. Accessed December 9, 2012.
- Resnick B. *Restorative Care Nursing for Older Adults*. New York, NY: Springer; 2011.

- Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. *Cochrane Database Syst Rev*. 2012;3:CD006504.
- Simon W, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. *BMJ*. 2010;341:c4675.
- Stamp L, Jordan S. The challenges of gout management in the elderly. *Drugs Aging*. 2011;28:591-603.
- U.S. Preventive Services Task Force. Screening for coronary heart disease: recommendation statement. *Ann Intern Med*. 2004;140:569-572.
- Yang CL, Lin KC, Chen HC, Wu CY, Chen CL. Pilot comparative study of unilateral and bilateral robot-assisted training on upper-extremity performance in patients with stroke. *Am J Occup Ther*. 2012;66:198-206.

SUGGESTED READING

- Guccione AA, Wong RA, Avers D. *Geriatric Physical Therapy*. St Louis, MO: Elsevier; 2011.
- Kanis J, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. *Osteoporos Int*. 2012;23:2239-2256.
- van der Ploeg HP, Chey T, Korda MJ, Banks E, Bauman A. Sitting time and all-cause mortality risk in 222,497 Australian adults. *Arch Intern Med*. 2012;172:494-500.

This page intentionally left blank

PART III

GENERAL MANAGEMENT STRATEGIES

This page intentionally left blank

CHAPTER 11

Cardiovascular Disorders

In older adults, heart disease is the leading cause of death worldwide and is the most common cause for hospitalization. Physiological changes of the cardiovascular system in aging may modify the presentation of cardiac disease.

PHYSIOLOGICAL CHANGES

In using data on physiological changes of the cardiovascular system, it is important to recognize the selection criteria of the population studied. Because the prevalence of coronary artery disease in asymptomatic individuals may be 50% in the eighth and ninth decades of life, screening to exclude occult cardiovascular disease may modify findings.

In a population screened for occult coronary artery disease, there is no change in cardiac output at rest over the third to eighth decades (Gerstenblith, Renlund, and Lakatta, 1987) (Table 11-1). There is a slight decrease in heart rate and a compensatory slight increase in stroke volume. This is in contrast to studies in unscreened individuals, where cardiac output falls from the second to the ninth decades. Consistent with the principle of decreased responsiveness to stress in aging, during maximal exercise, other changes are manifest even in the screened population (Table 11-2). Heart rate response to exercise is decreased in older adults compared to younger individuals, reflecting a diminished β -adrenergic responsiveness in aging. Cardiac output is decreased slightly. Cardiac output is maintained by increasing cardiac volumes—increasing end-diastolic and end-systolic volumes. With this increase in workload and the work of pumping blood against less-compliant arteries and a higher blood pressure, cardiac hypertrophy occurs even in the screened elderly population.

Because myocardial reserve mechanisms are used to maintain normal function in aging, older persons are more vulnerable to developing dysfunction when disease is superimposed.

Diastolic dysfunction—retarded left ventricular filling and higher left ventricular diastolic pressure—is present both at rest and during exercise in older persons. Older persons are more dependent on atrial contraction, as opposed to ventricular relaxation, for left ventricular filling, and thus are more likely to develop heart failure if atrial fibrillation ensues. Heart failure may occur in the absence of systolic dysfunction or valvular disease.

HYPERTENSION

Hypertension is the major risk factor for stroke, heart failure, and coronary artery disease in older adults; all are important contributors to mortality and functional disability. Because hypertension is remediable and its control may reduce the incidence

TABLE 11-1. Resting Cardiac Function in Persons Age 30 to 80 Years Old Compared with That in Persons Age 30 Years Old

	Unscreened for occult CAD	Screened for occult CAD
Heart rate	—	—
Stroke volume	— —	+
Stroke volume index	— —	0
Cardiac output	— —	0
Cardiac index	— —	0
Peripheral vascular resistance	++	0
Peak systolic blood pressure	++	++
Diastolic pressure	0	0

CAD, coronary artery disease; +, slight increase; ++, increase; —, slight decrease; —, decrease; 0, no difference.

of coronary heart disease and stroke, increased efforts at detection and treatment of high blood pressure are indicated.

Hypertension is defined as a systolic blood pressure of 140 mm Hg or greater and/or a diastolic blood pressure of 90 mm Hg or greater. Isolated systolic hypertension is defined as a systolic pressure of 140 mm Hg or greater with a diastolic pressure of less than 90 mm Hg. With these definitions, as many as 67% of individuals older than age 60 may be hypertensive (Osthega et al., 2007).

Despite the high prevalence of hypertension in older adults, it should not be considered a normal consequence of aging. Hypertension is the major risk factor for cardiovascular disease in older adults, and that risk increases with each decade. Both elevation of systolic blood pressure and pulse pressure are better predictors of adverse

TABLE 11-2. Performance at Maximum Exercise in Sample Screened for Coronary Artery Disease, Age 30 to 80 Years

	Compared with 30-year-olds
Heart rate	— —
End-diastolic volume	++
Stroke volume	++
Cardiac output	—
End-systolic volume	++
Ejection fraction	— —
Total peripheral vascular resistance	0
Systolic blood pressure	0

++ , increase; —, slight decrease; — —, decrease; 0, no difference.

events than diastolic pressure. This is particularly relevant to older individuals, in whom isolated systolic hypertension predominates and may be present in 90% of hypertensive patients over the age of 80 (reviewed in Chobanian, 2007).

■ Evaluation

The diagnosis should be made on serial blood pressures. In patients with labile hypertension, blood pressure should be averaged to make the diagnosis, because these patients are at no less risk than those patients with stable hypertension. The history and physical examination should be directed toward assessing the duration, severity, treatment, and complications of the hypertension (Table 11-3). Atherosclerosis may interfere with occlusion of the brachial artery by a blood pressure cuff, leading to erroneously elevated blood pressure determinations, or “pseudohypertension.” Such an effect can be determined by the Osler maneuver. The cuff pressure is raised above systolic blood pressure. If the radial artery remains palpable at this pressure, significant atherosclerosis is probably present and may account for a 10- to 15-mm Hg pressure error. Standing blood pressure should also be determined. Initial laboratory evaluation should include urinalysis; complete blood cell count; measurements of blood electrolytes and calcium, estimated glomerular filtration rate, fasting glucose, and lipids; and 12-lead electrocardiogram (ECG). Although not all hypertension experts agree, the recent guidelines from the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) recommend using ambulatory blood pressure monitoring to confirm the diagnosis of hypertension (Krause et al., 2011).

TABLE 11-3. Initial Evaluation of Hypertension in Older Adults	
History	
Duration	
Severity	
Treatment	
Complications	
Other risk factors	
Physical examination	
Blood pressure, including Osler maneuver and standing determinations	
Weight	
Funduscopy, vascular, and cardiac examination for end-organ damage	
Abdominal bruit	
Neurological examination for focal deficits	
Laboratory tests	
Urinalysis	
Electrolytes	
Estimated glomerular filtration rate	
Calcium	
Thyrotropin (TSH)	
Chest radiograph	
Electrocardiogram	

TABLE 11-4. Secondary Hypertension in Older Persons

Renovascular disease (atherosclerotic)
Primary hyperaldosteronism
Hyperparathyroidism (calcium)
Estrogen administration
Renal disease (decreased creatinine clearance)

Secondary forms of hypertension are uncommon in older adults but should be considered in treatment-resistant patients and in those with diastolic pressures greater than 115 mm Hg (Table 11-4). Pheochromocytoma is uncommon in older adults and is particularly unusual in those older than age 75. Atherosclerotic renovascular hypertension and primary hyperaldosteronism may occur more frequently in older persons. With the use of automated calcium determinations, the frequency of diagnosis of primary hyperparathyroidism is increasing, particularly in postmenopausal women. Because there is a causal link between this disorder and hypertension, the diagnosis and treatment of hyperparathyroidism may ameliorate the elevated blood pressure.

Estrogen therapy in the postmenopausal woman may be associated with hypertension. Such an association can be assessed by withdrawing estrogen therapy for several months and following the blood pressure response.

Treatment

The issue of treatment of systolic/diastolic or isolated systolic hypertension in older individuals has been resolved. Multiple large trials have demonstrated that treating hypertension in older adults decreases morbidity and mortality from coronary artery disease and stroke (reviewed in Joint National Committee, 2004; for NICE guidance, see Krause et al., 2011). Although there has been concern about the hazard of treating individuals with cerebrovascular disease, the evidence suggests that the presence of cerebrovascular disease is an indication for, rather than a contraindication to, hypertensive therapy.

Some of the treatment trials that have included individuals up to 84 years suggest that there should be no age cutoff above which high blood pressure is not treated. A study specifically directed to hypertensive patients (systolic blood pressure of 160 mm Hg or more) age 80 years or older demonstrated a 30% reduction in the rate of fatal and nonfatal stroke, a 21% reduction in the rate of death from any cause, a 23% reduction in the rate of death from cardiovascular causes, and a 64% reduction in the rate of heart failure (Beckett et al., 2008). Relatively healthy older persons at any age should be treated unless they have severe comorbid disease that will clearly limit their life expectancy or unless the toxicity of treatment is so great that it outweighs potential benefits. The treatment goal for uncomplicated hypertension is a blood pressure less than 140/90 mm Hg. Despite the NICE guidance, controversies on management and treatment blood pressure goals persist (Godlee, 2012). Cardiovascular outcomes may not be

improved with blood pressures below 130/85 mm Hg. Systolic blood pressures below 120 mm Hg may be associated with increased all-cause mortality in those age 85 and older (Molander et al., 2008), and higher blood pressure is associated with better cognitive function in those over 85 (Euser et al., 2009).

■ Specific Therapy

Guidance from the American College of Cardiology and the American Heart Association (AHA) for the treatment of hypertension in older adults has recently been published (Aronow et al., 2011). Lifestyle changes are not easily accomplished but should be attempted, including maintaining ideal body weight, limiting dietary sodium intake, eating fruits and vegetables and low-fat dairy products, reducing saturated and total fats, and engaging in aerobic exercise. Foods rich in potassium, calcium, and magnesium should be consumed. Excess sodium intake and potassium deficit have adverse effects on arterial pressure and should be reversed as part of the management of all hypertensive patients (Adrogué and Madias, 2007). Other risk factors, such as smoking, dyslipidemia, and diabetes mellitus, should also be modified.

If dietary measures fail to control blood pressure, drug therapy should be considered. Physiological and pathologic changes of aging should be considered in individualizing the therapy. Changes in volumes of distribution and hepatic and renal metabolism may alter pharmacokinetics (see Chapter 14). Changes in vessel elasticity and baroreceptor sensitivity may alter responses to posture and drug-induced falls in blood pressure.

Thiazide diuretics are usually the initial step in therapy, especially in older patients with isolated systolic hypertension. They are well tolerated, are relatively inexpensive, and can be given once a day (Table 11-5). Many older hypertensive patients can be treated with diuretics as the only medication. Low-dose thiazides, for example, 12.5 to 25 mg of chlorthalidone, are efficacious in lowering blood pressure, while minimizing metabolic side effects. Many experts prefer chlorthalidone over hydrochlorothiazide as a better antihypertensive. Higher doses have a minimal additional effect on blood pressure with a more marked effect on hypokalemia. Thiazides are

TABLE 11-5. Thiazide Diuretics for Antihypertensive Therapy

Advantages	Adverse effects
Well tolerated	Hypokalemia
No central nervous system side effects	Volume depletion
Relatively inexpensive	Hyponatremia
Infrequent dosing	Hyperglycemia
Good response rate	Hyperuricemia
Orthostatic hypotension uncommon	Impotence
Can be used in conjunction with other agents	
Effective in advanced age	
Effective in systolic hypertension	

contraindicated in patients with gout. Postural hypotension is uncommon, but serum potassium should be monitored. Diabetics may have increased requirements for insulin or oral hypoglycemic agents.

Although β -blockers are also recommended as initial-step therapy, several meta-analyses have called this strategy into question (reviewed in Panjrath and Messerli, 2006). These meta-analyses indicate that traditional β -blockers do have efficacy in lowering blood pressure but are not known to be effective in preventing coronary artery disease, cardiovascular mortality, or all-cause mortality in older adults. When compared to each other, thiazides are superior to β -blockers in older adults (MRC Working Party, 1992). In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), thiazides were superior to angiotensin-converting enzyme (ACE) inhibitors in reducing cardiovascular disease, stroke, and heart failure (ALLHAT Collaborative Research Group, 2002). However, another trial suggests that ACE inhibitors are superior in older subjects, particularly men, in reducing cardiovascular events and mortality, but not stroke (Wing et al., 2003). β -Blocking agents may be used as the initial drug when another indication for their use exists, such as coronary heart disease, myocardial infarction (MI), heart failure, tachyarrhythmias, or essential tremor.

If thiazides alone do not control blood pressure, a second agent is added (Table 11-6) or a thiazide is added if one of the other agents has failed. The choice should be individualized and usually selected from among β -blockers, calcium channel antagonists, ACE inhibitors, or angiotensin-receptor blockers (ARBs) (The Medical Letter, 2001). β -Blockers are indicated for treatment of angina, heart failure, previous MI, and tachyarrhythmias in association with hypertension. These agents are contraindicated in patients with cardiac conduction deficits, bradyarrhythmias, and reactive airways disease. The more water-soluble β -blockers may be well suited for the geriatric population because they enter the central nervous system less readily and thus have fewer of the central nervous system side effects such as somnolence and depression; this would be a particular advantage in older adults. However, if cardiac output is decreased, renal perfusion and glomerular filtration rate may be affected. One concern with β -blockers is the production of bradycardia with reduced cardiac output. One simple test to monitor for this side effect is the patient's response to mild exercise after each dosage increase; a failure to increase pulse by at least 10 beats per minute is an indication to reduce the dosage. If a patient is to be taken off a β -blocking agent, withdrawal should be done slowly over a period of several days to avoid rebound of original symptoms.

Calcium channel antagonists are peripheral vasodilators with the advantage of maintaining coronary blood flow. These agents appear to have increased potency with age, possibly as a result of the decreased reflex tachycardia and myocardial contractility in older adults as compared with younger individuals. Headache, sodium retention, negative inotropic effects—especially in combination with β -blockers—and conduction abnormalities may limit their use. Calcium channel antagonists are effective in reducing stroke incidence in older patients with isolated systolic hypertension (Staessen et al., 1997). However, these drugs do not significantly reduce the

TABLE 11-6. Antihypertensive Medications

Agent*	Advantages	Disadvantages
β -Blockers	Useful in angina, previous myocardial infarction, heart failure Water-soluble agents have fewer central nervous system side effects Must be withdrawn slowly in presence of coronary artery disease	Contraindicated in cardiac conduction defects and reactive airways disease May cause bronchospasm, bradycardia, impaired peripheral circulation, fatigue, and decreased exercise tolerance
Calcium channel blockers	Peripheral vasodilator Coronary blood flow maintained Potency increased with age or in systolic hypertension	Headaches Sodium retention Negative inotropic effect Conduction abnormality
Angiotensin-converting enzyme inhibitors	Preload and afterload reduction Use in congestive heart failure, diabetes mellitus, other nephropathy with proteinuria	Hyperkalemia Hypotension Decreased renal function Cough Angioedema
Angiotensin-receptor antagonists	Use in angiotensin-converting enzyme inhibitor-induced cough, congestive heart failure, diabetes mellitus, other nephropathy with proteinuria	Hyperkalemia Angioedema (rare)
Clonidine	Increased renal perfusion	Somnolence, depression Dry mouth, constipation Rarely, withdrawal hypertensive crisis
α -Blockers	Useful in benign prostatic hypertrophy	Orthostatic hypotension
Hydralazine	May be useful in systolic hypertension	Reflex tachycardia, aggravation of angina Lupus-like syndrome at high dosage
Eplerenone	Aldosterone-receptor antagonist Fewer side effects than spironolactone and avoidance of gynecomastia	Hyperkalemia Contraindicated in renal insufficiency (creatinine >2.0) and in the presence of albuminuria

*With all these agents, initiation with low dosage and careful titration may minimize side effects

risk of heart failure (Blood Pressure Lowering Treatment Trialists' Collaboration, 2000).

ACE inhibitors are effective and well tolerated for treatment of hypertension. They are both preload and afterload reducers and thus are particularly useful in the face of congestive heart failure. They prolong survival in patients with heart failure or left ventricular dysfunction after an MI. Long-acting agents may have an advantage in adherence. Renal function, which may deteriorate on administration of these agents, must be monitored carefully. These agents may also induce hyperkalemia and should generally not be used with a potassium-sparing diuretic. Older adults are also more vulnerable to the hypotensive effects of these drugs.

ARBs are effective in lowering blood pressure without causing cough. They and ACE inhibitors are appropriate initial therapy in patients with diabetes mellitus, renal disease, or congestive heart failure (August, 2003). ARBs are superior to β -blockers in the treatment of patients with isolated systolic hypertension and left ventricular hypertrophy (Kjeldsen et al., 2002).

Clonidine may cause somnolence and depression, but it increases renal perfusion. The clonidine transdermal patch may lessen some of these adverse effects. However, local skin reactions may occur in about 15% of users. The once-per-week application of the patch may be an asset in improving adherence.

The major side effect of α -blockers is orthostatic hypotension; this is especially problematic with initial doses of prazosin. Newer agents with lesser hypotensive effects are now being used to treat symptomatic benign prostatic hypertrophy. In ALLHAT, the α -blocker arm was stopped early because of a higher incidence of congestive heart failure. Consequently, α -blockers are not recommended as monotherapy for hypertension.

Although hydralazine is usually a third-step drug, it may occasionally be used as a second-step drug in older adults because reflex tachycardia rarely occurs. If used with diuretics alone, it should be initiated in low doses, which should be increased slowly. It should not be used in the absence of a β -blocker if coronary artery disease is present.

A newer available agent is eplerenone, an aldosterone-receptor antagonist. It has a better side effect profile than spironolactone, particularly the avoidance of gynecomastia in men, but needs to be used with caution in patients with renal insufficiency and microalbuminuria, and potassium must be monitored for development of hyperkalemia.

With the newer, more effective agents, drug-resistant hypertension is unusual. In such cases, drug adherence should be monitored and sodium intake assessed. If such factors are not contributing to drug resistance, secondary causes of hypertension should be considered, especially renovascular disease and primary hyperaldosteronism.

STROKE AND TRANSIENT ISCHEMIC ATTACKS

Although the incidence of stroke is declining, it is still a major medical problem affecting approximately 50,000 individuals in the United States every year. It is the

TABLE 11-7. Stroke

Cause	Relative frequency, %	Mortality rate, %
Subarachnoid hemorrhage	10	50
Intracerebral hemorrhage	15	80
Cerebral infarction (thrombosis and embolism)	75	40

third leading cause of death and is also a major cause of morbidity, long-term disability, and hospital admissions. Stroke is clearly a disease of older adults; approximately 75% of strokes occur in those older than age 65. The incidence of stroke rises steeply with age, being 10 times greater in the 75- to 84-year-old age group than in the 55- to 64-year-old age group.

Table 11-7 lists the types and outcomes of stroke. In cerebral infarct, thrombosis, usually arteriosclerotic, is the most common cause, with embolization from an ulcerated plaque or myocardial thrombosis being less frequent causes. Table 11-8 lists outcomes for survivors.

Table 11-9 lists the modifiable risk factors for ischemic stroke. Hypertension is the major risk factor. Systolic hypertension is associated with a three- to fivefold increased risk for stroke. Hypertension accelerates the formation of atheromatous plaques and damages the integrity of vessel walls, predisposing to thrombotic occlusion and cerebral infarction. Hypertension also promotes growth of microaneurysms in segments of small intracranial arteries. Those lesions are sites of intracranial hemorrhage and lacunar infarcts.

Whether diabetes mellitus is a modifiable risk factor remains an unresolved issue. Tight glycemic control trials in type 2 diabetes have not shown improved outcomes for stroke.

Patients with a history of transient ischemic attacks (TIAs) are at substantial risk for subsequent stroke, particularly within the first few days. Completed stroke as a sequel of TIA is reported to occur in 12% to 60% or more of untreated TIA patients. In retrospective studies of patients with completed stroke, previous TIA is reported to have occurred in 50% to 75% of patients.

TABLE 11-8. Outcome for Survivors of Stroke

Outcome	Percentage
No dysfunction	10
Mild dysfunction	40
Significant dysfunction	40
Institutional care	10

TABLE 11-9. Modifiable Risk Factors for Ischemic Stroke

Alcohol consumption (>5 drinks/day)
Asymptomatic carotid stenosis (>50%)
Atrial fibrillation
Elevated total cholesterol level
Hypertension
Obesity
Physical inactivity
Smoking

The keystone to the diagnosis of stroke is a clear history of sudden, acute neurological deficit. When the history is not clear, especially if the deficit could have had a gradual onset, consideration should be given to a mass lesion. Brain scanning with computed tomography or magnetic resonance imaging is required to distinguish cerebral infarction from intracerebral hemorrhage. Laboratory testing should include glucose level, complete blood count, and prothrombin time and partial thromboplastin time, especially if thrombolysis is considered. Electroencephalography is only occasionally helpful in the differential diagnosis. An ECG should be performed routinely in cases of TIA or stroke because it may relate the episode to MI or cardiac arrhythmia. Invasive techniques are usually unnecessary in stroke patients.

In older adults, symptoms acceptable as evidence of cerebral ischemia are often misinterpreted. [Table 11-10](#) lists the presenting symptoms for TIA in the carotid and vertebral–basilar systems.

Treatment

The U.S. Food and Drug Administration has approved, and committees of the AHA and the American Academy of Neurology have published guidelines endorsing, the use of tissue plasminogen activator (tPA) within 3 hours of onset of ischemic stroke. The AHA and the European Stroke Organization have recently updated their guidelines to extend the treatment window to 4.5 hours (Wechsler, 2011). Thrombolytic therapy increases the risk for early death and intracranial hemorrhage but decreases the combined end point of death or dependency at 3 to 6 months. The use of intravenous tPA among warfarin-treated patients (international normalized ratio [INR] ≤ 1.7) was not associated with increased symptomatic intracranial hemorrhage risk compared with non-warfarin-treated patients (Xian et al., 2012). In two large randomized trials, the use of aspirin initiated within 48 hours after onset of stroke and continued for 2 weeks or until discharge reduced rates of death or dependency at discharge or at 6 months. A meta-analysis found no evidence that anticoagulants in the acute phase of stroke improve functional outcomes (therapies of acute stroke reviewed in van der Worp and van Gijn, 2007).

For primary prevention of stroke, adequate blood pressure reduction, smoking cessation, treatment of hyperlipidemia, glucose control in patients with diabetes, use

TABLE 11-10. Transient Ischemic Attack: Presenting Symptoms

Symptom	Carotid	Vertebrobasilar
Paresis	+++	++
Paresthesia	+++	+++
Binocular vision	0	+++
Vertigo	0	+++
Diplopia	0	++
Ataxia	0	++
Dizziness	0	++
Monocular vision	++	0
Headache	+	+
Dysphasia	+	0
Dysarthria	+	+
Nausea and vomiting	0	+
Loss of consciousness	0	0
Visual hallucinations	0	0
Tinnitus	0	0
Mental change	0	0
Drop attacks	0	0
Drowsiness	0	0
Light-headedness	0	0
Hyperacusia	0	0
Weakness (generalized)	0	0
Convulsion	0	0

+++ , most frequent; 0, least frequent.

of antithrombotic therapy in patients with atrial fibrillation, and antiplatelet therapy in patients with MI are effective and supported by evidence from several randomized trials (Straus, Majumdar, and McAlister, 2002). These same strategies are effective in secondary prevention of stroke, as is carotid endarterectomy in patients with severe carotid artery stenosis.

Lowering blood pressure in hypertensive individuals is effective in the prevention of hemorrhagic and ischemic stroke. The benefits of antihypertensive treatment extend to patients older than 80 years (Gueyffier et al., 1999). Thiazide diuretics, ACE inhibitors, and long-acting calcium channel blockers reduce the incidence of stroke. β -Blockers are less efficacious. In patients with a recent ischemic stroke, systolic blood pressures in the range of 120 to 140 mm Hg were associated with a lower risk of recurrent stroke than blood pressures below or above this range (Ovbiagele et al., 2011). Selection of a specific class of drugs is discussed earlier in this chapter.

Patients with atrial fibrillation have a mortality rate double that of age- and sex-matched controls without atrial fibrillation. The risk of stroke with nonrheumatic atrial fibrillation is approximately 5% a year. Adjusted-dose warfarin and aspirin reduce stroke in patients with atrial fibrillation, and warfarin is substantially more efficacious than aspirin (Hart et al., 2007). Major extracranial hemorrhage is minimally increased in warfarin-treated patients. Excess bleeding risk with warfarin in elderly patients can be similar to the low rates achieved in the randomized trials (Caro et al., 1999; Fang et al., 2006). Therapy with clopidogrel plus aspirin is not an alternative to warfarin because it is less effective and significantly increases the risk of bleeding (ACTIVE Writing Group, 2006). Strokes that occur in patients receiving warfarin or aspirin are not more severe than those occurring in placebo-treated patients. Stroke risks and benefits of antithrombotic therapy are similar for patients with paroxysmal or chronic atrial fibrillation (Hart et al., 2000). Direct thrombin inhibitors and factor Xa inhibitors are discussed later in the Arrhythmias section.

The risk of ischemic stroke is increased after an MI, particularly in the first month. Aspirin reduces the risk of nonfatal stroke in patients who have experienced an MI (Antiplatelet Trialists' Collaboration, 2002). Aspirin decreases the risk of stroke in patients with previous TIA or stroke, and there appears to be no dose–response relationship in doses of 50 to 1500 mg/day. Clopidogrel is modestly more effective than aspirin in decreasing risk of the combined endpoint of stroke, MI, or vascular death (Straus, Majumdar, and McAlister, 2002).

Carotid endarterectomy decreases the risk of stroke or death in patients with symptomatic carotid disease and severe carotid artery stenosis (70%-99%). In patients with symptomatic moderate carotid artery stenosis (50%-69%), benefits were more marginal. Carotid stenting is less invasive than endarterectomy, but in a study of patients with symptomatic carotid stenosis of 60% or more, the rates of death and stroke at 1 and 6 months were lower with endarterectomy than with stenting (Mas et al., 2006). Patients with lesser degrees of stenosis (<50%) may be harmed by surgery. For people with asymptomatic carotid disease, the optimal therapy is unclear. However, identifying carotid artery stenosis in asymptomatic individuals can involve expensive and invasive diagnostic procedures. The costs of screening large numbers of asymptomatic people outweigh the benefits to the number of individuals screening would identify.

■ **Stroke Rehabilitation**

Table 11-11 presents factors in the prognosis for rehabilitation of elderly stroke patients. Although the benefit of stroke rehabilitation is controversial, it should be initiated early

TABLE 11-11. Factors in Prognosis for Rehabilitation	
Availability and implementation of sound program	
Mentation	
Motivation	
Prognosis for neurological return	
Vigor	

TABLE 11-12. Stroke Rehabilitation**Acute phase**

- Change of patient's position at least every 2 h
- Positioning of patient's joints to prevent contractures
- Positioning of patient to prevent aspiration pneumonia
- Range-of-motion exercises

Later phase

- Activities of daily living training
- Ambulation training
- Functional activities for affected side
- Muscle reeducation exercises
- Perceptual training
- Training in transfer technique

in the course if it is to be of benefit. Stroke patients may fare better in acute rehabilitation facilities than in skilled nursing facilities (Kane et al., 1996; Schlenker et al., 1997). Generally, most neurological return occurs during the first month after the stroke. By the end of the third month, little, if any, further return can be expected. Not all dysfunctions result in the same level of disability. Motor loss is often the least disabling. Perceptual and/or sensory loss, aphasia, loss of balance, hemicorporal neglect, hemianopsia, and/or cognitive damage may cause more severe and often untreatable disabilities.

In the immediate rehabilitation stage, treatment is directed toward avoiding complications such as pressure sores, contractures, phlebitis, pulmonary embolism, aspiration pneumonia, and fecal impaction.

In the next stage of rehabilitation, treatment is directed toward reeducating muscles (affected areas) and enhancing remaining capabilities (unaffected areas) (reviewed in Dobkin, 2005). [Table 11-12](#) describes measures to be taken during this phase. In patients 3 to 9 months within a first stroke, constraint-induced movement therapy produced significant and clinically relevant improvements in arm motor function (Wolf et al., 2006).

When the patient stops making progress after intensive therapy, the goal of rehabilitation shifts to finding ways for the patient to cope with the dysfunction. At this stage, the patient is assessed for the need for braces and assistive devices for both ambulation and performance of activities of daily living. With a sound program of rehabilitation, the older patient who survives a stroke can return to the community.

CORONARY ARTERY DISEASE

The frequency of both coronary artery disease and MI increases with age. Older patients have more severe disease than younger patients, and the mortality rate is higher after an acute MI.

Hypertension is the major risk factor for coronary artery disease in older adults. Hypercholesterolemia and cigarette smoking become less important risk factors

in this age group, although they are still significant. Risk factor reduction should include treatment of hypertension and dyslipidemia and smoking cessation.

Angina pectoris has a similar presentation in both older adults and in younger patients, with familiar pain characteristics and radiation. Pharmacologically, acute episodes of angina pectoris can be treated with sublingual nitroglycerin, which should be taken in the sitting position to avoid severe orthostatic hypotension. Primary therapy for chronic stable angina is aspirin and β -blockers. Both are under-used in the elderly, especially after acute MI. Secondary therapy includes long-acting nitrates and calcium channel blockers, but their use may be limited by orthostatic hypotension in older patients.

Younger patients with chronic symptomatic coronary artery disease benefit from revascularization. Procedure-related mortality increases with age both after coronary artery bypass graft (Alexander et al., 2000) and after percutaneous coronary intervention (Batchelor et al., 2000). In those without significant comorbidity, mortality approaches that seen in younger patients. One-year outcomes in older patients with chronic angina are similar with regard to symptoms, quality of life, and death or nonfatal infarction with invasive versus optimized medical strategies (Pfisterer et al., 2003). Older patients with angina refractory to standard drug therapy have a choice between an early invasive strategy that carries a certain early intervention risk and an optimized medical strategy that carries a chance of late hospitalization and revascularization. After 1 year, quality-of-life outcomes and survival will be similar.

Older patients with an acute MI often present with symptoms other than chest pain (Table 11-13). Treatment of the older patient with acute MI is similar to that of the younger patient. Particular attention should be paid to avoiding drug toxicity and to beginning early mobilization when possible. Early mobilization may decrease deconditioning, orthostatic hypotension, and thrombophlebitis. No specific trials in older patients have assessed percutaneous coronary intervention versus thrombolysis for treatment of acute MI. However, subgroup analyses indicate better outcomes with percutaneous coronary intervention (reviewed in Ting, Yang, and Rihal, 2006). Coronary artery surgery can be performed with excellent symptomatic results in older patients but with increased morbidity and mortality. The strongest indication for surgery is angina pectoris refractory to medical management. In patients with left main coronary artery disease, surgery significantly improves survival over medical therapy. Patients with three-vessel disease may also have improved survival.

TABLE 11-13. Presenting Symptoms of Myocardial Infarction	
Chest pain	
Confusion	
Dyspnea	
Rapid deterioration of health	
Syncope	
Worsening congestive heart failure	

In older adults, however, improved survival must be considered in light of the patient's projected life expectancy and the higher operative risk.

Long-term administration of β -blockers to patients after MI improves survival. Pooled analysis of intravascular ultrasound studies demonstrates that β -blockers can slow progression of coronary atherosclerosis (Sipahi et al., 2007). Despite these data, physicians are reluctant to administer β -blockers to many patients, such as older patients (Krumholz et al., 1998) and those with chronic pulmonary disease, left ventricular dysfunction, or non-Q-wave MI. However, all of these subgroups benefit from β -blocker therapy after MI (Gottlieb, McCarter, and Vogel, 1998). Given the higher mortality rates in these subgroups, the absolute reduction in mortality was similar to or greater than that among patients with no specific risk factors. Other secondary prevention interventions should include aspirin, ACE inhibitors, lipid-lowering agents, and smoking cessation. Observational studies support that doses of aspirin greater than 75 to 81 mg do not enhance efficacy, whereas larger doses are associated with an increased incidence of bleeding events (reviewed in Campbell et al., 2007). Intensive low-density lipoprotein cholesterol-lowering therapy has been shown to be beneficial in high-risk older patients with established cardiovascular disease (Wenger et al., 2007). Current data do not support adding ezetimibe to statin therapy to lower cholesterol in prevention of vascular disease (Kastelein et al., 2008).

VALVULAR HEART DISEASE

■ Calcific Aortic Stenosis

Pathologically, degenerative calcification of the aortic and mitral valves is common among older adults; it is found at autopsy in approximately one-third of individuals older than age 75. For many years, degenerative aortic stenosis was thought to be caused by the passive accumulation of calcium on the surface of the aortic valve leaflet. Recent studies have demonstrated, however, that the etiology of aortic valve disease has a similar pathophysiology to that of vascular atherosclerosis (Rajamannan, Bonow, and Rahimtoola, 2007). Aortic valve sclerosis is common in the elderly (29% in the Cardiovascular Health Study) and is associated with an increase in the risk of death from cardiovascular causes and the risk of MI, even in the absence of hemodynamically significant obstruction of left ventricular outflow (Otto et al., 1999). The frequency of aortic stenosis increases with age, appearing at autopsy in approximately 4% to 6% of those older than age 65. Isolated aortic stenosis is more common among men than women except in those older than age 80, where women predominate. Aortic insufficiency may coexist with calcific aortic stenosis, although regurgitation is usually mild and a regurgitant murmur is usually not heard.

The usual clinical presentation of aortic stenosis in older adults consists of fatigue, syncope, angina pectoris, and congestive heart failure. Because systolic murmurs are a frequent finding in older adults, differentiation of mitral regurgitation, aortic sclerosis, or aortic stenosis by auscultation is a challenge. The location of the murmur is usually along the lower left sternal border and apex and often does not radiate to the axilla or carotids. It is characteristically a crescendo-decrescendo late systolic

TABLE 11-14. Differentiation of Systolic Murmurs				
	Postpercutaneous Coronary Angioplasty*	Amyl Nitrate	Valsalva	Squatting
Aortic sclerosis	↑†	↑	↓	↑
Aortic stenosis	↑	↑↓	↓	↑
Idiopathic	↑	↑↑	↑↑	↓↓
Hypertrophic Subaortic stenosis				
Mitral regurgitation	—	↓	↓	—

*Best following a premature ventricular contraction.
†Effect of maneuver on intensity of murmur.

murmur ending before the second heart sound. Table 11-14 describes aspects that may help differentiate mitral regurgitation from aortic murmurs.

Differentiating aortic stenosis from aortic sclerosis can be difficult in older adults. The typical murmur and pulse of aortic stenosis may be modified in older adults. Systemic hypertension may shorten the systolic murmur of stenosis, giving it the characteristic of an aortic sclerosis murmur. Loss of vascular elasticity may modify the pulse pressure, so that the typical pulse contour of aortic stenosis is absent. Therefore, the physical examination alone is not reliable in diagnosing aortic stenosis in older adults. The addition of Doppler flow studies to echocardiography has improved the diagnostic accuracy of noninvasive procedures for aortic stenosis. Left ventricular catheterization remains the most reliable method of assessing aortic stenosis in older adults but should be reserved for patients who are symptomatic (angina, syncope, or dyspnea) and in whom surgery is contemplated.

Surgical mortality for valve replacement is higher in older individuals, but results have improved. Excellent early and late outcomes of aortic valve replacement in people age 80 and older have been described (Filsoufi et al., 2008). Significant coexistent coronary artery disease should be treated with bypass surgery at the time of valve replacement. In general, a biological prosthetic valve is preferred. Transcatheter aortic valve replacement has been shown to reduce death and hospitalization, with a decrease in symptoms, as an alternative to surgery in high-risk patients (Kodali et al., 2012; Makkar et al., 2012).

■ **Calcified Mitral Annulus**

Mitral ring calcification is a disease of older adults and is most frequently found in patients older than age 70. It is reported in 9% of autopsies in individuals older than age 50 and has a striking increase with advancing age, particularly in women, in whom it rises from 3.2% in women younger than age 70 to 44% in women older than age 90.

This lesion often results in mitral insufficiency or conduction abnormalities and rarely in stenosis. It is an important contributing factor to congestive heart failure in older adults and is a site for endocarditis. As many as two-thirds of patients with mitral annulus calcification present with an apical systolic murmur of mitral regurgitation.

Echocardiography is the best technique for diagnosing mitral annulus calcification. Regurgitation is usually mild to moderate, and surgery is usually indicated only if endocarditis is superimposed. There is a higher incidence of cerebral embolism in this disorder, and thus anticoagulation with warfarin (Coumadin) may be indicated.

■ Mitral Valve Prolapse

Mucoid degeneration affects mainly the mitral valve. This process allows stretching of the mitral valve leaflet under normal intracardiac pressure, with subsequent prolapse into the left atrium during systole.

Although the classic murmur is late systolic, the murmur can occur any time in systole. Mucoid degeneration of the mitral valve has been described in approximately 1% of autopsies on patients older than age 65. It is associated with mitral insufficiency; left atrial dilatation and regurgitant murmurs are common. Mitral insufficiency caused by this disorder is usually well tolerated and rarely requires surgery. Some patients with this syndrome have abnormal ECGs and chest pain suggestive of coronary artery disease; sudden death has been reported. (Evaluation and treatment are reviewed in Foster, 2010.)

Death directly from valve disease is usually related to rupture of the chordae tendineae. Although mucoid degeneration also predisposes to infective endocarditis, prophylaxis for subacute bacterial endocarditis is no longer recommended by the AHA (Wilson et al., 2007).

■ Idiopathic Hypertrophic Subaortic Stenosis

In older adults, idiopathic hypertrophic subaortic stenosis (IHSS) may be misdiagnosed as aortic valve stenosis or mitral regurgitation. Presenting symptoms are similar to those of aortic stenosis or coronary artery disease. The presence of a bisferious arterial pulse in the presence of a systolic ejection murmur and in the absence of an aortic regurgitation murmur should suggest IHSS. The IHSS murmur usually does not radiate to the carotids. Squatting, which increases left ventricular filling, usually decreases the murmur of IHSS. Factors that decrease left ventricular volume (Valsalva maneuver, standing) increase the intensity of the murmur.

Documentation of IHSS is accomplished by echocardiography.

Therapy usually relies on β -adrenergic antagonists. Symptoms may be worsened by cardiac glycosides, which increase myocardial contractility, and diuretics, which create volume depletion. Atrial fibrillation is poorly tolerated and may require cardioversion in the rapidly deteriorating patient. In patients refractory to medical therapy, surgery should be considered after cardiac catheterization to assess severity of outflow obstruction and state of coronary artery flow.

ARRHYTHMIAS

Although the prevalence of arrhythmias increases with age, most of older patients without clinical heart disease are in normal sinus rhythm.

Atrial fibrillation occurs in 5% to 10% of asymptomatic ambulatory older adults and more frequently in hospitalized patients. It is usually associated with underlying heart disease; the causes are the same as in younger individuals. Atrial fibrillation does, however, occur more frequently in older patients with thyrotoxicosis. Recently, pulse pressure has been demonstrated to be an important risk factor for incident atrial fibrillation (Mitchell et al., 2007). Long-term treatment of hypertension with ACE inhibitors, ARBs, or β -blockers reduces the risk for atrial fibrillation (Schaer et al., 2010).

Patients with recent-onset atrial fibrillation and hemodynamic instability or angina should undergo urgent cardioversion (Falk, 2001). If the patient's condition is stable, heart rate should be controlled with intravenous diltiazem, a β -blocker, or digoxin. If atrial fibrillation persists and onset is ≤ 48 hours, cardioversion may be attempted after initiation of heparin therapy. If onset is >48 hours, treatment should include 3 weeks of anticoagulation prior to cardioversion, unless a transesophageal echocardiogram reveals no atrial thrombus at presentation. Anticoagulation for persistent and intermittent atrial fibrillation was discussed earlier in the section on treatment of stroke and TIAs. The net clinical benefit of warfarin therapy is higher among patients age 75 to 84 and highest among those age 85 and older (Singer et al., 2009). In patients in whom warfarin therapy is difficult, newer agents that do not require INR monitoring, including direct thrombin inhibitors and factor Xa inhibitors, have favorable therapeutic and side effect profiles (Connolly et al., 2009; Connolly et al., 2011). Doses may need to be reduced in those over age 80. Despite the advantage of not needing to monitor INR levels, postmarketing studies have raised concerns about an increased risk of bleeding (Radecki, 2012). Frail older adults may be most vulnerable to the adverse bleeding effects (Harper et al., 2012). Life-threatening bleeding from warfarin may be predictably reversed with fresh frozen plasma. Direct thrombin inhibitors have no widely accepted reversal agent. For long-term rate control, verapamil, diltiazem, and β -blockers should be the initial drugs of choice. β -Adrenergic blockers are especially effective in the presence of thyrotoxicosis and increased sympathetic tone. Digoxin should be considered only in patients with congestive heart failure secondary to impaired systolic ventricular function or in those in whom β -blocker or calcium channel blocker treatment is limited by hypotension. In some patients, combinations of these drugs may be needed to control ventricular response. The maintenance dose of digoxin is usually lower in older adults because of decreased muscular mass and decreased renal clearance. In patients with recurrence of persistent atrial fibrillation after electrical cardioversion and in patients with heart failure, rate control is not inferior to rhythm control (repeated cardioversion or antiarrhythmics) for prevention of death and morbidity from cardiovascular causes (Van Gelder et al., 2002; Marshall et al., 2004; Roy et al., 2008). Sinus rhythm can be maintained long term by means of circumferential pulmonary vein ablation with a significant decrease in both the severity of symptoms and the left atrial diameter (indications and outcomes reviewed in Wazni, Wilkoff, and Saliba, 2011).

TABLE 11-15. Manifestations of Sick Sinus Syndrome

Angina pectoris
Congestive heart failure
Dizziness
Insomnia
Memory loss
Palpitations
Syncope

The incidence of premature ventricular contractions increases with age and occurs in approximately 10% of ECGs and in 30% to 40% of Holter monitorings. The decision to treat with antiarrhythmic therapy is difficult except in the immediate post-MI period, when it is recommended. Criteria for therapy in older patients are the same as for therapy in younger patients. The half-life of antiarrhythmic drugs is prolonged in the elderly. Therapy should be initiated at lower doses, and blood levels should be monitored (see Chapter 14).

The sick sinus syndrome is particularly common among older patients. Diagnosis is made by Holter monitor. [Table 11-15](#) lists the symptoms of sick sinus syndrome, which are usually related to decreased organ perfusion. There is no satisfactory medical therapy. Symptomatic patients may require pacemakers, which do not seem to decrease mortality in this syndrome but can alleviate symptoms. A pacemaker may be indicated in patients with cardiac side effects from drugs used to control tachycardias in the bradycardia–tachycardia syndrome.

HEART FAILURE

Although congestive heart failure is prevalent in older adults, it is often overdiagnosed. Pedal and pretibial edema is not sufficient to warrant the diagnosis. Venous stasis may produce a similar picture. Care is needed to establish the presence of other signs of congestive heart failure (eg, cardiac enlargement, S_3 heart sound, basilar crackles, jugular venous distention, enlarged liver). Determination of ejection fraction by echocardiography assists in the diagnosis. NICE recommendations for the diagnosis of heart failure were updated in 2010, with echocardiography as the initial diagnostic test in individuals with a previous MI and measurement of serum natriuretic peptide in those without a previous MI (Mant et al., 2011). Assessment by a specialist should be considered. The NICE treatment recommendations are also reviewed in Mant et al. (2011).

More than 75% of cases of overt heart failure in older patients are associated with hypertension or coronary heart disease. Diastolic dysfunction, not systolic dysfunction, is the primary cause of heart failure in older patients and is associated with marked increases in all-cause mortality (Redfield et al., 2003; Bursi et al., 2006). Diuretics should be used to treat pulmonary congestion or peripheral edema, and β -blockers should be used to control heart rate. Few large randomized

controlled trials studying the drug treatment of diastolic heart failure have been designed, and trials studying digoxin and ARBs have shown minimal benefit (Shah and Gheorghiade, 2008). Comorbidities common in patients with diastolic heart failure, including hypertension, coronary artery disease, atrial fibrillation, and diabetes mellitus, should be treated.

The mainstays of therapy for congestive heart failure as a result of systolic dysfunction in older patients, as in younger patients, are diuretics for fluid overload, ACE inhibitors or ARBs, β -blockers, and aldosterone blockers (reviewed in McMurray, 2010). To improve function and survival, all patients with chronic symptomatic congestive heart failure that is associated with reduced systolic ejection or left ventricular remodeling should be treated with ACE inhibitors. β -Blockers also improve symptoms and survival (McAlister et al., 2009). Low doses of spironolactone decrease mortality in severe heart failure (The Medical Letter, 1999), and eplerenone, a mineralocorticoid inhibitor with fewer side effects than spironolactone, has been shown to be of benefit in patients with mild symptoms (Zannad et al., 2011). Statin use in adults with heart failure with or without coronary heart disease is associated with lower risk of death and hospitalization (Go et al., 2006).

If symptoms persist despite medical therapy, referral to a specialist and cardiac resynchronization therapy with or without a defibrillator should be considered (Mant et al., 2011; Sun and Joglar, 2011).

Although low serum concentrations of digoxin (0.5-0.9 ng/mL) have been shown to reduce mortality and hospitalization in older heart failure patients, the use of digitalis preparations must be approached with caution (Ahmed, 2007). Once begun on digoxin, patients tend to remain on it long after the indications have ceased. Subtle signs of toxicity may be missed, as the drug accumulates in the presence of decreased renal function. Because of decreases in lean body mass and glomerular filtration rate, lower doses of digoxin are generally required in older patients. Initial maintenance doses should be lower, and blood levels should be monitored to avoid toxic levels. Because the therapeutic window is narrowed in older adults, patients who have been on digoxin therapy for long periods of time after an acute episode of cardiac decompensation not related to arrhythmias should be considered for discontinuation of digoxin. Weight should be monitored closely so that digoxin can be reinstated before congestive symptoms occur. With such evaluation and monitoring, some older patients on chronic digoxin therapy for other than antiarrhythmic treatment may not require digoxin therapy.

PERIPHERAL VASCULAR DISEASE

The prevalence of peripheral vascular disease (PVD) increases with age. Cigarette smoking and diabetes mellitus are the strongest risk factors. The risk of limb loss for patients without diabetes is low. Cardiovascular disease is the major cause of death (reviewed in White, 2007, from which this section was modified). Typical intermittent claudication is present in 20% of patients, and many patients present with atypical symptoms of leg fatigue, difficulty walking, and atypical leg pain. (Also see Chapter 10, Immobility, for a discussion of PVD and its effects on mobility.)

TABLE 11-16. Calculation of the Ankle–Brachial Index

Formula

Ankle–brachial index = highest right (left) ankle pressure (mm Hg)/highest arm pressure (mm Hg)

Interpretation of Calculated Index

Above 0.90—normal

0.71–0.90—mild obstruction

0.41–0.70—moderate obstruction

0.00–0.40—severe obstruction

Data from White, 2007.

The examination should focus on pulses, hair loss, skin color, and trophic skin changes of the lower legs and feet. The initial screening test is calculation of the ankle–brachial index (Table 11-16). A result of 0.9 or less is adequate to make the diagnosis of peripheral arterial disease. In uncertain diagnosis, further imaging with duplex ultrasound, computed tomographic angiography (CTA), or magnetic resonance angiography (MRA) may be useful. The gold standard is invasive digital subtraction angiography if an endovascular intervention is planned.

Evidence Summary

Do's

- Treat hypertension in older adults, including those over age 80.
- Monitor standing blood pressure in patients on antihypertensive therapy.
- Use adjusted-dose warfarin in patients with atrial fibrillation.
- Administer β -blockers to patients after an acute MI.
- Perform echocardiogram as the first test in diagnosis of heart failure in those with previous MI.
- Measure serum natriuretic peptide as the first test in diagnosis of heart failure in those without previous MI.

Don'ts

- Use short-acting calcium channel antagonists for long-term therapy of hypertension.
- Use clopidogrel in combination with aspirin for stroke prevention for longer than 3 months.
- Withhold anticoagulation for atrial fibrillation because of fall risk.

Consider

- Limiting initial therapy with β -blockers in older patients with hypertension to those with compelling indications, such as coronary heart disease, MI, heart failure, or certain arrhythmias.
- Thiazide diuretics or angiotensin-converting enzyme inhibitors as first-line therapy of hypertension.
- Percutaneous coronary intervention over thrombolysis for treatment of acute MI.
- Aortic valve replacement for aortic stenosis, including in patients over age 80.

Treatment includes risk factor modification (smoking cessation, lowering lipids, controlling hypertension, and managing diabetes), an exercise program, and antiplatelet therapy. Antiplatelet therapy is initiated with low-dose aspirin. Clopidogrel may be considered as an alternative. Cilostazol (100 mg twice a day) has been shown to improve walking distance, whereas pentoxifylline appears to be no better than placebo. If warranted for symptomatic relief, revascularization (endovascular or surgical) may be considered when the risk–benefit ratio is favorable.

REFERENCES

ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet*. 2006;367:1903-1912.

Adrogué HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. *N Engl J Med*. 2007;356:1966-1978.

Ahmed A. Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. *J Gerontol A Biol Sci Med Sci*. 2007;62A:323-329.

Alexander KP, Anstrom KJ, Muhlbaier LH, et al. Outcomes of cardiac surgery in patients > or = 80 years: results from the National Cardiovascular Network. *J Am Coll Cardiol*. 2000;1:731-738.

ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002;288:2981-2997.

Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. *BMJ*. 2002;324:71-86.

Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Task Force on Clinical Expert Consensus documents in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. *J Am Coll Cardiol*. 2011;57:2037-2114.

August P. Initial treatment of hypertension. *N Engl J Med*. 2003;348:610-617.

Batchelor WB, Anstrom KJ, Muhlbaier LH, et al. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration. *J Am Coll Cardiol*. 2000;36:723-730.

Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*. 2008;358:1-12.

Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomized trials. *Lancet*. 2000;356:1955-1964.

Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. *JAMA*. 2006;296:2209-2216.

Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease. *JAMA*. 2007;297:2018-2024.

- Caro JJ, Flegel KM, Orejuela ME, et al. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. *CMAJ*. 1999;161:493-497.
- Chobanian AV. Isolated systolic hypertension in the elderly. *N Engl J Med*. 2007;357:789-796.
- Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. *N Engl J Med*. 2011;364:806-817.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009;361:1139-1151.
- Dobkin BH. Rehabilitation after stroke. *N Engl J Med*. 2005;352:1677-1684.
- Euser SM, van Bommel T, Schram MT, et al. The effect of age on the association between blood pressure and cognitive function later in life. *J Am Geriatr Soc*. 2009;57:1232-1237.
- Falk RH. Atrial fibrillation. *N Engl J Med*. 2001;344:1067-1078.
- Fang MC, Go AS, Hylek EM, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. *J Am Geriatr Soc*. 2006;54:1231-1236.
- Filsoufi F, Rahmanian PB, Castillo JG, et al. Excellent early and late outcomes of aortic valve replacement in people aged 80 and older. *J Am Geriatr Soc*. 2008;56:255-261.
- Foster E. Mitral regurgitation due to mitral-valve prolapse. *N Engl J Med*. 2010;363:156-165.
- Gerstenblith G, Renlund DG, Lakatta EG. Cardiovascular response to exercise in younger and older men. *Fed Proc*. 1987;46:1834-1839.
- Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. *JAMA*. 2006;296:2105-2111.
- Godlee F. Controversies over hypertension guidelines. *BMJ*. 2012;344:e653.
- Gottlieb SS, McCarter RJ, Vogel RA. Effects of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. *N Engl J Med*. 1998;339:489-497.
- Gueyffier F, Bulpitt C, Borssel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. *Lancet*. 1999;353:793-796.
- Harper P, Young L, Marriman E. Bleeding risk with dabigatran in the frail elderly. *N Engl J Med*. 2012;366:864-866.
- Hart RG, Pearce LA, Aguilar MI, et al. Met-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007;146:857-867.
- Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during ASA therapy. *J Am Coll Cardiol*. 2000;35:183-187.
- Joint National Committee. *The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure*. Bethesda, MD: National Institutes of Health; 2004.
- Kane RL, Chen Q, Blewett LA, et al. Do rehabilitative nursing homes improve the outcomes of care? *J Am Geriatr Soc*. 1996;44:545-554.
- Kastelein JJP, Akdim F, Strokes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N Engl J Med*. 2008;358:1431-1443.
- Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention for End Point Reduction (LIFE) substudy. *JAMA*. 2002;288:1491-1498.
- Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. *N Engl J Med*. 2012;366:1685-1695.
- Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. *BMJ*. 2011;343:1-6.
- Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of β -blockers for the treatment of elderly patients after acute myocardial infarction. *JAMA*. 1998;280:623-629.

- Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. *N Engl J Med*. 2012;366:1696-1704.
- Mant J, Al-Mohammad A, Swain S, et al. Management of chronic heart failure in adults: synopsis of the National Institute for Health and Clinical Excellence Guideline. *Ann Intern Med*. 2011;155:252-259.
- Marshall DA, Levy AR, Vidaillet H, et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. *Ann Intern Med*. 2004;141:653-661.
- Mas J-L, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. *N Engl J Med*. 2006;355:1660-1671.
- McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. *Ann Intern Med*. 2009;150:784-794.
- McMurray JJV. Systolic heart failure. *N Engl J Med*. 2010;362:228-238.
- Mitchell GF, Vasan RS, Keyes MJ, et al. Pulse pressure and risk of new-onset atrial fibrillation. *JAMA*. 2007;297:709-715.
- Molander L, Lovheim H, Norman T, et al. Lower systolic blood pressure is associated with greater mortality in people aged 85 and older. *J Am Geriatr Soc*. 2008;56:1853-1859.
- MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. *BMJ*. 1992;304:405-412.
- Ostchega Y, Dillon CF, Hughes JP, et al. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. *J Am Geriatr Soc*. 2007;55:1056-1065.
- Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. *N Engl J Med*. 1999;341:142-147.
- Ovbiagele B, Diener H-C, Yusuf S, et al. Level of systolic blood pressure within normal range and risk of recurrent stroke. *JAMA*. 2011;306:2137-2144.
- Panjrath GS, Messerli FH. Beta-blockers for primary prevention in hypertension: era bygone? *Prog Cardiovasc Dis*. 2006;49:76-87.
- Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy. One-year results of the randomized TIME trial. *JAMA*. 2003;289:1117-1123.
- Radecki RP. Dabigatran: uncharted waters and potential harm. *Ann Intern Med*. 2012;157:66-68.
- Rajamannan NM, Bonow RO, Rahimtoola SH. Calcific aortic stenosis: an update. *Nat Clin Pract Cardiovasc Med*. 2007;4:254-262.
- Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community. Appreciating the scope of the heart failure epidemic. *JAMA*. 2003;289:194-202.
- Roy D, Taljic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med*. 2008;358:2667-2677.
- Schaer BA, Schneider C, Jick SS, et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs. *Ann Intern Med*. 2010;152:78-84.
- Schlenker RE, Kramer AM, Hrinkevich CA, et al. Rehabilitation costs: implications for prospective payment. *Health Serv Res*. 1997;32:651-668.
- Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction. *JAMA*. 2008;300:431-433.
- Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. *Ann Intern Med*. 2009;151:297-305.
- Sipahi I, Tuzcu M, Wolski KE, et al. Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. *Ann Intern Med*. 2007;147:10-18.

- Staessen JA, Fagard R, Thijs L, et al. Morbidity and mortality in the placebo-controlled European trial on isolated systolic hypertension in the elderly. *Lancet*. 1997;350:757-764.
- Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention. Scientific review. *JAMA*. 2002;288:1388-1395.
- Sun S, Joglar JA. Cardiac resynchronization therapy: prospect for long-lasting heart failure remission. *J Investig Med*. 2011;59:887-892.
- The Medical Letter. Spironolactone for heart failure. *Med Lett Drugs Ther*. 1999;41:81-84.
- The Medical Letter. Drugs for hypertension. *Med Lett Drugs Ther*. 2001;43:17-22.
- Ting HH, Yang E, Rihal CS. Narrative review: reperfusion strategies for ST-segment elevation myocardial infarction. *Ann Intern Med*. 2006;145:610-617.
- van der Worp HB, van Gijn J. Acute ischemic stroke. *N Engl J Med*. 2007;357:572-579.
- Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. *N Engl J Med*. 2002;347:1834-1840.
- Wazni O, Wilkoff B, Saliba W. Catheter ablation for atrial fibrillation. *N Engl J Med*. 2011;365:2296-2304.
- Wechsler LR. Intravenous thrombolytic therapy for acute ischemic stroke. *N Engl J Med*. 2011;364:2138-2146.
- Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary disease. *Ann Intern Med*. 2007;147:1-9.
- White C. Intermittent claudication. *N Engl J Med*. 2007;356:1241-1250.
- Wilson W, Taubert KA, Gewitz M, et al. Presentation of infective endocarditis. *Circulation*. 2007;116:1736-1754.
- Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med*. 2003;348:583-592.
- Wolf SL, Winstein CJ, Miller JP, et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke. *JAMA*. 2006;296:2095-2104.
- Xian Y, Liang L, Smith EE et al. Risks of intracranial hemorrhage among patients with acute stroke receiving warfarin and treated with intravenous tissue plasminogen activator. *JAMA*. 2012;307:2600-2608.
- Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med*. 2011;364:11-21.

SUGGESTED READINGS

- Carabello BA. Aortic stenosis. *N Engl J Med*. 2002;346:677-682.
- Chen MA. Heart failure with preserved ejection fraction in older adults. *Am J Med*. 2009;122:713-723.
- Haider AW, Larson MG, Franklin SS, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham heart study. *Ann Intern Med*. 2003;138:10-16.
- Kahn N, McAlister FA. Review: beta-blockers differ in their efficacy for preventing major cardiovascular events in younger and older patients. *CMAJ*. 2006;174:1737-1742.
- Kane GC, Karon BL, Mahoney DW, et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. *JAMA*. 2011;306:856-863.
- Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. *JAMA*. 2002;288:2144-2150.

- Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. *JAMA*. 2011;306:2588-2593.
- Mitka M. New guidance covers ways to prevent and treat hypertension in elderly patients. *JAMA*. 2011;305:2394-2398.
- Van Gelder IC, Groenveld HF, Crijns HJGM. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med*. 2010;362:1363-1373.
- Weber KT. Aldosterone in congestive heart failure. *N Engl J Med*. 2001;345:1689-1697.
- Wilber DJ, Pappone C, Neuzel P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation. *JAMA*. 2010;303:333-340.

CHAPTER 12

Decreased Vitality

Older adults frequently report decreased vitality, which has a host of underlying causes. This chapter deals with metabolic factors that may lead to decreased energy in the older adults: endocrine disease, anemia, poor nutrition, and infection. Lack of exercise is discussed in Chapter 5.

ENDOCRINE DISEASE

■ Carbohydrate Metabolism

Approximately 50% of older people have glucose intolerance with normal fasting blood sugar levels. Although poor diet, obesity, and lack of exercise may account for some of these findings, aging itself is associated with deteriorating glucose tolerance, primarily attributable to a change in peripheral glucose utilization, although beta-cell dysfunction and decreased insulin secretion are also contributing factors. Glucose intolerance alone is not sufficient to diagnose diabetes mellitus. However, such individuals are at increased risk of developing diabetes mellitus. Prediabetes is identified as impaired fasting glucose (fasting plasma glucose level of 100-125 mg/dL), as impaired glucose tolerance (plasma glucose level of 140-199 mg/dL 2 hours after 75 g of glucose), or as a glycosylated hemoglobin of 5.7% to 6.4% (diagnosis of diabetes and prediabetes is reviewed in Inzucchi, 2012). Lifestyle modification, including weight loss and exercise, prevents or forestalls the development of type 2 diabetes in individuals with glucose intolerance (Diabetes Prevention Program Research Group, 2002; reviewed in Gillies et al., 2007). Both the U.S. Preventive Services Task Force (USPSTF) and the American Diabetes Association (ADA) recommend these interventions for patients at risk for diabetes (U.S. Preventive Services Task Force, 2003).

More than 25% of individuals age 65 and older in the United States have diabetes mellitus (Ligthelm et al., 2012). Many of these patients are unaware that they have the disease. The USPSTF concludes that the evidence is insufficient to recommend for or against routinely screening asymptomatic adults for type 2 diabetes, except that those with hypertension or hyperlipidemia should be screened as an approach to reducing cardiovascular risk. The ADA recommends that screening should begin at age 45 at 3-year intervals, but at shorter intervals in high-risk patients. The diagnosis of diabetes should be made based on a fasting plasma glucose level of ≥ 126 mg/dL or a glycosylated hemoglobin of $\geq 6.5\%$ and confirmed by either test. Initial evaluation in patients with type 2 diabetes should include glycosylated hemoglobin level, fasting lipid profile, basic metabolic panel, urine dipstick for overt proteinuria or screen for microalbuminuria, and electrocardiography.

The therapeutic goal for relatively healthy, nonfrail older diabetic patients is the same as that for younger patients: normal fasting plasma glucose without hypoglycemia.

According to the American Geriatrics Society, the Canadian Diabetes Association, the ADA, and the European Diabetes Working Party, a hemoglobin A1c (HbA1c) value of 7% or less is reasonable for healthy and well-functioning adults. However, in frail individuals and those with short life expectancies (including many nursing home residents), the therapeutic goal may be modified to eliminate symptoms associated with hyperglycemia, to reduce hypoglycemia, and to enhance quality of life. This can be accomplished by lowering the blood sugar to levels that avoid glycosuria. A less restrictive HbA1c (<8%) may be more appropriate for these patients. The age at which tight control is no longer indicated has not been defined; however, studies that demonstrated benefit of tight control were 4 to 6 years in duration. Among older diabetic patients, the presence of multiple comorbid illnesses or functional impairments is a more important predictor of limited life expectancy and diminishing expected benefits of intensive glucose control than is age alone (Huang et al., 2008). Although glycemic control may provide benefit in many older individuals, the greater risk of hypoglycemia in older adults must be considered when managing diabetes mellitus in this population (Ligthelm et al., 2012). Large randomized trials in patients with type 2 diabetes suggest that tight glycemic control burdens patients with complex treatment programs, hypoglycemia, weight gain, and costs and offers uncertain benefit in return (Montori and Fernandez-Balsells, 2009). There is also an association between tight glycemic control (HbA1c <7%) and a greater risk of hip fracture (Puar et al., 2012). In community-dwelling, nursing home-eligible individuals with diabetes mellitus, HbA1c of 8.0% to 8.9% is associated with better functional outcomes at 2 years than HbA1c of 7.0% to 7.9%, suggesting that even the current American Geriatrics Society guideline recommending an HbA1c target of 8% or less for older adults with limited life expectancy may be lower than necessary to maintain function (Yau et al., 2012).

Because most patients with adult-onset diabetes are obese, weight reduction should be attempted, although only approximately 10% will maintain a prolonged weight loss. Dietary fats should be reduced. Aerobic exercise can both delay the onset of type 2 diabetes mellitus and improve insulin resistance in individuals with established disease (Boulé et al., 2001). A combination of aerobic and resistance training is effective in lowering HbA1c levels in patients with type 2 diabetes mellitus (Church et al., 2010).

Several groups of oral hypoglycemic agents, each with a different mechanism of action, are now available. Comparative effectiveness and safety of medications for type 2 diabetes and clinical practice guidelines have been published (Bennett et al., 2011; Qaseem et al., 2012). Sulfonylureas act primarily by increasing beta-cell insulin secretion. They increase circulating insulin levels and are frequently associated with weight gain and may cause hypoglycemia. HbA1c reduction is in the 1% to 2% range. Although package inserts carry a warning on the increased risk of cardiovascular disease, the United Kingdom Prospective Diabetes Study (UKPDS) Group reported no adverse cardiovascular outcomes in sulfonylurea-treated patients (United Kingdom Prospective Diabetes Study Group, 1998a).

Acarbose reduces postprandial plasma glucose by inhibiting small intestine brush-border α -glucosidases. It has a small effect on metabolic control (HbA1c reduction of 0.5%-1%) and causes frequent gastrointestinal distress with bloating and flatulence.

Metformin, a biguanide, exerts its major metabolic effect by inhibiting hepatic glucose production. Metformin leads to significant improvement in glucose control when used alone (HbA1c reduction of 1%-2%) or in combination with a sulfonylurea (Inzucchi et al., 1998). Unlike sulfonylureas, which often lead to weight gain, metformin therapy is associated with weight loss, a benefit to most type 2 diabetic patients. Weight should be monitored closely in thin diabetic patients. A serious side effect of metformin is lactic acidosis. It should not be used in patients with renal insufficiency or chronic heart failure. In patients age 80 years or older, creatinine clearance should be measured before therapy is initiated. Metformin should be discontinued during illnesses associated with volume depletion and prior to surgery.

Thiazolidinediones lower blood sugar by improving target-cell insulin sensitivity. Besides the potential for hepatic toxicity, which requires frequent liver function testing, thiazolidinedione therapy may be associated with marked weight gain. Fluid retention occurs more frequently in combination with insulin and in heart failure, making these conditions contraindications for the use of these agents. The thiazolidinedione, rosiglitazone, is associated with an increased risk of heart failure, acute myocardial infarction, and death (Lipscombe et al., 2007; Singh, Loke, and Furberg, 2007). This appears to be limited to rosiglitazone because, although pioglitazone is associated with an increased risk for serious heart failure, it is not associated with increased risk for death, myocardial infarction, or stroke (Lincoff et al., 2007).

Meglitinide analogues (nateglinide and repaglinide) are nonsulfonylurea insulin secretagogues with shorter onset of action and half-life than sulfonylureas, a greater decrease in postprandial glucose level, and a lower risk of hypoglycemia. They may be good choices for individuals with irregular mealtimes but are more expensive than other oral diabetes drugs, and morbidity and mortality effects are unknown (reviewed in Black et al., 2007).

Two other classes of agents have been approved: incretin mimetics and dipeptidyl peptidase IV (DPP-4) inhibitors (reviewed in Amori, Lau, and Pittas, 2007). The first incretin mimetic, exenatide, has the same glucoregulatory action as glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone (reviewed in Drucker, 2007). It enhances glucose-dependent insulin secretion, suppresses inappropriately high glucagon secretion, slows gastric emptying, decreases food intake, promotes beta-cell proliferation and neogenesis, reduces adiposity, and increases insulin-sensitizing effects. It is administered by subcutaneous injection twice daily, with a major side effect of nausea and vomiting. Adding twice-daily exenatide injections improved glycemic control without increased hypoglycemia or weight gain in patients with uncontrolled type 2 diabetes who were receiving insulin glargine treatment (Buse et al., 2011). In 2006, the U.S. Food and Drug Administration (FDA) approved sitagliptin, a DPP-4 inhibitor. By inhibiting the breakdown of GLP-1

and glucose-dependent insulinotropic polypeptide, it leads to a lower blood glucose, stimulates insulin secretion, and decreases levels of circulating glucagon. It does not inhibit gastric emptying or promote satiety and does not lead to weight loss. It is well tolerated without nausea or vomiting. Sitagliptin is one of the less effective glycemia-lowering drugs (HbA1c reduction of 0.5%-0.9%) (Nathan, 2007).

Table 12-1 presents a step-care approach to the treatment of type 2 diabetes. Because of the results of the UKPDS study, close control of blood glucose in type 2 diabetes is now in vogue. Intensive blood glucose control with sulfonylureas or insulin decreased the risk of microvascular complications but not macrovascular disease. Intensive treatment

TABLE 12-1. Step-Care Approach to the Treatment of Type 2 Diabetes		
Step	Criteria and recommendations	Monitoring
Step 1: Evaluation and nonpharmacologic approaches	Newly diagnosed or current therapy ineffective: initiate or reinforce diet, exercise, home blood glucose monitoring, formal diabetes education Current therapy effective: continue therapy	Success: continue step 1 Failure after 2-3 months: go to step 2*
Step 2: Oral monotherapy	Obese or dyslipidemic: first line—metformin; second line—thiazolidinedione or acarbose Nonobese: first line—sulfonylurea or metformin; second line—acarbose	Success: continue step 2 Failure: go to step 3
Step 3: Oral combination therapy	Previously on metformin: add sulfonylurea Previously on sulfonylurea: add metformin or thiazolidinedione Previously on thiazolidinedione: add sulfonylurea Previously on acarbose, obese: add metformin Previously on acarbose, not obese: add sulfonylurea	Success: continue step 3 Failure: go to step 4
Step 4: Insulin initiation or insulin + oral therapy	FBG <200-240: eliminate one drug and always thiazolidinedione, start bedtime glargine FBG >200-240: eliminate one drug, start bedtime glargine and prandial lispro†	Success: continue step 4 Failure: consult specialist

*Severe hyperglycemia (FBG >300) may require initiation of insulin therapy.
†Other long-acting soluble insulin may be substituted for glargine for basal control. Other rapid-acting insulin may be substituted for lispro for prandial control.
FBG, fasting blood glucose.

did increase the risk of hypoglycemia. Intensive blood glucose control with metformin in overweight patients decreased the risk of both microvascular and macrovascular complications and was associated with less weight gain and fewer hypoglycemic attacks than insulin and sulfonylureas (United Kingdom Prospective Diabetes Study Group, 1998b). Metformin is recommended as first-line pharmacological therapy in overweight patients. It is important to observe patients closely for hypoglycemic reactions and their ability to respond to this stress if any of these regimens is prescribed. Although each agent is effective as monotherapy, the majority of patients need multiple therapies to attain glycemic target levels in the longer term.

Patients who do not achieve adequate glycemic control with a combination of oral medications are candidates for insulin treatment. Insulin therapy may be combined with oral therapy to better achieve target glucose control. Glucose monitoring is essential for titrating the insulin dose. Multiple insulin regimens are possible, but most begin with a basal insulin of once-daily glargine or twice-daily neutral protamine Hagedorn (NPH) insulin. Insulin glargine has modestly better glycemic benefits than NPH insulin with a low risk of hypoglycemia (Lee et al., 2012). Fast-acting insulin may be added with meals to attain better glycemic control (reviewed in Mooradian, Bernbaum, and Albert, 2006; Holman et al., 2009).

Pramlintide has been approved for use with mealtime insulin. It is a synthetic form of the hormone amylin, which is produced and secreted along with insulin by pancreatic beta-cells. It enhances insulin action and is administered subcutaneously before each meal. Again, as with other new agents, there are no long-term morbidity or mortality data.

A new agent, dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2, improves glycemic control, stabilizes insulin dosing, and reduces weight without increasing major hypoglycemic episodes in patients with inadequately controlled type 2 diabetes mellitus (Wilding et al., 2012). Currently, there are no specific data on this agent in older adults.

Diabetics are at increased risk of macrovascular disease. Other atherosclerotic risk factors such as smoking, dyslipidemia, and hypertension should be eliminated or treated. Therapy of these risk factors may be of greater benefit than tight glucose control in older diabetics. Blood pressure control reduces both micro- and macrovascular complications in type 2 diabetes (United Kingdom Prospective Diabetes Study Group, 1998c). There is no evidence from randomized trials to support a strategy of lowering systolic blood pressure below 135 to 140 mm Hg in persons with type 2 diabetes mellitus (Cushman et al., 2010). A meta-analysis of cholesterol-lowering and blood pressure-lowering trials demonstrated large, significant effects on reducing macrovascular disease in type 2 diabetes (Huang, Meigs, and Singer, 2001). Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) attenuate progression of nephropathy in both type 1 and type 2 diabetic patients with hypertension and in normotensives with microalbuminuria. They also attenuate decline in renal function in normotensive, normoalbuminuric type 2 diabetic patients (reviewed in Strippoli et al., 2006). The antihypertensive regimen of diabetics should include an ACE inhibitor or ARB, and such therapy should be initiated in normotensive albuminuric patients.

Intensified multifactorial intervention with tight glucose regulation and the use of renin–angiotensin system blockers, aspirin, and lipid-lowering agents has been shown to reduce the risk of nonfatal cardiovascular disease and the rates of death from cardiovascular causes and death from any cause (Gaede et al., 2008).

The goals for glycemic control are less well established for hospitalized than for ambulatory patients. However, data suggest that maintaining blood glucose at 80 to 110 mg/dL in critically ill patients reduces mortality and that hyperglycemia adversely affects wound healing and increases the risk for infection (reviewed in Inzucchi, 2006). Although sliding scale insulin regimens are frequently used in hospitalized patients with diabetes, it is the opinion of the authors that they should not be used. The University of Washington has developed an algorithm to replace sliding scale insulin orders (Fig. 12-1).

Older adults have an increased incidence of hyperosmolar nonketotic (HNK) coma. Characteristic symptoms and signs help the physician distinguish this syndrome from diabetic ketoacidotic (DKA) coma. Table 12-2 compares HNK and DKA. Whereas DKA frequently develops over hours, HNK typically develops over days to weeks. Focal or generalized seizures are common in HNK and unusual in uncomplicated DKA. The fluid deficit is greater in HNK, thus leading to a higher serum sodium and more marked rise in blood urea nitrogen. Therapy in HNK must therefore address the volume and hyperosmolar state of the patient. Because these patients may be quite sensitive to insulin, lowering of glucose should be done cautiously. Volume replacement should be initiated with normal saline. This therapy alone may reduce blood glucose levels, as renal perfusion is enhanced and glucose is lost in the urine. If, after 1 hour of volume repletion, blood glucose levels are not reduced, a bolus of 20 U of regular insulin should be administered intravenously. If glucose levels do not respond, an insulin drip may be started. Such an approach should allow repletion of volume without lowering serum osmolality too rapidly.

■ Thyroid

The changes with aging in the hypothalamic-pituitary-thyroid axis have been reviewed (Habra and Sarlis, 2005). Although thyroid function is generally normal in aging, clinicians should be aware of the norms for thyroid function tests for this age group (Table 12-3). The majority of data indicate that thyroxine (T_4) levels are normal. Triiodothyronine (T_3) levels may be lower in healthy older people when compared to younger individuals but are still in the normal range. It has been suggested that the lower T_3 levels reported in several studies are caused by undiagnosed illness and the low T_3 syndrome described later. Thyroid-stimulating hormone (TSH) levels are also normal, whereas the TSH response to thyroid-releasing hormone (TRH) is decreased in males and normal in females. Thus, the TRH test is less valuable in older males. Metabolic clearance of thyroid hormones is decreased in aging. With intact feedback loops, normal thyroid function is maintained despite this change. However, with exogenous replacement of thyroid hormone, such regulatory mechanisms are not maintained; thyroid replacement doses in older adults should be lower to take into





FIGURE 12-1 Flow diagram for treatment of hospitalized (nonintensive care unit) patients with type 2 diabetes mellitus. CHF, congestive heart failure; NPH, neutral protamine Hagedorn (insulin); NPO, nothing by mouth; PO, by mouth; TPN, total parenteral nutrition. (Reproduced with permission from Ku, 2002.)



* Basal insulin doses should only be adjusted every few days.
† Pioglitazone and rosiglitazone are contraindicated in patients with CHF, and thus should be discontinued in patients admitted with congestive heart failure.
‡ Following any procedure which alters renal function, metformin needs to be held for 48 hours or until renal function returns to baseline.

FIGURE 12-1 (Continued)

TABLE 12-2. Hyperosmolar Nonketotic (HNK) Coma and Diabetic Ketoacidosis (DKA)

	HNK*	DKA
Time of development	Days to weeks	Hours
Seizures	Common	Uncommon
Fluid deficit	Marked	Present
Serum sodium	↑↑	↑
Blood urea nitrogen	↑↑	↑

*Double arrow signifies a higher increase than a single arrow. Correction factor for sodium: 100 mg/dL of glucose = 1.6 mEq/L of sodium.

account the lower metabolic clearance. Laboratory evaluation tests most useful in thyroid disease are summarized in [Table 12-4](#).

Hypothyroidism

Hypothyroidism is primarily a disease of those age 50 to 70 years. Goiter is rarely seen with hypothyroidism in older adults except when it is iodide induced. Diagnosis is usually made by a low free T_4 and an elevated TSH. Because total T_4 levels may be depressed in seriously ill patients, diagnosis of hypothyroidism should not be made on the basis of low T_4 levels alone. [Table 12-5](#) lists laboratory characteristics of the low T_4 syndrome associated with nonthyroidal illness. Not all free T_4 methods distinguish the low T_4 syndrome from hypothyroidism; physicians should be aware of the type of determination and interpretation used in their laboratory. Because the T_3 level may be in the normal range in hypothyroidism, this is not a helpful test. The low T_3 level associated with a host of acute and chronic nonthyroidal illnesses also contributes to the poor specificity of this test in hypothyroidism. Approximately 75% of circulating T_3 is derived from peripheral conversion from T_4 . The enzymes that convert T_4 to T_3 or reverse T_3 are under metabolic control. During illness, more T_4 is converted to reverse T_3 , leading to the characteristic laboratory findings of the low T_3 syndrome.

The radioactive iodine uptake is also not helpful because normal values are so low that they overlap with hypothyroidism. The TRH stimulation test can be used in females, but decreased responsiveness to TRH in older males does not allow this

TABLE 12-3. Thyroid Function in the Normal Elderly

Normal	Decreased
T_4	TSH response to TRH in males
Free T_4	Thyroid hormone production rate
T_3	Metabolic clearance rate of thyroid hormone
TSH	

TRH, thyroid-releasing hormone; TSH, thyroid-stimulating hormone.

TABLE 12-4. Laboratory Evaluation of Thyroid Disease in the Elderly

	Hypothyroidism	Hyperthyroidism
T ₄	E	E
TSH	E	E
Free T ₄	E	E
T ₃	O	D
Radioactive iodine uptake	O	D
TRH test	D (Females) O (Males)	D (Females) O (Males)
Reverse T ₃	D	D
TSH stimulation	D	O
T ₃ suppression	O	O

D, helpful in confirming diagnosis or in differentiation of difficult cases; E, test for initial evaluation; O, not helpful in diagnosis or not indicated; TRH, thyroid-releasing hormone; TSH, thyroid-stimulating hormone.

test to distinguish normal from pathologic states. In males, a TSH stimulation test may help to confirm the presence of hypothyroidism.

Hypothyroidism may be accompanied by other laboratory abnormalities. Creatine phosphokinase (CPK) levels may be elevated. A normocytic, normochromic anemia, which responds to thyroid hormone replacement, may be present. There is an increased incidence of pernicious anemia in hypothyroidism, but the microcytic anemia of iron deficiency remains the most common anemia associated with hypothyroidism.

The symptoms and signs of hypothyroidism may be overlooked when such complaints as fatigue, memory loss, and decreased hearing are ascribed to aging without further investigation. The prevalence of undiagnosed hypothyroidism in healthy older people has varied from 0.5% to 2% in multiple studies; consequently, a general screening program is not cost-effective. The prevalence among older adults who are ill, however, is sufficient to support screening for hypothyroidism in this population, comprising individuals who have already presented themselves for care.

TABLE 12-5. Thyroid Function Tests in Nonthyroidal Illness

	Low T ₄ syndrome	Low T ₃ syndrome
T ₄	Decreased	Normal
Free T ₄	Normal or increased	Normal
T ₃	Decreased	Decreased
Reverse T ₃	Normal or increased	Normal or increased
Thyroid-stimulating hormone	Normal	Normal

Therapy for hypothyroidism should be started at 0.025 to 0.05 mg of sodium levothyroxine (Synthroid) per day and increased by the same dose at 1- to 3-week intervals. The decreased metabolic clearance rate of thyroid hormone in aging may lead to a lower maintenance dose of T_4 . The physician should monitor heart rate response and symptoms of angina and, in the laboratory, the TSH level. When indicated for symptomatic cardiovascular disease, a β -blocker may be added to the T_4 regimen. In patients with coronary artery disease, therapy can be initiated with T_3 5 μ g/day and increased by 5 μ g at weekly intervals to a level of 25 μ g/day, at which time the patient can be converted to T_4 therapy. Because T_3 has a shorter half-life than T_4 , symptoms will remit more rapidly after discontinuance of therapy if the patient develops cardiovascular complications. A β -blocker can also be added to the T_3 regimen. T_4 monotherapy, rather than T_4 - T_3 combination, should remain the treatment of choice for clinical hypothyroidism (Grozinsky-Glasberg et al., 2006).

Subclinical Hypothyroidism

Subclinical hypothyroidism is characterized by increased serum TSH concentrations with normal free T_4 and free T_3 levels. It occurs in 10% to 15% of the general population. The presentation is nonspecific, and symptoms are usually subtle. In a prospective follow-up study, based on the initial TSH level (4 to 6, >6 to 12, or >12 mIU/L), the incidence of overt hypothyroidism after 10 years was 0%, 42.8%, and 76.9%, respectively (Huber et al., 2002). The incidence of overt disease was increased in those with positive microsomal antibodies. Subclinical hypothyroidism is associated with an increased risk of coronary heart disease (CHD) events and CHD mortality in those with higher TSH levels, particularly in those with a TSH concentration of 10 mIU/L or greater (Rodondi et al., 2010), and is associated with left ventricular diastolic dysfunction that is improved with T_4 therapy (Biondi et al., 1999). Others have not found an association of subclinical hypothyroidism with cardiovascular disorders or mortality (Cappola et al., 2006). The decision to treat patients remains controversial (Fatourech, 2007). Contributing to this controversy is the question of the age-specific distribution of TSH (Surks and Hollowell, 2007). This is further complicated by data showing reduced mortality risk in untreated mild hypothyroid subjects age >85 years (Mariotti and Cambuli, 2007). Despite the controversy, some experts favor treating most patients because (1) some studies do report improvement in some outcomes (eg, cognition, lipids, and heart function); (2) the risks of thyroid replacement therapy are low; (3) the cost of thyroid replacement therapy is low; and (4) it will prevent the development of symptoms of clinical hypothyroidism, which occurs in 5% of patients per year (Gharib, 2008). If therapy is contemplated, an algorithm for the management of subclinical hypothyroidism has been proposed (Fig. 12-2).

Myxedema Coma

Most patients with myxedema coma are older than age 60 (Table 12-6). In approximately 50% of the cases, the coma is induced in the hospital by treating




FIGURE 12-2 An algorithm for the management of subclinical hypothyroidism. LDL, low-density lipoprotein. (Reproduced with permission from Cooper, 2001.)

TABLE 12-6. Myxedema Coma
Usually older than age 60 years
50% induced by hypnotics
Neck scar
Hypothermia
Delayed relaxation of tendon reflex
Respiratory failure and apnea

hypothyroid patients with hypnotics. A neck scar, from previous thyroid surgery, is a clue to the cause of coma. Because patients with this disorder die of respiratory failure, hypercapnia requires prompt attention. These patients should be treated in an intensive care setting, with intubation and respiratory assistance instituted at the first sign of respiratory failure. The cerebrospinal fluid protein level is often more than 100 mg/dL and should not in itself be used as an indicator of other central nervous system pathology. Therapy includes an initial dose of T_4 intravenously. Although studies have not been done to demonstrate the efficacy of glucocorticoids in this syndrome, it is generally recommended that these patients receive 50 mg of hydrocortisone every 6 hours for the first 1 or 2 days. Patients with concomitant adrenal insufficiency will require continued steroid therapy.

Hyperthyroidism

Approximately 20% of hyperthyroid patients are older adults; 75% have classic signs and symptoms. Ophthalmopathy is infrequent. Approximately one-third have no goiter. Toxic multinodular goiter is more frequent in older persons than in the young. Severe nonthyroidal disease may disguise thyrotoxicosis (apathetic hyperthyroidism). Congestive heart failure (CHF), stroke, and infection are common disorders associated with masked hyperthyroidism. There should be a high threshold of suspicion for hyperthyroidism in older adults. Unexplained heart failure or tachyarrhythmia, recent onset of a psychiatric disorder, or profound myopathy should raise questions about masked hyperthyroidism. The triad of weight loss, anorexia, and constipation, which may raise the possibility of neoplastic disease, occurs in 15% of older thyrotoxic patients. Diagnosis is made by T_4 , T_3 , and/or radioactive iodine uptake (see Table 12-4). The ultrasensitive TSH assays can differentiate hyperthyroidism from normal. In the absence of acute nonthyroidal disease, this test alone may confirm the clinical diagnosis of hyperthyroidism. In the presence of acute illness, concomitant determination of TSH and free T_4 may be more appropriate. A T_3 suppression test should not be done in older adults because of the risk of angina or myocardial infarction.

Therapy is usually by radioactive iodine ablation. Often patients are first treated with antithyroid medications to control hyperthyroidism and deplete the thyroid gland of hormone prior to the radioactive iodine treatment (reviewed in Cooper, 2005). Surgery is reserved for patients with thyroid glands that are causing local obstructive symptoms.

Severe thyrotoxicosis is treated with antithyroid drugs (preferably propylthiouracil because it blocks peripheral conversion of T_4 to T_3) to inhibit new hormone synthesis, iodides to block thyroid hormone secretion, and β -blockers to decrease the peripheral manifestations of thyroid hormone action. In older adults with underlying cardiac disease, β -blocker therapy may be a problem; thus the cardiovascular response must be closely monitored. In patients allergic to antithyroid medications or where β -blockers are contraindicated, calcium ipodate (Oragrafen), 3 g every 3 days, can be used because it inhibits peripheral conversion of T_4 to T_3 . Dexamethasone 2 mg

every 6 hours inhibits peripheral conversion of T_4 to T_3 and may be added to any of the above regimens.

For the management guidelines of hyperthyroidism and other causes of thyrotoxicosis from the American Thyroid Association and the American Association of Clinical Endocrinologists, see Bahn et al. (2011).

Subclinical Hyperthyroidism

Subclinical hyperthyroidism is defined as a combination of serum TSH of less than 0.45 mIU/L and normal serum free T_4 and T_3 . Subclinical hyperthyroidism is associated with a 24% increase in mortality, a 29% increase in CHD mortality, and 69% incident atrial fibrillation in 9 years (Collet et al., 2012), and older subclinical hyperthyroid individuals are significantly more likely to have cognitive dysfunction than those who are euthyroid (hazard ratio, 2.26) (Ceresini et al., 2009). If the TSH level is less than 0.1 mIU/L, treatment is generally recommended with iodine-131 ablation. In patients with a TSH level of 1.0 to 4.5 mIU/L and atrial fibrillation, cardiovascular disease, or low bone density, or those with multinodular goiter, treatment is also recommended. If treatment is deferred, TSH and free T_4 and T_3 should be measured in 6 months.

■ **Hyperparathyroidism**

One-third of patients with hyperparathyroidism are older than age 60. Symptoms are the same in older adults as in those who are younger but may be overlooked. Bone demineralization, weakness, and joint complaints may be ascribed to aging when they may actually indicate parathyroid disease. Primary hyperthyroidism is common in postmenopausal women with forearm fracture and low bone mineral density (Bergström, Landgren, and Freyschuss, 2007). Basic laboratory screening is indicated in these individuals. A National Institutes of Health Workshop has developed guidelines for surgery in patients with asymptomatic primary hyperthyroidism (Bilezikian et al., 2002, and reviewed in Marcocci and Cetani, 2011). Surgery is recommended if one of the following is present: serum calcium concentration greater than 1.0 mg/dL above upper limit of normal; 24-hour urinary calcium greater than 400 mg; creatinine clearance reduced by 30%; bone mineral density T-score lower than -2.5 at any site; and age less than 50 years. In those older than 50, surgery can be delayed with monitoring for the above criteria.

Table 12-7 contrasts some of the basic patterns of the common laboratory tests in hyperparathyroidism with those of other metabolic bone diseases that are common in older adults.

■ **Vasopressin Secretion**

Basal vasopressin levels are unaltered in normal older individuals. Infusion of hypertonic saline, however, leads to a greater increase in plasma vasopressin in older compared with younger persons. In contrast to the response to the hyperosmolar challenge, volume changes related to the assumption of upright posture are associated with less of a vasopressin response in older subjects as compared with the young.

TABLE 12-7. Laboratory Findings in Metabolic Bone Disease

Disease	Ca	P	Alk	PTH
Hyperparathyroidism	High	Low/normal	High/normal	High
Osteomalacia	Low/normal	Low	High/normal	High
Hyperthyroidism	High	High	High/normal	Low
Osteoporosis	Normal	Normal	Normal	Normal/high
Paget disease	Normal/high	Normal/high	High	Normal

Alk, alkaline phosphatase; Ca, calcium; P, phosphorus; PTH, parathyroid hormone.

Both of these findings might be explained by impaired baroreceptor input to the supraoptic nucleus. Volume expansion decreases osmoreceptor sensitivity. Hypertonic saline infusion results in volume expansion and thus decreases osmoreceptor sensitivity. If baroreceptor input is impaired in older adults, volume expansion would lead to a lesser dampening effect, and thus, the vasopressin response to hyperosmolar stimuli would be increased.

Hyponatremia is a serious and often overlooked problem of the older patient (reviewed in Miller, 2006; Ellison and Berl, 2007). This syndrome is often associated with one of three general causes: (1) decreased renal blood flow with a decreased ability to excrete a water load; (2) diuretic administration leading to water intoxication (this condition is rapidly corrected by discontinuing diuretics); and (3) excess vasopressin secretion. Although a host of pulmonary disorders (eg, pneumonia, tuberculosis, tumor) and central nervous system disorders (eg, stroke, meningitis, subdural hematoma) are associated with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in any age group, older adults seem more prone to develop this complication. Certain drugs, such as chlorpropamide and barbiturates, may cause this syndrome more frequently in older individuals.

In addition to treatment directed at correcting the underlying cause, water restriction and hypertonic saline are indicated when the patient is symptomatic or the sodium level is below 120 mEq/L. Demethylchlortetracycline therapy may be needed in resistant patients with SIADH. This agent induces a partial nephrogenic diabetes insipidus and thus corrects the hyponatremia. Serum creatinine and blood urea nitrogen should be closely monitored.

■ Anabolic Hormones

Aging is associated with a decline in anabolic hormones (Lamberts, van den Beld, and van der Lely, 1997). The declining activity of the growth hormone insulin-like growth factor-1 (IGF-1) axis with advancing age may contribute to the decrease in lean body mass and the increase in mass of adipose tissue that occur with aging. Increased lean body mass and decreased fat mass have been demonstrated to occur in men and women with growth hormone treatment. Men had marginal improvement of muscle strength and maximum oxygen consumption (VO_{2max}), but women had no

significant change. Adverse effects were frequent, including glucose intolerance and diabetes (Blackman et al., 2002; Liu et al., 2007).

Normal male aging is accompanied by a decline in testicular function, including a fall in serum levels of total testosterone and bioavailable testosterone. Only some men become hypogonadal. Androgens have many important physiological actions, including effects on muscle, bone, and bone marrow. However, little is known about the effects of the age-related decline in testicular function on androgen target organs. Studies of testosterone supplementation in older males demonstrate significant increases in lean body mass and significant decreases in biochemical parameters of bone resorption with testosterone treatment. Testosterone supplementation in older men with low-normal testosterone concentration did not affect functional status or cognition (Emmelot-Vonk et al., 2008). However, there was a significant increase in hematocrit and a sustained stimulation of prostate-specific antigen (Gruenewald and Matsumoto, 2003). Based on these results, growth hormone administration and testosterone supplementation cannot be recommended at this time for older men with normal or low-normal levels of these anabolic hormones. Although clinical trial data are limited, current practice guidelines recommend testosterone replacement therapy in symptomatic men with low testosterone levels to improve bone mineral density; muscle mass, strength, and physical performance; sexual function; and quality of life (Page et al., 2005; Kazi, Geraci, and Koch, 2007; Kenny et al., 2010).

ANEMIA

Anemia is common in older adults but should not be attributed simply to old age. Increased weakness, fatigue, and a mild anemia should not be dismissed as a manifestation of aging. In healthy older individuals, there is generally no change in normal levels of hemoglobin from younger adult values. A low hemoglobin concentration at old age signifies disease and is associated with increased mortality, disability, and hospitalization (Izaks, Westendorp, and Knook, 1999; Longo, 2005; Maraldi et al., 2006; Penninx et al., 2006; Dong et al., 2008), although the actual mechanism has not been elucidated. Higher red cell distribution width (RDW) is also a predictor of mortality in community-dwelling older adults with and without age-associated diseases (Patel et al., 2010). The biological mechanisms underlying this association are unknown.

Signs and symptoms of anemia may be subtle. [Table 12-8](#) lists some of these manifestations. Anemia should be considered in these circumstances. If anemia is

TABLE 12-8. Signs and Symptoms of Anemia	
Weakness	Ischemic chest pain
Postural hypotension	Congestive heart failure
Syncope	Exertional dyspnea
Falls	Pallor
Confusion	Tachycardia
Worsened dementia	

present, a diagnostic evaluation is indicated to define the cause. The appearance of the peripheral blood smear along with the history and physical examination should direct the diagnostic evaluation as described below. However, despite intensive evaluation, unexplained anemia predominates in older adults (Artz and Thirman, 2011). Unexplained anemia is characterized by a hypoproliferative mild-to-moderate anemia with suppressed serum erythropoietin.

■ Iron Deficiency

Iron deficiency is the most common anemia with a known etiology in older adults. Laboratory findings include hypochromia, microcytosis, low reticulocyte count, decreased serum iron, increased total iron-binding capacity (TIBC), low transferrin saturation, and absent bone marrow iron stores. A low serum iron and elevated TIBC indicate iron deficiency even in the absence of changes in red cell morphology. Because transferrin is reduced in many diseases, the TIBC may be normal or low in older patients with iron deficiency. However, a transferrin saturation of less than 10% would suggest iron deficiency even in the presence of a low TIBC. A low serum ferritin level is valuable in confirming the diagnosis because serum ferritin levels are below 12 mg/L in iron-deficiency anemia. Because inflammatory disease can elevate ferritin levels and liver disease can influence ferritin levels in either direction, the diagnosis of iron deficiency based on a ferritin level must be made with knowledge of the clinical situation.

Once iron deficiency is identified, it should be treated, and the cause of the anemia must be identified and corrected. Poor dietary intake of iron may contribute to iron deficiency in older adults. A dietary evaluation is important, both for foods that contain iron and for substances such as tea, which inhibit iron absorption. However, even in the presence of poor nutrition, evaluation for a bleeding lesion must be completed.

The stool should be examined for occult blood. Evaluation for a gastrointestinal lesion should be carried out in a patient with unexplained iron deficiency, even if the stool is negative for occult blood. Although gastrointestinal bleeding may be caused by drugs (especially certain analgesics, steroids, and alcohol), a gastrointestinal lesion must be excluded. Diverticulosis is a common cause of bleeding. Vascular ectasia of the cecum and ascending colon is increasingly a recognized cause of bleeding in older adults.

Replacement of iron should usually be by daily oral administration. The hemoglobin should improve in 10 days and be normal in approximately 6 weeks. Normal bone marrow iron stores should occur in an additional 4 months. If the anemia does not improve, one should consider nonadherence, continued bleeding, or an incorrect diagnosis. In unreliable patients, or when oral iron is not tolerated, parenteral iron replacement is indicated. Tolerance should be monitored with a test dose, and the patient should be closely observed for an acute reaction. Severe reactions occur less frequently with ferric gluconate, but a test dose should be used as well. Parenteral iron should not be used routinely, but it is an important therapeutic modality in the appropriate patient.

■ **Chronic Disease**

The anemia of chronic disease (ACD) may display many similarities with iron-deficiency anemia (reviewed in Weiss and Goodnough, 2005; Keel and Abkowitz, 2009). In older adults, this anemia is frequently associated with chronic inflammatory diseases or neoplasia. There is a defect in bone marrow red cell production and a shortening of erythrocyte life span. The finding of hypochromia, low reticulocyte count, and low serum iron may lead to confusion with iron deficiency. When a high TIBC does not confirm the presence of iron deficiency, a ferritin level can differentiate the two anemias. It is low in iron deficiency and high-normal or elevated in ACD. Treatment is addressed to the underlying chronic illness, because there is no specific therapy for this type of anemia.

■ **Sideroblastic Anemia**

Sideroblastic anemia should be considered in an older patient with hypochromic anemia who does not have iron deficiency or a chronic disease. Serum iron and transferrin saturation are increased. Hence, synthesis is defective, leading to increased iron stores and the diagnostic finding of ringed sideroblasts in the marrow.

In older adults, sideroblastic anemia is commonly of the acquired type. The idiopathic group is usually refractory; only a few patients have a partial response to pyridoxine, but all should have a trial of pyridoxine. Although the prognosis is fairly good, approximately 10% of patients develop acute myeloblastic leukemia. Secondary sideroblastic anemia may be associated with underlying diseases such as malignancies and chronic inflammatory diseases. Certain drugs and toxins can induce sideroblastic anemia (eg, ethanol, lead, isoniazid, chloramphenicol). The drug-induced syndromes are corrected by administering pyridoxine. [Table 12-9](#) lists the tests that will assist in the differential diagnosis of hypochromic anemias.

■ **Vitamin B₁₂ and Folate Deficiency**

Both vitamin B₁₂ and folate deficiency may occur on a nutritional basis, although folate deficiency is more common. Older people who live alone or who are alcoholics are most likely to have poor nutrition. Poor dietary intake of fresh fruits and

TABLE 12-9. Differential Tests in Hypochromic Anemia			
Item	Iron deficiency	Chronic disease	Sideroblastic anemia
Serum iron	Low	Low	High
Total iron-binding capacity	Usually increased*	Low	Normal
Transferrin saturation	Low	Low	High
Ferritin	Low	High	Normal
Bone marrow iron	Absent	Adequate	Increased ringed sideroblasts

*May be normal or even low in older adults.

vegetables may lead to folate deficiency; lack of meat, poultry, fish, eggs, and dairy products may lead to vitamin B₁₂ deficiency. Vitamin B₁₂ deficiency also occurs with the loss of intrinsic factor (pernicious anemia) and in gastrointestinal disorders associated with malabsorption of vitamin B₁₂.

The laboratory findings are similar in the two deficiencies and include macrocytosis, hyperchromasia, hypersegmented neutrophils, and megaloblasts in the marrow. Leukopenia and thrombocytopenia may be present, and serum lactic dehydrogenase and bilirubin may be increased. The two are differentiated by measuring serum vitamin B₁₂ and folate levels.

Treatment is with vitamin B₁₂ or folic acid, as appropriate. However, because folate will correct the hematological disorder but not the neurological abnormalities of vitamin B₁₂ deficiency, a correct diagnosis is essential before treatment.

■ Erythropoietin

A longitudinal analysis of erythropoietin (Epo) levels in the Baltimore Longitudinal Study on Aging revealed a significant rise in Epo levels with age (Ershler et al., 2005). Subjects who developed anemia but did not have hypertension or diabetes had the greatest rise in Epo slope over time, whereas those with hypertension or diabetes had the lowest slope. In very advanced age or in those with compromised renal function, an inadequate compensatory mechanism leads to anemia.

Epo effectively corrects the anemia in patients with chronic kidney disease (CKD) who do not yet require dialysis and may improve anemia-induced symptoms and cardiovascular function and perhaps decrease mortality (Jones et al., 2004). An adequate response to Epo requires the maintenance of sufficient iron stores. Iron status should be evaluated and iron supplements given when there is evidence of iron deficiency. The FDA recommendation indicates that patients with CKD, who are not on dialysis, should have a hemoglobin (Hgb) count of 10 g/dL prior to starting treatment. However, better outcomes have been demonstrated with Hgb values above 11 g/dL (hematocrit of 33%). There is also evidence for little benefit and potential risk for maintaining Hgb levels ≥ 13 g/dL (hematocrit 39%). The recommended target is Hgb levels between 11 and 12 g/dL. Future recommendations may be lower because of the boxed warning to adjust Epo dose to maintain the Hgb level necessary to avoid the need for blood transfusion.

The FDA has issued a black box safety alert indicating that treating the anemia of cancer with Epo in patients who are not receiving chemotherapy offers no benefit and may cause serious harm (Steensma, 2008). As in CKD, the FDA recommendation is to gradually increase the Hgb concentration to the lowest level sufficient to avoid blood transfusions in patients who are receiving chemotherapy.

The preferred therapy for anemia of chronic disease (ACD) is correction of the underlying disorder, rather than transfusion or Epo therapy. Studies in humans of therapy with Epo in ACD have been limited. Although one of the hallmarks of ACD is reduced bone marrow response to endogenous or exogenous Epo, some patients may respond. Epo has been helpful in ACD in patients with rheumatoid arthritis or acquired immunodeficiency syndrome (AIDS) who have low Epo levels (<500 mU/mL).

With the present FDA recommendations and cautions, Epo therapy in older adults should be reserved for those who meet the criteria for therapy described earlier.

NUTRITION

A discussion of nutrition and aging is limited by the lack of adequate studies, defined methods, and standards. Although it is generally accepted that intake moderately above recommended allowances is optimal, animal studies demonstrate increased longevity with lower caloric levels than recommended. In establishing nutritional requirements in humans, we must contend with the multiple factors that confine interpretation of available data, for example, genetic factors, social environment, economic status, selection of food, and weak methods of assessing nutritional status.

Several national surveys have assessed nutrition in older adults. Taken as a whole, these surveys do not indicate poor nutritional status or marked deficiency among older individuals in the United States, and suggest that intake relates more to health and poverty than to age.

■ Vitamins, Protein, and Calcium

Table 12-10 summarizes nutritional requirements in older adults and demonstrates that there is no general increase in vitamin requirements with age. Studies on vitamin metabolism and requirements reveal no correlation between age and the requirement for vitamins A, B₁, B₂, or C. Vitamin B₆ and vitamin B₁₂ requirements also do not increase with age. However, because folate and vitamin B₁₂ deficiencies are associated with an increased incidence of coronary artery disease and predict cognitive decline (Morris, Selhub, and Jacques, 2012), vitamin D deficiency is associated with osteoporosis, and vitamins A, C, and E have antioxidant effects, and because most people do not consume an optimal amount of all vitamins alone, some authors recommend that all adults take vitamin supplements (Fletcher and Fairfield, 2002).

Studies on protein requirements are not in agreement. Based on nitrogen balance studies, estimates of protein requirement varied from 0.5 to more than 1.0 g/kg daily. In an analysis of the Women's Health Initiative, higher protein consumption, as a fraction of energy, is associated with a strong, independent, dose-responsive lower risk of incident frailty in older women (Beasley et al., 2010). Data on amino acid requirements are also conflicting; some data show increased requirements with age, and other data show no change.

TABLE 12-10. Nutritional Requirements in Older Persons	
Vitamins	Unchanged in older persons
Protein	0.5 to >1.0 g/kg/day
Amino acids	Unchanged to increased
Calcium	850-1020 mg/day
Calories	Declines by 12.4 cal/day/year (maturity to senescence)

For calcium, estimated requirements vary from 850 to 1020 mg/day, and some recommendations are as high as 1500 mg/day for postmenopausal women. Data on the correlation of dietary calcium intake and osteoporosis are conflicting. However, calcium and vitamin D supplementation do improve postmenopausal osteoporosis. It may be necessary to use calcium and vitamin D supplements to ensure adequate intake.

■ Nutritional Deficiency and Physiological Impairments

There is little evidence to correlate age-associated nutritional deficiency with clinical findings. There was no significant correlation between vitamin A levels and dark adaptation, epithelial cells excreted, or percentage of keratinization. There was no correlation between vitamin C levels and gingivitis or vitamin B₁₂ and lactic acid, lactic dehydrogenase, or hematocrit. Despite their proposed antioxidant effects, neither vitamin E nor vitamin C supplementation reduced the risk of major cardiovascular events (Sesso et al., 2008). Older people with limited sun exposure may be at risk of vitamin D deficiency. Older individuals in nursing homes require at least 800 IU of vitamin D per day, double the usual recommended daily requirement to maintain normal vitamin D levels. Total 25-hydroxy vitamin D [25-(OH)D] levels should be measured. However, the recommended therapeutic target serum level varies. The International Osteoporosis Foundation recommends a target of 30 ng/mL, whereas an Institute of Medicine report suggests a level of 20 ng/mL (Rosen, 2011). The threshold concentration of 25(OH)D associated with increased risk for relevant clinical disease events is likely near 20 ng/mL (De Boer et al., 2012). Until recently, vitamin D was only considered as one of the calciotropic hormones. Recent data have demonstrated that vitamin D has an important role in cell differentiation, function, and survival (Montero-Odasso and Duque, 2005). Muscle and bone are significantly affected by the presence or absence of vitamin D. In bone, vitamin D stimulates bone turnover while protecting osteoblasts from apoptosis, whereas in muscle it maintains the function of type II fibers, preserving strength and preventing falls. Both osteoporosis and sarcopenia have been linked to the development of frailty in older adults. In the Cardiovascular Health Study, vitamin D deficiency was associated with poorer physical performance, lower muscle strength, and prevalent mobility and activities of daily living disability (Houston et al., 2011). In noninstitutionalized older adults, serum 25(OH)D levels had an independent, inverse association with cardiovascular disease and all-cause mortality (Ginde et al., 2009). Vitamin D functions as an endocrine inhibitor of the renin-angiotensin system, the likely link to cardiovascular disease (Li, 2011). Vitamin D deficiency is associated with increased autoimmunity and an increased susceptibility to infection (Aranow, 2011).

Although data on the effect of vitamin D supplementation have been conflicting, a recent meta-analysis demonstrated a benefit of vitamin D in preventing falls (Jackson et al., 2007). The U.S. Preventive Services Task Force has concluded that vitamin D supplementation can reduce fracture risk and that the effects on cancer risk are uncertain (Chung et al., 2011). The recommended dose for supplementation has varied from 800 to 2000 IU daily (Holick, 2011; Muir and Montero-Odasso,

2011; Bischoff-Ferrari et al., 2012; Heany, 2012). Studies on the effects of vitamin D supplementation have generally used fixed doses and not measured baseline 25(OH)D levels. The dose may be too low for those with marked deficiency, and those with high levels would not benefit. The Endocrine Society has recommended 1500 to 2000 IU daily (for the Endocrine Society practice guideline on evaluation, treatment, and prevention of vitamin D deficiency, see Holick et al., 2011). Data are conflicting on correlation of dietary calcium intake and osteoporosis. Problems in assessing this correlation include reduced calcium intake in older adults, altered calcium and phosphorus ratio, decreased protein intake, and acid–base balance.

■ Reversal of Deficiency by Supplementation

There is no impairment of vitamin or protein absorption in older adults; low vitamin levels in older adults can be reversed by administration of oral supplementation. Because these deficiencies can be corrected by dietary supplementation, they are most likely related to decreased intake.

■ Caloric Needs

A study of 250 individuals age 23 to 99 demonstrated an age-associated decline in total caloric intake at the rate of 12.4 cal/day for a year. A yearly decline in basal metabolic rate accounted for 5.23 cal/day, while 7.6 cal/day related to reduction in other requirements, including physical exercise (McGandy et al., 1966).

■ Dietary Restriction and Food Additives

In rats, mice, *Drosophila*, and other lower organisms, caloric restriction delays maturation and increases life span. The mechanism, however, is not understood, but studies suggest that it may be related to decreased levels of IGF-1. Animals fed isocaloric diets but decreased protein have an increased life span. Based on the free radical theory of aging, it has been proposed that reducing agents would prolong life. Although the data are conflicting, some studies support this hypothesis. In certain animal models, caloric restriction decreases the incidence and delays the onset of disease, including chronic glomerulonephritis, muscular dystrophy, and carcinogenesis. In humans, however, body weight below ideal is not associated with increased life span, and in primates, caloric restriction is not associated with increased life span (see the section on Theories of Aging in Chapter 1).

Although the influence of dietary fiber on colonic carcinoma and diverticular disease is controversial, the use of dietary fiber to maintain bowel regularity has significant support, especially in older adults, where constipation may present a difficult clinical problem. When dietary intake of fiber is low, bran can be used as a supplement, particularly in cereals and breads or as bran powder. Intake of bran can be adjusted to maintain normal bowel movements. Adequate fluid intake should also be assured.

Although the food industry is slowly responding, most canned foods still contain large amounts of added sodium and sugar. Because some of these are less expensive than fresh or frozen foods, older adults with limited incomes may use such prepared

foods exclusively. When refined carbohydrates or sodium need to be restricted, these patients should be educated about the use of canned products.

■ Obesity

The prevalence of obesity among older persons is growing. Although increased mortality rate from all causes extends into the seventh decade, controversy exists about the potential harms of obesity in older adults and the relation between obesity in old age and total or disease-specific mortality (Zamboni et al., 2005; see also Chapter 5). A meta-analysis indicated that a body mass index (BMI) in the overweight range (BMI 25-29.9 kg/m²) is not associated with a significantly increased risk of mortality in older adults, whereas a BMI in the moderately obese range (BMI >30 kg/m²) is only associated with a modest (10%) increase in mortality risk (Janssen and Mark, 2007). Central fat and relative loss of fat-free mass may become relatively more important than BMI in determining the health risk associated with obesity in older ages. However, obesity causes serious medical complications, impairs quality of life, can exacerbate the age-related decline in physical function, and can lead to frailty (Villareal et al., 2005). The prevalence of many of the medical complications associated with obesity, for example, hypertension, diabetes, cardiovascular disease, and osteoarthritis, increases with age. All components of the metabolic syndrome are prevalent in older populations. High BMI is associated with an increased risk of knee osteoarthritis in older persons. Obesity is associated with pulmonary function abnormalities, obesity-hypoventilation syndrome, and obstructive sleep apnea. An increase in urinary incontinence is associated with increased BMI. Obesity is associated with an increased risk of several types of cancer including breast, colon, pancreas, renal, bladder, and prostate. Self-reported functional capacity, particularly mobility, is markedly diminished in overweight and obese compared with lean older adults. Older persons who are obese (BMI >30 kg/m²) have a greater rate of nursing home admissions than those who are not obese. Obesity impairs quality of life in older persons. Beneficial effects of obesity include an increased bone mineral density and decreased osteoporosis and hip fracture in older men and women.

Weight-loss therapy improves physical function, quality of life, and the medical complications associated with obesity in older persons (Villareal et al., 2005). Weight-loss therapy that minimizes muscle and bone losses is recommended for older persons who are obese and who have functional impairments or metabolic complications that can benefit from weight loss. The primary approach is to achieve lifestyle change. Modest goals are key components of a weight management program for older adults. A modest reduction in energy intake (500-700 kcal/day) is recommended. Regular physical activity is particularly important in obese older persons to improve physical function and help preserve muscle and bone mass. The available data are insufficient to determine the efficacy and safety of pharmacotherapy for obesity in older persons. Bariatric surgery is the most effective weight-loss therapy for obesity. Perioperative morbidity and mortality are greater but relative weight loss and improvement in obesity-related medical complications are lower in older than in younger patients. Bariatric surgery should be reserved for a select group of older

subjects who have disabling obesity that can be ameliorated with weight loss and who meet the criteria for surgery.

INFECTIONS

Although it is proposed that alterations in host defense mechanisms predispose older adults to certain infections, there is little evidence to support this hypothesis. It may well be that environmental factors, physiological changes other than in the immune system, and specific diseases are the major elements in the increased frequency of certain infections in older adults (Table 12-11).

Because elderly persons more often have acute and chronic illnesses necessitating hospitalization and have longer hospital stays, they are at greater risk for nosocomial infections. Such hospitalizations put older patients at greater risk for gram-negative and *Staphylococcus aureus* infections. Physiological alterations (see Chapter 1)—in the lungs, bladder function, and the skin—and glucose homeostasis may also predispose older adults to infections.

The incidence of malignancies is increased in older adults. Many of these neoplastic disorders, especially those of the hematological system, are associated with a higher frequency of infection. Immunosuppression during therapy is also a predisposing factor. The prevalence of diabetes mellitus is higher in older adults, thus

TABLE 12-11. Factors Predisposing to Infection in Older Adults	
More frequent and longer hospital stays	
Nosocomial infections	
Gram-negative bacilli	
<i>Staphylococcus aureus</i>	
Physiological changes	
Lung	
Bladder	
Skin	
Glucose homeostasis	
Chronic disease	
Malignancy	
Multiple myeloma and leukemia	
Immunosuppression from therapy	
Diabetes mellitus	
Urinary tract infection	
Soft-tissue infections	
Osteomyelitis	
Prostatic hypertrophy	
Urinary tract infection	
Host defenses	
Phagocytosis unaltered	
Complement unaltered	
Cellular and humoral immunity diminished	

predisposing them to more frequent urinary tract, soft-tissue, and bone infections. Prostatic hypertrophy with obstruction predisposes the older male to urinary tract infections.

Phagocytic function appears to be unaltered in aging, as is the complement system. Cell-mediated immunity and, to a lesser extent, humoral immunity are diminished in aging. The role that these changes play in predisposing older individuals to infection has not been well defined.

Many infections occur more frequently in older adults and are often associated with a higher morbidity and mortality. Atypical presentation of infection in some older patients may delay diagnosis and treatment. Underreporting of symptoms, impaired communication, coexisting diseases, and altered physiological responses to infection may contribute to altered presentations.

As an example, failure of patients to seek medical evaluation is one factor in the higher morbidity and mortality of appendicitis in older adults. Difficulties in communication may also alter presentation. Infections not directly involving the central nervous system may cause confusion in the elderly, particularly in individuals with preexisting dementia. The mechanism by which this occurs has not been defined. Acute unexplained functional deterioration should also alert the physician to a potential acute infectious process.

Existing chronic disease may mask an acute infection. Septic arthritis usually occurs in a previously abnormal joint. It may be difficult to distinguish clinically between exacerbation of the underlying arthritis and acute infection. Therefore, the physician should not be hesitant to examine synovial fluid in elderly patients with acute exacerbation of joint disease.

Febrile response may be blunted or absent in some older individuals with bacterial infections. This may obscure diagnosis and delay therapy. A poor febrile response may also be a negative prognostic factor. Conversely, a febrile response is more likely to indicate a bacterial rather than viral illness in older patients, particularly in the very old. The absence of leukocytosis in older patients should also not exclude consideration of a bacterial infection.

Antibiotic therapy in older adults, as in the young, is directed to the specific organism isolated. However, when empiric antimicrobial therapy is initiated, consideration should be given to including a third-generation cephalosporin and/or aminoglycoside because gram-negative infections are more common regardless of the site. With all antibiotics, but particularly with the aminoglycosides, renal function must be considered and monitored for toxicity. Monitoring of drug blood level and renal function is mandatory with the aminoglycosides.

The spectrum of pathogens causing common infections in the elderly is often different than that in younger adults (Table 12-12). The frequency of gram-negative bacilli increases in each category. Pneumonia is the most frequent cause of death caused by infection in geriatric patients. *Streptococcus pneumoniae* is the most common cause of pneumonia in the elderly, but gram-negative bacilli increase in prevalence, particularly in the nursing home setting. Pneumonia in nursing homes or long-term care facilities is considered as health care-associated pneumonia with

TABLE 12-12. Pathogens of Common Infections in Older Adults

Infection	Common pathogens in adults	Common pathogens in older adults
Pneumonia	<i>Streptococcus pneumoniae</i> Anaerobic bacteria	<i>Streptococcus pneumoniae</i> Anaerobic bacteria <i>Haemophilus influenzae</i> gram-negative bacilli
Urinary tract	<i>Escherichia coli</i>	<i>Escherichia coli</i> <i>Proteus</i> sp. <i>Klebsiella</i> sp. <i>Enterobacter</i> sp. <i>Enterococcus</i>
Meningitis	<i>Streptococcus pneumoniae</i> <i>Neisseria meningitidis</i>	<i>Streptococcus pneumoniae</i> <i>Listeria monocytogenes</i> gram-negative bacilli
Septic arthritis	<i>Neisseria gonorrhoeae</i> <i>Staphylococcus aureus</i>	<i>Staphylococcus aureus</i> gram-negative bacilli

a broader spectrum of pathogens than community-acquired pneumonia. These patients have worse outcomes and require a broader spectrum of antibiotics (Venditti et al., 2009). Annual immunization against influenza and at least one pneumococcal vaccine are recommended for all persons 65 years of age and older. During 10 seasons, influenza vaccination was associated with significant reductions in the risk of hospitalizations for pneumonia or influenza (hazard ratio, 0.75) and in the risk of death (hazard ratio, 0.52) among community-dwelling older persons (Nichol, Nordin, and Nelson, 2007). Nearly 50% of infective endocarditis cases occur in older adults. The underlying cardiac lesion is often caused by atherosclerotic and degenerative valve diseases, as well as by prosthetic valves. Bacterial meningitis is an infection primarily of early childhood and late adulthood. Mortality in the elderly ranges from 50% to 70%. *S pneumoniae* is the most frequent pathogen, but older patients may be infected with *Listeria monocytogenes* or gram-negative bacilli.

Residents in long-term care facilities (LTCFs) are at great risk for infection. Older age and comorbidities complicate recognition of infection (eg, typically defined fever is absent in more than one-half of LTCF residents with serious infections). The Infectious Diseases Society of America provided guidelines for evaluation of fever and infection in LTCF residents (High et al., 2009). Infection should be suspected in LTCF residents with decline in functional status, increasing confusion, incontinence, falling, deteriorating mobility, reduced food intake, or failure to cooperate with staff. Fever is defined as a single oral temperature of >100°F, repeated oral temperature of >99°F, or an increase in temperature of >2°F. A complete blood cell (CBC) count should be performed if an infection is suspected. An elevated white blood cell (WBC) count of 14,000 cells/mm³ or a left shift >6%

warrants a careful assessment for bacterial infection. Urinalysis and urine cultures should not be performed for asymptomatic residents. In residents with long-term indwelling urethral catheters, evaluation is indicated for fever, shaking chills, hypotension, or delirium. In older adult nursing home residents, blood cultures have a low yield and rarely influence therapy. If pneumonia is clinically suspected, pulse oximetry should be performed for residents with a respiratory rate of >25 . Chest radiograph should be performed if hypoxemia is documented or suspected. At the onset of a suspected respiratory viral infection outbreak, nasopharyngeal wash or swab should be obtained for virus isolation and rapid diagnostic testing for influenza A virus and other common viruses. If a resident exhibits symptoms of colitis (eg, severe fever, abdominal cramps, and/or diarrhea, with or without blood and/or WBCs in the stool), initial evaluation for *Clostridium difficile* should be performed.

The incidence of tuberculosis is on the rise again. Older persons of both sexes among all racial and ethnic groups are especially at risk for tuberculosis. This cohort has lived through a period of higher incidence of tuberculosis, has probably not been treated with isonicotinic acid hydrazide (INH) prophylaxis, and may have predisposing factors such as physiological changes, malnutrition, and underlying disease that may lead to reactivation. Older patients are also at increased risk for primary infection. This is particularly the case for older patients in LTCFs.

Tuberculosis screening programs should be implemented in LTCFs because of this increased risk and because of the potential to prevent active disease among patients whose skin test converts to a strongly positive reaction (see Chapter 16). The American Thoracic Society now recommends preventive therapy for certain types of patients regardless of age, including insulin-dependent diabetic patients, those on steroids and other immunosuppressive treatment, patients with end-stage renal disease, and patients who have lost a large amount of weight rapidly. A useful rule in geriatric care is to suspect tuberculosis when a patient is inexplicably failing.

Several studies suggest that bacteriuria is associated with increased mortality in the elderly. However, other studies do not confirm this finding. Most of these nonconfirming studies did not differentiate between the effect of bacteriuria and age and/or concomitant disease on mortality. When adjusted for age, fatal diseases associated with bacteriuria account for the increase in mortality among older patients with bacteriuria.

Several previous studies in elderly hospitalized or institutionalized patients have not revealed antimicrobial therapy for bacteriuria to be effective because of the high rate of recurring infection. One study in older ambulatory nonhospitalized women with asymptomatic bacteriuria demonstrated that short-course antimicrobial therapy is effective in eliminating bacteriuria in most of the women for at least a 6-month period. Survival was not an outcome measure.

Bacteriuria in older persons is common and usually asymptomatic. At present, in the absence of obstructive uropathy, no evidence exists to support the routine use of antimicrobial therapy for asymptomatic bacteriuria in older persons. Among bacteriuric patients with urinary incontinence and no other symptoms of urinary tract infection, the bacteriuria should be eradicated as part of the initial assessment of the incontinence (see Chapter 8).

The incidence of herpes zoster (HZ) increases with aging. In a prospective vaccine trial, the incidence of herpes was 11.8 cases per 1000 persons per year in those more than 60 years of age, whereas the incidence rate in all ages is 1.2 to 3.4 per 1000 persons per year (reviewed in Schmader, 2007). Increasing age is also the strongest risk factor for developing postherpetic neuralgia (PHN). Acyclovir, famciclovir, and valacyclovir reduce acute pain and the duration of chronic pain if started within 72 hours of rash onset. Analgesics for relief of acute pain are important. Those with moderate to severe pain may require opioids. The addition of corticosteroids or gabapentin may be considered if pain persists. Corticosteroids have not been shown to reduce the incidence of PHN in the elderly. Topical lidocaine patch, gabapentin, and pregabalin are FDA approved for treatment of PHN, but nortriptyline and opioids have also been shown to be of benefit. In some cases, combination therapy may be necessary. A live, attenuated varicella-zoster vaccine has been developed and shown to be safe and to reduce the incidence of HZ (hazard ratio, 0.45), including ophthalmic HZ (hazard ratio, 0.37), and hospitalizations for HZ (hazard ratio, 0.35) (Simberkoff et al., 2010; Tseng et al., 2011).

Vaccination recommendations also include tetanus vaccination with Td every 10 years. This should be replaced at least once with Tdap to cover pertussis immunization, since the immune response to pertussis has been shown to wane.

DISORDERS OF TEMPERATURE REGULATION

Temperature dysregulation in the elderly demonstrates the narrowing of homeostatic mechanisms that occurs with advancing age. Older adults may have a mean oral body temperature lower than 37°C, and older nursing home residents may have lower body temperature and fail to demonstrate a diurnal rise (Gomolin et al., 2005). Older persons are less able to adjust to extremes of environmental temperatures. Hypo- and hyperthermic states are predominantly disorders of older adults. Despite underreporting of these disorders, there is evidence that morbidity and mortality increase during particularly hot or cold periods, especially among ill elderly. Much of this illness is caused by an increased incidence of cardiovascular disorders (myocardial infarction and stroke) or infectious diseases (pneumonia) during these periods.

Hypothermia is a common finding among older adults during the winter, when homes are heated at less than 21°C (70°F).

■ Pathophysiology

Impaired temperature perception, diminished sweating in hyperthermia, and abnormal vasoconstrictor response in hypothermia are major pathophysiological mechanisms in these disorders.

■ Hypothermia

Hypothermia is defined as a core temperature (rectal, esophageal, tympanic) below 35°C (95°F). Essential to the diagnosis is early recognition with a low-recording thermometer.

TABLE 12-13. Clinical Presentation of Hypothermia

Early signs (89.6°-95°F [32°-35°C])	Late signs (82.4°-86°F [28°-30°C])	Later signs (<82.4°F [28°C])
Fatigue	Cold skin	Very cold skin
Weakness	Hypopnea	Rigidity
Slowness of gait	Cyanosis	Apnea
Apathy	Bradycardia	No pulse—ventricular fibrillation
Slurred speech	Atrial and ventricular arrhythmias	Areflexia
Confusion		
Shivering (±)	Hypotension	Unresponsiveness
Cool skin	Semicoma and coma	Fixed pupils
Sensation of cold (±)	Muscular rigidity	
	Generalized edema	
	Slowed reflexes	
	Poorly reactive pupils	
	Polyuria or oliguria	

Table 12-13 illustrates the clinical spectrum of hypothermia. Because early signs are nonspecific and subtle, a high index of suspicion must exist to allow an early diagnosis. A history of known or potential exposure is helpful, but older patients can become hypothermic at modest temperatures. Frequently, the most difficult differential diagnosis in more severe hypothermia is hypothyroidism. A previous history of thyroid disease, a neck scar from previous thyroid surgery, and a delay in the relaxation phase of the deep tendon reflexes may assist in diagnosing hypothyroidism. Patients may sometimes be mistaken for dead. Case reports reveal patients who have survived after being discovered without respiration and pulse.

The most significant early complications are arrhythmias and cardiorespiratory arrests. Later complications involve the pulmonary, gastrointestinal, and renal systems. Electrocardiogram (ECG) abnormalities are frequent. The most specific ECG finding is the J wave (Osborn wave) following the QRS complex. This abnormality disappears as temperature returns to normal.

General supportive therapy for severe hypothermia consists of intensive care management of complicated multisystem dysfunctions. Every attempt should be made to assess and treat any contributing medical disorder (eg, infection, hypothyroidism, hypoglycemia). Hypothermia in older patients should promptly be treated as sepsis unless proven otherwise. While patients should have continuous ECG monitoring, central lines should be avoided if possible because of myocardial irritability. Because there is delayed metabolism, most drugs have little effect on a severely hypothermic patient, but they may cause problems once the patient is rewarmed. It is preferable to stabilize the patient and immediately undertake specific rewarming techniques. Serious arrhythmias, acidosis, and fluid and electrolyte disorders will usually respond to therapy only after rewarming has been accomplished.

Passive rewarming is generally adequate for those with mild hypothermia ($>32^{\circ}$ [$>89.6^{\circ}\text{F}$]). Active external rewarming has been associated with increased morbidity and mortality because cold blood may suddenly be shunted to the core, further decreasing core temperature; peripheral vasodilatation can precipitate hypovolemic shock by decreasing circulatory blood volume. For more severe hypothermia ($<32^{\circ}\text{C}$ [$<89.6^{\circ}\text{F}$]), core rewarming is necessary. Several techniques for core rewarming have been used, but positive results have been reported only from small, uncontrolled studies. Peritoneal dialysis and inhalation rewarming may be the most practical techniques in the majority of institutions.

Mortality is usually greater than 50% for severe hypothermia. It increases with age and is particularly related to underlying disease.

■ **Hyperthermia**

Heat stroke is defined as a failure to maintain body temperature and is characterized by a core temperature of $>40.6^{\circ}\text{C}$ ($>105^{\circ}\text{F}$), severe central nervous system dysfunction (psychosis, delirium, coma), and anhidrosis (hot, dry skin). The two groups primarily affected are older adults who are chronically ill and the young undergoing strenuous exercise. Mortality is as high as 80% once this syndrome is manifest.

There are multiple predisposing factors for heat stroke in older adults, but most often there is a prolonged heat wave (reviewed in O'Malley, 2007). The diagnosis requires a high level of suspicion. In view of the poor survival, efforts must be directed toward prevention. Older patients should be cautioned about the dangers of hot weather. For those at particularly high risk, temporary relocation to more protected environments should be considered.

Early manifestations of heat exhaustion are nonspecific (Table 12-14). Later, severe central nervous system dysfunction and anhidrosis develop.

Table 12-15 lists some of the more serious complications resulting from heat damage to organ systems. Once the full syndrome has developed for any length of time, the prognosis is very poor. While management at this stage requires intense multi-system care, the key is rapid specific therapy consisting of cooling to 38.9°C (102°F)

TABLE 12-14. Clinical Presentation of Hyperthermia	
Early signs	Later signs
Dizziness	Central nervous system dysfunction
Weakness	Psychosis
Sensation of warmth	Delirium
Anorexia	Coma
Nausea	Anhidrosis
Vomiting	Hot, dry skin
Headache	
Dyspnea	

TABLE 12-15. Complications of Heat Stroke

Myocardial damage
Congestive heart failure
Arrhythmias
Renal failure (20%-25%)
Cerebral edema
Seizures
Diffuse and focal findings
Hepatocellular necrosis
Jaundice
Liver failure
Rhabdomyolysis
Myoglobinuria
Bleeding diathesis
Disseminated intravascular coagulation
Electrolyte disturbances
Acid-base disturbances
Metabolic acidosis
Respiratory alkalosis
Infection
Aspiration pneumonia
Sepsis
Dehydration and shock

Evidence Summary**Do's**

- Screen patients with hypertension or hyperlipidemia for diabetes.
- Use metformin as first-line therapy in overweight diabetic patients.
- Treat other atherosclerotic risk factors (smoking, dyslipidemia, hypertension) in diabetic patients.
- Screen ill older patients for hypothyroidism.
- Screen older adults for vitamin D deficiency.
- Screen for primary hyperparathyroidism in patients with fracture and low bone mineral density.

Don'ts

- Use metformin in patients with renal insufficiency or heart failure.
- Use thiazolidinediones in patients with heart failure.
- Recommend testosterone supplementation in older men with low normal testosterone concentrations.

Consider

- Life expectancy and quality of life in setting goals for glucose control.

within the first hour. Ice packs and ice-water immersion are superior to convection cooling with alcohol sponge baths or electric fans.

Prevention appears to be the most appropriate approach to management of temperature dysregulation in older adults. Education of older adults to their susceptibility to hypo- and hyperthermia in extremes of environmental temperature, education as to appropriate behavior in such conditions, and close monitoring of the most vulnerable older adults should help reduce the morbidity and mortality from these disorders.

REFERENCES

- Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. *JAMA*. 2007;298: 194-206.
- Aranow C. Vitamin D and the immune system. *J Invest Med*. 2011;59:881-886.
- Artz AS, Thirman MJ. Unexplained anemia predominates despite an intensive evaluation in a racially diverse cohort of older adults from a referral anemia clinic. *J Gerontol A Biol Sci Med Sci*. 2011;66A: 925-932.
- Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and the American Association of Clinical Endocrinologists. *Thyroid*. 2011;21:593-646.
- Beasley JM, LaCroix AZ, Neuhaus ML, et al. Protein intake and incident frailty in the Women's Health Initiative Observational Study. *J Am Geriatr Soc*. 2010;58:1063-1071.
- Bennett WL, Maruthar NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and drug combinations. *Ann Intern Med*. 2011;154:602-613.
- Bergström I, Landgren BM, Freyschuss B. Primary hyperparathyroidism is common in postmenopausal women with forearm fracture and low bone mineral density. *Acta Obstet Gynecol Scand*. 2007;861:61-64.
- Bilezikian JP, Potts JT, Fuleihan GE-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism. *J Clin Endocrinol Metab*. 2002;87:5353-5361.
- Biondi B, Fazio S, Palmieri EA, et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. *J Clin Endocrinol Metab*. 1999;84:2064-2067.
- Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. *N Engl J Med*. 2012;367:40-49.
- Black C, Donnelly P, McIntyre L, et al. Meglitinide analogues for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2007;18:CD004654.
- Blackman MR, Sorkin JD, Munzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. *JAMA*. 2002;288: 2282-2292.
- Boulé NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. *JAMA*. 2001;286:1218-1227.
- Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes. A randomized, controlled trial. *Ann Intern Med*. 2011;154:103-112.
- Cappola AR, Fried LP, Arnold, AM, et al. Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults. *JAMA*. 2006; 295:1033-1041.

- Ceresini G, Lauretani F, Maggio M, et al. Thyroid function abnormalities and cognitive impairment in elderly people: results of the Invecchiare in Chianti Study. *J Am Geriatr Soc*. 2009;57:89-93.
- Chung M, Lee J, Terasawa T, et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2011;155:827-838.
- Church TS, Blair SN, Cocroham S, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes. A randomized controlled trial. *JAMA*. 2010;304:2253-2262.
- Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. *Arch Intern Med*. 2012;172:799-809.
- Cooper DS. Subclinical hypothyroidism. *N Engl J Med*. 2001;345:260-265.
- Cooper DS. Antithyroid drugs. *N Engl J Med*. 2005;352:905-917.
- Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1575-1585.
- De Boer IH, Levin G, Robinson-Cohen C, et al. Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults. *Ann Intern Med*. 2012;156:627-634.
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393-403.
- Dong XQ, Mendes de Leon C, Artz A, et al. A population-based study of hemoglobin, race, and mortality in elderly persons. *J Gerontol Med Sci*. 2008;63A:873-878.
- Drucker DJ. The role of gut hormones in glucose homeostasis. *J Clin Invest*. 2007;117:24-32.
- Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. *N Engl J Med*. 2007;356:2064-2072.
- Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. *JAMA*. 2008;2:39-52.
- Ershler WB, Sheng S, McKelvey J, et al. Serum erythropoietin and aging: a longitudinal analysis. *J Am Geriatr Soc*. 2005;53:1360-1365.
- Fatourechi V. Upper limit of normal serum thyroid-stimulating hormone: a moving and now and aging target? *Endo J*. 2007;92:4560-4562.
- Fletcher RH, Fairfield KM. Vitamins for chronic disease prevention: clinical applications. *JAMA*. 2002;287:3127-3129.
- Gaede P, Lund-Anderson H, Parving H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med*. 2008;358:580-591.
- Gharib H. Commentary. ACP Journal Club. *Ann Intern Med*. 2008;148:6.
- Gillies CL, Abrams KR, Lambert PC, et al. Review: lifestyle or pharmacologic interventions prevent or delay type 2 diabetes in impaired glucose tolerance. *BMJ*. 2007;334:299-307.
- Ginde AA, Scragg R, Schwartz RS, et al. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. *J Am Geriatr Soc*. 2009;57:1595-1603.
- Gomolin IH, Aung MM, Wolf-Klein G, et al. Older is colder: temperature range and variation in older people. *J Am Geriatr Soc*. 2005;53:2170-2172.
- Grozinsky-Glasberg S, Fraser A, Nahshoni E, et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab*. 2006;91:2592-2599.

- Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. *J Am Geriatr Soc.* 2003;51:101-115.
- Habra M, Sarlis NJ. Thyroid and aging. *Rev Endocr Metab Disord.* 2005;6:145-154.
- Heany RP. Vitamin D: baseline status and effective dose. *N Engl J Med.* 2012;367:77-78.
- High KP, Bradley SF, Gravenstein S, et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Disease Society of America. *J Am Geriatr Soc.* 2009;57:375-394.
- Holick MF. Vitamin D: a D-lightful solution for health. *J Investig Med.* 2011;59:872-880.
- Holick MF, Brinkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. 2011;96:1911-1930.
- Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. *N Engl J Med.* 2009;361:1736-1747.
- Houston DK, Tooze JA, Davis CC, et al. Serum 25-hydroxyvitamin D and physical function in older adults: the Cardiovascular Health Study All Stars. *J Am Geriatr Soc.* 2011;59:1793-1801.
- Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. *Am J Med.* 2001;111:633-642.
- Huang ES, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. *Ann Intern Med.* 2008;149:11-19.
- Huber G, Staub J-J, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. *J Clin Endocrinol Metab.* 2002;87:3221-3226.
- Inzucchi SE. Management of hyperglycemia in the hospital setting. *N Engl J Med.* 2006;355:1903-1911.
- Inzucchi SE. Diagnosis of diabetes. *N Engl J Med.* 2012;367:542-550.
- Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. *N Engl J Med.* 1998;338:867-872.
- Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. *JAMA.* 1999;281:1714-1717.
- Jackson C, Gaugris S, Sen SS, et al. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. *QJM.* 2007;100:185-192.
- Janssen I, Mark AE. Elevated body mass index and mortality risk in the elderly. *Obesity Rev.* 2007;8:41-59.
- Jones M, Ibels L, Schenkel B, et al. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. *Kidney Int.* 2004;65:757-767.
- Kazi M, Geraci SA, Koch CA. Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. *Am J Med.* 2007;120:835-840.
- Keel SB, Abkowitz JL. The microcytic red cell and the anemia of inflammation. *N Engl J Med.* 2009;361:1904-1906.
- Kenny AM, Kleppinger A, Annis K, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels low bone mass, and physical frailty. *J Am Geriatr Soc.* 2010;58:1134-1143.
- Ku S. Algorithms replace sliding scale insulin orders. *Drug Ther Topics.* 2002;31:49-53.
- Lamberts SWJ, van den Beld AW, van der Lely A-J. The endocrinology of aging. *Science.* 1997;278:419-424.
- Lee P, Chang A, Blaum C, et al. Comparison of safety and efficacy of insulin glargine and neutral protamine Hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis. *J Am Geriatr Soc.* 2012;60:51-59.

- Li YC. Molecular mechanism of vitamin D in the cardiovascular system. *J Investig Med*. 2011;59:868-871.
- Ligthelm, RJ, Kaiser M, Vora J, et al. Insulin use in elderly adults: risk of hypoglycemia and strategies for care. *J Am Geriatr Soc*. 2012; 60:1564-1570.
- Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. *JAMA*. 2007;298:1180-1188.
- Lipscombe LL, Gomes T, Lévesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. *JAMA*. 2007;298:2634-2643.
- Liu H Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. *Ann Intern Med*. 2007;146:104-115.
- Longo DL. Closing in on a killer: anemia in elderly people. *J Gerontol Biol Sci Med Sci*. 2005;60A:727-728.
- Maraldi C, Ble A, Zuliani G, et al. Association between anemia and physical disability in older patients: role of comorbidity. *Aging Clin Exp Res*. 2006;8:485-492.
- Marcocci C, Cetani F. Primary hyperthyroidism. *N Engl J Med*. 2011;365:2389-2397.
- Mariotti S, Cambuli VM. Cardiovascular risk in elderly hypothyroid patients. *Thyroid*. 2007;17:1067-1073.
- McGandy RB, Barrows CH Jr, Spanias A, et al. Nutrient intakes and energy expenditures in men of different ages. *J Gerontol*. 1966;21:581-587.
- Miller M. Hyponatremia and arginine vasopressin dysregulation: mechanisms, clinical consequences, and management. *J Am Geriatr Soc*. 2006;54:345-353.
- Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. *Mol Aspects Med*. 2005;26:203-219.
- Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidenced-based about face? *Ann Intern Med*. 2009;150:803-808.
- Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. *Ann Intern Med*. 2006;145:125-134.
- Morris MS, Selhub J, Jacques PF. Vitamin B-12 and folate status in relation to decline in scores on the Mini-Mental State Examination in the Framingham Heart Study. *J Am Geriatr Soc*. 2012;60:1457-1464.
- Muir SW, Montero-Odasso M. Effect of vitamin D supplementation on muscle strength, gait, and balance in older adults: a systematic review and meta-analysis. *J Am Geriatr Soc*. 2011;59:2291-2300.
- Nathan DM. Finding new treatments for diabetes—how many, how fast . . . how good? *N Engl J Med*. 2007;356:437-536.
- Nichol KL, Nordin JD, Nelson DB. Effectiveness of influenza vaccine in the community-dwelling elderly. *N Engl J Med*. 2007;357:1373-1381.
- O'Malley PG. Commentary on heat waves and heat-related illness. *JAMA*. 2007;298:917-919.
- Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. *J Clin Endocrinol Metab*. 2005;90:1502-1510.
- Patel KV, Semba RD, Ferrucci L, et al. Red cell distribution width and mortality in older adults: a meta-analysis. *J Gerontol A Biol Sci Med Sci*. 2010;65A:258-265.
- Penninx BWJH, Pahor M, Woodman RC, et al. Anemia in old age is associated with increased mortality and hospitalization. *J Gerontol Biol Sci Med Sci*. 2006;61A:474-479.
- Puar TH, Khoo JJ, Cho LW, et al. Association between glycemic control and hip fracture. *J Am Geriatr Soc*. 2012;60:1493-1497.

- Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* 2012;156:218-231.
- Rodondi N, den Elzen WPJ, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *JAMA.* 2010;304:1365-1374.
- Rosen CJ. Vitamin D insufficiency. *N Engl J Med.* 2011;364:248-254.
- Schmader K. Herpes zoster and postherpetic neuralgia in older adults. *Clin Geriatr Med.* 2007;23:615-632.
- Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physician's Health Study II randomized controlled trial. *JAMA.* 2008;300:2123-2133.
- Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the Shingles Prevention Study: a randomized trial. *Ann Intern Med.* 2010;152:545-554.
- Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. *JAMA.* 2007;298:1189-1195.
- Steensma DP. Is anemia of cancer different from chemotherapy induced anemia? *J Clin Oncol.* 2008;26:1022-1024.
- Strippoli GF, Craig MC, Schena FP, et al. Review: ACE inhibitors delay onset of microalbuminuria in diabetes without nephropathy and reduce mortality in diabetic nephropathy. *J Am Soc Nephrol.* 2006;17:S153-S155.
- Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. *J Clin Endocrinol Metab.* 2007;92:4575-4582.
- Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. *JAMA.* 2011;305:160-166.
- United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet.* 1998a;352:837-852.
- United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet.* 1998b;352:854-865.
- United Kingdom Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ.* 1998c;317:703-712.
- U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. *Ann Intern Med.* 2003;138:212-214.
- Venditti M, Falcone M, Carrao S, et al. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. *Ann Intern Med.* 2009;150:19-26.
- Villareal DT, Apovian CM, Kushner RF, et al. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. *Am J Clin Nutr.* 2005;82:923-934.
- Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med.* 2005;352:1011-1023.
- Wilding JPH, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. *Ann Intern Med.* 2012;156:405-415.
- Yau CK, Eng C, Censer IS, et al. Glycosylated hemoglobin and functional decline in community-dwelling nursing home-eligible elderly adults with diabetes mellitus. *J Am Geriatr Soc.* 2012;60:1215-1221.

Zamboni M, Mazzali G, Zoico E, et al. Health consequences of obesity in the elderly: a review of four unresolved questions. *Int J Obesity*. 2005;29:1011-1029.

SUGGESTED READINGS

- Bartlett JG. Antibiotic-associated diarrhea. *N Engl J Med*. 2002;346:334-339.
- Belshe RB. Influenza prevention and treatment: current practices and new horizons. *Ann Intern Med*. 1999;131:621-623.
- Bentley DW, Bradley S, High K, et al. Practice guideline for evaluation of fever and infection in long-term care facilities. *J Am Geriatr Soc*. 2001;49:210-222.
- Bouchama A, Knochel JP. Heat stroke. *N Engl J Med*. 2002;346:1978-1988.
- Brady MA, Perron WJ. Electrocardiographic manifestations of hypothermia. *Am J Emerg Med*. 2002;20:314-326.
- Chandalia M, Garg A, Lutjohann D, et al. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. *N Engl J Med*. 2000;342:1392-1398.
- Davis PJ, Davis FB. Hyperthyroidism in patients over the age of 60 years. *Medicine (Baltimore)*. 1974;53:161-181.
- Elia M, Ritz P, Stubbs RJ. Total energy expenditure in the elderly. *Eur J Clin Nutr*. 2000;54:S92-S103.
- Federman DD. Hyperthyroidism in the geriatric population. *Hosp Pract*. 1991;26:61-76.
- Finucane TE. "Tight control" in geriatrics: the emperor wears a thong. *J Am Geriatr Soc*. 2012;60:1571-1575.
- Gambert SR. Effect of age on thyroid hormone physiology and function. *J Am Geriatr Soc*. 1985;33:360-365.
- Gress TW, Nieto J, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. *N Engl J Med*. 2000;342:905-912.
- Hak AE, Pols HAP, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. *Ann Intern Med*. 2000;132:270-278.
- Ismail-Beigi F, Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. *Ann Intern Med*. 2011;154:554-559.
- Lipschitz DA. An overview of anemia in older patients. *Older Patient*. 1988;2:5-11.
- Mateen FJ, Mills EJ. Aging and HIV-related cognitive loss. *JAMA*. 2012;308:349-350.
- Morley JE, Mooradian AD, Silver AJ, et al. Nutrition in the elderly. *Ann Intern Med*. 1988;109:890-904.
- Mylonakis E, Calderwood SB. Infective endocarditis in adults. *N Engl J Med*. 2001;345:1318-1330.
- Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster postherpetic neuralgia in older adults. *N Engl J Med*. 2005;352:2271-2284.
- Sawin CT, Castelli WP, Hershman JM, et al. The aging thyroid: thyroid deficiency in the Framingham Study. *Arch Intern Med*. 1985;145:1386-1388.
- Stead WW, To T, Harrison RW, et al. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. *Ann Intern Med*. 1987;107:843-845.
- The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012;367:319-328.
- Thomas FB, Mazzaferri EL, Skillman TB. Apathetic thyrotoxicosis: a distinctive clinical and laboratory entity. *Ann Intern Med*. 1970;72:679-685.
- Treatment of hypothermia. *Med Lett Drugs Ther*. 1986;28:123-124.

- Trevino A, Bazi B, Beller BM, et al. The characteristic electrocardiogram of accidental hypothermia. *Arch Intern Med.* 1971;127:470-473.
- Trivalle C, Doucet J, Chassagne P, et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. *J Am Geriatr Soc.* 1996;44:50-53.
- Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med.* 2001;344:1343-1350.
- United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ.* 1998;371:713-719.
- Yoshikawa TT. Infectious diseases. *Clin Geriatr Med.* 1992;8:701-945.
- Yoshikawa TT. Tuberculosis in aging adults. *J Am Geriatr Soc.* 1992;40:178-187.

CHAPTER 13

Sensory Impairment

Because as many as 75% of older adults have significant visual or auditory dysfunction not reported to their physicians, adequate screening for these problems is important. These disorders may limit functional activity and lead to social isolation and depression. Correction of remediable conditions may improve ability to perform daily activities.

VISION

■ Physiological and Functional Changes

The visual system undergoes many changes with age (Table 13-1). Decreases in visual acuity in old age may be caused by morphological changes in the choroid, pigment epithelium, and retina, or by decreased function of the rods, cones, and other neural elements. Older patients frequently have difficulties turning their eyes upward or sustaining convergence. Intraocular pressure slowly increases with age.

The refractive error may become either more hyperopic or more myopic. In younger persons, hyperopia may be overcome by the accommodative power of the ciliary muscle on the young lens. However, with age, this latent hyperopia becomes manifest because of loss of accommodative reserve.

Other older patients may show an increase in myopia with age, caused by changes within the lens. The crystalline lens increases in size with age as old lens fibers accumulate in the lens nucleus. The nucleus becomes more compact and harder (nuclear sclerosis), increasing the refractive power of the lens and worsening the myopia.

Another definitive refractive change of aging is the development of presbyopia from nuclear sclerosis of the lens and atrophy of the ciliary muscle. As a result, the closest distance at which one can see clearly slowly recedes with age. At approximately age 45, the near point of accommodation is so far that comfortable reading and near work become cumbersome and difficult. Corrective lenses are then needed to enable the patient to move that point closer to the eyes.

Diminished tear secretion in many older patients, especially postmenopausal women, may lead to dryness of the eyes, which can cause irritation and discomfort. This condition may endanger the intactness of the corneal surface. The treatment consists mainly in substitution therapy, with artificial tears instilled at frequent intervals.

The corneal endothelium often undergoes degenerative changes with aging. Because these cells seldom proliferate during adult life, the cell population is decreased. This may leave an irregular surface on the anterior chamber side, where pigments may accumulate. This type of endothelial dystrophy is frequently seen in older patients, and dense pigment accumulation may slightly decrease visual acuity.

TABLE 13-1. Physiological and Functional Changes of the Eye

Functional change	Physiological change
Visual acuity	Morphological change in choroid, pigment epithelium, or retina Decreased function of rods, cones, or other neural elements
Extraocular motion	Difficulty in gazing upward and maintaining convergence
Intraocular pressure	Increased pressure
Refractive power	Increased hyperopia and myopia Presbyopia Increased lens size Nuclear sclerosis (lens) Ciliary muscle atrophy
Tear secretion	Decreased tearing Decreased lacrimal gland function Decreased goblet cell secretion
Corneal function	Loss of endothelial integrity Posterior surface pigmentation

In some patients, the endothelial dystrophy will spontaneously progress and lead to corneal edema. Such cases require corneal transplants.

■ **Visual Impairment and Blindness**

The prevalence of visual problems and blindness increases with age (Fig. 13-1). The most common causes of blindness are cataracts, glaucoma, macular degeneration, and diabetic retinopathy. Screening for these disorders should include testing visual acuity, performing an ophthalmoscopic evaluation, and checking intraocular pressure (Table 13-2).

Senile Cataract

Opacification of the crystalline lens is a frequent complication of aging. In the Framingham Eye Study, the prevalence of cataracts was associated with age and reached 46% at ages 75 to 85 (Kini et al., 1978). The development of age-related cataract is a painless, progressive, but variable, process. Cataract formation is typically bilateral and often asymmetrical. Patients usually complain of problems with night driving, reading road signs, and difficulty with fine print.

The cause of age-related cataracts is unknown, but the opacifications in the lens are associated with the breakdown of the g-crystalline proteins. Epidemiological data and basic research suggest that ultraviolet light may be a contributing factor in cataract development. The pathological process may occur in either the cortex or the nucleus of the lens. Cortical cataracts have various stages of development. Early in the process, opacities are in the periphery and do not decrease visual acuity.




FIGURE 13-1 Prevalence of vision problems in older persons, 1984. (From Havlik, 1986.)

At the mature stage, opacifications are more widespread and involve the pupillary area, leading to a slow decrease in visual acuity. In the mature stage, the entire lens becomes opaque. The nuclear cataract does not have these stages of development, but is a slowly progressing central opacity, which frequently shows a yellowish discoloration, therefore preventing certain colors from reaching the retina.

Cataracts of mild degree may be managed by periodic examination and optimum eyeglasses for an extended period. Ultraviolet lenses may be of benefit. When a cataract progresses to the point where it interferes with activities, cataract surgery is generally indicated. The surgeon may use several methods to remove it, and the decision regarding the best method for each patient should be made by the ophthalmologist.

In intracapsular cataract extractions, the entire cataract and surrounding capsule are removed in a single piece. This removes the entire opacity. In extracapsular cataract extractions, the cataractous lens material and a portion of the capsule are removed. The posterior capsule is left in place to hold an intraocular lens implant.

TABLE 13-2. Ophthalmological Screening

Visual acuity	Ability to read newspaper-sized print
Lens, fundus	Ophthalmoscopic examination
Intraocular pressure	Tonometry
	Visual fields

TABLE 13-3. Restoring Vision After Cataract Surgery

Intraocular lenses

- Correct central and peripheral vision
- Increase image size by 1%
- Can be used after surgery on one or both eyes
- Are useful for older adults unable to wear contact lenses
- Require bifocal eyeglasses
- Introduce added surgical and postsurgical complications

The intraocular lens is surgically placed inside the iris and is expected to remain permanently in place. This lens corrects the focus of the eyes and permits central and peripheral vision; object size is increased by only 1%. It is appropriate for patients with cataracts in one or both eyes and is particularly useful for patients unable to wear a contact lens. Because the lens cannot change shape to accommodate, the lens can be chosen to provide good near or far vision and glasses prescribed to compensate for the other type of vision. (Table 13-3).

Contact lenses correct the focus of the eye, permit both central and peripheral vision, and increase apparent object size by 6%. However, handling contact lenses is difficult for some individuals, and most lenses must be removed and inserted daily. Extended-wear contact lenses are available, and approximately 50% to 70% of elderly patients are able to wear them after surgery. Contacts are useful in patients who have had cataract surgery in one or both eyes. The lenses correct for distant vision, but eyeglasses are required for reading. Bifocal lenses are available but require some active adjustment.

Visual impairment is a known risk factor for falls and fractures, while patients who have had cataract surgery have a lower risk for hip fracture (Tseng et al., 2012).

Glaucoma

The glaucomas are a group of eye disorders characterized by increased intraocular pressure, progressive excavation of the optic nerve head with damage to the nerve fibers, and a specific loss in the visual field. Visual field testing should be performed. Initial changes lead to peripheral vision loss, with loss of central vision as the disease progresses. Most cases of primary glaucoma occur in older patients. In the Framingham Eye Study, prevalence of open-angle glaucoma increased with age to 7.2% at ages 75 to 85, with men having much higher rates than women (Kini et al., 1978).

Angle-closure glaucoma is an acute and relatively infrequent type of glaucoma, characterized by a sudden painful attack of increased intraocular pressure accompanied by a marked loss in vision. The treatment consists of normalizing the intraocular pressure by the application of miotic eye drops or other medication (such as carbonic anhydrase inhibitors or osmotic agents). The definitive treatment, however, is surgical excision of a peripheral piece of iris or, more frequently now, by laser iridectomy,

ensuring free flow of aqueous humor. Because the disease is usually bilateral, some physicians propose prophylactic iridectomy on the second eye.

Chronic open-angle glaucoma is the more frequent variety of primary glaucoma. (See Kwon et al., 2009, for a review.) It is the second leading cause of blindness in the United States and the leading cause of blindness among black Americans. The irido-corneal angle is open, but aqueous outflow is diminished. The neuroretinal rim of the optic nerve becomes progressively thinner, leading to optic-nerve cupping. Its cause is the loss of retinal ganglion cell axons. Primary open-angle glaucoma is characterized by an insidious onset, slow progression, and the appearance of typical defects of the visual fields. Early in the disease, intraocular pressure is only moderately elevated, and optic nerve head excavation progresses slowly and sometimes asymmetrically. While central visual acuity may remain normal for a long time, the defects in the peripheral visual field are characteristic and gradually progressive. Initially, there is a paracentral scotoma, which may coalesce. A nasal step of the visual field is another important sign. Finally, the entire field will constrict and eventually involve the visual centers.

The treatment is usually medical, with miotics of various kinds used first. β -Blocking agents may also be used and have the advantage of not changing the diameter of the pupil. However, care should be taken because these agents may be systemically absorbed and interact with other functions mediated by β agonists. In severe cases, combination drops may be used with systemic medications such as carbonic anhydrase inhibitors. Surgery or laser therapy is indicated only if disease progresses on maximal medical therapy.

Age-Related Macular Degeneration

The macular area of the retina lying at the posterior pole of the globe is the site of highest visual acuity. This area depends entirely on choriocapillaries for nutrition.

Any disturbance in the vessel wall of the choroidal capillaries, in the permeability or thickness of the Bruch membrane, or in the retinal pigment epithelium may interfere with the exchange of nutrients and oxygen from the choroidal blood to the central retina. Such disturbances occur frequently in older patients. Age-related degeneration of the macula is one of the most frequent causes of visual loss in older adults and is the commonest cause of legal blindness (20/200 or worse) (see Chakravarthy, Evans, and Rosenfeld, 2010, for a review). In the Framingham Eye Study, the prevalence was 28% at ages 75 to 85 years, with a higher rate in women than in men (Kini et al., 1978). In addition to older age, risk factors include family history of the disorder, cigarette smoking, low dietary intake or plasma concentrations of antioxidant vitamins and zinc, and white race for “wet” lesions (Fine et al., 2000). Age-related macular degeneration (AMD) is a common disease caused by the interplay of genetic predisposition and exposure to modifiable risk factors. Two susceptibility genes have been identified (*CFH* and *LOC387715*). Carrying the susceptibility alleles of either increases the risk between three- and eightfold, whereas having two copies of the susceptibility alleles in both genes increases the risk 50-fold (Schaumburg et al., 2007). The combined effect of these polymorphisms carries an attributable risk of 60% (Haines and Pericak-Vance, 2007).

Cigarette smoking and obesity multiply the risks associated with these variants. High lifetime exposure to sunlight is also a risk factor.

Ophthalmoscopic findings vary and do not always parallel loss of vision. In the geographic atrophy form of degeneration, there are areas of depigmentation alternating with zones of hyperpigmentation caused mainly by changes in the retinal pigment epithelium. In another form, the degeneration involves the Bruch membrane, leading to the pigmentation of well-circumscribed, roundish yellow areas. As lesions coalesce and involve the central macula, there is progressive worsening of vision to legal blindness.

In the second type of degeneration, there is an acute exudative pathology as a consequence of neurovascularization. Here there is an elevated focus in the macular area, which at first contains serous fluid but later contains blood derived from blood vessels sprouting from the choroid to the subretinal space. The blood may become organized and form a plaque. Geographic atrophy AMD may produce a slow deterioration of central vision. Neurovascular AMD can cause a rapid distortion and loss of central vision.

In all these cases, central visual acuity will be markedly affected. Reading, driving, and recognizing faces become difficult. The atrophic type has no proven treatment or prevention. Verteporfin photodynamic (PTD) therapy has been shown to be beneficial in the treatment of advanced wet-type AMD (reviewed in Bourla and Young, 2006). PTD therapy combines the intravenous infusion of the light-sensitive dye verteporfin with low-intensity laser targeted to the neovascular tissue, causing occlusion of the abnormal choroidal vessels. However, recent therapy has been directed to vascular endothelial growth factor (VEGF) antagonism (reviewed in Chakravarthy, Evans, and Rosenfeld, 2010). VEGF may play a critical role in the pathogenesis of neovascularization. Several VEGF antagonists, both systemic and intraocular injections, are available, but ranibizumab given monthly by intravitreal injection is the first drug demonstrated to not only slow progression but to improve vision in patients with neovascular AMD. Total blindness does not occur, as patients retain peripheral vision and therefore are able to perform activities that do not necessitate acute central vision. In the United Kingdom guidance by the National Institute for Health and Clinical Excellence has resulted in ranibizumab being adopted as the treatment of choice. However, the high cost of ranibizumab, along with the much cheaper and positive clinical experience with bevacizumab (Martin et al., 2011), has resulted in the majority of patients in the United States and other countries being treated with the latter drug. Visual rehabilitation is an important part of therapy for AMD. Patients may benefit from reading glasses or magnification devices. Clinical depression may occur as a consequence of reductions in quality of life and should be treated.

Diabetic Retinopathy

In the geriatric population, a significant amount of visual loss is attributed to diabetic retinopathy. The Framingham Eye Study showed an age-associated increase in prevalence up to 7% at ages 75 to 85 years (Kini et al., 1978). In adult-onset diabetes with background changes, the visual loss is usually related to vascular changes in and

around the macula leading to central visual loss. Leakage of serous fluid from vessels surrounding the macula leads to macular edema and deterioration of visual acuity. This may respond to laser photocoagulation.

Hemorrhages within the macula may lead to more permanent visual loss. A loss of retinal capillaries may lead to macular ischemia and poor prognosis of visual recovery.

Intensive blood glucose control and tight blood pressure control reduce the risk of microvascular disease, including retinopathy in type 2 diabetes (see Chapter 12). Panretinal and focal retinal laser photocoagulation reduces the risk of visual loss in patients with severe diabetic retinopathy and macular edema, respectively (reviewed in Mohamed, Gillies, and Wong, 2007). There is currently insufficient evidence for routine use of other treatments, such as VEGF antagonists.

■ General Factors

Table 13-4 summarizes the general patterns of signs and symptoms associated with common visual problems of older adults. In addition to the specific treatment discussed earlier, some simple techniques, such as use of a magnifying device, large-print reading material, lighting intensifiers, and reduction of glare, can help maximize visual function (**Table 13-5**).

Clinicians should also be aware of the significant systemic absorption of ophthalmic medications (Anand and Eschmann, 1988). These agents may lead to other organ system dysfunction and interact with other medications (**Table 13-6**). The patient's other medical problems and medications should be assessed, and the minimum dose to achieve the desired effect should be used. Patients should also be monitored for systemic toxicity.

HEARING

This section covers four areas related to hearing problems in older adults: a review of the major parts of the auditory system, tests used to evaluate the hearing system, effects of aging on hearing performance, and specific pathologic disorders affecting the auditory system.

Hearing problems are common in the older adults, especially in a highly industrialized society where noise and age interact to cause hearing loss (**Fig. 13-2**). In the 2005–2006 cycle of the National Health and Nutrition Examination Survey, hearing loss was present in 63% of those surveyed age 70 and older. (See Pacala and Yueh, 2012, for a review of epidemiology, evaluation, and management of hearing loss in older adults.) Screening is endorsed by most professional organizations, including the U.S. Preventive Services Task Force. Screening tests that reliably detect hearing loss are use of an audioscope, a hand-held combination otoscope and audiometer, and a self-administered questionnaire, the Hearing Handicap Inventory for the Elderly–Screening (reviewed in Bogardus, Yueh, and Shekelle, 2003, and Yueh et al., 2003). Hearing loss screening is a required element of the initial Medicare annual wellness visit. All patients with hearing loss should be referred to an audiologist for audiometric testing. Cerumen accumulation is common in older adults and can lead to significant hearing loss. Hearing loss in older adults is usually of the sensorineural

TABLE 13-4. Signs and Symptoms Associated with Common Visual Problems in Older Adults

Signs and symptoms	Cataract	Open-angle glaucoma	Angle-closure glaucoma	Macular degeneration	Temporal arteritis	Diabetic Retinopathy
Pain			x		x	
Red eye			x			
Fixed pupil			x			
Retinal vessel changes					x	x
Retinal exudates				x		x
Optic disk changes		x			x	
Sudden visual loss			x		x	
Loss of peripheral vision		x				
Glare intolerance	x					
Elevated intraocular pressure		x	x			
Loss of visual acuity	x			x		x

TABLE 13-5. Aids to Maximize Visual Function

Magnifying device
 Lighting intensifiers without glare
 Tinted glasses to reduce glare
 Night light to assist in adaptation
 Large-print newspapers, books, and magazines

type, caused by damage of the hearing organ, the peripheral nervous system, and/or the central nervous system. Individuals with hearing loss require hearing aids, aural rehabilitation, and understanding as the major avenues of remediation.

■ The Auditory System

On a functional basis, the auditory system can be divided into three major parts: peripheral, brainstem, and cortical areas ([Table 13-7](#)). Each part of the hearing system has unique functions, which combine to allow hearing and understanding of speech. [Table 13-8](#) lists these functions.

The main functions of the peripheral auditory system are to change sound into a series of electrical impulses and to transmit those to the brainstem. The major brainstem function is binaural interaction. Binaural interaction allows localization of sound and extraction of a signal from a noisy environment. The cortex brings sound

TABLE 13-6. Potential Adverse Effects of Ophthalmic Solutions

Drug	Organ system	Responses
β-Blockers (eg, timolol)	Cardiovascular	Bradycardia, hypotension, syncope, palpitation, congestive heart failure
	Respiratory	Bronchospasm
	Neurological	Mental confusion, depression, fatigue, light-headedness, hallucinations, memory impairment, sexual dysfunction
	Miscellaneous	Hyperkalemia
Adrenergics (eg, epinephrine, phenylephrine)	Cardiovascular	Extrasystoles, palpitation, hypertension, myocardial infarction
	Miscellaneous	Trembling, paleness, sweating
Cholinergic/ anticholinesterases (eg, pilocarpine, echothiophate)	Respiratory	Bronchospasm
	Gastrointestinal	Salivation, nausea, vomiting, diarrhea, abdominal pain, tenesmus
	Miscellaneous	Lacrimation, sweating
Anticholinergics (eg, atropine)	Neurologic	Ataxia, nystagmus, restlessness, mental confusion, hallucination, violent and aggressive behavior
	Miscellaneous	Insomnia, photophobia, urinary retention




FIGURE 13-2 Prevalence of hearing problems in older persons, 1984. (From Havlik, 1986.)

TABLE 13-7. Peripheral and Central Auditory Nervous System

- A. External ear and peripheral hearing mechanism
 - 1. Auricle
 - 2. Tympanic membrane
 - 3. Ossicular chain
 - 4. Eustachian tube
 - 5. Cochlea
 - a. Bony labyrinth
 - b. Membranous labyrinth
 - 6. Cochlear nerve
- B. Auditory areas in the brainstem
 - 1. Entrance of the eighth cranial nerve
 - 2. Cochlear nucleus
 - 3. Superior olivary complex
 - 4. Lateral lemniscus
 - 5. Inferior colliculus
 - 6. Medial geniculate
 - 7. Auditory radiations (brainstem-to-cortex tract)
- C. Auditory areas in the cortex
 - 1. Temporal lobe
 - 2. Parietal lobe
 - 3. Corpus callosum

TABLE 13-8. Functional Components of the Auditory System

- A. Transmission of signals in the periphery
 - 1. Molecular motion (ear canal)
 - 2. Mechanical vibration (eardrum and ossicles)
 - 3. Hydromechanical motion (inner ear)
 - 4. Electrical impulse (eighth nerve)
- B. Binaural interaction in the brainstem
 - 1. Localization and lateralization of sound
 - 2. Extraction of signals from environmental noise
- C. Speech processing in the cortex
 - 1. Conscious sensation of hearing
 - 2. Interpretation of speech
 - 3. Initiation of response to sound

to consciousness and allows interpretation of speech and initiation of appropriate reactions to sound signals.

■ Assessment

Although the United States Preventive Services Task Force currently does not recommend screening of older adults for hearing loss, careful history may reveal symptomatic individuals who otherwise deny a deficit. Assessment of hearing function can be divided into three kinds of hearing tests: standard, binaural, and difficult speech. The standard tests are useful for evaluating the peripheral system, binaural tests for evaluating the brainstem, and difficult speech tests for evaluating cortical problems (Table 13-9). Standard tests are performed by presenting pure tones or single words at varying intensity. An audiometer (AudioScope, Welch-Allyn, Inc.) that will deliver pure tones is available for office screening of hearing deficits.

Tympanic membrane movement is assessed with a probe. Loudness comparison assesses the individual's ability to balance intensity of sound coming from both ears;

TABLE 13-9. Assessment of Hearing Function

- A. Standard test measures
 - 1. Sensitivity for tones and speech
 - 2. Speech discrimination/understanding
 - 3. Movement of tympanic membrane
- B. Binaural tests
 - 1. Loudness comparison
 - 2. Lateralization
 - 3. Masking level differences
- C. Difficult speech tests
 - 1. Monotic degraded tasks
 - 2. Dichotic tasks

TABLE 13-10. Effects of Aging on the Hearing Mechanism

Atrophy and disappearance of cells in the inner ear
Angiosclerosis in the inner ear
Calcification of membranes in the inner ear
Bioelectric and biomechanical imbalances in the inner ear
Degeneration and loss of ganglion cells and their fibers in the eighth cranial nerve
Eighth nerve canal closure, with destruction of nerve fibers
Atrophy and cell loss at all auditory centers in the brainstem
Reduction of cells in auditory areas of the cortex

lateralization tests the individual’s ability to fuse sounds from both ears; and masking level differences assess the ability to pick out specific sounds from a background of noise. Monotic degraded tasks present difficult sounds such as noise background, filtered sound, and time-compressed speech; dichotic tasks simultaneously present sense and nonsense speech, which the individual is asked to repeat.

■ **Aging Changes**

Many changes in the peripheral and central auditory system during aging have effects on the hearing mechanism (Table 13-10). These changes lead to diminished performance by older subjects (Table 13-11), including the loss of sensitivity and distortion of signals that succeed in passing to higher levels, difficulty in localizing signals and in taking advantage of two-ear listening, difficulty understanding speech under unfavorable listening conditions, and problems with language, especially when aging is compounded by stroke.

Three major factors enhance the progression of hearing loss with advancing age: previous middle-ear disease, vascular disease, and exposure to noise. These factors alone, however, do not account for the hearing loss of old age, called *presbycusis*. Although clinically and pathologically complex, this is a distinct progressive sensorineural hearing loss associated with aging. The deterioration is not limited to the peripheral sensory receptor and includes brainstem and cortical functions. Presbycusis affects 60% of

TABLE 13-11. Hearing Performance in Older Adults

A. Peripheral pathology
1. Hearing loss for pure tones
2. Hearing loss for speech
3. Problems understanding speech
B. Brainstem pathology
1. Problems localizing sounds
2. Problems in binaural listening
C. Cortical pathology
1. Problems with difficult speech
2. Language problems

individuals older than age 65 in the United States. However, only a fraction of these have a functional deficit necessitating aural rehabilitation.

■ Sensitivity

Beginning with the third decade of life, there is deterioration in the hearing threshold. At first, sensitivity at the high frequencies declines gradually. This age-associated loss has been confirmed in populations not exposed to high levels of noise. This gradual impairment is sensorineural and can be tested by pure-tone audiometry, which reveals useful information about the physiological condition of hearing, but does not disclose some important aspects of deterioration.

■ Speech

Although there is a close relationship between pure-tone loss and the ability to hear speech, the audiogram does not precisely measure hearing for speech. To assess this auditory function, speech audiometry can be performed by presenting the undistorted test words above threshold intensities in the absence of background noise.

Older people with hearing impairment may have difficulty understanding speech under less-favorable conditions, as with background noise, under poor acoustic conditions, or when speech is rapid. This difficulty may be caused in part by the longer time required by higher auditory centers to identify the message. Such hearing loss may necessitate testing of desired signals with the presentation of a competing signal. This will more accurately reflect hearing of speech in social circumstances.

Speech occurring in rooms that cause long reverberations is also much less intelligible to older individuals. Auditory temporal discrimination and auditory reaction time and frequency discrimination also decline with age. Because consonant sounds are of higher frequency and shorter duration, the loss of high-frequency hearing in the elderly may affect these sounds, which encode much of speech information. Lip reading may compensate to some extent for this effect on understanding speech, but other factors of processing information still remain.

■ Loudness

A common auditory problem of the elderly is abnormal loudness perception. This can occur as hypersensitivity to sounds of high intensity and appears as increased “loudness recruitment,” in which gradually increasing loudness, such as amplified sound, is unpleasantly harsh and difficult to tolerate. In older adults with hearing impairment, this abnormality is manifest when a speaker is asked to speak louder or the output of a hearing aid is increased. It may result from a sensorineural loss attributable to changes in the hair cells of the inner ear.

■ Localization

Sound localization contributes to effectiveness of signal detection and helps with discrimination. Loss of directional hearing results in greater hearing difficulty in a noisy environment. Localization is disturbed in older adults with hearing loss and may be partly caused by the aging brain's deranged processing of interaural intensity

differences and time delays. A strongly asymmetrical hearing loss also disturbs localization.

■ **Tinnitus**

Tinnitus, an internal noise generated within the hearing system, occurs in many types of hearing disorders at all ages, but is much more frequent in older adults. Tinnitus, however, is not necessarily associated with hearing loss and may occur in older adults without hearing impairment. Estimates of prevalence of tinnitus in the United States are about 10%, with the majority of persons with tinnitus being 40 to 80 years of age (Peifer, Rosen, and Rubin, 1999). Treatment is generally unsatisfactory.

■ **Other Hearing Disorders**

One of the most easily treatable but too easily overlooked causes of hearing loss is cerumen that occludes the external auditory canal (Table 13-12). Cerumen usually affects low-frequency sounds and complicates existing hearing impairments.

Hearing loss in the geriatric patient may be caused by scarring of the tympanic membrane. In tympanosclerosis, there is calcification of the tympanic membrane that results in stiffening of the drumhead.

Otosclerosis may cause fixation of the ossicular chain and lead to a conduction hearing loss. The bony capsule may also be affected, leading to sensorineural loss. Paget disease may also lead to both kinds of hearing loss and should be evaluated radiologically and by an alkaline phosphatase determination.

Ototoxic medication is an acquired cause of hearing loss producing cochlear damage. The aminoglycoside antibiotics require special caution. At high doses, ethacrynic acid and furosemide may be ototoxic.

High doses of aspirin may cause a reversible hearing impairment. Unfortunately, except for aspirin, removal of the offending drug usually does not reverse the sensorineural loss.

Sound trauma is an environmental factor with neurosensory consequences. Superimposed on the changes of aging, sound trauma can have a severe impact on a patient's communicative ability.

TABLE 13-12. Disorders of Hearing in Older Adults

Cerumen plug
Tympanosclerosis
Otosclerosis
Paget disease
Ototoxic medications
Sound trauma
CNS lesions
Pseudo-deafness (depression)

CNS, central nervous system.

Vascular or mass lesions may affect hearing at one of several levels, including the middle and inner ear, auditory nerve, brainstem, and cortex.

■ Aural Rehabilitation

Every individual who has communication difficulties caused by a permanent hearing loss should have an ear, nose, and throat evaluation to rule out remediable disease and then an audiological evaluation to assess the roles of amplification and aural rehabilitation. **Table 13-13** lists the factors that should be considered during the evaluation for a hearing aid. In the severely impaired, in addition to a hearing aid, aural rehabilitation with speech reading may be necessary.

Patients may initially be resistant to using a hearing aid. Patient and family counseling may overcome this resistance and improve use of and satisfaction with a hearing aid. Realistic expectations should be explained to the patient. Hearing aids are most useful in one-on-one conversations and are less effective in noisy, group settings. They are also less useful in improving understanding of less-familiar accents and languages, for example, a British accent in a movie or television production. Such understanding can be improved by use of the closed caption feature on television. Facing the speaker and lip reading also improves understanding. Improvements and modifications in design and construction of hearing aids, now digital, have enabled a greater proportion of the hearing-impaired population to profit from amplification. The old adage that hearing aids will not help people with sensorineural loss is simply not true. The aid can be adjusted to a specific frequency rather than all frequencies, thus decreasing loudness problems, improving discrimination, and making the aid more acceptable. Binaural aids improve sound localization and discrimination.

The hearing aid that is worn on the body provides the greatest amplification but is necessary only for patients with the most severe hearing loss. The controls are large and therefore more easily managed by some elderly persons. However, many elderly people prefer behind-the-ear or in-the-ear devices. The in-the-ear devices are small, cosmetically more acceptable, but more difficult to manipulate. Currently, not all

TABLE 13-13. Factors in Evaluation for a Hearing Aid

Exclude contraindicating medical or other correctable problem
Greatest satisfaction is achieved with aid if loss is 55-80 dB; there is only partial help if loss is >80 dB
Less satisfaction is achieved when poor discrimination is present
Aid is specifically designed for face-to-face conversation; patient's expectations should be realistic
Aid may need to be combined with lip reading
Loudness perception abnormalities may make aid unacceptable
More severe hearing loss requires aid worn on the body rather than behind-the-ear device
Assess for monaural or binaural aids
Assess for patient's ability to handle aid independently
Assess patient's motivation for using an aid

state Medicaid programs cover hearing aids, Veterans Affairs insurance covers only those with service-connected hearing loss, and Medicare does not cover hearing aids. This constitutes a major out-of-pocket expense. Pocket talkers are less expensive and may be used by those who cannot afford hearing aids.

Surgical treatment of sensorineural hearing loss is safe and effective in older adults with severe hearing loss not corrected by hearing aids. Middle ear implant devices and cochlear implants are emerging options for such individuals.

TASTE

During aging, there is a significant loss of lingual papillae and an associated diminution of ability to taste. Salivary secretion also diminishes, thus decreasing solubilization of flavoring agents. Upper dentures may cover secondary taste sites and decrease taste acuity.

Olfactory bulbs also show significant atrophy with old age. In a population-based, cross-sectional study of adults age 53 to 97, the prevalence of impaired olfaction by olfaction testing was 24.5% and increased with age to 62.5% of 80- to 97-year-olds (Murphy et al., 2002). Taste and olfactory changes together may account for the lessened interest in food shown by older adults.

POLYNEUROPATHY

Patients with polyneuropathy have impairments in balance and an increased risk for falls and falls causing injury (Richardson, 2002). Epidemiological data on polyneuropathy are relatively limited. In a study from Italy of subjects age 55 and older, the prevalence of polyneuropathy was 11%. Diabetes mellitus was the most common risk factor (44% of patients with polyneuropathy). The next most common risk factors were alcoholism, nonalcoholic liver disease, and malignancy (Beghi and Monticelli, 1998). In a natural history study of type 2 diabetes mellitus, 42% of the diabetic population had nerve conduction abnormalities consistent with polyneuropathy after 10 years (Partanen et al., 1995). The prevalence of diabetes mellitus in older persons is increasing, and therefore, the prevalence of polyneuropathy is likely to increase as well. Poor vitamin B₁₂ levels (deficient B₁₂ status and low serum B₁₂) are associated with worse sensory and motor peripheral nerve function in older adults (Leishear et al., 2012).

In chronic polyneuropathies, such as diabetes mellitus, symptoms usually begin in the lower extremities, and sensory symptoms usually precede motor symptoms. In demyelinating polyneuropathies, such as Guillain-Barré syndrome, weakness rather than sensory loss is more typical. The physical examination should focus on the sensory examination, including pin prick, light touch, vibration, cold, and proprioception, and on muscle strength testing and appearance of muscle wasting. Extensive diagnostic testing is usually not necessary in a patient with mild symptoms and a known underlying diagnosis such as diabetes mellitus or alcohol abuse. In patients with no clear etiology, electrodiagnostic testing should be the initial diagnostic study (Dyck et al., 1996). Rutkove (2012) has described an algorithm for a diagnostic approach to polyneuropathy (Fig. 13-3). Laboratory tests, which




FIGURE 13-3 Diagnostic approach to polyneuropathy. Ab, antibody; ANA, antinuclear antibody; CIDP, chronic inflammatory demyelinating polyneuropathy; EMG, electromyography; GM1, ganglioside antibodies; HIV, human immunodeficiency virus; Hu, human; IPEP, immunoprotein electrophoresis; IVIG, intravenous immunoglobulin; MAG, myelin-associated glycoprotein; RPR, rapid plasma reagin; SPEP, serum protein electrophoresis; TSH, thyroid-stimulating hormone; VDRL, Venereal Disease Research Laboratory; UPEP, urine protein electrophoresis. (Reproduced with permission from: Rutkove SB. Overview of polyneuropathy. In: UpToDate, Basow DS (Ed), UpToDate, Waltham, MA 2013. Copyright © 2013 UpToDate, Inc. For more information visit <http://www.uptodate.com/>)

might include a complete blood count, erythrocyte sedimentation rate, thyroid-stimulating hormone, serum and urine protein electrophoresis, blood glucose, glycohemoglobin, vitamin B₁₂ level, antinuclear antibody, rheumatoid factor, heavy metals, and HIV, should be directed by the electrodiagnostic testing results.

Treatment should address the underlying disease process and alleviation of symptoms. Avoidance of toxins, such as alcohol or drugs, is the most important step. In patients with diabetes, tight control may help maintain nerve function (see Chapter 12). In painful neuropathies, tricyclic antidepressants are effective, as is gabapentin. In patients with weakness, physical therapy evaluation is important, and use of ankle-foot orthosis, splints, and walking-assistance devices can improve function. Proper foot and nail care is important in reducing risk for foot ulcers.

ACKNOWLEDGMENT

The authors wish to thank Dr. Douglas Noffsinger for his assistance in preparing material for an earlier version of the section on hearing in this chapter.

Evidence Summary
Do's
<ul style="list-style-type: none">• Screen for visual and auditory dysfunction in older adults.• Refer all patients with age-related macular degeneration (AMD) for visual rehabilitation.• Initiate intensive blood glucose control and tight blood pressure control to reduce retinopathy in type 2 diabetes.• Evaluate for treatable causes of hearing loss such as cerumen impaction and chronic otitis media.• Refer patients with definite hearing loss to an audiologist.
Consider
<ul style="list-style-type: none">• Cataract surgery when cataract progresses to interfering with activities.• Glaucoma when defects in the peripheral visual field are present.• AMD when central visual acuity is affected.

REFERENCES

Anand KB, Eschmann E. Systemic effects of ophthalmic medication in the elderly. *NY State J Med.* 1988;88:134-136.

Beghi E, Monticelli ML. Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation of risk factors for polyneuropathy in two Italian communities. *J Clin Epidemiol.* 1998;51:697-702.

Bogardus ST, Yueh B, Shekelle PG. Screening and management of adult hearing loss in primary care: clinical applications. *JAMA.* 2003;289:1986-1990.

Bourla DH, Young TA. Age-related macular degeneration: a practical approach to a challenging disease. *J Am Geriatr Soc.* 2006;54:1130-1135.

Chakravarthy U, Evans J, Rosenfeld PJ. Age related macular degeneration. *BMJ.* 2010;340:526-530.

- Dyck PJ, Dyck PJB, Grant IA, et al. Ten steps in characterizing and diagnosing patients with peripheral neuropathy. *Neurology*. 1996;47:10-17.
- Fine SL, Berger JW, Maguire MG, et al. Age-related macular degeneration. *N Engl J Med*. 2000;342:483-492.
- Haines JL, Pericak-Vance MA. Rapid dissection of the genetic risk of age-related macular degeneration. *JAMA*. 2007;297:401-402.
- Havlik RJ. Aging in the eighties, impaired senses for sound and light in persons age 65 years and over. *NCHS Advance Data*. 1986;25.
- Kini MM, Liebowitz HM, Colton T, et al. Prevalence of senile cataract, diabetic retinopathy, senile macular degeneration, and open-angle glaucoma in the Framingham Eye Study. *Am J Ophthalmol*. 1978;85:28-34.
- Kwon YH, Fingert JH, Kuehn MH, et al. Primary open-angle glaucoma. *N Engl J Med*. 2009;360:1113-1124.
- Leishear K, Boudreau RM, Studenski SA, et al. Relationship between vitamin B12 and sensory and motor peripheral nerve function in older adults. *J Am Geriatr Soc*. 2012;60:1057-1063.
- Martin DF, Maguire MG, Ying G, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2011;364:1897-1908.
- Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. *JAMA*. 2007;298:902-916.
- Murphy C, Schubert CR, Cruickshanks KJ, et al. Prevalence of olfactory impairment in older adults. *JAMA*. 2002;288:2307-2312.
- Pacala JT, Yueh B. Hearing deficits in the older patient: "I didn't notice anything." *JAMA*. 2012;307:1185-1194.
- Partanen J, Niskonen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes mellitus. *N Engl J Med*. 1995;89:89-94.
- Peifer KJ, Rosen GP, Rubin AM. Tinnitus: etiology and management. *Clin Geriatr Med*. 1999;15:193-204.
- Richardson JK. Factors associated with falls in older patients with diffuse polyneuropathy. *J Am Geriatr Soc*. 2002;50:1767-1773.
- Rutkove SB. Overview of polyneuropathy. *UpToDate* 2012. Available at: <http://www.uptodate.com>. Last updated February 10, 2012.
- Schaumberg DA, Hankinson SE, Guo Q, et al. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. *Arch Ophthalmol*. 2007;125:55-62.
- Tseng VL, Yu F, Lum F, Coleman AL. Risk of fractures following cataract surgery in Medicare beneficiaries. *JAMA*. 2012;308:493-501.
- Yueh B, Shapiro N, MacLean CH, et al. Screening and management of adult hearing loss in primary care: scientific review. *JAMA*. 2003;289:1976-1985.

SUGGESTED READINGS

- Folk JC, Stone EM. Ranibizumab therapy for neovascular age-related macular degeneration. *N Engl J Med*. 2010;363:1648-1655.
- Friedland DR, Runge-Samuelson C, Baig H, et al. Case-control analysis of cochlear implant performance in elderly patients. *Arch Otolaryngol Head Neck Surg*. 2010;136:432-438.
- Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. *N Engl J Med*. 2008;358:2606-2617.
- Lin FR. Hearing loss in older adults who's listening? *JAMA*. 2012;307:1147-1148.

Mulrow CD, Lichtenstein MJ. Screening for hearing impairment in the elderly: rationale and strategy. *J Gen Intern Med.* 1991;6:249-258.

Uhlmann RF, Rees TS, Psatz BM, et al. Validity and reliability of auditory screening tests in demented and non-demented older adults. *J Gen Intern Med.* 1989;4:90-96.

Zahng X, Saaddine JB, Chou C-F, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. *JAMA.* 2010;304:649-656.

WEB LINKS

American Academy of Audiology: <http://www.audiology.org>

American Academy of Ophthalmology: <http://www.aao.org/>

American Glaucoma Society: <http://www.glaucomaweb.org/>

American Macular Degeneration Foundation: <http://www.macular.org>

Clinical Advisory: NIDCD/VA Clinical Trial Finding Can Benefit Millions with Hearing Loss: <http://www.nlm.nih.gov/databases/alerts/hearing.html>

Facts about Age-Related Macular Degeneration: http://www.nei.nih.gov/health/maculardegen/armd_facts.asp

Healthy Hearing: <http://www.healthyhearing.com>

Hearing Aid Help: <http://www.hearingaidhelp.com/>

Hearing Handicap Inventory for the Elderly Screening: <http://teachhealthk-12.uthscsa.edu/curriculum/vision-hearing/pa06pdf/0608E-eng.pdf>

“Learn about Glaucoma”: <http://www.glaucoma.org/>

Lighthouse for the Blind: <http://www.lighthouse-sf.org/>

Macular Degeneration Foundation: <http://www.eyesight.org/>

Macular Degeneration International: <http://www.maculardegeneration.org>

Macular Degeneration Partnership: <http://www.amd.org>

CHAPTER 14

Drug Therapy

Geriatric patients are sometimes viewed as “walking chemistry sets” because they are frequently prescribed multiple drugs in complex dosage schedules. This is often the result of older people seeing multiple prescribing clinicians who do not communicate with each other and a lack of a comprehensive medication list either electronically or in hard copy. With older patients, polypharmacy is common because of the presence of multiple chronic medical conditions, the proven efficacy of an increasing number of drugs for these conditions, and practice guidelines that recommend their use. The nature of drug therapy in managing chronic disease has changed greatly. Many conditions can be better controlled, but at a cost. In many instances, however, complex drug regimens are unnecessary; they are costly and predispose to nonadherence and adverse drug reactions. Many older patients are prescribed multiple drugs, take over-the-counter drugs, and are then prescribed additional drugs to treat the side effects of medications they are already taking. This scenario can result in an upward spiral in the number of drugs being taken and commonly leads to polypharmacy.

Several important pharmacological and nonpharmacological considerations influence the safety and effectiveness of drug therapy in the geriatric population. This chapter focuses on these considerations and gives practical suggestions for prescribing drugs for older patients. Drug therapy for specific geriatric conditions is discussed in several other chapters throughout this text.

NONPHARMACOLOGICAL FACTORS INFLUENCING DRUG THERAPY

Discussions of geriatric pharmacology frequently center on age-related changes in drug pharmacokinetics and pharmacodynamics. Detailed reviews of these areas are provided in the Suggested Readings section at the end of the chapter. Although these changes are often of clinical importance, nonpharmacological factors can play an even greater role in the safety and effectiveness of drug therapy in the geriatric population. Several steps make drug therapy safe and effective (Fig. 14-1). Many factors can interfere with this scheme in the geriatric population, and as can be seen, most of them come into play before pharmacological considerations arise.

Effective drug therapy requires accurate diagnoses. Many older patients underreport symptoms; patient complaints may be vague and multiple. Symptoms of physical diseases frequently overlap with symptoms of psychological illness. To add to this complexity, many diseases present with atypical symptoms. Consequently, making the correct diagnoses and prescribing the appropriate drugs are often difficult tasks in the geriatric population.

Health-care professionals tend to treat symptoms with drugs rather than to evaluate the symptoms thoroughly. Because older patients often have multiple problems and complaints and consult several health-care professionals, they can readily end up with prescriptions for several drugs. Moreover, older patients or their family




FIGURE 14-1 Factors that can interfere with successful drug therapy.

members sometimes exert pressure on health-care professionals to prescribe medication, thus adding to the tendency for polypharmacy. This pressure is intensified by direct-to-consumer advertising of drugs.

Older patients typically see many different clinicians, each of whom may prescribe medications. Frequently, neither the patients nor the health-care providers have a clear picture of the total drug regimen. New patients undergoing initial geriatric assessment should be asked to empty their medicine cabinets and to bring all bottles to their first appointments. Simple medication records, such as the one shown in [Figure 14-2](#), carried by the patient and maintained as an integral part of the overall medical record, may help to eliminate some of the polypharmacy and nonadherence common in the geriatric population. Such records should be updated at each patient visit. Drug regimens should be simplified whenever possible, and patients should be instructed to discard old medications. Incorporation of medication lists into electronic medical records with medication adjudication at each visit can be very helpful in maintaining an accurate medication list, reducing polypharmacy, and improving adherence. A good principle is to consider each time a new drug is added if one can be discontinued.

NAME _____ DOCTOR _____ PHONE: () _____

MEDICATION NAME	REASON FOR USE	DESCRIBE OR TAPE MEDICINE HERE	WHEN TO TAKE MEDICINE				SPECIAL NOTES

REMEMBER

BRING THIS CHART TO ALL DOCTOR APPOINTMENTS
INCLUDE ALL THE MEDICATIONS YOU ARE TAKING
DO NOT CHANGE THE WAY YOU TAKE THE MEDICATIONS WITHOUT CALLING THE DOCTOR
DO NOT SHARE MEDICATIONS
IF YOU HAVE ANY QUESTIONS, CALL THE DOCTOR

FIGURE 14-2 Example of a basic medication record.

Adherence plays a central role in the success of drug therapy in all age groups (see Fig. 14-1). In addition to the tendency for polypharmacy and complex dosage schedules, older patients face other potential barriers to adherence. The chronic nature of illness in the geriatric population can play a role in nonadherence. The consequences of these illnesses are often delayed (as opposed to the more dramatic effects of acute illnesses), and chronic illnesses necessitate ongoing prophylactic or suppressive rather than relatively short and time-limited courses of therapy. Adherence tends to be poor for these types of drug regimens. Diminished hearing, impaired vision, poor literacy, and poor short-term memory can interfere with patient education and adherence. Individuals with mild cognitive impairment may be at particular risk for nonadherence to medication regimens (Campbell et al., 2012). Problems with transportation can make getting to a pharmacy difficult. Outpatient prescriptions are now covered by Medicare to some extent, but many older persons still have to pay for some of the costs of their drugs from a limited income. Even if the older person gets to the pharmacy, can afford the prescription, understands the instructions, and remembers when to take it, the use of childproof bottles and tamper-resistant packaging may hinder adherence in those with arthritic or weak hands.

Several strategies can improve adherence in the geriatric population (Table 14-1). As few drugs as possible should be prescribed, and the dosage schedule should be as simple as possible. All drugs should be given on the same dosage schedules whenever possible, and the administration should correspond to a daily routine in order to enhance the consistency of taking the drugs and adherence. For many drugs, once-daily dosing is available and should be prescribed when clinically appropriate. Relatives or

TABLE 14-1. Strategies to Improve Compliance in the Geriatric Population

1. Make drug regimens and instructions as simple as possible
 - a. Use the same dosage schedule for all drugs whenever feasible (eg, once or twice per day)
 - b. Time the doses in conjunction with a daily routine
2. Instruct relatives and caregivers on the drug regimen
3. Enlist others (eg, home health aides, pharmacists) to help ensure compliance
4. Make sure the older patient can get to a pharmacist (or vice versa), can afford the prescriptions, and can open the container
5. Use aids (such as special pillboxes and drug calendars) whenever appropriate
6. Perform careful medication adjudication and patient/family education at the time of every hospital discharge
7. Keep updated medication records (see Fig. 14-2) and review them at each visit
8. Review knowledge of and compliance with drug regimens regularly

other caregivers should be instructed in the drug regimen, and they, as well as others (eg, home health aides and pharmacists), should be enlisted to help the older patient comply. Specially designed pill dispensers and frequent human reminders can be useful. Geriatric patients and their health-care providers should keep an updated record of the drug regimen (see Fig. 14-2). For older patients who are hospitalized, medication adjudication and education should be performed at the time of discharge, because posthospital medication discrepancies are common in the older population and can have serious consequences (Coleman et al., 2005). Patients and families need to be carefully instructed on which medications have been discontinued and where dosages have been changed. Medication misuse can result, in avoidable emergency room visits. A handful of medications (warfarin, insulin, oral hypoglycemic and oral antiplatelet agents, and digoxin) account for a substantial portion of these visits (Budnitz et al., 2007; Budnitz et al., 2011). Medications should be brought to appointments, and patients and families should show all medications to their physicians, particularly on initial visits to new primary care physicians or at a consultation with a specialist. Health-care professionals should regularly inquire about other medications being taken (prescribed by other physicians or purchased over the counter) and review their patients' knowledge of and compliance with the drug regimen.

ADVERSE DRUG REACTIONS AND INTERACTIONS

Primum non nocere ("first, do no harm"), a watchword phrase in the practice of medicine, is nowhere more applicable than when drugs are being prescribed for the geriatric population. Concerns are frequently heard about inappropriate prescribing of medications with serious side effects in older people. Numerous studies over the last three decades have described the frequency of "inappropriate" drug therapy in a variety of settings. For example, a recent study of over 200,000 inpatient surgical admissions in patients age 65 and older found that one-quarter had received a potentially inappropriate medication (Finlayson et al., 2011). The American Geriatrics Society

has recently completed a comprehensive review and updated the Beers Criteria, which detail potentially inappropriate medications for older adults as well as drug–drug and drug–disease interactions that should be avoided. Readers are referred to this resource for information on specific drugs to assist in preventing adverse drug reactions and interactions (American Geriatrics Society 2012 Beers Criteria Update Expert Panel, 2012; also available at http://www.americangeriatrics.org/health_care_professionals/clinical_practice/clinical_guidelines_recommendations/2012).

Adverse drug reactions are the most common form of iatrogenic illness (see Chapter 5). The incidence of adverse drug reactions in hospitalized patients increases from approximately 10% in those between 40 and 50 years of age to 25% in those older than age 80 (Lazarou, Pomeranz, and Corey, 1998). They account for between 3% and 10% of hospital admissions of older patients each year and result in several billion dollars in yearly health-care expenditures. Many drugs can produce distressing, and sometimes disabling or life-threatening, adverse reactions (Table 14-2). Psychotropic drugs, all drugs with substantial anticholinergic activity, and cardiovascular agents are common causes of serious adverse reactions in the geriatric population. In part, this is because of the narrow therapeutic-to-toxic ratio of many of these drugs and the sensitivity of the aging brain to anticholinergic drugs. In some instances, age-related changes in pharmacology, such as diminished renal excretion and prolonged duration of action, predispose to adverse reactions. Some side effects can have a therapeutic benefit and may be key factors in drug selection (see below).

Because symptoms can be nonspecific or may mimic other illnesses, adverse drug reactions may be ignored or unrecognized. Patients and family members should be educated to recognize and report common and potentially serious adverse reactions. In some instances, another drug is prescribed to treat these symptoms, thus contributing to polypharmacy and increasing the likelihood of an adverse drug interaction. The problem of polypharmacy is exacerbated by visits to multiple physicians, who may prescribe still more drugs and the use of multiple pharmacies. Medication records kept by the patient (see Fig. 14-2), the physician's medical record, and the increasing use of electronic medical records should help to prevent unnecessary polypharmacy when many physicians are involved. Several drugs commonly prescribed for the geriatric population can interact with adverse consequences (American Geriatrics Society 2012 Beers Criteria Update Expert Panel, 2012; Hines and Murphy, 2011). Table 14-3 lists some of the more common potential adverse drug–drug interactions. The more common types are drug displacement from protein-binding sites by other highly protein-bound drugs, induction or suppression of the metabolism of other drugs, and additive effects of different drugs on blood pressure and mental function (mood, level of consciousness, etc.). Interactions among drugs metabolized by the cytochrome P450 system in the liver are especially common (see Wilkinson, 2005, for a review). Because many older patients are treated with warfarin for atrial fibrillation or venous thrombosis, clinicians must be aware of the many potential drug–drug and drug–nutrient interactions with this medication (Holbrook et al., 2005). In addition to the potential to interact with other

TABLE 14-2. Examples of Common and Potentially Serious Adverse Drug Reactions in the Geriatric Population

Drug	Common adverse reactions
Analgesics (see Chap. 10)	
Anti-inflammatory agents, aspirin	Gastric irritation and ulcers Chronic blood loss
Narcotics	Constipation
Antimicrobials	
Aminoglycosides	Renal failure Hearing loss
Other antimicrobials	Diarrhea
Antiparkinsonian Drugs (see Chap. 10)	
Dopaminergic agents	Nausea Delirium Hallucinations Postural hypotension
Anticholinergics	Dry mouth Constipation Urinary retention Delirium
Cardiovascular Drugs (see Chap. 11)	
Angiotensin-converting enzyme (ACE) inhibitors	Cough Impaired renal function
Antiarrhythmics	Pulmonary toxicity, bradycardia, hypotension (amiodarone) Diarrhea (quinidine) Urinary retention (disopyramide)
Anticoagulants	Bleeding complications
Antihypertensives	Hypotension
Calcium channel blockers	Decreased myocardial contractility Edema Constipation
Diuretics	Dehydration Hyponatremia Hypokalemia Incontinence
Digoxin	Arrhythmias Nausea Anorexia
Nitrates	Hypotension
Statins	Myopathy, hepatotoxicity

(Continued)

TABLE 14-2. Examples of Common and Potentially Serious Adverse Drug Reactions in the Geriatric Population (*Continued*)

Drug	Common adverse reactions
Hypoglycemic Agents	
Insulin	Hypoglycemia
Oral agents	Edema (glitazones) Diarrhea (metformin)
Lower Urinary Tract Drugs (see Chap. 8)	
Antimuscarinics	Dry mouth, eyes
Oral agents	Constipation Esophageal reflux
α -Blockers	Postural hypotension
Psychotropic Drugs (see Tables 14-8 and 14-9)	
Antidepressants	(See Chapter 7)
Antipsychotics	Death Sedation Hypotension Extrapyramidal movement disorders Weight gain
Cholinesterase inhibitors	Falls Syncope Nausea, diarrhea
Lithium	Weakness Tremor Nausea Delirium
Sedative and hypnotic agents	Excessive sedation Delirium Gait disturbances and falls
Others	
Alendronate, risedronate	Esophageal ulceration
Aminophylline, theophylline	Gastric irritation Tachyarrhythmias
Carbamazepine	Anemia Hyponatremia Neutropenia

See American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) for a complete list.

TABLE 14-3. Examples of Potentially Clinically Important Drug–Drug Interactions

Interaction	Examples	Potential effects
Interference with drug absorption	Antacids interacting with digoxin, isoniazid, antipsychotics, enteral tube feedings, and liquid phenytoin; iron; and ciprofloxacin	Diminished drug effectiveness
Displacement from binding proteins	Warfarin, oral hypoglycemics, and other highly protein-bound drugs	Enhanced effects and increased risk of toxicity
Altered distribution	Digoxin and quinidine	Increased risk of toxicity
Altered metabolism	Antifungals, erythromycin, clarithromycin SSRIs, with antihistamines, calcium channel blockers, and others*	Decreased metabolism, increased levels of toxicity
Altered excretion	Lithium and diuretics	Increased risk of toxicity and electrolyte imbalance
Pharmacological antagonism	Antimuscarinic drugs (for the bladder) and cholinesterase inhibitors	Decreased effectiveness
Pharmacological synergism	α -Blockers (for lower urinary tract symptoms in men) and antihypertensives	Increased risk of hypotension

*See Wilkinson (2005).
SSRI, selective serotonin reuptake inhibitor.
See American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) for a complete list.

drugs, several drugs can interact adversely with underlying medical conditions in the geriatric population, creating “drug–patient” interactions (American Geriatrics Society 2012 Beers Criteria Update Expert Panel, 2012; see [Table 14-4](#) for examples). A good example of this problem is the increased risk of hospitalization for congestive heart failure (CHF) among older patients taking diuretics who are told to take a nonsteroidal anti-inflammatory drug (Heerdink et al., 1998).

Health-care professionals should have a thorough knowledge of the more common drug side effects, adverse reactions to drugs, and potential drug interactions in the geriatric population. Electronic databases available on the World Wide Web or on personal digital assistants (PDAs) can be very helpful in this regard. Careful questioning about side effects should be an important part of reviewing the drug regimen at each visit. Many institutions use computers to detect potential adverse drug interactions and to prevent their occurrence. Software programs are available to assist in identifying potential adverse drug interactions. Special attention should be given

TABLE 14-4. Examples of Potentially Clinically Important Drug–Patient Interactions

Drug	Patient factors	Clinical implications
Diuretics	Diabetes Poor nutritional status	Decreased glucose tolerance Increased risk of dehydration and electrolyte imbalance
Angiotensin-converting enzyme (ACE) inhibitors	Urinary frequency, urgency Renovascular disease (severe)	Incontinence may result Worsening renal function
β -Blockers	Stress incontinence Diabetes Chronic obstructive lung disease Congestive heart failure (CHF) Peripheral vascular disease	Precipitate incontinence (cough) Sympathetic response to hypoglycemia may be masked Increased bronchospasm Decreased myocardial contractility Increased claudication
Narcotic analgesics	Chronic constipation	Worsening symptoms, fecal impaction
Antimuscarinics, tricyclic antidepressants, antihistamines, and other drugs with anticholinergic effects	Constipation, glaucoma, prostatic hyperplasia, reflux esophagitis	Worsening of symptoms
Antipsychotics	Parkinsonism	Worsening of immobility
Psychotropics	Dementia	Further impairment of cognitive function
Nonsteroidal anti-inflammatory drugs	CHF, on diuretics	Increased risk of exacerbation of CHF

to the potential for any newly prescribed drug to interact with drugs already being taken or with underlying medical or psychological conditions. Many drugs can be stopped safely as demonstrated by use of the aforementioned Beers Criteria, STOPP criteria (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions) (Gallagher and O'Mahony, 2008), and other strategies such as the Good Palliative-Geriatric Practice algorithm (Garfinkel and Mangin, 2010). Consultant pharmacists with specialized expertise in geriatrics can be extremely helpful in recommending strategies for discontinuing specific medications.

AGING AND PHARMACOLOGY

Several age-related biological and physiological changes are relevant to drug pharmacology (Table 14-5). With the exception of changes in renal function, however, the effects of

these age-related changes on dosages of specific drugs for individual patients are variable and difficult to predict. In general, an understanding of the physiological status of each patient (taking into account factors such as state of hydration, nutrition, and cardiac output) and how that status affects the pharmacology of a particular drug is more important to clinical efficacy than are age-related changes. Drug delivery systems, such as oral sustained-release preparations and skin patches, may be useful in designing strategies to account for the effect of aging changes on pharmacodynamics and to make many drugs safer in the geriatric population. Given these caveats, the effects of aging on each pharmacodynamic process are briefly discussed in the following sections.

Absorption

Several age-related changes can affect drug absorption (see Table 14-5). Most studies, however, have failed to document any clinically meaningful alterations in drug absorption with increasing age. Absorption, therefore, appears to be the pharmacological parameter least affected by increasing age.

Distribution

In contrast to absorption, clinically meaningful changes in drug distribution can occur with increasing age. Serum albumin, the major drug-binding protein, tends to decline, especially in hospitalized patients. Although the decline is numerically small, it can substantially increase the amount of free drug available for action. This effect is of particular relevance for highly protein-bound drugs, especially when they are used simultaneously and compete for protein-binding sites (see Table 14-3).

Age-related changes in body composition can prominently affect pharmacology by altering the volume of distribution (Vd). The elimination half-life of a drug varies with the ratio of Vd to drug clearance. Thus, even if the rate of clearance of a drug is unchanged with age, changes in Vd can affect a drug's half-life and duration of action.

TABLE 14-5. Age-Related Changes Relevant to Drug Pharmacology	
Pharmacological parameter	Age-related changes
Absorption	Decreases in absorptive surface splanchnic blood flow Increased gastric pH Altered gastrointestinal motility
Distribution	Decreases in total body water, lean body mass, serum albumin Increased fat Altered protein binding
Metabolism	Decreases in liver blood flow, enzyme activity, enzyme inducibility
Excretion	Decreases in renal blood flow, glomerular filtration rate, tubular secretory function
Tissue sensitivity	Alterations in receptor number, receptor affinity, second-messenger function, cellular and nuclear responses

Because total body water and lean body mass decline with increasing age, drugs that distribute in these body compartments, such as most antimicrobial agents, digoxin, lithium, and alcohol, may have a lower Vd and can, therefore, achieve higher concentrations from given amounts of drugs. On the other hand, drugs that distribute in body fat, such as many of the psychotropic agents, have a large Vd in geriatric patients. The larger Vd will thus cause a prolongation of the half-life unless the clearance increases proportionately, which is unlikely to happen with increasing age.

■ Metabolism

The effects of aging on drug metabolism are complex and difficult to predict. They depend on the precise pathway of drug metabolism in the liver and on several other factors, such as gender and amount of smoking (Wilkinson, 2005). The pharmacokinetics and elimination of drugs commonly used in the elderly are now readily available on the Internet and several PDA-based programs.

There is some evidence that the first, or preparative, phase of drug metabolism, including oxidations, reductions, and hydrolyses, declines with increasing age, and that the decline is more prominent in men than in women. In contrast, the second phase of drug metabolism (biotransformation, including acetylation and glucuronidation) appears to be less affected by age. There is also evidence that the ability of environmental factors (most importantly smoking) to induce drug-metabolizing enzymes declines with age. Even when liver function is obviously impaired, as by intrinsic liver disease or right-sided CHF, the effects of aging on the metabolism of specific drugs cannot be precisely predicted. It is *not* safe to assume, however, that geriatric patients with normal liver function tests can metabolize drugs as efficiently as can younger individuals.

The cytochrome P450 system in the liver has been extensively studied. More than 30 isoenzymes have been identified and classified into families and subfamilies. Genetic mutations in some of these enzymes, while relatively uncommon, can impair metabolism of specific drugs. Although aging may affect this system, the effects of commonly used drugs are probably more important (Wilkinson, 2005).

■ Excretion

Unlike metabolism, the effects of aging on renal function are somewhat more predictable. The tendency for renal function to decline with increasing age can affect the pharmacokinetics of several drugs (and their active metabolites) that are eliminated predominantly by the kidney. These drugs are cleared from the body more slowly, their half-lives (and duration of action) are prolonged, and there is a tendency to accumulate to higher (and potentially toxic) drug concentrations in the steady state.

Several considerations are important in determining the effects of age on renal function and drug elimination:

1. There is wide interindividual variation in the rate of decline of renal function with increasing age. Thus, although renal function is said to decline by 50% between the ages of 20 and 90 years, this is an *average* decline. A 90-year-old individual may not have a creatinine clearance of only 50% of normal. Applying average declines to individual elderly patients can result in over- or underdosing.

- 2. Muscle mass declines with age; therefore, daily endogenous creatinine production declines. Because of this decline in creatinine production, serum creatinine may be normal at a time when renal function is substantially reduced. Serum creatinine, therefore, does not reflect renal function as accurately in elderly people as it does in younger persons.
- 3. A number of factors can affect renal clearance of drugs and are often at least as important as age-related changes. State of hydration, cardiac output, and intrinsic renal disease should be considered in addition to age-related changes in renal function.

Several formulas and nomograms have been used to estimate renal function in relation to age. **Table 14-6** shows one of the most widely used and accepted formulas. Another commonly used equation is the Modification of Diet in Renal Disease (MDRD) equation, which is used by many clinical laboratories to estimate glomerular filtration rate. MDRD calculators are readily available on the Internet (eg, <http://mdrd.com>). These formulae are useful in *initial estimations* of creatinine clearance for the purpose of drug dosing in the geriatric population. However, both the Cockcroft–Gault equation (Cockcroft and Gault, 1976) and the MDRD may over- or underestimate creatinine clearance in individual patients. Clinical factors (such as state of hydration and cardiac output), which vary over time, should be considered in determining drug dosages.

When drugs with narrow therapeutic-to-toxic ratios are being used, actual measurements of creatinine clearance and drug blood levels (when available) should be used.

■ **Tissue Sensitivity**

A proportion of the drug or its active metabolite will eventually reach its site of action. Age-related changes at this point—that is, responsiveness to given drug concentrations (without regard to pharmacokinetic changes)—are termed *pharmacodynamic changes*. Older persons are often said to be more sensitive to the effects of drugs. For some drugs, this appears to be true. For others, however, sensitivity to drug effects may decrease rather than increase with age. For example, older persons may be more sensitive to the sedative effects of given blood levels of benzodiazepines but less sensitive to the effects of drugs mediated by α -adrenergic receptors. There are several possible explanations for these changes (see Table 14-5). The effects of age-related pharmacodynamic changes on dosages of specific drugs for individual geriatric patients remain largely unknown.

TABLE 14-6. Renal Function in Relation to Age*	
Cockcroft–Gault Equation	
$\text{Creatinine clearance} = \frac{(140 - \text{age}) \times \text{body weight (kg)}}{72 \times \text{serum creatinine level}} (\times 0.85 \text{ for women})$	

*Several other factors can influence creatinine clearance (see text).
Data compiled from Cockcroft and Gault (1976).

GERIATRIC PRESCRIBING

■ General Principles

Several considerations make the development of specific recommendations for geriatric drug prescribing very difficult. These include the following:

1. Multiple interacting factors influence age-related changes in drug pharmacology.
2. There is wide interindividual variation in the rate of age-related changes in physiological parameters that affect drug pharmacology. Thus, precise predictions for individual older persons are difficult to make.
3. The clinical status of each patient (including such factors as state of nutrition and hydration, cardiac output, and intrinsic renal and liver disease) must be considered in addition to the effects of aging.
4. As more research studies with newer drugs are carried out in well-defined groups of older subjects, more specific recommendations will be possible.

Adherence to several general principles can make drug therapy in the geriatric population safer and more effective (Table 14-7). Quality indicators for medication use (American Geriatrics Society 2012 Beers Criteria Update Expert Panel, 2012; Shrank, Polinski, and Avorn, 2007) and federal guidance to surveyors on drug therapy in nursing homes (F-Tag 329; see <http://cms.gov/site-search/search-results.html?q=tag%20F329>) provide helpful information for geriatric prescribing practices. Because psychotropic drugs are so commonly used in the geriatric population, they are discussed in greater detail in the following section.

GERIATRIC PSYCHOPHARMACOLOGY

Psychotropic drugs can be broadly categorized as antidepressants (discussed in detail in Chapter 7), antipsychotics (Table 14-8), and sedative/hypnotics (Table 14-9). These drugs are probably the most misused class of drugs in the geriatric population and cause a high incidence of adverse reactions. Several studies show that more than half of nursing home residents are prescribed at least one psychotropic drug and that these prescriptions are changed frequently. Other studies suggest that psychotropic drugs are commonly prescribed inappropriately in the nursing home setting. Federal rules and regulations given in the Omnibus Budget Reconciliation Act of 1987 and the updated F-Tag 329, mentioned earlier, emphasize avoiding the use of frequent “as needed” dosing for nonspecific symptoms (eg, agitation, wandering) and the inappropriate use of these drugs as chemical restraints. The appropriate use of antipsychotics for psychosis and several behavioral symptoms associated with dementia must, however, be distinguished from their use as “chemical restraints.”

Several considerations can be helpful in preventing the misuse of psychotropic drugs in the geriatric population:

1. Psychological symptoms (depression, anxiety, agitation, insomnia, paranoia, disruptive behavior) are often caused or exacerbated by medical conditions in geriatric patients. A thorough medical evaluation should therefore be done

TABLE 14-7. General Recommendations for Geriatric Prescribing

1. Evaluate geriatric patients thoroughly to identify all conditions that could (a) benefit from drug treatment; (b) be adversely affected by drug treatment; and (c) influence the efficacy of drug treatment
2. Manage medical conditions without drugs as often as possible
3. Know the pharmacology of the drug(s) being prescribed
4. Consider how the clinical status of each patient could influence the pharmacology of the drug(s)
5. Avoid potential adverse drug interactions
6. For drugs or their active metabolites eliminated predominantly by the kidney, use a formula or nomogram to approximate age-related changes in renal function and adjust dosages accordingly
7. If there is a question about drug dosage, start with smaller doses and increase gradually
8. Drug blood concentrations can be helpful in monitoring several potentially toxic drugs used frequently in the geriatric population
9. Help to ensure adherence by paying attention to impaired intellectual function, diminished hearing, and poor vision when instructing patients and labeling prescriptions (and by using other techniques listed in Table 14-1)
10. Monitor older patients frequently for adherence, drug effectiveness, and adverse effects, and adjust drug therapy accordingly

before symptoms are attributed to psychiatric conditions alone and psychotropic drugs are prescribed.

2. Reports of psychiatric symptoms, such as agitation, are often presented to physicians by family caregivers and nursing home personnel who are inexperienced in the description, interpretation, and differential diagnosis of these symptoms. “Agitation” or “disruptive behavior” may, in fact, have been a reasonable response to an inappropriate interaction or situation created by the caregiver. Psychotropic drugs should, therefore, be prescribed only after the physician has clarified what the symptoms are and what correctable factors might have precipitated them.
3. Psychological symptoms and signs, like physical symptoms and signs, can be nonspecific in the geriatric patient. Therefore, appropriate drug treatment often depends on an accurate psychiatric diagnosis. Psychiatrists and psychologists experienced with geriatric patients should be consulted, when available, in order to identify and help target psychotropic drug treatment to the major psychiatric problem(s).
4. Many nonpharmacological treatment modalities can either replace or be used in conjunction with psychotropic drugs in managing psychological symptoms. Behavioral modification, environmental manipulation, supportive psychotherapy, group therapy, recreational activities, and other related techniques can be useful in eliminating or diminishing the need for drug treatment (see Chapter 6).
5. Within each broad category of psychotropic drug, there are considerable differences among individual agents with regard to effects, side effects, and potential

TABLE 14-8. Examples of Antipsychotic Drugs*

Drug	Usual geriatric daily dose range (mg)	Relative sedation	Potential for Side Effects	
			Hypotension	Extrapyramidal effects†
Aripiprazole	2.5-20‡	Moderate	Moderate	Moderate
Haloperidol (Haldol)	0.25-5	Low	Low	Very high
Olanzapine (Zyprexa)	2.5-10	Low	Low	Low
Quetiapine (Seroquel)	12.5-150	Moderate	Moderate	Low
Risperidone (Risperdal)	0.25	Low	Low	Low
Ziprasidone (Geodon)	20-40	Low	Moderate	Low

*Other agents are also available. All of the second-generation antipsychotics have been associated with increased mortality, and their efficacy in treating behavioral symptoms associated with dementia has been questioned (see text).

†Rigidity, bradykinesia, tremor, akathisia.

‡Geriatric dosage ranges not well studied.

TABLE 14-9. Examples of Hypnotics Approved for Insomnia by the U.S. Food and Drug Administration*

	Dose (mg)	Duration of action	Half-life (h)†
Benzodiazepines‡			
Lorazepam (Ativan)	0.5-2.5	Intermediate	10-20
Temazepam (Restoril)	7.5-30	Intermediate	8-15
Benzodiazepine Receptor Agonists			
Eszopiclone (Lunesta)	1-3	Intermediate	5-7
Zaleplon (Sonata)	5-20	Ultra short	1
Zolpidem (Ambien)	5-10	Short	3
Zolpidem extended release (Ambien CR)	6.5 or 12.5	Short	3§
Melatonin Receptor Agonist			
Ramelteon	8	Short	2-5

*Other drugs are also approved. Effectiveness for short-term use in the elderly is questioned (Glass et al., 2005).

†Half-life includes active metabolites.

‡Long-acting benzodiazepines should not be used in geriatric patients.

§Duration of action larger because of extended-release preparation.

interactions with other drugs and medical conditions. Rational prescription of these drugs necessitates careful consideration of the characteristics of each drug in relation to the individual patient.

6. Because geriatric patients are, in general, more sensitive to the effects and side effects of psychotropic drugs, initial doses should be lower, increases should be gradual, and monitoring should be frequent.
7. Careful, ongoing assessment of the response of target symptoms and behaviors to psychotropic drugs is essential. In addition to reports from patients themselves, objective observations by trained and experienced professionals should be continuously evaluated in order to adjust psychotropic drug therapy.

Nonpharmacological approaches should be used before psychotropic drugs are prescribed, unless the patient is clearly psychotic and/or an immediate danger to themselves or others around them. A variety of nonpharmacological measures can be effective in geriatric patients with agitation or excessive anxiety. Behavioral and other nonpharmacological therapeutic approaches are discussed in some of the Suggested Readings at the end of this chapter (see also Chapter 6). These measures, however, are often unavailable, impractical, inappropriate, or unsuccessful. Patients with severe impairment of cognitive function can be especially difficult to manage with nonpharmacological measures alone, particularly when their physical and/or verbal agitation is interfering with their care (or the care of others around them). Thus, drug treatment of physical and/or verbal agitation is necessary in some patients.

All psychotropic drugs must be used judiciously in geriatric patients because of their potential side effects. The most common and potentially disabling side effects of psychotropic drugs fall into four general categories: changes in cognitive status (eg, sedation, delirium, dementia) and extrapyramidal, anticholinergic, and cardiovascular effects. Psychotropic drugs can contribute to cognitive impairment and are associated with hip fractures in the geriatric population. Extrapyramidal side effects are most common with several older antipsychotic drugs but may occur with newer atypical antipsychotics (see Table 14-8). These effects, which include pseudoparkinsonism (rigidity, bradykinesia, tremor), akathisia (restlessness), and involuntary dystonic movements (such as tardive dyskinesia), can be severe and may cause substantial disability. Rigidity and bradykinesia can lead to immobility and related complications. Akathisia can make the patient appear more anxious and agitated and can lead to the inappropriate prescription of more medication. Tardive dyskinesia can cause permanent disability as a consequence of continuous orolingual movements and difficulty with eating.

The use of antipsychotics to treat the neuropsychiatric symptoms of dementia is highly controversial (Sink, Holden, and Yaffe, 2005; Ayalon et al., 2006; Schneider et al., 2006; Maher et al., 2011). All of the second-generation antipsychotics have been associated with an increase in mortality in older patients (Schneider, Dagerman, and Insel, 2005; Wang et al., 2005), as well as weight gain. Atypical antipsychotics now have black box warnings from the U.S. Food and Drug Administration because of the increased risk of death associated with their use (Schneider, Dagerman, and Insel,

2005; Gill et al., 2007). Moreover, the U.S. Centers for Medicare and Medicaid Services has announced a campaign to improve the appropriateness and reduce the use of these drugs in nursing homes. For severely demented patients who develop physical or verbal agitation without an obvious underlying cause, empiric treatment with acetaminophen has shown some efficacy (Husebo et al., 2011). Insomnia, like agitation, can be the manifestation of depression or physical illness. It is a very common complaint in geriatric patients, and causes of sleep disorders such as sleep apnea and restless leg syndrome should be sought. Nonpharmacological measures (such as increasing activity during the day, diminishing nighttime noise, and ensuring cooler nighttime temperatures) are sometimes helpful. Several alternatives are available for drug treatment of insomnia (see Table 14-9). The long-term effects of chronic hypnotic use in the geriatric population are unknown, but rebound insomnia can become a problem in patients who use hypnotics (especially benzodiazepine hypnotics and melatonin) regularly and then discontinue them. Whatever the indication, it is extremely important that, after a hypnotic drug is prescribed, the patient be closely monitored for the effects of the drug on the target symptoms and side effects and that the drug regimen be adjusted accordingly.

Evidence Summary

Do's

- Simplify drug regimens as much as possible.
- "Start low and go slow," but increase doses to maximum if appropriate based on response.
- Carefully assess for drug effectiveness and side effects.
- Help ensure adherence by education, attention to out-of-pocket costs, and availability of caregiver's support for patients with cognitive impairment.
- Utilize the expertise and education available through pharmacists.
- Keep careful medication records and review them at each visit.

Don'ts

- Automatically prescribe all drugs that may be indicated in younger patients for older patients with multiple comorbidities.
- Use two drugs when one may be effective.
- Make drug regimens unnecessarily complicated.
- Use multiple psychotropic drugs, except in very limited circumstances.
- Prescribe antipsychotics for behavioral symptoms associated with dementia unless underlying treatable conditions have been excluded and nonpharmacological interventions have failed or unless the patient is an immediate danger to themselves or others around them.

Consider

- Drug-drug and drug-disease interactions when prescribing for older patients.
- Using specially designed pillboxes or technological approaches (eg, devices that help monitor adherence) for selected patients.

REFERENCES

- American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc.* 2012;60:616-631.
- Ayalon L, Gum AM, Feliciano L, et al. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia. *Arch Intern Med.* 2006;166:2182-2188.
- Budnitz DS, Lovegrove MC, Shehbab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. *N Engl J Med.* 2011;365:2002-2012.
- Budnitz DS, Shehab N, Kegler SR, et al. Medication use leading to emergency department visits for adverse drug events in older adults. *Ann Intern Med.* 2007;147:755-765.
- Campbell NL, Boustani, MA, Skopeljia EN, et al. Medication adherence in older adults with cognitive impairment: a evidence-based systematic review. *Am J Geriatr Pharmacother.* 2012;10:165-177.
- Cockcroft DW, Gault MH. Predictions of creatinine clearance from serum creatinine. *Nephron.* 1976;16:31-41.
- Coleman EA, Smith JD, Raha D, et al. Posthospital medication discrepancies. *Arch Intern Med.* 2005;165:1842-1847.
- Finlayson E, Maselli J, Steinman MA, et al. Inappropriate medication use in older adults undergoing surgery: a national study. *J Am Geriatr Soc.* 2011;59:2139-2144.
- Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. *Age Ageing.* 2008;37:673-679.
- Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults. *Arch Intern Med.* 2010;170:1648-1654.
- Gill SS, Bronskill SE, Normand S-LT, et al. Antipsychotic drug use and mortality in older adults with dementia. *Ann Intern Med.* 2007;146:775-786.
- Glass J, Lancot KL, Herrmann N, et al. Sedative-hypnotics increase adverse effects more than they improve sleep quality in older persons with insomnia. *BMJ.* 2005;331:1169-1172.
- Heerdink ER, Leufkens HG, Herings RMC, et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. *Arch Intern Med.* 1998;158:1108-1112.
- Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. *Am J Geriatr Pharmacother.* 2011;9:364-377.
- Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. *Arch Intern Med.* 2005;165:1095-1106.
- Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomized trial. *BMJ.* 2011;343:d4065.
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA.* 1998;279:1200-1205.
- Maher M, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults. *JAMA.* 2011;306:1359-1369.
- O'Mahony D, Gallagher PF. Inappropriate prescribing in the older population: need for new criteria. *Age Ageing.* 2008;37:138-141.
- Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. *JAMA.* 2005;294:1934-1943.

- Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *N Engl J Med*. 2006;355:1525-1538.
- Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. *J Am Geriatr Soc*. 2007;55:S373-S382.
- Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. *JAMA*. 2005;293:596-608.
- Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. *N Engl J Med*. 2005;353:2335-2341.
- Wilkinson GR. Drug metabolism and variability among patients in drug response. *N Engl J Med*. 2005;352:2211-2221.

SUGGESTED READINGS

- Bain KT. Management of chronic insomnia in elderly persons. *Am J Geriatr Pharmacother*. 2006;4:168-192.
- Board of Directors of the American Association for Geriatric Psychiatry, Clinical Practice Committee of the American Geriatrics Society, and Committee on Long-Term Care and Treatment for the Elderly. Psychotherapeutic medications in the nursing home. *J Am Geriatr Soc*. 1992;40:946-949.
- Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. *Am J Geriatr Pharmacother*. 2007;5:263-303.
- Selma TP, Beizer JL, Higbee MD. *Geriatric Dosage Handbook*. 12th ed. Hudson, OH: Lexi-Comp; 2007.
- Silber MH. Chronic insomnia. *N Engl J Med*. 2005;353:803-810.
- Steinman MA, Hanlon JT. Managing medications in complex elders. *JAMA*. 2010;304:1592-1601.

This page intentionally left blank

CHAPTER 15

Health Services

Geriatrics can be thought of as the intersection of chronic disease care and gerontology. The latter refers largely to the contents of this book: the syndromes associated with aging, the atypical presentations of disease, and the difficulties of managing multiple, simultaneous, interactive problems. Health care for older persons consists largely of addressing the problems associated with multiple chronic illnesses. However, medical care continues to be practiced as though it consisted of a series of discrete encounters. What is needed is a systematic approach to chronic care that encourages clinicians to recognize the overall course expected for each patient and to manage treatment within those parameters. Chapter 4 traces a number of strategies designed to improve the management of chronic disease.

Several initiatives are under way that may help to address this dilemma. The Patient Protection and Affordable Care Act specifically addresses attention to transitions for patients discharged from hospitals. Payments for rehospitalizations are denied, and penalties for excessive rates are levied. The accountable care organization concept calls for better integration of hospital care, primary care, postacute care (PAC), and nursing home care. It may extend to recognizing the need for better social integration as well. The health care home effort to incent practices for more comprehensive care represents a step in this direction.

Care for frail older persons has been impeded by an artificial dichotomy between medical and social interventions. This separation has been enhanced by the funding policies, such as the auspices of Medicare and Medicaid, but it also reflects the philosophies of the dominant professions. A prerequisite for effective coordination is shared goals. Until the differences in goals are reconciled, there is little hope for integrated care. Medical practice has been driven by what may be termed a therapeutic model. The basic expectation from medical care is that it will make a difference. The difference may not always be reflected in an improvement in the patient's status. Indeed, for many chronically ill patients, decline is inevitable, but good care should at least delay the rate of that decline. Because many patients do get worse over time, it may be difficult for clinicians to see the effects of their care. The invisibility of this benefit makes it particularly hard to create a strong case for investing in such care.

Appreciating the benefits of good care in the context of decline in function over time may require a comparison between what happens and what would have occurred in the absence of that care. In effect, the yield from good care is the difference between what is observed and what is reasonable to expect; but without the expected value, the benefit may be hard to appreciate. **Figure 15-1** (which also appears in Chapter 4) provides a theoretical model of these two curves. Both trajectories show decline, but the slope associated with better care is less acute. The area between them represents the effects of good care. Unfortunately, that benefit




FIGURE 15-1 Theoretical model of observed versus expected clinical course. The area between the observed and expected outcomes represents the benefits of good care. Thus, a patient’s condition may deteriorate and still be considered as an indication of good care if the rate of deterioration is less than expected.

is invisible unless specific steps are taken to demonstrate the difference between the observed and expected course. Appreciating the need to make this benefit visible is essential to make the political and social case for a greater investment in chronic disease and long-term care (LTC). Without such evidence, people simply see decline and view this area as not worth investing in.

The alternative model, usually associated with social services, is compensatory care. Under this concept, a person is assessed to determine deficits, and a plan of care is developed to address the identified deficits. Good care is defined as providing services that meet the profile of dependencies and thereby allow the client to enjoy as normal a lifestyle as possible without incurring any adverse consequences.

These two approaches seem at odds, but they could be compatible. Although there is some risk of encouraging dependency with excessive support, providing needed services should enhance functioning or at least slow its decline. Care for the frail older patient requires a synthesis of medical and social attention. One thing is certain. If the medical and social systems are to work together harmoniously, they must share a common set of goals. The first step in collaboration is to identify the common ground to assure both elements are working in the same direction.

The medical care system has not facilitated that interaction. Managed care could provide a framework for achieving this coordination, but the track record so far does not suggest that the incentives are yet in place to produce this effect. A few notable programs have been able to merge funding and services for this frail population. Probably the best example of creative integration is seen in the Program of All-Inclusive Care of the Elderly (PACE), which uses pooled capitated funding from Medicare and Medicaid to provide integrated health and social services to older persons who are deemed to be eligible for nursing home care but who are still living in the community (Kane et al., 2006; Wieland, 2006). The PACE programs have increased, but they are limited because they target a very specific group (persons receiving both Medicare and Medicaid who are eligible for nursing home care but live in the community) and they are expensive. Whether managed care will achieve

its potential as a vehicle for improving coordination of care for older persons remains to be seen. In any event, care for older persons will require such integration, and eventually some reconciliation must be achieved about what constitutes the desired goals of such care.

Geriatric care thus implies team care. This concept implies trust in other disciplines with special skills and training to undertake the tasks for which they have the requisite skills. However, these colleagues must not be expected to operate alone. Good communication and coordination will avoid duplication of effort and lead to a better overall outcome. To play a useful role on the health-care team, physicians need to appreciate what other health professions can do and know how and when to call on their skills. Efficient team care does not involve extensive meetings. Rather, information can be communicated by various means. However, good team care will not arise spontaneously. Just as sports teams spend long hours practicing to work collectively, so too must health-care teams develop a knowledge and trust of each other's inputs. They need a common language and common playbook. Effective teamwork thus requires an investment of effort. Thus, careful thought must be given to when such an investment is justified.

The nature of health care has changed over the past several decades. **Figure 15-2** contrasts the patterns of health-care expenditures between 1980 and 2010. There has been a proportionately sharp decrease in the use of hospitals and a marked increase in expenditures on drugs. The costs of physician care (now expanded to include care from nurse practitioners and physicians' assistants) have risen slightly,




FIGURE 15-2 Distribution of personal health-care expenditure, by type of service: selected calendar years 1980, 1990, 2000, and 2010. Other includes other professional services; dental services; other health, residential, and personal care home health care; durable medical equipment; and other nondurable medical equipment. (Source: Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group. <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareMedicaidStatSupp/2011.html>. Accessed April 2012.)

and the use of nursing homes has declined a little. It is important to recall, however, that spending on health care has increased dramatically from only about \$217.2 billion in 1980 to \$2,186 trillion in 2010, an increase of about ninefold compared to an increase due to inflation of about 2.65.

PUBLIC PROGRAMS

Clinicians caring for elderly patients must have at least a working acquaintance with the major programs that support older people. We are accustomed to thinking about care of older people in association with Medicare. In fact, at least three parts (called *Titles*) of the Social Security Act provide important benefits for the elderly: Title XVIII (Medicare), Title XIX (Medicaid), and Social Services Block Grants (formerly Title XX). Medicare was designed to address health care, particularly acute-care hospital services. The Medicare program is in flux. Changes in the payment system have been introduced to counter what some saw as abuses (certainly expansions) of the previous system. Medicare was intended to deal with LTC only to the extent that LTC can supplant more expensive hospital care, leaving the major funding for LTC to Medicaid. However, the funding demarcation between acute-care and LTC services became blurred. The imposition of a prospective payment for hospitals created a new market for what became PAC, care that was formerly provided in hospitals but could now be delivered and billed separately by nursing homes, rehabilitation units, or home health care. (The role of Medicare-covered home health care has been made vaguer by a recent court case that seems to broaden its coverage mandate to include at least some chronic care.) The prospective payment approach has been applied to PAC as well. Payment for each type of PAC is based on a separate calculation. Thus, three silos were created, with different approaches to providing similar services. New programs that bundle the payments for PAC and even combine hospital and PAC payments are being proposed and tested.

The distinction in programmatic responsibility between Medicare and Medicaid is a very important one. Whereas Medicare is an insurance-type program to which persons are entitled after contributing a certain amount, Medicaid is a welfare program, eligibility for which depends on a combination of need and poverty. Thus, to become eligible for Medicaid, a person must not only prove illness but also exhaust their personal resources—hardly a situation conducive to restoring autonomy.

The pattern of coverage is quite different for the various services covered. [Figures 15-3](#) and [15-4](#) trace spending on health care for elderly persons by Medicare and Medicaid, respectively. Medicare is a major payer of hospital and physician care but pays for only a small portion of nursing home care, whereas just the reverse applies to Medicaid. (Medicare has played a larger role in nursing home and home health care as the role of PAC grew, but new funding priorities have attempted to reduce that role.) Medicare also has a Part D that covers medications; all dually eligible (Medicare and Medicaid) beneficiaries receive their medications through Part D. For Medicare-only beneficiaries, Part D is elective.




FIGURE 15-3 Percent distribution of Medicare program payments, by type of service: calendar years 1967 and 2010. Note: The Medicare hospice benefit was authorized (effective November 1983) under the Tax Equity Fiscal Responsibility Act of 1982. (Source: Centers for Medicare and Medicaid Services, Office of Information Services. Data from the Medicare Decision Support Access Facility. <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareMedicaidStatSupp/2011.html>. Accessed April 2012.)

Medicare

Eligibility for Medicare differs for each of its two major parts. Part A (Hospital Services Insurance) is available to all who are eligible for Social Security, usually by virtue of paying the Social Security tax for a sufficient number of quarters. This program is supported by a special payroll tax, which goes into the Medicare Trust Fund. Part B (Medical Services Insurance) is offered for a monthly premium, paid by the individual but heavily subsidized by the government (which pays approximately 70% of the cost from general tax revenues). Almost everyone older than age 65 is automatically covered by Part A. One exception is older immigrants, who may not have worked long enough to generate Social Security coverage.

The introduction of prospective payment for hospitals under Medicare created a new set of complications. Hospitals are paid a fixed amount per admission according to the diagnosis-related group (DRG), to which the patient is assigned on the basis of the admitting diagnosis. The rates for DRGs are, in turn, based on expected lengths of stay and intensity of care for each condition. The incentives under such an approach run almost directly contrary to most of the goals of geriatrics. Whereas geriatrics addresses the functional result of multiple interacting problems, DRGs encourage concentration on a single problem. Extra time required to make an appropriate discharge plan is discouraged. Use of ancillary personnel, such as social workers, is similarly discouraged. As a result of DRGs, hospital lengths of stay have




FIGURE 15-4 Distribution of Medicaid vendor payments, by type of service: fiscal years 1975 and 2008. Percentages may not add to 100 because of rounding. Other service in 2008 included 22.9% for prepaid health insurance premiums. ICF/MR, intermediate-care facility/mentally retarded. (Source: Centers for Medicare and Medicaid Services, Center for Medicaid and State Operations. Statistical report on medical care: eligible, recipient, payments, and services (HCFA 2082) and the Medicaid Statistical Information System (MSIS). <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareMedicaidStatSupp/2010.html>. Accessed April 2012.)

decreased, leading to the phenomenon of “quicker and sicker” discharges. Many of these former hospital patients are now cared for through home health and nursing homes. In effect, Medicare is paying for care twice: It pays for the hospital stay regardless of length and then pays for the posthospital care. The rapid rise in this latter sector has led Medicare to search for solutions. Different types of Medicare prospective payment for the different types of posthospital care have been established. Nursing homes are paid on a per-diem basis, whereas home health agencies and rehabilitation units are paid on a per-episode basis. A more effective solution would be to combine the payment for hospital and posthospital care into a single bundled payment, although some fear that such a step would place too much control in the hands of hospitals. The Balanced Budget Act of 1997 (BBA) included a small step in this direction. For selected DRGs, hospital discharges to PAC are treated as transfers. Hospitals receive a lower payment than the usual DRG payment if the length of stay is less than the median.

Up until recently, the payment system was even more paradoxical. The DRG payment was higher for patients with complications, even if those complications arose from treatment during the hospitalization. That approach has been modified to

exclude iatrogenic complications, creating a better business case for involving geriatricians in the care of frail patients. Hospitals must now report complications present on admission to avoid having them declared unreimbursable because they arose as part of the hospital care. Likewise, Medicare will not pay for some readmissions within 30 days for the same DRG and imposes a penalty for excessive readmission rates.

The payment systems now in effect create much confusion for Medicare beneficiaries. Although hospitals are paid a fixed amount per case, the patients continue to pay under a system of deductibles and copayments. The majority of Medicare beneficiaries have purchased some form of Medigap insurance to cover these costs, but many variations exist. The picture is even more confused when the Medigap insurance also covers Part D deductibles and copays.

Managed care is aggressively being pursued as an option to traditional fee-for-service care. Under that arrangement, the managed care organizations receive a fixed monthly payment from Medicare in exchange for providing at least the range of services covered by Medicare. In some areas the managed care plans also charge recipients for an additional premium depending on the regional rates. Although many managed care companies were initially attracted to this business because of the generous rates offered, subsequent reductions have made the business less attractive, and many are exiting the program, leaving beneficiaries to scramble for alternative coverage, especially for Medigap policies.

The pricing system used by Medicare to calculate managed care rates basically reflects the prices paid for fee-for-service care in each county. Managed care organizations are paid a fixed amount calculated on the basis of the average amount Medicare paid for its beneficiaries in that county. This adjusted average per capita cost (AAPCC) varies widely from one location to another. Newer approaches to calculating Medicare-managed care premiums use prior utilization and other factors in what is called hierarchical clinical conditions (HCCs). The BBA called for a shift to national pricing. In an effort to attract more providers into managed care, the BBA broadened the definition of what kinds of organizations can provide managed care to Medicare beneficiaries, removing many of the restrictions (especially financial surety bonding) that left managed care largely in the hands of insurance companies. Unlike managed care enrollees in the rest of the population, who are locked into health plans for a year, Medicare beneficiaries have the right to disenroll at any time. Some evidence suggests that Medicare beneficiaries may move in and out of managed care as they use up available benefits. Managed care has become more popular among Medicare beneficiaries, partly fueled by the introduction of Part D. In 2011, Medicare Advantage (the name for managed care under Medicare, often termed Part C) covered 25% of Medicare beneficiaries.

The likelihood of managed care achieving its potential symbiosis with geriatrics appears dim. Ideally, managed care could provide an environment where many of the principles of geriatrics could be implemented to the benefit of all; on the other hand, the performance to date suggests that managed care for Medicare beneficiaries has so far responded more to the incentives from favorable selection (recruiting healthy patients and getting paid average rates), discounted purchasing of services,

and barriers to access than to the potential benefits from increased efficiency derived from a geriatric philosophy (Kane, 1998).

The newer approaches use what might be thought of as point-of-service capitation, where payments for service packages are grouped rather than a single payment for all services. Such an approach may make the role of geriatric care more obvious, but this remains to be seen. More likely, investments will focus on using ancillary personnel to coordinate care. For example, medical (or health care) homes may use case coordinators.

Although Medicare does pay for authorized posthospital services in nursing homes and through home health care, the payment for physicians does not encourage their active participation. For example, while a physician would be paid a regular consultation visit fee for daily rounds on a Medicare patient in a hospital, if the patient is discharged to a nursing home the following day, both the rate of physician reimbursement for a visit and the number of visits per week considered customary decrease dramatically. Although physician home visits are still a rarity, payment for these services has increased substantially in recent years. There are now physician groups that have made a business out of nursing home care and home health care. Increasingly the care of nursing home residents falls to nurse practitioners working as part of geriatric care teams. These teams can play two roles in avoiding hospitalizations: (1) They can provide more effective primary care that prevents an episode that would require a hospital transfer. (2) They can manage events that do arise in the nursing home, thus alleviating the need for a transfer.

Medicare coverage is important but not sufficient for three basic reasons: (1) To control use, it mandates deductible and copayment charges for both Parts A and B. (2) It sets physicians' fees using a complicated formula called the Resource-Based Relative Value Scale (RBRVS). The RBRVS is designed to pay physicians more closely according to the value of their services as determined both within a specialty and across specialties. Theoretically, both the value of the services provided and the investment in training are considered in setting the rates. This new payment approach was intended to increase the payment for primary care relative to surgical specialties, but early reports suggest that, ironically, many geriatric assessment services have been reimbursed at a level lower than before its introduction. Under Medicare Part B, physicians are generally paid less than they would usually bill for the service. (Some physicians opt to bill the patient directly for the difference, but a number of states have mandated that physicians accept "assignment" of Medicare fees, that is, they accept the fee [plus the 20% copayment] as payment in full.) (3) The program does not cover several services essential to patient functioning, such as eyeglasses, hearing aids, and many preventive services (although the benefits for the latter are expanding). Medicare specifically excludes services designed to provide "custodial care"—the very services often most critical to LTC. (However, as noted earlier, the boundary between acute-care and LTC exclusions seems to be eroding.) Work is currently under way to change the way physician fee increases are determined. Basically some combination of cost and quality will be used. In lieu of across the board increases, payments will be based on physician performance.

A major expansion of the Medicare program occurred in 2005 with the passage of the Medicare Modernization Act, which included Part D coverage of drugs. This legislation also provides substantial incentives to Medicare Advantage providers and creates a new class of managed care coverage, Special Needs Plans. These are groups of beneficiaries presumed to be at high risk and hence eligible for higher premiums.

The 2010 Patient Protection and Affordable Care Act (PPACA) was primarily aimed at improving access to care for those currently uninsured. Its direct impact on Medicare is modest.

Under Part D, the coverage of prescription drugs involves a complicated formula, often referred to as the “doughnut hole,” because of the odd design of benefits. Basically, the patient pays a deductible (\$320 in 2012, but the PPACA reduced the payment). Then the patient pays a copayment (usually around 25%) on yearly drug costs from \$320 to \$2,930, and the plan pays the majority of these costs. Then the patient pays 100% of the next \$1,770 in drug costs (unless she has bought additional drug insurance), and after that, the patients pays a coinsurance amount (eg, 5% of the drug cost) or a copayment (eg, \$2.25 or \$5.60 for each prescription) for the rest of the calendar year after the patient has spent \$4,700 out of pocket. The patient’s plan pays the rest. Part D is administered by a series of drug management firms that offer a confusing array of plans, from a basic plan that covers the Part D pattern to more inclusive coverage that eliminates the doughnut hole. Of course, the premium cost rises as the coverage expands. Plans are required to cover at least two drugs in each identified category, but the choice of drugs is left to them. Medicare beneficiaries must scramble to find the most affordable plan that covers the drugs they need, but even then there is no guarantee that those drugs will continue to be covered.

As a result of these three factors, a substantial amount of the medical bill is left to the individual. Today, elderly persons’ out-of-pocket costs for health care represent about 12.5% of their income. In general, out-of-pocket costs are less for those in managed care.

■ Medicaid

Medicaid, in contrast to Medicare, is a welfare program designed to serve the poor. It is a state-run program to which the federal government contributes (50%–78% of the costs, depending on the state’s capita income). In some states, persons can be covered as medically indigent even if their income is above the poverty level if their medical expenses would impoverish them. As a welfare program, Medicaid has no deductibles or coinsurance (although current proposals call for modest charges to discourage excess use). It is, however, a welfare program cast in the medical model.

Medicaid is essentially two separate programs, serving two distinct populations. Mothers and young children are covered under Aid to Families with Dependent Children, whereas elderly persons are eligible if they receive Old Age Assistance. The other major route to eligibility for older people is the medically needy program, whereby eligibility is conferred when medical costs—usually nursing homes—exceed a fixed fraction of a person’s income.

Mothers and children use less care per recipient. They use some hospital care around birth and for the small group of severely ill children. A large portion of the Medicaid dollar goes to the services needed by the elderly enrollees, most of whom are also eligible for Medicare, but the services needed are not covered by Medicare; namely, nursing home care and community-based LTC. (Most states automatically enroll eligible Medicaid recipients in Medicare Part B.)

It is important to appreciate that the shape of the Medicaid expenditures for older people is determined largely by the gaps in Medicare. Medicaid has been described as a universal health program that has a deductible of all of your assets and a copay of all of your income. Medicaid is the major source of nursing home payments. It requires physicians to certify a patient's physical limitations in order to gain the patient admittance to a nursing home. In some cases, physicians are put in a position of inventing medical justifications for primarily social reasons (ie, lack of social supports necessary to remain in the community).

Because it pays about half of the nursing costs but covers almost 70% of the residents, Medicaid shapes nursing home policies. The payment discrepancy is explained by the policies that require residents to expend their own resources first. Thus, Social Security payments, private pensions, and the like are used as primary sources of payment, and Medicaid picks up the remainder. However, it does not directly pay for most physician care in the nursing home; that is covered by Medicare. Medicaid would pay the deductibles and copayments and those services not covered under Medicare. The separation in payment raises policy issues. More aggressive care in nursing homes (paid by Medicaid) can prevent emergency department visits and hospital admissions (paid by Medicare). The nursing homes (and Medicaid) thus underwrite (or cross-subsidize) Medicare savings.

Medicaid also supports home- and community-based LTC services (HCBS). In some states, personal care is included as mandatory Medicaid service under the state's basic Medicaid coverage plan, but in many states, HCBS is offered as a waived service. Under this arrangement, the federal government allows states to use money that would otherwise have gone to nursing homes to fund HCBS. The waiver allows states to offer the service in only specific areas and to limit the numbers of persons enrolled in the program. In theory, these funds are supposed to be offset by concomitant savings in nursing home care. The use of HCBS has greatly expanded over the last few decades. Once viewed as simply a cheaper alternative to nursing home care, HCBS is now viewed as the preferred LTC option in many situations (Kane and Kane, 2012).

Whereas going on Medicaid was once seen as a great social embarrassment, associated with accepting public charity, there appears to be a growing sense among many older persons that they are entitled to receive Medicaid help when their health-care expenses, especially their LTC costs, are high. The stigma appears to be displaced by the idea that they paid taxes for many years and are now entitled to reap the rewards. As a result of this shift in sentiment, at least in the states with generous levels of Medicaid eligibility, a burgeoning industry of financial advisers has arisen to assist older persons in preparing to become Medicaid eligible. Because eligibility is

usually based on both income and assets, such a step necessitates advance planning. Usually state laws require that assets transferred within 2 or more years (the period varies by state) of applying for Medicaid funds are considered to still be owned. (The situation is more complicated in the case of a married couple, where provisions have been made to allow the spouse to retain part of the family's assets.) This requirement means that older persons contemplating becoming eligible for Medicaid must be willing to divest themselves of their assets at least several years in advance of the time they expect to need such help. This step places them in a very dependent position, financially and psychologically. Much has been made of the “divestiture phenomenon” whereby older people scheme to divest themselves of their assets in order to qualify for Medicaid, but there is no good evidence about the scale of the phenomenon.

The anticipated LTC Medicaid payment crisis resulting from the demographic shifts has prompted enthusiasm for promoting various forms of private LTC insurance. This coverage, in effect, protects the assets of those who might otherwise be marginally eligible for Medicaid or who simply want to preserve an inheritance for their heirs. Like any insurance linked to age-related events but to a greater degree, LTC insurance is quite affordable when purchased at a young age (when the likelihood of needing it is very low) but becomes quite expensive as the buyer reaches age 75 or older. Thus, those most likely to consider buying it late in life would have to pay a premium close to the average cost of LTC itself and may have prior conditions that render them ineligible. Only a small number of young persons have shown any interest in purchasing such coverage, especially when companies are not anxious to add it to their employee benefit packages as a free benefit. Although economic projections suggest that private LTC insurance is not likely to save substantial money for the Medicaid program, several states have developed programs to encourage individuals to purchase the insurance by offering linked Medicaid benefits.

The decision to purchase LTC insurance needs to be made thoughtfully and carefully. People need to understand the actuarial risks and the financial implications. Purchasing this coverage early means investing money in something you will not likely use for some time with the understanding that this money is not recoverable (because it is term insurance). At the least, potential buyers should be encouraged to purchase plans with cash benefits that are not tied to specific services, because the nature of LTC is likely to change considerably.

A specific group of older people of great policy interest are the so-called “dual-eligibles” or “duals,” who are jointly covered by both Medicare and Medicaid. Not surprisingly, they use more care than those in one program alone. They tend to have more problems. They fall into subgroups. Those receiving LTC use more Medicaid funds, whereas those with multiple comorbidities use more Medicare resources. Given the need for better program coordination and concerns about cross-subsidization, states have shown growing interest in using managed care to take on the care of these groups. Federal programs have been initiated specifically to address care for the dual population. Many of these programs appear to involve active use of managed care.

■ Other Programs

The third part of the Social Security legislation pertinent to older persons is Title XX, now administered as Social Services Block Grants. This is also a welfare program targeted especially to those on categorical welfare programs such as Aid to Families with Dependent Children and, more germane, Supplemental Security Income. The latter is a federal program that, as the name implies, supplements Social Security benefits to provide a minimum income. Title XX funds are administered through state and local agencies, which have a substantial amount of flexibility in how they allocate the available money across a variety of stipulated services. The state also has the option of broadening the eligibility criteria to include those just above the poverty line.

Another relevant federal program is Title III of the Older Americans Act. This program is available to all persons over the age of 60 regardless of income. The single largest component goes to support nutrition through congregate meal programs where elderly persons can get a subsidized hot meal, but it also provides meals-on-wheels (home-delivered meals) and a wide variety of other services. Some services duplicate or supplement those covered under Social Security programs; others are unique. Recently, the former Administration on Aging (AoA) supported a number of preventive care initiatives and the Aging and Disability Resource Centers (ADRC), which provide a point of entry into LTC in most states. In 2012, the AoA was reorganized to merge responsibility for all persons with disability. The new organization, the Administration for Community Living, will bring together the AoA, the Office on Disability, and the Administration on Developmental Disabilities into a single agency that supports both cross-cutting initiatives and efforts focused on the unique needs of individual groups, such as children with developmental disabilities or seniors with dementia. This new agency will work on increasing access to community supports and achieving full community participation for people with disabilities and seniors.

Table 15-1 summarizes these four programs and their current scope. It is important to appreciate that this summary attempts to condense and simplify a complex and ever-changing set of rules and regulations. Physicians should be familiar with the broad scope and limitations of these programs but will have to rely on others, especially social workers, who are familiar with the operating details.

LONG-TERM CARE

A proportion of older patients require substantial LTC. There is no uniform definition for LTC, but LTC can be thought of as range of services that addresses the health, personal care, and social needs of individuals who lack some capacity for self-care. Services may be continuous or intermittent but are delivered for sustained periods to individuals who have a demonstrated need, usually measured by some index of functional incapacity. This statement emphasizes the common thread of most discussions of LTC: the dependence of an individual on the services of another for a substantial period. The definition is carefully vague about who provides those services or what they are. Figure 15-5 illustrates the diverse sources of care for frail older people and

TABLE 15-1. Summary of Major Federal Programs for Elderly Patients			
Program	Eligible population	Services covered	Deductibles and copayments
Medicare (Title XVIII of the Social Security Act) Part A: Hospital Services Insurance	All persons eligible for social security and others with chronic disabilities, such as end-stage renal disease, plus voluntary enrollees age 65+ years	Per benefit period, “reasonable cost” (DRG-based) for 90 days of hospital care plus 60 lifetime reserve days; 100 days of skilled nursing facility (SNF); home health visits (see text); hospice care*	Full coverage for hospital care after a deductible of about 1 day for days 2-60; then copay for days 61-90. Can use 60 “lifetime reserve” days thereafter. 20 SNF days (after 3-day hospital stay) fully covered; copay for days 21-100; up to 100 days of home health care for homebound persons (after 3-day hospital stay)
Part B: Supplemental Medical Insurance	All those covered under Part A who elect coverage; participants pay a monthly premium	80% of “reasonable cost” for physicians’ services; supplies and services related to physician services; outpatient occupational, physical, and speech therapy; diagnostic tests and radiographs; mammograms; surgical dressings; prosthetics; ambulance; durable medical equipment; home health care not covered under Part A	Deductible and 20% copayment (no copay after a limit reached)
Part C: Medicare Advantage (MA)	Beneficiaries can opt to enroll in a certified managed care program; enrollment is voluntary	MA plans must cover at least all Part A and Part B services. They can reduce copayments and may offer additional services. They also provide Part D coverage.	Plans can charge a monthly premium in addition to the Part B premium

(Continued)

TABLE 15-1. Summary of Major Federal Programs for Elderly Patients (*Continued*)

Program	Eligible population	Services covered	Deductibles and copayments
Part D	Beneficiaries can opt to participate in a standard prescription drug plan. A variety of plans are available through drug benefit companies. Medicaid beneficiaries must be enrolled. Monthly premium varies with coverage arrangement.	Drugs covered in each of a series of mandatory classes but specific drugs vary with each plan.	Annual deductible. Then cost-sharing until the “doughnut hole.” Then plan pays 95% of costs above that
Medicaid (Title XIX of the Social Security Act)	Persons receiving Supplemental Security Income (SSI) (such as welfare) or receiving SSI and state supplement or meeting lower eligibility standards used for medical assistance criteria in 1972 or eligible for SSI or were in institutions and eligible for Medicaid in 1973; medically needy, who do not qualify for SSI but have high medical expenses are eligible for Medicaid in some states; eligibility criteria vary from state to state	Mandatory services for categorically needy: inpatient hospital services; outpatient services; SNF; limited home health care; laboratory tests and radiographs; family planning; early and periodic screening, diagnosis, and treatment for children through age 20 Optional services vary from state to state Dental care; therapies; drugs; intermediate-care facilities; extended home health care; private duty nurse; eyeglasses; prostheses; personal-care services; medical transportation and home health-care services (states can limit the amount and duration of services)	None, once patient spends down to eligibility level Spend-down based on income and assets

		Some states use extended home care as part of their state plans. Many home- and community-based services are provided under special waivers that allow limited enrollment.	
Social Services Block Grant (Title XX of the Social Security Act)	All recipients of TANF and SSI; optionally, those earning up to 115% of state median income and residents of specific geographic areas	Day care; substitute care; protective services; counseling; home-based services; employment, education, and training; health-related services; information and referral; transportation; day services; family planning; legal services; home-delivered and congregate meals	Fees are charged to those with family incomes >80% of state's median income
Title III of the Older Americans Act	All persons age 60 and older; low-income, minority, and isolated older persons are special targets	Homemaker; home-delivered meals; home health aides; transportation; legal services; counseling; information and referral plus 19 others (50% of funds must go to those listed)	Some payment may be requested

*Certified hospice providers are paid a preset amount when a patient who is certified as terminal opts for this benefit in lieu of regular Medicare. DRG, diagnosis-related group; TANF, Temporary Assistance for Needy Families.




FIGURE 15-5 Distribution of place of residence among older persons with disabilities, 1999 and 2004. (Source: Redfoot DL, House A. *More older people with disabilities living in the community: trends form the National Long-Term Care Survey, 1984-2004*. AARP Public Policy Institute analysis of NLTC data. Washington, DC: AARP Public Policy Institute; 2010.)

traces changes between 1999 and 2004. Over two-thirds live in the community. Of these, the majority relies solely on unpaid care, and another large group uses a mixture of paid and unpaid care. A little more than 20% are in nursing homes, and another 8% are in some other form of residential care. As noted earlier, the pattern of LTC has changed substantially over the last decades. HCBS is now a major venue for older persons as well as younger persons with disabilities.

LTC is certainly not the exclusive purview of the medical profession; in fact, most of the LTC in this country is not provided by professionals at all but by a host of individuals loosely referred to as *informal support*. These persons may be family, friends, or neighbors.

Informal care has been and remains the backbone of LTC. In many instances, the family (and often nonrelatives) is the first line of support. The ideal program would keep older people at home, relying on family care and bolstering their efforts with more formal assistance to provide professional services and occasional respite care. More than 80% of all the care given in the community comes from informal sources. (In truth, the proportion is higher because much of the formal care is made possible by a substrate of informal care.) Surprisingly, this figure seems to remain fairly constant in countries with more generous provision of formal LTC. Many observers have questioned whether the informal care role, which is largely performed by women, can be sustained as more women enter the labor force and are already managing several roles. Despite dire predictions about its inevitable collapse, there is yet no evidence of serious decline in informal care. It is important to bear in mind that




FIGURE 15-6 Age-adjusted disability rates among the 65+ population, 1984-2004. ADL, activity of daily living; IADL, instrumental activity of daily living. (Source: Redfoot DL, House A. *More older people with disabilities living in the community: trends from the National Long-Term Care Survey, 1984-2004*. AARP Public Policy Institute analysis of NLTC data. Washington, DC: AARP Public Policy Institute; 2010.)

as the age of frailty rises, the “children” of these frail older people may themselves be in their seventh and eighth decades.

The best estimates suggest that about 15% of the elderly population need the help of another person to manage their daily lives. The good news is that the prevalence of disability among older persons has declined about 1% per year over the last several decades, as shown in [Figure 15-6](#). The improvement is seen in each age group and generally in the lower levels of impairment. At the same time, the proportion of persons who need various levels of assistance increases with age ([Fig. 15-7](#)). The summative effect of the relative decline in disability and the substantial growth in the elderly population will produce major increases in the numbers of disabled persons (Cutler, 2001). That forecast is pictured in [Figure 15-8](#). [Figure 15-9](#) shows the various payment sources for covering LTC costs. Medicaid covers about half the costs, Medicare almost a fourth, and out-of-pocket payments represent about a fifth of the costs.

Family caregivers are often ill prepared for the stresses of caregiving. They need support and assistance right from the outset. They have to make difficult decisions about what sort of care is best based on limited information and often great time pressures and anxiety (Kane, 2011; Kane and Ouellette, 2011). Clinicians have a responsibility to be active family advocates and to help them make the best decisions possible. While most clinicians cannot personally direct families to useful resources, they should be able to make informed referrals. They should recognize the spectrum of care options and encourage family members to consider all of them. They should encourage careful consideration of overarching care goals and recognize risk aversion when it arises.




FIGURE 15-7 Disability prevalence and the need for assistance by age: 2005. Note: The need for assistance with activities of daily living was not asked of children under 6 years. (Source: U.S. Census Bureau. Survey of Income and Program Participation, June-September 2005.)

Typical family scenarios feature efforts to maintain someone at home until the situation collapses. Then they turn to a nursing home. Alternatively, hospital discharge planners may urge nursing homes because the planning process is easier and faster. However, many of these people can be cared for in the community.




FIGURE 15-8. Projected growth in numbers of older persons with disabilities, 1996-2050. ADL, activity of daily living; IADL, instrumental activity of daily living. (Reproduced with permission from The Lewin Group based on the Long Term Care Financing Model.)




FIGURE 15-9 Long-term care spending, by payer CY 2007. The total percentages do not add to 100 due to rounding. (Source: Congressional Research Service estimates based on the calendar year [CY] 2007 National Health Expenditure Data, Centers for Medicare and Medicaid Services. Stone J. Long-term care (LTC): financing overview and issues for Congress. February 1, 2010. <http://aging.senate.gov/crs/aging27.pdf>. Accessed December 2012.)

For each person in a nursing home today, there are between one and three equally disabled persons living in the community. Thus, the first instincts are not always the best. Clinicians have been conditioned to respond to dependent elderly persons by thinking of admission to a nursing home. Because clinicians have great influence, they need to be proactive advocates. Nursing home placement should be the *last* resort, not the first. Physicians should consider the importance of maximizing both quality of care and quality of life. For many frail older persons, the personal price of living in a nursing home is too high. Many would prefer to remain in the community, even if it means taking the risk of getting less care, which is not necessarily the case.

Current practice has succeeded in shifting the balance between institutional care and home- and community-based services to emphasize use of the latter (Kane and Kane, 2012). The waiver programs noted earlier are designed to do just that. Another major factor that has reduced the use of nursing homes has been assisted living. As discussed later, this concept has taken on a variety of meanings as it has been actively marketed.

Why then does our system rely so heavily on the nursing home? Several reasons can be posited. First, nursing homes are available; there are more nursing home beds than acute-care hospital beds in this country. Nonetheless, there is usually a waiting list to get in, especially into a relatively good home. (That situation is beginning to change, however. With the growth in alternatives, especially assisted living, we are seeing for the first time substantial numbers of empty nursing home beds.) Second, nursing home care is cheap; it runs around \$100 a day in most states, whereas a hospital day costs over \$1,000, and even a good hotel room costs more than \$150. Finally, and related to the first two points, the nursing home comes as an already assembled package of services. The programs to cover LTC services have become a complex maze of eligibility and regulations, which has not encouraged anyone to develop innovative alternatives. The pressure for faster discharge from hospitals has created a new industry of postacute nursing home care. Although changes in Medicare payment have dampened some of the enthusiasm, this sector is still vital.

There have been periodic efforts to develop alternatives to nursing home care. Some were the result of deliberate public policies; others arose as new marketing efforts. For a period of time, the mantra was finding less expensive ways of caring for people needing LTC in the community. The upshot of these efforts was the recognition that community care is preferable in many cases, but the overall cost was not always cheaper. A major difficulty in controlling the cost of this care is the potential for widespread use. Because a large number of dependent older persons live in the community, a dependency-based eligibility system will include many people who would not opt for a nursing home even if eligible. This need to control entry has stimulated great interest in case management. The continuing need to improve community care has led to some innovations, including Medicaid waiver programs that allow use of nursing home funds for community care if the total long-term care budget is kept constant. As a result, there has been uneven development of community programs in different parts of the country.

The emphasis on seeking community-based alternatives to nursing home care has shifted to some extent to developing other mechanisms for providing the combined housing and service functions. Among these are assisted living and adult foster care. Assisted living, in effect, renders the recipient first and foremost a tenant, who has control over her singly occupied living space (eg, a lock on the door and determination about waking and retiring times). In addition to single occupancy, the client's autonomy is reinforced by providing modest cooking and refrigeration facilities, which allow the person to function independently without relying exclusively on the services of the institution and even to entertain modestly (Kane, 2001). However, as assisted living became a more desirable product, it began to lose its identity. A variety of providers have surfaced, many of whom offer very different services under that name. The extent of personal care and nursing assistance varies widely. Some assisted living facilities discharge residents when they become too burdensome (Kane and West, 2005). Many accept only private pay clients and discharge them when their

money runs out. Today, it is hard to know just what one is getting under the rubric of assisted living.

Adult foster care homes are usually limited to a small number of clients in any home (usually no more than five). Single rooms are not required; the situation is more analogous to individuals taking clients into their own homes, with small numbers of flexibly deployed nonprofessional staff. Recent trends suggest that the historic growth in nursing home use is changing. The last few years have witnessed a decline in nursing home occupancy. At least some of this effect undoubtedly comes from the growing availability of other residential models, which consumers find more attractive.

At the same time, there is concern that a preoccupation with a search for alternatives to nursing homes may distract efforts from the sorely needed work to improve the quality of nursing home care. Even in the best situation, a substantial number of older persons will continue to need such care. One scenario for the future holds that the form of nursing homes will change. Many of the residents currently cared for in nursing homes will be treated in more flexible situations, like assisted living, which emphasize living arrangements with nursing and other services brought to the residents on a more individualized basis. Those patients needing more intensive care will be treated in more medically oriented facilities. Alternatively, the playing field can be leveled by changing the current payment arrangements. If services were universally covered and room and board were paid by each recipient, the distinction between nursing homes and community care would effectively disappear.

THE NURSING HOME

Despite its frequent vilification, the nursing home is an important part of the health-care delivery system for frail older persons. Virtually without planning, it has emerged as the touchstone of LTC. Given its origins as the stepchild of the almshouse and the hospital, it is not surprising that it has enjoyed a poor reputation. Since the passage of the Medicaid legislation in 1965, the nursing home industry has gone through growth and transformation. As a reaction to scandals during the early years, nursing homes are heavily regulated.

Chapter 16 reviews the clinical aspects of nursing home care in more detail. Today's nursing homes serve two different client groups, which complicates any attempt to describe them. For one group of clients admitted from hospitals for rehabilitation, they function as Medicare posthospital care providers, responsible for administering rehabilitative and restorative services to get these persons back into community living as soon as possible. For another stream of clients (often supported by Medicaid), they provide LTC, which may last a lifetime.

Many observers consider the term *nursing home* a misnomer. Although these institutions are better staffed and run than in the past, they remain generally somber places that offer their residents neither a great deal of real nursing care nor a very homelike environment.

Most nursing home residents are still required to share their rooms. There is little privacy and few opportunities to retain control over even small parts of one's life. Fire regulations or nursing home policies often prevent residents from bringing personal furniture into the homes. Nursing homes are smaller and less well-staffed than hospitals, but they are not miniature hospitals. Whereas a hospital has a ratio of greater than three staff for each bed, the nursing home has only about a sixth of that number, and most of those staff are aides. Nursing homes are licensed to provide care that is presumably not available in purely residential facilities that can provide little or no nursing care. But even here the boundaries are blurred. Some forms of assisted living seek to serve a population that heavily overlaps the LTC groups served by nursing homes.

Admission to a nursing home is a function of age. [Figure 15-10](#) illustrates two separate trends in the nursing home utilization picture. (1) There is a sharp rise in the rate of nursing home use with each decade after age 65, such that only about 1% of people age 65 to 74 are in nursing homes, but 4% of those age 74 to 85 and 14% of those age 85 or more are in nursing homes. (2) At the same time, the proportion of older persons who reside in nursing homes has decreased substantially from 1973 to 2012. The greatest change has been seen in the oldest group. Much of this shift can be traced to the use of alternative residential settings. [Figure 15-11](#) contrasts the patterns of institutional care use in 1985 and 2004. Especially among those age 85+, there was substantial use of alternative residential settings. [Figure 15-12](#) examines this phenomenon from a different perspective by looking at the rate of institutional use for persons at different levels of disability. There is a reduction within each disability group.

Many nursing homes actually provide two types of care: LTC and PAC. A substantial portion of nursing home admissions represent short-stay residents who are admitted under Medicare for rehabilitation and recuperation. Many of these




FIGURE 15-10 Change in the rate of nursing home use by age group, 1973-2004. (From 1973-1974, 1997, 1985, 1995, 1997, 1999, and 2004 National Nursing Home Survey.)




FIGURE 15-11 Use of different types of institutional long-term care by age group, 1985 and 2004. (From 1985 and 2004 National Nursing Home Survey and 2002 Medicare Current Beneficiary Survey.)




FIGURE 15-12 Rate of institutional use among persons age 65+ by level of disability, 1984 and 2004. ADL, activity of daily living; IADL, instrumental activity of daily living. (Source: Redfoot DL, House A. More older people with disabilities living in the community: trends form the National Long-Term Care Survey, 1984-2004. AARP Public Policy Institute analysis of NLTCs data. Washington, DC: AARP Public Policy Institute; 2010.)

TABLE 15-2. Remaining Lifetime Use of Long-Term Supportive Services (LTSS) by People Turning 65 in 2005

Type of care	Avg. years of care	% of People using	Avg. years of care among users
All LTSS need	3.0	69	4.3
At home			
Informal care only	1.4	59	2.4
Formal care	0.5	42	1.2
Any care at home	1.9	65	2.9
In facilities			
Nursing facilities	0.8	35	2.3
Assisted living	0.3	13	2.3
Any care in facilities	1.1	37	3.0

Reproduced with permission from Kemper P, Komisar HL, Alecxih L. Long-term care over an uncertain future: what can current retirees expect? *Inquiry*. 2005/2006;42:335-350.

residents leave by 21 days, when Medicare imposes a copayment. Almost all are gone by 90 days. Persons entering nursing homes for relatively brief periods will have different goals and expectations. They are also different medically, representing a set of PAC diagnoses rather than chronic conditions like dementia. It is thus important to appreciate that descriptions of nursing home samples will differ, depending on whether one is describing an admission cohort, a discharge cohort, or a cross-section.

Table 15-2 shows the dynamic nature of LTC today. A cohort of persons turning 65 can expect, on an average, to require 3 years of care. Of those who actually use care, the span will be about 4.3 years. Overall, the care will be divided between community care (1.9 years) and facility-based care (1.1 years). For the actual users, the split between community and institutional care is about even, as is the split between time in assisted living and in a nursing home.

Forecasts of nursing home demand must consider the growing number of people who are suffering from diseases that reflect lifestyle choices. As shown in Figure 15-13, the risk of nursing home use rises sharply with the presence of conditions like hypertension and diabetes. Moreover, both are exacerbated by a lack of physical activity.

Nursing home residents are distinguishable from older persons living in the community on several basic parameters. As shown in Table 15-3, in addition to being older, they are more likely to be female, unmarried, and have multiple chronic problems. However, the former discrepancy in use by race has disappeared.

Nursing home users appear to have become more disabled in the last several years. Some attribute this change to the impact of DRGs, but the trend had begun well in advance of that change. The contemporary nursing home user is older and more disabled than in the past.




FIGURE 15-13 Relative likelihood of using a nursing home as function of potentially changeable lifestyle disease. BP, blood pressure. (Source: Data compiled from Valiyeva E, Russell LB, Miller JE, Safford MM. Lifestyle-related risk factors and risk of future nursing home admission. *Arch Intern Med.* 2006;166:985-990.)

TABLE 15-3. Comparison of Nursing Home Residents and the Noninstitutionalized Population Age 65, 1995		
	Percentage of nursing home residents*	Percentage of noninstitutionalized population†
Age (years)		
65-74	17.5	55.9
75-84	42.3	33.2
85+	40.2	10.8
Sex		
Male	24.7	40.8
Female	75.3	59.2
Race		
White	89.5	89.6
Black	8.5	8.1
Other	2	2.3
Marital status		
Married	16.5	56.9
Widowed	66	33.2
Divorced and/or separated	5.5	5.7
Never married/single	11.1	4.2
Unknown	0.8	—

*From Dey AN. *Characteristics of Elderly Nursing Home Residents: Data from the 1995 National Nursing Home Survey. Advance Data from Vital and Health Statistics.* Hyattsville, MD: National Center for Health Statistics; 1997.

†From US Census Bureau, 1996.

Any effort to describe the nursing home resident population must recognize that the nursing home plays multiple roles. It caters to a wide variety of clientele. At least five distinct groups of residents can be identified.

1. Those actively recuperating or being rehabilitated. These are largely persons discharged from hospitals and are expected to have a short course in the nursing home before returning home. This care has been called “subacute” or “transitional.” The evidence of the nursing home’s capacity to provide effective care of this type is mixed (Kane et al., 1996; Kramer et al., 1997).
2. Those with substantial physical dependencies. These residents need regular and usually frequent assistance during the day. Their care could be managed in the community with sufficient formal and informal support.
3. Those with primarily severe cognitive losses. These people present special management problems because of their behavior and their propensity to wander. Some favor separate facilities for them, primarily to remove them from the environment of those who are cognitively intact. There is no evidence of improvement in the outcomes of demented residents from these “special care units” (Phillips et al., 1997).
4. Those receiving terminal care. This hospice care is directed toward making the person as comfortable as possible. Palliative care is provided, but no heroic efforts are undertaken.
5. Those in a permanent vegetative state. This group is distinguished by its inability to relate to the environment. Care is primarily directed toward avoiding complications (eg, decubitus ulcers).

For those who are sensitive to their environments and likely to be in the nursing home for some time (ie, groups 2 and 4), quality-of-life issues will be at least as salient as traditional quality-of-care issues (Kane, 2001).

Especially in the wake of changing hospital practice and the rise of “subacute care,” great care must be exercised in using nursing home data because of the differences in the characteristics of those entering or leaving and those residing at any point in time. The latter are more likely to have chronic problems such as dementia, whereas the former will have problems that either benefit from rehabilitation or are fatal (eg, hip fracture and cancer). This distinction complicates discussions about nursing home patients and may explain the often contradictory findings of research on the total nursing home population.

The problem with data about nursing home residents is made more confusing when different approaches to sampling are used. The characteristics of admissions or discharges are different from those of a cross-section of residents. The former have shorter lengths of stay, whereas the latter have a preponderance of dementia.

Payment for nursing home care has been increasingly based on measures that reflect the costs of providing that care. Although this type of payment is often called “prospective reimbursement,” it is important to recognize that it is quite different from that used with hospitals. Nursing home prospective payment is calculated on

a daily rate basis in contrast to the episode basis used for hospitals. Hence as a person's status changes, so does the payment. Medicare payments now use a daily prospective payment rate based on case mix, and many states are adapting a corresponding approach for Medicaid payments, although the specific systems may use fewer categories. This form of case-mix reimbursement is largely driven by the costs of the nursing personnel, who provide that care. The costs are usually calculated by estimating these costs based on a set of observed times spent by different types of personnel (nurses' aides, licensed practical nurses, and registered nurses) for different classes of residents. In some cases, the time spent is self-reported by the staff; in other instances, it is based on observations. These data are then used to construct models that relate the cost of professional time to the characteristics of the clients. This approach has two major problems.

1. The models generally rely on looking at what kind of care is being given rather than what sort of care is actually needed; the care is not related to outcomes obtained nor is it based on any models of especially good care.
2. The logic behind this approach to estimating payments is inherently perverse. If carried to its logical extreme, this system of payment rewards nursing homes for residents becoming more dependent instead of more independent.

The most commonly used case-mix system is the resource utilization groups (RUGs). It has been revised several times and is now linked to the Minimum Data Set (MDS) (described in Chapter 16), which is the mandated assessment approach for nursing home care. The current RUG-IV creates 66 groups of nursing home residents, each linked to a case-mix index that presumably reflects different levels of staffing needs. This approach has been used by some Medicaid programs and is the basis for Medicare skilled nursing facility payments. [Table 15-4](#) shows the basic components of the RUGs classification approach. A major determining factor is activity of daily living (ADL) needs, but other elements are also considered. The case-mix index generated is then weighted differently for urban and rural areas.

The physician's role in nursing home care is discussed in greater detail in Chapter 16. Suffice it to say here that the nursing home has not been an attractive place for physicians to practice. However, conditions are changing. Clinicians can play a critical role in setting the tone for the care of patients in the nursing home. Clinicians' expectations of professional performance and their advocacy of their patients' needs can be very influential in shaping staff behavior. Some physicians now find nursing home practice attractive because of the lack of office overhead, and the role of the medical director has been professionalized through a certification program of the American Medical Directors Association.

New types of personnel can be used effectively to deliver primary care to nursing home patients. Nurse practitioners and physician assistants deliver high-quality care in this setting (Kane et al., 2003). Medicare regulations covering Part B were altered to allow greater use of physician assistants and nurse practitioners. Similarly, clinical pharmacists are very helpful for simplifying drug regimens and avoiding potential drug interactions.

TABLE 15-4. RUG-IV Classification System	
Major RUG group	Hierarchical classification*
Rehab Plus Extensive	Ultra high intensity Very high intensity High intensity Medium intensity Low intensity
Rehab	Ultra high intensity Very high intensity High intensity Medium intensity Low intensity
Extensive Services	Tracheotomy and ventilator/respirator Tracheotomy or ventilator/respirator Isolation for active infectious disease
Special Care High	Depressed Not depressed
Clinically Complex	Depressed Not depressed
Behavioral Symptoms and Cognitive Performance	Nursing rehab 2+ Nursing rehab 0 to 1
Reduced Physical Functioning	Nursing rehab 2+ Nursing rehab 0 to 1

*Multiple subgroups for each based on activity of daily living scores.
RUG, resource utilization group.

A managed care program directed specifically at Medicare costs for nursing home patients points to the art of the possible. Building on the prior successes of using nurse practitioners as key figures to provide primary care to nursing home residents, the Evercare program has developed Medicare-managed care risk contracts specifically for long-stay nursing home patients. Under this arrangement, Evercare is responsible for all the residents' Medicare costs (both Part A and Part B) but not their nursing home costs. The underlying concept is that by providing more aggressive primary care, they can prevent hospital admissions.

Evercare places nurse practitioners in each participating nursing home to work with the residents' own physicians. The nurse practitioners provide closer follow-up and work closely with the nursing home staff to identify problems early. In some cases, Evercare will pay the nursing home extra to increase nursing attention for patients in order to treat that person in the nursing home rather than admitting the patient to a hospital. The theory is that the savings from avoided or shortened hospital stays will offset the added costs of more attentive primary care provided by

the nurse practitioners. The apparent success of the Evercare model has spawned similar approaches.

A study by the Institute of Medicine pointed to the need for reforms, many of which were incorporated into the Omnibus Budget Reconciliation Act of 1987 (OBRA 1987). The implementation of the OBRA 1987 regulations has produced a number of changes in the way nursing homes are operated. In addition to the standardized assessment mandated in the Minimum Data Set (MDS), the emphasis in regulation has shifted more toward addressing the outcomes of patient care, but some increases in process measures have also been introduced. For example, guidelines for the use of psychoactive drugs have been mandated. All residents admitted and already living in the nursing home must be screened to determine if they are there primarily because of chronic mental illness. If so, a specific plan of care must be developed with appropriate participation from mental health professionals. Those residents who do not require skilled care are supposed to be transferred to more appropriate care settings. More training is mandated for nurses' aides, and the staffing requirements overall have been upgraded.

The new version, MDS 3.0, incorporates more valid assessment in some areas and more focus on the voice and preferences of the residents. Although the MDS was created as an assessment tool, data elements from the MDS have been used to create a series of quality indicators, which are intended to reflect potential areas of poor care in need of further exploration by state surveyors. In a move to foster informed consumer choice, some of these quality indicators are now being posted on websites to provide consumers and their families with better information about the quality of nursing home care. While some states have their own nursing home report cards, the nationally available data set is Nursing Home Compare (<http://www.medicare.gov/NursingHomeCompare/>).

New models of nursing home care are being developed despite regulatory constraints on creativity. In some settings, large institutions are being converted into smaller living communities, where residents exert more control over their lives. The Eden Alternative has provided a model for how to humanize nursing home care. The Wellspring Movement is trying to pursue a quality improvement agenda by empowering nursing home staff to take greater responsibility for identifying ways to improve care. Although both are attractive concepts, neither has yet been shown to produce dramatic improvements in residents' quality of care or quality of life.

ASSISTED LIVING

"Assisted living" describes a form of care for many persons who formerly required nursing home care. It is designed to provide services to persons as they require them, in a setting that more closely resembles a person's home. In effect, service recipients need not lose their personhood and their autonomy to get care. Residents still live in institutional settings that house many people within the same facility, thus maximizing efficiency of service delivery. They use common facilities, such as a dining room, but they also retain their privacy. Basically, each resident is treated as a tenant and

has control over a living unit. At a minimum, each individually occupied dwelling unit contains space for living and sleeping, a bathroom, and at least minimal cooking facilities. (The stove can be disconnected for those for whom it might pose a serious danger.) Each unit can be locked by the occupant.

Under this approach, control is ideally shifted toward empowering the recipient of care. In contrast to the situation in a nursing home, where residents are expected to conform to the norms of the institution, in an assisted living facility, individualized care is stressed. As the tenant, the resident has control over the use of her space: care providers must be invited in, and care plans must be accepted by the resident. These shifts, while subtle at one level, are fundamental at another. They imply a dramatically altered approach to care, some of which is tangible and some of which is not. The lore of nursing homes is laden with evidence of learned helplessness and enforced dependency. This approach to care is aimed at maximizing a resident's sense of self and independence as much as possible.

Unfortunately, assisted living has been implemented in a variety of ways. Many assisted living facilities offer basic room and board with packages of services. In some instances, the individualized care promised can be obtained only by hiring a personal attendant. There is also a move to provide specialized units for dementia care, often euphemistically called "reminiscence therapy." These are often locked units.

Especially for those chronically impaired persons who have retained an appreciation of their environment, such a philosophy of care makes great sense. Examples of such care are becoming more prevalent. Assisted living has been able to serve quite disabled persons, although most recipients are less impaired. The majority of assisted living exists as a privately paid service. Medicaid in most states has been slow to cover this service, and where it has, it covers only the services component, leaving Social Security and welfare payments to address the room and board costs. This coverage situation can mean that older persons are admitted to assisted living until they use up their resources. Then they are discharged, most likely to a nursing home that accepts Medicaid.

The costs of assisted living are usually less than comparable nursing home care. But one has to be careful comparing costs, especially when an assisted living facility requires that the family purchase their own personal care attendant. One reason that assisted living is less expensive and more flexible is that it has thus far been spared the heavy regulatory mantle laid on nursing homes. Staffing patterns are not as intense or as professionally dictated. Staff performs multiple functions. If it is regulated in the same way, it will inevitably come to resemble nursing home care.

Once again, the form of care is determined by society's willingness to accept some risks. At a minimum, those who receive the care should have an opportunity to choose what kind of care they want to get.

At the same time, assisted living has come under criticisms reminiscent of those addressed at nursing homes in years past. The growth and diversity of models now encompassed by this name make it hard to know just what is being offered by whom. Some standardized taxonomy is needed to allow consumers to make more informed choices. Concerns about quality are frequently expressed, especially with regard to the management of the frailer and more medically complex residents.

HOME CARE

As already noted, we have developed a backward system of LTC in this country that focuses on the nursing home. We tend to speak of the nursing home and alternatives to it, when we should begin with the premise that elderly people belong at home and want to be cared for at home. Institutional care will be needed in some cases, when the strain on caregivers is too great, but it should not be the resource of first resort. Our system has not evolved that way, and the resources available for home care are meager, but not so underdeveloped as to be ignored. Even today, most communities have at least some home care services, and more are likely to develop.

Home care involves at least two basic types of care: home health services, and homemaking and chore services. As shown in Table 15-5, different programs provide

TABLE 15-5. Home Care Provided Under Various Federal Programs

	Medicare	Medicaid	Title XX
Eligibility criteria	Must be homebound; need skilled care; need and expect benefit in a reasonable period; need certification by physician	State can use homebound criterion; not limited to skilled care; need certification by physician	Vary from state to state
Payment to provider	Final costs per episode based on functional status, case needs, and diagnoses	Varies with state	Three modes of payment possible: (1) direct provision by government agency; (2) contract with private agency; (3) independent provider
Services covered	Home health services, skilled nursing, physical, or speech therapy as primary services; secondary services (social worker and home health aide) available only if primary service is provided; position of occupational therapy in service hierarchy ambiguous*	Limited home health care mandatory; expanded home care optional; personal care in home optional	Wide variety of home services allowed, including home health aide, homemaker, chore worker, meal services

*Occupational therapy is considered an “extended” secondary service, which may continue if needed after primary services are discontinued.

one or both types. Most elderly people treated at home require homemaking more than home health services.

Sometimes the differences between the two are purely arbitrary. If we consider that the homemaker replaces or supplements a family member, many of the tasks involved are extensions of home nursing (eg, supervising medication or giving baths). The definitions have emerged to fit the regulations governing a particular program. The physician will usually find that the home health agency is familiar with these regulations and how to deal with them.

The major problem at present is getting services. In response to political pressures some years ago, Medicare broadened its LTC benefit (including waiving the former requirement that a person have a prior hospital stay of at least 3 days, but Medicare reinstituted the requirement less than a year later) and moved the program from Part B to Part A, thereby removing the copayment requirement. The subsequent enormous growth in home health care under Medicare subsequently led the program to take steps to curtail services. In 1997, they instituted prospective payment and made revisions in coverage that moved part of the program back under Part B. (Home health care not related to a prior 3-day hospital stay or visits after the 100th visit if related to a stay are covered under Part B.)

Today, there is concern that the criteria for eligibility for these services severely restrict their use. To get home health services for a patient, a physician must certify that the patient is homebound and that intermittent skilled care is likely to produce a benefit in a reasonable time. Thus, a large number of dependent older persons who need continuing home nursing but are “custodial” are ineligible unless the physician misrepresents their situation. *Skilled service* is defined as a skilled service offered by a nurse, a physical therapist, or a speech therapist. A recent court case has successfully challenged this restriction and new rules for Medicare home health are likely.

If one of these establishing services is present, the patient may also receive the skilled services of an occupational therapist or medical social worker and/or the services of a home health aide if required by the plan. Medicare has begun to allow home health agencies to continue to serve clients who need case management, thus permitting some cases to remain open longer than the “intermittent” rule might otherwise imply. All reimbursed services must be given by a certified home health agency. (To be certified, the agency needs to offer nursing plus at least one of the five other services.) The requirement for using a certified agency greatly increases the costs of the services, although the assumption is that this certification assures at least a minimal level of professional oversight. A recurring question is how much administrative overhead is affordable as the pressure on the LTC dollar grows.

Medicare-certified home health agencies are required to complete an Outcome and Assessment Information Set (OASIS) form at several stages of care to track outcomes and need for care. This recording burden has proven onerous for many agencies.

Medicaid funds can be used to provide home health care to persons eligible for nursing home care. Until recently, home care has not been a prominent part of state Medicaid plans, but this situation is changing as more states are using waivers.

Home care under Medicaid must have a physician's authorization, but the patient need not be homebound, and the care need not be "skilled." All agencies delivering home care under Medicaid must meet Medicare certification standards, but if no organized home health agencies exist in a region, a registered nurse may be reimbursed for the services. Home care is a mandated service under Medicaid, and it can also be part of a waived service package (ie, services authorized in lieu of nursing home care). In practice, states have often modeled their Medicaid home care benefits after the medically oriented Medicare benefit and thus restricted its use. Under Medicaid, the nursing care is a required component of home health services, and the state has the option to provide physical, occupational, and speech therapy; medical social services; and personal care services. Medicaid allows homemaking assistance on a more generous basis than does Medicare. Personal care services must be prescribed by a physician and supervised by a registered nurse. These services may not be delivered by persons related to the patient. (However, under waiver programs, this restriction is softened to allow some family members to be paid.)

Recent changes in legislation have broadened the permissible use of Medicaid moneys to support a wide variety of LTC services in an effort to reduce nursing home costs. A number of states have received waivers to develop this broader package of services in lieu of nursing home care, but most of these waived services are limited in the numbers of "slots" they are allowed. The waivers require some evidence of budget neutrality. The assumption is that as more care is provided in the community, fewer people will use nursing homes.

Another development has been consumer-directed care, whereby older persons receive cash (or more typically voucher equivalents) to be spent on their care. They can hire whom they wish. The idea is to make the money go further. Consumers get less money but fewer restrictions. Some states provide administrative assistance that handles taxes and workers' compensation.

Despite the growth of home care under Medicaid and the growing number of alternative waiver programs, the large bulk of Medicaid LTC funds continue to flow to nursing homes. However, the relative dominance of spending on nursing home care varies widely from state to state.

Additional homemaking services are provided under Title III and Title XX. Title XX provides at least four methods of payment: local public agencies can provide the service directly; they can contract with agency providers (perhaps using competitive bidding); they can purchase services from agencies at negotiated prices; or they can permit the recipient to enter into agreement with independent providers, who do not work for an agency. It is possible to have all these arrangements operating in the same community.

This provision for independent vendors has prompted controversy because maintaining standards is difficult in the absence of any supervisory system or institutional responsibility. Under Title XX, an employment category known as *chore worker* has emerged; although performing functions similar to the home health aide and the homemaker, chore workers do not need to be tightly supervised and cannot be reimbursed under Medicare or Medicaid.

Persons eligible for cash assistance from the state and other persons with low incomes and unmet service needs are eligible for Title XX as long as 50% of a state's annual federal allotment is expended on those receiving cash assistance. Fees are charged to those whose family income exceeds 80% of the state's median income for a family of four.

Home services are one of four priority items under Title III of the Older Americans Act. Although the dollar volume is low, this source is important because means testing (whereby eligibility is set by income) is prohibited for programs under the Older Americans Act, making it possible to target a group that cannot afford private care but is ineligible for Title XX or Medicaid. Generally speaking, the Area Agency on Aging subcontracts for home care services rather than providing them directly. Services vary from area to area but can include personal care, homemaker service, chore service, and service for heavier jobs (eg, minor home repairs or renovations, insect eradication, gardening, and painting). The provisions for assistance under the Area Agency on Aging are sharply limited by their constrained budgets and the competing demands for programs.

The extent of services under these several programs is still limited at present, although enthusiasm for in-home care is growing. The total sum of public dollars spent on home care remains only a fraction of that devoted to nursing homes.

Although still a small minority of practice, the number of physicians making home visits has risen. A small industry of physician (and nurse practitioner) home care is developing. A demonstration project is under way to test whether such care is cost-effective for high-risk older persons.

OTHER SERVICES

A number of other modes of care can be tapped on behalf of elderly patients. [Table 15-6](#) lists some of these services. However, despite their growing availability, they are still not widely used. The most frequently used service in that set is the senior center, a service designed for the well elderly person.

Day care can fulfill a number of needs. Most day care programs provide some combination of recreational and restorative activity. In contrast to senior centers, which are usually sponsored by recreational departments and targeted at the well

TABLE 15-6. Examples Of Community Long-Term Care Programs	
Home care (home nursing and homemaking)	Caregiver support
Adult day care	Congregate housing
Adult foster care	Home repairs
Assisted living	Meals (congregate and in-home)
Geriatric assessment	Respite care
Hospice/terminal care	Emergency alarms
Telephone reassurance	

elderly, day care programs serve persons with limited functional ability. Some are for cognitively impaired persons. The programs provide supervised activities, which may improve basic ADL skills and social skills. At the very least, they provide an important respite for the primary caregiver and thus may make the critical difference for allowing an impaired older person to remain at home. To increase efficiency, most programs serve any given client fewer than 5 days a week, usually 2 or 3 days.

Other forms of day care can include a larger medical component. Some areas have developed day hospitals for seniors, where virtually all the services of the hospital are available on an ambulatory basis. Emphasis is usually placed on rehabilitation, especially occupational and physical therapy. The adult day health center is an intermediate model that combines day care with nursing, physical therapy, and perhaps social work. Such sites can also be used for periodic ambulatory care clinics.

A problem common to all day care programs is transportation. It is hard to arrange, expensive, and time consuming. Special vans are usually needed, and to avoid excessive travel times, services are usually confined to very limited areas.

In many communities, a variety of services exist to help seniors: ombudsmen, peer counselors, mental health clinics, transportation, congregate meal sites, and meals-on-wheels—just to name a few. Availability varies greatly from place to place. Good sources of information are the social work department in a hospital and the Area Agency on Aging.

The physician cannot be expected to know all the resources available for geriatric patients and will have to rely on other professionals to make appropriate arrangements to take advantage of them. But a physician should have a good sense of what can be done in general and what needs to be done for any particular patient. Often knowing what is needed but not locally available can lead to its development, particularly if responsible professionals take an active role on behalf of their patients.

There is growing interest in providing older people and their families with better information with which to make more informed decisions about LTC choices. Most states have developed some form of web-based information system that provides information about LTC options. Medicare provides online information about the quality of nursing homes (Nursing Home Compare) and home health agencies (Home Health Compare), as well as comparative reports on hospital quality indicators (Hospital Compare). The Administration on Aging and Centers for Medicare and Medicaid Services have jointly funded a network of Aging and Disability Resource Centers (ADRCs) designed to help older persons and their families locate resources and decide what types of LTC are most suitable. ADRCs are located in almost every state. Much of this information is online.

CASE MANAGEMENT

The growing interest in the plethora of community LTC services has sparked some concerns about the need to control use. A frequent answer is *case management*. This term has been widely and variably used. Some people refer to case management as “political pixie dust,” because whenever the legislature finds itself proposing a LTC program that will be hard to implement, they call for case management to make it

work as desired. The basic components of case management are assessment, prescription, authorization, coordination, and monitoring. Although it is an intrinsically appealing concept, the effectiveness of case management has not been well established. Much of the confusion about the effectiveness of case management can be traced to the confusion about just what is being described. [Table 15-7](#) distinguishes several different types of case management.

TABLE 15-7. Variations in Case Management		
Type of case management	Case manager	Components
Eligibility management	Social worker or nurse	Assessment to see if client reaches threshold for eligibility Care plan Implementations Cursory monitoring for change in status that would affect eligibility
Care coordination	Social worker or nurse	Structured assessment to identify needs Care plan addressing each need Arrange services to meet each need Follow up to assure services are delivered Reassess periodically and adjust care plan
Utilization management	Usually a nurse	Identify high-volume/high-cost cases Work with high users to change clinical course Monitor intensively Counsel to encourage compliance Seek ways to prevent problems Flag charts to alert clinicians
Disease management	Usually a nurse, possibly MD	Focus on a single disease Provide reminders Counseling Monitoring Usually not coordinated with primary care
Chronic care coordination	Nurse or nurse practitioner	Establish expected clinical course Monitor salient parameter for each condition followed Patients can do most of the monitoring Communicate with clinicians by phone, web Intervene when actual course differs from expected course Indication for active intervention See clients primarily when their condition changes significantly Can monitor many conditions simultaneously Can address function as well as diseases

Of these five variants of case management, eligibility management may be the most common. It is hardly likely to affect care directly. Disease management and chronic care coordination are closely related to the activities of primary care and hence may lead to some concern about role overlap between the case manager and the primary care physician. Disease management is often conducted independently of primary care by an organization contracted by insurance companies. By contrast, chronic care coordination is the basis for proactive primary care. It is possible for physicians to serve as case managers, but most do not have the interest or the resources to perform this task. It is usually more efficient to look to other disciplines to perform this function but to recognize the important role of the physician in the overall care of the LTC patient. Where a full range of geriatric services is available, case management is usually included.

Regardless of discipline, the case manager faces some difficult tasks. There is often a discrepancy between responsibility and authority. It is very different to prescribe, authorize, or mandate.

Case managers may or may not have the purchasing authority to pay for services they feel are necessary. Case managers may easily find themselves in the same bind as physicians. Specifically, they are expected to serve simultaneously as patient advocates and gatekeepers. The two roles are incompatible. For everyone's peace of mind, it is important to clarify at the outset who is the principal client. Because many decisions involve advocating on behalf of one group over another, this distinction is critical. It is very different to work on behalf of a client to obtain all the resources you believe they need than it is to work to distribute a fixed pool of resources to those who will best use them.

Case management has also become a mainstay of managed care. In this context, cases are usually identified based on some risk indicators—either a record of heavy use of services or the presence of risk factors that imply such a pattern in the future. While some case management within managed care is patient centered, operating on the premise that closer care can stave off costly problems, much of it revolves primarily around utilization controls.

Several states have used a program called “cash and counseling.” Modeled after successful programs in California and Europe, disabled seniors can receive direct cash payments for care, which they can, in turn, use to purchase services, including from relatives. The preliminary reports have been enthusiastic. Clients have been able to purchase more care for less money with no evidence of untoward effects. In general, these clients are on the low end of the disability spectrum, but the program shows promise. It is, after all, simply creating a situation analogous to what people would do with their own funds. There is still some uneasiness about just how much discretion such programs should allow; many still require limited choices of vendors and evidence that the funds were used for the intended purposes. Nonetheless, these efforts represent a new direction of giving frail older clients more leeway in how to obtain services.

REFERENCES

- Cutler DM. Declining disability among the elderly. *Health Aff.* 2001;20:11-27.
- Kane RA. Long-term care and a good quality of life: bringing them closer together. *Gerontologist.* 2001;41:293-304.

- Kane RL. Managed care as a vehicle for delivering more effective chronic care for older persons. *J Am Geriatr Soc*.1998;46:1034-1039.
- Kane RL. Finding the right level of posthospital care: “we didn’t realize there was any other option for him.” *JAMA*.2011;305:284-293.
- Kane RL, Chen Q, Blewett LA, Sangl J. Do rehabilitative nursing homes improve the outcomes of care? *J Am Geriatr Soc*.1996;44:545-554.
- Kane RL, Homyak P, Bershadsky B, Flood S. Variations on a theme called PACE. *J Gerontol A Biol Sci Med Sci*. 2006;61:689-693.
- Kane RL, Kane RA. HCBS: the next thirty years. *Generations*. 2012;36:131-134.
- Kane RL, Keckhafer G, Flood S, Bershadsky B, Siadaty MS. The effect of Evercare on hospital use. *J Am Geriatr Soc*.2003;51:1427-1434.
- Kane RL, Ouellette J. *The Good Caregiver*. New York, NY: Avery; 2011.
- Kane RL, West JC. *It Shouldn’t Be This Way: The Failure of Long-Term Care*. Nashville, TN: Vanderbilt University Press; 2005.
- Kramer AM, Steiner JF, Schlenker RE, et al. Outcomes and costs after hip fracture and stroke: a comparison of rehabilitation settings. *JAMA*.1997;277:396-404.
- Phillips CD, Sloane PD, Hawes C, et al. Effects of residence in Alzheimer disease special care units on functional outcomes. *JAMA*.1997;278:1340-1344.
- Wieland D. The Program of All-Inclusive Care for the Elderly [PACE]. In: Schulz R, Noelker LS, Rockwood K, Sprott R, eds. *The Encyclopedia of Aging*. 4th ed. New York, NY: Springer; 2006:973-975.

SUGGESTED READINGS

- Boult C, Boult L, Pacala JT. Systems of care for older populations of the future. *J Am Geriatr Soc*. 1998;46:499-505.
- Kane RA, Kane RL, Ladd R. *The Heart of Long-Term Care*. New York, NY: Oxford University Press; 1998.
- Lachs MS, Ruchlin HS. Is managed care good or bad for geriatric medicine? *J Am Geriatr Soc*. 1997;45:1123-1127.
- Morgan RO, Virnig BA, DeVito CA, et al. The Medicare–HMO revolving door—the healthy go in and the sick go out. *N Engl J Med*. 1997;337:169-175.
- Sloan J. *A Bitter Pill: How the Medical System Is Failing the Elderly*. Vancouver, BC, Canada: Greystone Books; 2009.
- Wunderlich GS, Kohler P (eds). *Improving the Quality of Long-Term Care. Report of the Institute of Medicine*. Washington, DC: National Academy Press; 2001.

CHAPTER 16

Nursing Home Care

The focus of this chapter is the clinical care of nursing home residents. Some of the basic demographic and economic aspects of nursing home care are discussed in Chapters 2 and 15. Ethical issues relevant to nursing home care and palliative care are discussed in Chapters 17 and 18, respectively. Many older people who would have otherwise been in nursing homes are now residing in assisted living facilities or in their own homes. Management of older people with multiple medical problems and geriatric conditions in this setting is challenging. Chapter 15 and the Suggested Readings at the end of this chapter provide more information on this level of care.

The poor quality of care provided in many nursing homes has been recognized for decades (Institute of Medicine, 2000). Since the Institute of Medicine issued its critical report in 1986 (Institute of Medicine, 1986) and the mandating of the Resident Assessment Instrument in 1987, the overall quality of care has improved. More recently, the Centers for Medicare and Medicaid Services (CMS) has instituted several changes that are designed to improve the quality of nursing home care. These include the Nursing Home Compare website (<http://www.medicare.gov/nhcompare/home.asp>), which shows consumers (and nursing homes) how individual homes perform on surveys and specific quality indicators; the new federal survey process employing the Quality Indicator Survey (QIS; <http://www.cms.gov>); the Five-Star rating system (<http://www.Medicare.gov>); and the new requirement in the Patient Protection and Affordable Care Act that all nursing homes must have a Quality Assurance and Performance Improvement (QAPI) program. Because older people who are typically in nursing homes suffer from multiple underlying diseases, good medical care is especially important. Despite the logistical, economic, and attitudinal barriers that can foster inadequate medical care in the nursing home, many straightforward principles and strategies can improve the quality of medical care for nursing home residents. Fundamental to achieving these improvements is a clear perspective on the goals of nursing home care, which differ in many respects from the goals of medical care in other settings and patient populations.

THE GOALS OF NURSING HOME CARE

The modern nursing home serves multiple roles. [Table 16-1](#) lists the key goals of nursing home care. While the prevention, identification, and treatment of chronic, subacute, and acute medical conditions are important, most of these goals focus on the functional independence, autonomy, quality of life, comfort, and dignity of the residents. Physicians and other clinicians who care for nursing home residents must consider these goals while the more traditional goals of medical care are being addressed.

TABLE 16-1. Goals of Nursing Home Care

1. Provide a safe and supportive environment for chronically ill and dependent people
2. Restore and maintain the highest possible level of functional independence
3. Preserve individual autonomy
4. Maximize quality of life, perceived well-being, and life satisfaction
5. Provide effective rehabilitative, medical, nursing, and psychosocial care to individuals discharged from an acute hospital to facilitate their transition to their previous living environment
6. Provide comfort and dignity for terminally ill patients and their loved ones
7. Stabilize and delay progression, whenever possible, of chronic medical conditions
8. Prevent acute medical and iatrogenic illnesses, and identify and treat them rapidly when they do occur

The heterogeneity of the nursing home population results in a diversity of goals for nursing home care. Nursing home residents can be subgrouped into six basic types (Fig. 16-1). While it is not always possible or desirable to isolate these different types of residents geographically, and although residents often overlap or change between the types described, subgrouping nursing home residents in this manner will help the clinician and interdisciplinary team to focus the care-planning process on the most critical and realistic goals for individual residents.

The underlying social contract implied by nursing home admission is quite different for each of these groups. In some cases, access to treatment takes precedence over the living environment; in other circumstances, the environment may be the most critical element of care. Those admitted to a nursing home with the intent of active treatment and discharge home may be willing to accept a living situation akin to that of a hospital in the expectation that the benefit they receive from treatment will offset any discomfort or inconvenience. For terminally ill persons under the hospice model, the living environment is made as flexible and supportive




FIGURE 16-1 Basic types of nursing home patients.

as possible. Efforts are directed toward making these patients comfortable and permitting them to enjoy, to the extent possible, their last days. For the other groups in the middle of this distribution, attention to both making their living situation comfortable and active primary care are important. Ideally, a nursing home should be able to provide what the name implies: active nursing (and medical care) and a homelike environment.

CLINICAL ASPECTS OF CARE FOR NURSING HOME RESIDENTS

In addition to the different goals for care in the nursing home, several factors make the assessment and treatment of nursing home residents different from those in other settings (Table 16-2). Many of these factors relate to the process of care. A fundamental difference in nursing home care compared to care in other settings is that medical evaluation and treatment must be complemented by an assessment and care-planning process involving staff from multiple disciplines. The integral involvement of nurses' aides in the development and implementation of care plans is crucial to high-quality nursing home care. Data on medical conditions and their treatment are integrated with assessments of the functional, mental, and behavioral status of the resident in order to develop a comprehensive database and individualized plan of care.

Several factors complicate medical evaluation and clinical decision making for nursing home residents. Unless the physician has cared for the resident before nursing home admission, it may be difficult to obtain a comprehensive medical database. Residents may be unable to relate their medical histories accurately or to describe their symptoms, and medical records are frequently unavailable or incomplete, especially for residents who have been transferred between nursing homes and acute-care hospitals. When acute changes in status occur, initial assessments are often performed by nursing home staff with limited skills and are transmitted to physicians by telephone. Even when the diagnoses are known or strongly suspected, many diagnostic and therapeutic procedures among nursing home residents are associated with an unacceptably high risk–benefit ratio. For example, an imaging study may require sedation with its attendant risks; nitrates and other cardiovascular drugs may precipitate syncope or disabling falls in frail ambulatory residents with baseline postural hypotension; and adequate control of blood sugar may be extremely difficult to achieve without a high risk for hypoglycemia among cognitively impaired diabetic residents with marginal or fluctuating nutritional intake, who may not recognize or complain of hypoglycemic symptoms.

Further compounding these difficulties is the inability of many nursing home residents to participate effectively in important decisions regarding their medical care. Their previously expressed wishes are often not known, and an appropriate or legal surrogate decision maker has often not been appointed. These issues are discussed further later in this chapter and in Chapter 17.

Table 16-3 lists the most commonly encountered clinical disorders in the nursing home population. They represent a broad spectrum of chronic medical illnesses;

TABLE 16-2. Factors That Distinguish Assessment and Treatment in the Nursing Home Different From Assessment and Treatment in Other Settings

1. The goals of care are often different (see Table 16-1)
2. Specific clinical disorders are prevalent among nursing home residents (see Table 16-3)
3. The approach to health maintenance and prevention differs (see Table 16-6)
4. Mental and functional status are just as important, if not more so, than medical diagnoses
5. Assessment must be interdisciplinary, including:
 - a. Nursing
 - b. Psychosocial
 - c. Rehabilitation
 - d. Nutritional
 - e. Other (eg, dental, pharmacy, podiatry, audiology, ophthalmology)
6. Sources of information are variable:
 - a. Residents often cannot give a precise history
 - b. Family members and nurses' aides with limited assessment skills may provide the most important information
 - c. Information is often obtained over the telephone
7. Administrative procedures for record keeping in both nursing homes and acute-care hospitals can result in inadequate and disjointed information
8. Clinical decision making is complicated for several reasons:
 - a. Many diagnostic and therapeutic procedures are expensive, unavailable, or difficult to obtain and involve higher risks of iatrogenic illness and discomfort than are warranted by the potential outcome
 - b. The potential long-term benefits of "tight" control of certain chronic illnesses (eg, diabetes mellitus, congestive heart failure, hypertension) may be outweighed by the risks of iatrogenic illness in many very old and functionally disabled residents
 - c. Many residents are not capable (or are questionably capable) of participating in medical decision making, and their personal preferences based on previous decisions are often unknown (see Table 16-7)
9. The appropriate site for and intensity of treatment are often difficult decisions involving medical, emotional, ethical, economic, and legal considerations that may be in conflict with each other in the nursing home setting
10. Logistic considerations, resource constraints, and restrictive reimbursement policies may limit the ability of and incentives for physicians to carry out optimal medical care of nursing home residents

neurological, psychiatric, and behavioral disorders; and problems that are especially prevalent in frail older adults (eg, incontinence, falls, nutritional disorders, chronic pain syndromes). Although the incidence of iatrogenic illnesses has not been systematically studied in nursing homes, it is likely to be as high as or higher than that in acute-care hospitals. The management of many of the conditions listed in Table 16-3 is discussed in some detail in other chapters of this text.

TABLE 16-3. Common Clinical Disorders in the Nursing Home Population

Medical conditions

- Congestive heart failure
- Degenerative joint disease
- Diabetes mellitus
- Gastrointestinal disorders
 - Reflux esophagitis
 - Constipation
 - Diarrhea
- Conjunctivitis
- Gastroenteritis
- Kidney disease (chronic kidney disease, renal failure)
- Lung disease (chronic obstructive, emphysema, asthma)
- Malignancies

Neuropsychiatric conditions

- Dementia
 - Behavioral disorders associated with dementia
 - Wandering
 - Agitation
 - Aggression
 - Depression
- Neurological disorders other than dementia
 - Stroke
 - Parkinsonism
 - Multiple sclerosis
 - Brain or spinal cord injury
- Pain: musculoskeletal conditions, neuropathies, malignancy

Geriatric conditions and syndromes

- Delirium
- Incontinence
- Gait disturbances, instability, falls
- Malnutrition, feeding difficulties, dehydration
- Pressure sores
- Insomnia

Functional disabilities necessitating rehabilitation

- Stroke
- Hip fracture
- Joint replacement
- Amputation

Iatrogenic disorders

- Adverse drug reactions
- Falls
- Nosocomial infections
- Induced disabilities
 - Restraints and immobility, catheters, unnecessary help with basic activities of daily living

Palliative care and end-of-life care

PROCESS OF CARE IN THE NURSING HOME

The process of care in nursing homes is strongly influenced by numerous state and federal regulations, the highly interdisciplinary nature of nursing home residents' problems, and the training and skills of the staff that delivers most of the hands-on care. Federal rules and regulations contained in the Omnibus Budget Reconciliation Act of 1987 (OBRA 1987) and implemented in 1991 place heavy emphasis on assessment and care planning as a means of achieving the highest practicable level of functioning for each resident and the use of the Resident Assessment Instrument (<http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/MDS30RAIManual.html>). The Minimum Data Set (MDS), recently updated to version 3.0, is the foundation of clinical assessment and care planning for individual residents. In addition to the MDS, each resident or responsible health-care agent should be assisted in articulating the goal for the patient's nursing home care (ie, short-term rehabilitation of medical and nursing management with the goal of returning home; long-term care of chronic conditions; or palliative or hospice care). Detailed guidance for state and federal surveyors has been developed for several clinical care areas, such as unnecessary drugs and urinary incontinence. Failure to adhere to the clinical recommendations contained in the regulations and related surveyor guidance can result in citations and, in some instances, financial penalties for the nursing home. Failure to appropriately manage medical conditions in the nursing home puts the facility and physician at risk for lawsuits (Stevenson and Studdert, 2003).

Physician involvement in nursing home care and the nature of medical assessment and treatment offered to nursing home residents are often limited by logistic and economic factors. Few physicians have offices based either inside the nursing home or in close proximity to the facility. Many physicians who do visit nursing homes care for relatively small numbers of residents, often in several different facilities. Many nursing homes, therefore, have numerous physicians who make rounds once or twice per month, who are not generally present to evaluate acute changes in resident status, and who attempt to assess these changes over the telephone. Increasingly, practice patterns are shifting to a model of physician–nurse practitioner practice teams caring for large numbers of residents in several nursing homes. Such physician–nurse practitioner teams have been shown to improve care and reduce hospitalization rates (Burl et al., 1998; Reuben et al., 1999; Kane et al., 2003; Konetzka, Spector, and Limcangco, 2008). Many nursing homes do not have ready availability of laboratory, radiological, and pharmacy services with the capability of rapid response, further compounding the logistics of evaluating and treating acute changes in medical status. Thus, nursing home residents are often sent to hospital emergency rooms, where they are evaluated by personnel who are generally not familiar with their baseline status and who frequently lack training and interest in the care of frail and dependent elderly patients.

Medicare and Medicaid reimbursement policies also dictate certain patterns of nursing home care. While physicians are required to visit nursing home residents only every 30 to 60 days, many residents require more frequent evaluation and

monitoring of treatment—especially with the shorter acute-care hospital stays brought about by the prospective payment system. Many of these visits can be made by a nurse practitioner or physician assistant. While Medicare reimbursement for physician visits in nursing homes has improved, reimbursement for a routine visit is sometimes inadequate for the time that is required to provide good medical care in the nursing home, including travel to and from the facility; assessment and treatment planning for residents with multiple problems; communication with members of the interdisciplinary team and the resident's family; and proper documentation in the medical record. Activities often essential to good care in the nursing home, such as attending interdisciplinary conferences, family meetings, complex assessments of decision-making capacity, and counseling residents and surrogate decision makers on treatment plans in the event of terminal illness, are generally not reimbursable at all. Medicare intermediaries sometimes restrict reimbursement for rehabilitative services for residents not covered under Part A skilled care, thus limiting the treatment options for many residents. Although Medicaid programs vary considerably, many provide minimal coverage for ancillary services that are critical for optimum medical care and may restrict reimbursement for several types of drugs that may be especially helpful for nursing home residents.

Amid these logistic and economic constraints, expectations for the care of nursing home residents are high. [Table 16-4](#) outlines the various types of assessment generally recommended for the optimal care of nursing home residents. Physicians are responsible for completing an initial assessment within 1 week of admission and for arranging for monthly visits thereafter for the next 90 days. More frequent visits are generally necessary for residents admitted on a Medicare Part A skilled nursing benefit. Registered nurses assess new residents as soon as they are admitted and on a daily basis, and they generally summarize the status of each resident weekly. The nationally mandated MDS must be completed within 14 days of admission and updated when a major change in status occurs; several sections must be routinely updated on a quarterly basis. The MDS is intended to assist nursing home staff in identifying important clinical problems that need further evaluation, management, and monitoring. It is also used as the basis for calculating daily reimbursement rates for residents on the Medicare Part A skilled benefit by generating a resource utilization group (RUG) that reflects case mix and needed staffing levels (a number of states also use the version of the RUGS for Medicaid payments) and as the basis for calculating various quality measures, including those on the Nursing Home Compare website and those used for the Five-Star rating system.

The extent of involvement of other disciplines in the assessment and care-planning process varies depending on the residents' problems, the availability of various professionals, and state regulations. Representatives from nursing, social services, dietary, activities, and rehabilitation therapy (physical and/or occupational) participate in an interdisciplinary care-planning meeting. Residents are generally discussed at this meeting within 2 weeks of admission and quarterly thereafter. The product of these meetings is an interdisciplinary care plan that separately lists interdisciplinary

TABLE 16-4. Important Aspects of Various Types of Assessment in the Nursing Home

Type of assessment	Timing	Major objectives	Important aspects
Medical initial	Within 72 h to 1 week after admission	Verify medical diagnoses Medication reconciliation Document baseline physical findings, mental and functional status, vital signs, and skin condition Attempt to identify potentially remediable, previously unrecognized medical conditions Get to know the resident and family (if this is a new resident) Establish goals for the admission and a medical treatment plan	A thorough review of medical records and physical examinations is necessary Relevant medical diagnoses and baseline findings should be clearly and concisely documented in the patient's record Medication lists should be carefully reviewed and only essential medications continued Request for specific types of assessment and input from other disciplines should be made A database should be established (see example in Fig. 16-2)
Periodic	Monthly or every other month	Monitor progress of active medical conditions Update medical orders Communicate with patient and nursing home staff	Progress notes should include clinical data relevant to active medical conditions and focus on changes in status Unnecessary medications, orders for care, and laboratory tests should be discontinued Mental, functional, and psychosocial status should be reviewed with nursing home staff and changes from baseline noted The medical problem list should be updated

As needed	When acute changes in status occur	Identify and treat causes of acute changes	<p>Onsite clinical assessment by the physician (or nurse practitioner or physician assistant), as opposed to telephonic consultations, will result in more accurate diagnoses, more appropriate treatment, and fewer unnecessary emergency room visits and hospitalization</p> <p>Vital signs, food and fluid intake, and mental status often provide essential information</p> <p>Infection, dehydration, and adverse drug effects should be at the top of the differential diagnosis for acute changes in status</p>
Major reassessment	Annual	Identify and document any significant changes in status and new potentially remediable conditions	<p>Targeted physical examination and assessment of mental, functional, and psychosocial status and selected laboratory tests should be done (see Table 16-6)</p>
Nursing	<p>On admission, and then routinely with monitoring of daily and weekly progress</p> <p>Complete Minimum Data Set (MDS) within 14 days, update when major change in status occurs and annually; update selected sections quarterly</p>	<p>Identify biopsychosocial and functional status, strengths and weaknesses</p> <p>Develop an individualized care plan</p> <p>Document baseline data for ongoing assessments</p>	<p>Particular attention should be given to emotional state, personal preferences, and sensory function</p> <p>Careful observation during the first few days of admission is important to detect effects of relocation</p> <p>Potential problems related to other disciplines should be recorded and communicated to appropriate members of the interdisciplinary care team</p>

(Continued)

TABLE 16-4. Important Aspects of Various Types of Assessment in the Nursing Home (*Continued*)

Type of assessment	Timing	Major objectives	Important aspects
Psychosocial	Within 1-2 weeks of admission and as needed thereafter	Identify any potentially serious psychosocial signs and symptoms and refer to mental health professional if appropriate Determine past social history, family relationships, and social resources Become familiar with personal preferences regarding living arrangements	Getting to know the family and their preferences and concerns is critical to good nursing home care Relevant psychosocial data should be communicated to the interdisciplinary team Discharge potential should be assessed
Rehabilitation (physical and occupational therapy)	Within days of admission and daily or weekly thereafter (depending on the rehabilitation program)	Determine functional status as it relates to basic activities of daily living Identify specific goals and time frame for improving specific areas of function Monitor progress toward goals Assess progress in relation to potential discharge	Small gains in functional status can improve chances for discharge as well as quality of life Not all residents have areas in which they can reasonably be expected to improve; strategies to maintain function should be developed for these residents Assessment of and recommendation for modifying the environment can be critically important for improving function and discharge planning
Nutritional	Within days of admission and then periodically thereafter	Determine nutritional status and needs Identify dietary preferences Plan an appropriate diet	Restrictive diets may not be medically necessary and can be unappetizing Weight loss should be identified and reported to nursing and medical staff

Interdisciplinary care plan	Within 1-2 weeks of admission and every 3 months thereafter	Identify interdisciplinary problems Establish goals and treatment plans Determine when maximum progress toward goals has been reached	Each discipline should prepare specific plans for communication to other team members based on their own assessment
Capacity for medical decision making*	Within days of admission and then whenever changes in status occur	Determine which types of medical decisions the resident is capable of participating in A resident who is still capable of making decisions independently should be encouraged to identify a surrogate decision maker in the event the resident later loses this decision-making capacity If the resident lacks capacity for many or all decisions, appropriate surrogate decision makers should be identified (if not already done)	Residents with varying degrees of dementia may still be capable of participating in many decisions regarding their medical care Attention should be given to potentially reversible factors that can interfere with decision-making capacity (eg, depression, fear, delirium, metabolic and drug effects) Concerns of the family and health professional should be considered, but the resident's desires should be paramount The resident's capacity may fluctuate over time because of physical and emotional conditions
Preferences regarding treatment intensity* and nursing home routines	Within days of admission and periodically thereafter	Determine resident's wishes as to the intensity of treatment he or she would want in the event of acute or chronic progressive illness	Attempt to identify specific procedures the resident would or would not want This assessment is often made by ascertaining the resident's prior expressed wishes (if known), or through surrogate decision makers (legal guardian, durable power of attorney for health care, family)

*See Table 16-7 and Chapter 17.

problems (eg, restricted mobility, incontinence, wandering, diminished food intake, poor social interaction), goals for the resident related to the problem, approaches to achieving these goals, target dates for achieving the goals, and assignment of responsibilities for working toward the goals among the various disciplines. These care plans are an important force in driving nursing staff behavior and expectations and should be reviewed by the primary physician.

Staffing limitations in relation to the amount of time and effort required makes intensive interdisciplinary care planning and teamwork unrealistic in many nursing homes. Although physicians are seldom directly involved in the care-planning meetings in most facilities, they are generally required to review and sign the care plan, and may find the team's perspective very valuable in planning subsequent medical care.

The general pressure for better documentation of care and assessments should provide a welcome improvement in the quality of care for nursing home residents. Federal and state regulations, as well as evolving guidance to surveyors, will inevitably mean that physicians will be asked to make more detailed clinical notes, especially with respect to indicating the underlying reasons for their actions. Electronic health records specific for nursing homes (typically closely linked to the MDS assessments) are now widely available, and some contain thorough documentation templates that both provide decision support and efficiently improve the clarity and detail of documentation.

STRATEGIES TO IMPROVE MEDICAL CARE IN NURSING HOMES

Better medical care of nursing home residents should lead to fewer serious problems and hence to lower use of emergency rooms and hospitals (Ouslander and Berenson, 2011). Several strategies might improve the process of medical care delivered to nursing home residents. Four strategies are briefly described: (1) the use of improved documentation practices; (2) a systematic approach to screening, health maintenance, and preventive practices for the frail, dependent nursing home population; (3) the use of nurse practitioners or physician assistants; and (4) the use of practice guidelines and related quality improvement activities.

In addition to these strategies, strong leadership of a medical director who is appropriately trained and dedicated to improving the facility's quality of medical care is essential to develop, implement, and monitor policies and procedures for medical services. Certification through the American Medical Directors Association should be encouraged (<http://www.amda.com>). The medical director should set standards for medical care and serve as an example to the medical staff by caring for some of the residents in the facility. He/she should also be involved in various committees (eg, quality, infection control) and should try to involve interested medical staff in these committees, as well as in educational efforts through formal in-service presentations, teaching rounds, and appropriate documentation procedures. Quality indicators, developed through literature review and expert consensus, can be used to track improvements in medical and overall care in the nursing home setting (Saliba and Schnelle, 2002; Saliba et al., 2004; Saliba et al., 2005). Medical directors should use these indicators and other approaches (eg, Kane, 1998; Mor, 2006) in their quality improvement programs.

Documentation Practices

As mentioned earlier, electronic health records specific for nursing homes are now widely available, and when used properly, they can greatly improve clinical documentation. However, currently these records are not linked to physicians' electronic records. Nursing home residents often have multiple coexisting medical problems and long previous medical histories. Residents often cannot relate their medical histories, and their previous medical records are frequently unavailable or incomplete. There is also a danger in perpetuating old diagnoses that are inaccurate. This is especially true for psychiatric diagnoses, but may also occur for other medical diagnoses such as congestive heart failure and stroke. Thus, it is difficult and sometimes impossible to obtain a comprehensive medical database. The effort should, however, be invested and not wasted. Critical aspects of the medical database should be recorded on one page or face sheet of the medical record.

Figure 16-2 shows an example of a format for a face sheet. Additional standardized documentation should contain social information, such as individuals to contact at critical times and information about the resident's treatment status in the event of acute illness. These data are essential to the care of the resident and should be readily available in one place in the record, so that when emergencies arise, when medical consultants see the resident, or when members of the interdisciplinary team need an overall perspective, they are easy to locate. The face sheet should be copied and sent to the hospital or other health-care facilities to which the resident might be transferred. Time and effort are required to keep the face sheet updated. Electronic health records can facilitate incorporating the face sheet into a database and periodic updating.

Medical documentation in progress notes for routine visits and assessments of acute changes is frequently scanty, uninformative, and/or illegible. Statements such as "stable" or "no change" are too frequently the only documentation for routine visits. While time constraints may preclude extensive notes, certain standard information should be documented. The SOAP (subjective, objective, assessment, plan) format for charting routine notes is especially appropriate for nursing home residents (Table 16-5). Simple forms, flow sheets, or databases with word-processing capabilities can be used to enable physicians to efficiently produce legible, concise, yet comprehensive progress notes. Another tool for documenting change in residents over time is the benchmark approach using flow sheets (see Chapter 4).

Another area where medical documentation is often inadequate relates to the residents' decision-making capacity and treatment preferences. These issues are discussed briefly at the end of this chapter as well as in Chapter 17. In addition to placing critical information in a standardized format in readily accessible locations, it is essential that physicians thoroughly and legibly document all discussions they have had with the resident, family, or legal guardians; they must also document any durable power of attorney for health care about these issues. Failure to do so may result not only in poor communication and inappropriate treatment, but also in substantial legal liability. Notes about these issues should not be removed from the medical record and are probably best kept on a separate page behind the face sheet.

MEDICAL FACE SHEET											
<p style="text-align: center; margin-bottom: 10px;">ACTIVE MEDICAL PROBLEMS</p> <p>1. _____</p> <p>2. _____</p> <p>3. _____</p> <p>4. _____</p> <p>5. _____</p> <p>6. _____</p> <p>7. _____</p> <p>8. _____</p>	<p style="text-align: center; margin-bottom: 10px;">NEUROPSYCHIATRIC STATUS</p> <p>A. Dementia <input type="checkbox"/> Absent <input type="checkbox"/> Present</p> <p style="padding-left: 40px;">If present:</p> <p style="padding-left: 40px;"><input type="checkbox"/> Alzheimer <input type="checkbox"/> Mixed</p> <p style="padding-left: 40px;"><input type="checkbox"/> Multi-infarct <input type="checkbox"/> Uncertain/Other</p> <p>B. Psychiatric/behavioral disorders</p> <p>1. _____</p> <p>2. _____</p> <p>C. Usual mental status</p> <p style="padding-left: 20px;"><input type="checkbox"/> Alert, oriented, follows simple instructions</p> <p style="padding-left: 20px;"><input type="checkbox"/> Alert, <i>disoriented</i>, but <i>can</i> follow simple directions</p> <p style="padding-left: 20px;"><input type="checkbox"/> Alert, <i>disoriented</i>, <i>cannot</i> follow simple directions</p> <p style="padding-left: 20px;"><input type="checkbox"/> Not alert (lethargic, comatose)</p> <p>D. Most recent Mini Mental State Score</p> <p style="padding-left: 20px;">____/30 (Date ____ / ____ / ____)</p>										
<p style="text-align: center; margin-bottom: 10px;">PAST HISTORY</p> <p>A. Acute hospitalizations since admission to JHA</p> <table border="0" style="width: 100%;"> <thead> <tr> <th style="text-align: center; width: 40%;">Diagnoses</th> <th style="text-align: center; width: 20%;">Month/Year</th> </tr> </thead> <tbody> <tr> <td>1. _____</td> <td>____ / ____</td> </tr> <tr> <td>2. _____</td> <td>____ / ____</td> </tr> <tr> <td>3. _____</td> <td>____ / ____</td> </tr> <tr> <td>4. _____</td> <td>____ / ____</td> </tr> </tbody> </table>		Diagnoses	Month/Year	1. _____	____ / ____	2. _____	____ / ____	3. _____	____ / ____	4. _____	____ / ____
Diagnoses	Month/Year										
1. _____	____ / ____										
2. _____	____ / ____										
3. _____	____ / ____										
4. _____	____ / ____										

FIGURE 16-2 Example of a face sheet for a nursing home record.

B. Major surgical procedures <i>before</i> admission to JHA		A. Ambulation		D. Vision	
Procedure	Year	___ Unassisted		___ Adequate for regular print	
1. _____	_____	___ With cane		___ Impaired—can see large print	
2. _____	_____	___ With walker		___ Highly impaired—but can get around	
3. _____	_____	___ Unable		___ Severely impaired—has difficulty getting around	
4. _____	_____	Transfer: ___ Ind ___ Dep			
C. Allergies		B. Continenence		E. Hearing	
		Cont	Inc		
		Urine	___	___ Adequate	
		Stool	___	___ Minimal difficulty	
1. _____		C. Basic ADL		___ Hears only w/amplifier	
		Ind	Dep	___ Highly impaired—no useful hearing	
2. _____		Bathing	___		
		Dressing	___		
		Grooming	___		
		Feeding	___		
<u>TREATMENT STATUS</u> (See treatment Status Sheet Note Date ___/___/___)					
___ Full code		___ DNR		___ DNR, do no hospitalize	
				___ No tube feeding	
This form completed by _____ Date ___/___/___					

FIGURE 16-2 (Continued)

TABLE 16-5. SOAP Format for Medical Progress Notes on Nursing Home Residents

Subjective	New complaints Symptoms related to active medical conditions
Objective	General appearance and mood Weight Vital signs Physical findings relevant to new complaints and active medical conditions Laboratory data Reports from nursing staff Progress in rehabilitative therapy (if applicable) Reports of other interdisciplinary team members Consultant reports
Assessment	Presumptive diagnosis(es) for new complaints or changes in status Stability of active medical conditions Responses to psychotropic medications (if applicable)
Plans	Changes in medications or diet Nursing interventions (eg, monitoring of vital signs, skin care) Assessments by other disciplines Consultants Laboratory studies Discharge planning (if relevant)

All of these recommendations can and should be incorporated into electronic medical records as nursing homes increasingly begin to use health information technology.

■ **Screening, Health Maintenance, and Preventive Practices**

A second approach to improving medical care in nursing homes is developing and implementing selected screening, health maintenance, and preventive practices. [Table 16-6](#) lists examples of such practices. With few exceptions, the efficacy of these practices has not been well studied in the nursing home setting. In addition, not all the practices listed in this table are relevant for every nursing home resident. For example, some of the annual screening examinations are inappropriate for short-term residents or for many long-term residents with end-stage dementia (see Fig. 16-1). Thus, the practices outlined in Table 16-6 must be tailored to the specific nursing home population, as well as for the individual resident, and must be creatively incorporated into routine care procedures as much as possible to be time-efficient, cost-effective, and reimbursable by Medicare.

■ **Nurse Practitioners and Physician Assistants**

A third strategy that may help to improve medical care in nursing homes is making greater use of nurse practitioners and physician assistants. This approach appears to

TABLE 16-6. Screening, Health Maintenance, and Preventive Practices in the Nursing Home

Practice	Recommended frequency*	Comment
Screening		
History and physical examination	Yearly	Focused examination including rectal, breast, and, in some women, pelvic examination
Weight	Monthly	Generally required Persistent weight loss should prompt a search for treatable medical, psychiatric, and functional conditions
Functional status assessment, including gait and mental status testing and screening for depression†	Yearly	Functional status assessed periodically by nursing staff using the Minimum Data Set (MDS) Systematic global functional assessment done at least yearly using MDS to detect potentially treatable conditions (or prevent complications) such as early dementia, depression, gait disturbances, urinary incontinence
Visual screening	Yearly	Assess acuity, intraocular pressure, identify correctable problems
Auditory	Yearly	Identify correctable problems
Dental	Yearly	Assess status of any remaining teeth, fit of dentures, and identify any pathology
Podiatry	Yearly	More frequently in diabetics and residents with peripheral vascular disease Identify correctable problems and ensure appropriateness of shoes
Tuberculosis	On admission and yearly (may vary by state)	All residents and staff should be tested Booster testing recommended for nursing home residents (see text)

(Continued)

TABLE 16-6. Screening, Health Maintenance, and Preventive Practices in the Nursing Home (*Continued*)

Practice	Recommended frequency*	Comment
Laboratory tests Stool for occult blood Complete blood count Fasting glucose Electrolytes Renal function tests Albumin, calcium, phosphorus Thyroid function tests (including thyroid-stimulating hormone level)	Yearly	These tests have reasonable yield in the nursing home population
Monitoring in selected residents		
All residents Vital signs, including weight	Monthly	More often if unstable or subacutely ill
Diabetes Fasting and postprandial glucose, glycosylated hemoglobin A1c (HbA1c)	Every 1-2 months when stable (fasting) Every 4-6 months (HbA1c)	Fingerstick tests may be useful, but should not be overused for stable residents
Residents on diuretics or with renal insufficiency (creatinine >2 or blood urea nitrogen [BUN] >35): electrolytes, BUN, creatinine	Every 2-3 months	Nursing home residents are more prone to dehydration, azotemia, hyponatremia, and hypokalemia
Anemic residents who are on iron replacement or who have hemoglobin <10: hemoglobin/hematocrit	Monthly until stable, then every 2-3 months	Iron replacement and/or erythropoietin should be discontinued once hemoglobin value stabilizes

(Continued)

TABLE 16-6. Screening, Health Maintenance, and Preventive Practices in the Nursing Home (*Continued*)

Practice	Recommended frequency*	Comment
Blood level of drug for residents on specific drugs, for example: Anticonvulsants Digoxin Lithium	Every 3-6 months	More frequently if drug treatment has just been initiated
Prevention		
Influenza vaccine	Yearly	All residents and staff with close resident contact should be vaccinated
Oseltamivir, zanamivir	Within 24-48 hours of outbreak of suspected influenza	Residents and staff should be treated throughout outbreak
Zoster vaccination	Once	Selected residents
Pneumococcal/ pneumonia bacteremia Pneumococcal vaccine	Once	
Tetanus booster	Every 10 years, or every 5 years with tetanus-prone wounds	Many older people have not received primary vaccinations; they require tetanus toxoid, 250-500 units of tetanus immune globulin, and completion of the immunization series with toxoid injection 4-6 weeks later and then 6-12 months after the second injection
Tuberculosis Isoniazid 300 mg/ day for 9-12 months	Skin-test conversion in selected residents	Residents with abnormal chest film (more than granuloma), diabetes, end-stage renal disease, hematological malignancies, steroid or immunosuppressive therapy, or malnutrition should be treated
Antimicrobial prophylaxis for residents at risk	Generally recommended for dental procedures, genitourinary procedures, and most operative procedures	Chronically catheterized residents should not be treated with continuous prophylaxis

(Continued)

TABLE 16-6. Screening, Health Maintenance, and Preventive Practices in the Nursing Home (*Continued*)

Practice	Recommended frequency*	Comment
Body positioning and range of motion for immobile residents	Ongoing	Frequent turning of very immobile residents is necessary to prevent pressure sores Semiupright position is necessary for residents with swallowing disorders or enteral feeding to help prevent aspiration Range of motion to immobile limbs and joints is necessary to prevent contractures
Infection-control procedures and surveillance	Ongoing	Policies and protocols should be in effect in all nursing homes Surveillance of all infections should be continuous to identify outbreaks and resistance patterns
Environmental safety	Ongoing	Appropriate lighting, colors, and the removal of hazards for falling are essential in order to prevent accidents Routine monitoring of potential safety hazards and accidents may lead to alterations that may prevent further accidents

*Frequency may vary depending on resident’s condition. Not all recommendations are relevant to every resident.

†The MDS can be supplemented by various standardized tools (see Chapter 3).

be cost-effective in both managed care and fee-for-service settings (Ackerman and Kemle, 1998; Burl et al., 1998; Reuben et al., 1999; Kane et al., 2003; Konerzka, Spector, and Limcangco, 2008). These health professionals may be especially helpful in carrying out specific functions in the nursing home setting. Physician assistants and nurse practitioners can bill for services under fee-for-service Medicare; moreover, several states will reimburse their services, and individual facilities and/or physician groups can hire them on a salaried basis. Evercare is a managed care program for long-stay nursing home residents that uses a nurse practitioner–based model of care and is available in several states. Nurse practitioners may have an especially helpful perspective in interacting with nursing staff about the nonmedical aspects of care for nursing home residents. Nurse practitioners and physician assistants can be very helpful in implementing some of the screening, monitoring, and preventive

practices outlined in Table 16-6 and in communicating with interdisciplinary staff, families, and residents at times when the physician is not in the facility. One of the most appropriate roles for nurse practitioners and physician assistants is in the initial assessment of acute or subacute changes in resident status. They can perform a focused history and physical examination and can order appropriate diagnostic studies. Several care paths have been developed for this purpose, one of which is shown in Figure 16-3. The use of a similar algorithm for pneumonia resulted in reduced hospitalizations and related costs in 22 Canadian nursing homes (Loeb et al., 2006). This strategy enables the onsite assessment of acute change, the detection and treatment of new problems early in their course, more appropriate utilization of acute-care hospital emergency rooms, and the rapid identification of residents who need to be hospitalized.

■ Clinical Practice Guidelines and Quality Improvement Activities


Several clinical practice guidelines relevant to nursing home care have been developed by the American Medical Directors Association (<http://www.amda.com>). In addition, quality indicators for a number of conditions have been developed (Saliba et al., 2004). While these guidelines and quality indicators are largely based on expert opinion rather than on controlled clinical trials, they are helpful as a basis for standards of practice that will improve care. Implementation and maintenance of practice guidelines can be difficult in nursing homes, as it is in other practice settings (Schnelle et al., 1997; Saliba et al., 2005).

Clinical practice guidelines can be useful tools in an overall quality improvement program. Nursing homes are required to have an ongoing quality assurance committee, and as mentioned earlier, there will be a new regulation requiring a QAPI program in the near future. One effective approach is based on principles of total quality management or continuous quality improvement (CQI) (Schnelle et al., 1993). These approaches use front-line staff to monitor objective outcomes (eg, frequency of falls, severity of incontinence, adverse drug reactions, and skin problems) and to identify work processes that can be modified to continuously improve these outcomes. Nursing home administrators, directors of nursing, and medical directors must create an environment that provides incentives for ongoing CQI activities to maintain these programs over time. The Medicare Quality Improvement Organization program and the American Medical Directors Association and its journal (*Journal of the American Medical Directors Association*) have substantial resources for assisting nursing home providers with quality improvement initiatives. In addition, CMS will be providing educational resources and tools for nursing homes to help them meet the QAPI requirement.

POSTACUTE CARE AND THE NURSING HOME—ACUTE-CARE HOSPITAL INTERFACE

The increasing acuity of nursing home residents, a high incidence of acute conditions, and the need for high levels of skilled postacute care will continue to place increased demands on nursing homes. Health maintenance organizations commonly

CARE PATH
Fever



*Refer also to the other INTERACT Care Paths as indicated by symptoms and signs

©2011 Florida Atlantic University, all rights reserved. This document is available for clinical use, but may not be resold or incorporated in software without permission of Florida Atlantic University.

FIGURE 16-3 Example of an INTERACT VERSION 3.0 care path for managing acute change in condition in a nursing home. ADL, activity of daily living; BP, blood pressure; C&S, culture and sensitivity; HR, heart rate; IV, intravenous; NP, nurse practitioner; PA, physician assistant; WBC, white blood cell.

admit patients with acute but relatively stable conditions (eg, deep vein thrombosis, cellulitis) directly to nursing homes without an acute hospital stay. As a result, nursing homes are providing more and more high-level skilled care. The term *postacute care* has many connotations; for the purposes of this chapter, it refers to skilled care reimbursed by Medicare Part A (or by a capitated system) in a free-standing nursing home. Caring for patients in a free-standing nursing home who are recovering from an acute illness and hospitalization intensifies many of the challenges already alluded to in this chapter (see Table 16-2). This level of care requires greater involvement of physicians, nurse practitioners, and physician assistants; nursing staff trained for more acute patients; ready availability of ancillary services such as laboratory, x-ray, and physical and respiratory therapy; and more intensive discharge planning. Moreover, Medicare reimbursement for Part A services is “bundled,” so that nursing homes are at financial risk for services ordered by medical staff, including drugs, laboratory tests, x-rays, and therapies. This reimbursement structure requires close cooperation between physicians and nursing home administrators to make this form of subacute care economically viable.

As a result of the increasing acuity and frailty of the nursing home resident population, transfer back and forth between the nursing home and one or more acute-care hospitals is common. About one in four nursing home residents admitted from a hospital are readmitted to the hospital within 30 days (Mor et al., 2010). The major reasons for transfer include infection and the need for parenteral antimicrobials and hydration as well as acute cardiovascular conditions. Transfer to an acute-care hospital is often a disruptive process for a chronically or subacutely ill nursing home resident and is especially hazardous for nursing home residents with dementia (Gozalo et al., 2011). In addition to the effects of the acute illness, nursing home residents are subject to acute mental status changes and a myriad of potential iatrogenic problems. The most prevalent of these iatrogenic problems are related to immobility, including deconditioning, difficulty regaining ambulation and/or transfer capabilities, incontinence and catheter use, polypharmacy, delirium, and the development of pressure sores.

Because of the risks of acute-care hospitalization, the decision to transfer a resident to the emergency room or hospitalize a resident must carefully balance a number of factors. A variety of medical, administrative, logistic, economic, and ethical issues can influence decisions to hospitalize nursing home residents. Decisions regarding hospitalization often boil down to the capabilities of the physician and the nursing home staff to provide services in the nursing home, the preferences of the resident and the family, and the logistic and administrative arrangements for acute hospital care. If, for example, the nursing home staff has been trained and has the personnel to institute intravenous therapy without detracting from the care of the other residents, or if it has arranged for an outside agency to oversee intravenous therapy and there is a nurse practitioner or physician assistant to perform follow-up assessments, the resident with an acute infection who is otherwise medically stable may best be managed in the nursing home. Hypodermoclysis may be helpful in preventing some acute-care transfers (Remington and Hultman, 2007). Better advance care planning and

advance directive use can also help to avoid unnecessary hospitalization of severely impaired nursing home residents (Molloy et al., 2000).

As a result of the Patient Protection and Affordable Care Act, multiple health-care reform initiatives are under way in the United States to reduce unnecessary transfers of nursing home residents to hospitals, with a particular focus on potentially preventable hospital readmissions (Ouslander and Berenson, 2011). Changes in Medicare payment, such as bundled payments and the development of accountable care organizations that include postacute care, will provide potent financial incentives for better coordinated care at the nursing home–hospital interface. Savings from such programs can be shared with providers to make further improvements in care. Expansion of the Program of All-Inclusive Care of the Elderly or statewide programs for dually eligible Medicare and Medicaid beneficiaries will also incentivize better transitional care and will address the problematic cost-shifting that currently occurs between the Medicare and Medicaid programs.

The American Medical Directors Association has developed a clinical practice guideline and related tools on care transitions (<http://www.amda.com/tools/clinical/TOCCPG/index.html>), and a quality improvement program (Interventions to Reduce Acute Care Transfers [INTERACT]) with related educational resources and tools has been developed and shown promise in reducing unnecessary hospital transfers (<http://interact2.net>) (Ouslander et al., 2011). The INTERACT program uses three basic strategies to improve the management of acute changes in condition and prevent unnecessary hospital transfers: (1) proactive identification of conditions before they become severe enough to require hospital care (eg, dehydration, delirium); (2) management of some conditions (eg, pneumonia, congestive heart failure) without transfer when safe and feasible; and (3) improving advance care planning to consider palliative or comfort care as an alternative when the risks of hospitalization may outweigh the benefits.

ETHICAL ISSUES IN NURSING HOME CARE

Ethical issues arise as much or more in the day-to-day care of nursing home residents as in the care of patients in any other setting. These issues are discussed in Chapter 17. [Table 16-7](#) outlines several common ethical dilemmas that occur in the nursing home. Although most attention has been directed toward those marginally able to express their preferences, important daily ethical dilemmas also face those who are capable of decision making. These more subtle problems are easily overlooked. Physicians, nurse practitioners, and physician assistants providing primary care must serve as strong advocates for the autonomy and quality of life of nursing home residents.

Nursing homes care for a high concentration of individuals who are unable or questionably capable of participating in decisions concerning their current and future health care. Among these individuals, severe functional disabilities and terminal illnesses are prevalent. Thus, questions regarding individual autonomy, decision-making capacity, surrogate decision makers, and the intensity of treatment that

TABLE 16-7. Common Ethical Issues in the Nursing Home*

Ethical issue	Examples
Preservation of autonomy	Choices in many areas are limited in most nursing homes (eg, mealtimes, sleeping hours) Families, physicians, and nursing home staff tend to be paternalistic
Decision-making capacity	Many nursing home residents are incapable or questionably capable of participating in decisions about their care There are no standard methods of assessing decision-making capacity in this population
Surrogate decision making	Many nursing home residents have not clearly stated their preferences or appointed a surrogate before becoming unable to decide for themselves Family members may be in conflict, have hidden agendas, or be incapable of or unwilling to make decisions
Quality of life	This concept is often entered into decision making, but it is difficult to measure, especially among those with dementia Ageist biases can influence perceptions of nursing home residents' quality of life
Intensity of treatment	A range of options must be considered, including cardiopulmonary resuscitation and mechanical ventilation, hospitalization, treatment of specific conditions (eg, infection) in the nursing home without hospitalization, enteral feeding, comfort, or supportive care only

*See also Chapters 17 and 18.

should be given at the end of life arise on a daily basis. These questions are both troublesome and complex, but they must be dealt with in a straightforward and systematic manner to provide optimal medical care to nursing home residents within the context of ethical principles and state and federal laws. Nursing homes should be encouraged to develop their own ethics committees or to participate in a local existing committee in another facility. Ethics committees can be helpful in educating staff; developing, implementing, and monitoring policies and procedures; and providing consultation in difficult cases. Some practical methods of approaching ethical issues are discussed in Chapter 17, and palliative care is discussed in Chapter 18.

REFERENCES

Ackerman RJ, Kemle KA. The effect of a physician assistant on the hospitalization of nursing home residents. *J Am Geriatr Soc.* 1998;46:610-614.
Burl JB, Bonner A, Rao M, et al. Geriatric nurse practitioners in long-term care: demonstration of effectiveness in managed care. *J Am Geriatr Soc.* 1998;46:506-510.
Gozalo P, Teno JM, Mitchell SM, et al. End-of-life transitions among nursing-home residents with cognitive issues. *N Engl J Med.* 2011;365:1212-1221.

- Institute of Medicine. *Improving the Quality of Care in Nursing Homes*. Washington, DC: National Academy Press; 1986.
- Institute of Medicine. *Improving the Quality of Nursing Home Care*. Washington, DC: National Academy Press; 2000.
- Kane RL. Assuring quality in nursing home care. *J Am Geriatr Soc*. 1998;46:232-237.
- Kane RL, Keckhafer G, Flood S, et al. The effect of Evercare on hospital use. *J Am Geriatr Soc*. 2003;51: 1427-1434.
- Konetzka RT, Spector W, Limcangco RM. Reducing hospitalizations from long-term care settings. *Med Care Res Rev*. 2008;65:40-66.
- Loeb M, Carusone SC, Goeree R, et al. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. *JAMA*. 2006;295:2503-2510.
- Molloy DW, Guyatt GH, Russo R, et al. Systematic implementation of an advance directive program in nursing homes: a randomized controlled trial. *JAMA*. 2000;283:1437-1444.
- Mor V. Defining and measuring quality outcomes in long-term care. *J Am Med Dir Assoc*. 2006;7:532-540.
- Mor V, Intrator I, Feng V, et al. The revolving door of hospitalization from skilled nursing facilities. *Health Aff*. 2010;29:57-64.
- Ouslander JG, Berenson RA. Reducing unnecessary hospitalizations of nursing home residents. *N Engl J Med*. 2011;365:1165-1167.
- Ouslander JG, Lamb G, Tappen R, et al. Interventions to reduce hospitalizations from nursing homes: evaluation of the INTERACT II Collaborative Quality Improvement Project. *J Am Geriatr Soc*. 2011;59: 745-753.
- Remington R, Hultman T. Hypodermoclysis to treat dehydration: a review of the evidence. *J Am Geriatr Soc*. 2007;55:2051-2055.
- Reuben D, Buchanan J, Farley D, et al. Primary care of long-stay nursing home residents: a comparison of 3 HMO programs with fee-for-service care. *J Am Geriatr Soc*. 1999;47:131-138.
- Saliba D, Schnelle JF. Indicators of the quality of nursing home residential care. *J Am Geriatr Soc*. 2002;50:1421-1430.
- Saliba D, Solomon D, Rubenstein L, et al. Quality indicators for the management of medical conditions in nursing home residents. *J Am Med Dir Assoc*. 2004;5:297-309.
- Saliba D, Solomon D, Rubenstein L, et al. Feasibility of quality indicators for the management of geriatric syndromes in nursing home residents. *J Am Med Dir Assoc*. 2005;6:S50-S59.
- Schnelle J, Ouslander JG, Cruise PA, et al. Policy with technology: a barrier to improving nursing home care. *Gerontologist*. 1997;37:527-532.
- Schnelle JF, Ouslander JG, Osterweil D, et al. Total quality management: administrative and clinical applications in nursing homes. *J Am Geriatr Soc*. 1993;41:1259-1266.
- Stevenson DG, Studdert DM. The rise of nursing home litigation: findings from a national survey of attorneys. *Health Aff*. 2003;22:219-229.

SUGGESTED READINGS

- American Medical Directors Association. *Health Maintenance in the Long Term Care Setting Clinical Practice Guideline*. Columbia, MD: American Medical Directors Association; 2012.
- Casarett D, Karlawish J, Morales K, et al. Improving the use of hospice services in nursing homes. *JAMA*. 2005;294:211-217.
- Osterweil D (ed). Medical directors role in nursing home quality improvement: an educational symposium of the New York Medical Directors Association. *J Am Med Dir Assoc*. 2007;3(Suppl):1-41.

- Ouslander J, Osterweil D, Morley J. *Medical Care in the Nursing Home*. 2nd ed. New York, NY: McGraw-Hill; 1996.
- Stefanacci RG, Podrazik PM. Assisted living facilities: optimizing outcomes. *J Am Geriatr Soc*. 2005;53: 538-540.
- Vladek B. *Unloving Care: The Nursing Home Tragedy*. New York, NY: Basic Books; 1980.

SELECTED WEBSITES (ACCESSED SEPTEMBER 15, 2012)

- American Health Care Association (<http://www.ahcancal.org>)
- American Medical Directors Association (<http://www.amda.com>)
- Interventions to Reduce Acute Care Transfers (INTERACT) (<http://interact2.net>)
- Leading Age (<http://www.leadingage.org>)
- Long-Term Care Focus (<http://ltcfocus.org>)
- National Association of Directors of Nursing Administration (<http://www.nadona.org>)
- Nursing Home Regulations Plus (<http://www.hpm.umn.edu/nhregsplus>)

This page intentionally left blank

CHAPTER 17

Ethical Issues in the Care of Older Persons

Ethics is a fundamental part of geriatrics. Ethics, or the provision of ethical care, refers to a framework or guideline for determining what is morally good (ie, right) or bad (ie, wrong). Ethical problems arise when there is conflict about what is the “right” thing to do. This dilemma generally occurs when decisions need to be made whether or not a medical intervention should be implemented and whether or not the intervention is futile. The answers to ethical questions are not straightforward; they involve a complex integration of thoughts, feelings, beliefs, and evidence-based data. Ageism can play a strong role in these decisions. Acknowledging and acting on the wishes of the older individual are a critical component of ethical care.

While ethical dilemmas are central to the practice of medicine itself, the dependent nature of the older adult and the imminence of death raise special concerns. Discussions of ethics and aging seem to focus on the roles of autonomy and cost containment, since a significant portion of the cost of delivering health care is incurred at the end of life.

AUTONOMY AND BENEFICENCE

Table 17-1 provides a description of major ethical principles. The ethics of medicine is based on four principles: autonomy, beneficence, nonmaleficence, and justice, which are geared toward maximizing benefits over harm and doing the greatest good for the greatest number. *Autonomy* refers to one’s right to control one’s destiny, that is, to exert one’s will. Obviously, there are limits to how freely such control can be expressed, but for geriatric purposes the principal issue revolves around whether the patient is able to assess the situation and make a rational decision independently. This raises the second concept, *beneficence*, which refers to the duty to do good for others, to help them directly, and to avoid harm. *Nonmaleficence* involves doing no harm and avoiding negligence that leads to harm. Lastly, *justice* focuses on fairness in the treatment of others.

The principles of autonomy and beneficence (doing good and putting others’ interests first) conflict when others act in the “best interests” of the older individual. Clinicians can sometimes become paternalistic and undermine the personal autonomy of the individual. If acting in the older individuals’ “best interests” is consistent with the greater good of the community, then overriding autonomy is justified.

The challenge then comes down to several fundamental issues:

- 1. Is the patient capable of understanding the dilemma?
- 2. Is the patient able to express a preference?

TABLE 17-1. Major Ethical Principles

Goal of ethical Care

Voiding or minimizing harms and maximizing benefits. The concern and focus should be on preserving and respecting personhood. This is done through recognition of wants, collaboration, play, validating, facilitation, and giving. At the same time, ethics must recognize and deal with competition between organizational/ community interests vs. individual interests

Autonomy

Refers to one's right to control one's destiny, that is, to exert one's will. The principal issue revolves around whether the older adult is able to assess the situation and make a rational decision independently

Beneficence

Refers to the duty to do good for others, and specifically to avoid harm in the process

Nonmaleficence

Involves doing no harm and avoiding negligence that leads to harm. Lastly, justice focuses on fairness in the treatment of others

Justice

Justice focuses on nondiscrimination and the duty to treat individuals fairly; not to discriminate on the basis of irrelevant characteristics. This involves a duty to distribute resources fairly, nonarbitrarily, and noncapriciously

Fidelity

Duty to keep promises

3. Are there clear options? Have they been made clear?
4. Has the patient received accurate information about the benefits and risks of the options?
5. Are the patient's expectations realistic with regard to treatment decisions?
6. What happens when the patient's preferences are contrary to the preferences of their family or the physician?

COMPETENCE AND INFORMED CONSENT

In the case of older adults, much of the concern is directed toward the issue of whether or not the individual can understand, and remember, the information being provided and whether or not he or she can express an opinion. Individuals who are comatose or who have expressive or receptive aphasia or moderate to severe dementia may not be able to communicate effectively. It is important to preserve autonomy and assess these individuals carefully for what they can understand and communicate.

There is an important difference between the concepts of competence and decision-making capability. A clinician may evaluate a patient's capacity to make decisions, but *competence* is a legal term that implies that the individual has been deemed competent or incompetent by a court of law. Competence refers to a person's ability to act reasonably after understanding the nature of the

situation being faced. Someone not competent to act on his or her own behalf requires an agent to act *for* them.

In the case of dementia, persons may or may not be capable of understanding and interpreting complex situations and making rational decisions. Intellectual deficits are spotty. A person may get lost easily or forget things but still be able to make decisions with appropriate prompting. The presence of a formal diagnosis of dementia, even by type, may not be a sufficient indicator of the individual's ability to comprehend and express a meaningful preference. Just as it is wrong to infantilize such patients by directing questions to others who are quicker to respond, so, too, might it be inappropriate to prejudge their ability to participate in decisions about their own care.

Determining cognitive ability and decision-making capacity is not easy. One must distinguish memory from understanding. Decisional capacity is predicated on four elements: (1) understanding, or the ability to comprehend the disclosed information about the nature of the situation/medical problem, the procedures involved in testing for example, and the risks and benefits of undergoing or not undergoing testing or treatment; (2) appreciation of the significance of the disclosed information and the potential risks and benefits for one's own situation and condition; (3) reasoning, which involves the ability to engage in a reasoning process about the risks and benefits of a procedure or treatment; and (4) choice, or being able to choose whether or not to undergo further testing or treatment.

No cognitive screening tests are appropriate to determine residents' decision-making capacity. Screening tools that focus on executive function such as the Clock Drawing Test or the Executive Interview are more likely to be associated with decisional capacity than other measures such as the Mini-Mental State Examination (see Chapter 6). Specific tests have been developed to determine decisional capacity, but these are generally difficult for older adults to complete because they require consideration of hypothetical situations and complex abstract thinking.

One useful and practical criterion for decision making, often used when completing an informed consent process with a resident, is to recheck with the patient after a period of time to be certain that he or she understands the situation and consistently states preferences related to a specific care situation. Depending on the setting of care, this may or may not be practical. Ideally, the decision-making process should be structured to allow the individual (and perhaps the family) to review all possible options, understand the risks and benefits associated with each, and identify which outcomes (from a large menu) they would like to achieve. In geriatrics, however, evidence-based information is typically less available to inform the individual. For example, the impact of a chemotherapeutic agent in a 50-year-old patient in terms of efficacy, side effect profile, and risk will not be the same as it is in a 90-year-old patient. Moreover, treatment options are often not clear-cut in terms of cost/benefit for the older individual, and clinicians may make decisions about which studies or findings to report to the individual in any given situation.

Although different in nature from treatment-related decisions (eg, surgery), decisions about transitions to alternative levels of care require the same level of serious attention accorded to those about treatments. Other members of the health-care

team, such as social workers or nurse case managers, may be the best at delineating the choices and implications of such moves, and older individuals should be referred to these individuals as appropriate. Specific information that needs to be presented includes cost and cost-based alternatives, privacy issues, safety, social issues, and access to appropriate health care.

ADVANCE CARE PLANNING

Advance care planning involves helping patients begin to think about their priorities, beliefs, and values and how they want to be cared for in the face of persistent chronic illnesses and at the end of life. Topics to address include such things as whether they want to receive cardiopulmonary resuscitation, whether they want to be on a respirator, and whether they want to receive intravenous hydration or artificial nutrition, blood transfusions, organ or tissue donation, or medical devices. Other topics to include might be whether they want to get transferred to an acute-care setting for aggressive interventions, what type of funeral or memorial service they want, and whether they want to be buried or cremated. Additional information is also provided in Chapter 18.

ADVANCE DIRECTIVES

There have been significant initiatives (eg, federal laws) intended to encourage health-care facilities and clinicians, including attending physicians, to discuss with older persons their preferences in an advance directive (AD). An AD is a legal document that allows patients to convey their decisions about what type of care they want to receive in the event that they are unable to express their wishes. An important reason to encourage patients to complete their AD is that they begin to think about their care preferences prior to a crisis situation. ADs are helpful ways for patients to give direction and simplify the decision-making process. Moreover, they help an adult child feel confident, regardless of the child's own beliefs and desires, that he or she has done what the parent wanted at the end of the parent's life. In a same-sex relationship, an AD may be the only way in which a couple may be able to ensure who is the decision maker because the other may not have the rights of a spouse.

A living will is one way in which to express an AD. Specifically, a living will specifies care preferences when in a terminal state at the end of life. The living will is limited because it generally addresses specific clinical situations (vegetative states or terminal illness) and a few treatment options such as cardiopulmonary resuscitation, intubation, implementation of artificial food and hydration, dialysis, or intravenous use. Living wills provide a means to indicate that the patient prefers heroic measures not be initiated.

In geriatrics, however, it is helpful to carefully consider the many decisions that go into and are centered around care in end-of-life situations. Deciding when an antibiotic treatment might be life supporting versus comfort care is often difficult, and these types of decisions are not delineated in a living will. In contrast to the living will, an AD can be established that allows a health-care agent or proxy to make

medical decisions on the patient's behalf. A proxy is an individual authorized to act on the patient's behalf if that person is unable to communicate (ie, understand and express) his or her health-care preferences. This designation can be done by using a durable power of attorney, previously used to transfer control of property. States must specifically extend their durable power of attorney statutes to cover medical decisions. Under this approach, one can specify both the person one wish to act as agent and the conditions under which such a proxy should be exercised. **Table 17-2** shows the components of a durable power of attorney for health care. When the proxy is not certain exactly how the patient might respond in a given situation, the principle of beneficence can be used to guide decisions. The proxy can make medical decisions by weighing the benefits for the patient versus the burdens/risks that might be imposed on him or her to do nothing or to initiate, for example, a specific treatment (eg, excision of a lesion).

TABLE 17-2. Components of a Durable Power of Attorney for Health Care*

Creation of durable power of attorney for health care
Statement that gives intention and refers to statute(s) authorizing such
Designation of health-care agent
Statement naming and facilitating access to (address, telephone number) agent;
state laws will vary as to who may serve as agent—some states preclude providers
of health care or employees of institutions where care is given; person designated
as agent should have agreed to assume this role
General statement of authority granted
Statement about circumstances under which the agent is granted power and
indications of the power the agent will have in that event (usually a general
statement about right to consent or refuse or withdraw consent for care, treatment,
service or procedure, or release of information subject to any specific provisions
and limitations indicated)
Statement of desires, special provisions, and limitations
Opportunity to indicate general preferences (eg, wish not to have life prolonged if
burdens outweigh benefits; wish for life-sustaining treatment unless in coma that
physicians believe to be irreversible, then no such efforts; wish for all possible
efforts regardless of prognosis); opportunity for specific types of things wanted to be
done or not done and indications for such actions
Signatures
Individual dated signature
Witnesses (better notarized): witnesses cannot be those named as agents, providers
of health care, or employees of facilities giving such care
Conditions
Form should have place where person signing indicates awareness of rights,
including the right to revoke the document and the conditions under which the
document comes into force; some states require a mandatory maximum period
where such a document can be valid without renewal

*Many state medical associations can provide a copy of a basic form of a durable power of attorney for health care.

The establishment of ADs has been viewed as an effective way in which to spare older adults from unnecessary suffering and is believed to improve the quality of end-of-life care. However, making end-of-life judgments at a time of relatively good health may be challenging as it is hard to conceptualize how one will feel in an acute situation. There is a tendency to believe that older adults, particularly those in their 90s and 100s, have lived a good long life and are ready to die. This should not be assumed. Many of these “old-old” are not necessarily ready to die; they want to receive careful evaluations of their medical problems and discuss treatment options. Thus ongoing discussions between patients and clinicians should be encouraged throughout the aging process. What a patient wants for end-of-life care at 85 years of age may be different at 97 years of age.

Federal law requires that all persons entering a hospital or a nursing home be offered the opportunity to indicate ADs. However, this is not the ideal time to expect the individual to make clear, thoughtful decisions. Too often, this exercise involves asking older persons about possible procedures they would want to have if the occasion arose. Done poorly, the experience can provoke unnecessary anxiety and lead to poor decisions that may be regretted later. Ideally, the health-care provider has discussed establishing an AD with the patient and/or proxy, and all have given time and thought to the development of appropriate documents. The acute event requires only that these previously stated decisions be revisited to make sure the choices are consistent with the individual's current philosophy. The advantage of asking new residents in long-term care settings or newly admitted hospitalized patients about their AD is that it prompts the health-care provider to obtain this information and the older individual and/or family to make sure the appropriate forms have been completed. If it is more appropriate to postpone the discussion until the individual has adjusted to the new environment, systems should be in place to be sure the information is obtained at a later date. Most states have established a process for developing ADs, and standard forms are available on the Web for patients and/or families to download and complete (<http://www.aetnacompassionatecareprogram.com/EOL/ihtEOL/t.WSEOL000/st.36926/t.36985.html>). Individuals who spend part of the year in one state and part in another should be aware that state laws may vary in terms of criteria around when a living will becomes effective.

With both the living will and the durable power of attorney, there is some potential for misuse. Decisions once made can be difficult to revoke. In addition, it can be difficult to determine when an individual no longer has decisional capacity and the ability to state his or her own health-care preferences. By the same token, physicians need to educate patients and proxies that a course of treatment, once started, need not always be continued. Sometimes a trial of a particular treatment may be attempted and later removed. There is currently no test of mental competence that allows one to change one's mind about a decision to not use life-support systems.

In the absence of any specification of actions or agents, someone must be identified to act for a person who is unable to act on his or her own behalf. There are legal procedures to accomplish this, which vary from state to state. In general, the two major classes of legally empowered agents are conservators and guardians. The latter

usually have greater powers. A formal legal decision is needed to establish such a condition.

A critical question is: who is best qualified to assume that responsibility? Common wisdom suggests that it is the next of kin, but some argue that it should be the person most familiar with the patient's preferences, the person who can most closely estimate what the patient would have wanted. A rarely seen relative might know much less about the patient's wishes or lifestyle than a close friend, clergyman, or even the attending physician. The choice for who should be the proxy should rest on the level of knowledge possessed. Where there are multiple contenders for the role, the courts may have to decide who is best positioned to know the patient's preferences. This can become contentious. In cases where there is no one appropriate, the court may appoint a public guardian.

Agents, whether designated by durable power of attorney or chosen as the best available person, are vulnerable to pursuing their own interests rather than the patient's. At best, they must make inferences about the patient's wishes from their knowledge of the patient or the choice indicated in the durable power document. Surrogates' decisions may not be congruent with the wishes of the individuals they represent. They can be sincerely torn between acting in what they perceive to be the individual's wishes versus what may actually be their best interests in the given situation. The law typically imposes a standard of conduct on proxies appointed under ADs, proxies qualifying under applicable law, and guardians appointed by a court.

A number of obstacles influence the development of ADs for older adults. These include difficulty an older individual (and/or their proxies) may have in understanding the complexity of the situations that can arise; difficulty in understanding research findings that support medical practice; difficulty for patients, clinicians, and families to discuss death and make end-of-life decisions; and/or difficulty in conceptualizing future treatment preferences. Health-care clinicians, therefore, play a vital role in helping older adults to engage in developing ADs and in evaluating geriatric patients' current capacity to give direction about care. Specifically, such direction includes withholding or withdrawing life-sustaining procedures and establishing willingness to receive pain medications, antibiotics, intravenous infusions, and other therapies. A key step in starting the discussion about AD includes specifically eliciting the older individuals' preferences for medical treatments under a variety of conditions, and encouraging older individuals to specify a proxy and discuss their end-of-life care preferences.

■ POLST/MOLST

To further facilitate the process of assuring that patients explicitly express their end-of-life care preferences, State Departments of Health in many states have approved the implementation of a provider order form referred to as Physician Orders for Life-Sustaining Treatment (POLST) or Medical Orders for Life-Sustaining Treatment (MOLST). The POLST or MOLST initiative is intended to facilitate end-of-life medical decision making and assure patients' wishes are carried out. It effectively provides standing orders for end-of-life actions based on a person's AD. The order

can be used statewide by health-care practitioners and facilities. POLST or MOLST is particularly critical for patients with serious health conditions who: (1) want to avoid receiving any or all life-sustaining treatment; (2) reside in a long-term care facility or require long-term care services; and/or (3) might die within the next year.

Completing the POLST or MOLST begins with a conversation or a series of conversations between the patient, the patient's health-care agent or surrogate, and his or her primary care clinician or specialist with whom he or she has had interactions. The clinician should help delineate the patient's goals for care, review possible treatment options, and facilitate informed medical decision making. The completed form can then also be used as a medical order for that individual in health-care settings where this type of order would be appropriate. Examples of forms vary based on state requirements, and examples are available at the Department of Health in states that recognize these forms (see Web-Based References).

■ Issues to Consider

Life-and-death decisions attract the greatest attention and have a major impact on cost of care. These decisions include whether to initiate or withdraw treatment or whether to start dialysis, insert an intravenous line for hydration, or insert a feeding tube for artificial nutrition. Certainly, these are important questions posed in the context of real-world situations. Surprisingly, however, they arise much less often than do the less heralded ethical dilemmas that confront clinicians and older patients each day as they decide about discharge from hospitals, make decisions about appropriate levels of care such as nursing home or assisted living, make decisions about screening for diseases such as breast, prostate, or bowel cancer, or recommend therapies. Consideration of the ethics of geriatric care must address the full spectrum of these issues.

Some key points are worthy of special consideration:

- Ethics and law are separate, but overlapping. Ethical guidance may come from a variety of sources, such as national and state professional societies, local and national standards of practice, and other sources. However, health-care professional licensing boards commonly include among licensing standards and grounds for disciplinary action references to “unethical” conduct. Sometimes these may be based on an external standard incorporated by reference into local law, and in other states, there may be a specific code of ethics incorporated into the licensing regulations. Health-care clinicians are advised to consider this in the states in which they practice.
- In the area of end-of-life care, state law typically governs. A health-care decisions act or similar law may set out the obligations of health-care clinicians, health-care facilities, patients, and persons who may be authorized to act as proxies for an incapacitated individual. Those statutes and the regulations or interpretations of agencies and attorneys general can affect the expectations imposed on health-care clinicians. Case law may reflect “common law” principles that guide expectations and conduct of health-care clinicians. Any general reading, including a chapter such as this, should be measured against applicable state law.

- Many health-care facilities have “ethics committees,” which are interdisciplinary committees empowered to bring together involved staff, independent advisors from various disciplines, and involved family members to provide ethical guidance. Depending on state law, there may be legal protection for health-care clinicians following the recommendations of such committees.
- Informed consent is a routine and fundamental part of provider–patient interactions. A patient who makes an informed decision about health care makes a decision and gives direction that has a continuing effect. Patients have a right to change their minds. For example, a competent individual who refuses otherwise-needed dialysis despite knowing the consequences does not surrender his or her right to reconsider that decision.
- Patients can express their wishes about future health care in several ways. For example, geriatric patients not presently faced with a decision about artificial feeding via a tube may give direction about their future wishes, should that need arise. This may be done in a written form. In some states, state law permits an AD to be made verbally and may subsequently require such directives to be documented in a particular way. For example, these documents may require one or more physician determinations of a particular kind. Specifically, it may be necessary to include a determination of whether the patient was competent at the time an AD was signed, whether the patient is presently competent at the time someone wishes to invoke the document because the patient is incapacitated, and whether the patient is in a particular condition, such as terminal illness, a vegetative state, or some other condition the effect of which is to permit, or not permit, health care to be given, withheld, or withdrawn, even when it is life sustaining.
- State law may set out a process by which, in the absence of an AD from the patient, an individual may act as a surrogate, proxy, or similar title, making health-care decisions for others. This may require a physician determination of competency and evidence that the patient is in a particular clinical condition (eg, terminal).
- State guardianship laws authorize a court to appoint someone as guardian of the person. This is typically based on physician certification of incapacity.
- State law may recognize that health-care clinicians are not only ethically obligated to furnish care, but also empowered to refuse to furnish care that is medically futile and therefore not provided for ethical reasons. However, there have also been compelling arguments made against the use of the futility principle (Murray, 2012). In the United States, there is not currently a consensus in medicine about the use of unilateral physician decision making concerning medical futility. Alternatively, some clinicians recommend obtaining “informed assent” from a patient or family. In these situations, the patient/family is explicitly offered the choice to defer to clinicians’ judgment about withholding or withdrawing life-sustaining therapy. This is particularly useful and helpful to families who do not want to carry the burden of stopping a treatment or wrestling with feelings of withholding care from a loved one.

END-OF-LIFE CARE

End-of-life (EOL) care decisions differ from ADs in that the latter address hypothetical situations, whereas the patient is experiencing the implications of EOL. Whether being made by the patient or the proxy, the many end-of-life decisions that need to be made are extremely difficult. In the United States, patients/proxies have the right to refuse the initiation (withholding treatment) and the continuation of treatments (withdrawing treatment). These decisions are often based on decisions around comfort and quality of life, and the patient/proxy may decide to transition from aggressive treatment options to symptom management or what is referred to as palliative care. Palliative care (see Chapter 18) is interdisciplinary care that focuses on symptom management to eliminate discomfort and improve quality of life. In palliative care, the treatments provided are not intended to cure the underlying condition and generally focus on management of such things as pain, constipation, nausea, anxiety, and cough.

Substantial controversy surrounds EOL care with concerns around cost of care and cost versus benefit for the patient and society as a whole, particularly when the treatment being implemented is futile. While care is never futile, medical interventions can be futile. Medical futility is described as proposed therapy that should not be performed because available data show that it will not improve the patient's medical condition. In some situations, however, proxies may opt to engage in futile and expensive care.

EOL decisions are often driven by quantitative and qualitative assessments of futility. The former refers to an expectation that death is highly likely and that further efforts to postpone it are not likely to succeed. The latter addresses the quality of life if the patient survives. Will it be a life worth living? By the same token, clinicians need to be cautious to avoid imposing decisions about another's quality of life or making a decision that care should not be ordered because it will not be effective, that is, it will not work.

The President's Council on Bioethics report entitled, "Taking Care: Ethical Caregiving in our Aging Society" (The President's Council on Bioethics, 2005) acknowledges the uniqueness of each case and helps health-care clinicians consider the relevant questions to facilitate decisions. These questions include:

1. What will happen if the patient is untreated?
2. Will nontreatment lead to increased suffering?
3. What are the possible indirect consequences of nontreatment?
4. What are the treatment options?
5. Are there reasonable alternative treatments?
6. Would "slowing down" a disease be a reasonable alternative to attempting cure?

Clinicians may feel uncomfortable about encouraging patients/families/proxies to consider the option of saying no when we believe care is futile. It could be argued that this is the patient's/family's/proxy's right to decide. The ethics of medicine includes the principle of justice, which is geared toward maximizing benefits over harm and doing the greatest good for the greatest number. Using health-care resources to

provide a medical intervention that prolongs life but may worsen the quality of that life may not be the best decision for the community at large. Health-care clinicians have a duty to inform patients/families/proxies about the known anticipated outcomes of care, and when medically futile, palliative interventions, as described earlier, should be considered so as to conserve resources for the entire community.

THE CLINICIAN'S ROLE IN END-OF-LIFE CARE

The decision to withdraw life support or life-sustaining treatments can be emotionally difficult for patients, families, and/or proxies. Clinicians play a vital role in providing clinical and evidence-based information as available to help make decisions and achieve EOL goals (Table 17-3). Managing the end of a patient's life is a serious undertaking. In addition to facilitating decisions about the extent of heroic measures to be tried, much can be done to make that period as peaceful and pleasant as possible. Chapter 18 provides information about palliative care and ways in which health-care providers can manage unpleasant symptoms, such as pain, nausea, and shortness of breath. In addition to avoiding inappropriate prolongation of dying, other end-of-life tasks include helping the patient to achieve a sense of control, relieving burdens, and strengthening relationships with loved ones.

Most older individuals, along with their families, want to have input into EOL decisions. In some cases, however, the older individual may ask his or her clinician

TABLE 17-3. Goals of Care and Symptoms Requiring Management at the End of Life

Be kept clean
Have a designated decision maker
Have caregivers with whom one feels comfortable and can trust
Know what to expect about one's physical condition at the end of life
Have caregivers who will listen and help manage physical and psychological symptoms
Maintain one's dignity
Have financial affairs in order
Have pain optimally managed
Maintain humor and integrate humor into care and end-of-life challenges
Have an opportunity to say goodbye to loved ones
Experience optimal control of shortness of breath
Experience optimal control of feelings of anxiety
Have appropriate individuals to discuss/express fears
Opportunities to resolve unfinished business with family or friends
Have opportunities for appropriate levels of physical touch
Have providers whom you know and who know you
Help older individuals feel reassured the family is prepared for their impending death
Assure the presence of family
Assure older individual that their end-of-life preferences are known to all providers
A plan in place for optimal death (eg, who will be at the bedside etc)
Provide opportunities for life review

to make health-care-related decisions. Families or proxies may not want to make EOL decisions for personal or emotional reasons. Moreover, for some families or proxies, these decisions can result in persistent anxiety and depression and long-term feelings of guilt. In these situations, the humane option is to obtain “informed assent” from the family/proxy. The “informed assent” process allows the clinician to explicitly offer families/proxies the choice to defer to the provider’s judgment about withholding or withdrawing life-sustaining therapy or whatever the EOL treatment decision might be. When assent is obtained, it should be clearly documented in the patient’s medical record.

Alternatively, the clinician may be asked his or her professional and personal opinion about EOL decisions for a patient, either by the patient, family, or proxy. In these situations, the clinician must decide how actively personal preferences should be voiced. Clinicians also continually have to make decisions about what information and how much information to provide to patients/families or proxies. According to the doctrine of informed consent, clinicians must disclose enough information for the patient to make an “informed” decision. Informed consent laws and principles do not specify, however, exactly how much or what information is the right amount and what exactly must be disclosed. It is difficult to be fully objective in many instances, and the decisions are often not going to be clearly evidence based because the evidence may be variable, not relevant to older adults, or contradictory. Basically, clinicians are obligated to provide the following information: (1) condition being treated; (2) nature and character of the proposed treatment or surgical procedure; (3) anticipated results; (4) recognized possible alternative forms of treatment; and (5) recognized serious possible risks, complications, and anticipated benefits involved in the treatment or surgical procedure, as well as the recognized possible alternative forms of treatment, including nontreatment.

There has been increased emphasis on patient-centered care and shared decision making between clinicians and patients. This philosophy of care has many advantages, although it is sometimes difficult to know for sure how much information the patient/proxy has heard and/or understood and how much will be retained over time (Thomas, 2012). Improved communication is needed to optimize the transfer of information and assure patient understanding. Clinician values may unconsciously distort the way options are portrayed; risks may be minimized or even overlooked. In addition, there are some clinicians who tend to think of themselves simply as conduits of information, whereas others believe strongly that their opinions should be counted. In an era of litigation, clinicians are increasingly sensitive to their responsibility to provide information and tend to provide more rather than less information. At the same time, clinicians may offer their opinions and give their reasons. Frequently, this is done in the context of what the clinician might do for his or her mother or family member. Situations may arise in which the clinician disagrees with the decision of the patient or proxy for ethical reasons. This might occur, for example, if the treatment requested by a patient is believed to be futile based on current research findings, or if the patient refuses care that the clinician feels would be of benefit. These patients can be referred to another clinician, and/or resources such as the health-care facility’s

ethics committee, social services staff, or agencies that advocate for older adults at the EOL can be contacted.

To help guide clinicians in understanding their ethical responsibilities to patients, a committee of the American College of Physicians and the American Society of Internal Medicine (Meisel, Snyder, and Quill, 2000) identified seven legal myths about EOL care that may prevent adequate care. These myths include:

1. Forgoing life-sustaining treatment for patients without decision-making capacity requires evidence that this was the patient's actual wish.
2. Withholding or withdrawing artificial fluids and nutrition from terminally ill or permanently unconscious patients is illegal.
3. Risk-management personnel must be consulted before life-sustaining treatment can be terminated.
4. ADs must comply with specific forms, are not transferable across states, and govern all future treatment decisions; oral ADs are unenforceable.
5. If a physician prescribes or administers high doses of medication to relieve pain or discomfort in a terminally ill patient, which results in death, the physician will be criminally prosecuted.
6. When a terminally ill patient's suffering is overwhelming despite palliative care, and the patient requests a hastened death, there are no legally permissible options to ease suffering.
7. The 1997 U.S. Supreme Court decisions outlawed physician-assisted suicide.

PHYSICIAN-ASSISTED SUICIDE

In the United States, physician-assisted suicide has been legalized or is being considered for legalization in *some* states. Each state has been left to make its own laws in this regard. Oregon legalized physician-assisted suicide in 1997. Of note, however, since legalization, very few terminally ill patients have actually requested physician assistance to facilitate suicide. Even in states where physician-assisted suicide is legal, physicians are not required to participate.

SPECIAL PROBLEMS WITH NURSING HOME RESIDENTS

Nursing home residents present some unique ethical challenges with regard to end-of-life decisions related to care. Older adults are usually admitted to nursing homes because of a reduced capacity to function either physically or mentally. Many suffer from some degree of cognitive impairment. Consequently, there may be some caregivers who assume that their quality of life is miserable and their lives have limited value.

Clinical decisions in treating long-term care patients pose some of the greatest ethical dilemmas. Beyond the usually considered question of resuscitation, the clinician faces difficult decisions in determining when it is appropriate to transfer a patient from a nursing home to a hospital or when to intervene aggressively to treat changes in physiological status from fluid imbalance or infection. Perhaps one of the most perplexing areas is when to pursue heroic measures to maintain nutritional supports.

Artificial feeding decisions seem to arouse more controversy than other life-sustaining treatment issues, especially when the individual has not clearly stated his or her preferences. There is no evidence to support improved quality of life for individuals through use of a feeding tube. Thus, increasingly, clinicians are suggesting a more humane option, which is to provide “comfort feeding only” (Palecek et al., 2010). This allows for an individualized approach to helping the individual eat what he or she is able and willing to eat. Moreover, it avoids the negative feelings evoked in clinicians and families/proxies that withholding food and fluid creates.

Clinicians must be diligent in working to preserve the patient’s personhood. Essentially, nursing home residents should not lose any of their rights as people just because they enter a nursing home. They should be eligible to participate in a full range of activities and to make choices about their lives and their health care at their optimal ability both mentally and physically. Unless the individual has been noted to be without decisional capacity, he or she should be the first one consulted about changes in his or her condition or therapy. Because nursing home residents are vulnerable, special care is needed to protect their rights. The general goal is to maximize the resident’s autonomy in making decisions about treatment. A resident’s bill of rights, which outlines the choices that should be available and the protections that can be sought for residents, has been developed for all individuals in long-term care facilities. Federal law mandates that all nursing homes have written policies that describe the resident’s bill of rights. Another useful approach to address ethical issues in long-term care facilities is to establish an ethics committee composed of persons within and outside the facility. Ethics committees are required in hospitals and long-term care facilities accredited by The Joint Commission. Most long-term care facilities, however, do not have accreditation by The Joint Commission. Traditionally, the function of the ethics committee has been on case reviews; education of health-care clinicians, residents, and families; and policy review as relevant to the committee. Such committees are especially useful when they operate in a proactive manner, exploring issues in advance rather than assessing actions already taken.

SPECIAL CASE OF DEMENTIA

As with all nursing home residents, it should not be assumed that residents with dementia no longer have decisional capacity and/or that they have a reduced quality of life. In addition to end-of-life ethical concerns with older adults with dementia, daily ethical issues can arise in the care of these individuals. Ethical decisions arise simply related to providing information around the diagnosis of dementia. For some individuals, it may be devastating to be given this diagnosis, while others want the information so as to optimize treatment and make plans for the future. The decision of how to proceed in these situations may be best made by taking the lead from the older adult. For example, if the individual is asking about cognitive changes and expressing concern about these changes, then information around a diagnosis will more likely be heard and appreciated. Conversely, if an individual is denying changes and does not want to hear about his or her impairment, then it may be futile

to provide the information. Other care-related issues that commonly create ethical challenges in older adults include such things as refusal of care, wandering, disinhibited speech or behavior that is upsetting to staff and other residents, or aggressive behavior. Wandering, either deliberate or aimless, can be intrusive for other residents or neighbors if the individual is living in the community and a significant clinical problem. Ethical issues arise when a resident with dementia invades the privacy and space of another resident, who does not consent to the visit. The balance between the autonomy of the individual who is wandering versus the greater good of the community must be resolved. Ethically based options to manage these situations include such things as moving the resident who wanders or putting up a stop sign on the door to prevent entry. Alternatively, a resident with dementia may refuse to engage in any type of care activity, just wanting to lie in bed. If allowed to make this decision, the individual will be at risk for pressure ulcers, deconditioning, falling, and contractures and will ultimately require higher level nursing interventions and resources. Preventing these problems would benefit not only the individual in terms of preventing pain and suffering but the community at large. Ethical choices need to be made to resolve the discrepancies between individual choice versus allowing harm to occur. In this situation, ongoing motivational interventions and capturing the individual at the opportune moment to engage him or her in activities would help to resolve the ethical dilemma.

POLICY ISSUES

Older adults are prime targets for rationing efforts because they consume disproportionately large amounts of medical care and because they are seen as having already lived their lives. At a more subtle level, measures of program effectiveness tend to use something equivalent to the quality-adjusted life-year. This term implies that valuable life must be lived free of dependency. Such proxies for program effectiveness incorporate ethical components subtly. Society has not established the base on which to put a value on life lived at some level of dependency. To assume that it has no value, as is implied by active life years, appears to contradict the very purpose for geriatrics, which treats primarily dependent older people. Many older people would actively challenge the tenet that disability implies an absence of quality of life. Severely disabled persons at various ages can continue to enjoy pleasant and productive lives. As advocates for their patients, geriatricians must be extremely vigilant to how such terms are used both in everyday speech and in analyses. It is important to bear in mind that any measure that uses life expectancy will inevitably be biased against the elderly. One that relies on dependency as the primary outcome implies that those who are dependent no longer count; by such logic, disability is equivalent to death. At a time when there is an increased focus on allocation of health-care resources, care must be taken to avoid ageism and assumptions of negative quality of life among those who are cognitively or physically impaired and/or institutionalized.

The issue of futile care and the impact the implementation of futile care interventions have on the individual as well as community in terms of resource use are critical.

Avoiding futile care, with the full understanding and acceptance of the older individual and his or her family, is consistent with ethical mandates. Consequently, there has been a strong emphasis on establishing advanced directives and facilitating the process by which medical orders can be written via use of the MOLST or POLST forms. ADs have been shown to improve the quality of life at the end of life and assure that older adults receive the type of care they want. As noted, there is increased focus now on symptom management and assuring that optimal EOL treatment is provided. There continue to be many older adults in long-term care facilities who have not completed ADs, and increased focus is needed to assure that discussions around end-of-life care have been completed and that appropriate paper work has been secured.

The role of policy and policy initiatives is critical to encourage the development and use of ADs. In 1991, the Patient Self-Determination Act (PSDA) was established. The PSDA requires that most U.S. hospitals, nursing homes, hospice programs, home health agencies, and health maintenance organizations provide adults, at the time of inpatient admission or enrollment, information about their rights under state laws governing ADs, including: (1) the right to participate in and direct their own health-care decisions; (2) the right to accept or refuse medical or surgical treatment; (3) the right to prepare an AD; and (4) information on the provider's policies that govern the utilization of these rights. The act prohibits institutions from discriminating against a patient who does not have an AD. The PSDA further requires institutions to document patient information and provide ongoing community education on ADs. The law does not state, however, that an AD must be established.

The passage of the PSDA, unfortunately, has had minimal impact on increasing the numbers of individuals with ADs. At the state level, AD laws have similarly not been particularly effective, and there are recommendations to relax requirements involved with completion of ADs, such as removing the requirement to have the AD be witnessed. Currently, as noted earlier, states are moving toward the development of POLST and MOLST forms to facilitate not only the establishment of ADs, but also to assure that the medical order is provided so that the directive can be carried out when older adults are institutionalized.

The Health Information Technology for Economic and Clinical Health (HITECH) Act, enacted as part of the American Recovery and Reinvestment Act of 2009, promotes and requires the transition to electronic medical record systems across all levels of care. While there continue to be challenges to the full transition of this process, it is anticipated that ultimately the use of a seamless system between settings will assure that ADs follow the patient regardless of where care is being provided.

ETHICAL ISSUES CONCERNING CAREGIVERS

An important ethical issue closely linked to long-term care policy concerns the appropriate role of caregivers. Informal caregivers provide a significant amount of caregiving at the end of life with limited resources. In Chapter 15, we noted the central role played by informal caregivers, who constitute the backbone of long-term care. For example, the Family Medical Leave Act asserts that an employee cannot

be denied leave if the employee has a medically certified condition or is caring for a covered individual who has a medically certified condition. The question then is, how much of such care should they be expected to provide? What is the nature of the obligation of one generation to another, or even to spouses and siblings from the same generation? A substantial portion of informal care is undoubtedly provided out of love and compassion. This approach works well when it is left up to the family to decide how much care they can give, but what happens when such care becomes mandated? Pressure to control public costs of long-term care could easily lead to demands to require care from families or to require that families pay directly for a certain amount of that care. Concerns have already been expressed about the possibility that older persons are manipulating their assets to become unfairly eligible for Medicaid coverage or that younger generations gain control over elders' assets to ensure that funds are left to the next generation through the use of public funding to care for indigents. Although there is little substantiation for these claims of divestiture, advertisements for seminars on how to do it create an image of exploitation. Federal law plays a role in issues surrounding divestiture of assets to qualify for public assistance. Policies focused on familial responsibility would undoubtedly create a new demand for private long-term care insurance, because preservation of older persons' assets primarily benefits the heirs.

There has been significant press around the cost of care in the last year of life, with much of that cost associated with acute-care admissions as well as long-term care services. There is increased interest and support for providing care in the home settings with the development of models of care to deploy interdisciplinary teams to provide that care, regardless of level of acuity. Moreover, transitional care models are being developed to prevent the need for rehospitalizations among older adults discharged following an acute event, particularly rehospitalizations within 30 days of discharge. A major aspect of those coordinated care approaches is to establish ADs and establish what level of care and intervention the older adult wants to receive at the end of life. Increased completion of advanced directives has been shown to decrease the cost of care and improve patients' satisfaction with care received.

SUMMARY

Ethical issues around care of older people are played out at all levels. Policy issues largely address questions of access and coverage, but these can be influenced by an individual clinician's beliefs about what elements of care are "appropriate" for older people. These beliefs, in turn, can reflect stereotypes. Microethical issues occur at the bedside when decisions about initiating or continuing treatment are made.

These decisions, too, are based on beliefs about appropriateness, including who should have the ultimate word about how much and what kind of care is rendered. Some of these decisions are couched as ethical issues because the requisite facts are not known. When there is evidence of efficacy or futility, the discussion changes, and decisions can be made on more substantial facts. Often, other factors than age are much better predictors of who will likely benefit from a given type of treatment. Great care must be taken to avoid couching rationing decisions as ethical dilemmas.

Measures that discount older or frail people will inevitably lead to decisions against treating older persons.

Older adults should not lose their rights to full consideration of options and participation in the decisions that affect their care. The principles of autonomy and beneficence, which form a central part of the ethics of medicine in general, are strained with dependent older persons because the temptation toward paternalism is greater in the presence of the tendency to infantilize frail elderly patients, especially when they cannot readily communicate. Concerns about how to make decisions for persons unable to express their own preferences are often couched in terms of fear of litigation, but the growing body of experience suggests that carefully pursued efforts to establish agency and act accordingly will not put health-care clinicians or institutions at great risk of lawsuits. Rather, there is a risk of litigation if the wishes of the patient are not followed. Finally, it is important to recognize that the life of dependent older persons, especially those in nursing homes, is composed of many little incidents. The daily loss of dignity, privacy, and self-respect may be too readily ignored or may need to be balanced through negotiation based on the needs of the entire community. To be truly the patient's advocate, the health-care provider must be vigilant to these small but critical ethical insults and work toward optimal solutions for the good of all.

Clinicians should bear in mind that ethics is not a "slang" term without a particular meaning or that it simply reflects a set of general principles. Rather, state law may set out ethical standards with particularity. Moreover, clinicians can be effective advocates for patients, both while they are competent and after they are no longer authorized to act for themselves, based on both helping to facilitate ADs and making the various clinical findings that are relevant concerning capacity, levels of care needed, and whether the particular care will be clinically effective or, instead, simply futile. Knowledge of the distinctions between types of ADs, how others may act as proxy, and the availability of ethics committees are all important tools. While health-care clinicians do not dictate care, they have not been reduced to passive participants in the process. By understanding both the clinical situation and choices and the ethical and legal context that exists at a particular time, clinicians are empowered to act in an ethical way, in the best interest of patients.

REFERENCES

- Meisel A, Snyder L, Quill T. Seven legal barriers to end-of-life care: myths, realities, and grains of truth. *JAMA*. 2000;284:2495-2501.
- Murray B. Informed consent: what must a physician disclose to a patient? *Am Med Assoc J Ethics*. 2012;14:563-566.
- Palecek EJ, Teno JM, Casarett DJ, Hanson LC, Rhodes RL, Mitchell SL. Comfort feeding only: a proposal to bring clarity to decision-making regarding difficulty with eating for persons with advanced dementia. *J Am Geriatr Soc*. 2010;58:580-584.
- The President's Council on Bioethics. Taking care: ethical caregiving in our aging society. Electronic Version, 2005. Available at: www.bioethics.gov. Accessed September, 2007.
- Thomas JD. When patients seem overly optimistic. *Am Med Assoc J Ethics*. 2012;14:539-544.

WEB-BASED REFERENCES (LAST ACCESSED JULY 2012)

- American Family Physician. End-of-life care. Available at: <http://www.aafp.org/afp/topic-Modules/viewTopicModule.htm?topicModuleId=57>
- Berman A. Living life in my own way and dying that way as well. *Health Aff.* 2012;31:871-874. Available at: <http://content.healthaffairs.org/content/31/4/871.full.html>
- Interventions to Reduce Acute Care Transfers (Interact II). Available at: <http://interact2.net/tools.html> and <http://interact2.net/care.html>
- Patient Protection and Affordable Care Act, 42 USC 18001, sec 3506 Program to Facilitate Shared Decision-Making, sec 936 (d)(2). Available at: <http://www.gpo.gov/fdsys/pkg/PLAW-111publ148/html/PLAW-111publ148.htm>
- Physician Orders for Life-Sustaining Treatment. Available at: <http://www.ohsu.edu/polst/>
- Virtual Mentor. *Am Med Assoc J Ethics.* 2012;14:589-596. Available at: <http://virtualmentor.ama-assn.org/2012/07/pdf/vm-1207.pdf>

This page intentionally left blank

CHAPTER 18

Palliative Care

Much attention has been focused on the importance of making end-of-life (EOL) care decisions before one is in a crisis situation. Some older adults, however, are ambivalent about what they want at the end of life and may change their minds about treatment options when actually threatened by an illness that can cause death (Caron, Griffith, and Arcand, 2005; Cherlin et al., 2005). An option that allows for realistic EOL supportive care without rescinding all efforts at treatment is palliative care. Palliative care is focused on symptom management and relieving suffering and improving quality of life of individuals rather than focusing on cure and lengthening of life. Avoidance of unnecessary, and potentially harmful, tests is initiated, and care is focused on comfort. Palliative care is a philosophy of care that is provided simultaneously with all other appropriate medical management of the patient.

Hospice differs from palliative care. Hospice is a comprehensive care system for patients with limited life expectancy who are living at home or in institutional settings. Hospice is a Medicare benefit that was established in 1982. To be eligible for hospice, the patient's primary health-care clinician must certify that the patient has a remaining life expectancy of approximately 6 months or less, and the patient must elect hospice and agree to accept care from an identified hospice team. The patient's primary health-care clinician may elect to continue to provide care for the patient and work with the hospice team. Services provided through hospice are shown in [Table 18-1](#). Hospice services also include coverage of necessary supplies such as a bedside commode or medications.

Having discussions with older patients and their families/caregivers about how they want care managed as they age and at the end of life is a critical aspect of geriatrics. There are numerous resources to help providers with this process (see Web-Based References). One practical method is to follow a five-step approach (Balaban, 2000). The steps, described in more detail in [Table 18-2](#), include:

1. Initiating the discussion
2. Clarifying the prognosis
3. Evaluating the patient/family
4. Identifying end-of-life goals
5. Developing a plan of care

A major emphasis during all discussions of end-of-life care should be on the types of care that will be provided. Statement such as "there is nothing more we can do for you" should be avoided. Rather, the discussion should focus on what types of care interventions will be provided (eg, pain medications, positioning therapies as appropriate, nonpharmacologic pain-relieving modalities). Following these steps can help to assure that communication is clearly provided, fears are allayed, and the

TABLE 18-1. Hospice Services

Service provided	Description
Nursing	Registered nurses coordinate the care for every patient, provide direct patient care, and check symptoms and medication. Patient and family education is an important part of every visit. The nurse is the link between the patient and his or her family and the physician. The nurse can also help evaluate the patient’s condition.
Social services	The social worker provides advice and counseling to the patient and all family members during the crisis period. The social worker assists other care team members in understanding the family dynamics and acts as an advocate for the patient and the family in making use of community resources.
Physician services	The patient’s physician approves the plan of care and works with the hospice team. In a full hospice program, a hospice medical director is available to the attending physician, the patient, and the hospice care team as a consultant and a resource.
Spiritual/ counseling	Clergy and other counselors are available to visit and provide spiritual support to the terminally ill at home. Programs also use churches and congregations to aid the patient and family as requested.
Home health care/ homemaker	Home care aides provide personal care for the patient, such as bathing, shampooing, shaving, and nail care, and homemakers may be available for light housekeeping or meal preparation.
Continuous home health care	If the patient’s needs require it or if the family can no longer manage the level of care required around the clock, hospice staff will provide care for 8- to 24-hour periods on a short-term basis.
Therapy/ rehabilitation services	Daily living tasks such as walking, dressing, or feeding oneself can become frustrating and impossible during an illness. Therapists help the patient develop new ways to accomplish these tasks.
On-call team support	A hospice team member is on call 24 hours a day, 7 days a week. If a problem should arise, the team member may offer advice over the phone and, if necessary, make a visit.
Respite care	To provide relief for family members, the hospice may arrange a brief period of in-patient care for the patient.
Bereavement counseling	Bereavement is the time of mourning that we all experience following a loss. The hospice care team works with surviving family members to help them through the grieving process. Support may include a trained volunteer or counselor visiting the survivors at specific periods during the first year, or phone calls and/or letter contact and the opportunity for family members to participate in support groups. The hospice will refer survivors to medical or other professional care if necessary.

TABLE 18-2. A Five-Step Framework for Discussing Care Choices at the End of Life

Step	Description
Step I: Initiating the discussion	Schedule a private location and adequate time for this discussion. Plan what you will say to the patient/family. Gather current evidence-based facts/numbers to present (eg, percentage of older adults likely to survive CPR after the age of 80).
Step II: Evaluating the patient/family	Ask the patient/family to state what their thoughts are about the older adult's current status. Ask the patient/family to state their goals in terms of care (eg, focus on life prolongation versus quality of life). Ask if the patient/family is willing to discuss options in care.
Step III: Clarifying the prognosis	Provide the facts on current status, life expectancy, and anticipated disease(s) trajectory. If new diagnosis, provide specific detail (eg, this is a malignant melanoma with some evidence of spreading). Deliver information in straightforward way; don't use euphemisms; use words the patient/family can understand.
Step IV: Identifying end-of-life goals	Provide treatment choices and options with known evidence for outcomes. Focus on care and what will be provided. Establish goals based on all given information.
Step V: Developing a plan of care and ongoing support	Establish a current plan of care (eg, address symptoms or current problems). Provide ongoing support to the patient and family for the choices they have made. Separate personal feelings from patient/family choices. Focus on how ongoing care will occur and what will be provided.

CPR, cardiopulmonary resuscitation.

patients are helped to achieve the goals they want at the end of life such as dying with minimal pain.

It is important to initiate discussions about care philosophies regarding the end of life with patients and their families. While it may be difficult to do this during the first patient visit, it is helpful to have the discussion early in the provider–patient relationship. One option is to ask the patient/family if they have had discussions about EOL care and, if so, to ask them to bring any documents addressing preferences to the next appointment. If this has not been previously addressed, then a plan to discuss this in more detail at the next visit can be initiated.

For older adults in long-term care settings, one important fact to obtain and clarify during the first visit with a patient involves identifying who will be the primary/first contact to call with changes in the patient's condition (see Chapter 17). When there are differences of opinion between siblings or caregivers about how treatment should proceed (eg, to go to the hospital or not), the clinician may be asked to facilitate

a discussion around the pros and cons of different treatment options. While time consuming, these conversations can help to ease the anxiety experienced among the caregivers and help the entire family feel comfortable with the decisions that are made. The primary care clinician may need to help families explain difficult situations to a patient. Examples include such things as helping a patient with mild cognitive impairment understand that refusing dialysis may result in death. The clinician may also have to interpret behavioral responses to interventions for families of individuals who are not able to verbally express their thoughts (eg, pulling out tubes or turning down feedings may be indicative of refusal).

SLOW MEDICINE

Slow medicine is a philosophy of care that was developed to help older adults and their families and caregivers manage some of the changes that occur with aging and the declines that commonly occur (McCullough, 2008). Slow medicine is a common sense approach to care of older adults in which careful consideration is given to the pros and cons of each treatment option. The underpinning of slow medicine is a sustained relationship with a primary care clinician who the patient and family come to trust. This sustained relationship allows time for EOL issues to be broached and revisited, a situation in stark contrast to the requirement that such topics be broached on admission to a medical facility. Decisions are strongly based on quality-of-life factors, comfort, and the risk of doing more harm than good with any given intervention. In many situations in geriatrics, a “tincture of time” may in fact be the best approach to see if a symptom will resolve prior to initiating an intervention that may cause harm (eg, an antibiotic with side effects). The slow medicine philosophy can be used to help with decisions around prevention practices (eg, use of statins) as well when managing acute situations.

Older adults and/or families often request that tests and treatments be provided for themselves or their loved ones that may not necessarily be of benefit to them. In addition, clinicians may recommend tests and procedures based on guidelines and data provided for younger individuals or as a way to cover all possible outcomes. Increasingly, there are beliefs and concerns over testing and subsequent harm to older adults. In response to these concerns, the ABIM Foundation (2012) joined with nine leading medical specialty societies to develop a list of tests and procedures that should not be recommended for older adults. The goal of choosing wisely is to help health-care providers and older adults think about and talk about undergoing expensive interventions that are not likely to be beneficial for optimizing quality of life.

HELPING OLDER ADULTS AND FAMILIES UNDERSTAND AND DECIDE ON PALLIATIVE CARE APPROACHES

Discussing EOL care and decisions about how to approach care at the later stages of an older individual’s life are difficult. Usually these discussions occur during a significant change in the patient’s condition, following an acute event such as

pneumonia or a fall, when a patient is suffering and aggressive treatment is not likely to help that suffering, around an aging milestone such as turning 100, or simply when the patient/family wants to discuss them. As delineated in Table 18-2, clinicians should use a step approach and discuss prognosis clearly, offer hope as needed, provide evidence-based options, coordinate transitions of care as needed and progression of disease, and relieve suffering, both physical and emotional. It is critical to determine what the patient/family wants to know and how much information they want to receive, be prepared to provide care and treatment-related options, be unbiased and open to what the patient/family wants, and be prepared to offer emotional support.

FRAILITY AND A PALLIATIVE CARE FOCUS

Unlike in other areas of medicine, in geriatrics there is unlikely a single diagnosis that contributes to cause of death. Rather, we are managing multiple comorbidities and frailty. Frailty, which is caused by age-related physiological decline and/or a combination of disease states, has been defined as a diminishing capacity to manage stress with subsequent risk of negative outcomes in terms of physical health and function. Frailty is associated with a progressive decline in function that impacts quality of life and thus raises patient/family interests and provider inclination to discuss palliative care. Frailty is commonly associated with the following symptoms: loss of strength, weight loss, decreased physical activity and poor endurance, and slowing of performance. There may be associated changes in cognition, balance, and emotional health with subsequent falls, trauma, and depression. Identification, understanding, and acknowledgement of frailty are important for patients and families. Moreover, given the many factors and lack of a cure for frailty, it is a useful stepping stone for discussing palliative care. Table 18-3 provides an

TABLE 18-3. Signs and Symptoms of Frailty	
Patient symptom	Objective finding/sign
Decreased appetite/loss of weight	A greater than 5% loss of body weight in the past year A loss of 10 lb or more not intended Clothes no longer fitting
Weakness and less able to do what he or she used to do	A decline in grip strength if prior testing had been done Time to walk 15 ft at usual pace (slow ≥7 seconds for men or tall women; ≥6 seconds for others)
Fatigue	A decrease in usual activities
Pain	Rate pain on a scale of 0 to 10 and explore if pain interferes with normal activity
Depression	Evaluate patient for affect (appearing sad or blue) Ask patient directly if he or she is depressed
Falls	Observe gait changes and risk for falls based on function

overview of common signs and symptoms of frailty that can be used to establish evidence for this condition. Fried and colleagues (2007) developed an operational definition of frailty that included the following indicators: unintentional weight loss, slow walking speed, subjective exhaustion, low grip strength, and low levels of physical activity. Having three or more of these indicators was associated with poor clinical outcomes (eg, institutionalizations and death). Conversely, Rockwood and Mitnitski (2005) suggest that frailty is based on an accumulation of deficits and use a list of 30 indicators to suggest that individual is frail. In addition to the indicators suggested by Fried et al. (2007), they considered such things as falls, decreasing vision and hearing, urinary and fecal incontinence, and cognitive status. Both measures are highly correlated with each other.

ESTABLISHING A PALLIATIVE CARE APPROACH

Depending on the setting of care, a palliative care approach can be initiated and established in different ways. Increasingly, acute-care hospitals are establishing palliative care teams that include members from a variety of disciplines (eg, nursing, medicine, social work, pastoral services) to facilitate the discussions (as addressed earlier) and initiate the palliative care orders. This might include discontinuing certain procedures or treatments (eg, stopping intravenous fluids) and focusing on managing unpleasant symptoms that the older adult was experiencing. A preset order form (New Jersey Medical School, 2012) may be used with treatment options incorporated (eg, use of oxygen for shortness of breath, routine pain medication). In long-term care settings (nursing homes or assisted living settings), the initiation of a palliative care approach may be started during a care plan meeting and/or by a health-care provider during a regulatory or acute visit. As with patients in the acute-care setting, a palliative care order form addressing symptom management will then be completed by the health-care provider.

CULTURAL CHALLENGES AND PALLIATIVE CARE

Culture is known to influence individuals' decisions about EOL care and care decisions. Conflicts may occur due to differing beliefs, communication styles, and goals, and this may impact the patient-provider relationship. Understanding and addressing the patient's cultural beliefs without making assumptions is critical to assuring optimal palliative care. It is critical to ask patients and/or families about their cultural beliefs and expectations and to discuss these in open format. Basic cultural information can be obtained through a number of resources (EthnoMed, 2012; Robert Wood Johnson Foundation, 2012; National Institutes of Health, 2012). In addition, the ABCDE (attitudes, beliefs, context, decision making, and environment) approach (McPhee et al., 2011) can be used to guide health-care providers in managing cultural issues associated with palliative care. Obtaining information, for example, about EOL customs or religious rituals and providing assurance to patients and families that these customs and rituals will be respected can help optimize the palliative care experience.

MANAGEMENT OF SYMPTOMS IN PALLIATIVE CARE

Symptoms such as pain, shortness of breath, anxiety, and fatigue, among others, can cause distress as people age with chronic or life-threatening illnesses. These symptoms can all be addressed using a palliative care approach with a variety of pharmacological and nonpharmacological interventions. An overview of treatment options is provided in [Table 18-4](#) for many of these symptoms, and the most prevalent symptoms are described in more detail in the following sections.

■ Pain

Pain management will vary based on the cause and whether or not this is acute versus chronic pain. The goal is to treat pain proactively, to find the minimum dose that can prevent the pain. Older adults may fear pain at the end of life, and assurance is needed that their pain will be managed using a variety of approaches. Recommendations for pain management are discussed in detail in Chapter 10. With regard to palliative care, however, pain management decisions need to consider the entire patient/family situation. For example, because a caregiver is not available to provide frequent dosing of a medication, a decision may be made to use a fentanyl patch versus an injection or oral treatment. Despite an interest in taking a palliative care approach, some older adults and/or family members may continue to fear use of opioids due to concerns about addiction or a fear that use of morphine will lead to death. In these situations, education to help patients and families work through these feelings should be initiated. In addition, patients and families should be helped to understand that there may be side effects to opioid use that can likewise be managed. These include such things as nausea and vomiting, sedation, delirium, respiratory depression, constipation, multifocal myoclonus, and seizures. Opioid dosage can be decreased, and adjuvant coanalgesic medications and treatments can be added ([Table 18-5](#)). Nonpharmaceutical interventions should also be initiated, including positioning, heat or ice, music or other types of distractions, acupuncture, and massage (Hassett and Williams, 2011).

■ Constipation

Constipation is a common symptom that often needs to be managed during palliative care treatment. Constipation is addressed in detail in Chapter 8. As with use of opioids, patients and families need to be assured that the patient need not worry about dependence on a laxative. Moreover, preventive measures for constipation such as increasing fluid and fiber may be useful for prevention of constipation but are not likely to be effective to treat acute symptoms of constipation. Rather, drug therapy of the patient's choice should be considered. For example, a patient who wants immediate relief may want to get a suppository versus an oral agent. Once constipation is identified as a problem, preventive treatment should be initiated with increases in fiber, fluid, and physical activity as tolerable and possible and/or regular laxative use. Dosing of laxatives and use of combination drugs will likely need ongoing management. Methylnaltrexone is a new treatment option for opioid-induced

TABLE 18-4. Management of Symptoms Noted at End of Life	
Symptom	Management
Myoclonus	Treat underlying cause of myoclonus if possible (may be due to opioid use) Maintain adequate hydration Rotate to alternate opioid Low-dose lorazepam or a benzodiazepine
Dyspnea	Use opioids (small, frequent doses as needed for opioid-naïve patients) Use benzodiazepines if anxiety is present Use glucocorticoids or bronchodilators for bronchospasm Use antibiotics if it is believed that a bacterial infection is exacerbating dyspnea and treatment will likely improve symptoms Use oxygen only when hypoxia is present and patient finds it helpful An open window or fan may be comforting Patient position, including measures such as elevating the head of the bed and sitting up in a chair Encouraging physical activity as tolerated Complementary treatment should be considered including acupuncture or massage.
Fatigue/apathy	Pharmacological treatment options include methylphenidate (Ritalin) 2.5 mg twice daily (in morning and at noon) and increase up to 30 mg/day. Modafinil (Provigil) 50-100 mg/day to start has likewise been used, and this can be increased to 100-200 mg/day Assure that fatigue is normal and suggest energy-conservation methods Employ sleep hygiene measures to facilitate optimal nighttime sleep
Cough	Consider etiology (infection, bronchospasm, effusions, lymphangitis, cardiac failure) and treat accordingly Use opioids for cough suppression; particularly use opioids if cough prevents the patient from sleeping Use other antitussives such as guaifenesin or dextromethorphan Use glucocorticoids if it is believed that the cough is due to irritation or is inflammatory in nature Use bronchodilators, as appropriate (eg, for bronchospasm) and beneficial such as albuterol 2-3 inhalations every 4-5 hours Use diuretics if it is believed that the cough may be due to congestive heart failure and fluid overload
Excessive secretions	Pharmacological interventions Scopolamine transdermal patch, 1.5 mg (start with one or two patches; if ineffective, switch to 50 µg/h continuous IV or SQ infusion and double the dose every hour, up to 200 µg/h)

(continued)

TABLE 18-4. Management of Symptoms Noted at End of Life (*continued*)

Symptom	Management
	<p>Use glycopyrrolate, 1-2 mg PO or 0.1-0.2 mg IV or SQ every 4 hours; or 0.4-1.2 mg/day continuous infusion</p> <p>Atropine, 0.4 mg SQ every 15 minutes PRN; this can be used orally as well</p> <p>Hyoscyamine, 0.125-0.25 mg PO or SL every 4 hours</p> <p>Monitor for excessive fluid intake and reduce intake as acceptable to the patient</p> <p>Do not suction</p>
Delirium	<p>Review for underlying cause of the delirium (Chapter 6) and eliminate if possible</p> <p>If symptoms are upsetting to the patient or put him or her at danger or put others at danger, pharmacological interventions such as antipsychotic medications in low dosages and/or sedative hypnotics for hyperactive delirium may be helpful; hypoactive delirium may respond to treatments consistent with fatigue as delineated above</p>
Fever	<p>Use antimicrobials if consistent with goals of care and do not cause additional symptoms (eg, diarrhea, nausea)</p> <p>Use antipyretics such as acetaminophen either orally or rectally</p> <p>Bathe with tepid or cool water as tolerated by the patient</p>
Depression	<p>Antidepressants are less likely to be immediately effective, although they could be initiated depending on situation</p> <p>Counseling, pastoral or otherwise, should be considered if acceptable to patient</p>
Pain	<p>Pharmacological interventions should be initiated as described in Chapter 10 and Table 18-5</p> <p>Nonpharmacological interventions should be considered including positioning, distraction, music, acupuncture, massage, laughter, or lifelong patient preferences for management and coping with pain</p>
Hemorrhage	<p>Decrease visualization of excessive external bleeding from patient and family by using dark (versus white) towels</p> <p>Treat associated anxiety that may occur due to the bleeding (see above management of anxiety with lorazepam or other anxiolytic)</p>

IV, intravenous; PO, oral; PRN, as needed; SL, sublingual; SQ, subcutaneous.

constipation (Slatkin et al., 2009). It should be reserved, however, for patients who do not respond to other laxatives.

In acute bowel obstruction, attempts should be made to disimpact the patient manually and/or with enemas and prevent reoccurrence. Octreotide in combination with analgesics, corticosteroids, and antiemetics also has been noted to be useful

TABLE 18-5. Adjuvant Treatments for Pain Management

Drug group	Route	Pain indication	Addition information
Nonsteroidal anti-inflammatory drugs	Oral Topical	Neuropathic Visceral Bone Inflammatory	May cause gastrointestinal or renal side effects
Corticosteroids	Oral Intravenous	Spinal/nerve compression Neuropathic Bone	May cause gastrointestinal symptoms, hyperglycemia, or psychosis
Benzodiazepines	Oral (liquid or tablet) Intramuscular	Anxiety associated with the pain	May cause sedation or confusion/delirium and alter function
Anesthetics	Intravenous Topical	Intractable pain Neuropathic pain	May cause gastrointestinal side effects, confusion, urinary retention, headache, or anxiety

for patients with intestinal obstruction due to bowel cancer or malignancy affecting bowel function (Weber and Zulian, 2009).

■ **Diarrhea**

Diarrhea, defined as the passage of more than three unformed bowel movements within 24 hours, is also a common symptom that requires management when engaging in palliative care. Diarrhea may be due to malignancy, prior cancer-related treatment (eg, radiation), side effects from drugs used to manage other symptoms at the end of life, or long-term chronic problems (eg, irritable bowel syndrome). For new-onset diarrhea, it is useful to rule out or treat any unidentified underlying cause such as impaction, drug side effects, or infection. Treatment should include bulking agents and over-the-counter agents such as loperamide. Questran can be particularly effective as a bulking agent if the patient is able and willing to ingest this in adequate amounts.

■ **Nausea and Vomiting**

Nausea and vomiting should be evaluated to determine whether an underlying cause can be identified and attempts made to eliminate the cause. Nausea may be due to central causes in the chemoreceptor trigger zone of the brain. Conversely, peripherally caused nausea is mediated in the gastrointestinal system and the vestibular system. Receptors, including serotonin, dopamine, histamine, and acetylcholine, are involved in mediating nausea. Treatments such as haloperidol or metoclopramide act on the chemoreceptor trigger zone. Ondansetron and other serotonin 5-hydroxytryptamine-3 receptor antagonist are dopaminergic antagonists and act

in the chemoreceptor trigger zone along with the peripheral areas to decrease nausea. They are most effective for chemotherapy-induced nausea and less effective for opioid-induced nausea. Antihistamines are helpful in situations in which it is believed the vestibular system is involved. Lastly, corticosteroids can further augment the treatment of nausea, particularly when there are concerns about increased intracranial pressure.

■ Decreased Appetite and Weight Loss

Decreased appetite and weight loss may impact quality of life for older adults. If, however, the patient is not bothered by these symptoms, there is no need to treat the problem. If appetite and weight loss are concerns of the family or caregivers, then education can be provided about normal age changes and the advantages to decreased intake (eg, energy conservation, decreased bowel and bladder function). Associated mouth dryness can be managed with moist compresses and ointment such as Vaseline. Appetite may be pharmaceutically induced with corticosteroids, some antidepressants (eg, mirtazapine), or megestrol. Nonpharmaceutical appetite stimulants include a glass of wine or a cocktail prior to eating and focusing on food preferences and assuring that eating experiences are in pleasant situations and settings.

■ Shortness of Breath

Dyspnea, or shortness of breath, is particularly common in patients with chronic obstructive pulmonary disease or end-stage cardiac disease. The cause of the underlying dyspnea may be multifactorial and difficult to determine. There is a physiological interaction between chemoreceptors in the respiratory tract and central nervous system, upper airway receptors, stretch receptors in the chest wall, irritant receptors in the airway epithelium, and C fibers in the alveolar walls and blood vessels, and psychiatric symptoms (eg, anxiety) can further exacerbate dyspnea. Patients may experience benefits from direct use of oxygen via nasal cannula or face mask, increased oxygen in the patient's immediate environment, or having a fan blow cool air on the patient. Pharmacotherapy can include use of benzodiazepines to control the associated anxiety. Opioids are used to decrease respiratory drive and also to decrease the associated anxiety. These two treatment options (benzodiazepines and opioids) can be used together to provide a synergistic effect and allow for lower dosages of each drug group and thus less side effects experienced from either agent.

■ Excessive Secretions and Cough

Excessive secretions that the patient can't expectorate can be particularly bothersome to both the patient and the family/caregivers. Rather than have the patient endure the discomfort of suctioning, pharmacological treatment can be initiated. Treatment includes use of anticholinergic agents such as hyoscyamine or atropine given orally (National Comprehensive Cancer Network, 2012).

The excessive secretions experienced by a patient may result in a cough, or the cough may be particularly bothersome at the end of life due to mucus, blood,

foreign material, or stimulation of the receptors in the airway due to some type of irritation. Symptomatic treatment will vary based on the cause. For example, if the patient is in heart failure, the use of additional diuretics may help resolve the cough. Antibiotics appear to be useful if it is believed that an upper respiratory infection and excessive mucus are stimulating the cough. Cough suppressants such as dextromethorphan can be helpful in decreasing cough centrally without causing significant side effects. Elixirs with codeine may be used if the patient can tolerate these without side effects.

■ **Psychiatric Symptoms: Anxiety, Depression, Hallucinations, and Delirium**

Anxiety, delirium, depression, hallucinations, and associated agitation are not unusual, particularly as patients near the end of life. These symptoms are bothersome to patients and even more so to families and caregivers who witness them and are providing the ongoing management of the patient. If the patient is not bothered by the symptom (eg, the hallucinations are not unpleasant), then no treatment is required, and assurance and support for families and caregivers can be provided. Management of these problems is discussed in detail in Chapters 6, 7, and 14. Treatment should generally be initiated in the most expedient way possible with consideration of quality-of-life factors associated with symptoms experienced and treatment side effects (eg, sedation from anxiolytics).

Challenging situations often arise in which treatment for one symptom at the end of life results in another unpleasant symptom such as delirium. For example, opioids used to decrease pain may cause significant changes in cognition and delirium. It may be helpful to change pain treatment regimens by switching to another opioid or a different route of administration (eg, use of a patch versus oral treatment).

CONCLUSION

Providing patients with the opportunity to receive palliative care is a critical aspect of geriatrics and is as important as the diagnosis and management of acute medical problems. Decisions of when to consider palliative care may occur at different points in time for each patient. Offering this approach as an option for patients and their caregivers/loved ones should always be considered. Ongoing discussions may be needed, and decisions may be revisited throughout the course of aging. Understanding cultural differences and exploring patient and family knowledge, goals, and expectations are important aspects of palliative care. Most importantly, providers should remind patients and their families/caregivers that palliative care does not mean *no* care. Rather, focusing on treatment and the many ways in which we can treat symptoms that occur during the aging process should be emphasized. Although discussions around palliative care approaches and management often require significant time and energy on the part of the provider, the benefits are great. Patients and families are often spared unnecessary and unpleasant symptoms, and health-care providers have the opportunity to focus exclusively on comfort and symptom management.

REFERENCES

- ABIM Foundation. Choosing Wisely Campaign. Available at: <http://www.abimfoundation.org/>. Accessed September 2012.
- Balaban RB. A physician's guide to talking about end-of-life care. *J Gen Intern Med*. 2000; 15:195-200.
- Caron CD, Griffith J, Arcand M. Decision making at the end of life in dementia: how family caregivers perceive their interactions with health care providers in long-term-care settings. *J Appl Gerontol*. 2005;24:231-247.
- Cherlin E, Fried T, Prigerson HG, Schulman-Green D, Johnson-Hurzeler R, Bradley EH. Communication between physicians and family caregivers about care at the end of life: when do discussions occur and what is said? *J Palliat Med*. 2005;8:1176-1185.
- EthnoMed. Ethnic medicine informational. Available at: <http://ethnomed.org>. Accessed December 23, 2012.
- Fried LP, Tangen CM, Walston J, Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. *J Gerontol Med Sci*. 2007;61:262-266.
- Hassett AL, Williams DA. Non-pharmacological treatment of chronic widespread musculoskeletal pain. *Best Pract Res Clin Rheumatol*. 2011;25:299-309.
- McCullough D. *My Mother, Your Mother: Embracing "Slow Medicine," the Compassionate Approach to Caring for Your Aging Loved Ones*. New York, NY: HarperCollins Books; 2008.
- McPhee SJ, Winker MA, Rabow MW, Pantilat SZ, Markowitz AJ. *Care at the Close of Life*. New York, NY: McGraw Hill; 2011.
- National Comprehensive Cancer Network. NCCN practice guidelines for palliative care. Available at: <http://www.nccn.org/index.asp>. Accessed December 23, 2012.
- National Institutes of Health. Culture, diversity and health disparities in medicine. Available at: <http://bioethics.od.nih.gov/culturalcomp.html>. Accessed December 23, 2012.
- New Jersey Medical School. Palliative Care Order Form. Available at: <http://www.aacn.org/WD/Palliative/Docs/umdnj2.pdf>. Accessed December 23, 2012.
- Robert Wood Johnson Foundation. Last Acts. Available at: <http://www.rwjf.org/pr/product.jsp?id=20938>. Accessed December 23, 2012.
- Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. *J Gerontol Med Sci*. 2005;62:722-727.
- Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. *J Support Oncol*. 2009;7:39-46.
- Weber C, Zulian GB. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics. *Am J Hospice Palliat Care*. 2009; 26:84-88.

WEB-BASED REFERENCES

- American Academy of Hospice and Palliative Medicine. Available at: <http://www.aahpm.org>
- Center for Palliative Care. Available at: <http://palliativecare.medicine.duke.edu>
- Center for Palliative Care Education. Available at: <http://depts.washington.edu/pallcare/>
- City of Hope Pain & Palliative Care Resource Center. Available at: <http://prc.coh.org>
- End of Life/Palliative Education Resource Center. Available at: <http://www.eperc.mcw.edu>
- Fried Frailty Index. Available at: <http://www.biostat.jhsph.edu/~kbroche/Aging%20-%20PDF/Frailty%20Ascertainment.pdf>
- National Consensus Project for Quality Palliative Care Consortium. Available at: <http://www.nationalconsensusproject.org/>
- National Hospice and Palliative Care Organization. Available at: <http://www.nhpco.org>

This page intentionally left blank

APPENDIX

Selected Internet Resources on Geriatrics

ORGANIZATIONS

Administration on Aging	www.aoa.gov/
AgeNet Eldercare Network	www.aplaceformom.com/
Alzheimer's Association	www.alz.org/
Alzheimer's Disease Education & Referral Center	www.nia.nih.gov/ alzheimers
American Academy of Pain Medicine	
American Association of Homes and Services for the Aging	www.aahsa.org
American Association of Retired Persons	www.aarp.org/
American Geriatrics Society	www.americangeriatrics. org/
American Geriatrics Society Foundation for Health in Aging	www.healthinaging.org/
American Health Care Association	www.ahca.org/
American Medical Directors Association	www.amda.com/
American Pain Foundation	www.painfoundation.org/
American Pain Society	www.ampainsoc.org/
American Parkinson Disease Association	www.apdaparkinson.org/
American Society on Aging	www.asaging.org/
American Society of Consultant Pharmacists	www.ascp.com/
Arthritis Foundation	www.arthritis.org/
Centers for Disease Control and Prevention	www.cdc.gov/
Center to Advance Palliative Care	www.capc.org
Gerontological Society of America	www.geron.org/
Medicare	www.medicare.gov/
National Association of Area Agencies on Aging (N4A)	www.n4a.org
National Association for Continence	www.nafc.org/
National Association of Directors of Nursing Administration/Long-Term Care	www.nadona.org/
National Association of Nutrition and Aging Services Programs	www.nanasp.org
National Council on the Aging	www.ncoa.org
National Institute on Aging	www.nih.gov/nia
National Parkinson Foundation	www.parkinson.org/

CLINICAL TOPICS—FOR PROFESSIONALS

■ Alzheimer Disease

Progress Report on Alzheimer’s Disease 2009

<http://www.nia.nih.gov/sites/default/files/2009%20AD%20Progress%20Report%20Final%20B.pdf>

2011/2012 Alzheimer’s Disease Progress

<http://www.nia.nih.gov/alzheimers/publication/2011-2012-alzheimers-disease-progress-report>

■ General

2012 Beers Criteria Update

http://www.americangeriatrics.org/health_care_professionals/clinical_practice/clinical_guidelines_recommendations/2012

Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians

http://www.americangeriatrics.org/annual_meeting/2012_meeting_handouts/amhandouts050512/guiding_principles050512
www.abimfoundation.org

Choosing Wisely | ABIM Foundation

■ Hearing Impairment

American Academy of Audiology
Hearing Loss

www.audiology.org
www.merck.com/mmpe/sec08/ch085/ch085a.html

■ Low Vision

American Academy of Ophthalmology
American Glaucoma Society
Foundation Fighting Blindness
Macular Degeneration Foundation
Macular Degeneration Partnership

www.aao.org/
www.glaucomaweb.org/
www.maculardegeneration.org
www.eyesight.org
www.amd.org/

■ Medications

American Society of Consultant Pharmacists

www.ascp.com/

■ Pain Management

The Management of Chronic Pain in Older Persons
American Society for Pain Management Nursing

www.scribd.com/doc/9276458/
www.aspmn.org

■ Parkinson Disease

American Parkinson Disease Association—Free brochures for patients and caregivers

www.apdaparkinson.org/

■ Urinary Incontinence

National Association for Continence

www.nafc.org/

CLINICAL TOPICS—FOR PATIENTS

■ Alzheimer Disease

Alzheimer's Disease Fact Sheet

[www.nia.nih.gov/Alzheimers/
Publications/adfact.htm](http://www.nia.nih.gov/Alzheimers/Publications/adfact.htm)

■ Depression

Depression and Bipolar Support Alliance
Depression in Older Adults

www.ndmda.org/
[http://www.nmha.org/go/
information/get-info/
depression/depression-in-
older-adults](http://www.nmha.org/go/information/get-info/depression/depression-in-older-adults)

■ General

American Geriatrics Society Foundation for
Health in Aging
Five Wishes

www.healthinaging.org/

Nursing Home Compare

[www.agingwithdignity.
org/5wishes.html](http://www.agingwithdignity.org/5wishes.html)
[www.medicare.gov/nhcompare/
home.asp](http://www.medicare.gov/nhcompare/home.asp)

Nursing Home Checklist

[http://nursing-homes.
aplaceformom.com/articles/
nursing-home-checklist/](http://nursing-homes.aplaceformom.com/articles/nursing-home-checklist/)

■ Hearing Impairment

Healthy Hearing
Hearing Aid Help

www.healthyhearing.com
www.hearingaidhelp.com/

■ Low Vision

American Macular Degeneration Foundation
Facts About Age-Related Macular Degeneration

www.macular.org/
[http://www.nei.nih.gov/
health/maculardegen/armd_
facts.asp](http://www.nei.nih.gov/health/maculardegen/armd_facts.asp)

Learn About Glaucoma

[http://www.glaucoma.org/
glaucoma/](http://www.glaucoma.org/)

Macular Degeneration Foundation

www.eyesight.org

Macular Degeneration International
Macular Degeneration Partnership

www.maculardegeneration.org
www.amd.org

■ **Medications**

Top Ten Dangerous Drug Interactions in
Long-Term Care

[http://www.amda.com/tools/
clinical/m3/topten.cfm](http://www.amda.com/tools/clinical/m3/topten.cfm)

■ **Pain Management**

Pain (PDQ): Supportive Care-Patients
Geriatric Pain, developed by Keela Herr at the
University of Iowa

www.cancernet.nci.nih.gov/
[http://www.geriatricpain.org/
pages/home.aspx](http://www.geriatricpain.org/pages/home.aspx)

■ **Parkinson Disease**

NINDS Parkinson's Disease Information Page

[www.ninds.nih.gov/health_
and_medical/disorders/
parkinsons_disease.htm](http://www.ninds.nih.gov/health_and_medical/disorders/parkinsons_disease.htm)

Parkinson's Disease—Hope Through Research

[www.ninds.nih.gov/health_
and_medical/pubs/
parkinson_disease_htr.htm](http://www.ninds.nih.gov/health_and_medical/pubs/parkinson_disease_htr.htm)

INDEX

Note: Page numbers followed by “t” indicate tables; page numbers followed by “f” indicate figures.

A

- abuse. *See* elder abuse
- acarbose, 305
- accountability, in chronic care, 80
- ACD. *See* anemia of chronic disease
- ACE inhibitors. *See* angiotensin-converting enzyme inhibitors
- ACOVE. *See* assessing care of vulnerable elders
- activities of daily living (ADLs)
 - dependencies in terms of, 29–30, 29t
 - in function assessment, 56–57
- acupuncture, 253
- acyclovir, 330
- AD. *See* advance directive; Alzheimer disease
- ADLs. *See* activities of daily living
- administration for community living, 392
- Administration on Aging (AoA), 392
- adult foster care homes, 401
- advance care planning, 450
- advance directive (AD)
 - development of, 453
 - end-of-life care and, 450, 452
 - federal law for, 452
 - health-care provider's role in development of, 452
 - increasing number of individuals with, 462
 - living will v., 450, 452
 - policy's role with, 462
 - proxy and, 451
 - PSDA for, 462
 - questions in creating, 454
 - same-sex relationship and, 450
 - state law and, 455
 - types of, 464
 - verbal, 455
- advertising, drugs and direct-to-consumer, 362
- aged persons. *See also* geriatric patients
 - bacteriuria in, 329
 - children of, 31
 - depression in, 159
 - diastolic dysfunction in, 277
 - drug problems of, 123
 - falls as caused in, 232, 233t–234t, 234–236
 - growth in population of, 25–28
 - iatrogenic problems of, 122t
 - infection in, 326–330, 326t
 - nutrition as assessed in, 322
 - obesity's prevalence among, 325
 - overmedicated, 123
 - pain in, 264
 - prevention's effectiveness in, 112, 113–116, 115f
 - resources for supporting, 26
 - suicide by, 160, 161t
 - temperature regulation of, 330
 - visual problems' sign/symptoms in, 347, 348t
 - vulnerability of, 124–125
- ageism, 93
 - ethics and, 447
- aging
 - anabolic hormones decline with, 317–318
 - biological changes occurring during, 3
 - biological theories on, 9
 - bladder in, 191
 - blindness and, 342
 - caloric restriction and, 13–14
 - cardiovascular system's physiological changes during, 277
 - central nervous system changes and, 160
 - changes associated with, 4–5, 6t–9t
 - chronological v. gerontological, 4
 - clinical implications of process of, 3–20
 - costs associated with, 23
 - damage theories of, 10
 - as defined, 3
 - depression and, 159–162, 161t, 162t
 - disease v., 10
 - DNA damage and, 14
 - environmental factors on, 4
 - evolution theory as theory of, 10
 - gene regulation of, 11
 - genetics in regulation of biological, 9
 - glucose tolerance deteriorating with, 303
 - gradual loss and changes associated with, 5
 - health-care provider role in, 15
 - hearing changes related to, 8t, 347, 349, 350f, 352–353, 352t
 - hypothalamic-pituitary-thyroid axis changes with, 308
 - HZ incidence increasing with, 330
 - instability and, 229–232, 231t
 - interventions for slowing, 13

- aging (*Cont.*):
- lifestyle behaviors and, 4
 - lifestyle interventions and, 15
 - medical management of, 4
 - as multifactorial process, 9
 - normal v. pathologic, 4
 - nutrition and, 322–323, 322*t*
 - pharmacology and, 369–370, 370*t*
 - process of, 4
 - psychosocial aspects of, 16
 - renal function effected by, 371–372, 372*t*
 - social factors on, 4
 - stress response reduced with, 17
 - successful, 4
 - taste and, 356
 - testicular function's decline with, 318
 - theories of, 9–15, 9*t*
 - thyroid function and, 308, 311, 311*t*
 - tissues, 11
 - treatments, 4
 - variability in, 15
 - vision's physiological/functional changes with, 341–342, 342*t*
- akathisia, 376
- albumin, 53*t*, 60
- Alzheimer disease (AD)
- cholinesterase inhibitors for treatment of, 151
 - death caused by, 28
 - diagnostic criteria for, 143, 143*t*
 - early-onset familial, 13
 - genes related to, 13
 - late-onset, 13
 - multi-infarct dementia v., 144*t*
 - risk factors for, 143
 - treatments for, 144
- amantadine, 257
- American Geriatrics Society, 58
- amylin, 307
- anabolic hormones, aging associated with decline in, 317–318
- analgesics, 253
- androgens, physiological actions of, 318
- anemia, 60, 67, 312
- of cancer, 321
 - Epo and, 321
 - folate deficiency and, 320–321
 - hypochromic, 320, 320*t*
 - iron deficiency as cause of, 319
 - sideroblastic, 320
 - symptoms of, 318, 318*t*
- anemia of chronic disease (ACD), 320
- therapy for, 321
- anesthesia, regional v. general, 67
- angina pectoris, 290
- angiotensin-converting enzyme (ACE) inhibitors
- congestive heart failure as treated with, 296
 - diabetes and, 307
 - hypertension and, 282, 284
- ankle-brachial index, 297*t*
- anorexia, 48
- ANP. *See* atrial natriuretic peptide
- antibiotics, 327
- antidepressants, 235
- atypical, 180*t*
 - characteristics of, 180, 181, 182*t*–183*t*
 - for geriatric patients, 179*t*–180*t*, 373
 - for pain, 265
 - tricyclic, 181
- antihypertensives, 235
- antimuscarinic drugs
- anticholinergic properties of, 216
 - maximum effect of, 216
 - for urgency incontinence, 216
- antipsychotics, 235, 375*t*
- dementia as treated with, 151
- AoA. *See* Administration on Aging
- aortic stenosis, 242
- calcific, 291–292
 - diagnosing, 292
 - differentiating, 292
 - frequency of, 291
 - management of, 291–292
 - presentation of, 291
- apathy, 152
- aphasia, 152
- appendicitis, 327
- appetite, decreased, 477
- arginine vasopressin (AVP), 192
- arrhythmia, 331
- causes of, 294
 - prevalence of, 294
- arthritis. *See also* gout; osteoarthritis
- disorders included in, 253–255
 - gout v. inflammatory, 254–255, 254*t*
 - septic, 327
 - treating, 254
 - types of, 254
- artificial feeding, 460
- artificial urinary sphincter, implantation, 221
- aspirin, 116
- hearing impairment from, 354
 - strokes and, 286, 288

- assessing care of vulnerable elders (ACOVE),
 - evidence-based recommendations derived from, 86, 87*t*
- assessment. *See also* confusion assessment
 - method; geriatric assessment; laboratory assessment
- of care in nursing homes as approached, 407, 408*t*
- environmental, 58
- of falls, 239, 240*t*–241*t*, 242
- functional, 49–58, 55*t*
- hearing, 351–352, 351*t*
- of immobile patients, 251–253, 251*t*, 252*t*
- for malnutrition, 61*t*
- in nursing homes, 421, 422*t*, 426*t*–429*t*
- of nutrition in aged persons, 322
- nutritional, 59–61, 60*t*–61*t*, 62*t*
- for pain, 58–59, 59*t*, 60*f*
- assisted living
 - approach of, 410
 - costs of, 410
 - as form of care, 409
 - independence of residents in, 410
 - recipients of, 410
- atrial fibrillation, 288, 316
 - cardioversion for, 294
 - incidence of, 294
- atrial natriuretic peptide (ANP), 192
- atrophy, muscle, 249
- attitudes
 - of caregivers, 3
 - of older adults, 3
 - of physicians, 120
- auditory system. *See also* hearing
 - brainstem, 349, 350*t*
 - cortical areas, 349, 350*t*
 - peripheral, 349–351, 350*t*
- autonomy
 - ethics of, 447
 - principle of, 447–448, 448*t*
- AVP. *See* arginine vasopressin

B

- bacterial meningitis, 328
- bacteriuria, 202–203
 - in aged persons, 329
 - mortality associated with, 329
- balance, after fall as examined, 239, 240*t*–241*t*, 242
- barbiturates, 317
- bariatric surgery, 325–326
- bathing, in hospitals, 126

- bed rest
 - complications of, 126, 126*t*
 - consequences of, 247, 249
- beneficence, principle of, 447–448, 448*t*
- benign prostate hyperplasia (BPH), 216
- bilirubin, 321
- biological theories, of aging, 9
- biphosphonates, 4, 121
- bipolar affective disorder, in geriatric patients, 160
- bipolar disorders, management of, 184
- birth rates, 25
- bladder
 - aging and, 191
 - neck suspension, 221
 - overactive, 197, 216, 220
 - retraining, 202*f*; 211, 213, 214*t*
 - surgery on, 221
 - training, 208, 211, 213
- blindness
 - aging and, 342
 - cataracts caused, 342
 - diabetic retinopathy caused, 342
 - glaucoma causing, 342
 - prevalence of, 342, 342*t*, 343*f*
 - screening for causes of, 342
- blood. *See also* blood pressure
 - glucose control, 306
 - loss, 138
 - vessels, 261
- blood pressure, 117
 - of diabetic patients, 307
 - elevated, 50*t*
 - high, 280, 281
 - lowering, 116
 - postural changes in, 50*t*
 - tight, 347
- BMD. *See* bone mass density
- body mass index (BMI), 59
- bone mass density (BMD), 15
- BPH. *See* benign prostate hyperplasia
- bradycardia-tachycardia syndrome, 295
- bradykinesia, 376
- brain. *See also* deep brain stimulation
 - longitudinal tissue loss for gray/white matter in, 15
- bupropion, 178, 181
- bursitis, 255

C

- calcified mitral annulus, 292–293
- calcitonin, 121

- calcium, 4, 53*t*, 323
- caloric restriction
 - aging and, 13–14
 - life span increased by, 324
- CAM. *See* confusion assessment method
- cancer, 28
 - anemia of, 321
 - delaying onset of, 13
 - developing, 11
 - of pancreas, 168
 - progression of, 114
 - screening for, 114
- carbohydrate metabolism, endocrine disease and, 303–308
- cardiorespiratory arrests, 331
- cardiovascular disease. *See also* valvular heart disease
 - hypertension as risk factor for, 278
 - statins and, 4
 - therapies for, 291
- cardiovascular disorders. *See also* cardiovascular disease; congestive heart failure; hypertension; peripheral vascular disease
 - aging and, 277
 - physical changes and, 277, 278*t*
- cardiovascular system, aging associated changes with, 6*t*
- cardioversion, 294
- care. *See also* assisted living; caregivers; dental care; end-of-life care; geriatric care; long-term care; medical care; nursing home care; postacute care; primary care
 - catheter, 221–222, 223*t*
 - compensatory, 382
 - day, 414–415
 - ethical, 448*t*
 - futility of, 461–462
 - goals of, 457*t*
 - group, 79
 - home, 411–414, 411*t*
 - informal, 396–397
 - maximizing quality of, 399
 - of myxedema coma patients, 313, 315
 - in nursing homes as improving, 401
 - of older v. younger patients, 3
 - palliative, 75–76, 456
 - restorative, 268
 - sources of, 396*f*
 - technology for, 84–86
- caregivers
 - attitudes of, 3
 - ethical issues concerning, 462–463
 - family as, 397–398
 - incontinence and, 213–216
 - women as, 30
- carotid endarterectomy, stroke risk reduced by, 288
- carpal tunnel syndrome, characteristics of, 255
- case management
 - benefits of, 79
 - efficacy of, 79
 - manager's role in, 417
 - term as used, 415–416
 - variants of, 416*t*, 417
- case managers, in disease management, 79
- cataracts, 51*t*
 - blindness caused by, 342
- cortical, 342–343
- development of, 342–343
- extracapsular extraction of, 343
- intracapsular extraction of, 343
- managing, 343
- prevalence of, 342
- senile, 342–344
- vision as restored after surgery for, 344*t*
- catheters
 - care, 221–222, 223*t*
 - chronic indwelling catheterization with, 222
 - external, 221
 - in incontinence management, 221–222, 223*t*
 - intermittent straight catheterization with, 222
 - types of, 221–222
- CBT. *See* cognitive behavioral therapy
- cells
 - endothelial, 11
 - marrow, 11
 - nonreplicating, 11
 - replicating in vitro, 11
 - replicative capacity of, 11
 - senescent, 11
 - stem, 9, 13
 - tissue-specific, 13
- cerebrovascular disease, 236
- cerumen, hearing loss from, 354, 354*t*
- children
 - of aged persons, 31
 - in hospitals, 127
- chlorpropamide, 317
- cholinesterase inhibitors, 151
- chondroitin, 253
- chronic care, 72*t*. *See also* chronic disease management

- accountability in, 80
- clinical glide path approaches meeting needs of, 78
- creativity in, 80
- data systems required by, 76
- effective, 76
- outcomes role in, 80–83, 82*t*
- quality of, 80–84, 81*t*
- systemic approach to, 381
- chronic disease management, 24*f*, 32. *See also*
 - geriatric disease management
 - approaches to, 79
 - basic tenets of, 72*t*
 - clinical glide paths in, 76–78, 77*f*
 - cure v., 73, 73*f*
 - drug therapy's nature in, 361
 - fee-for-service payment, 86–87
 - group care for, 79
 - health plans' use of, 79
 - models of, 71
 - preventing catastrophes, 71, 72*f*
 - principles of, 71
 - targeting/tracking in, 79–80
- chronic obstructive pulmonary disease (COPD), 28
- chronological aging, 4
- CI. *See* cognitive impairment
- CIND. *See* cognitive impairment, not dementia
- citalopram, 178
- clinical glide paths
 - in chronic disease management, 76–78, 77*f*
 - for chronic problems, 76–78
 - models, 76–78, 77*f*
 - underlying concept of, 76
- clinician's, in end-of-life care, 457–459
- clonidine, 284
- clopidogrel, 288
- cochlear implants, 356
- cognitive behavioral therapy (CBT), 177
- cognitive impairment (CI)
 - causes in geriatric population of, 135–136
 - differential diagnosis of, 135–136
 - geriatric patients exhibiting, 133
 - symptoms associated with, 152
- cognitive impairment, not dementia (CIND), 135
- colchicine, 255
- colon, irritable, 18
- coma. *See* diabetic ketoacidotic coma; hyperosmolar nonketotic coma; myxedema coma
- communication, 355
 - in end-of-life care, 458
 - in geriatric care, 383
- competence, informed consent and, 448–450
- competitive risks, theory of, 73
- computers
 - clinical medicine and technology of, 84–86
 - data kept on, 85–86
 - records, 85
 - redundancy reduced by, 84–85
- confusion. *See also* delirium; dementia
 - causes of, 133–145
 - diagnosis of causes of, 135
 - disorders causing, 135
 - geriatric patients exhibiting, 133
 - manifestation of, 133
 - multiple interacting processes causing, 135
- confusion assessment method (CAM), 133
 - delirium diagnosed with, 137
- congestive heart failure
 - ACE inhibitors for treatment of, 296
 - diagnosing, 295
 - diastolic dysfunction and, 295
 - as overdiagnosed, 295
 - therapy for, 296
- constipation
 - causes of, 223
 - chronic, 225
 - defining, 222–223
 - drugs for treating, 224, 225*t*, 473, 475–476
 - immobility and, 250
 - management of, 224, 473, 475–476
- consultation. *See* geriatric consultation
- contact lenses
 - extended-wear, 344
 - function of, 344
 - handling, 344
- continence, requirements of, 188, 189*t*
- COPD. *See* chronic obstructive pulmonary disease
- coronary artery disease
 - frequency of, 289
 - hypertension as risk factor for, 289
 - revascularization for, 290
 - risk factors for, 289
- corticosteroids, 255, 267, 330, 475, 477
- corticotrophin, 255
- cough and excessive secretions, 477–478
- CPK. *See* creatine phosphokinase
- creatine phosphokinase (CPK), 312
- creatinine, 53*t*
- creativity, in chronic care, 80

culture, in EOL care, 472
 cystoceles, 205*f*

D

damage theories, of aging, 10
 dapagliflozin, 307

Darwin, Charles, 10

day care, 414–415

DBS. *See* deep brain stimulation

death

- accidents as cause of, 229
- causes of, 27–28, 27*t*
- of elderly patients, 75
- in end-of-life care as discussed, 75
- from falls, 229
- physician's terms with, 75
- rates, 23
- talking about, 75

decisional capacity

- dementia and, 449
- as predicated, 449

deep brain stimulation (DBS), 260

defecation

- controlling, 226
- process of, 222

degenerative joint disease (DJD), 231, 247

dehydration, 168

dehydrogenase, 321

delirium

- CAM diagnosis of, 137
- causes of, 137, 138–139, 139*t*
- as characterized, 137
- confusion caused by, 133
- as defined, 136
- dementia v., 137, 138*t*
- development of, 136, 137
- diagnosing, 133, 134*t*, 136*t*, 137
- drugs causing/contributing to, 139, 140*t*
- management of, 478
- in postacute care settings, 136
- prevalence of, 136
- rapid recognition of, 137
- screening for, 133
- as superimposed on dementia, 133

dementia

- AD v. multi-infarct, 144*t*
- antipsychotics for treatment of, 151
- causes of nonreversible, 142*t*
- causes of reversible, 141*t*
- classifications for nonreversible, 141–142
- confusion caused by, 133
- decision-making capacity and, 449

- as defined, 140

- delirium as superimposed on, 133

- delirium v., 137, 138*t*

- diagnostic studies of, 148*t*

- drugs causing/contributing to, 139, 140*t*

- end-of-life ethical concerns for patients with, 460

- evaluation for, 145–149, 146*t*, 148*t*

- functional ability loss in, 140

- general principle for management of, 149

- history in evaluating, 145–146, 147*t*

- key features of, 140

- management of, 146–147, 150*t*

- MCI v., 140

- multi-infarct, 144, 144*t*, 145, 145*f*, 148

- nonpharmacological management of, 152–153

- nonreversible, 141–142, 142*t*

- nursing homes' special care units for, 152

- pharmacological treatment of, 149, 151–152

- physical environment alterations, for treatment of, 152

- physical examination, 148

- prevalence of, 133

- reversible, 140–141, 141*t*

- social history of patients with, 147

- special case of, 460–461

- symptoms indicating, 145, 146*t*

- tests for, 148

- vascular, 144, 145

- dementia with Lewy bodies (DLB), characteristics of, 142

- demethylchlortetracycline therapy, 317

- demography, of geriatric patients, 23–38

- dental care, 31

- depression, 114–115. *See also* antidepressants

- in aged persons, 159

- agent choice for pharmacological treatment of, 176, 178

- aging and, 159–162, 161*t*, 162*t*

- behavioral interventions for, 176

- causes of, 176

- diagnosis of, 159, 161*t*, 162–166, 162*t*, 167*t*, 169–171, 170*t*, 171*t*–173*t*, 173–174, 174*t*

- drug treatment of, 151

- evidence-based recommendations for interventions, 184

- exercise in treatment of, 177

- functional disability produced by, 177

- in geriatric patients, 18

- as identified, 163

- in immobilized patients, 249

- insomnia and, 165–166

- losses as contributory factor to, 162
- major, 162–163
- major v. other types of, 172*t*
- management of, 175–178, 175*t*, 179*t*–180*t*, 180–181, 182*t*–183*t*, 184, 478
- medical condition associated, 166–169, 167*t*
- medical conditions imitating, 166
- minor, 163
- nonpharmacological management of, 177
- in nursing homes, 373
- pharmacological treatment of, 177–178, 179*t*–180*t*, 180–181, 182*t*–183*t*, 184
- physical appearance and, 162–164
- predisposition toward, 160, 162*t*
- presentation of, 170, 170*t*, 171, 173
- psychosocial factors, 162
- psychotherapy for, 177
- screening tools for diagnosing, 169–170, 173*t*
- signs of, 159
- SSRIs and, 176, 178, 179*t*
- symptoms of, 162–166, 164*t*, 168
- TCAs and, 176, 178, 179*t*
- treatment modalities for managing, 175–177, 175*t*
- treatments for, 175–177
- depressive pseudodementia, 141
- diabetes, 67
 - ACE inhibitors and, 307
 - adult-onset, 117, 304
 - blood glucose control in type 2, 306
 - blood pressure of patients with, 307
 - development of, 303
 - diagnosis of, 303
 - exercise and, 304
 - glucose intolerance and, 303
 - insulin therapy for, 307, 309*f*–310*f*
 - macrovascular disease risk with, 307
 - obesity and, 304
 - oral hypoglycemic agents for, 304
 - polyneuropathy and, 356
 - screening for, 303
 - step-care approach to treatment of type 2, 306–307, 306*t*
 - therapeutic goal for patients with, 303–304
 - visual loss with, 346–347
- diabetic ketoacidotic (DKA) coma, 308, 311*t*
- diabetic retinopathy
 - in geriatric patients, 346–347
 - treatment for, 347
- diagnosis
 - of cognitive impairment causes, 135–136
 - of depression, 159, 161*t*, 162–166, 162*t*, 167*t*, 169–171, 170*t*, 171*t*–173*t*, 173–174, 174*t*
 - of diabetes, 303
 - for drug therapy, 361
 - of gout, 255
 - of hypertension, 279
 - of hyperthyroidism, 315
 - of hypothermia, 330–331
 - of sick sinus syndrome, 295
 - of strokes, 286
- diarrhea
 - causes of, 476
 - management of, 476
 - treatment for, 476
- diastolic dysfunction, in aged persons, 277
- dietary restriction (DR), for enhancing longevity, 13
- digoxin, 294, 296
- disability
 - as defined, 28
 - depression produced functional, 177
 - handicaps v., 29
 - measuring, 119
 - prevalence of, 397*f*, 398*f*
 - prevention of, 119–120
 - studying, 119
 - transient v. persistent states of, 119
- disease. *See also* Alzheimer disease; cardiovascular disease; chronic obstructive pulmonary disease; geriatric disease management; heart disease; iatrogenic diseases; lung disease; Parkinson disease
 - aging v., 10
 - coronary artery, 289–291
 - degenerative joint, 231, 247
 - endocrine, 303–308, 307, 308
 - in geriatric patient as presented, 19–20
 - metabolic bone, 316, 317*t*
 - middle-ear, 352
 - occult coronary artery, 277, 278*t*
 - parathyroid, 316
 - peripheral vascular, 296–298
 - processes associated with falls, 235
 - screening for, 112
 - stress of, 17
 - valvular heart, 291–294
 - vascular, 352
- diuretics, 196, 235
 - thiazide, 281, 281*t*
- dizziness, 234
- DJD. *See* degenerative joint disease
- DKA coma. *See* diabetic ketoacidotic coma

- DLB. *See* dementia with Lewy bodies
- donepezil, 151
- DR. *See* dietary restriction
- drug therapy
- adherence's role in successful, 362*f*, 363, 364*t*
 - adverse reactions/interactions to, 364–365, 366*t*, 368–369, 369*t*
 - in chronic disease management, 361
 - complex regimes of, 361
 - diagnosis for, 361
 - effective, 361
 - electronic databases for, 368–369
 - factors interfering with successful, 362*f*
 - in geriatric patients safety/effectiveness, 361, 362*f*
 - medication records for, 365
 - nonpharmacological factors influencing, 361, 364*t*, 365
 - pharmacodynamic changes and, 372
 - polypharmacy and, 362–363, 365
 - renal function and, 371–372, 372*t*
 - tissue sensitivity and, 372
- drugs. *See also* antimuscarinic drugs; drug therapy
- absorption of, 370
 - adverse reactions to, 364–365, 366*t*–369*t*, 368–369
 - aged persons' problems with, 123
 - antipsychotic, 373, 375*t*
 - antithyroid, 315
 - behavioral interventions prescribed in conjunction with, 216
 - for constipation treatment, 224, 225*t*
 - delivery system of, 370
 - dementia as treated with, 149, 151–152
 - dementia/delirium contributed to/caused by, 139, 140*t*
 - depression symptoms caused by, 169*t*
 - depression treated with, 151
 - direct-to-consumer advertising of, 362
 - distribution of, 370–371
 - excretion of, 371–372, 372*t*
 - falls and, 235
 - geriatric patients treatment with, 216, 220
 - hip fractures associated with psychotropic, 376
 - hypnotics, 373, 375*t*
 - immobility contributed to by side effects of, 249
 - incontinence treatment with, 216, 217*t*–219*t*, 220
 - interactions among, 365, 368
 - interactions of drug to, 368*t*–369*t*
 - Medicare covering prescription, 389
 - metabolism, 371
 - as metabolized, 123
 - misuse of psychotropic, 373–376
 - for osteoporosis treatment, 120–121
 - for pain, 265, 266*t*
 - pharmacodynamics, 361
 - pharmacokinetics, 361
 - pharmacology and, 369–370, 370*t*
 - psychotropic, 365, 373–376
 - second-generation antipsychotic, 376–377
 - sedatives, 235, 373
 - sensitivity to effects of, 372
- duloxetine, 178, 181, 220
- dyslipidemia, 290
- dyspnea, 477
- E**
- echocardiography, 292, 293
- edema, 52*t*, 295
- elder abuse
- risk factors for, 63
 - screening for, 63
- electrocardiogram, 53*t*
- electrolytes, 53*t*
- electromyography (EMG), 211
- EMG. *See* electromyography
- end-of-life (EOL) care, 467, 469*t*. *See also* hospice
- ADs and, 450, 452
 - clinician's role in, 457–459
 - communication in, 458
 - death as discussed in, 75
 - decisions in, 456
 - for dementia patients, 460
 - goals of, 457*t*
 - laws for, 454
 - legal myths about, 459
 - nursing home residents' decisions about, 459–460
 - physical concern with patient's functioning in, 75
 - values and, 458
- endocrine disease, carbohydrate metabolism and, 303–308
- endocrine system, aging related changes to, 8*t*
- environment
- aging and factors of, 4
 - assessment of, 58
 - dementia treated with alterations in physical, 152
 - function barriers, 54
 - as function's principle force, 119
 - of geriatric patients, 18, 58

immobility from changes in, 247, 249
 of immobilized patient, 251
 influencing, 123
 psychological, 119–120
 EOL. *See* end-of-life care
 eplerenone, 284
 Epo. *See* erythropoietin
 error catastrophe theory, 10–11
 erythropoietin (Epo)
 anemia and, 321
 levels, 321–322
 escitalopram, 178
 estrogen, 151
 oral, 220
 for stress incontinence, 220
 therapy, 280
 ethics
 ageism and, 447
 of autonomy, 447
 of caregivers, 462–463
 committees, 455, 460
 in geriatrics, 447
 laws v., 454
 of medicine, 456
 evaluation. *See also* assessment; geriatric
 assessment; preoperative evaluation
 for dementia, 145–149, 146*t*, 148*t*
 dietary, 319
 essential aspects of geriatric, 41–44, 42*f*, 43*t*
 of gait, 49
 of geriatric patient who falls, 236–239,
 238*t*–239*t*, 240*t*–241*t*, 242
 of hearing aids, 355–356, 355*t*
 of hypertension, 279–280, 279*t*
 of incontinence patients, 199–206, 200*t*,
 202*f*–203*f*, 204*t*, 207*t*–208*t*, 209*f*
 strategies for geriatric, 44
 evolution theory, as theory of aging, 10
 examination. *See* mental status examination;
 physical examination
 exercise, 66–67
 benefits of, 117, 267–268
 in depression treatment, 177
 diabetes and, 304
 for geriatric patients, 116
 for immobility prevention, 267–268
 for PD therapy, 260
 pelvic muscle, 209–210, 211
 types of, 116, 117*t*
 eyes
 age-related macular degeneration, 345–346
 corneal endothelium, 341

physiological/functional changes with age to,
 341–342, 342*t*
 tear secretion function of, 341–342

F

falls
 age-related factors contributing to, 229–232, 233*t*
 causes of, 229–236, 230*f*, 233*t*–234*t*, 244*t*
 complications of, 229, 230*t*
 consciousness loss after, 237
 disease processes associated with, 235
 drop attacks causing, 232, 234
 drugs and, 235
 environmental hazards for, 232, 234*t*
 evaluation of geriatric patient who, 236–239,
 238*t*–239*t*, 240*t*–241*t*, 242
 fear of, 229
 feet and, 238
 gait/balance assessment after, 239, 240*t*–241*t*,
 242
 hip fractures from, 229
 history in evaluating, 238*t*
 management of patient with history of,
 242–243, 243*t*
 neurological examination following, 238
 in nursing homes, 232, 234*t*
 physical examination of aged persons who,
 237, 239*t*
 physical therapy for, 243
 polyneuropathy increasing risk of, 356
 prevention, 229
 syncope and, 235
 treatment for underlying causes of, 244*t*
 unwitnessed, 237
 vertigo and, 234–235
 famciclovir, 330
 fatigue, 48
 fear, of falls, 229
 fecal impaction, 196
 feeding, artificial, 460
 feet, 238
 fever, 168
 fiber, dietary, 324
 fibroblasts, 11
 FIM. *See* Functional Independence Measure
 folate deficiency, 320–321
 foster care. *See* adult foster care homes
 frailty
 causes of, 471
 indicators of, 472
 palliative care focus and, 471–472, 471*t*
 symptoms of, 471, 471*t*

Framingham Eye Study, 342, 344, 345

function

- assessment tools for status of geriatric, 56–58
- environment as principle force of, 119–120
- environmental barriers to, 54
- in geriatrics as preserved, 119
- as geriatrics component, 52
- hip fractures causing decline in, 256
- improvement/preservation of, 119
- as influenced, 52–54
- measuring physical, 56–57, 56*t*
- mental, 56–58
- motivation and, 54
- organ, 5
- physical barriers to, 119
- principal forces of, 119
- psychological barriers to, 54
- psychological environment for, 119–120
- testicular, 318

functional incontinence, 199

Functional Independence Measure (FIM), 57

G

gabapentin, 330

gait

- changes in, 230, 233*t*
- evaluation of, 49
- after fall as examined, 239, 240*t*–241*t*, 242
- training, 243

galantamine, 151

gastrointestinal system, aging-associated changes with, 7*t*

genes

- aging regulated by, 11
- Alzheimer disease and, 13
- cloning, 12

genetics

- in biological aging regulation, 9
- hormone signaling and, 13

geriatric assessment

- approaches to, 42–43
- common physical findings in, 50*t*–52*t*
- controlled trials of, 42, 43*t*
- effectiveness of, 43
- environmental assessment in, 58
- of functional abilities, 42
- functional assessment in, 49–58, 55*t*
- histories as taken in, 44–48, 46*t*–47*t*
- in-home, 42
- laboratory assessment in, 49, 53*t*
- nutritional assessment in, 59–61, 60*t*–61*t*
- perspective required for, 41

physical exam in, 49, 50*t*–52*t*, 53*t*

sensitivity during, 41

setting of, 41

social history as component of, 48

techniques for, 42

term as used, 43

as tested, 42

geriatric care

- communication in, 383
- normal v. pathologic aging and, 4
- team care implied by, 383

geriatric consultation

- comprehensive, 61, 63
- request for, 61, 63, 64*t*–67*t*
- for specific clinical issues, 61, 63, 64*t*–67*t*
- systematic screening strategy for, 64*t*

geriatric disease management

- end-of-life care in, 75–76
- specific areas of, 75–76

geriatric patients

- antidepressants for, 179*t*–180*t*, 373
- bipolar affective disorder in, 160
- cognitive impairment exhibited by, 133
- demography of, 23–38
- depression in, 114–115
- diabetic retinopathy in, 346–347
- drug therapy adherence by, 363, 364*t*
- drug therapy's safety/effectiveness for, 361, 362*f*
- drug treatment for, 216, 220
- environment of, 58
- as evaluated after falls, 236–239, 238*t*–239*t*, 240*t*–241*t*, 242
- evaluation of, 41–67
- exercise for, 116
- factors influencing, 41–42
- federal programs for, 393*t*–395*t*
- functional assessment in population of, 55*t*
- glaucoma in, 344–345
- growth in number of, 25–28, 26*t*
- histories of, 44
- insomnia in, 377
- laboratory assessment of, 49, 53*t*
- LTC of, 392, 396
- muscle strength as graded in immobilized, 252*t*
- nonpharmacological approaches, 376
- occupational therapy in immobility management of, 269, 270*t*
- physical appearance of depressed, 162–164
- preoperative evaluation of, 63, 66–67, 66*t*
- rehabilitation of, 268*t*–270*t*
- risk-benefit ratio of treatments for, 71, 72*f*

- risk factors for functional decline in
 - hospitalization, 126*t*
 - social history of, 48
 - young patients v., 71
 - geriatric prescribing
 - as difficult, 373
 - general principles for, 373, 374*t*
 - geriatrics
 - ethics in, 447
 - function as component of, 52
 - function as preserved in, 119
 - functional assessment concepts in, 55*t*
 - infections in, 18
 - mobility in, 247
 - presenting problems in, 19–20
 - public programs in, 384–392
 - syndrome, 18–19
 - gerontological aging, 4
 - GH. *See* growth hormone
 - ginkgo biloba, 151
 - glaucoma
 - angle-closure, 344–345
 - blindness caused by, 342
 - as characterized, 344
 - chronic open-angle, 345
 - in geriatric patients, 344–345
 - primary, 344
 - treatment for, 345
 - glucosamine, 253
 - glucose, 53*t*
 - glucose intolerance
 - aging and, 303
 - diabetes and, 303
 - goiter, 311, 315
 - gout
 - acute phase of, 254
 - as characterized, 254
 - definitive diagnosis of, 255
 - treatment of, 255
 - growth hormone (GH), 13
 - as antiaging treatment, 13
 - signaling, 13
 - Guillain-Barré syndrome, 356
- H**
- handicaps, disabilities v., 29
 - health-care
 - nature of, 383–384
 - public programs for, 384
 - spending on, 383–384, 383*f*
 - health-care providers. *See* nurse practitioners; physicians
 - health promotion
 - popularity of, 93
 - web-based resources for, 16*t*
 - healthy people report card, 95*t*
 - hearing. *See also* hearing aids
 - aging-related changes to, 8*t*, 347, 349, 350*f*, 352–353, 352*t*
 - aspirin caused impairment of, 354
 - assessment, 351–352, 351*t*
 - aural rehabilitation for, 355–356
 - binaural tests for, 351, 351*t*
 - cerumen and loss of, 354, 354*t*
 - cochlear implants for, 356
 - communication difficulty from
 - loss of, 355
 - consonant sounds, 352
 - difficult speech tests for, 351, 351*t*
 - disorders, 352–355, 354*t*
 - impaired, 135
 - loss screening tests, 347, 349
 - loudness and, 351–352
 - loudness as perceived in, 353
 - middle ear implant, 356
 - progression of loss of, 352
 - sensitivity, 353
 - sound localization and, 353–354
 - for speech, 352
 - standard tests for, 351, 351*t*
 - tinnitus and, 354
 - tympanic membrane scarring caused loss of, 354
 - hearing aids
 - counseling for, 355
 - evaluation of, 355–356, 355*t*
 - expectations for, 355
 - use of, 355–356
 - Hearing Handicap Inventory for the Elderly-Screening, 347, 349
 - heart disease, 28
 - ischemic, 67
 - risk factors for, 118
 - heat stroke
 - complications of, 333*t*
 - as defined, 332
 - mortality for, 332
 - hepatocytes, 11
 - herpes zoster (HZ)
 - aging increasing incidence of, 330
 - pain and, 330
 - high-risk patients
 - identifying, 79
 - interventions for, 79–80

- hip fractures, 120
 - anthroplasty and, 257
 - from falls, 229
 - functional decline following, 256
 - location of, 256, 256*f*
 - management of, 257
 - prophylaxis in patients with, 257
 - psychotropic drugs associated with, 376
 - subcapital, 256
- histories. *See also* medical histories; social history
 - in fall evaluations, 238*t*
 - of incontinence patients, 200, 201*t*
- HNK coma. *See* hyperosmolar nonketotic coma
- home care
 - eligibility for, 412
 - growth of, 413
 - independent vendors for, 413–414
 - Medicaid funds for, 412–413
 - under Medicare, 412
 - services for, 412
 - services received in, 412
 - types of care involved in, 411, 411*t*
- hormone replacement therapy (HRT), 116, 121
- hormone signaling, genetics and, 13
- hormones. *See* anabolic hormones; growth
 - hormones; hormone replacement therapy;
 - thyroid-releasing hormone; thyroid-
 - stimulating hormone
- hospice
 - creation of, 75–76
 - evaluating, 75
 - movement, 75
 - palliative care v., 467
 - services, 467, 468*t*
- hospital discharge diagnoses and procedures, 33*t*
- hospitals
 - barriers presented by, 125
 - bathing in, 126
 - children in, 127
 - dependency bred by, 126
 - discharge planners of, 127–129
 - discharge to nursing homes, 127–128
 - geriatric units of, 127
 - hazards for patients in, 124, 125*t*
 - medical errors in, 124
 - Medicare and stay in, 385–386
 - special risks of, 124–127, 124*t*–126*t*
 - sundowning in, 125
- HRT. *See* hormone replacement theory
- hydralazine, 284
- hypercalcemia, 196
- hypercholesterolemia, 289
- hyperchromasia, 321
- hyperglycemia, 196
- hyperosmolar nonketotic (HNK) coma, 308, 311*t*
- hyperparathyroidism, 168, 280
 - age of patients with, 316
 - laboratory tests in, 317*t*
 - surgery for, 316
 - symptoms of, 316
- hypersegmented neutrophils, 321
- hypersexuality, 160
- hypertension, 67, 117
 - ACE inhibitors and, 282, 284
 - as coronary artery disease risk factor, 289
 - defined, 278
 - diagnosis of, 279
 - diet and, 281
 - estrogen therapy and, 280
 - evaluation of, 279–280, 279*t*
 - as ischemic stroke risk factor, 285
 - lifestyle changes for, 281
 - medications for, 281–282, 281*t*, 283*t*, 284
 - as remediable, 277
 - renovascular, 280
 - as risk factor, 278
 - risk factors for, 281
 - secondary forms of, 280, 280*t*
 - specific therapy for, 281–282, 284
 - systemic, 292
 - thiazide diuretics and, 281, 281*t*
 - treatment of, 280–281
- hyperthermia
 - clinical presentation of, 332*t*
 - complications from, 332
 - manifestations of, 332
 - prevention of, 334
- hyperthyroidism, 168. *See also* subclinical
 - hyperthyroidism
 - diagnosis of, 315
 - masked, 315
 - symptoms of, 315
 - therapy for, 315
- hypnotics, 373, 375*t*
- hypoglycemics, 235
- hyponatremia, 168, 220
 - causes of, 317
- hypotension, orthostatic, 235
- hypothermia
 - clinical spectrum of, 330–331, 331*t*
 - complications with, 331
 - as defined, 330
 - diagnosis of, 331

- hypothyroidism and, 331
- mortality for, 332
- passive rewarming and, 332
- therapy for, 331–332
- hypothyroidism, 168
 - age of patients with, 311
 - diagnosis of, 311, 312*t*
 - hypothermia and, 331
 - iodide-induced, 311
 - laboratory abnormalities accompanying, 312
 - prevalence of, 312
 - subclinical, 313
 - symptoms of, 312
 - tests for, 312*t*
 - therapy for, 313
 - TSH stimulation test for, 312
 - undiagnosed, 312
- hypoxia, 168
- HZ. *See* herpes zoster
- I**
- IADL. *See* instrumental activities of daily living
- iatrogenesis
 - in geriatrics, 18
 - prevention of, 121–124, 123*f*
 - risk of, 19
- iatrogenic diseases, prevention of, 93
- idiopathic hypertrophic subaortic stenosis (IHSS)
 - documentation of, 293
 - as misdiagnosed, 293
 - symptoms of, 293
- IGF-1. *See* insulin-like growth factor-1
- IHSS. *See* idiopathic hypertrophic subaortic stenosis
- immobility. *See also* bed rest
 - assessing patients with, 251–253, 251*t*, 252*t*
 - bone turnover exacerbated by, 249
 - causes of, 19, 247–249, 248*t*
 - complications of, 249–250, 250*t*
 - constipation and, 250
 - as defined, 247
 - depression in patients with, 249
 - DJD and, 247
 - drugs' side effects contributing to, 249
 - environment of patient with, 251
 - environmental causes of, 247, 249
 - exercise for preventing, 267–268
 - in geriatrics, 18
 - management of, 253–257, 254*t*, 256*f*, 258*t*–259*t*, 260–264, 262*t*, 263*t*, 264–266, 266*t*, 267–271, 268*t*–270*t*
 - muscle strength as graded in geriatric patients with, 252*t*
 - musculoskeletal complications associated with, 249
 - occupational therapy for management of, 269, 270*t*
 - pain as cause of, 264
 - physical changes causing, 247, 249
 - physical examination for patients with, 251
 - prevention, 267–268
 - psychological factors for, 247, 249
 - skin management in patients with, 249, 252, 261, 263*t*
 - after stroke, 247
- immune deficiency, in geriatrics, 18
- immunization, 113
 - for influenza, 328
- impotence, in geriatrics, 18
- incontinence
 - acute, 192, 195*t*
 - adverse affects of, 187, 188*t*
 - age-related changes contributing to, 191, 193*f*
 - artificial urinary sphincter and, 221
 - bacteriuria and, 202–203
 - behavioral interventions for, 208–211, 212*t*–213*t*, 213–216
 - bladder capacity and, 191
 - bladder record and, 202*f*
 - bladder training for, 208, 211, 213
 - caregiver-dependent interventions for preventing, 213–216
 - catheters in management of, 221–222, 223*t*
 - causes of, 190–193, 193*f*, 194*t*–195*t*, 195–196, 198*t*
 - characteristics of, 200
 - as defined, 187
 - drug treatment for, 216, 217*t*–219*t*, 220
 - estrogen for stress, 220
 - evaluation of patients with, 199–206, 200*t*, 202*f*–203*f*, 204*t*, 207*t*–208*t*, 209*f*
 - external catheters for intractable, 221
 - factors contributing to, 206
 - fecal, 222–226, 224*t*
 - fecal impaction and urinary, 196
 - functional, 199
 - general principles of management of, 206, 208
 - geriatric assessment and, 48
 - in geriatrics, 18
 - history of patients with, 200, 201*t*
 - identifying, 199–200
 - impact of, 200, 201*t*
 - involuntary detrusor contractions and, 192

incontinence (*Cont.*):

- management of, 206–222, 210*t*–211*t*, 212*t*–213*t*, 215*t*, 217*t*–219*t*, 223*t*
- medications causing, 196
- medications for, 195*t*
- monitoring record for, 203*f*
- neurological disorder causing fecal, 222
- nocturnal, 220
- as nursing home placement factor, 37*t*
- overactive bladder v., 198–199
- overflow, 196, 197*f*, 220
- pathophysiology of geriatric, 188
- pelvic muscle exercises for, 209–210, 211
- persistent, 196–199, 197*f*, 198*t*, 200*t*
- physical exam for, 201, 204, 204*t*
- postvoiding residual determination, 204
- prevalence of urinary, 187, 188*f*
- reversible factors contributing to, 192–193, 194*t*–195*t*, 195–196
- screening for, 199
- self-monitoring for urinary, 208
- severity of, 187
- social perception of, 187
- stress, 190, 191, 196, 197, 197*f*, 220
- surgery for urinary, 221
- treatment options for, 206, 210*t*–211*t*
- types of, 196, 198*t*, 199
- types of persistent, 196, 198*t*
- undergarments/pads for, 206
- urgency, 197, 197*f*, 216, 220
- urinary retention with overflow, 196
- urological v. neurological disorders causing, 190

incretin mimetics, 305

independence, 15. *See also* Functional

Independence Measure

- of residents in assisted living, 410

infections

- in aged persons, 326–330, 326*t*
- factors predisposing aged persons to, 326*t*
- in geriatrics, 18
- immunosuppression as predisposing factor for, 326
- morbidity associated with, 327
- pathogens causing common, 327–328, 328*t*
- presentation of, 327
- primary, 329
- urinary tract, 327

influenza, 28

- immunization against, 328

informed consent, 455

- competence and, 448–450

insight, as assessed, 134

insomnia

- depression and, 165–166
- evaluating complaint of, 165*t*
- factors underlying, 165*t*
- in geriatrics, 18, 377

instability

- age-related factors contributing to, 229–230, 233*t*
- aging and, 229–232, 233*t*
- in geriatrics, 18

instrumental activities of daily living (IADL)

- independence, 15
- tasks included in, 29–30

insulin therapy, for diabetes,

- 307, 309*f*–310*f*

insulin-like growth factor-1 (IGF-1), 317

insurance

- decision to purchase, 391
- Medigap, 387
- private, 391

integumentary system, aging-associated changes with, 6*t*

intellectual impairment, in geriatrics, 18

interventions

- behavioral, 176, 208–211, 212*t*–213*t*, 213–216
- for depression, 176, 184
- drugs in conjunction with behavioral, 216
- for high-risk patients, 79–80
- for incontinence, 208–211, 212*t*–213*t*, 213–216
- lifestyle, 15
- for OA, 253
- for slowing aging, 13

intraocular lens, 344

intrinsic sphincter deficiency (ISD), 197

iodide, 311

iron, 53*t*. *See also* total iron-binding capacity

- anemia caused by deficiency of, 319
- dietary evaluation for, 319
- identifying deficiency in, 319
- replacement for deficiency in, 319
- treatment of deficiency in, 319

ischemic stroke, risk factors for, 285, 286*t*, 288ISD. *See* intrinsic sphincter deficiency**J**

judgment, as assessed, 134

justice, principle of, 447, 448*t*, 456

L

- laboratory assessment
 - in geriatric assessment, 49, 53*t*
 - parameters of, 53*t*
- laws
 - AD and, 455
 - for end-of-life care, 454
 - ethics v., 454
- leukopenia, 321
- levodopa, 257
- life expectancy, life span v., 3–4
- lifestyle
 - behaviors, 4
 - interventions and aging, 15
- lip reading, 353
- living will
 - AD v., 450, 452
 - power of attorney component of durable, 451*t*, 452
- long-term care (LTC), 30*f*
 - community, 414*t*
 - dynamic nature of, 404, 404*t*
 - family as heart of, 30
 - nursing home in, 35
 - quality of, 82–84
 - spending on, 399*f*
 - types of, 403*f*
 - women as caregivers for, 30
- loudness
 - as perceived in hearing, 353
 - recruitment, 353
- LTC. *See* long-term care
- lung disease, 67
- lymphocytes, 12

M

- macrocytosis, 321
- macrovascular disease, 307
- macula, degeneration of, 345–346
- macular, degeneration, 342
- magnetic resonance imaging (MRI), 144
- malnutrition, 60–61
 - assessing for, 61*t*
 - in geriatrics, 18
 - protein-energy, 60
 - risk factors for, 61*t*
- mammalian TOR (mTOR), 14
- managed care
 - for nursing home patients, 408
 - potential of, 387
- MCI. *See* mild cognitive impairment

MDRD. *See* Modification of Diet in Renal Disease

MDS. *See* minimum data set

Medicaid

- coverage of, 384, 385*f*, 388
 - expenditures, 386*f*, 390
 - home care funded by, 412–413
 - Medicare v., 35, 384
 - nursing home payments by, 390
 - reimbursement policies of, 424–425
 - sentiment around, 390–391
 - as welfare program, 389
- medical care
- cost of, 25
 - cure v., 73, 73*f*
 - expectations of, 381
 - observed v. expected outcomes of, 381, 382*f*
 - office visits for, 34*t*
 - technology's growth in, 32
 - therapeutic model driving, 381
- medical futility, 456
- medical histories
- aspects of geriatric, 46*t*–47*t*, 48
 - in dementia evaluation, 145–147, 147*t*
 - difficulties in taking, 45*t*
 - in geriatric assessment, 44–48, 46*t*–47*t*
 - of geriatric patients, 44
 - pain and, 59*t*
 - techniques for taking, 44
- medical orders for life-sustaining treatment (MOLST), 453–454
- Medicare, 381
- beneficiaries, 26, 27*t*, 387–388
 - coverage, 384, 386*f*, 388
 - as designed, 384
 - eligibility for, 385–387
 - as in flux, 384
 - home care under, 412
 - hospital/posthospital stay paid for by, 386
 - Medicaid v., 35, 384
 - outpatient prescriptions covered by, 363
 - payment system of, 384
 - physicians and, 388
 - PPS with, 32
 - prescription drugs covered by, 389
 - preventive services covered by, 96*t*–110*t*, 112–113
 - public dollars for, 27
 - readmissions, 32
 - reimbursement policies of, 424–425
- Medicare Modernization Act, 389

medications. *See also* antidepressants; drug therapy; drugs

- antiaging, 13
- cost of, 111
- for dementia, 149, 151–152
- for hypertension, 281–282, 281*t*, 283*t*, 284
- inappropriate prescribing of, 364–365
- for incontinence, 195*t*
- incontinence caused by, 196
- management, 19
- for OA, 253
- ophthalmic, 349*t*
- ototoxic, 354
- for PD, 257, 258*t*–259*t*
- prevention strategy with, 111
- prophylactic management of, 4
- record, 362, 363*f*, 365

medicine, ethics of, 456

Medigap insurance, 387

meglitinide analogues, 305

memory

- components of, 134
- loss, 152

mental status examination

- abnormal thought content in, 134
- cognitive functioning in, 134
- judgment/insight as assessed in, 134
- key aspects of, 133–134, 134*t*
- mood/affect of patient during, 135

meperidine, 267

metabolic bone diseases, 316, 317*t*

metabolism. *See also* carbohydrate metabolism; oxidative metabolism

- drug, 371

metformin, 305

methylnaltrexone, 475

MI. *See* myocardial infarction

middle-ear disease, 352

mild cognitive impairment (MCI), 135

- dementia v., 140

mini-cog, 133, 145

Minimum Data Set (MDS), 57

mirtazapine, 178, 181

mitral insufficiency, 293

mitral ring calcification, 292

mitral valve, prolapse, 293

mobility

- in geriatrics, 247
- optimizing, 247

Modification of Diet in Renal Disease (MDRD), 372

MOLST. *See* medical orders for life-sustaining treatment

motivation

- function and, 54
- in prevention, 120

MRI. *See* magnetic resonance imaging

mTOR. *See* mammalian TOR

muscle, weakness, 52*t*, 231

musculoskeletal system, aging associated changes with, 7*t*

myocardial infarction (MI), 168

- acute, 290
- frequency of, 289
- risk of stroke after, 288
- symptoms of, 290, 290*t*

myxedema coma

- care of patients with, 315
- cases of, 313, 314*t*
- therapy for, 315

N

nausea and vomiting

- causes of, 476
- management of, 476–477
- treatment for, 476–477

neurologic system, aging associated changes with, 6*t*

nonmaleficence, principle of, 447, 448*t*

nonsteroidal anti-inflammatory drugs (NSAIDs), 253, 255, 265

- short-term, 255

normal aging

- changes associated with, 4–5
- pathologic aging v., 4

nortriptyline, 330

NSAIDs. *See* nonsteroidal anti-inflammatory drugs

nurse practitioners

- in nursing homes, 434, 438–439
- prevention and, 112
- primary care by, 73

nursing home care, 31, 78

- clinical aspects of, 421–422, 422*t*–423*t*
- goals of, 419–420, 420*t*
- improving, 401
- process of, 424–425, 426*t*–429*t*, 430
- special care units, 152
- staff limitations in, 430

nursing homes

- admission to, 402, 402*f*, 404, 420–421
- ADs in context of, 460
- alternatives to, 400

assessment approach for care in, 407, 408*t*
 care as improving in, 401
 chronic catheterization patients in, 222
 clinical care of residents in, 419
 clinical ethical decisions about residents of, 459
 common clinical disorders in population of, 421–422, 423*t*
 dementia special care units in, 152
 depression in, 373
 documentation practices in, 431, 432*f*–433*f*, 434
 end-of-life care decisions by residents of, 459–460
 ethical issues in, 442–443, 443*t*
 ethics committee of, 460
 factors for placement in, 36, 37*t*
 falls in, 232, 234*t*
 in health-care delivery, 401–402, 402*f*, 404–406, 409
 hospital discharge to, 127–128
 long-stay v. short-stay residents in, 35
 in LTC, 35
 managed care program for patients of, 408
 Medicaid payments for, 390
 nature of, 128
 need for, 31, 36–37
 nurse practitioners in, 434, 438–439
 operation of, 409
 patients as admitted to, 127
 patients in, 71
 payment systems for, 386
 payments for, 406–407
 physicians role in, 407
 placement from hospitals to, 36
 policies of, 390
 postacute care and, 439, 441–442
 preventive practices in, 434
 pricing system used by, 386–387
 regulation of, 402
 residents as grouped in, 420, 420*f*
 residents of, 404–406, 405*t*
 rooms shared in, 402
 strategies for improving medical care in, 430–431, 432*f*–433*f*, 434, 434*t*, 435*t*–438*t*, 438–439, 440*f*
 in system of care, 400
 use of, 35–38, 36*f*, 37*t*
 nutrition. *See also* malnutrition
 of aged persons as assessed, 322
 aged persons requirements of, 322–323, 322*t*
 aging and, 322–323, 322*t*
 assessment, 59–61, 60*t*–61*t*, 62*t*

caloric needs in, 324
 deficiency and physiological impairments, 323–324
 dietary restrictions and, 324–325
 food additives and, 324–325
 supplementation for, 324

O

OA. *See* osteoarthritis

OASIS. *See* outcome and assessment information set

obesity

bariatric surgery for, 325–326
 diabetes and, 304
 health risks of, 325
 lifestyle change and, 325
 prevalence of, 325
 therapy for, 325–326

observation stays, in nursing homes, 36

obstructive sleep apnea (OSA)

development of, 166
 risks associated with, 166
 occult coronary artery disease, 277, 278*t*
 occupational therapy
 in immobility management of geriatric patients, 269, 270*t*
 results of, 117, 119

octreotide, 473

Old Age Assistance, 389

older persons. *See* aged persons

olfactory bulbs, 356

ophthalmopathy, 315

opioids, 330

organ systems, function loss of, 5

orthostatic hypotension, 231

OSA. *See* obstructive sleep apnea

osteoarthritis (OA)

arthroscopic interventions for, 253
 BMD and, 15
 as characterized, 253
 inflammatory arthritis v., 254, 254*t*
 pharmacological management of, 253–254
 plain film radiography for assessing, 253
 progression, 253
 treating, 253

osteoporosis, 4, 323

delaying course of, 121
 drugs for treating, 120–121
 management of, 120–121
 screening, 121
 treatments, 120–121, 122*t*

otosclerosis, 354

outcome and assessment information set
(OASIS), 57

data system for, 80

outcomes

in chronic care role for assuring quality, 80–81,

81*t*–82*t*, 83

components of, 83

introducing, 81

monitoring, 80

rationale for using, 81*t*

as term, 80

use of approach of, 82–83

oxidative metabolism, 11

by-products of, 11

P

PACE. *See* Program of All-inclusive Care of the Elderly

pain

in aged persons, 264

antidepressants for, 265

assessment for, 58–59, 59*t*, 60*f*

characterizing, 264

differentiating, 265, 266*t*

drug therapy for, 265, 266*t*

history aspects in assessment of, 59*t*

HZ and, 330

immobility caused by, 264

intensity of, 60*f*

management, 264–266, 266*t*, 267, 473

persistent, 58, 264, 265

as underdiagnosed, 264

palliative care, 469–470

constipation treatment, 473, 475–476

cultural challenges and, 472

diarrhea, 476

establishing, 472

frailty and focus of, 471–472, 471*t*

hospice v., 467

management of symptoms, 473, 475–478

pain management, 473

slow medicine, 470

understand and decide on, 470–471

parathyroid disease, 316

Parkinson disease (PD), 135

dopamine-producing cells lost with, 257

exercise therapy for, 260

management of, 257, 258*t*–259*t*, 260

pharmacological treatment of, 257, 258*t*–259*t*

recognizing, 257

surgery for, 260

symptoms of, 257

parkinsonism, 257

paroxetine, 178

pathologic aging, normal aging v., 4

Patient Protection and Affordable Care Act
(PPACA), 25, 381

Patient Self-Determination Act, 462

patients. *See* geriatric patients; high-risk patients

peripheral vascular disease

prevalence of, 296

risk factors for, 296

screening for, 297

treatment of, 298

pets, 120

pharmacology, aging and, 369–370, 370*t*

pheochromocytoma, 280

physical activity, 4

benefits of regular, 15

physical examination

in geriatric assessment, 49, 50*t*–52*t*

of geriatric patient who falls, 237, 239*t*

for immobile patients, 251

for incontinence, 201, 204, 204*t*

interpreting, 49

physical therapists, 269, 368

physical therapy, for falls, 243, 269*t*

physician orders for like-sustaining treatment
(POLST), 453–454

physicians

assisted suicide, 459

attitudes of, 120

as authority figures, 120

death and, 75

Medicare and, 388

in nursing homes, 407

plasticity, of older adults, 14–15

pneumonia, 28

PNH. *See* postherpetic neuralgia

POLST. *See* physician orders for like-sustaining
treatment

polymyalgia rheumatica

symptoms of, 254

treatment of, 254

polyneuropathy

chronic, 356

demyelinating, 356

diabetes and, 356

diagnostic approach to, 357*f*

epidemiological data on, 356

fall risk increased with, 356

symptoms of, 356

treatment of, 358

polypharmacy, 362–363, 365

- polyuria, 196
 - postacute care, 32, 34*t*, 35. *See also* nursing homes
 - delirium in settings of, 136
 - market for, 384
 - postherpetic neuralgia (PNH), 330
 - postvoiding residual (PVR) determination, 204
 - power of attorney, living will and, 451*t*, 452
 - PPACA. *See* The Patient Protection and Affordable Care Act
 - PPS. *See* prospective payment system
 - Pra. *See* probability of repeat admissions
 - pramlintide, 307
 - prediabetes, as identified, 303
 - pregabalin, 330
 - preoperative evaluation
 - by geriatricians, 63, 66–67, 66*t*
 - summarizing results of, 65*t*
 - prescriptions. *See also* geriatric prescribing
 - of behavioral interventions, 216
 - inappropriate, 364–365
 - Medicare covered outpatient, 363
 - Medicare covering drug, 389
 - presenilin 1
 - early-onset familial Alzheimer disease and, 13
 - role of, 13
 - presenilin 2
 - identification of, 13
 - role of, 13
 - President's Council on Bioethics, 456
 - pressure sores
 - development of, 261
 - documentation of, 264
 - shearing forces and, 261
 - pressure ulcers. *See also* pressure sores
 - characteristics of, 262*t*
 - as classified into stages, 261
 - as defined, 261
 - management of, 261–264
 - prevention of, 261
 - risk factors for, 261
 - topical therapy for, 264
 - treatment of, 262–264
 - prevention, 122*t*
 - activities for, 93
 - behavior change as component of, 115, 115*f*
 - characteristics, 111–113
 - considerations in assessing, 94*t*
 - cost v. benefit in techniques of, 118
 - of disability, 119–120
 - effectiveness in older people of, 112, 113–116, 115*f*
 - efficacy of efforts in, 113
 - enthusiasm for, 112
 - of falls, 229
 - forms of, 93
 - generic approaches, 116–118
 - goals pursued in, 94
 - of iatrogenesis, 121–124, 123*f*
 - of iatrogenic diseases, 93
 - of immobility, 267–268
 - medication in strategies of, 111
 - motivation in, 120
 - nurse practitioners and, 112
 - primary, 93, 111, 112
 - proactive primary care as, 93
 - screening and medicare coverage, 96*t*–110*t*
 - secondary, 93
 - social support for, 118
 - strategies, 112
 - strategies for older persons in, 95*t*
 - of strokes, 286–287
 - term as used, 93
 - tertiary, 93
 - value of, 112, 113
 - primary care
 - by nurse practitioners, 73
 - prevention through proactive, 93
 - probability of repeat admissions (Pra), 65*t*, 79
 - problem-solving therapy (PST), 177
 - Program of All-inclusive Care of the Elderly (PACE), 382
 - prospective payment system (PPS)
 - introduction of, 32
 - postacute care and, 32, 35
 - prostatic hypertrophy, 327
 - proteins, 322
 - pseudoephedrine, 220
 - PST. *See* problem-solving therapy
 - psychiatric symptoms, 478
 - psychopharmacology, geriatric, 373–374, 376–377
 - psychotherapy, for depression, 177
 - pyridoxine, 320
- Q**
- QALYs. *See* quality-adjusted life years
 - quality-adjusted life years (QALYs), 28, 461
 - quality of life
 - defining, 28
 - geriatric assessment and, 48
 - maximizing, 399
 - questran, 476

R

radiographs, chest, 53*t*
rapamycin, 14
RBRVS. *See* Resource-Based Relative Value Scale
rehabilitation
 acute level of, 269
 aural, 355–356
 benefits of, 270–271
 of geriatric patients, 268–270, 268*t*–270*t*
 goals of, 268
 location of, 269–270
 after strokes, 260–261, 288–289, 288*t*–289*t*
rehabilitation therapists, 58
renal function
 aging effecting, 371–372, 372*t*
 drug therapy and, 371–372, 372*t*
reproductive system, aging associated changes
 with, 7*t*
Resource-Based Relative Value Scale (RBRVS),
 388
resource utilization group (RUG), 425
respiratory system, aging associated changes with,
 6*t*
restless leg syndrome (RLS)
 incidence of, 166
 sensations with, 166
Reuben's physical performance test, 57
rigidity, 376
risk factors
 for AD, 143
 for elder abuse, 63
 for geriatric patients' function decline in
 hospitalization, 126*t*
 for heart disease, 118
 of iatrogenesis, 19
 for malnutrition, 61*t*
rivastigmine, 151
RLS. *See* restless leg syndrome
rotigotine transdermal patch, 260
RUG. *See* resource utilization group

S

sclerosis, aortic valve, 291
screening
 for blindness causes, 342
 for cancer, 114
 for delirium, 133
 for depression, 169–170, 173*t*
 diabetes, 303
 for disease, 112
 for elder abuse, 63
 hearing loss, 347, 349

 for incontinence, 199
 ophthalmological, 342, 343*t*
 osteoporosis, 121
 routine, 115
 for tuberculosis, 329
 value of, 114
sedatives, 235, 373
selective serotonin reuptake inhibitors (SSRIs),
 depression and, 176, 178, 179*t*
self-help groups, 120
senile cataracts, cause of, 342
sensitivity
 to drug's effect, 372
 in geriatric assessment, 41
 hearing, 353
 tissue, 372
sensory system, aging-associated changes with, 8*t*
serotonin syndrome, 180, 184
serum albumin, 370
serum creatinine, 5
setraline, 178
sexual dysfunction, geriatric assessment and, 48
Short Form-36, 57
shortness of breath, 477
sick sinus syndrome
 diagnosis of, 295
 manifestations of, 295*t*
sirtuin, 14
sitagliptin, 305
skin
 friction on, 261
 management in immobile patients of, 252,
 261, 263*t*
 thrombosis of small blood vessels destroying,
 261
slow medicine, 470
smoking, cessation of, 116–117
social history
 dementia and, 147
 in geriatric assessment, 48
Social Security Act, 384
Social Services Block Grants, 392, 393*t*–395*t*
social support
 for prevention, 118
 systems, 118
sodium levothyroxine (Synthroid), 313
speech
 audiogram, 353
 hearing for, 353
 lip reading, 353
 rapid, 353
speech therapists, 269

SSRIs. *See* selective serotonin reuptake inhibitors

Staphylococcus aureus, 326

statins, cardiovascular disease and, 4

stem cells, therapy, 13

stress

- decreased response to, 5
- estrogen and, 220
- incontinence, 190, 191, 196, 197, 197*f*, 220
- response to, 17

strokes, 28, 118. *See also* ischemic stroke

- acute, 236
- aspirin and, 286, 288
- carotid endarterectomy and, 288
- diagnosis of, 286
- immobilization after, 247
- incidence of, 284–285
- management of, 260–261
- muscle reeducation after, 289
- outcomes for survivors of, 285, 285*t*
- prevention of, 286–287
- rehabilitation after, 288–289, 288*t*–289*t*
- rehabilitative therapy for, 260–261
- TIAs and, 285
- tissue plasminogen activator for, 286
- treadmill training in patients after, 260
- treatment for, 286–288
- types of, 285, 285*t*

subclinical hyperthyroidism, 316

- cause of, 316
- therapy for, 316

subdural hematoma, 229

suicide, by aged persons, 160

sulfonylureas, 304

sundowning, 125, 138

surgery

- artificial urinary sphincter implantation through, 221
- bariatric, 325–326
- bladder, 221
- cataract, 343
- coronary artery, 290
- for hyperparathyroidism, 316
- for PD, 260
- for urinary incontinence, 221

syncope, 232, 234

- falls and, 235

Synthroid. *See* sodium levothyroxine

systolic murmurs, 51*t*

- differentiation of, 292*t*
- location of, 291

T

tacrine, 151

tardive dyskinesia, 376

taste

- aging and, 356
- aging-related changes to, 8*t*

TCAs. *See* tricyclic antidepressants

technology

- computer, 84–86
- in medical care, 32
- for quality of care improvement, 84–86

teeth, missing, 51*t*

telomerase, 11

temperature regulation. *See also* heat stroke;

- hyperthermia; hypothermia
- of aged persons, 330
- disorders, 330–332, 331*t*, 334
- pathophysiology of disorder of, 330

tendinitis, 255

testicular function, decline with

- aging of, 318

testosterone, supplementation, 318

thiazide, 281, 281*t*, 282

thiazolidinediones, 305

thrombocytopenia, 321

thyroid

- aging and function of, 308, 311, 311*t*
- hormones, 311

thyroid-releasing hormone (TRH), test, 311–312

thyroid-stimulating hormone (TSH), 174, 311

thyrotoxicosis, 315

TIAs. *See* transient ischemic attacks

tincture of time, in geriatrics, 470

tinnitus

- hearing and, 354
- prevalence of, 354

tissue plasminogen activator, for strokes, 286

tissues, aging, 11

total iron-binding capacity (TIBC), 319

touch, aging-related changes to, 8*t*

tramadol, 267

transient ischemic attacks (TIAs), 285

- presenting symptoms of, 287*t*

transitional care, 74

treadmill, training, 260

TRH. *See* thyroid-releasing hormone

tricyclic antidepressants (TCAs), 179*t*, 181

- depression and, 176, 178
- pain and, 265

TSH. *See* thyroid-stimulating hormone

tuberculosis
 incidence of, 329
 screening for, 329
 tympanic membrane, scarring, 354

U

ulcerations, 50*t*
 ulcers. *See* pressure ulcers
 ultraviolet light, in cataract development, 343
 undergarments, for incontinence patients, 206
 urethra, weak, 197
 urgency incontinence, 197, 216
 urinalysis, 53*t*
 urinary system, aging-associated changes with, 7*t*
 urinary tract disorder, 236
 urinary tract infection, 327
 urination. *See also* incontinence
 continence requirements, 188
 normal, 188–190, 190*f*, 192*f*
 peripheral nerves and, 191*f*
 US Preventative Services Task Force, for screening
 older adults and medicare coverage, 94,
 96*t*–110*t*, 113

V

vaccines, 113
 valacyclovir, 330
 valvular heart disease, management of,
 291–294
 vascular disease, 352
 vasopressin
 basal, 316
 hypertonic saline and, 316
 plasma, 316
 secretion, 316–317
 venlafaxine, 178, 181
 verteporfin photodynamic therapy, 346
 vertigo, 234–235

viscosupplementation, 253
 vision. *See also* eyes
 aging-related changes to, 8*t*
 aid to maximize function of, 349*t*
 blindness, 342, 343*t*
 after cataract surgery, 344, 344*t*
 contact lenses for, 344
 functional changes in, 341–342
 physiological changes in, 341–342
 problems' sign/symptoms in aged persons,
 347, 348*t*
 problems with, 342
 visual impairment. *See* blindness
 vitality, decreased, 303–308, 306*t*, 309*f*–310*f*;
 311, 311*t*–312*t*, 313–332, 314*f*, 314*t*, 317*t*,
 318*t*, 320*t*, 322*t*, 326*t*, 332*t*
 vitamin(s)
 antioxidant, 116
 supplements, 322
 vitamin B, deficiency, 320–321
 vitamin D, 4, 251
 deficiency, 322
 functions of, 323
 vitamin E, 151

W

Wagner model, in chronic disease management,
 71
 warfarin, 288
 weight, 60. *See also* obesity
 changes, 50*t*
 diabetes and, 304
 hypertension and, 118
 loss, 117, 477
 reduction, 304
 Werner syndrome, 12
 women, as caregivers, 30
 World Health Organization, 94